Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C000 Final Proof page i 15...
419 downloads
4799 Views
13MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C000 Final Proof page i 15.11.2007 11:57am Compositor Name: VAmoudavally
Second Edition
Chemical Warfare Agents Chemistry, Pharmacology, Toxicology, and Therapeutics
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C000 Final Proof page ii 15.11.2007 11:57am Compositor Name: VAmoudavally
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C000 Final Proof page iii 15.11.2007 11:57am Compositor Name: VAmoudavally
Second Edition
Chemical Warfare Agents Chemistry, Pharmacology, Toxicology, and Therapeutics Edited by
James A. Romano, Jr. Brian J. Lukey Harry Salem
Boca Raton London New York
CRC Press is an imprint of the Taylor & Francis Group, an informa business
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C000 Final Proof page iv
15.11.2007 11:57am Compositor Name: VAmoudavally
CRC Press Taylor & Francis Group 6000 Broken Sound Parkway NW, Suite 300 Boca Raton, FL 33487-2742 © 2008 by Taylor & Francis Group, LLC CRC Press is an imprint of Taylor & Francis Group, an Informa business No claim to original U.S. Government works Printed in the United States of America on acid-free paper 10 9 8 7 6 5 4 3 2 1 International Standard Book Number-13: 978-1-4200-4661-8 (Hardcover) This book contains information obtained from authentic and highly regarded sources. Reprinted material is quoted with permission, and sources are indicated. A wide variety of references are listed. Reasonable efforts have been made to publish reliable data and information, but the author and the publisher cannot assume responsibility for the validity of all materials or for the consequences of their use. No part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers. For permission to photocopy or use material electronically from this work, please access www.copyright.com (http:// www.copyright.com/) or contact the Copyright Clearance Center, Inc. (CCC) 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged. Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe. Library of Congress Cataloging-in-Publication Data Chemical warfare agents : chemistry, pharmacology, toxicology, and therapeutics / editors, James A. Romano Jr. and Brian J. Lukey. -- 2nd ed. p. ; cm. Rev. ed. of: Chemical warfare agents : toxicity at low levels / edited by Satu M. Somani, James A. Romano, Jr. Includes bibliographical references and index. ISBN 978-1-4200-4661-8 (alk. paper) 1. Chemical agents (Munitions) I. Romano, James A. II. Lukey, Brian J. [DNLM: 1. Chemical Warfare Agents--poisoning. 2. Disaster Planning--methods. 3. Poisoning--prevention & control. 4. Poisoning--therapy. QV 663 C5177 2008] RA648.C546 2008 363.17’9--dc22 Visit the Taylor & Francis Web site at http://www.taylorandfrancis.com and the CRC Press Web site at http://www.crcpress.com
2007027747
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C000 Final Proof page v 15.11.2007 11:57am Compositor Name: VAmoudavally
Dedication The editors consider it a distinct honor to dedicate this book to the memory of our good friends and distinguished colleagues, Drs. Satu Somani and Brennie E. Hackley Jr. Dr. Somani, professor of pharmacology and toxicology at Southern Illinois University (SIU) since 1974, was internationally recognized as a scholar and educator, as well as a pharmacologist and toxicologist. He was dedicated to research and teaching, as well as to his students and his native India. He was a driving force in the planning of the 35th Annual Conference of the Indian Pharmacology Society on ‘‘Chemical and Biological Warfare’’ (CBW). He edited two books in the area of CBW, including the first edition of this work with James Romano in 2001. He was particularly devoted to working with medical students in India in implementing problem-based learning. This philosophy, although new to India’s medical schools, was a core philosophy at SIU. Conversely, he was eager to incorporate ayurvedic medicine into the medical pharmacology curriculum at SIU. Although Dr. Somani passed away on October 29, 2002, he remains a source of inspiration to the editors. Dr. Brennie E. Hackley Jr. was chief scientist and scientific advisor to the commander of the United States Army Medical Research Institute of Chemical Defense. He authored or coauthored more than 75 publications and 15 U.S. patents. His publications and patents contributed significantly to the development of medical antidotes for chemical warfare agents. During his career, Dr. Hackley studied the relationship between chemical structures and chemotherapeutic activity with reference to efficacy against toxic agents. He contributed to the elucidation of mechanisms of reactions of nucleophiles with organophosphorus compounds. He synthesized a number of oximes, one of which was adopted as an antidote against chemical agents by the U.S. Air Force. Dr. Hackley received numerous honors and commendations during 57 years of his continuous government service. He was an honorary life member of the American Chemical Society and fellow of the American Institute of Chemists. Dr. Hackley passed away on November 5, 2006. The field of medical chemical defense will struggle to overcome the loss of Drs. Somani and Hackley, but in the end will prevail because of their legacy of scholarly effort and compassionate mentoring.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C000 Final Proof page vi
15.11.2007 11:57am Compositor Name: VAmoudavally
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C000 Final Proof page vii 15.11.2007 11:57am Compositor Name: VAmoudavally
Contents Preface.............................................................................................................................................. xi Acknowledgments......................................................................................................................... xvii Editors ............................................................................................................................................ xix Contributors ................................................................................................................................... xxi
Chapter 1
Brief History and Use of Chemical Warfare Agents in Warfare and Terrorism............................................................................................................... 1 Harry Salem, Andrew L. Ternay Jr., and Jeffery K. Smart
Chapter 2
Chemistry of Chemical Warfare Agents ................................................................... 21 Petr Kikilo, Vitaly Fedorenko, and Andrew L. Ternay Jr.
Chapter 3
Chemical Warfare Agent Threat to Drinking Water ................................................. 51 Harry Salem, Christopher E. Whalley, Charles H. Wick, Thomas P. Gargan II, and W. Dickinson Burrows
Chapter 4
Health Effects of Low-Level Exposure to Nerve Agents ......................................... 71 John H. McDonough and James A. Romano Jr.
Chapter 5
Toxicokinetics of Nerve Agents................................................................................ 97 Marcel J. van der Schans, Hendrik P. Benschop, and Christopher E. Whalley
Chapter 6
Application of Genomic, Proteomic, and Metabolomic Technologies to the Development of Countermeasures against Chemical Warfare Agents ........................................................................................................ 123 Jennifer W. Sekowski and James F. Dillman III
Chapter 7
Novel Approaches to Medical Protection against Chemical Warfare Nerve Agents ........................................................................................................... 145 Ashima Saxena, Chunyuan Luo, Nageswararao Chilukuri, Donald M. Maxwell, and Bhupendra P. Doctor
Chapter 8
Nerve Agent Bioscavengers: Progress in Development of a New Mode of Protection against Organophosphorus Exposure ................................................ 175 David E. Lenz, Clarence A. Broomfield, David T. Yeung, Patrick Masson, Donald M. Maxwell, and Douglas M. Cerasoli
vii
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C000 Final Proof page viii 15.11.2007 11:57am Compositor Name: VAmoudavally
viii
Chapter 9
Butyrylcholinesterase and Its Synthetic C-Terminal Peptide Confer In Vitro Suppression of Amyloid Fibril Formation .............................................. 203 Erez Podoly, Sophia Diamant, Assaf Friedler, Oded Livnah, and Hermona Soreq
Chapter 10
Novel Medical Countermeasure for Organophosphorus Intoxication: Connection to Alzheimer’s Disease and Dementia ............................................... 219 Edna F.R. Pereira, David R. Burt, Yasco Aracava, Robert K. Kan, Tracey A. Hamilton, James A. Romano Jr., Michael Adler, and Edson X. Albuquerque
Chapter 11
Inhalation Toxicology of Nerve Agents................................................................ 233 Paul A. Dabisch, Stanley W. Hulet, Robert Kristovich, and Robert J. Mioduszewski
Chapter 12
Vesicants and Oxidative Stress ............................................................................. 247 Milton G. Smith, William Stone, Ren-Feng Guo, Peter A. Ward, Zacharias Suntres, Shyamali Mukherjee, and Salil K. Das
Chapter 13
Health Effects of Exposure to Vesicant Agents .................................................... 293 Charles G. Hurst and William J. Smith
Chapter 14
Cyanides: Toxicology, Clinical Presentation, and Medical Management ............ 313 Bryan Ballantyne and Harry Salem
Chapter 15
Chemicals Used for Riot Control and Personal Protection................................... 343 Harry Salem, Bryan Ballantyne, and Sidney Katz
Chapter 16
Mechanism of Action of Botulinum Neurotoxin and Overview of Medical Countermeasures for Intoxication ....................................................... 389 Michael Adler, George Oyler, James P. Apland, Sharad S. Deshpande, James D. Nicholson, Jaime Anderson, Charles B. Millard, and Frank J. Lebeda
Chapter 17
Ricin and Related Toxins: Review and Perspective ............................................. 423 Charles B. Millard and Ross D. LeClaire
Chapter 18
Screening Smokes: Applications, Toxicology, Clinical Considerations, and Medical Management ..................................................................................... 469 Bryan Ballantyne and Harry Salem
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C000 Final Proof page ix
15.11.2007 11:57am Compositor Name: VAmoudavally
ix
Chapter 19
Clinical Detection of Exposure to Chemical Warfare Agents .............................. 501 Benedict R. Capacio, J. Richard Smith, Richard K. Gordon, Julian R. Haigh, John R. Barr, and Brian J. Lukey
Chapter 20
Personal Protective Equipment: Practical and Theoretical Considerations........... 549 Michael R. Jones
Chapter 21
Chemical Warfare Agent Decontamination from Skin ......................................... 611 Brian J. Lukey, Harry F. Slife Jr., Edward D. Clarkson, Charles G. Hurst, and Ernest H. Braue Jr.
Chapter 22
Chemical Warfare, Chemical Terrorism, and Traumatic Stress Responses: An Assessment of Psychological Impact .............................................................. 627 James A. Romano Jr., Lucille A. Lumley, James M. King, and George A. Saviolakis
Chapter 23
Emergency Response to a Chemical Warfare Agent Incident: Domestic Preparedness, First Response, and Public Health Considerations ........ 653 David H. Moore and Barbara B. Saunders-Price
Chapter 24
Emergency Medical Response to a Chemical Terrorist Attack ............................ 675 Stephen A. Pulley and Michael R. Jones
Index............................................................................................................................................. 713
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C000 Final Proof page x 15.11.2007 11:57am Compositor Name: VAmoudavally
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C000 Final Proof page xi
15.11.2007 11:57am Compositor Name: VAmoudavally
Preface We previously published a book on chemical warfare agents (CWAs) in 2001. There have been many changes in this area in past years, driven by world events that have created a sense of urgency to this field. We believe it is time to update our previous work, citing the numerous developments in the field since 2001. We believe these to include epidemiological or clinical studies of exposed or potentially exposed populations, new treatment concepts and products, improved organization of the national response apparatus in the United States to address the potential for CWA terrorism, and improved diagnostic tests that enable rapid diagnosis and treatment. In the preface to our earlier work, we provided a rationale as to why an increased national investment had begun in the United States. That preface was written in January 2001. As in our earlier work, we consider our chapter contributors to be experts who are recognized for their contributions to the science of toxic chemicals. Their contributions are summarized in the following paragraphs. Salem, Ternay, and Smart tell us that chemicals have been used in warfare since almost the beginning of recorded history. Use of chemicals started out crudely using malodorous materials, irritants, poisonous plants and animals, as well as decaying bodies. Since the birth of chemistry, toxic chemicals have been created specifically for war. Lethal and disabling chemicals were developed, which incapacitated or killed the enemy without disfiguring or mutilating the body and without affecting or destroying the infrastructure. These chemicals appeared to offer distinct advantages. It is important to recognize that the advances in biotechnology, nanotechnology, genetic engineering, neurobiology, and computer sciences, among others, may assist not only in the proliferation of traditional CWAs, but also stimulate the emergence of nontraditional agents as well. Advances have also occurred in the delivery systems of these agents. The authors concluded that while the use of CWAs in terrorist activities appears to have been limited, this may not accurately reflect the potential of their future use. Kikilo, Fedorenko, and Ternay provide an overview of the chemistry of selected substances that have been thought of as CWAs at one time or another. In general, this chapter is written from the perspective of an organic chemist. The authors begin with some general remarks regarding nomenclature and categories, followed by discussions of physical properties, synthesis, and chemical reactions. This chapter covers the chemistry of pulmonary (choking), asphyxiating (blood), nerve, and blister agents, as well as a brief discussion of incapacitating (one instance) and riot-control agents (one instance). Salem, Whalley, Wick, Gargan, and Burrows point out that water supplies and their distribution systems are potential targets for terrorist activity in the United States. Even short-term disruption of water service can significantly impact a community and lead to serious medical, public health, societal, and economic consequences. In the United States, most of the water supply is treated and contains a disinfectant, such as free chlorine or chloramines, to destroy or control the growth of bacteria. Maintaining a residual free chlorine concentration of 0.5 mg=L for public water supplies, and 2.0 mg=L for field drinking water for deployed troops could provide adequate protection from most biological contamination. The authors considered chemical threats to the water supply and concluded that although it may be possible to contaminate a water supply system, a high degree of physical security, combined with maintaining a higher-than-usual residual chlorine level, should ensure its safety. McDonough and Romano provide an update of their earlier contribution on ‘‘Health Effects of Low-Level Exposure to Nerve Agents.’’ They bring this area up-to-date by reviewing epidemiological or clinical studies of exposed or potentially exposed populations and new treatment
xi
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C000 Final Proof page xii 15.11.2007 11:57am Compositor Name: VAmoudavally
xii
concepts and products to mitigate nerve agent toxicity. They point out the significant human epidemiological and clinical literature that has appeared since 2001. These studies are based on further follow-up of military volunteers from earlier research programs in the United States and the United Kingdom, and more intensive follow-up of the victims of Japanese terrorist attacks involving nerve agents in 1994 and 1995. They conclude by discussing four new potential ‘‘product lines’’ of improved treatment for these deadly nerve gases. Van der Schans and Benschop present the rationale for toxicokinetic=toxicodynamic studies of nerve agents. They argue that toxicokinetic studies are of ultimate importance because the time period of the intoxication by nerve agents, perhaps contrary to earlier thinking, might span several hours. This suggests that the timing of the antidote administration has to be adapted to the toxicokinetic process. A section discussing the importance of distinguishing the stereoisomers of nerve agents precedes the discussion of the toxicokinetics of nerve agents. The distribution of sarin through tissues is discussed as part of a characterization of the elimination pathways of nerve agents. Finally, the toxicokinetics of soman in anesthetized, atropinized, and artificially ventilated, naive, and HuBuChE-pretreated guinea pigs were studied, demonstrating the utility of the toxicokinetic approach in evaluating the effectiveness of scavengers. Sekowski and Dillman tell us that over the past several years, there has been a move away from a reductionist approach of studying one gene or protein at a time toward a more global approach of studying molecular and cellular networks and how these networks integrate information and respond to the environment. Recent technological developments allow researchers to study the function of a single gene or protein in the context of cellular and molecular networks, or to study the response of numerous genes or proteins to an environmental stimulus (e.g., CWA exposure). These new molecular techniques allow for global analysis of gene expression (genomics, transcriptomics), global analysis of protein expression, modification, function (proteomics), and global analysis of metabolism and metabolites (metabonomics, metabolomics). Within the Army life science research community, Sekowski and Dillman and many of their colleagues are following the lead of the pharmaceutical and biotechnology industries in applying these global approaches and associated technologies to the problem of CWA countermeasures. In this chapter, they provide an overview of each of these technologies and their current state-of-the-art, and provide examples of how these approaches are being applied to the development of CWA countermeasures. Saxena, Luo, Chilukuri, Maxwell, and Doctor describe novel approaches to medical protection against CWAs. They begin by discussing enzyme-based pretreatments, to include both stoichiometric and catalytic scavenging enzymes, their isolation and purification, and the like. Interestingly, the authors speculate on the delivery of scavenging enzymes by gene therapy and carefully describe the benefits of that approach. Next, they consider advances in oximebased, postexposure therapy, going beyond the treatment offered by McDonough and Romano in considering even more recently synthesized agents comparable to, or perhaps superior to, MMB-4. Finally, they consider centrally acting pretreatment drugs. They agree with the sentiment of Periera et al. in that a number of centrally acting pretreatments, many designed for treatment of Alzheimer’s disease, and clearly superior to pyridostigmine bromide, are emerging from research in this area. Lenz, Broomfield, Yeung, Masson, Maxwell, and Cerasoli describe the use of scavenger enzymes as alternatives to conventional approaches to the management of nerve agent casualties. This approach, described by them in our earlier volume, avoids side effects associated with current multidrug antidotal regimens. It also obviates the requirement, often difficult to achieve in a military setting, for rapid administration of pharmacologically sufficient drug to attain its therapeutic aim. Candidate bioscavenger proteins, which react quickly, specifically, and irreversibly with organophosphorus compounds, are presented and discussed. This bond may be stoichiometric and sequester substrate or may be catalytic, hydrolyzing substrate into biologically inert products. Promising examples of each approach are presented, and the advantages of the novel approach over conventional approaches are discussed.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C000 Final Proof page xiii 15.11.2007 11:57am Compositor Name: VAmoudavally
xiii
Podoly, Diamant, Friedler, Livnah, and Soreq, at the Hebrew University of Jerusalem, demonstrated that BuChE, in addition to its endogenous scavenging of drugs, therapeutics, and CWAs, appears to attenuate the formation of amyloid fibrils in the human brain. Thus, BuChE may provide neuroprotection not only in the short term, but also within a longer time frame, increasing its potential for future therapeutic uses. These provocative findings suggest a common direction for both Alzheimer’s research and research into the protection against nerve CWAs. Pereira, Burt, Aracava, Kan, Hamilton, Romano, Adler, and Albuquerque describe the possible utility of Alzheimer’s disease drugs in protecting against central as well as peripheral effects of nerve agents. One such drug, galantamine (also called galanthamine), has recently been found by the authors to be a superior antidote against intoxication by soman and other nerve agents, effective when administered both before and soon after exposure. It has been suggested that the neuroprotective effect of galantamine is a result of activation of a number of kinases, including the extracellular signal-regulated kinase, secondary to the nicotinic allosteric potentiating action of the alkaloid. It is likely that selective block of AChE versus BuChE, ability to penetrate the blood– brain barrier, and allosteric potentiation of nAChRs all contribute to the effectiveness of galantamine as a medical countermeasure against organophosphate (OP) poisoning. The data summarized here indicate that the introduction of galantamine into clinical practice for OP poisoning will provide a major advance. Dabisch, Hulet, Kristovich, and Mioduszewski present an overview of the toxic effects associated with inhalation of a nerve agent vapor or aerosol. Many studies cited were conducted at the U.S. Army Chemical Biological Center from the 1950s up to the present day. The authors point out that the challenge for laboratory studies is to safely generate stable vapor or aerosol atmospheres and verify their atmospheric concentration, chemical characterization, and stability during the exposure period. The results of such well-controlled studies enhance human risk assessment modeling tools, support the operational risk management decision process, and help define physiologically relevant nerve agent detection thresholds. Smith, Stone, Guo, Ward, Suntres, Mukherjee, and Das focus on the oxidative stress aspects of vesicant exposure, a subject that has received little attention previously. The authors discuss three key intermediate mechanisms in the pathogenesis of the mustard injury—activation of PARP, formation of toxic metabolites, and signaling pathways that invoke the action of a number of proinflammatory mediators, looking particularly at sphingomyelinase-produced ceramides as apoptotic triggers. The authors discuss approaches to antidotes or ameliorative measures for a family of vesicants and the pulmonary toxicants chlorine and phosgene. The results presented here provide a molecular and cellular basis for developing strategies for pharmacological intervention, with potential for clinical application. Hurst and Smith discuss the health effects of exposure to vesicant agents. They consider the mustards (nitrogen and sulfur mustard) and lewisite. They describe the biochemical and physiological roots of the pathogenesis of these vesicating agents, the principal target organs, the clinical course of the pathology in each instance, residual long-term health effects, and medical management of casualties of vesicant exposure. The authors also provide a brief history of the circumstances of exposure of humans to vesicating agents, whether in warfare, volunteers in research, or, in the case of mustards, in medical treatment. This chapter considers current research and concludes, ‘‘Although much effort is being expended in developing therapeutic interventions that will limit the extent of tissue pathology, the best immediate approaches involve prevention of contact between mustard and tissues and medical procedures that ease patient trauma and discomfort.’’ Ballantyne and Salem discuss the experimental and human clinical toxicology of cyanides with particular reference to their potential for application as chemical warfare weapons and use by terrorists. They consider repeated exposure toxicity as well as specific organ, tissue, and functional end-point toxicity. Among the functional end-point toxicities, they review neurotoxicity, cardiotoxicity, vascular toxicity, developmental and reproductive toxicity, and genotoxicity. They conclude this review of the toxicology of cyanide by describing emergency first aid and poison-control
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C000 Final Proof page xiv 15.11.2007 11:57am Compositor Name: VAmoudavally
xiv
measures in current usage as well new approaches, still in the research stage, to the management of the problem of cyanide poisoning. Salem, Ballantyne, and Katz present the argument that when chemicals are used to control civilian disturbances, it is necessary to use substances of low health hazard potential and employ delivery methods that carry the minimum potential for injury. This chapter reviews the nature and effects of chemicals used, and proposed for use in peacekeeping operations. Particular attention is given to their operational uses in various circumstances, pharmacology, toxicology, evaluation of safety-in-use, delivery, effects on humans, consequences and medical management of overexposure and injury, and the need for preparedness planning. Adler, Oyler, Apland, Deshpande, Nicholson, Anderson, Millard, Keller, and Lebeda use the insights gained in their understanding of the mechanism of botulinum neurotoxin (BoNT) action to establish a conceptual framework within which to develop effective treatment strategies for intoxication. The authors also suggest that some vaccine approaches have proven effective, but generally require multiple inoculations and incubation times of up to a year from onset to generate adequate protection. In addition, vaccinated individuals may be precluded from the use of local BoNT administration for treatment of spasticity or movement disorders that may develop during their lifetime. These limitations argue strongly in favor of a supplementary pharmacological approach for the management of botulism. They point out that efforts to develop pharmacological inhibitors of BoNT have increased substantially during the last decade. The major focus of the current research is the design and synthesis of specific metalloprotease inhibitors. Most of the ongoing drug discovery efforts were initiated prior to the availability of the crystal structure for BoNT and will be aided enormously by the availability of precise structural information. Millard and LeClaire reported that several aspects of ricin, including its significant human toxicity, past military interest, wide availability in ton quantities from castor seed meal, and increased attention from the world news media, have contributed to the international regulation of the toxin as a potential ‘‘weapon of mass destruction.’’ They provide an overview of this literature for scientists who are working toward practical medical solutions to prevent or mitigate the consequences of chemical warfare or bioterrorism. They summarize the biochemistry and pathophysiology of ricin and briefly review studies with experimental animal models to aid in preventing, diagnosing, and treating the poorly characterized human response to ricin exposure. Throughout the chapter, they compared ricin to several closely related proteins toxins of comparable potency of the same plant genus. This is done to clarify the gaps in our current understanding for this important class of plant toxins. Ballantyne and Salem present the concept of screening smokes, for example, a fog-like atmosphere composed of light-scattering particles that limit visibility of troops or vehicles. These particles should not be of a biologically reactive nature, lest they be classified as CWAs under the Geneva Convention. In their chapter, they discuss the acute and chronic toxicity, as well as the environmental and ecotoxicological impact, of the most common screening smokes. They conclude by discussing the medical management of patients overexposed to screening smokes, which can in rare cases cause systemic toxicity. Capacio, Smith, Gordon, Haigh, Barr, and Lukey describe some of the most recent approaches to improving nerve agent diagnostics. They describe efforts to develop portable, reliable, prompt (i.e., near real-time) assays capable of detecting exposure even when administered after some time. They remind us that these assays are compared to the delta pH method of Ellman, the historical standard for measurement of ChE as the biomarker of exposure. Lukey and his colleagues point to successful efforts to measure regenerated nerve agent in blood. Thus, given the potential increase in urban terrorism that may include the use of chemical warfare organophosphate agents, federal, state, and local authorities now have a variety of sensitive and accurate cholinesterase and OP detection assays for appropriate containment, decontamination, and treatment measures. Jones provides an assessment of the importance of physical protection equipment in supporting effective prehospital interventions. He describes the requirements for, availability of, and
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C000 Final Proof page xv 15.11.2007 11:57am Compositor Name: VAmoudavally
xv
physiological burden associated with, various components of PPE. These include masks, respirators, protective suits, gloves, and the like. He discusses their ability to meet Occupational Safety and Health Administration (OSHA) standards. He considers alternatives to traditional PPE, such as Skin Exposure Reduction Paste Against Chemical Warfare Agents (SERPACWA), a barrier cream of demonstrated efficacy against a number of CWAs and skin irritants. He also considers how work– rest cycles and use of wet-bulb temperature information can be factored into response planning. Finally, he discusses how new Federal OSHA chemical, biological, radiological, and nuclear standards have ‘‘taken the guesswork’’ out of response planning for many local agencies. Lukey, Slife, Clarkson, Hurst, and Braue describe the problems associated with the decontamination of CWAs from the skin. They begin by describing skin barrier and metabolizing properties. They move to describing historical approaches to protecting the skin, to include protective ensembles, skin barrier creams, both inert barriers and active (decontaminating or inactivating) creams, and to describing the properties of effective skin decontaminants. They review the effectiveness of a number of candidates or fielded skin-decontaminating kits, foams, solutions, and field-expedient measures. The authors conclude by stating their guiding principle; the best decontaminants are those that most rapidly remove threat agents from the skin. Romano, King, Lumley, and Saviolakis discuss the concept of CWAs used in terrorism within the framework of the generalized catastrophe literature, that is, disasters, chemical spills, terrorism, and warfare. They suggest likely psychological, physiological, and neurobehavioral effects that may be encountered if CWAs are employed against U.S. forces, or even more troublesome, against U.S. citizens. Moreover, they discuss possible outcomes if CWAs are threatened or employed on a target population, drawing widely on historical disaster, warfare, and terrorism literature. In this chapter, they consider some of the latest physiological data and experimental results, which describe the underlying physiological basis of posttraumatic stress syndrome and relate those data to the nonlethal effects of nerve CWAs. Moore and Saunders-Price describe the organization and capabilities of the ever-evolving national response apparatus to a domestic or international terrorist use of a ‘‘weapon of mass destruction (WMD).’’ This apparatus involves many Federal agencies, one new since 2001 (The United States Department of Homeland Security), which support and complement local and state response systems that respond to such incidents. Over the past 5 years, subsequent to the publication of the last edition of this text, enormous emphasis has been placed on domestic preparedness for possible use of WMD. Chemical warfare agents, along with nuclear weapons and biological warfare agents, are included in this category. The reader is referred to the previous edition, where much of the information on medical and public health considerations of CWAs remains accurate. Moreover, recognition of the possible terrorist use of toxic industrial chemicals and materials (TICs and TIMs) has presented additional challenges. This chapter expands on the previous work and puts this information into a more current context. Pulley and Jones suggest that parts of this text are highly technical, discussing major chemical toxins, their physiologic and health consequences, and how to manage the toxins with antidotes and decontamination. The intent of their chapter is to create a framework where the emergency medical community can understand, and then employ, the basics of an organized response to a large-scale chemical event. The interested reader can then turn to the other chapters for more detailed technical information to increase the breadth of your plan and subsequent response. These major areas include command and control, communications, security, transportation and traffic, and planning and preparation. The editors point to the passing of several contributors to our first volume, scientists of great accomplishment in the area of medical chemical defense. They include our great friend and mentor, Dr. Satu Somani of Southern Illinois University, Dr. Frederick Sidell, formerly of the United States Army Medical Research Institute of Chemical Defense, a dedicated physician and scholar, and Dr. Robert Sheridan, also of the United States Army Medical Research Institute of Chemical Defense, a gentle, soft-spoken scholar who contributed greatly to this field. The field of medical
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C000 Final Proof page xvi 15.11.2007 11:57am Compositor Name: VAmoudavally
xvi
chemical defense will struggle to overcome their loss, but in the end will prevail because of their leadership and efforts. The editors of this text have been working in the area of chemical defense toxicology and medical response for many years. Colonel (Ret.) James Romano is currently a Program Manager at Science Applications International Corporation, Frederick, Maryland. Science Applications International Corporation is a leading provider of scientific, engineering, systems integration, and technical and biomedical services and solutions. He was formerly commander of the United States Army Medical Research Institute of Chemical Defense and deputy commander of the United States Army Medical Research and Materiel Command. Dr. Harry Salem is a senior biological scientist at the Edgewood (Maryland) Chemical and Biological Center, United States Army Research, Development, and Engineering Command. The Edgewood Chemical and Biological Center is the Army’s lead research establishment for development of physical countermeasures to CWAs, such as protective ensembles, decontaminating solutions, sensors, and area survey devices. Its outstanding physical sciences capabilities have allowed it to be an effective inhalation toxicology laboratory and an excellent collaborator to the United States Army Medical Research Institute of Chemical Defense (USAMRICD), collocated at Aberdeen Proving Ground, Maryland. The USAMRICD is the Army’s lead laboratory for the development of medical countermeasures to chemical warfare agents. Colonel Brian Lukey is currently commander of the USAMRICD. The USAMRICD has a long history of discovery and development of pretreatments, therapeutics, diagnostics, and skin barrier creams to protect against CWAs. The USAMRICD functions as a subordinate command of the United States Army Medical Research and Materiel Command, Fort Detrick, Maryland. Finally, the editors wish to thank Candy Romano, the Salem family (Flo, Jerry, Amy, Joel, Marshall, and Abby Rose), and Marita Lukey and for their patience and encouragement. As with all previous efforts by the editors, they have been steadfast in their support and reassuring in their conversations. With their support, this task proved achievable and enriching.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C000 Final Proof page xvii 15.11.2007 11:57am Compositor Name: VAmoudavally
Acknowledgments The editors wish to thank Ms. Patricia Hurst whose persistence, attention to detail, and sense of purpose kept the editors and many of the contributors on track. Ms. Hurst skillfully polished the rough edges of nearly all the chapters of this book, while maintaining a positive and goal-directed demeanor. The editors also wish to thank Ms. Sandra Loukota for her excellent administrative contributions. In addition, the assistance of the Edgewood Chemical Biological Center Library Staff, Patsy D’Eramo, Edward Gier, Corky Smith, and Carolyn Sullivan, is greatly appreciated, as are the contributions of Judith Hermann, Mary Frances Tracey, Megan Lynch, and Susan Biggs of the Chemical and Biological Information Analysis Center.
xvii
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C000 Final Proof page xviii
15.11.2007 11:57am Compositor Name: VAmoudavally
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C001 Final Proof page 1 16.11.2007 12:15pm Compositor Name: VAmoudavally
History and Use of 1 Brief Chemical Warfare Agents in Warfare and Terrorism Harry Salem, Andrew L. Ternay Jr., and Jeffery K. Smart CONTENTS I. Introduction ........................................................................................................................... 1 II. Chemical Warfare Agents in Ancient Times BCE ............................................................... 2 III. Chemical Warfare Agents in the CE to World War I .......................................................... 2 IV. Chemical Warfare Agents Used in World War I (1914–1918)............................................ 5 V. Chemical Warfare Agents between World War I and World War II................................. 10 VI. Chemical Warfare Agents in World War II........................................................................ 11 VII. Chemical Warfare Use After World War II ....................................................................... 13 VIII. Chemical Warfare Agents Used in Terrorism .................................................................... 16 IX. Conclusions ......................................................................................................................... 17 References ....................................................................................................................................... 17
I. INTRODUCTION Poisons and incendiary weapons first described in ancient myths included arrows dipped in serpent venom, water poisoned with drugs, plagues unleashed on armies, and secret formulas for combustible weapons. Exploiting lethal forces of nature was not just mythical fantasy, but was supported by numerous nonfiction authors in ancient times, to include Near Eastern records of 1770 BCE (before the Common Era), Greek myths recorded by Homer in about 750 BCE and Greek historians from 500 BCE through the second century of the Common Era (CE). From 500 BCE on, weapons of poison and combustible chemicals in China and Japan were described in military and medical treatises. The development of Greek fire and other incendiaries was described in Byzantine and Islamic sources of late antiquity from the seventh century through the fourteenth century CE. Archers in antiquity created toxic projectiles with snake venoms, poisonous plants, and bacteriological substances. Contamination of the enemy’s water and food supplies was also accomplished (Mayor, 2003). There were descriptions of the use of calmatives to tranquilize, disorient, or knockout enemies so they were unable to defend themselves. These were applied in warfare by ancient Greeks when they conquered Ionia which is modern Turkey. Intoxicants were used to gain victories by ancient armies in Gaul, North Africa, Asia Minor, and Mesopotamia. The calmatives and intoxicants of antiquity included toxic honey, drugged sacrificial bulls, barrels of alcohol, and mandrake-laced wine. Malodors also had their origins in antiquity when, over two millennia ago, armies in Asia and Germany employed noxious smells to overwhelm their foes.
The contents of this chapter are not to be construed as an official Department of the Army position, unless so designated by other authorizing documents.
1
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C001 Final Proof page 2 16.11.2007 12:15pm Compositor Name: VAmoudavally
2
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
II. CHEMICAL WARFARE AGENTS IN ANCIENT TIMES BCE One of the earliest examples of chemical warfare was in the late Stone Age (10,000 BCE). Hunters known as the San, in southern Africa, used poison arrows. They dipped the wood, bone, and stone tips of their arrows in poisons obtained from scorpion and snake venoms, as well as poisonous plants (CBW Info, 2005; Tagate, 2006; Wikipedia, 2007a). In about 2000 BCE, soldiers in India used toxic fumes on the battlefield. Chinese writings from as far back as the seventh century BCE contain hundreds of recipes for the production of poisonous and irritating smokes for use in war, along with numerous accounts of their use. These accounts describe the arsenic containing ‘‘soul-hunting fog’’ and the use of finely divided lime dispersed into the air (Geiling, 2003; DeNoon, 2004; Tagate, 2006). The Assyrians in 600 BCE contaminated the water supply of their enemies by poisoning their wells with rye ergot (Mauroni, 2003). Solon of Athens used hellebore roots, a purgative that caused diarrhea, to poison the water in an aqueduct leading to the Pleistrus River, around 590 BCE, during the siege of Cirrha. The Cirrhaeans drank the water and developed violent and uncontrollable diarrhea, and were thus quickly defeated (Hemsley, 1987; United Kingdom Ministry of Defense, 1999; Noji, 2001; Robey, 2003; Tschanz, 2003; CBW Info, 2005; Tagate, 2006; Wikipedia, 2007a). In the Peloponnesian War between Athens and Sparta in the fifth century BCE, the Spartan forces used noxious smokes and flame unsuccessfully against the Athenian city of Plataea. Later the Boeotians successfully used noxious smokes and flame during the siege of Delium by placing a lighted mixture of coal, brimstone, and pitch at the end of a hollow wooden tube. Bellows pushed the resulting smoke through the tube and up to the walls of the besieged city, driving the defenders away (Thucydides, 1989). During the fourth century BCE, the Mohist sect in China used bellows to pump smoke from burning balls of mustard and other toxic vegetables into tunnels being dug by a besieging army (Tagate, 2006). In 200 BCE, the Carthaginians spiked wine with Mandrake root, a narcotic to sedate their enemies, feigned a retreat to allow the enemy to capture the wine, and then when the enemy was sleeping, returned to kill them (Batten, 1960; United Kingdom Ministry of Defense, 1999).
III. CHEMICAL WARFARE AGENTS IN THE CE TO WORLD WAR I Around 50 CE, Nero eliminated his enemies with cherry laurel water that contained hydrocyanic acid (Hickman, 1999). Plutarch described irritating smokes in some of his writings around 46– 120 CE. In 1000 CE, the Mongols used gas bombs made of sulfur, nitre, oil, aconite, powdered charcoal, wax, and resin. These bombs weighed about 5 pounds each. Aconite was a favorite poison which is derived from the perennial herb of the genus Aconitum. It is in the buttercup family and is also known as monkshood and wolfsbane. Aconite (Aconitum napellus) is an alkaloid acting on the central nervous system, heart, and skin. It first stimulates and then paralyzes the nerves and heart. The effects begin with a tingling of the mouth, fingers, and toes, and then spread over the entire body surface. Body temperature drops quickly and is followed by nausea, vomiting, and diarrhea. Fatal doses are marked by intense pain, irregular breathing, and a slowed and irregular heartbeat. Death results from heart failure or asphyxiation. Aconite has been used as a poison on arrowheads and to taint enemy water supplies, and it was also used as a poison by Indian courtesans when they applied it as a lipstick as the ‘‘Kiss of Death’’ (PDR Health, 2006). In about 660 CE, Callinicus of Heliopolos invented a weapon called Greek fire, also referred to as Byzantine fire, wildfire, and liquid fire (Figure 1.1). Because its formulation was a carefully guarded military secret, the exact ingredients are unknown. It probably consisted of naphtha, niter, sulfur; petroleum, quicklime sulfur; or phosphorus and saltpeter. It may have been ignited by a flame, or ignited spontaneously when it came into contact with water. If it was the latter, the active ingredient could have been calcium phosphide, made by heating lime, bones, and charcoal. On contact with
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C001 Final Proof page 3 16.11.2007 12:15pm Compositor Name: VAmoudavally
Brief History and Use of Chemical Warfare Agents in Warfare and Terrorism
3
FIGURE 1.1 Drawing of a fake dragon shooting Greek fire; U.S. Army (1918), The Gas Defender.
water, calcium phosphide releases phosphine, which ignites spontaneously. However, Greek fire was also used on land. The ingredients were apparently heated in a cauldron and then pumped out through a siphon or large syringe, known as a siphonarios, mounted on the bow of the ship. Greek fire could also be used in hand grenades made of earthenware vessels that may have contained chambers for fluids that when mixed, ignited when the vessel broke on impact with the target. It was used very effectively in naval battles as it continued burning even under water, and was known to the Byzantine enemies as a wet, dark, sticky fire because it stuck to the unfortunate objects hit and was impossible to extinguish. It was also very effective on land as a counter force suppression weapon used on besieging forces. Greek fire was first used on the battlefield to repel the Arab siege of Constantinople in 674–677 CE then at the Battle of Syllaeum, in 717–718 CE against the Moslems, and later against the Russian attacks in 941 and 1043 CE. The Byzantines also used Greek fire against the Vikings in 941 CE and against the Venetians during the fourth Crusade (Waitt, 1942; CBW Info, 2005; Wikipedia, 2007b). Chinese soldiers during the period 960–1279 CE used arsenical smokes in battle (CNS, 2001), and the Germans used noxious smokes in 1155 CE. In the fifteenth and sixteenth centuries, the Venetians used poison filled mortar shells and poison chests to taint wells, crops, and animals (Geiling, 2003). Leonardo da Vinci (1452–1519) described the preparation of Greek fire in his notebooks. His recipes included boiling charcoal of willow, saltpeter, sulfuric acid, sulfur, pitch, frankincense, camphor, and Ethiopian wool together. Liquid varnish, bituminous oil, turpentine, and strong vinegar were then mixed in and dried in the sun or oven. After forming balls, sharp spikes were added, leaving an opening for a fuse (Richter, 1970). Leonardo da Vinci also proposed throwing poison powder on enemy ships. For poison, he recommended chalk, fine sulfide of arsenic, and powdered verdigris (basic copper salts) (MacCurdy, 1938; Dogaroiu, 2003). To protect the friendly soldiers, da Vinci described a simple protective mask made of fine cloth dipped in water that covered the nose and mouth. This is the earliest known description of a protective mask (MacCurdy, 1938; Women in Military Service for America Memorial Foundation, Inc., 2007). During the Thirty Years War (1618–1648), stink bomb grenades were used against fortifications. These were made from shredded hoofs, horns, and asafetida mixed with pitch. In 1672, during the siege of the city of Groningen, soldiers belonging to Christoph van Galen, the Bishop of Munster, used flaming projectiles and poisoned fireworks, but without much success (Beebe, 1923). Three years
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C001 Final Proof page 4 16.11.2007 12:15pm Compositor Name: VAmoudavally
4
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
later, in 1675, the French and Germans concluded the Strasbourg Agreement, the first international agreement that banned the use of poison bullets (Hemsley, 1987; Tagate, 2006). During the Crimean War in 1854, British chemist Lyon Playfair proposed to fill a hollow shell with cacodyl cyanide [(CH3)2AsCN] for use against Russian ships (Miles, 1957b; Camerman and Trotter, 1963). The enclosed space of a ship would allow the chemical agent to be more deadly. The British military, however, considered chemical warfare inappropriate and thought it similar to poisoning water wells (Browne, 1922). In his letter to the Prince Consort, Playfair responded that ‘‘why a poisonous vapor which could kill men without suffering is to be considered illegitimate is incomprehensible.’’ He further added that ‘‘no doubt, in time, chemistry will be used to lessen the suffering of combatants’’ (Browne, 1922). Other British proposals for chemical weapons during the Crimean War included ammonia shells, sulfur dioxide smoke clouds, and cacodyl oxide shells (Miles, 1957a, 1958a; Hemsley, 1987). The many suggestions, inventions, and concepts proposed during the American Civil War were among the forerunners of chemicals used on a much larger scale during World War I (Smart, 2004). In 1861, Confederate Private Isham Walker wrote a letter to the Secretary of War Lucius Walker proposing the use of poison gas balloons against Fort Pickens and the Federal ships guarding it near Pensacola, Florida. The plan was not accepted (Wiley, 1968). On April 5, 1862, the same day that the Union Army began the siege operations against the extensive fortifications at Yorktown, Virginia, John Doughty of New York City, a school teacher, sent a letter to the War Department suggesting that shells filled with chlorine be shot at the Confederates (Figure 1.2). He envisioned the shells exploding over the Confederate trenches and creating a chlorine cloud that would either disable or drive the defenders away. He also addressed the moral question of introducing chemical warfare and concluded that it ‘‘would very much lessen the sanguinary character of the battlefield and at the same time render conflicts more decisive in their results’’ (Haydon, 1938). Also in April 1862, shortly after the naval engagement between the USS Monitor and the CSS Virginia ended in a draw, Commodore L.M. Goldsborough reported a rumor that the Confederates were going to use chloroform as a knockout gas against the USS Monitor to produce insensibility of their crew. A similar suggestion was made by Joseph Lott from Hartford, Connecticut in 1862 to load hand pumped fire engines with chloroform and spray it on the enemy troops behind their earthworks defending Yorktown, Virginia, and Corinth, Mississippi (Thompson and Wainwright, 1918). During the siege of Petersburg, Virginia, in 1864, Forrest Shepherd of New Haven sent a letter to President Abraham Lincoln, suggesting mixing sulfuric acid with hydrochloric or muriatic acid to form a dense toxic cloud. Being slightly heavier than the atmosphere and a visible white color,
FIGURE 1.2 Drawing of John Doughty’s proposed chlorine shell in 1862; National Archives.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C001 Final Proof page 5 16.11.2007 12:15pm Compositor Name: VAmoudavally
Brief History and Use of Chemical Warfare Agents in Warfare and Terrorism
5
the cloud would conceal the operator while the breeze blew it across enemy lines. Once it hits the enemy lines, it would cause coughing, sneezing, and tearing, which would prevent the enemy from aiming their guns, but would not kill them (Miles, 1958b). Also during the siege, Confederate Colonel William Blackford directed that tunnels be dug toward the Union lines to discover Union tunneling operations and, when the enemy tunnels were found, to use cartridges of smoke to suffocate or drive out enemy troops in them. The composition of the smoke was not clearly defined but could have been generated from gunpowder with a much higher proportion of sulfur to create a sulfur dioxide cloud when burned. Another possibility was that the material was similar to the mixture used in stink bombs, which would contain sulfur, rosin, pitch, asafetida, horse-hoof raspings, as well as other materials designed to produce nauseating smokes (Blackford, 1945; Miles, 1959). The use of stink shells was also suggested by Confederate Brigadier General William Pendleton in 1864 to break the siege of Petersburg. He wanted a shell that combined an explosive with an offensive gas that would ‘‘render the vicinity of each falling shell intolerable’’ (U.S. War Department, 1891). Also in 1864, Captain E.C. Boynton described a cacodyl glass grenade that combined an incendiary with a toxic gas. He envisioned this for use against wooden ships. The cacodyl (C4H6As3), a heavy oily liquid, bursts into flame on contact with the air and also produces toxic fumes (Boynton, 1864). During the 1899 Boer War, the British used picric acid in their shells. Although the shells were not particularly effective, the Boers protested their use (Hersh, 1968; Hemsley, 1987; Tintinalli, 2003). At the First Hague Peace Conference in 1899, Article 23(a) banned the use of poisons or poisoned arms and was ratified by the United States. A separate declaration banning asphyxiating gasses in shells was rejected by the United States even though the major European powers all signed it (Taylor and Taylor, 1985). The Russo–Japanese War also saw limited use of toxic chemical weapons. The Japanese used arsenical rag torches against Russian trenches. The torches were pushed toward the enemy by long bamboo poles to create a choking cloud (Chemical Warfare Service, 1939).
IV. CHEMICAL WARFARE AGENTS USED IN WORLD WAR I (1914–1918) World War I has been called the ‘‘Chemist’s War’’ because it ushered in the beginning of the modern era of chemical warfare. Most of the key chemical warfare agents used during the war, however, were eighteenth- and nineteenth-century discoveries. These included: chlorine (1774); hydrogen cyanide (1782); cyanogen chloride (1802); phosgene (1812); mustard agent (1822); and chloropicrin (1848) (Sartori, 1939). Chlorine (Cl2), designated Cl by the United States and Betholite by the French, is the only substance that has been used in its elementary state as a war gas. It is a greenish-yellow gas with an irritating and disagreeable odor. Chlorine causes spasm of the larynx muscles, burning of the eyes, nose, and throat, bronchitis, and asphyxiation. Its asphyxiating properties were first recognized by the Swedish chemist Karl Wilhelm Scheele in 1774. Chlorine was the first chemical agent used on a large scale by the Germans in April 1915 (Sartori, 1943; Field Manual 3–11.9, 2005). Although substances containing cyanide have been used for centuries as poisons, it was not until 1782 that hydrogen cyanide or hydrocyanic acid (HCN) was also isolated and identified by Karl Scheele, who later may have died from cyanide poisoning in a laboratory accident. The agent is a colorless liquid with a faint odor of bitter almonds. It causes faintness, pain in the chest, difficulty in breathing, and ultimately death. Hydrogen cyanide, also referred to as prussic acid, was designated AC by the United States and called Vincennite and Manganite by the French. It was reportedly first used by the Austrians in September 1915 (Foulkes, 1934; Baskin and Brewer, 1997; Field Manual 3–11.9, 2005). Cyanogen chloride (CNCl) was discovered by Wurtz and first prepared by Berthollet in 1802. It is a colorless gas with an irritating odor that immediately attacks the oral–nasal passages.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C001 Final Proof page 6 16.11.2007 12:15pm Compositor Name: VAmoudavally
6
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Its symptoms are similar to hydrogen cyanide and in high concentrations, it eventually causes death. The U.S. designation was CC which was later changed to CK. The French called it Mauguinite and Vitrite. It was first used by the French in October 1916 (Sartori, 1943; Field Manual 3–11.9, 2005). Phosgene (COCl2) or carbonyl chloride, designated CG by the United States, Collongite by the French, and D-Stoff by the Germans, was obtained in 1812 by Humphrey Davy when he exposed a mixture of chlorine and carbon monoxide to sunlight. Phosgene is a colorless gas with an odor like musty hay that attacks the lungs causing pulmonary edema and eventually death. It was first used by the Germans as a war gas in December 1915 (Sartori, 1943; Field Manual 3–11.9, 2005). Mustard agent or dichloroethyl sulfide (S(CH2CH2)2Cl2) was discovered by Despretz who obtained it by the reaction of ethylene on sulfur chloride in 1822. It is normally a pale yellow to dark brown oily liquid with odor like garlic (although the German mustard agent had an odor similar to mustard). The agent normally attacks the eyes and blisters the skin. The U.S. designated it HS, and then later HD after a purified version was developed in 1944. The French called it Yperite and the Germans Lost. The German name was derived by taking the first two letters of the two Germans Lommel and Steinkopf, who proposed and studied the use of this agent in warfare. The first use of mustard agent by the Germans near Ypres, Belgium, in July 1917, marked the beginning of a new phase of chemical warfare, and inflicted about 15,000 British casualties in three weeks (Prentiss, 1937; Sartori, 1943; Field Manual 3–11.9, 2005). Chloropicrin or trichloronitromethane (CCl3NO2) was prepared in 1848 by Stenhouse and was extensively used in World War I. It is a pungent, colorless, oily liquid that caused oral–nasal irritation, coughing, and vomiting. In high dosages, it causes lung damage and pulmonary edema. It was first employed dissolved in sulfuryl chloride by the Russians in 1916 in hand grenades. In Germany it was known as Klop, in France as Aquinite, and PS in the United States. It has also been used as an insecticide and fungicide, as well as for eradicating rats from ships (Sartori, 1943). At the beginning of World War I, both sides used munitions filled with irritants such as ethylbromoacetate (CH2BrCOOC2H5), chloroacetone (CH3COCH2Cl, or French Tonite, German A-Stoff), o-dianisidine chlorosulfonate, xylyl bromide (C6H4CH3CH2BR, German T-Stoff), or benzyl bromide (C6H5CH2Br) (Dogaroiu, 2003). Other irritants used in World War I included acrolein (CH2CHCHO, French Papite), bromoacetone (CH3COCH2Br, U.S. BA, German B-Stoff, French Martonite), and bromobenzyl cyanide (C6H5CHBrCN, U.S. CA, British BBC, French Camite) (Salem et al., 2006). Thus, the first use of chemicals in World War I involved nonlethal tear gases, which were used by both the French and the Germans in late 1914 and early 1915 (Figure 1.3). Germany was the leader in first using chemical weapons on the battlefield and then introducing or developing new chemical agents to counter new developments in protective equipment. Fritz Haber was the designer behind many of Germany’s chemical weapons. Although he was not a toxicologist, he profoundly influenced the science of chemical toxicology. Haber and colleagues conducted acute inhalation studies in animals with numerous chemical agents thought to be useful in chemical warfare. He also developed Haber’s Law which is usually interpreted to mean that identical products of the concentration of an airborne agent and duration of exposure will yield similar biological responses (Witschi, 2000). Actually, the product of the concentration (C) of the gas in air in parts per million (ppm) and the duration of the exposure (t) in minutes was referred to as Haber’s Constant (Haber, 1986). It was also referred to as the mortality-product, the Haber Product W (C 3 t ¼ W), or the lethal index, the lower the product or the index number, the greater the toxic power (Sartori, 1939). Although Haber’s Law has been used by toxicologists to define acute inhalation toxicity for toxic chemicals, it can also be useful for quantitative risk or safety assessment (Rozman and Doull, 2001). Germany’s use of chemical weapons on the battlefield began on October 27, 1914 when they fired shells loaded with dianisidine chlorosulfonate, a tear gas, at the British near Neuve Chapelle. This tear gas normally produces violent sneezing. In this case, however, the chemical dispersed so rapidly in the air that the British never knew they were attacked by gas (Charles, 2005). Following this experiment, the Germans continued to test other potential chemical weapons.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C001 Final Proof page 7 16.11.2007 12:15pm Compositor Name: VAmoudavally
7
Brief History and Use of Chemical Warfare Agents in Warfare and Terrorism
Brass
Steel
Steel
T.N.T bursting charge
Lead container
25 mm
Felt wad
34 mm
555 mm
Paraffin or cement
FIGURE 1.3 The German 150 mm xylyl bromide (T-Stoff) shell; Army War College (1918), Gas Warfare, Part I, German Methods of Offense.
In mid December 1914, Haber’s assistant was killed while working on an arsenic containing weapon (cacodyl: (CH3)2As–As(CH3)2). In January of 1915, the Germans used xylyl bromide (T-stoff) against the Allies, but it was so cold that the gas froze and settled in the snow. By the spring of 1915, Haber convinced the German High Command to use chlorine gas, and to create a special gas unit, the 35th Pioneer Regiment. This unit included Otto Hahn, Wilhelm Westphal, Erwin Madelung, James Franck, and Gustav Hartz. Three of these were future Nobel Laureates, Hahn, Franck, and Hertz (Charles, 2005). In preparation for the release of chlorine gas, Haber arranged for over 5000 chlorine cylinders to be placed near Ypres, Belgium (Figure 1.4). Only some of the ordinary German soldiers had protective masks made of cotton gauze, while Haber had provided Draeger masks for the Pioneers. While waiting for the wind to blow in the right direction, enemy fire hit some of the chlorine cylinders, and released their gas. Three German soldiers were reportedly killed and 50 were injured. On April 22, 1915, a strong wind from the northeast arrived, and at 5 PM, Haber’s gas troops opened the valves on the 5730 high-pressure steel tanks containing about 168 tons of chlorine along a four mile frontline. The chlorine drifted southward toward the French and Canadian lines. It formed a yellow–green smoke wall about 50 feet high and 4 miles long. The wind shifted and the cloud moved to the east toward the trenches occupied by the 45th Algerian Division (French). Those who tried to stay were quickly overcome, retching and gasping for air as they died. The rest fled in panic, stumbling and falling, and throwing away their rifles. The cloud moved on at about 100 ft=min and opened up a four mile wide hole
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C001 Final Proof page 8 16.11.2007 12:15pm Compositor Name: VAmoudavally
8
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
FIGURE 1.4 German trench with a gas cylinder ready for discharge; Army War College (1918), Gas Warfare, Part I, German Methods of Offense.
in the Allied front. After 15 minutes, the German troops emerged from their trenches and advanced cautiously. Had the German High Command provided enough reserves to sustain the offensive, they might have been able to break through the Allied defensives and capture Ypres. Instead, the German forces gained only about two miles of territory. The French soldiers used rudimentary defensive equipment including cans of water, along with wads of cotton that they were supposed to soak and hold to their faces. Estimated casualties for the battle ranged from 3,000 to 15,000 killed and wounded (McWilliams and Steel, 1985; Charles, 2005; MSN, 2005; Landersman, 2003). Following this attack, the Germans led repeated chlorine gas attacks on the Allies and drove them back almost to Ypres, but were unable to capture the objective. The initial attacks caught the Allies completely unprepared. However, shortly after the first attack, the British troops were told to urinate on their handkerchiefs, and tie them over their faces for emergency protection. This caused problems for some soldiers when there were multiple gas attack alerts within a short time. Within a week of the first attack, Emergency Pad Respirators made of cotton waste soaked in sodium carbonate and sodium thiosulfate (hypo) were available for British soldiers. By early 1916, protective masks included goggles, exhaust valves, and provided adequate protective against most of the chemical agents being used on the battlefield. This was the beginning of a competition between the developers of chemical warfare agents that could penetrate the masks and the developers of protective equipment. The developers of protective equipment were ahead in the competition until the summer of 1917. Mustard agent (HS) was first used by the Germans against the French on July 12, 1917, also near Ypres (Harris and Paxman, 1982; Mitretek, 2005a). The attack led to about 15,000 Allied casualties. Unlike phosgene, which was disseminated as a gas, mustard agent is relatively nonvolatile and looks much like motor oil. It is persistent and will remain on objects for long periods of time. The introduction of mustard agent on the battlefield created a dilemma for the protective equipment developers. No longer were the oral–nasal passages and the eyes the only areas that needed protection. Mustard agent required full body protection for both soldiers and all animals used on the battlefield for transportation and communication (Figure 1.5). Unprotected soldiers suffered blisters on all exposed skin that appeared hours after the initial exposure. Less than 5% of the mustard casualties who reached medical aid stations died, but the average convalescent period was greater than six weeks. Mustard agent damages eyes, lungs, and skin, and ties up large amounts of medical resources (Figure 1.6). On March 9, 1918, a German chemical bombardment began between St. Quentin and Ypres firing half a million shells containing mustard agent and phosgene at the rate of about 700 shells=min. On that day, a total of 1000 tons of chemicals were used by Germany. The Germans
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C001 Final Proof page 9 16.11.2007 12:15pm Compositor Name: VAmoudavally
Brief History and Use of Chemical Warfare Agents in Warfare and Terrorism
9
FIGURE 1.5 Rider and horse protected against mustard agent during World War I; U.S. Army.
also attacked Salient du Fey on March 9, 1918, where Colonel Douglas MacArthur led the capture of a German machine gun nest and was awarded the Distinguished Service Cross. Two days later, MacArthur was among those gassed by the Germans, and for this he received the Purple Heart. On March 19, 1918, the British launched a pre-emptive retaliatory strike against the German positions near St. Quentin. They used nearly 85 tons of phosgene and killed 250 German troops. There were attempts late in the war to develop more potent vesicants than mustard agent. In 1918, Associate Professor Winford Lee Lewis left Northwestern University to become director of the Offensive Branch of the Chemical Warfare Service Unit at Catholic University. This Unit was called Organic Unit No. 3 and was tasked to develop and produce novel gases containing arsenic. Lewisite (dichloro-(2-chlorovinyl) arsine) (C2H2AsCl3) was developed based on early research conducted in 1904 at the university by J.A. Nieuwlands. It is a brown liquid that smells like geraniums. The new agent was also designated G-34 or M-1. For the popular press, it was referred to as Methyl or the ‘‘Dew of Death.’’ Like mustard agent, it is also a vesicating agent that attacks the eyes and blisters the skin, but its effects occur much quicker than mustard agent. Developed late
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
10
46616_C001 Final Proof page 10
16.11.2007 12:15pm Compositor Name: VAmoudavally
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
FIGURE 1.6 Sample of mustard agent; U.S. Army.
in the war, it was not used on the battlefield (Anonymous, 1921; Vilensky and Sinish, 2005; Field Manual 3–9.11, 2005). By the end of the war, it was estimated that approximately 1.2 million soldiers were wounded by the use of gas and over 91,000 were killed. Reportedly, the Russians alone suffered approximately half a million chemical casualties. Over 113,000 tons of chemicals were released and over 66 million gas shells were fired during World War I. What started as innocent, peaceful, and even humanitarian commercial use of chemical products led to the horrors of chemical warfare on the battlefield. Haber, the scientist who synthesized ammonia from nitrogen and hydrogen, and for which he was awarded the Nobel Prize in 1918, shifted his interests from fertilizer to gunpowder production in collaboration with I.G. Farben. The Germans used chlorine as a weapon, rather than the more deadly phosgene, and finally mustard agent. Mustard was the most effective casualty causing agent used in World War I. It produced about eight times the casualties of all other German chemicals and no effective defense was developed against it during the war (Landersman, 2003). It was also Haber’s group that developed the use of hydrogen cyanide as an insecticide for flour mills and granaries. Known as Zyklon A, the gas contained an odorous marker as a warning system to prevent poisoning. One of his insecticides, Zyklon B, later became a standard means for killing detainees in Nazi concentration camps during the World War II Holocaust. Among the victims reportedly were some of Haber’s relatives (Wilson, 2006).
V. CHEMICAL WARFARE AGENTS BETWEEN WORLD WAR I AND WORLD WAR II Following the end of World War I, many nations attempted to ban chemical warfare. In 1925, 16 of the world’s major nations signed the Geneva protocol pledging never to use gas in warfare again. The United States signed the agreement, but the U.S. Senate refused to ratify it due to a growing
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C001 Final Proof page 11
16.11.2007 12:15pm Compositor Name: VAmoudavally
Brief History and Use of Chemical Warfare Agents in Warfare and Terrorism
11
isolationism sweeping the country and also concerns that the nation needed to continue preparing in case chemical weapons were used again. Not until 1975 did the United States ratify the protocol. Despite the Geneva protocol, there were continued incidents of chemical weapon usage. During the Rif War (1921–1926) in Spanish occupied Morocco, Spanish forces reportedly fired gas shells and dropped mustard agent bombs on the Riffians (Anonymous, 1923; Waitt, 1942; SIPRI, 1971). In 1935, Italy used chemical weapons during their invasion of Ethiopia. The Italian military primarily dropped mustard agent in bombs, and experimentally sprayed it from airplanes and spread it in powdered form on the ground. In addition, there were reports that the Italians used chlorine and tear gas. Some sources estimated chemical casualties were 15,000, mostly from mustard (Clark, 1959; SIPRI, 1971). Japan used chemical weapons against Chinese forces during their war starting in 1937. Reports indicated that the Japanese used mustard agent, lewisite, phosgene, hydrogen cyanide, and tear gases filled in bombs, shells, and smoke pots (SIPRI, 1971). The Soviet Union also used chemical weapons on its own people during this period reportedly using them to suppress a massive peasant uprising around Tambov (Wikipedia, 2007a). Until the mid 1930s, the World War I chemical agents, phosgene and mustard agent, were considered the most dangerous chemical weapons. They could readily be identified by their smell. That changed when Germany discovered nerve agents. The history of nerve agents began on December 23, 1936 when Dr. Gerhard Schrader of I.G. Farben in Germany accidentally isolated ethyl N, N-dimethylphosphoramidocyanidate (C5H11N2O2P) while engaged in his program to develop new insecticides since 1934. It was a colorless to brown liquid with a faintly fruity odor. Controlled animal laboratory studies revealed that death could occur within 20 min of exposure. In January 1937, Schrader and his assistant were the first to experience the effects on humans. A small drop spilled on a laboratory bench caused both of them to experience miosis and difficulty in breathing. Schrader reported the discovery to the Ministry of War which was required by the Nazi decree passed in 1935 that required all inventions of military significance be reported. The chemical was quickly recognized as a new, more deadly, chemical warfare agent. It was initially designated as Le-100, and later as Trilon-83. It would eventually become known as Tabun. The United States, when it became aware of the agent, designated it GA for German Agent A. Tabun was designated a chemical warfare agent by the military. The first Tabun production was at Elberfeld. In 1940, production was relocated to Dyhernfurth. Tabun was apparently tested on German death camp inmates (SIPRI, 1971; Harris and Paxman, 1982; MTS, 2005a, 2005b; CBW; Field Manual 3–9.11, 2005). In 1938, Schrader discovered a second potent nerve agent, isopropyl methylphosphonofluoridate (C4H10FO2P), whose name Sarin is an acronym for the names of the members of the development team: Schrader, Ambrose, Rudriger, and van der Linde. The Germans designated it T-144 or Trilon-46. The United States eventually designated it GB. It is a colorless liquid with no known odor. Animal tests indicated that it was 10 times more effective than Tabun (Harris and Paxman, 1982; MTS, 2005a; Field Manual 3–11.9, 2005).
VI. CHEMICAL WARFARE AGENTS IN WORLD WAR II With the start of World War II, Germany filled bombs, shells, and rockets with Tabun nerve agent. The Germans, however, never used them on the battlefield. They remained in storage until the end of the war when the Allies captured them and discovered their existence (Figure 1.7). The reasons Germany did not use nerve agents or any other chemical weapons are still debated. One possible explanation was that Adolph Hitler had been exposed to mustard agent as a young soldier and did not want to use chemical agents again. Another possible reason was that by the time nerve agents could have made a difference on the battlefield, Germany had already lost air superiority and risked massive attack against their cities. President Franklin Roosevelt’s pledge in 1943 to not use chemical weapons unless the United States was attacked first probably also helped convince the Germans not to initiate chemical warfare (Landersman, 2003).
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
12
46616_C001 Final Proof page 12
16.11.2007 12:15pm Compositor Name: VAmoudavally
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
FIGURE 1.7 German Tabun bombs discovered after the defeat of Germany in 1945; Office of the Chief of Chemical Corps (1947), The History of Captured Enemy Toxic Munitions in the American Zone European Theater, May 1945 to June 1947.
The U.S. preparation for chemical warfare, however, came at a cost. As part of their preparations in case Germany or Japan did use chemical weapons, the U.S. forward positioned chemical agent stockpiles around the world. The only U.S. casualties from mustard agent in hostile action during World War II, were those injured or killed following a German air raid on the harbor of Bari, Italy, that was heavily congested with merchant ships off-loading war supplies on December 2, 1943. Among the ships was the SS John Harvey whose cargo included 100 tons of mustard agent bombs. German bombers attacked the harbor sinking 16 ships and damaging 8 others. The John Harvey was one of the first hit, and all those on board knowledgeable of the chemical weapons were killed. The destroyed ship spread a mixture of oil and mustard agent across the harbor. Hospitals were unaware of the contamination and were unprepared to treat the patients. There were over 600 mustard agent casualties of whom 83 died within a month (Harris and Paxman, 1982; Landersman, 2003). During the war, research continued on both sides to find new chemical warfare agents. Soman (pinacolyl methyl phosphonofluoridate) (C7H16FO2P), eventually designated GD by the United States, was developed by the Germans in 1944. Its name might have been either derived from the Greek verb ‘‘to sleep’’ or the Latin stem ‘‘to bludgeon.’’ It is a colorless liquid with a fruity or camphor odor. Soman was discovered by Dr. Richard Kuhn, a Nobel Laureate while he was working for the German Army on the pharmacology of Tabun and Sarin (SIPRI, 1971; MTS, 2005a; Field Manual 3–9.11, 2005). Soman combines features of both Sarin and Tabun (CBW). Initial tests showed that Soman was even more toxic than Tabun and Sarin (Harris and Paxman, 1982). The Germans also apparently researched two other nerve agents, later designated GE (ethyl Sarin, C5H12FO2P) and GF
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C001 Final Proof page 13
16.11.2007 12:15pm Compositor Name: VAmoudavally
Brief History and Use of Chemical Warfare Agents in Warfare and Terrorism
13
(cycloSarin, C7H14FO2P) which were not discovered by the Allies until they overran Germany in 1945 (Harris and Paxman, 1982). The United States developed a process to purify mustard agent by distillation in 1944 and designated it as HD (C4H8Cl2S). The World War I mustard agent, referred to as Levinstein mustard, had a higher percentage of sulfur which made it less effective and less stable in storage. Distilled mustard (HD) had less smell, had a greater blistering capability, and was more stable in storage. The United States and the British also researched mixing different chemicals with mustard agent. This work identified HL (a mixture of mustard agent and lewisite), HQ (sesqui mustard), HT (a mixture that was more persistent and had a lower freezing point), and HV (a thickened mustard agent). Both sides also researched the nitrogen mustard agents. First identified in the 1930s by Kyle Ward Jr., eventually three nitrogen mustard agents were identified during the war. HN-1 (C6H13Cl2N), HN-2 (C5H11Cl2N), and HN-3 (C6H12Cl3N) were all similar to mustard agent but had quicker reaction in the eyes. The United States focused on HN-1, while the British concentrated on HN-2 and HN-3. The Germans focused on HN-3 and filled it in shells and rockets (Brophy et al., 1959).
VII. CHEMICAL WARFARE USE AFTER WORLD WAR II As the Allies overran Germany in 1945, they discovered the German nerve agent program for the first time. Both the United States and the Soviet Union took the German technology and made it their primary focus for chemical warfare agents. In the United States, Sarin (GB) was the nerve agent produced during the 1950s at Rocky Mountain Arsenal in Colorado (Figure 1.8). The agent was filled in bombs, shells, and rockets.
FIGURE 1.8 The U.S. Sarin (GB) nerve agent plant at Rocky Mountain Arsenal, CO; U.S. Army.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
14
46616_C001 Final Proof page 14
16.11.2007 12:15pm Compositor Name: VAmoudavally
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Within less than a decade, however, a new nerve agent was discovered by the British. The new agent, eventually designated VX (V for venomous), was developed at the ICI Protection Laboratory in 1952. VX (C11H26NO2PS), both an organophosphate and an organosulfate compound which was immediately toxic to mammals as well as to insects was discovered by the British chemist Dr. Ranajit Ghosh. Its chemical name is O-ethyl S-[2-(diisopropylamino)ethyl] methylphosphonothiolate. VX is a colorless and odorless liquid. The research was originally intended to find a replacement for the insecticide DDT, but as it was too lethal to employ as a pesticide, it was passed to the Chemical and Biological Weapons Facility at Porton Down. Because the British were already committed to the production of Tabun and Sarin, they passed the compound on to the United States and Canada. Knowledge of the VX project somehow leaked to the Soviets who developed their own version of VX which they designated as VR-55. It was later discovered that VR-55 was only a thickened version of Soman. In 1960, the United States completed a VX plant at Newport, Indiana (Figure 1.9). VX was filled in shells, rockets, and a newly designed land mine. The nerve agents are the most toxic of the known chemical warfare agents. They are hazards in their liquid and vapor states and can cause death within minutes after exposure. Nerve agents inhibit acetylcholinesterase in tissue, and their effects are caused by the resulting excess of acetylcholine. Nerve agents are liquids under temperate condition. When dispersed, the more volatile ones constitute both a vapor and a liquid hazard. Others are less volatile and represent primarily a liquid hazard. The G-agents are more volatile than VX. GB (Sarin) is the most volatile, but evaporates less readily than water. GF is the least volatile of the G-agents (FAS). VX is persistent, that is, it does not degrade or wash away easily. The consistency of VX is similar to motor oil, so it is primarily a contact hazard. The United States never used nerve agents on the battlefield. However, continued testing and long-term storage created dangers that eventually impacted the entire U.S. chemical weapons
FIGURE 1.9 The U.S. VX nerve agent plant at Newport, IN; U.S. Army.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C001 Final Proof page 15
16.11.2007 12:15pm Compositor Name: VAmoudavally
Brief History and Use of Chemical Warfare Agents in Warfare and Terrorism
15
program. In 1968, VX apparently leaked from an aerial spray tank which was believed to be empty, and drifted across Skull Valley over the borders of Dugway Proving Ground, Utah, and sickened or killed 6000 sheep. In 1969, GB leaked from a Navy bomb, part of a secret chemical weapons stockpile stored on the island of Okinawa, injuring 23 soldiers and one civilian. As a direct result of these accidents, President Richard Nixon issued an executive order in 1969 to halt U.S. production of chemical warfare agents (Newby, 1969; CBW; Mitretek, 2005b; Wikipedia, 2007c). Following World War II, there were incidents of chemical weapon usage around the world. During the Yemen Civil War (1963–1967), Egypt reportedly used tear gas, mustard agent, and possibly nerve agents against the Yemeni Royalists (SIPRI, 1971; Taylor and Taylor, 1985). The Soviets allegedly used chemical weapons during their invasion of Afghanistan (1979–1989). Intelligence reports indicated the Soviets used nerve agents, phosgene oxime (CHCl2NO), and tear gas (Haig, 1982). The most significant use of chemical weapons occurred when Iraq used them against Iran during the Iran–Iraq War (1980–1988). The reports indicated extensive mustard agent and probable nerve agent usage. There was no consideration of international law and little deterrence, although Iran may have retaliated with chemical weapons of their own near the end of the war. Iraq had ratified the 1925 Geneva Protocol against chemical warfare agent use in 1931 (United Nations, 1986; Pringle, 1993; Landersman, 2003). Toward the end of the war, in 1988, Iraq’s military conducted a massive chemical agent attack by aircraft against their own people in Halabja, an unprotected city of 45,000 Iraqi Kurds, knowing they could not retaliate. There were 5000 total casualties with 200 fatalities (Landersman, 2006). Libya reportedly used mustard agent against Chad in 1987 (Pringle, 1993). In all these incidents, there was little outcry or objection from the rest of the world, although the United Nations investigated some of the incidents. There was no deterrence because only one side had chemical weapons in most cases. In addition, the chemical weapons were only marginally effective in their use and did not win the war. Following these incidents, the United States decided to again produce GB nerve agent in 1987 for a retaliatory capability. However, instead of the 1950s version, they produced binary nerve agent (Figure 1.10). The nerve agent GB was broken down into two less-than-lethal precursor chemicals
FIGURE 1.10 The binary nerve agent plant at Pine Bluff Arsenal, AR; U.S. Army.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
16
46616_C001 Final Proof page 16
16.11.2007 12:15pm Compositor Name: VAmoudavally
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
that were stored in separate canisters for loading into artillery shells. The production of binary chemical agents continued until 1990 when the Soviets agreed to end chemical weapons production. Eventually in 1993, many countries joined to sign the Chemical Weapons Convention that banned all chemical weapons development, production, acquisition, stockpiling, transfer, or use and also required the destruction of all existing stockpiles (Field Manual 3–11.9, 2005; Smart, 1997). The Russians apparently continued to research new nerve agents after World War II. According to public disclosures, the Russians developed a highly toxic binary nerve agent series designated Novichuk during the 1980s. In Russian, Novichok means newcomer. Other than tidbits disclosed by defectors and disgruntled scientists, very little else about the Novichuk series is publicly known. For the Russians, the advantage of having new chemical agents is that they have never been previously used on the battlefield. Thus the agents are not banned by treaty, there is no existing detection and warning devices, and the current protective equipment is not effective (Englund, 1992, 1993; Khripunov and Averre, 1999; Wikipedia, 2007c).
VIII. CHEMICAL WARFARE AGENTS USED IN TERRORISM The FBI has defined terrorism as the unlawful use of force or violence against persons or property to intimidate or coerce a government, civilian population, or any segment thereof, to furtherance of political or social objectives (FBI, 2003). The first large-scale chemical terrorism incident occurred in the United States in 1982 (Cooke, 2002). Seven relatively young people in the Chicago, Illinois area collapsed suddenly and died after taking Tylenol capsules that had been laced with 65–100 mg cyanide per capsule. The lethal dose of cyanide is approximately 0.5–1.0 mg=kg or about 70 mg for an adult person (Cai, 1998). These were the first victims to die from product tampering. The police believed that the murderer bought or stole the products from the stores, tampered with them, and returned them to the stores. The police speculated that the terrorist could have had a grudge against the producers of Tylenol, society in general, or even the stores where the tainted products were found, and he or she may have even lived in the area of the stores. The perpetrator was never apprehended even though Johnson and Johnson, maker of the capsules offered a $100,000 reward (Kowalski, 1997). As a result of these events in 1983, congress passed the Federal Anti-Tampering Act. This legislation made it a federal crime to tamper with food, drugs, cosmetics, and other consumer products. In addition, many manufacturers have made their products tamper resistant (Fearful, 2003). Copycat tampering followed in 1986 with Lipton Cup a Soup, Excedrin, and Tylenol again, and Sudafed in 1991 and Goodies Headache Powder in 1992, resulting in deaths. Sporadic tamperings have continued in the Chicago vicinity, Detroit, and Tennessee (Kowalski, 1997). After the first World Trade Center bombing in 1993, sodium cyanide was reported to have been in the bomb, but had burned in the heat of the explosion. It was speculated that had it vaporized, the cyanide would have been dispersed into the North Tower and all in the Tower would have been killed, whereas only six people died in the explosion (Mylroie, 1994; 1995=96; Phillips, 1994). Not all chemical terrorism incidents involved lethal chemicals. For example, a Palestinian homicide bomber sprinkled an anticoagulant rat poison among the nuts and bolts of his bomb that he exploded in a bus in Jerusalem, Israel. Among the survivors, a 14 year old girl was bleeding uncontrollably from every one of her puncture wounds. Use of a coagulant drug eventually stopped the young victim’s bleeding (Hammer, 2002). Perhaps the most publicized incident involving chemical terrorism occurred in Japan in 1995. The Aum Shinrikyo, a Japanese religious doomsday sect used Sarin against civilians in Japan on June 27, 1994. The sect targeted a dormitory in Matsumoto where three judges who ruled against them in a land deal trial lived. The sect attempted to spread Sarin in the open, however, the chemical reaction did not work right and the wind changed direction. The judges survived, but became ill. Seven victims in the neighborhood died that evening and over 144 civilians were injured. Aum Shinrikyo’s next attempt was to spread Sarin in a closed area. They chose the subway system in
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C001 Final Proof page 17
16.11.2007 12:15pm Compositor Name: VAmoudavally
Brief History and Use of Chemical Warfare Agents in Warfare and Terrorism
17
Tokyo, Japan on March 20, 1995, where five trains would meet at 8:15 AM. Members of the sect on the trains pierced plastic bags containing 30% Sarin with sharp tipped umbrellas and let the Sarin evaporate into a lethal gas cloud. Twelve passengers on the train died and about 5500 sought medical treatment (Biema, 1995; Ohbu and Yamashina, 1997).
IX. CONCLUSIONS Chemicals have been used in warfare since almost the beginning of recorded history. It started out crudely using malodorous materials, irritants, poisonous plants and animals, as well as decaying bodies. Since the birth of chemistry, toxic chemicals have been created specifically for war. Less than lethal and lethal chemicals were developed that incapacitated or killed the enemy without disfiguring or mutilating the body, and without affecting or destroying the infrastructure. These appeared to be distinct advantages offered by the use of these chemicals. In asymmetric warfare and terrorism, it is sometimes difficult to recognize or identify the enemy. Because terrorists may avail themselves of toxic industrial chemicals and materials that are transported and already stockpiled, a working knowledge of the chemistry of chemical warfare agents is no longer a necessity. It is important to recognize that the advances in biotechnology, nanotechnology, genetic engineering, neurobiology, computer sciences among others, may assist not only in the proliferation of traditional chemical warfare agents, but also stimulate the emergence of nontraditional agents as well. Advances have also occurred in the delivery systems of these agents. Although the use of chemical warfare agents in terrorist activities appears to have been limited, this may not accurately reflect the potential of their future use.
REFERENCES Anonymous, 1921. Lewisite. Chemical Warfare 7(10): 12–13. Anonymous, 1923. Use of chemical agents at Alhucemas. Chemical Warfare 9(9): 19. Baskin, S.I. and Brewer, T.G. (1997). Cyanide Poisoning. In: Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare. Washington, DC, Office of The Surgeon General, Chapter 10, pp. 271–286. Batten, J.K. (1960). Chemical warfare history. Armed Forces Chemical Journal 14(2): 17. Beebe, C.H. (1923). Some additional instances of the early use of gas warfare. Chemical Warfare 9(9): 3. Biema, D.V. (1995). Prophet of poison. Time. April 3, 1995. pp. 27–33. Blackford, W.W. (1945). War Years with Jeb Stuart. New York, Charles Scribner’s Sons. p. 263. Boynton, E.C. (1864). Greek fire and other inflammables. United States Service Magazine 1(1): 54. Brophy, L.P., Miles, W.D., and Cochrane, R.C. (1959). The Chemical Warfare Service: From Laboratory to Field. Office of the Chief of Military History, Washington, DC. 69–70. Browne, C.A. (1922). Early references pertaining to chemical warfare. The Journal of Industrial and Engineering Chemistry 14(7): 646. Cai, Z. (1998). Cyanide. In: Encyclopedia of Toxicology. P. Wexler, Ed. Vol. I, 387–389. Academic Press, San Diego. Camerman, N. and Trotter, J. (1963). Stereochemistry of arsenic: VIII. Canadian Journal of Chemistry 41: 460–464. Available from URL: http:==pubs.nrc-cnrc.gc.ca=cgi-bin=rp=rp2_abst_e?cjc_v63-063_41_ns_nf_cjc2-63] (accessed January 2007). CBW Info. (2005). Ancient times to the 19th century. Available at URL: http:==www.cbwinfo. com=History=ancto19th.shtml (accessed January 2007). Charles, D. (2005). Master Mind. Harper Collins Publishers. pp. 152, 154–157. Chemical Warfare Service. (1939). The Story of Chemical Warfare. Office of the Chief of the Chemical Warfare Service, Washington, DC. p. 1. Clark, D.K. (1959). Effectiveness of Toxic Chemicals in the Italo-Ethiopian War. The Johns Hopkins University, Bethesda, MD. 11.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
18
46616_C001 Final Proof page 18
16.11.2007 12:15pm Compositor Name: VAmoudavally
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
CNS. (2001). Chronology of State use and biological and chemical weapons control. Available from URL: http:==www.cns.miis.edu=research=cbw=pastuse.htm (accessed January 2007). Cooke, R.J. (2002). PSU alumnus recalls 1982 Tylenol murders. The Digital Collegian, October 18. Available from URL: http:==www.collegian.psu.edu=archives=2002=10=10-18-02news-06.asp (accessed January 2007). Dogaroiu, C. (2003). Chemical warfare agents. Rom. J. Leg. Med. 11(2): 132–140. DeNoon, D. (2004). Biological and chemical terror history. Available at URL: http:==www.webmd. com=content=article=61=67268.htm?printing¼true (accessed January 2007). Englund, W. Ex-Soviet scientist says Gorbachev’s regime created new nerve gas in ’91. The Baltimore Sun. September 16, 1992. Englund, W. 2 Russian papers investigated after new disclosures on chemical arms. The Baltimore Sun. June 11, 1993. FAS. Available from URL: http:==www.fas.org=nuke=guide=usa=doctrine=army=mmcch=NervAgnt.htm (accessed January 2007). FBI (2003). FBI Denver Division: FBI Policy and Guidelines. Definitions available from URL: http:==denver. fbi.gov=interr.htm (accessed January 2007). Fearful. (2003). Was the person behind the Tylenol poisonings in the 1980s ever caught? Available from URL: http:==ask.yahoo.com=ask=20030=30.html (accessed January 2007). Field Manual 3–11.9. (2005). Potential Military Chemical=Biological Agents and Compounds. I-2, II-9, 15, 18, 21, 31–33, 37–38, 50, III-13. Foulkes, C.H. (1934). Gas! The Story of the Special Brigade. William Blackwood and Sons, Ltd., London. p. 108. Geiling, J.A. (2003). Chemical Terrorism. Available at URL: http:==www.chestnet.org=education=online=pccu= vol16=lessons17_18=lesson18=print.php (accessed January 2007). Haber, L.F. (1986). The Poisonous Cloud. Clarendon Press, Oxford. Haig, A.M. (1982). Chemical Warfare in Southeast Asia and Afghanistan. Report to the Congress from Secretary of State Alexander M. Haig, Jr., March 22, 1982. Hammer, J. (2002). Code blue in Jerusalem. Newsweek. July 1, pp. 24–29. Harris, R. and Paxman, J. (1982). A Higher Form of Killing: The Secret Story of Chemical and Biological Warfare. New York: Hill and Wang, New York. pp. 24, 117–123, 141. Haydon, F. (1938). A proposed gas shell, 1862. Military Affairs 2(1): 52–54. Hemsley, J. (1987). The Soviet Biochemical Threat to NATO. St. Martin’s Press, New York. pp. 14, 66–67. Hersh, S.M. (1968). Chemical and Biological Warfare: America’s Hidden Arsenal. The Bobbs-Merrill Co., Indianapolis, New York. p. 4. Hickman, D.C. (1999). Seeking Asymmetric Advantage: Is Drinking Water an Air Force Achilles’ Heel? Air Command and Staff College, Air University, Maxwell Air Force Base, Alabama. Research Report AU=ACSC=084=1999–04. Khripunov, I. and Averre, D. (1999). Russia’s CBW closet poses ongoing threat. Jane’s Intelligence Review. May 1999. Kowalski, W. (1997). The Tylenol murders. Available from URL: http:==www.personal.psu.edu= users=w=x=wxk116=tylenol (accessed January 2007). Landersman, S.D. (2003). Chemical and biological warfare: facts and trends. Available from URL: http:==usni. org=Proceedings=Articles03=prolandersmaniraq.htm (accessed January 2007). MacCurdy, E. (1938). The Notebooks of Leonardo da Vinci, Vol. II pp. 206, Jonathan Cape, Bedford Square, London. Mauroni, A. (2003). Chemical and Biological Warfare. ABC CLIO Publishers. p. 80. Mayor, A. (2003). Greek Fire, Poison Arrows, and Scorpion Bombs: Biological and Chemical Warfare in the Ancient World. Overlook Duckworth Publishers. McWilliams, J.L. and Steel, R.J. (1985). Gas! The Battle for Ypres, 1915. Vanwell Publishing Limited, St. Catharines, Ontario. pp. 24–28, 41, 45–57, 220–221. Miles, W.D. (1957a). Admiral Cochrane’s plans for chemical warfare. Armed Forces Chemical Journal 11(6): 22. Miles, W.D. (1957b). The chemical shells of Lyon Playfair. Armed Forces Chemical Journal 11(6): 23. Miles, W.D. (1958a). The velvet-lined gas mask of John Stenhouse. Armed Forces Chemical Journal 12(3): 25. Miles, W.D. (1958b). Chemical warfare in the civil war. Armed Forces Chemical Journal 12(2): 26–27, 33. Miles, W.D. (1959). Suffocating smoke at Petersburg. Armed Forced Chemical Journal 13(4): 35.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C001 Final Proof page 19
16.11.2007 12:15pm Compositor Name: VAmoudavally
Brief History and Use of Chemical Warfare Agents in Warfare and Terrorism
19
Mitretek. (2005a). Chemistry of H (Mustard). Available from URL: http:==www.mitretek.org= ChemistryOfHMustard.htm (accessed January 2007). Mitretek. (2005b). Chemistry of VX. Available from URL: http:==www.mitretek.org=ChemistryOfVX.htm (accessed January 2007). MSN. (2005). Available from URL: http:==cc.msnscache.aspx?q ¼ 4952822919754andlang ¼ en-USandFORM¼ CVRE4 (accessed January 2007). MTS. (2005a). Available from URL: http:==www.mitretek.org=AShortHistoryOfTheDevelopmentOfNerveGases. htm (accessed January 2007). MTS. (2005b). Available from URL: http:==mitrtek.org=ChemistryOfGATabun.htm (accessed January 2007). Mylroie, L. (1994). WTC bombing—the case of ‘‘secret cyanide.’’ Wall Street Journal July 26, pp. A16. Mylroie, L. (1995=96). The World Trade Center Bomb: Who Is Ramzi Yousef? And Why It Matters. The National Interest. Winter. Available from URL: http:==www.fas.org=irp=wporld=iraq=956-tni.htm (accessed January 2007). Newby, T.B. (1969). Trip Report. Edgewood Arsenal. Noji, E.K. (2001). Bioterrorism: a ‘new’ global environmental health threat. Global Change and Human Health 2(1): 46–53. Ohbu, S. and Yamashina, A. (1997). Sarin poisoning on Tokyo subway. Southern Medical Journal 90: 587–593. PDR Health. (2006). Aconite. Available from URL: http:==www.pdrhealth.com=drug_info=nmdrugprofiles= herbaldrugs=100005.shtml (accessed January 2007). Phillips, J.A. (1994). The changing face of Middle Eastern terrorism. Available from URL: http:==www. Heritage.org=research=middleeast=bg1005.cfm (accessed January 2007). Prentiss, A.M. (1937). Chemicals in War. McGraw-Hill Book Company, Inc., New York. p. 180. Pringle, L. (1993). Chemical and Biological Warfare. Enslow Publishers, Inc., Hillside, NJ. p. 55, 57. Richter, J.P. (1970). The Notebooks of Leonardo da Vinci. Vol. 11, 280–281. Dover Publications, Inc. NY. Robey, J. (2003). Bioterror through time. Discovery Channel Series, February 21, 2003. Available at http:==dsc. discovery.com=anthology=spotlight=bioterror=history=history.html, p. 3 (accessed January 2007). Rozman, K.K. and Doull, J. (2001). Paracelsus, Haber and Arndt. Toxicology. 160: 191–196. Salem, H., Ballantyne, B., and Katz, S.A. (2006). Inhalation toxicology of riot control agents. In: Inhalation Toxicolocy, 2nd Edition. H. Salem and S.A. Katz, Eds. pp. 485–520. Taylor and Francis. Sartori, M. (1939). The War Gases: Chemistry and Analysis. D. Van Nostrand Co. Inc. NY. pp. 3, 33, 59, 165, 181, 188, 217. SIPRI. (1971). The Rise of CB Weapons. Humanities Press, New York, 1971, pp. 70–75, 142, 147, 280–282, 336–341. Smart, J.K. (1997). History of chemical and biological warfare: an American perspective. In: Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare. F.R. Sidell, E.T. Takafugi, and D.R. Franz, Eds. Office of the Surgeon General, Department of the Army, Washington, DC, Chapter 2, pp. 9–86. Available from URL: http:==www.usuhs.mil=cbw=history.htm (accessed January 2007). Smart, J.K. (2004). History notes: chemical and biological warfare research and development during the Civil War. CBIAC Newsletter 5(2): 3, 11–15. Tagate. (2006). Available at URL: http:==www.tagate.com=wars=history_of_warfare=chemical_warfare_4.shtml (accessed January 2007). Taylor, L.B. and Taylor, C.L. (1985). Chemical and Biological Warfare. Franklin Watts, New York. 26–27, 41. Thompson, R.M. and Wainwright, R. (1918). Confidential Correspondence of Gustavus Vasa Fox, Assistant Secretary of the Navy, 1861–1865. New York, De Vinne Press. 1: 263. Thucydides. (1989). The Peloponnesian War. D. Grene, Ed. The University of Chicago Press, Chicago. pp. 134, 286–287. Tintinalli, J.E. (2003). Tintinalli’s Emergency Medicine: A Comprehensive Study Guide, 6th Edition. McGraw-Hill. Available from URL: http:==www.accessmedicine.com=content.aspx?aID¼585607 (accessed January 2007). Tschanz, D.W. (2003). ‘‘Eye of newt and toe of frog’’: biotoxins in warfare. StrategyPage.com, October 20, 2003. Available from URL: http:==216.239.37.104=search?q¼cache:Tv-SBKjTGFIJ:www.strategypage. com=articles=biotoxin_files=BI, p. 3 (accessed January 2007). United Kingdom Ministry of Defense. (1999). Defending against the threat of biological and chemical weapons. Outline history of biological and chemical weapons. Available from URL: http:==www.mod. uk=issues.cbw=history.htm, p. 5 (accessed January 2007).
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
20
46616_C001 Final Proof page 20
16.11.2007 12:15pm Compositor Name: VAmoudavally
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
United Nations. (1986). Report of the Mission Dispatched by the Secretary-General to Investigate Allegations of the Use of Chemical Weapons in the Conflict Between the Islamic Republic of Iran and Iraq. United Nations Security Council S=17911. U.S. War Department. (1891). War of the Rebellion: A Compilation of the Official Records of the Union and Confederate Armies. Series 1, Volume 36, Part 3, 888. Government Printing Office. Vilensky, J.A. and Sinish, P.R. (2005). MHQ, Spring, 2005. Available from URL: http:==www.historynet. com=wars_conflicts=weaponry=3035881.html (accessed January 2007). Waitt, A.H. (1942). Gas Warfare. Duell, Sloan and Pearce, New York. pp. 7–8, 135. Wikipedia. (2007a). Available at URL: http:==www.en.wikipedia.org=wiki=Chemical_warfare. Wikipedia. (2007b). Greek fire. Available from URL: http:==www.wikipedia.org=wiki=Greek_fire (accessed January 2007). Wikipedia. (2007c). Nerve agent. Available from URL: http:==en.wikipedia.org=wiki=Nerve_agent (accessed January 2007). Wiley, B.I. (1968). Drop poison gas from a balloon. Civil War Times Illustrated 7(4): 40–41. Williams, S.R., Clark, R., and Dunford, J. (1995). Hunan hand syndrome. Annals of Emergency Medicine 25: 5. Wilson, E. (2006). Three takes on Haber. Chemical and Engineering News 84(6): Feb. 6, pp. 29–30. Witschi, H. (2000). Fritz Haber: 1868–1934. Toxicological Sciences 55: 1–2. Available from URL: http:== toxsci.oxfordjournals.org=cgi=content=full=55=1=1 Women in Military Service for America Memorial Foundation, Inc. Available from URL: http:==www. womensmemorial.org=HandC=Collections=photoexample.html (accessed January 2007).
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C002 Final Proof page 21
7.11.2007 5:16pm Compositor Name: BMani
of Chemical 2 Chemistry Warfare Agents Petr Kikilo, Vitaly Fedorenko, and Andrew L. Ternay Jr. CONTENTS I. Introduction ............................................................................................................................ 21 II. Specific Agents ...................................................................................................................... 22 A. Chlorine—Cl2 ................................................................................................................. 22 B. Sulfur Mustard—C4H8Cl2S............................................................................................ 24 C. Cyanogen Chloride—ClCN............................................................................................ 27 D. Hydrogen Cyanide—HCN ............................................................................................. 29 E. Chloropicrin—CCl3NO2 ................................................................................................ 32 F. Phosgene—COCl2 .......................................................................................................... 33 III. Nerve Agents—General Remarks.......................................................................................... 36 A. Nerve Agents—VX (C11H26NO2Ps).............................................................................. 36 B. Nerve Agents—GA (Tabun) (C5H11N2O2P) ................................................................. 37 C. Nerve Agents—GB (Sarin) (C4H10FO2P)...................................................................... 38 D. Nerve Agents—GD (Soman) (C7H16FO2P)................................................................... 39 E. BZ (C21H23NO3) ............................................................................................................ 40 F. CS (C10H5ClN2) ............................................................................................................. 41 References ....................................................................................................................................... 42
I. INTRODUCTION The purpose of this chapter is to provide an overview of the chemistry of selected substances that have been thought of as chemical warfare agents (CWAs) at one time or another. Although ‘‘toxins’’ are chemicals, they have not been included since, in some circles, they are thought of as biological threats even though they are perhaps better considered as toxic chemicals arising from various organisms. In general, this chapter is written from the perspective of an organic chemist. Given size and other restrictions, it was possible to mention only a fraction of the work that we might otherwise have included. The chemicals described in this chapter are identified using what appear to be their most common names. Alternative names and abbreviations are presented in each specific discussion, along with CAS numbers and molecular formulas. In this chapter, we focus on reactions that are representative or of special value. Each section includes, as appropriate, some general remarks, followed by discussions of physical properties and chemical reactions. With a few exceptions, discussions of analytical chemistry are not included. The core chemistry related to the decontamination of threat agents has been summarized elsewhere (Yang et al., 1992). Issues of biological reactions and syntheses are intentionally excluded.
21
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C002 Final Proof page 22
22
7.11.2007 5:16pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
II. SPECIFIC AGENTS A. CHLORINE—Cl2 General Remarks: Chlorine (molecular chlorine; dichlorine; CAS# 7782-50-5) is among the top 10 chemicals produced in the United States, and was the first chemical used as a weapon (Red Star) on a large scale during World War I (WWI). Mixed with 20% sulfur chloride (SCl2 or S2Cl2), it was used for a relatively short period under the name ‘‘Blue Star.’’ ‘‘White Star’’ was a mixture of chlorine (50%) and phosgene (50%) (Richter, 1992). Because it is very reactive, chlorine does not occur in nature as Cl2. It normally is produced from compounds that are relatively rich in chlorine, for example, sodium chloride. Manufactured in large quantities for commercial applications, chlorine now is considered to be a toxic industrial chemical (TIC). Physical Properties: Chlorine (atomic chlorine, Cl) has an atomic number of 17, an electronegativity of 3.2 (Pauling scale), and an atomic mass of 35.46. It is the third most electronegative element, behind fluorine and oxygen. Throughout this chapter, the term ‘‘chlorine’’ refers to Cl2, unless otherwise noted. Chlorine is a highly reactive nonmetal (halogen). It is a greenish-yellow gas with a density of 3.2 g=L at Standard Temperature and Pressure (STP). Solid chlorine melts at 1018C, and the gas liquefies at room temperature at 7.9 atm or at 348C at 1 atm. Chlorine has a water solubility of 0.64 g of Cl2=100 g of water at room temperature and a pungent odor. Synthesis and Reactivity: Chlorine was first prepared by the Swedish chemist K.W. Scheele in 1774 using the reaction of manganese dioxide with hydrochloric acid. Erroneously, he thought that it was a compound of oxygen, and ultimately it was named and identified as an element by Sir Humphry Davy in 1810. The reaction of hydrochloric acid with potassium permanganate provides a second convenient route to small quantities of chlorine. Commercial syntheses employ several techniques including those listed below. The first two of these are collectively called the chlor-alkali process and are responsible for the consumption of approximately 50% of the sodium chloride produced in the United States. 1. Electrolysis of brine (two types of cells used) to form chlorine at the anode 2. Electrolysis of fused NaCl 3. Electrolysis of hydrochloric acid When chlorine dissolves in water, it forms ‘‘chlorine water.’’ Only a portion of the chlorine remains intact in this solution, and the remainder converts to hypochlorous acid (aqueous HOCl) and hydrochloric acid (aqueous HCl). It is this formation of acid that enhances the corrosiveness of ‘‘moist’’ chlorine gas. By way of contrast, fluorine reacts with water to form HF and O2. Most organic functional groups, including those in biomolecules, react with chlorine. Some reactions yield products containing only one chlorine, whereas others yield products with two. Some slow reactions may be accelerated by altering conditions (e.g., solvent, temperature, catalyst). Chlorine reacts by either radical or ionic processes, depending on both substrate and reaction conditions. Radical reactions require some initiator, for example, heat, light, or radicals, and may involve the conversion of molecular to atomic chlorine. Reactions with alkanes most often are radical processes (Ternay, 1979). In a nonreactive solvent, alkenes can readily add chlorine to form vic-dichlorides by either radical or ionic mechanisms. Anti-addition is frequently observed, especially in ionic additions. For example, cyclohexene affords trans-1,2-dichlorocyclohexane. At high temperatures, chlorine can replace an allylic hydrogen by a radical process. The double bond is preserved in these allylic chlorinations. For example, propene yields allyl chloride and hydrogen chloride (Carey, 2000a). Alkenes, R2C ¼ CR2, can react with chlorine and water to form halohydrins, R2C(OH)C(Cl)R2. With alcohol (R0 OH) solvents, the product is a haloether, R2C(OR0 )C(Cl)R2. In the presence of a carboxylic acid (R0 CO2H), the products include the corresponding halohydrin esters, R2C(O2CR0 ) CClR2 (Wagner and Zook, 1965b).
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C002 Final Proof page 23
7.11.2007 5:16pm Compositor Name: BMani
23
Chemistry of Chemical Warfare Agents
In general, aromatic hydrocarbons are less nucleophilic than are simple alkenes. Chlorination of less nucleophilic aromatics, for example, C6H6, requires the use of a Lewis acid catalyst (e.g., anhydrous aluminum chloride) and either excess of the liquid aromatic or an inert solvent. The product, C6H5Cl, results from a net substitution process. Chlorination (ortho or para) of activated aromatics such as anisole, C6H5OCH3, may not require a catalyst. Alcohols (18 and 28) are oxidized to carbonyl-containing substances, the creation of a ketone from a secondary alcohol being typical. The oxidation, accelerated in alkaline solutions, involves a hypochlorite intermediate. H OH
R
H
Cl2
R
R
−HCl
O R
Cl
R O R
In the presence of base and excess chlorine, both a-chlorination and oxidation may occur. For example, a cyclohexanol-water-calcium carbonate mixture reacts to form 2-chlorocyclohexanone (Wagner and Zook, 1965a). Chlorine also reacts with the sulfur in sulfides to form reactive sulfonium salts. Cl
Cl
Cl ⊕ S
S
Cl
A reactive sulfonium salt
The reaction of chlorine with aqueous ammonia and ammonium salts is noteworthy since it leads to various chloramines, including the unstable (explosive) nitrogen trichloride, NCl3 (Chloramines, 1999). Both Faraday and Dulong were injured working with this substance (Cardillo, 2001). The reaction of chlorine with phosphorus represents a commercial route to PCl3 and PCl5. In turn, this becomes an important process in the synthesis of nerve agent precursors (Greenwood and Earnshaw, 1986). Chlorine reacts with many metals, often violently if the metal is finely divided, to form binary compounds such as iron (III) chloride, magnesium chloride, and so forth. Traces of water may accelerate the reaction. The product of the reaction of chlorine with calcium hydroxide is ‘‘bleaching powder.’’ Although sometimes shown as a mixed salt, CaCl(OCl), bleaching powder also has been represented as a mixture of Ca(OCl)2, CaCl2, and Ca(OH)2. Chlorine is more potent an oxidant than is bromine but less so than fluorine (Clifford, 1961a). Thus, chlorine is able to oxidize both bromide and iodide ions to Br2 and I2, respectively, whereas fluorine oxidizes chloride, bromide, and iodide to their corresponding halogens. The oxidizing ability of chlorine is the basis for the starch-iodide test for chlorine. Here, a mixture of potassium iodide, soluble starch, and zinc chloride produces a blue-violet color in the presence of chlorine. Unfortunately, and like many ‘‘spot tests,’’ this is a nonspecific test and gives a positive result with many oxidants, for example, bromine. Trichloroisocyanuric acid (TCCA) (Tilstam and Weinmann, 2002), itself an interesting oxidant, can be prepared in approximately 75% yield by passing a stream of chlorine into an alkaline solution of cyanuric acid (Monson, 1971). O
O HN O
NH N H
O
Cyanuric acid
Cl2 NaOH
NCl
ClN O
N Cl TCCA
O
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C002 Final Proof page 24
24
7.11.2007 5:16pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
In contrast to this imide-based synthesis, amides of the type RC(O)NH2 are decarbonylated to primary amines (RNH2) with chlorine in the presence of base. This process, often called the Hofmann reaction, involves an intermediate isocyanate (R–N ¼ C ¼ O) (Fieser and Fieser, 1961; Sandler and Karo, 1983). Aromatic oximes, lacking an a-hydrogen, react with chlorine to form intermediates that are converted to nitrile N-oxides with base. (Nitrile N-oxides are highly reactive species.)
RHC
N(OH)
OH−
Cl2
RC
O
N
0⬚C
B. SULFUR MUSTARD—C4H8Cl2S General Remarks: Sulfur mustard (2,20 -dichloroethyl sulfide; bis-(2-chloroethyl) sulfide; CAS# 505-60-2) was introduced during WWI as a blister agent (vesicant). Although often called ‘‘HD’’ (distilled sulfur mustard) today, it also has been known as ‘‘Lost,’’ ‘‘S-Lost,’’ ‘‘Yellow Cross,’’ ‘‘H’’ (a cruder form of sulfur mustard), ‘‘HS,’’ and ‘‘Yperite.’’ It is one member of a class of compounds known as mustards that generally bear a heteroatom (Z) separated from a leaving group (L) by two atoms, that is, contain the Z-(CH2)2-L fragment. Sulfur mustard has the structural formula ClCH2CH2SCH2CH2Cl. Nitrogen mustards, where Z ¼ N, have been considered as anticancer drugs and CWAs but are not now considered as likely chemical warfare or terrorist threats. They are not discussed in this chapter. Physical Properties: Sulfur mustard (mustard gas) is a colorless oil with bp of 2278C, mp of 148C, molecular dipole moment 1.78 D (hexane), and molecular mass of 159. It normally is encountered as an impure, pale yellow–brown, odoriferous liquid. The color generally deepens with increasing amounts of impurity. HD has a vapor density of 5.4 relative to air and a vapor pressure of 0.072 mm Hg at 208C. As a liquid, it is slightly denser than water (1.27 g=mL at 208C). It is miscible in typical organic solvents (e.g., carbon tetrachloride, acetone or chloroform) but has a lower solubility in water (0.092 g=100 g at 228C) (Sidell et al., 1998; Somani, 1992). Chemistry: There are several routes to sulfur mustard. The first production of sulfur mustard in reasonable yield is often credited to Meyer (1886). A second route (Levinstein process) produces elemental sulfur as a contaminant in the mustard. The Steinkopf synthesis of sulfur mustard involves S(CH2CH2OH)2. (Steinkopf et al., 1920). The reactions of sulfur mustard are dominated by its heteroatoms. First, divalent sulfur is a good nucleophile and encourages SN reactions (Whitman, 1995a). Sulfur’s location b to a good leaving group (chlorine) leads to neighboring group participation (Eliel and Wilen, 1994) and, hence, to episulfonium ion formation. This internal nucleophilic displacement is favored by entropic factors. The resulting episulfonium ion possesses substantial small-ring strain and is equally prone to ring opening at either ring carbon. Using water as an external nucleophile, repetition eventually affords a diol mustard analog, thiodiglycol. The intermediate hemi-mustard possesses vesicant properties.
S Cl
Cl An episulfonium ion
Cl H
S
O H
Cl
⊕ S
−Cl
⊕
H ⊕ O H
S Cl
Protonated hemi-mustard
Repeat HOH
S HO HO Thiodiglycol
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C002 Final Proof page 25
7.11.2007 5:16pm Compositor Name: BMani
25
Chemistry of Chemical Warfare Agents
Structural variations that hinder episulfonium ion formation or sulfur nucleophilicity reduce activity. Thus, S(C(O)CH2Cl)2 is reported to show little vesicant behavior (Sartori, 1939). Mustard is denser than water, not very water soluble, and hydrolyzes rather slowly in cold water. Thus, it can remain a threat for sometime in bodies of water even though it ultimately hydrolyzes to the relatively safe thiodiglycol. Depending on specific conditions, the hydrolysis also can produce 1,4-thioxane (O(CH2CH2)2S), 2-(vinylthio)ethanol (CH2 ¼CHSCH2CH2OH), and a variety of other compounds, some in quite minor amounts (D’Agostino and Provost, 1985). For example, mustard can react with thiodiglycol to form, depending on concentrations, mono- or disulfonium ions. One example in which the product is hazardous follows (Yang et al., 1992; Munro et al., 1999). HO S
S
HO
Cl
Thiodiglycol
OH OH
⊕ S
S
Cl
Cl Sulfur mustard-thiodiglycol adduct
Cl
If the external nucleophile is attached to a chain, then two consecutive attacks on HD lead to cross-linking of two chains. Nu
Nu
S(CH2CH2Cl)2
NuCH2CH2SCH2CH2Nu
Cross-linked chains
Nu = nucleophilic center
Molecules with more extensive separation between sulfur and leaving groups, such as chlorine (e.g., Cl(CH2)6S(CH2)6Cl), behave like simple aliphatic halides (or sulfides) since three-membered ring (episulfonium ion) formation is no longer possible. One convenient method for verifying the formation of an episulfonium ion intermediate involves isotopic carbon labeling. Since this ion is symmetric, it would ultimately lead to a nearly 1:1 distribution of an appropriately placed label, something not observed in a direct displacement. S
S Cl Label
R
R
Nu
Direct displacement
100% Nu
Episulfonium ion
Nu
S 50%
R +
S
R
Nu 50%
Sulfides, including HD, undergo oxidation at sulfur. Initial oxidation produces a sulfoxide, whereas further oxidation produces a sulfone (below). Oxidants include hydrogen peroxide, peroxyacids, nitric acid, permanganate ion, ozone, dinitrogen tetroxide, and dichromate ion. Oxides of mustard are not as volatile as mustard. This may help to explain why British air raid shelters were sometimes ‘‘painted’’ using the oxidant calcium hypochlorite (Ca(OCl)2). ‘‘Episulfonium’’ ion formation is less likely in the sulfoxide of HD than in HD itself.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C002 Final Proof page 26
26
7.11.2007 5:16pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics O
O S
S
[O]
Cl
Cl
Cl
Cl
Cl
Sulfide
S
[O]
O
Cl Sulfone
Sulfoxide
Titanium dioxide and iron oxide particles (anatase TiO2 and ferrihydrite) have been explored as ‘‘detoxification’’ materials for threat agents including HD and nerve agents (soman and VX). (Kleinhammes et al., 2005; Ohtani et al., 1987). TiO2 was found to be the more rapidly acting against HD and was able to convert HD into nontoxic materials with 99% effectiveness. Kinetic data for reactions involving both oxides and three threat agents at 258C are provided. Analyses focused on the disappearance of threat agents, and identification of products was not provided. The authors claim that these oxides are more reactive than AP-MgO (Stengl et al., 2005; Kopeer et al., 1999). Chloramine B oxidizes HD to its sulfoxide via an intermediate containing an S–N bond (Whitman, 1995b). O
⊕ Na
O
S N Cl
HOH
O
Ar S N O
H Cl
⊕
+ Na OH
A
Ar Cl A +S
−HOH Cl −NaCl
O Ar
S
Cl
Cl ⊕ N S
HOH Cl
⊕ O S
Cl
O
Strong bases (e.g., alkoxide) can dehydrochlorinate mustard and its sulfoxide and sulfone, converting one or both of their 2-chloroethyl fragments to vinyl groups. O S O
Cl Cl Sulfone
O xs base
S O
− 2HCl Divinylsulfone
Didehydrohalogenation of HD is reported to be complete within 1 min at room temperature using CH3OCH2CH2O as the base (Beaudry et al., 1992). This is a ‘‘component’’ of the decontaminating solution known as DS2 (a mixture of diethylene triamine, ethylene glycol monomethyl ether, and sodium hydroxide). Nanosize particles of calcium oxide have been shown to dehydrohalogenate HD (Wagner et al., 2000b). Although anhydrous mustard is not a substantial corrosion threat to most metals, hydrolysis forms hydrochloric acid and does contribute to mustard’s corrosive behavior. An interesting pmr and gas chromatograph–mass spectrometry (GC–MS) study of the hydrolysis of HD has been reported (Logan and Sartori, 2003). In this work, it was shown that hydrolysis (D2O at 228C) had a half-life of approximately 7 min, but that in the presence of sodium chloride, the half-life increased to approximately 24 min. These results are consistent with those reported by Bartlett and Swain (1949). Sulfur mustard has been shown to react with nucleic acid components and the N7-guanine adduct studied by several techniques (Rao et al., 2002).
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C002 Final Proof page 27
7.11.2007 5:16pm Compositor Name: BMani
27
Chemistry of Chemical Warfare Agents
C. CYANOGEN CHLORIDE—ClCN General Remarks: This substance CAS# 506-60-2 has several additional names, including (1) chlorine cyanide, (2) chlorocyanogen, (3) chlorcyan, and (4) CK (previously CC). It has been described as a ‘‘blood agent,’’ a term used to identify chemical threats first thought to act in the blood. They also have been thought of as ‘‘systemic agents’’ or ‘‘systemic poisons.’’ Generally, these contain the –CN fragment, form ‘‘cyanide’’ in the body, and include both hydrogen cyanide and cyanogen chloride. Although ‘‘cyanogen’’ is a distinct molecule (below), that term sometimes is used to describe any substance that forms cyanide in the body. By this extended definition, cyanogen chloride is a cyanogen. Cl Cl
N C Cl
N C C N
Molecular chlorine
Cyanogen chloride
Cyanogen
The correct formula for CK was first established by Gay-Lussac in 1815. Cyanogen chloride can be viewed either as the monocyanide of molecular chlorine or as the chloride of cyanogen. (Note: Like CK, cyanogen is poisonous.) Physical Properties: CK has a low bp (138C), a mp of 68C, and a molecular mass of 61.5. Under standard conditions (STP), CK has a vapor density of about 2.1, whereas that of HCN is 0.93. Its density at 08C is 1.2. A colorless gas at room temperature, cyanogen chloride is often handled as a cylinder of liquefied gas. The volatility of cyanogen chloride renders it a ‘‘nonpersistent’’ threat agent. Cyanogen chloride shows solubility in water (69 g=L) and in most organic solvents (e.g., ethanol, chloroform, or benzene). Chemistry: Cyanogen chloride’s first reported preparation was by French chemist Claude Louis Berthollet (1789). Jennings and Scott observed that various conditions can influence the stability of impure ClCN (Jennings and Scott, 1919). A larger-scale synthesis of CK appeared shortly after the end of WWI (Price and Green, 1920). A typical synthesis involves the reaction of chlorine with an aqueous solution of sodium cyanide. A related anhydrous procedure yields the desired product with a density of 1.2 at 08C. After purification, it can be stored (refrigerated) for months (Coleman et al., 1946). Cl2 þ NaCN ! ClCN þ NaCl: Commercially, ClCN has been produced, in the main, by the chlorination of aqueous HCN. An unintended synthesis of ClCN may occur during the treatment of cyanide-containing waste water with chlorine or hypochlorite. Aspects of this issue have been considered by Bailey and Bishop (1973a). Trimethylsilylcyanide has been used to produce cyanogen chloride (Nachbaur et al., 1978). The reaction of active nitrogen and chloromethanes (e.g., carbon tetrachloride) has been reported to involve formation of cyanogen chloride (Sobering and Winkler, 1958). Some of the reactions of cyanogen chloride are rationalized by the ‘‘addition–elimination’’ process shown below (‘‘Nu’’ represents a nucleophile). For example, diethyl malonate, CH2(CO2C2H5)2, reacts with cyanogen chloride in the presence of sodium ethoxide to produce diethyl cyanomalonate, CH(CN)(CO2C2H5)2. This helps to explain why nucleophilic solvents, such as ethanol or water, eventually lead to the decomposition of CK.
Cl Nu
C
N
Cl
C Nu
N
−Cl
Nu
C
N
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C002 Final Proof page 28
28
7.11.2007 5:16pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
During storage, CK tends to form the cyclic trimer cyanuric chloride (cyanuryl chloride (ClCN)3). Cl 3 Cl
C
N
N Cl
N N
Cl
Cyanuric chloride
Cyanuric chloride, being less toxic than CK, is of reduced value as a CWA. To minimize this, the French produced an agent for use in WWI that they called Vitrite (also identified as Vivrite), a mixture containing 70% cyanogen chloride and 30% arsenic trichloride. CK also can be stabilized using sodium pyrophosphate (Na4P2O7) (Kleber and Birdsell, 1959). Cyanogen chloride reacts with sodium sulfide, Na2S, to form sodium thiocyanate, NaSCN. An extension of this involves the reaction of thiolate anions, RS, with ClCN to form thiocyanates, RSCN. Similarly, the reaction of phenols produces aromatic cyanates (Kaupp et al., 1998). In such reactions, 38 amines are used to trap hydrogen chloride.
R-S
+ ClCN
ArOH + ClCN
−Cl −HCl
R-S-CN ArOCN
Some alkyl cyanates can be prepared by the reaction of alkoxide ions with cyanogen chloride. Their stability is enhanced by bulk around the OCN fragment since that inhibits subsequent trimerization (Kauer and Henderson, 1964). OH
OCN base
HO
ClCN NCO
The application of gas–solid reactions permits the synthesis of a variety of functionalities from ClCN (Kaupp et al., 1998). An example is shown below: ArNH2 þ ClCN þ N(Me)3 ! ArNHCN þ N(Me)3 Hþ Cl : CK hydrolyzes to form HCl and HOCl only slowly. However, the hydrolysis rate (Bailey and Bishop, 1973) increases in the presence of bases, such as sodium hydroxide. Although cyanogen chloride can be prepared by reacting cyanide with chlorine water, ClCN reacts with hypochlorite at pH 7–8 (Price et al., 1947). Complete hydrolysis (aqueous sodium hydroxide=heat) of cyanogen chloride produces ammonia, and the detection of this ammonia was the basis for an early, nonspecific test for ClCN. Ammonolysis of ClCN using ethanolic ammonia produces cyanamide, NH2CN (Cloez and Cannizzaro, 1851): ClCN þ 2NH3 ! NH2 CN þ NH4 Cl: Amines can be formed by the addition of cyanogen chloride to substituted alkenes (Smolin, 1955). The reaction occurs in the presence of sulfuric acid: CH3 CH2 C(CH3 ) ¼ CH2 þ ClCN þ H2 SO4 ! CH3 CH2 C(CH3 )2 NH2 (23%):
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C002 Final Proof page 29
7.11.2007 5:16pm Compositor Name: BMani
29
Chemistry of Chemical Warfare Agents
Cyanogen chloride reacts with sulfite ion as well as sulfur dioxide (Bailey and Bishop, 1973). With sulfur trioxide, ClCN adds to alkenes to produce sulfonyl chlorides (Arlt, 1970). The unstable (explosive when dry) cyanogen azide is formed when sodium azide reacts with cyanogen chloride (Noller, 1966b): MeCN
NaN3 þ ClCN ! NaCl þ N3 CN: A kinetic study of the shock tube decomposition of ClCN led to the conclusion that a set of six reactions are involved in this thermal decomposition (Schofield et al., 1965). Details of the valence shell photoionization of cyanogen halides have been published (Holland and Shaw, 2004), as have the UV absorption spectra of cyanogen halides (King and Richardson, 1966).
D. HYDROGEN CYANIDE—HCN General Remarks: Other names for hydrogen cyanide, HCN, include (1) prussic acid, (2) formonitrile, (3) methan(e)nitrile, (4) Blausaure, (5) hydrocyanic acid, and (6) carbon hydride nitride. It has CAS# 74-90-8. The terms ‘‘hydrocyanic acid’’ and ‘‘prussic acid’’ are best limited to aqueous solutions of hydrogen cyanide. Liquid HCN mixed with substances designed to reduce polymerization (e.g., cyanogen chloride) was dubbed ‘‘Zyklon B’’ in Germany. Hydrogen cyanide is currently identified by the military as ‘‘AC.’’ Like CK, it is described as a ‘‘blood agent’’ and owes its toxicity to the liberation of cyanide ion (CN) under physiological conditions. The importance of cyanides in commerce is indicated by the annual U.S. production capacity for HCN which, in 2004, was estimated to be over 1 billion pounds. Approximately one-half of the U.S. production is used to prepare adiponitrile for nylon 66. Its other uses include the preparation of acrylonitrile, methyl methacrylate (via acetone cyanohydrin), methionine, and cyanide salts. Physical Properties (http:==webbook.nist.gov): HCN is a highly toxic gas with a density of 0.94 relative to air. Its molecular dipole moment (gas) is 2.95 D, whereas that of cyanogen chloride (gas) is 2.80 D (McClellan, 1963). In these linear molecules, the nitrogen atom resides at the more negative end of the molecular dipole (Orville-Thomas, 1966). The liquid (density 0.687 g=mL at 108C) has a low bp (268C), a freezing point of 138C, and a molecular mass of 27.0. It has a closedup flash point of 188C. AC is colorless as both a gas and liquid and has a bitter, almond-like odor. The odor threshold is estimated to be 2–5 ppm, although some cannot detect it by odor, even at lethal concentrations. Estimates suggest that 40%–60% of the population may not be able to detect HCN by its odor (http:==web.princeton.edu). Its rather high vapor pressure (620 mm=Hg at 228C) ensures that this is a nonpersistent CWA. HCN is soluble in water, ethanol, chloroform, and benzene. Unlike sulfuric acid, hydrochloric acid, and so forth, hydrocyanic acid (i.e., aqueous HCN) is a rather weak acid with pKA ¼ 9.32 (Clifford, 1961b). An aqueous solution of HCN barely turns litmus red. While forming salts with strong bases, it does not with carbonates. Chemistry: Due to its high toxicity, when needed for laboratory use, it is common for HCN to be used in situ. A typical procedure employing potassium cyanide and dilute sulfuric acid is outlined by Streitwieser and Heathcock (1976). A synthesis using sodium cyanide and sulfuric acid is available (Ziegler, 1941). HCN can be prepared commercially by several routes, including the reaction of ammonia=air with methane. HCN is not completely stable and is marketed as a stabilized (often with H3PO4), flammable, anhydrous material. It reacts when heated, or in the presence of base or water, and may polymerize violently in contact with strong acids (e.g., sulfuric acid). Polymerization, once initiated, can be autocatalytic and, under confined conditions, lead to an explosion. It can be removed from waste streams by conversion to ammonium thiocyanate, a process involving scrubbing the waste stream with elemental sulfur in water (http:==www.chemalliance.org).
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C002 Final Proof page 30
30
7.11.2007 5:16pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
HCN undergoes many well-studied reactions (Cyanides in Organic Reactions; A Literature Review, 1962), the most famous of which may be addition to a carbonyl group (aldehyde or ketone). The products of these additions are called ‘‘cyanohydrins’’ or ‘‘hydroxynitriles’’ (Ziegler et al., 1990). This reaction, shown below, demonstrates the formation of a pair of enantiomers from an aldehyde. Rates of these addition reactions are pH dependent, maximum rates generally occurring at about pH 4–5. Substituents around the carbonyl group determine the position of such equilibria, steric hindrance destabilizing cyanohydrins. H
H
HCN
C
(R,S)O
C
−HCN
CN OH
Cyanohydrins derived from aldehydes are generally more stable than those from ketones (Ternay, 1976). Cyanohydrin formation is the first step in the well-known chain-lengthening sequence, the Kiliani–Fischer synthesis. For example, D-arabinose, an aldopentose, ultimately affords both D-glucose and D-mannose by this set of reactions (Carey, 2000b). Cyanohydrin formation, being reversible and occurring in nature, is relevant to the potential hazards from ingesting cyanohydrins. Thus, Prunus amygdalus dulcis is a source of an oil used in confectionery. However, when crushed, the kernels of Prunus amygdalus amara yield an oil commonly known as ‘‘oil of bitter almonds’’ (oleum amygdalae amarae). On hydrolysis, the latter produces as much as 6% of hydrogen cyanide (http:==en.wikipedia.org). Conjugated aldehydes or ketones can add HCN by a 1,4-addition pathway (‘‘conjugate addition’’ or ‘‘Michael addition’’) and produce b-cyano carbonyl compounds. For example, 1-phenylpropenone (C6H5C(O)CH¼CH2) adds HCN to afford 4-oxo-4-phenylbutanenitrile (C6H5C(O) CH2CH2CN) in approximately 65% yield. HCN also adds to alkenes in the presence of an appropriate catalyst (Arthur et al., 1954; Jackson and Lovel, 1982). Thus, cobalt carbonyl leads to Markownikov addition, for example, 1-propene yields isopropyl cyanide in approximately 75% yield. HCN adds to alkynes in the presence of metal complexes, and the use of a nickel complex may lead to syn addition (Jackson and Lovel, 1983; Jackson et al., 1988). Hydrogen cyanide reacts with conjugated dienes, the mechanism involving a p-allyl intermediate. The course of addition is complex and may lead to more than one product (Keim et al., 1982). NiL4
CN +
HCN
CN 34%
64%
Cyanide ion is a good nucleophile and is able to cleave various bonds including the disulfide linkage (Gould, 1959). R
S S
R'
RS-CN + R'S
NC
Epoxides can be ring opened by HCN. Thus, ethylene oxide reacts with HCN to form ethylene cyanohydrin (Mowry, 1948). A critical step in one commercial route to acrylonitrile involves the ring opening of ethylene oxide using HCN. O
HCN HO
CN −HOH
CN
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C002 Final Proof page 31
7.11.2007 5:16pm Compositor Name: BMani
31
Chemistry of Chemical Warfare Agents
The ring opening of epichlorohydrin with HCN begins a sequence that leads to carnitine (Yamagutchi, 1989). OH Cl
O
HCN
CN
Cl
TMA HOH
+
Me3N
CO2 OH
Ketones are converted to the corresponding nitrile by a sequence that begins with conversion of the ketone to a tosylhydrazone, followed by HCN addition across the C ¼ N bond. Thermolysis of the intermediate 1-cyanohydrazine affords the cyanide in acceptable yields (Buehler and Pearson, 1976). NNHTs
NHNHTs CN
HCN
H Heat
CN
The Gatterman aldehyde synthesis involves a Friedel–Crafts-type reaction on activated aromatic rings to afford aryl aldehydes (Noller, 1966a). OH
OH (a) HCN/HCl/ZnCl2 (b) HOH
OH
OH CHO
The Ritter reaction is a method for creating amides beginning with alkenes or alcohols (28 or 38) and cyanide (Reddy, 2003). Preparation of a formamide is shown below: H3 Oþ
! H C(O)NHCR3 : R3 COH þ HCN The interaction of methylphosphonocyanidate with HCN or CN has been described (Morozik et al., 2003). The ability of cyanide to form strong complexes with various metals explains its use in extracting gold from gold-containing rock, a process called ‘‘heap leaching’’ (http:==www.newmont.com). Cyanide ion reacts with iron salts to form complexes, such as is found in ferric ferrocyanide (also known as Prussian Blue, Hamburg Blue, Paris Blue, and mineral blue). The stronger affinity of cyanide for Fe(III) (ferric) than for Fe(II) (ferrous) ion provides the foundation for one therapy for cyanide poisoning (Baskin and Brewer, 1997). The binding of cyanide to carbonic anhydrase has been studied (13C nuclear magnetic resonance [NMR]), and it was concluded that the unprotonated cyanide binds to zinc (Feeney and Burgen, 1973). The color and bonding of cyanide complex ions has been summarized (Clifford, 1961). The infrared spectra of these complexes have been studied extensively (Rao, 1963; Bowser, 1993). The photoionization of hydrogen cyanide has been reported by Dibeler and Liston (1968), and the absorption spectrum of HCN has been compared with that of DCN (Nagate et al., 1981). HCN adds chlorine to form cyanogen chloride that, in turn, trimerizes to cyanuric chloride (see ‘‘Cyanogen chloride’’ section). Catalytic (platinum catalyst) hydrogenation of hydrogen cyanide affords methylamine (Barratt and Titley, 1919). A catalyst (Ag or Au) can be used in the hightemperature oxidation of HCN using oxygen. Products of this include HOCN (cyanic acid) and lesser amounts of cyanogen, (CN)2 (Zima, 1959).
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C002 Final Proof page 32
32
7.11.2007 5:16pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
The reaction of HCN with dilute aqueous sodium hydroxide can be used to produce sodium formate, and this reaction has served as the basis for an analytical method for measuring cyanide (Doizine et al., 1982).
E. CHLOROPICRIN—CCl3NO2 General Remarks: Alternate names for chloropicrin include (1) nitrochloroform, (2) trichloronitromethane, and (3) nitrotrichloromethane. During WWI, it was called ‘‘Aquinite’’ (French), ‘‘vomiting gas’’ (British), and ‘‘Klop’’ (Germans). Its CAS# is 76-06-2, and its military abbreviation is ‘‘PS’’ (or ‘‘PK’’ in older parlance). A mixture of 30% chloropicrin and 70% chlorine was called ‘‘Yellow Star,’’ which should not be confused with ‘‘Yellow Cross,’’ a term for sulfur mustard. ‘‘Green Star’’ was a mixture of chloropicrin (65%) and hydrogen sulfide (35%). PS was used during WWI as a tear gas and was found to be a useful fumigant by the end of the war. Now its use as a fumigant (Jackson, 1934) is almost phased out. Physical Properties: Chloropicrin is a colorless oil, bp of 1128C, and mp of 698C, with a pungent, stinging odor that has been described as ‘‘anise-like.’’ Its vapor pressure is approximately 20 mm=Hg at 208C, and its molecular mass is 164 (Redeman et al., 1948). This liquid has a density of 1.66 g=mL and a vapor density of 5.6 relative to that of air. PS has low solubility in water (approximately 2 g=L), but is quite soluble in typical organic solvents (chloroform, acetone, ethyl acetate, etc.). Chloropicrin dissolves a variety of organic compounds including, for example, benzoic acid and various resins. Although chloropicrin is nonflammable, contact with oxidizing agents may lead to fires or explosions. High temperatures can produce toxic gases, including phosgene and carbon monoxide, from PS. Chemistry: Chloropicrin’s first reported preparation, by the Scottish scientist John Stenhouse, was in 1848 and involved the reaction of a chlorinating agent (bleaching powder) with picric acid (sym-trinitrophenol). It is this synthesis that led to the name ‘‘chloropicrin,’’ even though the ring present in picric acid is absent in the product chloropicrin. HO
NO2
O2N
+ 11 NaOCl
3 Cl3CNO2 + 3 Na2CO3 + 3 NaOH + 2 NaCl Chloropicrin
Picric acid NO2
Another route to this compound involves the chlorination of nitromethane with chlorine in the presence of calcium carbonate (Orvik, 1980). The nitration of chloroform with nitric acid also has served as a route to chloropicrin on a large scale (Szmant, 1957). The reaction of chlorine gas and aqueous sodium hydroxide with 4-hydroxy-3,5-dinitrobenzoic acid can be used to prepare chloropicrin (Simandi and Soos, 1986). O2N HO
CO2H
NaOH/Cl2 HOH
Cl3CNO2
O2N
Chloropicrin does not decompose rapidly in either cold water or cold mineral acids (e.g., hydrochloric acid), is stable in cold, dilute aqueous sodium hydroxide, but slowly decomposes in ethanolic potassium hydroxide. It undergoes more rapid decomposition with sodium ethoxide or ethanolic sodium cyanide. As with many other highly chlorinated organics, PS’s stability is decreased in the presence of light as evidenced by color formation in solutions in benzene. Solutions of PS in acetone decompose slowly and deposit ammonium chloride.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C002 Final Proof page 33
7.11.2007 5:16pm Compositor Name: BMani
33
Chemistry of Chemical Warfare Agents
Slow thermolysis under reflux produces phosgene (COCl2) and nitrosyl chloride (NOCl). Photolysis acts similarly (Ashmore and Norrish, 1951; Castro and Belser, 1981). Heating with 20% fuming sulfuric acid rapidly decomposes PS to form NOCl and phosgene. Chloropicrin is dehalogenated with aqueous sulfite (SO32) to form dichloronitromethane (CHCl2NO2) (Croue and Reckhow, 1989). In the absence of sulfite, hydrolysis of PS is slow and rather independent of pH. Studies of the mass spectrum of PS exist (Murty et al., 2005). The vibrational spectra of bromoand chloropicrin have been analyzed (Mason et al., 1959), and electron diffraction studies of chloropicrin have been reported (Knudsen et al., 1966). Chloropicrin can be used to prepare orthocarbonates, C(OR)4, the process involving four replacements by alkoxide ions (Hennig, 1937): Cl3 CNO2 þ 4RONa ! chloropicrin
C(OR)4 þ an orthocarbonate
NaNO2 þ 3NaCl:
Similarly, chloropicrin reacts with iodide to form carbon tetraiodide (Kretov and Mehnikov, 1932). Chloropicrin has been shown to react with iron-bearing clay minerals to produce both chloronitromethane and dichloronitromethane (Cervini-Silva et al., 2000). An interesting discussion of the microdetermination of chloropicrin in air using a colorimetric procedure has been presented, and the authors demonstrated that analyses based on either chloride or nitrite afforded similar results (Feinsilver and Oberst, 1953).
F. PHOSGENE—COCl2 General Remarks: Phosgene, perhaps the most effective CWA of WWI, also has been called (1) carbonyl chloride (or dichloride), (2) ‘‘Collongite,’’ (3) ‘‘D-Stoff,’’ (4) chloroformyl chloride, and (5) CG (Ryan et al., 1996). Its CAS# is 75-44-5. It is estimated that recent annual U.S. production demand is approximately 5400 million pounds. Its most important industrial use is in the production of isocyanates (R–N¼C¼O) (http:==www.the-innovation-group.com). Physical Properties: Phosgene is a colorless gas at room temperature with a density, relative to air, of 3.4. It has mp of 1188C, bp of 88C, and vapor pressure of approximately 1200 mm at 208C. It is slightly soluble in water, in which it hydrolyzes, and rather soluble in most hydrocarbons (e.g., hexane and benzene) and in glacial acetic acid. Phosgene has an odor of newly mown or ‘‘musty’’ hay. It is estimated that the least detectable odor occurs at approximately 1 ppm, but that the lowest concentration affecting the eyes is about 4 ppm. Chemistry: Phosgene can be prepared in the laboratory using a reaction similar to its commercial synthesis. In this gas-phase process, equimolar amounts of chlorine and carbon monoxide are passed over a bed of activated charcoal granules. Phosgene is the acid dichloride of carbonic acid, HO–C(O)–OH, and, like all acid chlorides, reacts rapidly with water to produce the corresponding acid and hydrogen chloride. Since carbonic acid is unstable, the ultimate products of reaction with water are hydrogen chloride and carbon dioxide. The hydrogen chloride produced dissolves in excess water to form hydrochloric acid (corrosive). Accompanied by the loss of HCl, phosgene reacts with alcohols to produce either a chloroformate or a carbonate, depending on stoichiometry: ROH
C(O)Cl2 þ ROH ! ClC(O)OR ! O ¼ C(OR)2 : a choloroformate
a carbonate
The reaction of phosgene with vic-diols (including sugars) leads to cyclic carbonates (Kawabata et al., 1986).
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C002 Final Proof page 34
34
7.11.2007 5:16pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics H
H
OH
O
O=CCl2
O
Base
OH
O
H
H
A similar reaction may occur with proximal diols (Le Boulch et al., 1967).
C(O)Cl2 HO
OH
O
O
O
A number of important polymers, for example, polycarbonates, are synthesized using phosgene. For example, Lexan is made by reacting bisphenol A with phosgene in the presence of base. Me HO
C
OH
Bisphenol A
Me
Phosgene also has been used to lactonize an hydroxyacid (Wehrmeister and Robertson, 1968) and to convert a carboxylic acid to its anhydride (nicotinic acid to its anhydride) (Rinderknecht and Gutenstein, 1967). O
CO2H
COCl2
O
R3N
(CH2)9-CH(OH)CH3
Chloroform produces phosgene when exposed to light and oxygen or air. For this reason, chloroform has sometimes been stabilized with traces of ethanol since it reacts with any phosgene impurity to form ethyl carbonate. The reaction of phosgene with benzyl alcohol yields benzyl chloroformate (carbobenzoxy chloride), ClCO2CH2C6H5, useful in protecting (Ege, 1999) amino groups of amino acids. (Deprotection is accomplished with H2=Pd=C.) Reactions with nucleophiles other than alcohols can produce other carbonic acid derivatives. For example, reaction with anhydrous ammonia yields urea, O ¼ C(NH2)2. Aromatic primary amines can, depending on reaction conditions, react with phosgene to form carbamoyl chlorides (Csuros et al., 1969).
Ar
NH2 + COCl2
Ar
⊕
H
Cl
N
C
H
Cl
O
−HCl
O
Ar
N H
C Cl
Isocyanate formation from diamines is commercially quite important since they are polymer precursors (Khardin and Pershin, 1979). Under appropriate conditions, proximal diamines can be converted to cyclic structures, the preparation of the biotin skeleton being representative (Marx et al., 1977).
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C002 Final Proof page 35
7.11.2007 5:16pm Compositor Name: BMani
35
Chemistry of Chemical Warfare Agents O H2N
HN
NH2
S
NH
C(O)Cl2 S
(CH2)4CO2H
(CH2)4CO2H
Pyridine reacts with phosgene to form a complex containing two pyridine fragments per carbonyl chloride.
N
Pyr Cl
H
Cl
⊕N
Cl
Pyr
C(O)Cl
N
O
⊕ N
C(O)Cl2
Some amine N-oxides are reduced by phosgene. Thus, in the presence of base, 2-methylpyridine N-oxide is deoxygenated with phosgene (Ash and Pews, 1981). C(O)Cl2 Cl
Et3N
+ CO2
N
⊕N O
Aryl nitriles, ArCN, react with phosgene in the presence of HCl to yield triazines (Yanagida et al., 1969).
ArCN + C(O)Cl2
Cl
N
Ar HCl
N
N
+ ArC(O)Cl
Ar
Like chlorine, phosgene can add to alkenes by a free radical process. The addition can be initiated using CH3CO2. .
ClC(O)Cl C(O)Cl
R Cl
The photolytic cleavage of phosgene is believed to begin with a homolysis to form [COCl] and Cl. In turn, [COCl] rapidly decomposes to form carbon monoxide and a second chlorine atom (Wijnen, 1961). Like other acyl chlorides, phosgene can participate in Friedel–Crafts reactions. A classic example is the synthesis of Michler’s ketone, which is used to make some dyes (Robertson, 1937).
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C002 Final Proof page 36
36
7.11.2007 5:16pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Me2N
O=CCl2 ZnCl2
C=O
Me2N 2 Michler ’s ketone
With less-reactive aromatics, a stronger Lewis acid may be required, but the monosubstituted acyl chloride can be isolated. Under appropriate conditions, a symmetric, disubstituted ketone is formed. Thus, benzophenone can be isolated by the reaction with excess benzene (Wilson and Fuller, 1922). O O=CCl2
C(O)Cl
AlCl3
Benzophenone
III. NERVE AGENTS—GENERAL REMARKS The ‘‘nerve gas’’ (Black and Harrison, 1996b; Carlsen, 2005) era in chemical warfare is rooted in attempts to develop improved pesticides (Ecobichon, 1991b). These organophosphates (OPs) have a central phosphorus atom bonded to three heteroatoms. In each of these, the tetrahedral phosphorus is surrounded by four different groups. Organophosphates can be divided into two general types, V and G agents. The common G agents (GA, GB, and GD) were developed shortly before or during World War II (WWII) and possess two oxygen atoms bonded to phosphorus. Development in Germany led to their being dubbed as ‘‘G’’ agents. The V agent, VX, is an alkylphosphonothiolate. It was developed in the early 1950s and contains sulfur, as well as two oxygens bonded to phosphorus. VX is less volatile, hence more persistent, than are the G agents, for example, sarin. Among the nerve agents under discussion, the general order of volatility is sarin (GB) > soman (GD) > tabun (GA) > VX. Chemically, GA has a cyano group bonded to phosphorus, whereas GB and GD have fluorine bonded to phosphorus. GA, GB, and VX exist as a pair of enantiomers, whereas GD, with two stereogenic (chiral) centers, exists as four stereoisomers. As would be expected, these sets of stereoisomers have different biological activities. Rate constants for anticholinesterase activity of soman, sarin, tabun, and VX have been summarized (Benschop and De Jong, 1988). Much of the recent study of the chemistry (as opposed to biochemistry) of nerve agents has focused on routes to decomposition, decontamination, and destruction (Yang, 1995; Amitai et al., 2006). This also has led to studies of the analysis of various agents (Carrick et al., 2001; Cody et al., 2005). A description of enzyme inhibition by a variety of materials, including nerve agents, can be found in many modern biochemistry books (Mathews and Van Holde, 1996).
A. NERVE AGENTS—VX (C11H26NO2PS) General Remarks: Normally called VX, this nerve agent can be identified as (1) (O-ethyl S-[2-(diisopropylamino)ethyl)methylphosphonothioate; (2) O-ethyl S-[2-(diisopropylamino)ethyl) methylphosphonothiolate); or (3) methylphosphonothioic acid, S-[2-[bis(1-methylethyl)amino) ethyl O-ethyl ester. It bears CAS# 50782-69-9. Physical Properties: With a molecular mass of 267.4, VX has mp 518C, bp of 2988C, vapor pressure of 7 3 10–4 mm Hg at 208C, and a density similar to that of water (1.008 g=mL at 208C). It has a vapor density of 9.2 relative to air and is slightly soluble in water (approximately 30 g=L at room temperature). VX is both odorless and colorless.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C002 Final Proof page 37
7.11.2007 5:16pm Compositor Name: BMani
37
Chemistry of Chemical Warfare Agents
Chemistry: The most extensively studied of VX’s reactions are related to its decomposition (oxidation and hydrolysis) and this, in turn, may be related to its persistence. Hydrolysis occurs rather slowly (at pH 7; 258C; 1=2 30 days) and its products, of which there are several, are pH dependent. Thus P–S bond cleavage predominates at pH < 6 or > 10, but P–O cleavage is substantial in between. The former leads to 2-mercapto (N,N-diisopropyl)ethylamine, whereas the latter leads to S-(2-diisopropylaminoethyl) methyl phosphonothioate (Munro et al., 1999). Because nerve agents may hydrolyze over time (Yang et al., 1992), they have been stabilized for storage by moisture removal (Henderson, 2002): HOH
RN ¼ C ¼ NR ! RNHC(O)NHR: a diimide
rapid
a urea
Oxidation is a potentially important route to destroying nerve agents. The oxidation reaction between VX and gaseous ozone has been shown to lead to a wide variety of products. In general, the most reasonable sites for initial oxidation of VX are sulfur or nitrogen, the former yielding a ‘‘sulfoxide,’’ with the latter affording an amine oxide. Oxidation in a polar medium enhances S-oxide formation, perhaps (at least in part) by stabilizing the adjacent dipolar (S–O and P–O) bonds. It has been reported that VX was oxidized to ‘‘VX N-oxide’’ before the subsequent oxidation or hydrolysis to O-ethyl methylphosphonate using a variety of oxidants (Cassagne et al., 2001). The photochemical oxidation of both VX and sulfur mustard using TiO2 or acetonitrile has been examined. Although effective, the reported quantum yields are somewhat low (<0.3%) (Fox, 1983). Highly reactive, nanosize magnesium oxide offers potential for the destruction of a VX, as well as GD and sulfur mustard. Half-lives for these processes were determined, as were decomposition products (Wagner et al., 1999). It has been suggested that Cu(II) catalyzes the hydrolysis of both thiophosphoric esters and methylphosphonofluoridates (Ketelaar et al., 1956), although it does not significantly catalyze VX hydrolysis (Albizo and Ward, 1988). VX hydrolysis products may include a substance, EA2192, that is nearly as toxic as VX itself. The reactions of VX with a variety of reagents that should be capable of destroying it have been reviewed (Yang, 1999). The fate of VX in the environment, including the influence of solids on hydrolysis, has been studied (Davisson et al., 2005). Supercritical water oxidation is of interest in the destruction of CW agents, including VX (Yesodharan, 2002).
B. NERVE AGENTS—GA (TABUN) (C5H11N2O2P) General Remarks: Tabun and GA are the two most often used names for this nerve agent, although others include (1) O-ethyl N,N-dimethylphosphoramidocyanidate; (2) ethyl N,N-dimethylphosphoramidocyanidate; (3) Le-100; (4) N-Stoff; and (5) Trilon-83. It bears CAS# 77-81-6. Physical Properties: Tabun is a colorless compound, which is said to have a somewhat fruity odor. The odor changes with decomposition so that with lesser amounts of decomposition the odor of cyanide (like bitter almonds) is apparent, whereas with greater amounts the odor of dimethylamine (like fish) is apparent. Tabun’s vapor pressure is the lowest of all the G agents (approximately 0.04 mm Hg at 208C). This suggests that tabun could be a relatively persistent threat at lower temperatures. Tabun has a vapor density of 5.6 relative to air and a liquid density of 1.08 g=mL (258C). Its mp is 508C, and its bp is approximately 2408C. It is three times as water soluble (approximately 10% at 208C) as is VX, and also soluble in typical organic solvents (e.g., ethanol, diethyl ether, and chloroform). As with other nerve agents, dissolution in inert solvents (e.g., diethyl ether) enhances tabun’s stability.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C002 Final Proof page 38
38
7.11.2007 5:16pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Chemistry: After its discovery in 1936, tabun was produced in Germany on a large scale in 1942 (Borkin, 1997). Although others exist, one synthesis begins with phosphorus trichloride and employs the Arbuzov reaction (Kosolapoff, 1950). GA’s acidic hydrolysis initially produces C2H5OP(OH)(O)CN and dimethylamine (as salt) (Benes, 1963). The CN group is lost next, followed by the loss of the EtO fragment. The ultimate product of hydrolysis is phosphoric acid. Base-induced hydrolysis (and direct water hydrolysis) of tabun has been studied (Sanchez et al., 1993; McNaughton and Brewer, 1994). Analyzed by GC–MS, a number of previously unrecognized materials have been observed (D’Agostino and Provost, 1992). Larsson (1952) has reported a spectrophotometric study of tabun hydrolysis. Ultimately, depending on conditions (pH, reaction times, and so forth), tabun hydrolysis products may include: cyanide ion; hydrocyanic acid, the monoethyl ester of dimethylphosphoramidic acid, ethanol, dimethylamine, and phosphoric acid. Under acidic conditions the P–N bond is cleaved early, whereas under alkaline conditions the P–C bond cleaves much more readily than does P–N. Tabun has a half-life of about 7 h at pH 4–5, but this increases to about 8.5 h at pH 7. Tabun hydrolysis is less than 5% complete after 20 h at pH 8.5. Tabun has a stereogenic (chiral) phosphorus atom and exists as a pair of enantiomers. A gas chromatograph study of the enantiomers of tabun has been reported (Degenhardt et al., 1986). Separation was achieved through the use of bis[(1R)-3-(heptafluorobutyryl-camphorate)nickel(II). This approach also separated stereoisomers of both sarin and soman. These authors also reported the stereospecific hydrolysis of racemic tabun using phosphorylphosphatases. They noted the species (mouse, rat, horse) dependence of the hydrolysis. Dilute solutions of tabun in inert solvents (e.g., carbon tetrachloride) exhibit optical stability for months at 258C. Shift reagents have aided in the study of pmr spectra of tabun and other nerve agents (Van Den Berg et al., 1984). Two-dimensional NMR (1H-31P) has been applied to samples containing tabun (Albaret et al., 1997).
C. NERVE AGENTS—GB (SARIN) (C4H10FO2P) General Remarks: GB carries several names including (1) isopropoxymethylphosphoryl fluoride, (2) isopropylmethylphosphonofluoridate, (3) methylphosphonofluoridic acid, 1-methylethyl ester, (4) Trilon-46, (5) N-stoff, and (6) T-144. It has CAS# 107-44-8. Physical Properties: This colorless and odorless liquid has a molecular mass of 140.1 and a density of approximately 1.1 g=mL (208C). Its mp is 578C and its bp is approximately 1478C. Sarin is the most volatile of the G agents (vapor pressure 2.10 mm Hg at 208C). It has been reported that sarin will evaporate from a sandy surface in about 2 h at 108C (Sidell et al., 1998). Chemistry: Like tabun, sarin was first prepared (1938) by Schrader’s group at I.G. Farben. An early synthesis involved the use of methylphosphonic dichloride (CH3P(O)Cl2) as a starting material. An interesting route involves the reaction of a tetraalkoxysilane, (RO)4Si, as a source of the alkoxy fragment in GB (Black and Harrison, 1996a). The preparation of both nonradioactive (Bryant et al., 1960) and radioactive (at P) sarin has been reported (Reesor et al., 1960). Optically active (o.a.) sarin has been prepared using the enantiomeric sodium salts of O-isopropyl methylphosphonothioic acid. It has been found that o.a. sarin racemizes in less than 1 day when stored at 258C in a polarimeter tube. On the other hand, dilute solutions in some solvents exhibit greater optical stability (Boter et al., 1966). GB is both miscible with water and hygroscopic, and like GA, is subject to both basic and acidic hydrolysis. The initial step in these hydrolyses involves loss of fluoride. Hydrolysis of the C–F bond in both GB and GD (soman) is accelerated by the presence of bleach (hypochlorite ion), although the process is complex and both pH and concentration dependent (Epstein et al., 1956). The effect of micelle formation on the hypochlorite-induced decomposition of toxic esters of phosphorus has been examined (Dubey et al., 2002). The presence of the calcium and magnesium cations in sea water appears to accelerate the hydrolysis (Demek et al., 1970).
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C002 Final Proof page 39
7.11.2007 5:16pm Compositor Name: BMani
39
Chemistry of Chemical Warfare Agents
The reaction of sarin with hydrogen chloride has been reported and kinetics determined by H1 NMR imaging (Bard et al., 1970). With rate constants determined at 258C, 81.58C, and 1008C, Arrhenius analysis led to a calculated activation energy of 17.8 kcal=mole. The base-induced hydrolysis of sarin analogs and tabun was studied by Larsson (1958b) and the half-life of GA has been estimated to be 1.5 min at pH ¼ 11 at 258C. Ultimately, and depending on conditions (pH, reaction times, and so forth), hydrolysis products may include fluoride ion (or hydrogen fluoride), the 1-methylethyl ester of methylphosphonic acid, methylphosphonic acid, and 2-propanol. (þ)-Sarin is reported to be a weaker inhibitor of acetylcholinesterase (AChE) than is the enantiomer (Boter et al., 1966). Racemic sarin is reported to have an LD50 that is twice that of the () enantiomer. The kinetics of the fluoride-induced racemization of sarin is available (Christen and Van Den Muysenberg, 1965). Both sarin and soman react with aqueous KHSO5 to produce the corresponding phosphonic acids (Yang et al., 1992). Valuable studies of the use of hypervalent iodine derivatives (below) to hydrolyze phosphorus esters have been reported (Moss et al., 1983, 1984, 1986; Katritzky et al., 1988). O HO2C
I
Iodobenzoic acid
HO2C
I
O
Iodosobenzoic acid
HO2C
I
O
Iodoxybenzoic acid
Sarin undergoes thermolysis–dealkylation on reflux. After approximately 80 min at elevated temperatures, the decomposition is essentially complete (Hoffman and Reeves, 1961). At substantially higher temperatures (3008C–4008C), pyrolysis of sarin in the air leads almost exclusively to propylene and methyl phosphonofluoridic acid. Over platinized alumina, there are formed stoichiometric amounts of phosphoric acid, water, hydrogen fluoride, and carbon dioxide (Baier and Weller, 1967). Several reports exist on the effect of metal cations on sarin hydrolysis (Wagner-Jauregg et al., 1955; Gustafson and Martell, 1962; Epstein and Mosher, 1968). Some of the metal ions that appear to be effective include Cu(II), Au(II), Ag(I), Ni(II), and Zn(II). The effect of hypochlorite on sarin decomposition has been studied (Epstein et al., 1956), including the effect of surfactant micelles on the process (Dubey et al., 2002). It was shown that the use of cetyltrimethylammonium bromide substantially increased the speed with which sarin was destroyed by hypochlorite. The effect of surfactant on the oxidation of sarin (and other OPs) with o-iodosobenzoic acid has been examined (Hammond et al., 1989). As part of an extensive study of the reactivity of nerve agents, Larsson (1958a) conducted a study of hydrogen peroxide’s reaction with sarin. There is an interest in sorbents that can destroy chemical threats. A study at 238C of the reactivity of DFP (diisopropyl fluorophosphate, a nerve agent simulant) with (1) g-alumina, (2) Ambergard XE-555, and (3) base-impregnated divinylbenzene has been reported. Analyses were accomplished using 31P MAS NMR spectra. Divinylbenzene-based systems were the most reactive against DFP (Wagner and Bartram, 1999). Study of the use of enzymes to hydrolyze G agents is an active area of research (Cheng et al., 1999). The toxic solution used in the Tokyo subway attack was analyzed for sarin quantitatively using 31P-NMR (Miyata and Ando, 2001).
D. NERVE AGENTS—GD (SOMAN) (C7H16FO2P) Other names for this agent include (1) O-pinacolyl methylphosphonofluoridate, (2) pinacolyl methylphosphonofluoridate, (3) EA1210, (4) methyl pinacolyl phosphonofluoridate, (5) methyl pinacolyloxy phosphoryl fluoride, (6) T-300, and (7) PMFP. It carries CAS# 96-64-0. Thickened soman (TGD) (aka VR-55) is created by adding thickener to GD.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C002 Final Proof page 40
40
7.11.2007 5:16pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Physical Properties: Pure soman is a colorless liquid with a somewhat fruity odor. It has density 1.01 g=mL (208C), vapor pressure of 0.27 mm=Hg (208C), mp of 808C, and bp of 1908C (858C at 15 mm=Hg). Distillation is accompanied by decomposition that begins near 1308C. Soman’s solubility in water is about 20% at 258C. It is only about 20% as soluble in water as is tabun. With two different chiral centers, it exists as four stereoisomers (Benschop et al., 1985), each with a different toxicity. The lethal concentration (inhalation) in humans is estimated at approximately 25–50 mg min=m3 (Somani et al., 1992). Chemistry: The synthesis of soman is similar to that of sarin. The major alteration is that pinacolyl alcohol replaces isopropanol. Soman hydrolyzes over a range of pHs, with pinacolyl methylphosphonate and fluoride ions being the initial products. Subsequent hydrolysis of pinacolyl methylphosphonate is similar to the aging process associated with GD poisoning (below) (Michel et al., 1967). enz
enz O
ser O
P Me
OCH(CH3)C(CH3)3
Aging
O
ser O
P
OH
Me
In water (pH ¼ 7; 208C), the half-life for hydrolysis is approximately 80 h. Hydrolysis of this nerve agent is catalyzed by several reagents. The pH dependence of the hydrolysis of soman has been examined (Ward et al., 1988). Hydrolysis has a half-life of 45 h at pH 6.65 (258C) but is complete within minutes in 5% aqueous sodium hydroxide (lye). The effect of metal ions (Cu(II), Ce (II), and Mn(II)) on the hydrolysis (258C) of soman has been noted (Epstein and Rosenblatt, 1958). It has been reported (Wagner et al., 2000a) that GD (neat) does not react with gaseous ozone even after 1 h exposure. This is in contrast to the report of oxidation that was conducted using ozone-containing fluorocarbons (Snelson et al., 1986). Photochemical reactions in sunlight do not appear to be important for soman. Aging: Nerve agents inhibit AChE by forming an adduct with the enzyme via a serine residue on that enzyme. These adducts may be decomposed hydrolytically or, for example, by the action of some oximes and thereby regenerate the enzyme. A second reaction type, one in which the enzyme– OP complex undergoes a subsequent reaction, is usually described as ‘‘aging’’ (Bencsura et al., 1995). Once the enzyme–OP complex has aged it is no longer regenerated by the common, oxime reactivators. The rate of aging depends on the specific OP, with soman aging extremely rapidly (a few minutes) (Berry and Davies, 1966). Due to the implications in treating nerve agent exposure, there are numerous studies of the process (Coult et al., 1966; Bucht and Puu, 1984; Curtil and Masson, 1993; Segall et al., 1993; Shafferman et al., 1997; Kovach, 2004; Worek et al., 2004).
E. BZ (C21H23NO3) General Remarks: BZ, also known as (1) QNB, (2) 3-quinuclidyl benzilate, and (3) benzilic acid, 3-quinuclidinyl ester, is a synthetic glycolic ester. Its medical action is as a competitive muscarinic cholinergic receptor antagonist, that is, an incapacitating agent. Like other such agents, its purpose is to produce temporary disability, not death (Wiener and Nelson, 2004). Indeed, the onset of symptoms may not appear until several hours after exposure. Physical Properties: With one chiral center, BZ exists as a pair of enantiomers. The racemic mixture, a white solid, has mp of 1648C–1668C (Whitaker, 1966). It has a low vapor pressure, and in the environment, has an estimated half-life of approximately 1 month (258C). It has low solubility in water but is soluble in typical, polar organic solvents. Protonation of nitrogen enhances its solubility in dilute, aqueous acids. With a flash point of 2468C, it has significant thermal stability but is slowly hydrolyzed in refluxing aqueous solutions. The single crystal x-ray analysis of the hydrobromide salt has been reported (Meyerhoeffer and Carlstroem, 1969).
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C002 Final Proof page 41
7.11.2007 5:16pm Compositor Name: BMani
41
Chemistry of Chemical Warfare Agents
Chemistry: The transesterification of methyl benzilate with 3-quinuclidinol provides a convenient route to this ester. OH
N
N O
Base
+ H3CO2C C
O
OH
C6H5 C C6H5 OH
3-Quinuclidinol
Methyl benzilate
BZ
Like most bioactive substances that exist as enantiomeric pairs, the BZ enantiomers have different magnitudes of biological activity. The individual enantiomers have been prepared by beginning with the enantiomers of 3-quinuclidinol (Rzeszotarski et al., 1988). The R enantiomer exhibits a higher affinity for the muscarinic receptor than does the S enantiomer (guinea pig isolated ileum) (Lambrecht, 1979). Both 18O- and 11C-labeled analogs of BZ have been synthesized (Calvin et al., 1949). The source of the carbon label was labeled carbon dioxide (Prenant et al., 1989). The oxygen label was introduced as a result of reacting enriched water with quinuclidinone and then reducing the labeled ketone with borohydride (Sniegoski et al., 1989). The synthesis of a number of tritium labeled ‘‘neurochemicals,’’ including BZ, has been reported (Bloxsidge et al., 1981). The (ester) hydrolysis of BZ over a range of conditions of pH and temperature has been investigated (Hull et al., 1979). Bromocresol Green forms a colored complex with 3-quinuclidinyl esters of hydroxyacetic acids, which has been used in the spectrophotometric analysis of mixtures containing these esters and 3-quinuclidinol (Stan’kopv et al., 1997). Analysis of the mass spectra of a number of quinuclidine derivatives is available (Vincze et al., 1980). BZ has been safely destroyed pyrolytically (Jensen, 1991).
F. CS (C10H5ClN2) General Remarks: CS is a lacrimator and is used as a riot-control agent. It is one member of a group of compounds that includes, for example, 1-chloroacetophenone (CN), and 10-chloro-5,10-dihydrophenarszine (DM). These agents rapidly (seconds to minutes) induce irritation of the eyes and upper respiratory tract. H
CN C
C CN
CH2Cl C
H N
As Cl
Cl CS
O
CN
DM
Alternate names for CS include: (1) 2-chlorobenzylidene malononitrile; (2) o-chlorobenzylidenemalonitrile, (3) [(2-chlorophenyl)methylene]propanedinitrile, and (4) b,b-dicyano-o-chlorostyrene. Its CAS# is 2698-41-1. Physical Properties: This white solid has molecular mass of 188.6, mp of 958C, bp of 3138C, and vapor pressure at 208C of approximately 3.5 3 105 mm=Hg. It has a relatively low water solubility (52 mg=L at 258C), but is soluble in typical polar organic solvents. Chemistry: A reliable synthesis of CS was reported in 1928 by Corson and Stoughton. The procedure involved condensation of a starting aldehyde with malononitrile and was catalyzed with base. Even uncatalyzed reactions eventually were successful, although significantly slower.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C002 Final Proof page 42
42
7.11.2007 5:16pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
The sequence below is written to illustrate hydrolysis but the reverse represents the (uncatalyzed) synthesis of CS and similar a,b-unsaturated dinitriles (Corson and Stoughton, 1928). H H
H
O
O
O
H CH C(CN)2
H CH
C(CN)2
CH CH(CN)2
Cl Cl Proton transfer −CH2(CN)2
Cl
CH O Cl
Unlike simple alkenes, CS has a rather rapid rate of hydrolysis (t1=2 ¼ 15 min at 258C), and this is accelerated by the use of dilute, aqueous sodium hydroxide (Brooks et al., 1976). Potassium permanganate (aqueous) oxidizes CS and similar a,b-unsaturated dinitriles to the corresponding benzoic acids. It has been reported that aerosol exposure to CS leads to an increased excretion of thiocyanate. This, along with other data, suggested that cyanide is released after CS intraperitoneal administration (Frankenberg and Sorbo, 1973). The thermal (3008C, 5008C, 7008C, and 9008C) decomposition of CS has been shown to produce 14 products, including quinoline, o-dicyanobenzene, 2-chlorobenzaldehyde, 2,2-dicyano 3-(2-chlorophenyl)oxirane, and 2-chlorocinnamonitrile. The higher temperatures led to a greater diversity of products. Analysis was done by GC–MS (Wils and Hulst, 1985; Kluchinsky et al., 2002).
REFERENCES Albaret, C., Loeillet, D., Auge, P., and Fortier, P.-L. 1997. Application of two-dimensional 1H-31P inverse NMR spectroscopy to the detection of trace amounts of organophosphorus compounds related to the chemical weapons convention. Analytical Chemistry, 69: 2694–2700. Albizo, J.M. and Ward, J.R. 1988. Hydrolysis of GD and VX by 0.05M=0.10M copper(II) N,N,N0 ,N0 tetramethylenediamine (TMEN), in Proceedings, Army Science Conference (16th), Vol. 1, 25–27 October 1988: 33–37, AD-A203101. Amitai, G., Gaidukov, L., Adani, E., Yishay, S., Yacov, G., Kushnir, M., Teitiboim, S., Lindenbaum, M., Bei, P., Khersonsky, O., Tawfik, D.S., and Meshulam, H. 2006. Enhanced stereoselective hydrolysis of toxic organophosphates by directly evolved variants of mammalian serum paraoxonase. FEBS Journal, 273: 1906–1919. Arlt, D. 1970. Neue preparative Wege zu Kohlensauremid-Derivaten. Synthesis, 2: 20–22, and references cited therein. Arthur, P., England, D.C., Pratt, B.C., and Whitman, G.M. 1954. Addition of hydrogen cyanide to unsaturated compounds. Journal of the American Chemical Society, 76: 5364–5367. Ash, M.L. and Pews, R.G. 1981. The synthesis of 2-chloromethylpyridine from 2-picoline N-oxide. Journal of Heterocyclic Chemistry, 18: 939–940. Ashmore, P.G. and Norrish, G.W. 1951. Sensitized explosions. X. The kinetics of decomposition of chloropicrin and the hydrogen–oxygen and hydrogen–chlorine reactions sensitized by chloropicrin. Proceedings of the Royal Society of London, Series A, 204: 34–50. Baier, R.W. and Weller, S.W. 1967. Catalytic and thermal decomposition of isopropyl methyl fluorophosphonate. Industrial Engineering and Chemical Process Design and Development, 6: 380–385.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C002 Final Proof page 43
Chemistry of Chemical Warfare Agents
7.11.2007 5:17pm Compositor Name: BMani
43
Bailey, P.L. and Bishop, E.J. 1973a. Hydrolysis of cyanogen chloride. Journal of the Chemical Society, Dalton Transactions, 9: 912–916. Bailey, P.L. and Bishop, E. 1973b. Reactions of sulphite ions with cyanogen chloride. Journal of the Chemical Society, Dalton Transactions, 9: 917–921. Bard, J.R., Daasch, L.W., and Klapper, H. 1970. Kinetics of reaction between isopropyl methylphosphonofluoridate and hydrogen chloride. Journal of Chemical and Engineering Data, 15: 134–137. Barratt, S. and Titley, A.F. 1919. The catalytic reduction of hydrogen cyanide. Journal of the Chemical Society Transactions, 115: 902–907. Bartlett, P.D. and Swain, C.G. 1949. Kinetics of hydrolysis and displacement reactions of b,b0 -dichlorodiethyl sulfide (mustard gas) and of b-chloro-b0 -hydroxydiethyl sulfide (mustard chlorohydrin). Journal of the American Chemical Society, 71: 1406–1415. Baskin, S.I. and Brewer, T.G. 1997. Cyanide poisoning, in Medical Aspects of Chemical and Biological Warfare, edited by F.R. Sidell, E.T. Takafuji, and D.R. Franz. Washington, DC: Office of the Surgeon General at TMM Publications, Borden Institute, Walter Reed Army Medical Center: 271–286. Beaudry, W.T., Szafraniac, L.L., and Leslie, D.R. 1992. Reactions of Chemical Warfare Agents with DS2. Product Identification by NMR, CRDEC-TR-364, June, and references cited therein. Bencsura, A., Enyedy, I., and Kovach, I.M. 1995. Origins and diversity of the aging reaction in phosphonate adducts of serine hydrolase enzymes: what characteristics of the active site do they probe? Biochemistry, 34: 8989–8999. Benes, J. 1963. Kinetics of the hydrolysis of tabun in acid solutions. Acta Chemica Scandinavica, 17: 1783–1785. Benschop, H.P. and De Jong, L.P.A. 1988. Nerve agent stereoisomers: analysis, isolation and toxicology. Accounts of Chemical Research, 21: 368–374. Benschop, H.P., Bijleveld, E.C., Otto, M.F., Degenhardt, C.E., Van Helden, H.P., and De Jong, L.P. 1985. Stabilization and gas chromatographic analysis of the four stereoisomers of 1,2,2-trimethylpropyl methylphosphonofluoridate (soman) in rat blood. Analytical Biochemistry, 151: 242–253. Berry, W.K. and Davies, D.R. 1966. Factors influencing the rate of ‘‘aging’’ of a series of alkyl methylphosphonyl-acetylcholinesterases. Biochemical Journal, 100: 572–576. Berthollet, C.L. 1789. Sur l’Acide Prussique. Annales de chimie, 30–39. Black, R.M. and Harrison, J.M. 1996a. The chemistry of organophosphorus chemical warfare agents, in The Chemistry of Organophosphorus Compounds, Vol. 4, edited by F.R. Hartley, New York: John Wiley and Sons: 791. Black, R.M. and Harrison, J.M. 1996b. The chemistry of organophosphorus chemical warfare Agents, in The Chemistry of Organophosphorus Compounds, Vol. 4, edited by F.R. Hartley, New York: John Wiley and Sons: Ch. 10. Bloxsidge, J.P., Elvidge, J.A., Gower, M., and Jones, J.R. 1981. Tritium nuclear resonance spectroscopy. Part 13. Tritium labeled neurochemicals. Journal of Labeled Compounds and Radiopharmaceuticals, 18: 1141–1165. Borkin, J. 1997. The Crime and Punishment of I.G. Farben. New York: Barnes and Noble. Boter, H.L., Ooms, A.J.J., Van Den Berg, G.R., and Van Dijk, C. 1966. The synthesis of optically active isopropyl methylphosphonofluoridate (Sarin). Recueil des travaux chimiques des Pays-Bas, 85: 147–150. Bowser, J.R. 1993. Inorganic Chemistry. Belmont, CA: Wadsworth Inc.: 699–700. Brooks, M.E., Davis, P.M., and Sass, S. 1976. Demilitarization of CS, I. Chemical Disposal of CS by Hydrolysis. Springfield, VA 22161: National Technical Information Service: AD-A033469. Bryant, P.J.R., Ford-Moore, A.H., Perry, B.J., Wardrop, A.W.H., and Watkins, T.F. 1960. The preparation and physical properties of isopropyl methylphosphonofluoridate (Sarin). Journal of the Chemical Society, 1960: 1553–1555. Bucht, G. and Puu, G. 1984. Aging and reactivatability of plaice cholinesterase inhibited by soman and its stereoisomers. Biochemical Pharmacology, 33: 3573–3577. Buehler, C.A. and Pearson, D.A. 1976. Survey of Organic Syntheses, Vol. 2. New York: John Wiley and Sons: 873. Calvin, M., Heidelberger, C., Reid, J.C., Tolbert, B.M., and Yankwich, P.E. 1949. Isotopic Carbon. New York, John Wiley and Sons, Inc. Cardillo, P. 2001. Some historical accidental explosions. Journal of Loss Prevention in the Process Industry, 14: 69–76.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C002 Final Proof page 44
44
7.11.2007 5:17pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Carey, F.A. 2000a. Organic Chemistry. 4th Edition. New York: McGraw-Hill: Ch. 10. Carey, F.A. 2000b. Organic Chemistry. 4th Edition. New York: McGraw-Hill: 1001. Carlsen, L. 2005. A QSAR approach to physico-chemical data for organophosphates with special focus on known and potential nerve agents. Internet Electronic Journal of Molecular Design, 4: 355–366, http:== www.biochempress.com. Carrick, W.A., Cooper, D.B., and Muir, B. 2001. Retrospective identification of chemical warfare agents by high-temperature automatic thermal desorption–gas chromatography–mass spectrometry. Journal of Chromatography A, 925: 241–249. Cassagne,T., Cristau, H.-J., Delmas, G., Desgranges, M., Lion, C., Magnaud, G., Hgeilles, E., and Virieux, D. 2001. Destruction of chemical warfare agents VX and soman by a-nucleophiles as oxidizing agents. Heteroatom Chemistry, 12: 485–490. Castro, C.C. and Belser, N.O. 1981. Photohydrolysis of methyl bromide and chloropicrin. Journal of Agriculture and Food Chemistry, 29: 1005–1008. Cervini-Silva, J., Wu, J., Larson, R.A., and Stucki, J.W. 2000. Transformation of chloropicrin in the presence of iron-bearing clay minerals. Environmental Science and Technology, 34: 915–917. Cheng, T.C., DeFrank, J.J., and Rawstogi, V.K. 1999. Alteromonas prolidase for organophosphorus G-agent decontamination. Chemico-Biological Interactions, 119–120: 455–462. Chloramines. 1999, in Alternative Disinfectants and Oxidants EPA Guidance Manual. April, 1999, Ch. 6. Christen, P.J. and Van Den Muysenberg, J.A. 1965. Enzymic isolation and fluoride catalyzed racemization of optically active Sarin. Biochimica Biophyica Acta, 210: 217–220. Clifford A.F. 1961a. Inorganic Chemistry of Qualitative Analysis. Englewood Cliffs, NJ: Prentice-Hall: 362–363. Clifford, A.F. 1961b. Inorganic Chemistry of Qualitative Analysis. Englewood Cliffs, NJ: Prentice-Hall: 444. Cloez, S. and Cannizzaro, S. 1851. Recherches sur les amides cyaniques. Annalen der Chemie and Pharmacie, 78: 228–231. Cody, R.B., Laramee, J.A., and Durst, H.D. 2005. Versatile new ion source for the analysis of materials in open air under ambient conditions. Analytical Chemistry, 77: 2297–2302. Coleman, G.H., Leeper, R.W., and Shulze, C.C. 1946. Cyanogen chloride. Inorganic Synthesis, 2: 90–94. Corson, B.B. and Stoughton, R.W. 1928. Reactions of a, b-unsaturated dinitriles. Journal of the American Chemical Society, 50: 2825–2837. Coult, D.B., Marsh, D.J., and Read, G. 1966. Dealkylation studies on inhibited acetylcholinesterase. Biochemical Journal, 98: 869–873. Croue, J.-P. and Reckhow, D.A. 1989. Destruction of chlorination byproducts with sulfite. Environmental Science and Technology, 23: 1412–1419. Csuros, Z., Soos, R., Bitter, I., Szeghy, L., and Petnehazy, I. 1969. Acylation Reaction with Phosgene. Acta Chimica (Budapest), 61: 197. Curtil, C. and Masson, P. 1993. Aging of cholinesterase after inhibition by organophosphates. Annales Pharmaceutiques Françaises, 51: 63–77. Cyanides in Organic Reactions; A Literature Review, 1962. Wilmington: E.I. DuPont and Co.: A-27047. D’Agostino, P.A.D. and Provost, L.R. 1985. The Identification of Compounds in Mustard Hydrolysate (U), DRES Suffield Report 412, Ralston, Alberta, Canada. D’Agostino, P.A.D. and Provost, L.R. 1992. Mass spectrometric identification of products formed during degradation of ethyl dimethylphosphoramidocyanidate (tabun). Journal of Chromatography, 598: 89–95. Davisson, M.L., Love, A.H., Vance, A., and Reynolds, J.G. 2005. Environmental Fate of Organophosphorus Compounds Related to Chemical Weapons. UCRL-TR-209748. Degenhardt, C.E.A.M., Van Den Berg, G.R., De Jong, L.P.A., Benschop, H.P., Genderen, J.V., and Van de Meent, D. 1986. Enantiospecific complexation gas chromatography of nerve agents: isolation and properties of the enantiomers of ethyl N,N 0 -dimethylphosphoramidocyanidate (tabun). Journal of the American Chemical Society, 108: 8290–8291. Demek, M.M., et al. 1970. Behavior of Chemical Agents in Seawater, EATR 4417. August 1970, AD-873242. Dibeler, V.H. and Liston, S.K. 1968. Mass-spectrometric study of photoionization. IX. Hydrogen cyanide and acetonitrile. Journal of Chemical Physics, 48: 4765–4768. Doizine, T.W., Espositio, G.G., and Rinehart, D.S. 1982. Determination of hydrogen cyanide in air by ion chromatography. Analytical Chemistry, 54: 470–473.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C002 Final Proof page 45
Chemistry of Chemical Warfare Agents
7.11.2007 5:17pm Compositor Name: BMani
45
Dubey, D.K., Gupta, A.K., Sharma, M., Prabha, S., and Vaidyanathaswamy, R. 2002. Micellar effects on hypochlorite catalyzed decontamination of toxic phosphorus esters. Langmuir, 18: 10489–10492. Ecobichon, D.J. 1991. Toxic effects of pesticides, in Casarett and Doull’s Toxicology, 4th Edition, edited by M.O. Amdur, J. Doull, and C.D. Klassed, New York: Pergamon Press: Ch. 18, 565–622. Ege, S. 1999. Organic Chemistry. 4th Edition. Boston: Houghton-Mifflin: 998. Eliel, E.L. and Wilen, S.H. 1994. Stereochemistry of Organic Compounds. New York: John Wiley and Sons, Inc.: 725. Epstein, J. and Mosher, W.A. 1968. Magnesium ion catalysis of hydrolysis of isopropyl methylphosphonofluoridate. The charge effect ion metal ion catalysis. Journal of Physical Chemistry, 72: 622–625. Epstein, J. and Rosenblatt, D.H. 1958. Kinetics of some metal ion-catalyzed hydrolyses of isopropyl methylphosphonefluoridate (GB) at 258C. Journal of the American Chemical Society, 80: 3596–3598. Epstein, J., Bauer, B.V., Saxe, M., and Demek, M.M. 1956. The chlorine-catalyzed hydrolysis of isopropyl methylphosphonofluoridater (Sarin) in aqueous solution. Journal of the American Chemical Society, 78: 4068–4071. Feeney, J. and Burgen, A.E. 1973. Cyanide binding to carbonic anhydrase. A 13C-nuclear-magnetic-resonance study. European Journal of Biochemistry, 34: 107–111. Feinsilver, L. and Oberst, F.W. 1953. Microdetermination of chloropicrin vapor in air. Analytical Chemistry, 25: 820–821. Fieser, L.F. and Fieser, M. 1961. Advanced Organic Chemistry. New York: Reinhold Publishing Corp.: 499–501. Fox, M.A. 1983. Organic heterogeneous photocatalysis: chemical conversions sensitized by irradiated semiconductors. Accounts of Chemical Research, 16: 314–321. Frankenberg, L. and Sorbo, B. 1973. Formation of cyanide from o-chlorobenzylidene malononitrile and its toxicological significance. Archives of Toxicology, 31: 99–108. Gould, E.S. 1959. Mechanism and Structure in Organic Chemistry. New York: Henry Holt and Co.: 296–298. Greenwood, N.N. and Earnshaw, A. 1986. A Chemistry of the Elements. New York: Pergamon Press: 567–577. Gustafson, R.L. and Martell, A.E. 1962. A kinetic study of the copper(II) chelate-catalyzed hydrolysis of isopropyl methylphosphonofluoridate (Sarin). Journal of the American Chemical Society, 84: 2309–2316. Hammond, P.S., Forster, J.S., Lieske, C.N., and Durst, H.D. 1989. Hydrolysis of toxic organophosphorus compounds by o-iodosobenzoic acid and its derivatives. Journal of the American Chemical Society, 111: 7860–7866. Henderson, T.J. 2002. Quantitative NMR spectroscopy using coaxial inserts containing a reference standard: purity determinations for military nerve agents. Analytical Chemistry, 74: 191–196. Hennig, H. 1937. Chemical reactions of war gases. Gasschutz u. Luftschutz, 7: 18–21. Hoffman, F. and Reeves, A. 1961. Organic phosphorus compounds, VII. The preparation of methylphosphonic chlorofluoride. Journal of Organic Chemistry, 26: 3040–3041. Holland, D.M.P. and Shaw, D.A. 2004. A study of the valence shell photoionisation yields of the cyanogens halides. Chemical Physics, 297: 75–84. http:==en.wikipedia.org=wiki=Almond. Almond. Wikepedia (accessed January 2007). http:==web.princeton.edu=sites=ehs=sites=ehs=labsafetymanual=cheminfo=hcn.htm. Laboratory Safety Manual Princeton University (accessed January 2007). http:==webbook.nist.gov=cgi=cbook.cgi?Units¼SI&cTG¼on&cIR¼on&cTC¼on&cMS¼on&cTP¼on&cES ¼ on&cTR¼on&cPI¼on&cDI¼on&ID¼C74908. Hydrogen Cyanide, National Institute of Standard and Technology (accessed January 2007). http:==www.chemalliance.org=Handbook=plant=case_study.asp?CSID-326. Case Study. Chem Alliance (accessed January 2007). http:==www.newmont.com=en=social=cyanide=faq=index.asp. Cyanide Frequently Asked Questions, Newmont (accessed January 2007). http:==www.the-innovation-group.com=ChemProfiles=Phosgene.htm. Phosgene. The Innovation Group (accessed January 2007). Hull, L.A., Rosenblatt, D.H., and Epstein, J. 1979. 3-quinuclidinyl benzilate hydrolysis in dilute aqueous solution. Journal of Pharmaceutical Sciences, 68: 856–859. Jackson, K.E. 1934. Chloropicrin. Chemical Reviews, 14: 251–286. Jackson, W.R. and Lovel, C.G. 1982. The stereochemistry of metal catalyzed hydrogen cyanide addition to alkenes. Tetrahedron Letters, 23: 1621–1624.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C002 Final Proof page 46
46
7.11.2007 5:17pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Jackson, W.R. and Lovel, C.G. 1983. The stereochemistry of organometallic compounds. XXIV. Nickel(0)catalyzed additions of hydrogen cyanide to alkynes. Australian Journal of Chemistry, 36: 1975–1982. Jackson, W.R., Lovel, C.G., Perlmutter, P., and Smallridge, A. 1988. The stereochemistry of organometallic compounds. XXXI. Hydrocyanation of alkynols. Australian Journal of Chemistry, 41: 1099–1106. Jennings, W.L. and Scott, W.B. 1919. The preparation of cyanogen chloride. Journal of the American Chemical Society, 41: 1241–1247. Jensen, R.A. 1991. Successful destruction of chemical weapons and agent: the BZ experience. Annual Meeting and Exhibition Proceedings of the Air and Waste Management Association, 2–14. Katritzky, A.R., Duell, B.L., Durst, H.D., and Knier, B.L. 1988. Substituted o-iodoso- and o-iodoxybenzoic acids: synthesis and catalytic activity in the hydrolysis of active phosphorus esters and related systems. Journal of Organic Chemistry, 53: 3972–3978. Kauer, J.C. and Henderson, W.W. 1964. Aliphatic cyanates. Journal of the American Chemical Society, 86: 4732–4733. Kaupp, G., Schmeyers, J., and Boy, J. 1998. Quantitative gas–solid reactions with ClCN and BrCN: synthesis of cyanamides, cyanates, thiocyanates, and their derivatives. European Journal of Chemistry, 4: 2467–2474. Kawabata, O., Tanimoto, F., and Inoue, Y. 1986. Cyclic Carbonates, JP Patent 61130288. Keim, W., Behr, A., Luehr, H.O., and Weisser, J. 1982. Catalytic hydrocyanation of dienes and trienes. Journal of Catalysis, 78: 209–216. Ketelaar, J.A.A., Gersmann, H.R., and Beck, M.M. 1956. Metal-catalyzed hydrolysis of thiophosphoric esters. Nature, 177: 392–393. Khardin, A.P. and Pershin, V.V. 1979. Mono- and diisocyanates based on amino derivatives of adamantine. Zhurnal Vsesoyuznogo Khimicheskogo Obschestva, 24: 95. King, G.W. and Richardson, A.W. 1966. The ultraviolet absorption of cyanogen halides. Part II. Analysis of the B and C Systems. Journal of Molecular Spectroscopy, 21: 353–361, and other papers in this series. Kleber, B.E. and Birdsell, D. 1959. The Chemical Warfare Service: Chemicals in Combat. Washington, DC: Office of the Chief Military History, Department of the Army. Kleinhammes, A., Wagner, G.W., Kulkarni, H., Jia, Y., Zhang, Q., Qin, L.-C., and Wu, Y. 2005. Decontamination of 2-chloroethyl ethylsulfide using titanate nanoscrolls. Chemical Physics Letters, 411: 81–85. Kluchinsky Jr., T.A., Sheely, M.V., Savage, P.B., and Smith, P.A. 2002. Formation of 2-chlorobenzylidenemalononitrile (CS riot control agent) thermal degradation products at elevated temperatures. Journal of Chromatography A, 952: 205–213. Knudsen, R.E. George, C.F., and Karle, J. 1966. Molecular structure of CCl3NO2 by electron diffraction. Journal of Chemical Physics, 44: 2334–2337. Kopeer, O., Lucas, E., and. Klabunde, K.J. 1999. Development of reactive topical skin protectants against mustard and nerve agents. Journal of Applied Toxicology, 19: 859–870. Kosolapoff, G.M. 1950. Organophosphorus Compounds, New York: John Wiley. Kovach, I.M. 2004. Stereochemistry and secondary reactions in the irreversible inhibition of serine hydrolases by organophosphorus compounds. Journal of Physical Organic Chemistry, 17: 602–614. Kretov, A.E. and Mehnikov, N.M. 1932. Oxidizing properties of halonitromethanes. Journal of General Chemistry USSR, 2: 202–207. Lambrecht, G. 1979. Cyclische Acetylcholinanaloga IX. Darstellung und parasympatholytische Wirkung enantiomerer 3-Benziloyloxychinuclidine. European Journal of Medicinal Chemistry-Chimica Therapeutica, 14: 111–114. Larsson, L. 1952. A spectrophotometric study in infra-red of the hydrolysis of dimethylamido-ethoxy-phosphoryl cyanide (tabun). Acta Chemica Scandinavica, 6: 1470–1476; and references cited therein; see also The hydrolysis of dimethylamido-ethoxy-phosphoryl cyanide (tabun). Acta Chemica Scandinavica, 1953, 7: 306–314. Larsson, L. 1958a. The alkaline hydrolysis of two sarin analogues and of tabun. Acta Chemica Scandinavia, 12: 783–785. Larsson, L. 1958b. A kinetic study of the reaction of isopropoxy-methyl-phosphoryl fluoride (Sarin) with hydrogen peroxide. Acta Chemica Scandinavia, 12: 723–730. Le Boulch, N., Raoul, Y., and Ourisson, G. 1967. Epoxidation in the seco-steroid series. II. Configuration of the ergocalciferol epoxides. Bulletin de la Société chimique de France, 2413–2415. Logan, T.P. and Sartori, D.A. 2003. Nuclear magnetic resonance analysis of the solution and solvolysis of sulfur mustard in deuterium oxide. Toxicology Mechanisms and Methods, 13: 235–240.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C002 Final Proof page 47
Chemistry of Chemical Warfare Agents
7.11.2007 5:17pm Compositor Name: BMani
47
Marx, M., Marti, F., Reisdorf, J., Sandmeier, R., and Clark, S. 1977. A stereospecific total synthesis of (þ=)-biotin. Journal of the American Chemical Society, 99: 6754–6756. Mason (Banus), J. Dunderdale, J., and Castell, A.H. 1959. Vibrational spectra and assignments of chloropicrin and bromopicrin; some corrections and additions. Journal of the Chemical Society, 2014–2018. Mathews, C.K. and Van Holde, K.E. 1996. Biochemistry, 2nd Edition. New York: Benjamin Cummings: Ch. 11. McClellan, A.L. 1963. Tables of Molecular Dipole Moments. San Francisco, CA: W.H. Freeman and Co. McNaughton, M.G. and Brewer, J.H. 1994. Environmental Chemistry and Fate of Chemical Warfare Agents. SWRI Project 01–5864. San Antonio, TX: Southwest Research Institute. Meyer, V. 1886. Uber Thiodiglykolverbindungen. Berichte, 19: 3259–3266. Meyerhoeffer, A. and Carlstroem, D. 1969. Crystal and molecular structure of quinuclidinyl benzilate hydrobromide. Acta Crystallographica, B, 25: 1119–1126. Michel, H.O., Hackley, B.E., Berkowitz, L., List, G., Hackley, E.B., Gillilan, W., and Pankau, M. 1967. Aging and dealkylation of soman (pinacolyl-methyl phosphonofluoridate)-inactivated eel cholinesterase. Archives of Biochemistry and Biophysics, 121: 29–34. Miyata, Y. and Ando, H. 2001. Examination of an internal standard substance for the quantitative analysis of sarin using 31P-NMR. Journal of Health Science, 47: 75–77. Monson, R.S. 1971. Advanced Organic Synthesis. New York: Academic Press: 156–157. Morozik, Y.I., Aparkin, A.M., and Shcherbakov, A.A. 2003. Cyanide exchange between isobutyl methylphosphonocyanidate and hydrogen cyanide in the presence of amines. Russian Journal of General Chemistry, 73: 1152–1153. Moss, R.A., Alwis, K.W., and Bizzigotti, G.O. 1983. o-Iodosobenzoate: catalyst for the micellar cleavage of activated esters and phosphates. Journal of the American Chemical Society, 105: 681–682. Moss, R.A., Kim, K.Y., and Swarup, S. 1986. Efficient catalytic cleavage of reactive phosphates by an o-iodosobenzoate functionalized surfactant. Journal of the American Chemical Society, 108: 788–793. Moss, R.S., Alwis, K.W., and Shin, J.-S. 1984. Catalytic cleavage of active phosphate and ester substrates by iodoso- and iodoxybenzoates. Journal of the American Chemical Society, 106: 2651–2655. Mowry, D.T. 1948. The preparation of nitriles. Chemical Reviews, 42: 189–283. Munro, N.B., Talmage, S.S., Griffin, G.D., Waters, L.C., Watson. A.P., King, J.F., and Hauschild, V. 1999. The sources, fate, and toxicity of chemical warfare agent degradation products. Environmental Health Perspectives, 107: 933–974. Murty, M.R.V.S., Prabhakar, S., Lakshmi, V.S., Vijaya Saradhi, U.V.R., Jagadeshwar Reddy, T., and Vairamani, M. 2005. Mass spectral analysis of chloropicrin under negative ion chemical ionization conditions. Analytical Chemistry, 77: 3406–3410. Mustard Gas. www.frankmckinnon.com=mustard gas.htm Nachbaur, E., Kosmus, W., Krannich, H.J., and Sundermeyer, W. 1978. Beitrage zur Chemie der Kohlensaurederivate, 3. Neue Synsthesen von Tris(trimethylsilyl)cyanurat, N-Chlorosulfinylimid und Chlorcyan. Monatshefte fur Chemie, 109: 1211–1216. Nagate, T., Kondow, T., Ozaki, Y., and Kuchitsu, K. 1981. Absorption spectra of hydrogen cyanide and deuterium cyanide in the 130–80 nm range. Chemical Physics, 57: 45–53. Noller, C.R. 1966a. Chemistry of Organic Compounds. 3rd Edition. Philadelphia, PA: W.B. Saunders: 579. Noller, C.R. 1966b. Chemistry of Organic Compounds. Philadelphia, PA: W.B. Saunders: 341. Ohtani, B., Ogawa, Y., and Nishimoto, S.-I. 1987. Photocatalytic activity of amorphous-anatase mixture of titanium (IV) oxide particles suspended in aqueous solutions. Journal of Physical Chemistry B, 101: 3746–3752. Orvik, J.A. 1980. Kinetics and mechanism of nitromethane chlorination. A new rate expression. Journal of the American Chemical Society, 102: 740–743. Orville-Thomas, W.J. 1966. The Structure of Small Molecules. New York: Elsevier, New York. Prenant, C., Barre, L., and Crouzel, C. 1989. Synthesis of [11C]-3-quinuclidinylbenzilate (QNB). Journal of Labeled Compounds and Radiopharmaceuticals, 27: 1257–1265. Price, T.S. and Green, S.J. 1920. Preparation of cyanogen chloride on a large laboratory scale. Journal of Society of the Chemical Industries, 39: 98–100T. Price, C.C., Larson, T.E., Beck, K.M., Harrington, F.C., Smith, L.C., and Stephanoff, I. 1947. Hydrolysis and chlorinolysis of cyanogen chloride. Journal of the American Chemical Society, 69: 1640–1644. Rao, C.N.R. 1963. Chemical Applications of Infrared Spectroscopy. New York: Academic Press: 360–361.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C002 Final Proof page 48
48
7.11.2007 5:17pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Rao, M.K., Bhadury, P.S., Sharma, M., Dangi, R.S., Bhaskar, A.S.B., Raza, S.K., and Jaiswai, D.K. 2002. A facile methodology for the synthesis and detection of N7-guanine adduct of sulfur mustard as a biomarker. Canadian Journal of Chemistry, 80: 504–509. Reddy, K.L. 2003. An efficient method for the conversion of aromatic and aliphatic nitriles to the corresponding N-tert-butyl amides: a modified Ritter reaction. Tetrahedron Letters, 44: 1453–1455. Redeman, C.E., Chaikin, S.W., and Fearing, R.B. 1948. The vapor pressure of eleven organic compounds. Journal of the American Chemical Society, 70: 2582–2583. Reesor, J.B., Perry, B.J., and Sherlock, E. 1960. The synthesis of highly radioactive methylphosphonofluoridate (Sarin) containing P32 as a tracer element. Canadian Journal of Chemistry, 38: 1416–1427. Richter, D. 1992. Chemical Soldiers—British Gas Warfare in World War I. Lawrence: University of Kansas Press. Rinderknecht, H. and Gutenstein, M. 1967. Nicotinic anhydride. Organic Synthesis, 47: 89. Robertson, C.R. 1937. Laboratory Practice of Organic Chemistry. New York: The Macmillan Co.: 270–271. Ryan, T.A., Ryan, C., Seddon, E.A., and Seddon, K.R. 1996. Phosgene and Related Carbonyl Compounds. New York: Elsevier. Rzeszotarski, W.J., McPherson, D.W., Ferkanyi, J.W., Kinnier, W.J., Noronha-Blob, L., and KirkienRzeszotarski, A.J. 1988. Affinity and selectivity of the optical isomers of 3-quiniclidyl benzilate and related muscarinic antagonists. Journal of Medicinal Chemistry, 31: 1463–1466. Sanchez, M.L., Russell, C.R., and Randolph, C.L. 1993. Chemical Weapons Convention Signature Analysis, DNA-TR 92–73ADB171788. Alexandria, VA: Defense Technical Information Center. Sandler, S.R. and Karo, W. 1983. Organic Functional Group Preparations, Vol. 12-I. New York: Academic Press: 415–417. Sartori, M. 1939. The War Gases. New York: D. Van Nostrand Co. Inc.: 216. Schofield, D., Tsang, W., and Bauer, S.H. 1965. Thermal decomposition of ClCN. Journal of Chemical Physics, 42: 2132–2138. Segall, Y., Waysbort, D., Barak, N., Ariel, N., Doctor, B.P., Grunwald, J., and Ashani, Y. 1993. Direct observation and elucidation of the structures of aged and nonaged phosphorylated cholinesterases by 31P NMR spectroscopy. Biochemistry, 32: 13441–13450. Shafferman, A., Ordentlich, A., Barak, D., Stein D., Ariel, N., and Velan, B. 1997. Aging of somanylacetylcholinesterase adducts: facts and models. Biochemical Journal, 324: 996–998. Sidell, F.R., Patrick, W.C., and Dashiell, T.R. 1998. Jane’s Chem-Bio Handbook. Alexandria, VA: Jane’s Information Group: 92. Simandi, L. and Soos, J. 1986. Preparation of Chloropicrin by Reaction of 4-Hydroxy-3,5-Dinitrobenzoates with Hypochlorites, HU Patent 1986–3814. Smolin, E.M. 1955. Reactions of cyanogen chloride. II. Amines from cyanogen chloride and olefins. Journal of Organic Chemistry, 20: 295–301. Snelson, A., Clark, D., and Brabets, R. 1986. Fluorocarbon=Ozone and UV Decontamination Concept. Oct. 1986, CRDEC-CR-87017, APG, MD. Sniegoski, L.T., Byrd, G.D., and White, E. 1989. Synthesis of 3-quinuclidinol-180, benzilic-d5 acid, and 3-quinuclidinyl-180 benzilate-d5. Journal of Labeled Compounds and Radiopharmaceuticals, 27: 983–993. Sobering, S.E. and Winkler, C.A. 1958. The reaction of active nitrogen with chloromethanes. Canadian Journal of Chemistry, 36: 1223–1226. Somani, S.M. 1992. Chemical Warfare Agents. New York: Academic Press: 16. Somani, S.M., Solana, R.P., and Dube, S.N. 1992. Toxicodynamics of nerve agents, in Chemical Warfare Agents, edited by S.M. Somani, New York: Academic Press: Ch. 4. Stan’kopv, I.N., Lysenko, V.V., Zhmurova, M.I. Fadeev, V.N., and Pankov, D.L. 1997. Photometric determination of 3-quinuclidinol in 3-quinuclidinyl esters of some substituted hydroxyacetic acid. Journal of Analytical Chemistry, 52: 1103–1108. Steinkopf, W., Herold, J., and Stohr, J. 1920. b,b’-Dichloroethyl sulfide and some of its derivatives. Berichte, 53B: 1007–1012. Stengl, V., Marikova, M., Bakardjieva, S., Subrt, J., Oplustil, F., and Olsanska, M. 2005. Reaction of sulfur mustard gas, soman and agent VX with nanosized anatase TiO2 and ferrihydrite. Journal of Chemical Technology and Biotechnology, 80: 754–758. Streitwieser Jr., A. and Heathcock, C.H. 1976. Introduction to Organic Chemistry. New York: Macmillan Publishing Co.: 384.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C002 Final Proof page 49
Chemistry of Chemical Warfare Agents
7.11.2007 5:17pm Compositor Name: BMani
49
Szmant, H.H. 1957. Organic Chemistry. Englewood Cliffs, NJ: Prentice-Hall: Ch. 7. Ternay Jr., A.L. 1976. Contemporary Organic Chemistry. Philadelphia, PA: W.B. Saunders: 478. Ternay Jr., A.L. 1979a. Contemporary Organic Chemistry. 2nd Edition. Philadelphia, PA: W.B. Saunders: 311. Ternay Jr., A.L. 1979b. Contemporary Organic Chemistry. 2nd Edition. Philadelphia, PA: W.B. Saunders: Ch. 3. Tilstam, U. and Weinmann, H. 2002. Trichloroisocyanuric acid: a safe and efficient oxidant. Organic Process Research and Development, 6: 384–393. Van Den Berg, G.R., Beck, H.C., and Benschop, H.P. 1984. Stereochemical analysis of the nerve agents soman, sarin, tabun, and VX by proton NMR-spectroscopy with optically active shift reagents. Environmental Contamination Toxicology, 33: 505–514. Vincze, A., Gefen, L., Fisher, A., and Bel, P. 1980. Low resolution electron impact mass spectra of some quinuclidine and N-methylpiperidine glycolates. Journal of Forensic Sciences, 25: 655–665. Wagner, R.B. and Zook, H.D. 1965a. Synthetic Organic Chemistry. New York: John Wiley and Sons: 101. Wagner, R.B. and Zook, H.D. 1965b. Synthetic Organic Chemistry. New York: John Wiley and Sons: 109–110. Wagner, G.W. and Bartram, P.W. 1999. Reactions of the nerve simulant diisopropyl fluorophosphate with selfdecontaminating adsorbents. A 31P MAS NMR Study. Journal of Molecular Catalysis A: Chemical, 144: 419–424. Wagner, G.W., Bartram, P.W., Koper, O., and Klabunde, K.J. 1999. Reactions of VX, GD and HD with nanosize MgO. Journal of Physical Chemistry B, 103: 3225–3228. Wagner, G.W., Bertram, P.W., Brickhouse, M.D., Connell, T.R., Creasy, W.R., Henderson, V.D., Holvanec, J.W., Morrisey, K.M., Stuff, J.R., and Williams, B.R. 2000a. Reaction of VX and GD with gaseous ozone. Journal of the Chemical Society, Perkin Transactions, 2: 1267–1272. Wagner, G.W., Koper, O.B., Lucas, E., Decker, S., and Klabunde, K.J. 2000b. Reactions of VX, GD, and HD with nanosize CaO: autocatalytic dehydrohalogenation of HD. Journal of Physical Chemistry B, 104: 5118–5123. Wagner-Jauregg, T., Hackley Jr., B.E., Lies, T.A., Owens, O.O., and Proper, R. 1955. Model reactions of phosphorus-containing enzyme inactivators. IV. The catalytic activity of certain metal salts and chelates in the hydrolysis of diisopropyl fluorophosphate. Journal of the American Chemical Society, 77: 922–929. Ward, J.R., Yang, Y.-C., Wilson Jr., R.B., Burrows, W.D., and Ackerman, L.L. 1988. Base-catalyzed hydrolysis of 1,2,2-trimethylpropyl methylphosphonofluoridate—an examination of the saturation effect. Bioorganic Chemistry, 16: 12–16. Wehrmeister, H.L. and Robertson, D.E. 1968. Total synthesis of the macrocyclic lactone, dideoxyzearalane. Journal of Organic Chemistry, 33: 4173–4176. Whitaker, J.D. 1966. Benzilic Esters, U.S. Patent 3,252,981. Whitman G.H. 1995a. Organosulfur Chemistry. New York: Oxford University Press, and references cited therein. Whitman, G.H. 1995b. Organosulfur Chemistry. New York: Oxford Science Publications: 43. Wiener, S.W. and Nelson, L.S. 2004. Incapacitating agents, in Physician’s Guide to Terrorist Attack, edited by M.J. Roy. Totowa, NJ: Humana Press: Ch. 22. Wijnen, M.H.J. 1961. Photolysis of phosgene in the presence of ethylene. Journal of the American Chemical Society, 83: 3014–3017. Wils, E.R.J. and Hulst, A.G. 1985. Mass spectra of some derivatives of the irritant o-chlorobenzylidenemalononitrile (CS). Analytical and Bioanalytical Chemistry, 320: 357–360. Wilson, R.E. and Fuller, E.W. 1922. The reactions of phosgene with benzene and m-xylene in the presence of aluminum chloride. Journal of Industrial Engineering Chemistry, 14: 406–409. Worek, F., Thiermann, H., and Szinicz, L. 2004. Reactivation and aging kinetics of human acetylcholinesterase inhibited by organophosphonylcholines. Archives of Toxicology, 78: 212–217. Yamagutchi, H. 1989. Preparation of 4-Chloro-3-Hydroxybutyronitrile as an Intermediate for Carnitine, JP Patent 01139559. Yanagida, S., Hayama, H., Yokoe, M., and Komori, S. 1969. Reaction of nitriles with phosgene, III. New synthesis of 2-chloro-4,6-diaryl-s-triazines. Journal of Organic Chemistry, 34: 4125–4127. Yang, Y. 1999. Chemical detoxification of nerve agent VX. Accounts of Chemical Research, 32: 109–115.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C002 Final Proof page 50
50
7.11.2007 5:17pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Yang, Y.-C. 1995. Chemical reactions for neutralizing chemical warfare agents. Chemistry and Industry, 334–339. Yang, Y.-C., Baker, J.A., and Ward, J.R. 1992. Decontamination of chemical warfare agents. Chemical Reviews, 92: 1729–1743. Yesodharan, S. 2002. Supercritical water oxidation: an environmentally safe method for the disposal of organic wastes. Current Science, 82: 1112–1122. Ziegler, K. 1941. ‘‘Hydrogen cyanide (anhydrous).’’ Organic Syntheses, 1: 314. Ziegler, T., Horschm, B., and Effenberger, F. 1990. Ein einfacher Zugang zu (R)-a-Hydroxycarbonsauren und (R)-1-Amino-2-alkoholen aus (R)-Cyanohydrinen. Synthesis, 575–578. Zima, H. 1959. Cyanogen and (or) cyanic acid, DE Patent 1056101.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C003 Final Proof page 51
12.11.2007 12:49pm Compositor Name: VAmoudavally
Warfare Agent 3 Chemical Threat to Drinking Water Harry Salem, Christopher E. Whalley, Charles H. Wick, Thomas P. Gargan II, and W. Dickinson Burrows CONTENTS I. Introduction............................................................................................................................ 51 II. Background............................................................................................................................ 52 III. Approach and Methodology .................................................................................................. 56 IV. Results and Discussion .......................................................................................................... 63 A. Blood Agents (Hydrogen Cyanide) ............................................................................... 64 B. Blister Agents (Vesicants) ............................................................................................. 65 C. Incapacitating Agents..................................................................................................... 65 D. Toxins ............................................................................................................................ 65 E. Botulinum Toxins .......................................................................................................... 66 F. Ricin ............................................................................................................................... 66 G. Staphylococcal Enterotoxin B (SEB) ............................................................................ 66 H. Trichothecene Mycotoxin T-2 ....................................................................................... 67 V. Conclusions............................................................................................................................ 67 References ....................................................................................................................................... 67
I. INTRODUCTION The use of chemical warfare agents (CWAs) and other weapons of mass destruction (WMD) by terrorists to contaminate military drinking-water supplies and our domestic water systems is a reality. In addition to the WMD (which include Chemical, Biological, Radiological, Nuclear, and Explosive—CBRNE), toxic industrial chemicals (TICs) and toxic industrial materials (TIMs) are also of concern. TIMs, unlike TICs, which have a defined chemical structure, do not consist of an exact or constant composition of a particular chemical, but a variety or mixture of many chemicals. Examples of TIMs include asbestos (variety of fibers and minerals) and gasoline (composition varies with octane level, manufacturer, and season of manufacture) (Salem, 2006). On February 13, 2001, President George W. Bush, in an address at the Norfolk Naval Air Station in Norfolk, Virginia, stated ‘‘ . . . the grave threat from nuclear, biological, and chemical weapons has not gone away with the Cold War. It has evolved into many separate threats, some of them harder to see, and harder to answer. And the adversaries seeking these tools of terror are less predictable and more diverse’’ (Bush, 2001). Water infrastructure systems are highly linked with other infrastructures, especially electrical power, transportation, and the chemical industry, making security of all of them an issue of concern (Copeland and Cody, 2006). The spectrum of Chemical and Biological warfare agents that need to be considered as threats to both military and civilian populations is The contents of this chapter are not to be construed as an official Department of the Army position, unless so designated by other authorizing documents.
51
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
52
46616_C003 Final Proof page 52
12.11.2007 12:49pm Compositor Name: VAmoudavally
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
TABLE 3.1 Chemical and Biological Warfare Agents’ Threat Spectrum Clearly Chemical Warfare Agents Classic Chemicals Blood Vesicant Nerve Incapacitants Psychological Riot control agents Choking Toxic industrial chemicals
Clearly Biological Warfare Agents
Midspectrum Warfare Agents Emerging Chemicals
Bioregulators
Toxins
Pathogens
Protection defeating Physical incapacitant Nontraditional agents (NTAs)
Pain Sleep Blood pressure Mood enhancers
Plant Bacterial Venom Marine Fungal Algal
Bacteria Viruses Rickettsiae Genetic engineered microorganisms
presented in Table 3.1 (Salem, 2003). This spectrum is from the clearly chemical to the clearly biological, with midspectrum agents such as emerging chemicals, including those that are protection defeating, physical incapacitants, and nontraditional agents, as well as bioregulators producing pain, sleep, mood enhancers, and blood pressure effects, to toxins from plants, bacteria, or animals (Salem et al., 2004).
II. BACKGROUND The U.S. Army has had a long-standing concern about deliberate contamination of military drinking water, which has previously been addressed in collaboration with Lawrence Livermore National Laboratories (LLNL) and reported in 1990 (Daniels, 1990). Military drinking water includes source, treated, stored, and distributed water. In addition to drinking, these waters may also be used for cooking, washing, bathing, and showering. Thus, the routes of exposure could be oral, cutaneous, and inhalation. Contamination of the water supply could also occur by military action, deliberately directed to, or falling into the water supply, or by vandals or terrorists directly contaminating the water. In collaboration with LLNL, Tri-Service Standards (TSS) were developed by the Army in the 1980s and reported in 1990 (Daniels, 1990). These standards were developed as a defensive measure to protect military personnel in the event of a chemical attack with the nerve agent values based on a 50% reduction of red blood cell (RBC) cholinesterase activity (Dacre and Burrows, 1988; Daniels, 1990; Palmer, 1990). The National Research Council (NRC) Committee on Toxicology (COT) reviewed the adequacy and toxicity of the CWAs, and concluded that the TSS should be considered as guidelines for levels that should neither cause acute adverse health effects, nor cause degradation of military performance following ingestion for up to 7 days (NRC, 1995). The levels of contamination were based on 5 and 15 L of water ingested per day, representing consumption during normal and stressful activity, respectively, by our military personnel. The COT accepted the LLNL proposed standards, except for the nerve agents tabun (GA), sarin (GB), soman (GD), and VX, which they recommended be cut in half, corresponding to a 25% reduction in RBCs cholinesterase activity. The Army Medical Department did not accept the COT recommendation for nerve agents and a document supporting this position was prepared in late 1996 and signed by all of the service Surgeons General, justifying the looser standards. Among the supporting data was a study by Bauer et al. (1949). In their study of the effects of the oral ingestion of GB, rats that drank water contaminated with as much as 16 ppm GB for 9 days, showed relatively few signs of GB poisoning. Although the cholinesterase levels in their blood had dropped almost to zero, the animals were apparently healthy, lost no weight, and showed no gross or microscopic pathological
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C003 Final Proof page 53
Chemical Warfare Agent Threat to Drinking Water
12.11.2007 12:49pm Compositor Name: VAmoudavally
53
changes after sacrifice (Bauer et al., 1949). The North Atlantic Treaty Organization (NATO) has also accepted these U.S. military standards (STANAG 2136, 2002). These TSS values (TB MED 577, 2005) are presented in Table 3.2. These recommended standards were neither considered applicable to civilian populations, nor to water-quality standards for drinking water treated at properly functioning fixed installations (Daniels, 1990). The literature reports that deliberate chemical and biological contamination of water supplies has been common in history. These have ranged from crude dumping of human and animal cadavers into water supplies to well-orchestrated contamination with chemicals and biologicals such as rye ergot, hellebore root as well as anthrax and cholera. The crude contamination of water sources, including wells and reservoirs, meant for armies and civilian populations, with filth, cadavers, animal carcasses, and contagious materials, dates back to antiquity and continues even today (Christopher et al., 1997). It has been reported that as far back as 600 BCE the Assyrians poisoned wells with rye ergot, and Solon of Athens poisoned drinking water with hellebore roots during the siege of Krissa. The Cirrhaens drank the water and developed violent and uncontrollable diarrhea and were quickly defeated (Smart, 1997; U.K. MOD, 1999; Noji, 2001; Robey, 2003; Tschanz, 2003). During the Peloponnesian War in 430 BCE, when plague broke out in Athens, the Spartans were accused of poisoning most of the water sources in Athens (Tschanz, 2003). Persian, Greek, and Roman literature from around 300 BCE quote examples of dead animals used to contaminate wells and other sources of water (Dire, 2003). About 200 BCE, the Carthaginians spiked wine with mandrake root to sedate the enemy (Smart, 1997; U.K. MOD, 1999). For thousands of years, cyanide has been used as a waterborne poison. In ancient Rome around 50 CE, Nero eliminated his enemies with cherry laurel water, which contains hydrocyanic acid (Hickman, 1999). During the battle of Tortona in 1155 CE, Barbarossa used bodies of dead and decomposing soldiers to poison the enemy’s water supply (Smart, 1997; U.K. MOD, 1999; Dire, 2003). During the American Civil War in 1863, the confederate troops, under General Johnston, contaminated wells and ponds with animal carcasses during their retreat from Vicksburg. General Sherman and his troops, in pursuit of the Confederates, found the water en route unfit to drink (Harris, 1994; Smart, 1997; U.K. MOD, 1999; Robey, 2003). In World War II, the Japanese attacked at least 11 Chinese cities, intending to contaminate food and water supplies with anthrax, cholera, and various other bacteria. Hitler’s forces released sewage into a Bohemian reservoir, deliberately sickening the population. In deliberate violation of the Geneva Convention, Yugoslav federal forces or those allied with them appeared to have poisoned wells throughout Kosovo in October and November of 1998. They dumped animal carcasses and hazardous materials such as paints, oil, and gasoline in most of the wells in the area, deliberately sickening the populace and denying them the use of the wells (Smith, 1998; Hickman, 1999). Earlier, in 1939 and 1940, over 1000 Manchurian wells were laced with typhoid bacteria that were effective killers. Outbreaks of typhoid fever devastated many villages. About forty 13–15 year old youngsters who drank lemonade made from the contaminated well water contracted typhoid fever and subsequently died (Harris, 1994). In 1970, the Weather Underground, a revolutionary movement, planned to put incapacitating chemical and biological warfare agents into urban water supplies to demonstrate the impotence of the federal government (Tucker, 1999). A group of college students, influenced by ecoterrorist ideology and the 1990s drug culture, wanted to kill most of humanity to prevent the destruction of nature and restart the human race all over again with a select few. Their plan to use aerosol attacks to contaminate urban water supplies with eight microbial pathogens, including agents of typhoid fever, diphtheria, dysentery, and meningitis, was aborted upon discovery of these agents (Tucker, 1999). In 1980, the Marxist revolutionary group called the Red Army Faction, had cultivated botulinum toxins in a safe house in Paris, which was discovered along with plans to poison water supplies in Germany (Tucker, 1999). In spite of this historical background, various governmental agencies have conducted discordant assessments and have failed to evaluate the risk of sabotage contaminating water supplies with chemical and biological warfare agents. The President’s Commission on Critical Infrastructure Protection (PCCIP) indicated that most water-supply systems in the United States are vulnerable to
15
0.35 0.20 0.35 0.35 0.20 0.0175 0.0653 2.273 0.00045 0.0227 0.0129
Blood Agent HCN (hydrogen cyanide)
Vesicants HD (distilled mustard) HL (mustard=Lewisite)a HN3 (nitrogen mustard)a HT (60% HD and 40% T)a L (Lewisite)
Incapacitating Agent BZ (3-quinuclidinyl benzilate)
Biotoxins T-2 mycotoxin Ricina Botulinum toxinsa Staphylococcal enterotoxin B (SEB)a Aflatoxina 0.026 0.909 0.00018 0.0091 0.0052
0.007
0.14 0.08 0.14 0.14 0.08
6
0.140 0.028 0.012 0.012 0.015
0.0087 0.3033 0.00006 0.00303 0.00173
0.0023
0.047 0.027 0.047 0.047 0.027
2
0.046 0.009 0.004 0.004 0.005
Estimated TSS (none established by Lawrence Livermore National Laboratory).
0.350 0.070 0.030 0.030 0.037
GA (tabun) GB (sarin) GD (soman) GF (cyclosarin)a VX
15 L=day
0.0087 0.3033 0.00006 0.00303 0.0173
0.0023
0.047 0.027 0.047 0.047 0.027
2
0.046 0.009 0.004 0.004 0.005
0.0019 0.0649 0.000013 0.00065 0.0037
0.0005
0.01 0.006 0.01 0.01 0.006
0.43
0.01 0.002 0.0009 0.0009 0.001
Daily Human Oral Dose Ingested (mg=kg=day)
0.23–1.0532,42 5–2033 0.001–0.00634,35,42,49 0.05–0.3636 0.02–4.537
1006
1005 305 105 1005 305
0.71–1.434 2.922
0.357–0.7141,2 0.071–0.2861,2 0.071–0.2861,2 0.142 0.043–0.1431–3
Estimated Human Oral Acute LD50 (mg=kg)
0.51 0.50 0.47 0.45 0.40
0.0005
0.01 0.02 0.1 0.01 0.02
45
2.1 1.8 0.8 0.6 1.5
Average % of Estimated Human Oral Acute LD50
46616_C003 Final Proof page 54
a
2 L=day
Nerve Agents
Target Dose for Detection (mg=L)
54
TSS (mg=L) 5 L=day
TABLE 3.2 Tri-Service Standards (TSS) in Drinking Water (Chemical and Biological Agents)
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 12.11.2007 12:49pm Compositor Name: VAmoudavally
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C003 Final Proof page 55
Chemical Warfare Agent Threat to Drinking Water
12.11.2007 12:49pm Compositor Name: VAmoudavally
55
terrorist attacks through the distribution networks (CIAO, 1997). Senator Bill Frist, the Senate Majority Leader and the Senate’s only physician in 2002, stated that our water supply is generally considered safe, but that there is anxiety over the threat of bioterrorism on our water supply (Frist, 2002). The President’s Commission concluded that the water supplied to U.S. communities is potentially vulnerable to terrorist attack by insertion of chemical agents, biological agents, or toxins. The possibility of attack is of considerable concern, and the agents could be a threat if they were inserted at critical points in the system, theoretically causing a large number of casualties (CIAO, 1997). Bill Bracken of the Alabama Department of the Environmental Management Laboratory stated that after September 11, 2001, concern about safety of the nation’s drinking water has increased. He described a variety of chemical agents that could be placed on a community’s water supply. These included nerve agents, pesticides, cyanide, and radioactive materials (Corey, 2002). Nonfissionable radioactive materials, such as cesium-137, strontium-90, and cobalt-60, which cannot be used in nuclear weapons, can be used to contaminate water supplies, business centers, government facilities, or transportation networks. Although these radioactive attacks are unlikely to cause significant casualties, they could still cause damage to property and the environment, and produce societal and political disruption (Oehler, 1996). In April 1985, a threat was made to poison the water supply of New York City with plutonium. To evaluate the credibility of the threat, the New York City water supply was monitored for radioactivity. A sample taken on April 17, 1985, indicated a radioactive level of 21 femtocuries=L, which was a factor 100 times greater than that previously observed. This level, however, was substantially lower than the maximum of 5000 femtocuries considered safe for drinking water under federal guidelines (Purnick, 1985; Bogen et al., 1988). More recently, evidence has surfaced that terrorists trained in Afghanistan were planning to poison water supplies with cyanide, which would be easy to do and very hard to prevent (Brennan, 2001). In January 2002, a bulletin from the Federal Bureau of Investigation’s (FBI) National Infrastructure Protection Center, pointed out that members of al-Qaeda were trying to gain control of U.S. water supplies and waste-water treatment plants. Later, in July 2002, the FBI issued a series of warnings regarding possible terrorist attacks against American targets. The nation’s water utilities were told to prepare to defend against attacks on pumping stations and pipes that serve the cities and suburbs. This action was a result of documents discovered in Afghanistan, which indicated that al-Qaeda terrorists were investigating ways to disrupt the U.S. water supply on a massive scale (Isenberg, 2002). Additionally, President Bush noted in his State of the Union address, that captured al-Qaeda documents included detailed maps of several U.S. municipal public drinking-water systems (Bush, 2002). Also in 2002, the Italian police reported that they had foiled a major terrorist attack by a gang of Moroccans linked to al-Qaeda. They were plotting a chemical attack of the United States Embassy in Rome and the city’s water network. These sites were highlighted on a map found along with nine pounds of powdered potassium ferrocyanide, which is far less deadly than potassium cyanide (McGrory, 2002). As part of their 2002 Congressional Report, the NRC of the National Academy of Sciences (NAS) concluded that water-supply contamination and disruption should be considered a possible terrorist threat in the United States (NRC, 2003). Again, in September 2003, the FBI issued a warning of the potential use of nicotine and solanine by terrorists to poison the food and water supplies (Anderson, 2003). It has also been recognized that a greater threat to our water supply might exist from more commonly available chemicals and materials such as TICs and TIMs as well as naturally occurring pathogens (Salem et al., 2004). The nation’s largest outbreak of waterborne disease occurred in Milwaukee, Wisconsin, in the spring of 1993. Cryptsporidium, a protozoan, passed undetected through two water-treatment plants. It caused over 403,000 illnesses (mostly diarrhea), 4,000 hospitalizations, and 54 deaths in the 800,000 customers who drank the water. Investigators estimated that 725,000 productive days were lost as a result of the water-contamination event, at a cost in excess of $54 million in lost work time or additional expenses to residents and local authorities in Milwaukee. Although the cause was not clear, it confirmed that pathogens introduced
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
56
46616_C003 Final Proof page 56
12.11.2007 12:49pm Compositor Name: VAmoudavally
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
into the water supplies could cause death (Isenberg, 2002). In the year 2000, the municipal water supply of Walkerton, Ontario, Canada was contaminated with Escherichia coli 0157:H7, resulting in 2300 symptomatic residents and seven deaths attributed to the waterborne-disease outbreak. More than $11 million were required to reconstruct the community municipal water system and install temporary filtration after the contamination event. Estimates of the total cost of the Walkerton waterborne-disease outbreak and municipal-water contamination event reached $155 million (Meinhardt, 2005). The Marine Corps has confirmed and suggested that terrorists might employ TICs because they are easily available and accessible. In addition, recent attacks by terrorists have shown their preference to use assets of the host country, rather than smuggling in raw materials or weapon systems (Jakucs, 2003). Although aerosol dispersion of an agent may be more effective in contaminating a larger number of people than through contamination of our water supplies, the PCCIP considered most water-supply systems vulnerable to terrorist attacks primarily through the distribution network (CIAO, 1997). Ideal poisoning agents that can be used to contaminate water should be reasonably or highly toxic. They should be highly soluble or miscible in water, have no taste or odor, be chemically and physically stable, and be resistant to aqueous hydrolysis and water treatment. Additionally, ideal contaminants should be difficult to recognize and detect, as well as having delayed activity, and no known antidote (Deininger, 2000). Because of the critical need for water in every sector of our industrialized society, the water supplies and their distribution systems are potential targets for terrorist activity in the United States. Even short-term disruption of water service can significantly impact a community and lead to serious medical, public health, societal, and economic consequences (Meinhardt, 2005). In the United States and in areas where our troops are deployed, most of the water supply is treated and contains a disinfectant such as free chlorine or chloramines to destroy or control the growth of bacteria. Maintaining a residual free chlorine concentration of 0.5 mg=L for public water supplies and 2.0 mg=L for field drinking water for deployed troops could provide adequate protection from most biological contamination (Burrows and Renner, 1999). However, to effectively contaminate the water supplies, large amounts of sodium thiosulfate could be added to deactivate the chlorine. Deininger et al. (1999) stated that although it may be possible to contaminate a water-supply system, a high degree of physical security combined with maintaining a higher than usual residual chlorine level, should ensure the safety of our water supply. Deininger (2000) also described potential attack points to our water-supply system: upstream of the water intake or treatment plant (which would require large amounts of contaminant); the water intake or treatment plant; a service reservoir; and a point in the distribution system such as a fire hydrant. Individual houses and buildings, not isolated by backflow prevention devices, could also become attack points to the distribution system. He also concluded that there would be greater chances of success if contamination occurred after the treatment plant. There are many and varied agents that could be introduced into water-supply systems, and any one of the contaminants, or even the threat of contamination of the water supply, could cause panic, societal and political disruption.
III. APPROACH AND METHODOLOGY The intent of the authors (subject matter experts) was to review the published literature and to determine the impact of contamination of our drinking water with CWAs, whether in warfare or by terrorist activity. The CWAs that could effectively contaminate our water supplies as a viable threat were targeted. Literature searches were conducted, and the publications were retrieved and reviewed. Areas of interest included TSS (USACHPPM, 2003), oral toxicity doses, water solubilities or miscibilities, stabilities, and half-lives. Attempts were also made to identify toxic hydrolysis products. The data identified are presented in Tables 3.2 and 3.3, and their references are presented in Table 3.4.
HF and cyclohexyl methylphosphonic acid (CMPA)7
42 h at 258C39
1.8 min at 228C in 1.25 M NaOH 10.8 min at 228C in 0.25 M NaOH 31 min at 228C in 0.10 M NaOH 3.3 h at 228C in 0.01 M NaOH 20.8 h at 228C in 0.001 M NaOH 60 h at 228C in pure water7,27 350 days at 258C1,38 110–120 h in well water45 May survive up to 3 years47
3.7 at 208C 5.1 at 08C7,8 Insoluble10
5.0 at 21.58C14
GF (cyclosarin)
VX
VX hydrolyzes via three different pathways (P–S, P–O, and C–S), which vary significantly with temperature and pH. At pH below 12, the P–O bond cleavage path produces ethyl methylphosphonate (EMPA) and the toxic S-[2-diisopropylaminoethyl] methylphosphonothiolate ion (EA 2192). At room temperature, EA 2192 reacts very slowly with OH (EA 2192, t1=2 ¼ 7.4 days [1.0 M NaOH] eventually producing less toxic products) Using an equimolar ratio of VX and water at elevated temperatures appears to reduce the persistency of EA 21926,7,27
Pinacolyl methylphosphonic acid (PMPA) and HF39
3 h at 258C, pH 2 45 h at 258C, pH 6.65 60 h at 258C, pH 107,39
2.1 at 208C7,13 3.4 at 08C7
GD (soman)
46616_C003 Final Proof page 57
Chemical Warfare Agent Threat to Drinking Water (continued )
No4 (half-time for destruction by hypochlorite is 1.5 min at pH 10)
No4
No4
No4
Under acidic conditions, hydrogen fluoride (HF) and isopropyl methylphosphonic acid (IMPA) are formed which further hydrolyze to produce methylphosphonic acid (MPA) and isopropanol. Under alkaline condition, methylfluorophosphonic acid (MFPA) and isopropyl alcohol are initially formed which further hydrolyze to produce MPA and HF7,16
27 min at 208C, pH 1 3.5 h at 208C, pH 2 80 h at 208C, pH 7 5.4 min at 208C, pH 10 0.6 min at 208C, pH 117,24
Completely miscible7,11,12 Completely soluble9
GB (sarin)
No4
Chlorine Resistance
Hydrogen cyanide (AC), dimethyl-aminocyanophosphonic acid7,23 (may react with chlorine to form cyanogen chloride [CK])7
Hydrolysis Products
8.5 h at 208C, pH 77,23
Half-Life
7.2 at 208C 9.8 at 1008C7,8
Solubility in Water (gm=100 gm)
GA (tabun)
Nerve Agents
TABLE 3.3 Agent Physical Characteristics
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 12.11.2007 12:49pm Compositor Name: VAmoudavally
57
1.3 min at 258C7,19
Minutes7,25,26
4 g=L at 258C7,19
Slightly soluble in water7
HN3 (nitrogen mustard)
HT (60% HD and 40% T)
Hydrogen chloride, thiodiglycol, sulfonium aggregates; based on HD6,7
No4
No4
No4
No48
Chlorine Resistance
46616_C003 Final Proof page 58
Hydrochloric acid, ethyl diethylnolamine, cyclic ammonium salts, dimer7,19,29
Hydrogen chloride, thiodigylcol, sulfonium aggregates, 2-chlorovinylarsonous acid (CVAA), and Lewisite oxide based on HD and L6,7,28
Minutes7,19,20,25,26
Hydrogen chloride, thiodiglycol, and sulfonium ion aggregates— one of which is also highly toxic6,7
Ammonia, formic acid (HCOOH), and amorphous brown solids7,16 (may react with chlorine to form cyanogen chloride [CK])7
Hydrolysis Products
5 min at 258C7,25,26 60 min at 258C7,26
Stable but volatizes7,40
Half-Life
Slightly soluble in water7,16,17
Practically insoluble in distilled water 0.92=100 g at 228C7,18 Mustard can survive in sea water up to 5 years47
Miscible with water and common organic solvents, completely soluble in water7,15–17
Solubility in Water (gm=100 gm)
HL (mustard= Lewisite)
Vesicants HD (distilled mustard)
Blood Agent HCN (hydrogen cyanide)
Agent
58
TABLE 3.3 (Continued) Agent Physical Characteristics
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 12.11.2007 12:49pm Compositor Name: VAmoudavally
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Days
Days Unknown
Soluble42
Soluble
Practically insoluble
Practically insoluble
Ricin
SEB (staphylococcal enterotoxin B)
T-2 (trichothecene mycotoxin) Aflatoxin
Unknown
Days (spores may survive years)41,45
6.7 h at 258C, pH 9.87,30 1.8 min at 258C, pH 137,30 3–4 weeks at 258C, moist air pH 77,30 12 min at 348C, pH 127,21 1.4 h at 508C, pH 8.57,21 9.5 h at 1008C, pH 07,21
Minutes7,19,20
Soluble42
Approximately 1.18 g=L, slightly soluble in water7,13,21
Hydrolyzes to form Lewisite oxide (solid), which dissolves very slowly in water7,19,20
Biotoxins Botulinum toxins
Incapacitating Agent BZ (3-quinuclidinyl benzilate)
L (Lewisite)
3-Quinuclidinol and benzylic acid7,30
CVAA, 2-chlorovinylarsenious oxide (Lewisite oxide), and HCl (hydrochloric acid)7,28,43,44
Probably tolerant31,42
Resistant31,42
Unknown31 Contaminated articles disinfected with 0.05% hypochlorite46
Resistant at 10 ppm31,42
Inactivated, 6 ppm, 20 min31 Spores resistant to chlorine41
Yes4
No4
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C003 Final Proof page 59
Chemical Warfare Agent Threat to Drinking Water
12.11.2007 12:49pm Compositor Name: VAmoudavally
59
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
60
46616_C003 Final Proof page 60
12.11.2007 12:49pm Compositor Name: VAmoudavally
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
TABLE 3.4 References 1. 2. 3. 4. 5. 6. 7. 8.
9.
10.
11. 12.
13.
14. 15. 16. 17. 18.
19.
20.
21.
Somani, S.M., Solana, R.P., and Dube, S.N. (1992). Toxicodynamics of nerve agents. In: Chemical Warfare Agents, Somani, S.M. (ed). New York: Academic Press, Inc., pp. 67–123. Salem, H. and Sidell, F.R. (2005). Nerve agents. In: Encyclopedia of Toxicology, 2nd Ed. Wexler, P. (ed). UK: Elsevier, Ltd., p. 201. Ellison, D.H. (2000). Nerve agents. In: Handbook of Chemical and Biological Warfare Agents. Washington, D.C.: CRC Press. USAMRICD (2000). Medical Management of Chemical Casualties Handbook, 3rd Ed. Salem, H., Whalley, C.F., Wick, C.H., Gargan II, T.P., and Burrows, W.D. (2004). Chemical and Biological Warfare Threats to Military Drinking Water Supplies. ECBC-TR-366. Yang, Y., Baker, J.A., and Ward, J.R. (1992). Decontamination of chemical warfare agents. Chemical Reviews 92:1729–1743. Field Manual 3–11.9 (2005). Potential Military Chemical=Biological Agents and Compounds. Samuel, J.B., Penski, E.C., and Callahan, J.J. (1983). Physical properties of standard agents, candidate agents, and related compounds at several temperatures (U). Special Publication ARCSL-SP-83015. U.S. Army Armament Research and Development Command, Aberdeen Proving Ground, Maryland 21010. Agency for Toxic Substances and Disease Registry (ATSDR) (1997). Medical management guidelines (MMGs) for nerve agents: tabun (GA); sarin (GB); soman (GD); and VX. U.S. Department of Health and Human Services, Public Health Service, Atlanta, GA. Available from URL: http==www.atsdr.cdc.gov=MHMImmg166.html, p. 19. Augerson, W.S. (2000). Appendix B: data on nerve agents. In: A Review of the Scientific Literature as It Pertains to Gulf War Illnesses. Volume 5: Chemical and Biological Warfare Agents. Santa Monica, CA: Rand Publications. Available from URL: http==www.rand.org=publications=MR=MR1018.5appb.html, p. 8. Franke, S. (1968). Manual of Military Chemistry Volume I—Chemistry of Chemical Warfare Agents, ACSI-J-3890, Chemie der Kampstoffe, East Berlin, April 1968, UNCLASSIFIED Report (AD849866). Welchman, R.M.A. (1947). Preliminary report on the potential value of nerve gases as C.W. agents, Porton Report No. 2747 (PR2747), Chemical Defense Experimental Establishment, Porton, England, January 1947, UNCLASSIFIED Report. Witten, B. (1969). The search for toxic chemical agents (U). Edgewood Arsenal Technical Report EATR 4210. Department of the Army, Edgewood Arsenal Research Laboratories, Chemical Research Laboratory, Edgewood Arsenal, Maryland 21010, p. 103. Coulter, P.B., Callahan, J.J., and Link, R.S. (1959). Physical constants of thirteen V agents. U.S. Army Chemical Warfare Laboratories Technical Report CWLR 2346. Army Chemical Center, Maryland, p. 34. The Merck Index (2001): An Encyclopedia of Chemicals, Drugs and Biologicals, 13th Ed. Whitehouse Station, New Jersey: Merck & Company, Inc., p. 857. Clark, D.N. (1989). Review of reactions of chemical agents in water (Task 80) ADA 213287. U.S. Army Medical Research and Development Command, Ft. Detrick, Maryland, p. 71. USACHPPM Technical Guide 218 (1996). Detailed and general facts about chemical agents. U.S. Army Center for Health Promotion and Preventive Medicine, Aberdeen Proving Ground, Maryland. Buckles, M.F. (1956). CW vesicants: selected values for the physical properties of H, T, and Q (U), Special Report CRLR 542, Chemical Corps Chemical and Radiological Laboratories, Army Chemical Center, MD, May 1956, UNCLASSIFIED Report (AD108272). Kirner, W.R. (1946). Summary technical report of Division 9, NDRC Vol 1, Chemical warfare agents, and related chemical problems Part I–II, Chapter 7, p. 83, Office of Scientific Research and Development, Washington, D.C., 1946, UNCASSIFIED Report (AD234270). Buswell, A.M., Price, C.C., Roberts, R.M., Smith, C.W., and Velzen, B.H. (1944), The chemistry of certain arsenical chemical warfare agents as water contaminants, OSRD 4193, Division 9 National Defense Research Committee of the Office of Scientific Research and Development, June 1944, UNCLASSIFIED Report. Rosenblatt, D.H., Dacre, J.C., Shiotsuka, R.N., and Rowlett, C.D. (1977). Problem definition studies on potential environmental pollutants VIII: chemistry and toxicology of BZ (3-Quinuclidinyl Benzilate), USAMBRDL-TR 7710, USA Medical Bioengineering Research and Development Laboratory, Fort Detrick, Maryland, 1977, UNCLASSIFIED Report (ADB030349). (continued )
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C003 Final Proof page 61
Chemical Warfare Agent Threat to Drinking Water
12.11.2007 12:49pm Compositor Name: VAmoudavally
61
TABLE 3.4 (Continued) References 22. Dart, R.C. (2000) Cyanide. In: The 5 minute toxicology consult. Lippincott, Williams and Wilkins, p. 342. 23. Marsh, D.J., Williams, L.T.D., and Liddell, H.F. (1948). Kinetics of the hydrolysis of ethyl dimethylamino cyanophosphonate (and certain other related compounds) in water, Proton Technical Paper No. 85 (PTP-85), Chemical Defense Expiramental Establishment, Porton, England, December 1948, UNCLASSIFIED Report. 24. Epstein, J. (1948). Studies on hydrolysis of GB I. Effect of pH and temperature on hydrolysis rates II. Observations on hydrolysis of GB in sodium bicarbonate buffered waters, MDR 132, Chemical Warfare Laboratories, Army Chemical Center, Maryland, February 1948, UNCLASSIFIED Report. 25. Bartlett, P.D. and Swain, C.G. (1949). Kinetics of the hydrolysis and displacement reactions of b, b0 -[dichlorodiethyl sulfide (Mustard Gas)] and of b-chloro-b0 -hyroxidediethyl sulfide (Mustard Chlorohydrin). Journal of the American Chemical Society 71:1406, 1949. 26. Brookfield, K.J., Woodward, F.N., and Owens, R. (1942). The kinetics of the hydrolysis of vesicants part II-2:20 -Dichlorodiethylsulphide (H), SO=R=576, Military Intelligence Division, Great Britain, March 1942, UNCLASSIFIED Report. 27. Yang, Y., Szafraniec, L.L., Beaudry, W.T., Samuel, J.B., and Rohrbaugh, D.K. (1994). Hydrolysis of VX: activation energies and autocatalysis. In: Proceedings of the 1994 ERDEC Scientific Conference on Chemical Biological Defense Research 15–18 November 1994, UNCLASSIFIED Paper (ADE479900), ERDEC-SP-036, pp. 375–382, USA Edgewood Research, Development and Engineering Center, Aberdeen Proving Ground, Maryland, May 1996, UNCLASSIFIED Report (ADA313080). 28. Bossle, P.C., Ellzy, M.W., and Martin, J.J. (1989). Determination of Lewisite contamination in environmental waters by high performance liquid chromatography, CRDEC-TR-042, USA Chemical Research Development and Engineering Center, Aberdeen Proving Ground, Maryland, January 1989, UNCLASSIFIED Report (ADA206000). 29. Dawson, T.P. A memorandum report (1943): new compounds bis(B-Chloroethylioethyl) ether (T) and its mixtures with Mustard (HT), TDMR 534, USA Chemical Research and Development Laboratories, Army Chemical Center, Maryland, January 1943, UNCLASSIFIED Report (ADB960651). 30. Sass, S. and Master, I. (1961). Basic esters of glycolic acids (U): Part III analysis and chemical properties of microgram and larger quantities of EA 2277 and related compounds, CRDLR 2088, USA Chemical Research and Development Laboratories, Army Chemical Center, Maryland, August 1961, UNCLASSIFIED Report (AD325351). 31. Hickman, D.C. (1999). A chemical and biological warfare threat: USAF water systems at risk. Available from URL: http:==www.au.af.mil=au=awc=awcgate=cpc-pubs=hickman.htm 32. Wannemacher, R.W. and Weiner, S.L. (1997). Trichothecene mycotoxins. In: Textbook of Military Medicine, Part I Warfare, Weaponry, and the Casualty, Medical Aspects of Chemical and Biological Warfare. Sidell, F.R., Takafugi, E.T., and Franz, D.R. (eds), Office of the Surgeon General, Department of the Army, Washington, D.C., pp. 655–676. 33. Franz, D.R. and Jaax, N.K. (1997). Ricin toxin. In: Textbook of Military Medicine, Part I Warfare, Weaponry, and the Casualty. Medical Aspects of Chemical and Biological Warfare. Sidell, F.R., Takafuji, E.T., and Franz, D.R. (eds), Office of the Surgeon General, Department of the Army, Washington, D.C., pp. 631–642. 34. Gill, D.M. (1982). Bacterial toxins: a table of lethal amounts. Microbiological Reviews 46:86–94. 35. Schantz, E.J. and Johnson, E.A. (1992). Properties and use of botulinum toxin and other microbial neurotoxic medicine. Microbiological Reviews 56:80–99. 36. Robinson, J.P. (1973). Modern CB weapons and the defense against them. In: The Problem of Chemical and Biological Warfare. Volume 2. CB Weapons Today. Stockholm: Almquist Wicksell, pp. 27–115. 37. Bourgeois, C.H., Shank, R.C., Grossman, R.A., Johnsen, D.O., Wooding, W.L., and Chandavimol, P. (1971). Acute aflatoxin B toxicity in the Macaque and it’s similarities to Reye’s syndrome. Laboratory Investigation 24(3):206–216. 38. National Research Council (1995). Guidelines for chemical warfare agents in military field drinking water. Washington, D.C.: National Academy Press, p. 80. 39. Buckles, L.C. (1947). The hydrolysis rate of GD. Technical Command Informal Report 373, Project A 1.13, AD-B966 291. Chemical Research, Development, and Engineering Center, Aberdeen Proving Center, Maryland, p. 8. 40. Agency for Toxic Substances and Disease Registry (ATSDR) (1997). Public Health Statement for Cyanide. U.S. Department of Health and Human Services, Public Health Service, Atlanta, GA. Available from URL: http==www.atsdr. cdc.gov=toxprofiles=phs8.html, p. 8. 41. Burrows, W.D. and Renner, S.E. (1999). Biological warfare agents as threats to potable water. Environmental Health Perspectives 107(12):975–983.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
62
46616_C003 Final Proof page 62
12.11.2007 12:49pm Compositor Name: VAmoudavally
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
TABLE 3.4 (Continued) References 42. Hickman, D.C. (1999). Seeking asymmetric advantage: is drinking water an air force Achilles’ heel? Air Command and Staff College, Air University, Maxwell Air Force Base, Alabama. Research Report AU=ACSC=084=1999-04, p. 41. 43. Bossle, P.C., Pleva, S.G., and Martin, J.J. (1989). Determination of 2-chlorovinylarsonic acid in environmental waters by ion chromatography. Technical Report CRDEC-TR-206. U.S. Army Armament Munitions Chemical Command, Aberdeen Proving Ground, Maryland 21010–5423, 15 p. 44. Bossle, P.C., Ellzy, M.W., and Martin, J.J. (1989). Determination of Lewisite contamination in environmental waters by high-performance liquid chromatography. Technical Report CRDEC-TR-042. U.S. Army Armament Munitions Chemical Command, Aberdeen Proving Ground, Maryland 21010–5423, p. 13. 45. Lory, E., Cannon, S., Hock, V., Van Blaricum, V., and Cooper, S. (2002). Potable water CBR contaminated and counter measures. NBC Defense Collective Protection Conference. http:==www.dtic.mil=dodsrch=docView? c ¼ DD0C976002CAEB35&dk ¼ http%3A%2F%2Fnsc.natick.army.mil%2Fjocotas%2FColPro_Papers%2FHock.pdf 46. Staphhylococcal Enterotoxin B (SEB) (2002). Biological warfare defense information sheet. Available from URL: http:==www.emergency.com=seb.htm 47. Bull, J.M.R. (2006). House taken on Army’s offshore dumping. Available from URL: http:==ewatch.prnewswire.com 48. De Lorenzo, R.A. (1999). Cyanide: the deadly terror weapon that every EMS provider must know about. Journal of Emergency Medical Services JEM 24(10):54–58, 60–61, 64–65. 49. Middlebrook, J.L. and Franz, D.R. (1997). Botulinum toxins. In: Textbook of Military Medicine, Part I Warfare, Weaponry, and the Casualty. Medical Aspects of Chemical and Biological Warfare. Sidell, F.R., Takafuji, E.T., and Franz, D.R. (eds). Washington, D.C.: Office of the Surgeon General, Department of the Army, pp. 643–654.
Target doses for detection were estimated based on the TSS developed for field drinking water by the U.S. Army in collaboration with the LLNL. Because of the terrorist threat against civilian populations, we considered it prudent to include contamination of a daily water consumption of 2 L=day in table 3.2, because this is considered the daily water intake by civilian populations. The amount of allowable contamination in 2, 5, and 15 L=day were based on direct linear extrapolation (Deininger, 2000). Not considered in these calculations, however, was the dilution factor enhancing absorption, as well as the effects on distribution, metabolism (biotransformation) and excretion (ADME) over the 7 day ingestion or exposure period. Table 3.2 also includes estimated oral toxic doses and target doses for detection, based on the lowest concentration of the contaminant, as well as the estimated daily human oral doses ingested, and the estimated human acute oral LD50. In addition, Table 3.2 lists the percentages of the human oral LD50 ingested daily. Because the only toxin that had a previously established TSS was T-2, it was used to determine a constant to calculate estimated TSS for other toxins. Although the relationship between the TSS concentration at the 5 L=day consumption and the minimum reported LD50 may not be the same for all toxins, this was the value used in our calculations, that is C¼
TSS (5 L=day) mg=L=70 kg 0:026 ¼ ¼ 0:0016: Estimated minimum human LD50 =70 kg 16:1
Thus, the estimated TSS for toxins was derived using 0.0016 times the estimated minimum human LD50=70 kg individual for the other toxins in Table 3.2. If no estimated human oral toxicological data were available, the Army used an uncertainty factor of 10 for interspecies extrapolation from animals to human (NAS, 1995). This same methodology was used to establish the human LD50 for T-2 toxin, because there has not been an estimated human LD50 by the oral route. These tables are dynamic documents that will be updated as new data or more precise methods of extrapolation become available. ‘‘Weaponized’’ CWAs usually refer to those agents that have been treated or processed to enhance their abilities for dissemination and toxicity by the inhalation
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C003 Final Proof page 63
Chemical Warfare Agent Threat to Drinking Water
12.11.2007 12:49pm Compositor Name: VAmoudavally
63
and dermal routes of exposure. ‘‘Weaponization’’ can be accomplished by adding stabilizers to agents to prevent degradation and agglomeration, adding thickeners to increase viscosity and persistence, and by developing more effective means of dispersal (Seevers et al., 2002). It is not known if any agents have been weaponized specifically for use against water targets. Historically, nonweaponized agents have been used effectively to contaminate water supplies, thereby reducing unit readiness. Therefore, when considering contamination of water supplies, a more generic definition of weaponized would be needed to include all routes of exposure. Weaponization therefore, would include chemical agents that have been produced for dissemination in sufficient quantities to cause the desired effect by any route of exposure. The desired effect is scenario and mission dependent and may be illness, death, or deniability of life-sustaining drinking water or real estate. The agents selected for these tables were based on many factors, including technical, political, and social. The technical factors for effectiveness in water were stated above. The threat can be real or perceived and still result in civil and social disruption. If the public suddenly lost confidence in the integrity of the water system, a domino effect could result in a panic run on bottled water and alternative water supplies (Meeks, 2003).
IV. RESULTS AND DISCUSSION CWAs are chemicals designed for use in military operations to kill, injure, or incapacitate humans through physiological actions. These were classified into categories according to their effects on the body including nerve agents, vesicating or blistering agents, respiratory or pulmonary agents, blood agents, and incapacitating agents. Research into nerve agents began in the 1930s when they were developed in secrecy before and during World War II. Related substances are used in medicine as well as in other fields such as the use of pesticides in agriculture, but lack the potency of the military agents. They are extremely toxic and vary in persistence; some create a short-term battlefield hazard, whereas others linger for days or weeks. The nerve agents include: GA, GB, GD, GF, and VX. The G agents were given the code letter ‘‘G’’ because they originated in Germany, whereas the V allegedly stands for venomous. The nerve agents and related pesticides are organophosphates and function through the inhibition of the enzyme acetylcholinesterase (AChE). AChE is the critical regulatory enzyme for the conduction of neuromuscular activity because it breaks down the neurotransmitter acetylcholine. When the nerve agent binds to the active site on AChE, the enzyme can no longer function in destroying the neurotransmitter. Thus, the acetylcholine (neurotransmitter) builds up at the neuromuscular junction and causes continuous nerve impulse generation and organ stimulation. The organs with cholinergic receptors include smooth and skeletal muscles, central nervous system, and exocrine (secretory) glands. The effects of nerve agent exposure depend on dose, route and duration of exposure, and range from miosis through rhinorrhea secretions, muscle fasciculations, and convulsions to death from paralysis of respiratory muscles. These effects can be remembered by the acronym SLUDGE (salivation, lacrimation, urination, diarrhea, gastrointestinal cramping, and emesis) or by DUMBBELS (diarrhea, urination, miosis, bronchorrhea, bradycardia, emesis, lacrimation, and salivation—Salem, 2005). The data for the nerve agents are presented in Tables 3.2 and 3.3. Table 3.2 includes the TSS or estimated TSS, target dose for detection, daily human oral dose ingested, estimated human oral acute LD50, and average percent of estimated human oral acute LD50. Table 3.3 includes solubility in water, half-life in water, hydrolysis products, and chlorine resistance. Some of the CWAs (GF, HL, HN3, and HT) did not have TSS established by LLNL, so they were estimated based on studies in various animal species and by different routes of exposure. These data were based on the most toxic analog or compound in the mixture. For example, the estimated TSS dose equivalent for GF was estimated from GD, its closest analog, and for HL from L which is more toxic than HD, and for HT from HD which is more toxic than HT (Table 3.2). The target dose for detection is based on the lowest concentration found in the water that would not cause degradation of military performance if consumed for up to 7 days.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
64
46616_C003 Final Proof page 64
12.11.2007 12:49pm Compositor Name: VAmoudavally
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
In a previous publication (Salem et al., 2004), the authors calculated the target dose for detection in terms of mg=day for a 70 kg service member, irrespective of the volume of water consumed. However, reevaluation by the authors determined that the target dose for detection should be based on the daily consumption. Thus, the target dose for detection, in mg=L, in this publication is effectively lower than in the previous publication, because it assumes a daily drinking-water consumption of 15 L. Even so, these numbers are conservative because the entire volume of contaminated water (2, 5, or 15 L=day) is not consumed at one time, but over a period of hours. The calculated percentage of the oral LD50 consumed (Table 3.2) assumes that the entire dose of contaminated water is consumed at one time. In the study by Bauer et al. (1949) on the effects of oral ingestion of GB, rats were trained to consume all of their daily drinking water in a 15 min period. The LD50 values were also determined by intragastric administration. The authors reported that the total of GB consumed in drinking by the surviving rats can be as much as three times the LD50 if the total is received over a period of several days. Apparently, the intervals between consuming the contaminated water allow for metabolism or biotransformation and elimination, thereby diminishing the toxicity. The estimated oral LD50 for botulinum toxin A is 0.07 mg=70 kg person or 0.001 mg=kg. This number is reported by Robinson (1973) and Hickman (1999). This estimated LD50 is corroborated in publications by Martin and Adams (2003). The rat oral dose is usually a much higher number (less toxic) and is reported by Gill (1982) as many orders of magnitude less toxic than when administered parenterally (Meyer and Eddie, 1951; Lamanna, 1959). Botulinum toxin A is a simple protein comprising a single polypeptide chain, readily detoxified by heat, mechanical stress, and oxygen (Stevenson et al., 1947; Lamanna, 1959). In contaminated water, it remains highly toxic for several days but decays rapidly in open air. This toxin inhibits the release of acetylcholine at sites needed to transmit nerve impulse to muscles. Botulinum toxin by ingestion produces nausea and diarrhea, followed by headache, dizziness, fatigue, weakness, vertigo, extreme constipation, convulsions, and death due to paralysis of respiratory muscles. The nerve agents are liquid under temperate conditions. When dispersed, the more volatile ones (G Agents), constitute both a vapor and liquid hazard. Sarin (GB) is the most volatile, although it evaporates less readily than water. Of the G agents, GA is the least volatile. The much less volatile V agents (such as VX) represent primarily a liquid hazard. The nerve agents are organophosphorous cholinesterase inhibitors, inhibiting butyryl-cholinesterase in the plasma and AChE in the RBCs and at cholinergic receptor sites in tissue. Acetylcholine accumulates at the nerve in receptor sites and continues to stimulate the affected organs. The clinical effect from nerve agent exposure is caused by excess acetylcholine. When nerve agents are absorbed into the gastrointestinal (GI) tract, they cause an increased motility of the GI tract, increased secretion by the glands in the wall of the GI tract, and include cramps, salivation, diarrhea, vomiting, anorexia, and involuntary defecation (USAMRICD, 2000; Seevers et al., 2002).
A. BLOOD AGENTS (HYDROGEN CYANIDE) The cyanides are considered to belong to the ‘‘blood agents’’ that were introduced, and used by the French during World War I. No deaths were reported from its military use. It was considered to be militarily useless because of its volatility (Haber, 1986), and because it is rapidly detoxified in the body at the rate of 17 mg=kg body weight=min (USAMRICD, 2000). Hydrogen cyanide and cyanogen chloride affect bodily functions by inactivating the cytochrome oxidase system, which prevents cell respiration and the normal transfer of oxygen from the blood to body tissues (PMCBA, 2005). Cyanide salts in solid form or in solution are readily absorbed from the GI tract (USAMRICD, 2000). Cyanide is primarily an environmental contaminant of industrial processes and usually enters the drinking water as industrial waste (NRC, 1995). Chlorination of
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C003 Final Proof page 65
Chemical Warfare Agent Threat to Drinking Water
12.11.2007 12:49pm Compositor Name: VAmoudavally
65
water containing hydrogen cyanide results in the formation of cyanogen chloride, which is also highly toxic, but less toxic than hydrogen cyanide (Cotton and Wilkinson, 1980). Cyanogen chloride has limited solubility in water, persists for more than 24 h, and slowly hydrolyzes to the cyanate ion. All cyanates can persist in aerobic water at pH 7 at 208C for 10 days (Resnick et al., 1958).
B. BLISTER AGENTS (VESICANTS) The blister agents were introduced into warfare in World War I, to produce casualties, to degrade fighting efficiency, and to restrict use of terrain and equipment. The vesicants include sulfur mustard, commonly referred to as mustard. The original mustard (H) was Levinstein mustard that contained about 30% impurities, and thus was distilled to increase the purity (HD) (PMCBA, 2005). The nitrogen mustards (HN1, HN2, HN3), synthesized in the 1930s, were not produced in large amounts for warfare. Mechlorethamine (HN2, or Mustargen) became the prototypical cancer chemotherapeutic compound and remained the standard compound for this purpose for many years (USAMRICD, 2000). Because of their physical properties, mustards are persistent under cool conditions, but as temperature increases, mustards will evaporate. Persistency can be increased by dissolving them in thickeners (PMCBA, 2005). Lewisite (L) was synthesized during the late stages of World War I, but has probably not been used on the battlefield. The antidote, British Anti-Lewisite (BAL), is used in medicine today as a heavy-metal chelator (USAMRICD, 2000).
C. INCAPACITATING AGENTS Incapacitating agents induce an inability to perform any military task effectively and imply that the condition is achieved with the use of a nonlethal weapon. These agents differ from other CWAs in that their lethal dose is theoretically many times greater than the incapacitating dose. As a result, they do not seriously endanger life except in cases exceeding many times the effective incapacitating dose, and they do not produce permanent injury. Incapacitating agents include deliriants, stimulants, depressants, and psychedelics, and they interfere with higher functions of the brain such as attention, orientation, perception, memory, motivation, conceptual thinking, planning, and judgment. The chemicals that produce delirium demonstrate the incapacitant syndrome of confusion, hallucinosis, and disorganized speech and behavior. The subgroup of anticholinergics are regarded as the most likely to be used as military incapacitating agents. Of these, 3-quinuclidinyl benzilate (BZ) is considered the most likely candidate for military use (PMCBA, 2005). BZ is a glycolate anticholinergic compound related to atropine, scopolamine, and hyoscyamine. It acts as a competitive inhibitor of acetylcholine at postsynaptic and postjunctional muscarinic receptor sites in smooth muscle, exocrine glands, autonomic ganglia, and the brain. In addition, BZ causes peripheral nervous system effects opposite to those seen in nerve agent poisoning. Agent 15 is an (alleged Iraqi) incapacitating agent that is likely to be chemically identical to BZ, or closely related to it (USAMRICD, 2000).
D. TOXINS Toxins are poisonous byproducts of living organisms (microbes, snakes, insects, spiders, sea creatures, and plants). As with chemical agents, toxins have the potential to cause incapacitation as well as lethality. Depending on the goals of the adversary, incapacitation may be more effective than lethality. Large numbers of ill patients might overwhelm the medical and evacuation infrastructure, and create panic and disruption of the affected population (USAMRICD, 2005). The toxins included in this chapter are considered potential water threats, and botulinum toxins and ricin are considered to have been weaponized, whereas staphylococcal enterotoxin B (SEB) is considered to have probably been weaponized (Hickman, 1999).
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
66
46616_C003 Final Proof page 66
12.11.2007 12:49pm Compositor Name: VAmoudavally
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
E. BOTULINUM TOXINS Toxins of potential concern include botulinum toxins, a group of seven toxins (A through G) produced by Clostridium botulinum. The spores are ubiquitous and germinate into vegetative bacteria that produce toxins during anaerobic incubation. They can also be produced in large quantities for use as biological warfare agents by industrial-scale fermentation. Botulinum toxins are the most potent neurotoxins known. They are proteins with molecular masses of approximately 150,000 Da. Each of the seven, distinct but related neurotoxins is produced by a different strain of C. botulinum and all act by a similar mechanism of inhibition of presynaptic acetylcholine release. The clinical syndrome ‘‘botulism’’ begins with cranial nerve palsies, including ptosis, blurred vision, diplopia, dry mouth and throat, dysphagia and dysphonia, followed by symmetrical descending flaccid paralysis, with generalized weakness and progression to respiratory failure (PMCBA, 2005; USAMRICD, 2005). All seven types of botulinum toxins act by similar mechanisms of inhibition of presynaptic acetylcholine release and produce similar effects when inhaled or ingested and can be used to contaminate food or water. The clinical syndrome produced by these toxins is known as botulism. Although botulinum toxins do not cross the blood–brain barrier and do not cause central nervous system (CNS) disease, the psychological sequelae of botulism may be severe and may require specific intervention (USAMRICD, 2005). Botulinum toxins are inactivated by sunlight within 1–3 h or by heat at 808C for 30 min or at 1008C for several minutes. Chlorine will cause over 99.7% inactivation of botulinum toxins by 3 mg=L free available chlorine (FAC) in 20 min (USAMRICD, 2005).
F. RICIN Ricin is a potent protein cytotoxin, easily extracted from the beans of the castor plant (Ricinus communis), which is ubiquitous. When ingested, ricin causes severe GI symptoms followed by vascular collapse and death. Ricin is made up of two hemagglutinins and two toxins. The toxins, RCL III and RCL IV, are dimers with molecular masses of approximately 66,000 Da. The toxins are made up of two polypeptide chains (A and B) connected by a disulfide bond. The cytotoxicity of ricin is due to inhibition of protein synthesis, caused when the B chain binds to cell-surface receptors and the toxin–receptor complex is taken into the cell, and the A chain that has endonuclease activity and, at extremely low concentrations, will inhibit DNA replication and protein synthesis (USAMRICD, 2005). Ricin is stable under ambient conditions and can be detoxified by heat at 808C for 10 min, or 508C for an hour at a pH of 7.8. Chlorine inactivates over 99.4% by 100 mg=L FAC in 20 min. Low chlorine concentrations, such as 10 mg=L FAC, as well as iodine at up to 16 mg=L will have no effect on ricin (USAMRICD, 2005).
G. STAPHYLOCOCCAL ENTEROTOXIN B (SEB) SEB is an exotoxin protein of 28,494 Da produced as an extracellular product of Staphylococcus aureus. This pyrogenic toxin normally exerts its effects on the GI tract, and is thus called an enterotoxin. It belongs to a class of potent immune stimulants known as bacterial superantigens. Superantigens bind to monocytes at major histocompatibility complex type II receptors rather than the usual antigen-binding receptors. This leads to the direct stimulation of large populations of T-helper cells while bypassing the usual antigen processing and presentation. A brisk cascade of proinflammatory cytokines (tumor necrosis factor, interferon, interleukin-1, and interleukin-2) is induced with recruitment of other immune effector cells and relatively deficient activation of counter-regulatory negative feedback loops. This results in an intense inflammatory response that injures host tissues. Thus, the toxic effects of SEB are considered to be mediated via the released cytokines. Oral exposure results predominantly in GI symptoms including nausea, vomiting, and diarrhea, and may result in toxic shock and death (USAMRICD, 2005).
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C003 Final Proof page 67
Chemical Warfare Agent Threat to Drinking Water
12.11.2007 12:49pm Compositor Name: VAmoudavally
67
H. TRICHOTHECENE MYCOTOXIN T-2 The T-2 mycotoxins have a low molecular mass of 250–500 Da, are nonvolatile compounds produced by filamentous fungi or molds of the genus Fusarium, and are extremely stable in the environment. Of the multiple mechanisms of actions, many are poorly understood. However, their most notable effect stems from their ability to rapidly inhibit protein and nucleic acid synthesis. Thus, they are markedly cytotoxic to rapidly dividing cells, such as in the bone marrow, GI tract (mucosal epithelium), skin, and germ cells. This cytotoxic effect imitates the hematopoietic and lymphoid effect of radiation sickness, thus the mycotoxins are referred to as ‘‘radiomimetic agents.’’ The mycotoxins also alter cell-membrane structure and function, inhibit mitochondrial respiration, and inactivate certain enzymes. Decontamination requires the use of hypochlorite solution under alkaline conditions, such as 1% sodium hypochlorite and 0.1 M NaOH with 1 h contact time (USAMRICD, 2005).
V. CONCLUSIONS The estimates of human oral toxicities are based primarily on experimental animal studies. Although the data are reported as oral, the contaminants may have been administered by oral gavage or by allowing the animals to drink contaminated water. If this was the case, the results would be different. Also not considered is the dilution factor in 2, 5, or 15 L of consumption per day. Greater dilution of the contaminant could enhance absorption via enhanced surface contact. In addition, since the TSSs were based on 7 day consumption, not only is absorption a factor, but so is distribution, metabolism or biotransformation, as well as excretion. Another factor that complicates the definitive data used in making the extrapolations used in determining the threat is the type of water used in the studies. Some studies report the use of raw, distilled, or seawater. Based on these and other uncontrolled or undefined details, the threat defined in this chapter appears credible based on the available data. The literature reports that chemical and biological contamination of water supplies has been common in history since at least 600 BCE, some of which have been described in this chapter. The U.S. Army has had a long-standing concern about deliberate contamination of military drinking water and has previously addressed this in collaboration with LLNL by promulgating TSS for CWAs that might be used to contaminate military drinking water. Although in 1974, Epstein explained that it would be difficult to deposit a harmful amount of nerve agent into large drinking-water systems, Deininger (2000), described potential attack points in our water-supply systems. PCCIP indicated that most water-supply systems in the United States are vulnerable to terrorist attacks through the distribution networks (CIAO, 1997). Senator Bill Frist, the Senate Majority Leader, and the Senate’s only physician at the time, stated that our water supply is generally considered safe, but there is anxiety over the threat of bioterrorism on our water supply (Frist, 2002). In addition to the CWAs and toxins discussed in this chapter, contamination with readily available TICs and TIMs can also be a major contamination threat to our water supplies. Attempts to contaminate our water supply can have unnerving effects, including panic as well as societal and political disruption. The public would lose confidence in our government, the integrity of our water supply, and the resulting domino effect could cause a panic run toward bottled water and alternative water supplies (Meeks, 2003).
REFERENCES Anderson, C. (2003). FBI issues wanted bulletin for 4 men (possible terrorist threat). FreeRepublic.com, September 5, 2003. Available from URL: http:==209.157.64.200=focus=f-news=976791=posts, p. 4. Bauer, V.E., Epstein, J., Flannery, M.C., and Somers, L.M. (1949). The effect of the oral ingestion of GB in water on rats, Medical Division Report No. 186.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
68
46616_C003 Final Proof page 68
12.11.2007 12:49pm Compositor Name: VAmoudavally
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Bogen, D.C., Krey, P.W., Volchok, H.L., Feldstein, J., Calderon, G., Halverson, J., and Robertson, D.M. (1988). Threat to the New York City water supply-plutonium. Science of the Total Environment 70:101–118. Brennan, P. (2001). French terrorist chief warns of new attacks, possibly cyanide. Reprinted from NewsMax. com, Tuesday, November 27, 2001. Available from URL: http:==www.newsmax.com=cgi-bin=printerfriendly.pl?page ¼ http:==www.newsmax.com=archives=articles=2001=11=26=175352.shtml, p. 2. Burrows, W.D. and Renner, S.E. (1999). Biological warfare agents as threats to potable water. Environmental Health Perspectives 107(12):975–983. Bush, G.W. (2001). ‘‘Remarks by the President to the Troops and Personnel,’’ Norfolk Naval Air Station, February 13, 2001. Available at URL: http:==www.whitehouse.gov=news=releases=20010213-1.html Bush, G.W. (2002). ‘‘State of the Union Address,’’ The United States Capitol, Washington, D.C., January 29, 2002. Available at URL: http:==www.whitehouse.gov=news=releases=2002=01=20020129-11.html Christopher, G.W., Cieslak, T.J., Pavlin, J.A., and Eitzen, E.M. (1997). Biological warfare: a historical perspective. Journal of the American Medical Association 278(5):412–417. CIAO (Critical Infrastructures Assurance Office) (1997). The President’s Commission on Critical Infrastructure Protection (PCCIP) (1997). Critical foundations: protecting America’s infrastructures. Available from URL: http:==www.ciao.gov=resource=pccip=report_index.htm, p. 190. Copeland, C. and Cody, B.A. (2006). Terrorism and security issues facing the water infrastructure sector. Congressional Research Service, the Library of Congress. Corey, R. (2002). Short Course Examines Safety of Water Supply. TimesDaily.com, Alabama. Available at URL: http:==www.timesdaily=com=apps=pbcs.dll=article?Date¼20020813&Category¼NEWS&ArtNo¼ 208130324&SectionCat¼&Template¼printart, p. 1. Cotton, F.A. and Wilkinson, G. (1980). Advanced Inorganic Chemistry, A Comprehensive Text, 4th Ed. New York: John Wiley & Sons. Dacre, J.C. and Burrows, W.D. (1988). Recommended field drinking water criteria for chemical agent sulfur mustard. Technical Report 8816, AD A221745. U.S. Army Biomedical Research and Development Laboratory, Fort Detrick, MD Fredrick, MD. Daniels, J.J. (1990). Evaluation of Military Field-Water Quality. Vol. 4. Health Criteria and Recommendations for Standards. Part 2. Interim Standards for Selected Threat Agents and Risks from Exceeding These Standards. Lawrence Livermore National Laboratory and U.S. Army Biomedical Research and Development Laboratory. AD-A241 523. UCRL-21008, pp. 1–2, 7–16. Deininger, R.A. (2000). The threat of chemical and biological agents to public water supply systems. Water Pipeline Database, TSWG Task T-1211, SAIC Contract N 39998-00, 32 p. Deininger, R.A., Litherathy, P., and Bartram, J. (1999). Security of public water supplies. Proceedings of the NATO Advanced Research Workshop (Tihany, Hungary, June 1998), p. 264. Dire, D.J. (2003). Biological warfare. eMedicine, Instant Access to the Minds of Medicine. Available from URL: http:==www.emedicine.com=aaem=byname=biological-warfare.htm, p. 2. Frist, W. (2002). When Every Moment Counts: What You Need to Know About Bioterrorism from the Senate’s Only Doctor. New York: Rowman & Littlefield, Inc., p. 182. Gill, D.M. (1982). Bacterial toxins: a table of lethal amounts. Microbiological Reviews 46:86–94. Haber, L.F. (1986). The Poisonous Cloud: Chemical Warfare in the First World War. Oxford, U.K.: Clarendon Press. Harris, S.H. (1994). Factories of Death: Japanese Biological Warfare 1932–45 and the American Cover-up. New York: Routledge, p. 297. Hickman, D.C. (1999). Seeking asymmetric advantage: is drinking water an air force Achilles’ heel? Air Command and Staff College, Air University, Maxwell Air Force Base, Alabama. Research Report AU=ACSC=084=1999-04, 41 p. Isenberg, D. (2002). Securing U.S. water supplies. July 19, 2002. Center for Defense Information, Terrorism Project. Available from URL: http:==www.cdi.org=terrorism=water.cfm, p. 3. Jakucs, R.M. (2003). WMD with toxic industrial chemicals and the Marine Corps response. Marine Corps Gazette, Quantico 87(4):42–43. Available from URL: http:==pqasb.pqarchiver.com=mca-marines= Lamanna, C. (1959). The most poisonous poison. Science 130:763–772. Martin, C.O. and Adams, H.P. (2003). Neurological aspects of biological and chemical terrorism. Archives of Neurology 60:21–25. McGrory, D. (2002). al-Qaeda Plotted Cyanide Attack on Rome’s Water. Available at URL: http:==72.14.207.104=search?q¼cache:uPBtXaNo3a8J:www.chretiens-et-juits.org=article.ph
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C003 Final Proof page 69
Chemical Warfare Agent Threat to Drinking Water
12.11.2007 12:49pm Compositor Name: VAmoudavally
69
Meeks, B.N. (2003). U.S. water supply vulnerable. MSNBC News Terrorism & Security. Available from URL: http:==stacks.msnbc.com=news=685645.asp, p. 7. Meinhardt, P.L. (2005). Water and bioterrorism: preparing for the potential threat to U.S. water supplies and public health. Annual Review of Public Health 26:213–237. Meyer, K. and Eddie, B. (1951). Perspectives concerning botulism. In: Zeitschrift Fur Hygiene Und Infektionskrankheiten; Medizinische Mikrobiologie, Immunologie und Virolgie, Volumbe 133, pp. 255–263. NAS. (1995). Guidelines for chemical warfare agents in military field drinking water (1995). Commission on Life Sciences, National Academic Press. Noji, E.K. (2001). Bioterrorism: a new ‘global’ environmental health threat. Global Change and Human Health 2(1):46–53. NRC (National Research Council) (1995). Guidelines for chemical warfare agents in military drinking water. Committee on Toxicology, National Research Council, National Academy Press, Washington, D.C., p. 80. NRC (National Research Council) (2003). A review of the EPA water security research and technical support action plan: parts I & II Water & Science Technology Board. National Research Council, National Academy Press, Washington, D.C., pp. 11–13. Available at URL: http:==darwin.nap.edu=books= 0309089824=html=11.html Oehler, G.C. (1996). The threat of nuclear diversion. In: Speeches and Testimony, Statement for the Record by Dr. Gordon C. Oehler, Director, Nonproliferation Center to the Senate Armed Services Committee, ‘‘The Continuing Threat from Weapons of Mass Destruction’’ 27 March 1996. Central Intelligence Agency. Available from URL: http:==www.odci.gov=cia=public_affairs=speeches=1996=go_toc_032796. html, pp. 3–4. Palmer, W.G. (1990). Field-water quality standards for BZ. Technical Report 9001. U.S. Army Biomedical Research and Development Laboratory, Fort Detrick, MD Fredrick, MD. PMCBA (Potential Military Chemical=Biological Agents and Compounds) (2005). FM 3–11.9. Purnick, J. (1985). Plutonium found in city water; Koch says supply system is safe. New York Times, Late City Final Edition. July 27, Section 1, p. 1. Resnick, J.D., Moore, W.A., and Ettinger, M.B. (1958). Behavior of cyanates in polluted water. Industrial And Engineering Chemistry 50:71–72. Robey, J. (2003). Bioterror through time. Discovery Channel Series, February 21, 2003. Available from URL: http:==dsc.discovery.com=anthology=spotlight=bioterror=history=history.html, p. 3. Robinson, J.P. (1973). Modern CB weapons and the defense against them. In: The Problem of Chemical and Biological Warfare. Volume 2. CB Weapons Today. Stockholm: Almquist Wicksell, pp. 27–115. Salem, H. (2003). Issues in chemical and biological terrorism. International Journal of Toxicology 22:465–471. Salem, H. (2005). G-series nerve agents. Encyclopedia of Toxicology, 2nd Ed, Volume 2. Wexler, P. (ed), p. 473. UK: Elsevier Ltd. Salem, H. (2006). Homeland security and bioterrorism. In: Toxicology and Regulatory Process. Green, S. (ed). New York and London: Taylor and Francis. Salem, H., Whalley, C.F., Wick, C.H., Gargan II, T.P., and Burrows, W.D. (2004). Chemical and biological warfare threats to military drinking water supplies. ECBC-TR-366. Seevers, E., Gamache, R., Howell, J., Pontones, P., and Ingraham, L. (2002). Public Health Emergencies Reference Manual. Indiana State Department of Health. Available at URL: http:==www.in. gov=isdh=bioterrorism=manual=section_12.htm, p. 232. Smart, J.K. (1997). History of chemical and biological warfare: an American perspective. In: Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare. Sidell, F.R., Takafuji, E.T., and Franz, D.R. (eds), Office of the Surgeon General, Department of the Army, Washington, D.C., Chapter 2, pp. 9–86. Available from URL: http:==www.usuhs.mil=cbw=history.htm Smith, R.J. (1998). Poisoned wells plague towns all over Kosovo, Aid Organizations blame Yugoslav security forces. Washington Post, December 9, 1998, p. A30. STANAG 2136 (2002). Minimum standards of water potability during field operations and in emergency situations. North Atlantic Treaty Organization (NATO). Stevenson, J.W., Helson, A., and Reed, G.B. (1947). Preparation of clostridium parabotulinum Toxins. Can. J. Research 25:14–24. TB MED 577 (2005). Sanitary control and surveillance of field water supplies.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
70
46616_C003 Final Proof page 70
12.11.2007 12:49pm Compositor Name: VAmoudavally
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Tschanz, D.W. (2003). ‘‘Eye of Newt and Toe of Frog’’: biotoxins in warfare. StrategyPage.com, October 20, 2003. Available from URL: http:==216.239.37.104=search?q¼cache:Tv-SBKjTGFIJ:www.strategypage. com=articles=biotoxin_files=BI Tucker, J.B. (1999). Historical trends related to bioterrorism: an empirical analysis. Emerging Infectious Diseases 5(4):498–504. U.K. MOD (United Kingdom Ministry of Defense) (1999). Defending against the threat of biological and chemical weapons. Outline history of biological & chemical weapons. Available from URL: http:==www. mod.uk=issues=cbw=history.htm, p. 5. USACHPPM (2003). Technical guide 230. Chemical exposure guidelines for deployed military personnel. U.S. Army Center for Health Promotion and Preventive Medicine, Aberdeen Proving Ground, MD. USAMRICD (U.S. Army Medical Research Institute of Chemical Defense) (2000). Medical Management of Chemical Casualties Handbook, Aberdeen Proving Ground, MD, pp. 42, 44, 45, 56, 137. USAMRICD (U.S. Army Medical Research Institute of Infectious Defense) (2005). Medical Management of Biological Casualties Handbook, Fort Detrick, MD, pp. 168–171; 183–185; 189–192; 198–200.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C004 Final Proof page 71
6.11.2007 5:27pm Compositor Name: JGanesan
Effects of Low-Level 4 Health Exposure to Nerve Agents John H. McDonough and James A. Romano Jr. CONTENTS I. Introduction............................................................................................................................ 71 II. Review Papers, Epidemiological Research, and Experimental Studies of Health Effects of Exposure to Nerve Chemical Warfare .................................................................. 72 III. Chronic Health Effects of Acute Exposure ........................................................................... 74 IV. Chronic Health Effects of Repeated Low-Level Exposure ................................................... 81 V. Development of Improved Medical Countermeasures .......................................................... 87 A. Advanced Anticonvulsant System ................................................................................. 87 B. Improved Oxime Therapies for Nerve Agents .............................................................. 88 C. Carbamate Pretreatment ................................................................................................. 88 D. Enzymes as Scavengers ................................................................................................. 89 VI. Summary and Conclusions .................................................................................................... 89 References ....................................................................................................................................... 89
I. INTRODUCTION In 2000, when we wrote this chapter for our earlier work, we were influenced by two events: (1) the significant concern for the health of Persian Gulf War veterans as it might have been affected by possible exposure to low levels of chemical warfare agents and (2) an increase in research, both epidemiological and experimental, into the health effects of exposure to nerve chemical warfare agents. In fact, in a note of optimism, we closed the chapter with this statement ‘‘The authors close by expressing hope that the recent national investment into additional research will allow a more comprehensive assessment to unfold that will possibly contribute to better treatment.’’ In the intervening 6 years, a number of epidemiological and experimental studies have added to the literature regarding health effects of exposure to nerve chemical warfare agents. Additionally, Aas (2003) reviewed current medical therapy for nerve agent intoxication and discussed possible future improvement of medical therapies. Currently, several new approaches to improved treatment of nerve agent intoxication are in full-scale development in the United States. As a result of these developments, this chapter has been updated principally in two areas: (1) inclusion of recent reports on potential chronic health effects from either asymptomatic or symptomatic exposures to nerve agents and (2) discussion of developments leading to potentially improved care for such exposures. The nerve agents are highly toxic organophosphorous (OP) compounds that are chemically related to some insecticides (parathion, malathion). The five most common nerve agents are tabun (o-ethyl N,N-dimethyl phosphoramidocyanidate; military designation ¼ GA), sarin (isopropyl methyl phosphonofluoridate; military designation ¼ GB), soman (pinacolyl methyl phosphonofluoridate; military designation ¼ GD), cyclosarin (cyclohexyl methylphosphonofluoridate; military designation ¼ GF), and VX (o-ethyl S-2-N,N-diisopropylaminoethyl methyl phosphonofluoridate). These compounds exist as colorless and relatively odorless liquids and are meant for use in weapon 71
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
72
46616_C004 Final Proof page 72
6.11.2007 5:27pm Compositor Name: JGanesan
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
systems (shells, rockets, bombs) that are designed to deliver them as aerosols or fine sprays. They exert their toxic effects by inhibiting the cholinesterase (ChE) family of enzymes to include acetylcholinesterase (AChE; E.C.3.1.1.7), a critically important central nervous system (CNS) and peripheral nervous system (PNS) enzyme that hydrolyzes the neurotransmitter acetylcholine (ACh). Although the nerve agents can inhibit other esterases, their potency and specificity for inhibiting AChE account for their exceptionally high toxicity. For example, the rate constants for inhibition of AChE by soman, sarin, tabun, or VX are 2–3 orders of magnitude greater than for the more commonly known OP compounds such as DFP, paraoxon, or methylparaoxon (Gray and Dawson, 1987). Likewise, the rate constants for inhibition of AChE by the nerve agents are also 2–5 times greater than for trypsin (E.C.3.4.21.4), chymotrypsin (E.C.3.4.21.1), or carboxylesterase (E.C.3.1.1.1) (Maxwell and Doctor, 1992) indicative of selective inhibition of this enzyme. Nerve agents bind to the active site of the AChE enzyme, thus preventing it from hydrolyzing ACh. The enzyme is inhibited irreversibly and the return of esterase activity depends on the synthesis of new enzyme (approximately 1%–3% per day in humans). All agents are highly lipophylic and readily penetrate the CNS. Acetylcholine is the neurotransmitter at the neuromuscular junction of skeletal muscle, the preganglionic nerves of the autonomic nervous system, the postganglionic parasympathetic nerves, as well as muscarinic and nicotinic cholinergic synapses within the CNS. Following nerve agent exposure and the inhibition of approximately >40% of the AChE enzyme pool, levels of ACh rapidly increase at the various effector sites resulting in continuous overstimulation. It is this hyperstimulation of the cholinergic system at central and peripheral sites that leads to the toxic signs of poisoning with these compounds. The signs of poisoning include miosis (constriction of the pupils), increased tracheobronchial secretions, bronchial constriction, laryngospasm, increased sweating, urinary and fecal incontinence, muscle fasciculations, tremor, convulsions=seizures of CNS origin, and loss of respiratory drive from the CNS. The relative prominence and severity of a given sign are highly dependent on the route and degree of exposure. Ocular and respiratory effects occur rapidly and are most prominent following vapor exposure, whereas localized sweating, muscle fasciculations, and gastrointestinal disturbances are the predominant signs following percutaneous exposures and usually develop in a more protracted fashion. The acute lethal effects of the nerve agents are generally attributed to respiratory failure caused by a combination of effects at both central and peripheral levels and are further complicated by copious secretions, muscle fasciculations, and convulsions. There are several excellent reference sources that provide more detailed discussions of the history, chemistry, physiochemical properties, pharmacology, and toxicology of the nerve agents (Koelle, 1963; Sidell, 1992; Somani et al., 1992; Marrs et al., 1996; Taylor, 2001). Their rapid onset of effects and extreme toxicity has made the nerve agents eminently suitable for use as chemical warfare (CW) agents and, in some cases, many thousands of tons of these agents have been synthesized for military use. Exposure to lethal levels of nerve agents will produce toxicities that are precipitate in onset and catastrophic in effect (Sidell, 1974). For these reasons, the major medical research efforts since the 1940s focused on developing the best possible lifesaving therapeutic interventions, pretreatments, or, more recently, prevention of long-term changes in CNS function following a moderate to severe intoxication using anticonvulsant drugs (Dunn and Sidell, 1989).
II. REVIEW PAPERS, EPIDEMIOLOGICAL RESEARCH, AND EXPERIMENTAL STUDIES OF HEALTH EFFECTS OF EXPOSURE TO NERVE CHEMICAL WARFARE Due to the focus on lifesaving interventions, it was not until the early 1980s that the question of chronic health effects of low-level exposure to nerve agents was subjected to its first major review. The Committee on Toxicology, National Academy of Sciences, studied the available literature reports from the soldier-volunteer test program of the Army Chemical Center, Aberdeen Proving Ground (formerly Edgewood Arsenal, MD) (National Academy of Science, 1982). Soldier-volunteers
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C004 Final Proof page 73
Health Effects of Low-Level Exposure to Nerve Agents
6.11.2007 5:27pm Compositor Name: JGanesan
73
participated in this test program from 1958 to 1975. There were 15 anticholinesterases (anti-ChEs) tested on approximately 1400 subjects during this time frame with the great majority of anti-ChE agents being tested during the 1950s and 1960s. The National Academy of Sciences’ review found that mortality data compiled in 1981 did not indicate increased deaths among soldier-volunteers when compared with soldiers outside the testing program. There was no clear-cut indication of long-lasting CNS effects and no evidence for mutagenicity, carcinogenicity, male reproductive, or cataractogenic effects (1982). The National Academy of Sciences’ review committee also reported confidence that its analyses would have had the power to detect any major health effects, had they been present. In general, that viewpoint remained the ‘‘state-of-the-art’’ with very little contention until the appearance of Persian Gulf War Illness in the early years of the 1990s. It should be noted that a similar comprehensive review of the exposure to military chemical agents in human volunteers was recently published in the United Kingdom (Ministry of Defense, 2006). Porton Down, the UK chemical test center, had a human volunteer program in place since World War One. Many human exposure tests to nerve agents were conducted at Porton starting in the late 1940s and there is an excellent summary of these and similar US studies by Sidell (1996). Although the Ministry of Defense (2006) study was more to address the ethics of the human volunteer program, it did describe three follow-up studies performed to determine if there were potential long-term health effects of volunteer’s exposure to sarin (Technical Notes, 1972, 1973, 1989). All three studies concluded that there was no evidence that ‘‘the exposure of volunteers to low doses of nerve agents results in any adverse medical sequelae.’’ There were no statistical differences between the number of hospital admissions, out-patient appointments, and incidents of reporting sick or days lost through illness before or after the men’s visit to Porton for those exposed to sarin. Nor were there any differences on these measures between those exposed to sarin and control groups of volunteers who were not exposed. Likewise, there was no evidence of long-term psychiatric symptoms or in the type of illnesses that the exposed versus control groups experienced. As a result of concern regarding a high incidence of undiagnosed illness among veterans of Operation Desert Shield=Storm, a Presidential Advisory Committee was formed to analyze the full range of the Federal Government’s outreach, medical care, research, and coordinating activities pertinent to Gulf War Veterans’ Illness (GWI). The Presidential Advisory Committee also looked at short- and long-term health effects of selected Gulf War risk factors, for example, chemical=biological weapons, depleted uranium, infectious diseases, anti-biological warfare vaccines, pyridostigmine bromide, and so on. The Presidential Advisory Committee gave specific and serious attention to the question of health effects of low-level exposure to nerve agents. The Committee urged DoD to support additional research on the potential long-term health effects of low-level exposures to CW agents, the nerve agents in particular (Presidential Advisory Committee on Gulf War Veterans’ Illnesses, 1996). Such an increased level of research has already been initiated and some elements of it are discussed throughout this chapter. Correspondingly, this work had a proactive component to it. Much of the work within the DoD core research program addressed the question, ‘‘Is the current US military medical treatment doctrine, as well as physical protective measures (protective masks, clothing, and support systems), adequate to protect soldiers in future deployments from effects of exposure to low-levels of CW agents?’’ (GAO=NSIAD, 1998). Since the end of the first Gulf War there has developed a substantial literature, in the form of review papers, on potential long-term health effects from low-level exposure to nerve chemical warfare agents. These papers have presented slightly different analyses of this issue and, not surprisingly, they have reached slightly different conclusions. We do not intend to review this entire body of literature in this chapter. However, we do highlight several papers to show the controversies within the field, as well as areas of consensus. Brown and Brix (1998) argued that for nearly all accidental or wartime exposures to nerve agents or OP compounds, it is difficult to obtain reliable exposure data. Thus, they argued that exposures could be characterized as high,
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
74
46616_C004 Final Proof page 74
6.11.2007 5:27pm Compositor Name: JGanesan
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
intermediate, or low, depending upon factors such as intensity of cholinergic signs (e.g., rhinorrhea, salivation, neuromuscular effects, etc.), level of ChE inhibition, and type of medical treatment required. Clearly identified long-term effects have been noted at or above their defined intermediate level exposure. Long-term health effects, according to Brown and Brix (1998), are not reported in individuals experiencing repeated low-level exposure alone. In his brief review of chronic effects of low-level exposure to anti-ChEs, Roy (1998) concluded that ‘‘concerns about major adverse health effects of low-level exposure to anti-ChEs in general seem entirely unwarranted on the basis of currently available literature, but the data are at present insufficient to reflect the possibilities of subtle, agent-specific effects.’’ Riddle et al. (2003) in their review of potential Gulf War nerve agent exposures found (1) difficulties in documenting symptomatic exposures to nerve agents, (2) corresponding lack of specific exposure-related health effects, yet (3) commented that feelings of helplessness in face of an uncertain exposure could be overwhelming. In Section IV, we will also review the scientific basis for these health concerns. It is a common practice for toxicologists to differentiate exposure to chemicals based on the dose and the duration of exposure. Four time frames have been used to define duration of exposures: acute, subacute, subchronic, and chronic. It is useful in light of today’s interest in ‘‘long-term, lowlevel’’ exposures to clarify these terms. Acute exposure is defined as exposure to a chemical for less than 24 h. When referring to an inhalation exposure, the exposure duration most frequently used is 4 h. Subacute exposure refers to an exposure of 1 month or less, subchronic for 1–3 months, and chronic for more than 3 months. These exposures can be by any route; for most chemicals, it is the oral route with the chemical given in the diet (Klaasen and Eaton, 1991). All are intermittent. The limited animal studies using nerve agents have usually employed parenteral administration of the agent and virtually all of them involve acute or subacute durations of exposure. It is equally important to clearly define the term ‘‘low-level exposure.’’ This term has seen many different usages in the papers reviewed by these authors. These appear to range from any nonlethal exposure through ‘‘subtoxic’’ (defined by DeMenti [1999] as no clinical signs) to ‘‘subclinical’’ (defined by DeMenti [ibid.] as no clinical signs and no significant depression of ChE). Exposure, then, is any contact with a chemical that may induce a biochemical effect. Each definition suffers from arbitrariness and we see no way around this. For the purposes of this review, we will attempt to characterize each paper in terms of presence=absence of either clinical signs or symptoms (in the case of human studies) and level and type of ChE inhibition. With respect to epidemiological research studies, Smith, Gray, and colleagues reported on continuing efforts to assess plausible relationships among potential Gulf War exposures and health effect outcomes. In 1999, they issued their first report, suggesting there was no evidence that Gulf War veterans, possibly exposed to CWA at Khamisiyah, Iraq, were suffering increased hospital morbidity through September, 1995. Between 1999 and 2003 there were improvements and refinements of exposure estimates, as well as improvements in regression modeling of hospitalizations. Thus, in 2003, Smith and colleagues were able to determine the relative risk (RR) of hospitalization, using Cox regression modeling, for an extended sample of possibly exposed veterans versus a cohort not likely to have been exposed through the period ending 31 December, 2000. Recently, this same group reported that RR for hospitalization was actually slightly greater for post-Gulf War deployments to Southwest Asia or to Bosnia than for deployment to the first Gulf War (Smith et al., 2006). In summary, even after employing refined exposure estimates and up to a greater than 10 year postwar hospitalization window, these authors were unable to conclude that Gulf War veterans are at greater risk of hospitalization due to a specific exposure-related disease.
III. CHRONIC HEALTH EFFECTS OF ACUTE EXPOSURE Much of the data regarding long-term neurological sequel to exposures to ChE inhibitors in man have been gathered following accidental exposures to organophosphate pesticides. While pertinent, extrapolation from these exposures to predictions of effects from nerve agents may be subject to
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C004 Final Proof page 75
Health Effects of Low-Level Exposure to Nerve Agents
6.11.2007 5:27pm Compositor Name: JGanesan
75
risk. Several phenomena appear to differentiate nerve agent exposure from exposure to OP pesticides. These include: (1) the fact that the cholinergic crisis caused by acute, severe intoxication with the OP pesticides is generally much longer than that caused by OP nerve agents (days to weeks for pesticides versus hours for nerve agents), (2) many OP pesticides produce delayed peripheral neuropathy, a phenomenon known for more than 50 years, whereas nerve agents have caused polyneuropathy in animals only at doses manifold greater than the LD50—a phenomenon only seen in the presence of massive pretreatment and therapy with atropine and oxime (Davis, Holland and Reumens, 1960), and (3) the ‘‘intermediate syndrome,’’ a delayed manifestation of OP poisoning seen in perhaps up to 100 accidentally poisoned patients (Sidell and Hurst, 1997), has not been described after administration of nerve agents to animals nor in the instances of nerve agent poisoning in man (Sidell, 1997). Grob et al. (1947) described the effects of acute to subacute short-term exposure of humans to DFP (1–2 mg, i.m., daily for up to 7 days) on electroencephalographic (EEG) and psychological parameters. The changes produced by DFP included increases in EEG potential, frequency (especially noted was an increase in beta rhythm), more irregularities in rhythm, and by the intermittent appearance of abnormal waves similar to those seen in patients with grand mal epilepsy (high voltage waves of 3–6 Hz, usually most marked in frontal leads, and increased by hyperventilation). The CNS symptoms that were noted were excessive dreaming, insomnia, jitteriness and restlessness, increased tension, emotional lability, subjective tremulousness, nightmares, headache, increased libido, giddiness, drowsiness, paresthesias, mental confusion, and tremor. The EEG changes usually followed the onset of CNS symptoms. CNS symptoms and EEG changes were correlated with the depression of red-blood cell ChE to 70% and 60% of original activity, respectively. CNS symptoms disappeared within 1–4 days after exposure was stopped while the EEG changes persisted in a diminishing degree from 8 to 42 days (average 29 days). Holmes and Gaon (1956) described essentially similar CNS symptoms and EEG changes but occurring acutely in OP pesticide exposed workers. They also noted that the more severely exposed individuals or those with multiple exposures tended to display persistent symptoms that included forgetfulness, irritability, and confused thinking, although the duration of these persistent symptoms was never clearly defined. These CNS symptoms and EEG changes are virtually identical to those that have been reported to occur following symptomatic exposure to different nerve agents. Grob and Harvey (1953, 1958) described extensive studies of the effects of sarin in man, to include effects on ChE, EEG, and behavior. They noted behavioral and EEG effects virtually identical to those reported for DFP. These effects began coincident with the depression of plasma and red-blood cell ChE activity to approximately 60% and 50% of original activity, respectively, following a single i.v. dose, or 34% and 22% of original activity, respectively, following oral administration. These differences between i.v. and oral administration of sarin highlight the effect of rate of ChE inhibition, and consequently the rate of increase in CNS ACh, as a factor in the development of symptoms of exposure. Bowers et al. (1964) studied the effects of the nerve agent VX in man and described behavioral symptoms of anxiety, psychomotor depression, general intellectual impairment consisting of difficulties in concentration and retention, and sleep impairments generally involving insomnia due to excessive dreaming. Psychological=behavioral effects were typically evident before the occurrence of physical symptoms. These effects were associated with whole blood ChE inhibitions of >60%. There have been descriptions of the acute toxic effects in humans that follow high-dose exposure (>LD50) to the nerve agents soman (Lekov et al., 1966; Sidell, 1974), sarin (Sidell, 1974; Inoue, 1995; Nakajima et al., 1998), and VX (Nozaki et al., 1995). The same cluster of behavioral symptoms that are reported following lower doses (anxiety, psychomotor depression, intellectual impairment, and sleep disturbances) dominate the clinical picture in the immediate period following resolution of the acute toxic signs of intoxication and then slowly fade with time, sometimes taking months to fully resolve. There have been a number of investigations as to the possible long-term consequences of an acute symptomatic exposure to OP compounds. For the nerve agents, Burchfiel et al. (1976)
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
76
46616_C004 Final Proof page 76
6.11.2007 5:27pm Compositor Name: JGanesan
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
evaluated the long-term effects of an acute high dose (5 mg=kg, i.v.) of sarin on the EEG of rhesus monkeys. The animals were paralyzed and artificially respirated during exposure since this dose of sarin produced generalized seizure activity on the EEG that lasted an average of 2.5 h. At both 24 h and 1 year following the exposure there was a significant increase in the relative voltage in the beta frequency bands (13–22 Hz ¼ beta-1; 22–50 Hz ¼ beta-2) in the occipital–temporal EEG lead while the animals were awake in darkness. Similar EEG effects were seen in other animals in this study that were exposed to high doses of the chlorinated hydrocarbon, dieldrin. Functional behavioral tests of other rhesus monkeys exposed to sarin under identical conditions revealed no deficits in performance of a previously learned delayed response test 24 h after the exposure (Lattal et al., 1971). Duffy et al. (1979) performed a similar analysis of EEGs of manufacturer workers accidentally exposed to the nerve agent sarin at doses that produced clinical signs and symptoms of exposure and produced a reduction of erythrocyte ChE at least 25% below the individual’s preexposure baseline. Within the exposed group there was a maximally exposed subgroup that had experienced three or more such exposures. The study was performed at least 1 year after the last exposure. Univariate and multivariate analysis of the data show that the exposed group, especially the maximally exposed subgroup, displayed (1) elevated amounts of spectral energy in highfrequency beta activity, (2) visual inspection of the EEGs showed decreased amounts of alpha (9–12 Hz) activity along with increased amounts of slow activity (0–8 Hz, delta and theta) and an increased amount of ‘‘nonspecific’’ abnormalities in the EEG background, and (3) increased amounts of rapid eye movement (REM) sleep. The functional consequences of these EEG changes were not established, but this group reportedly had a high incidence of self-reported memory disturbances, difficulty maintaining alertness, and appropriate focusing of attention (Metcalf and Holmes, 1969). Several studies of the long-term effects of the sarin-exposure victims from Japan have been published. Murata et al. (1997) and Yokoyama et al. (1998a, 1998b) evaluated 18 victims of the Tokyo subway incident 6–8 months after the exposure. All but three of these victims had plasma ChE values below normal values on the day of exposure. Sarin-exposed individuals scored significantly lower than controls on a digit symbol substitution test; they scored significantly higher than controls on a general health questionnaire (GHQ) (psychiatric symptoms) and a profile of mood states (POMS) (fatigue) as well as having elevated scores on a posttraumatic stress disorder (PTSD) checklist; they had significantly longer P300 latencies on event-related brain evoked potentials and longer P100 latencies on brain visual evoked potentials. The P300 is a late positive wave that occurs between 250 and 800 ms after the onset of a meaningful stimulus and is related to the subject’s psychological reaction to the stimuli and not the physical characteristics of the stimulus. In contrast, the P100 latency and magnitude is directly linked to the physical characteristics of the stimulus. Female-exposed cases were reported to have significantly greater indexes of postural sway. Although exposed individuals of both sexes displayed greater R–R interval variability in their electrocardiograms, the magnitude correlated with degree of ChE inhibition on the day of exposure. The elevated scores on the GHQ and POMS were positively related to the increased PTSD scores and were considered to be due to PTSD and were not related with degree of ChE inhibition on the day of exposure. Some of the Tokyo subway victims have been studied as far out as 7 years after the exposure. Nishiwaki et al. (2001) and Miyaki et al. (2005) reported on rescue workers and police officers who were exposed, and these could be further broken down into high and low exposure groups. The earlier noted changes in postural sway failed to achieve conventional statistical levels of significance in these later studies. There were persistent significant, dose-dependent, changes in psychomotor function (reduced tapping frequency, dominant hand), and a memory test (e.g., shorter backward digit span) in comparison with a referent group. Nakajima et al. (1997, 1998) performed a cohort study of victims of the Matsumoto City sarin exposure 1 and 3 years following the incident. At 1 year following the exposure they report that 20 victims still felt some symptoms (fatigue, asthenopia, blurred vision, asthenia, shoulder stiffness, and husky voice), and that they had lower erythrocyte ChE activity than did those who did not have symptoms and had all lived close to the sarin
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C004 Final Proof page 77
Health Effects of Low-Level Exposure to Nerve Agents
6.11.2007 5:27pm Compositor Name: JGanesan
77
release site. (Note: Not all the symptoms seen at 1 year have been related to nerve agent exposure historically.) At 3 years, some victims still complained of experiencing these symptoms, although with a reduced degree and frequency. There have been two brief reports of severely poisoned nerve agent victims (one sarin, one VX) in Japan that experienced retrograde amnesia, possibly due to prolonged periods of seizures and hypoxia (Nozaki et al., 1995; Hatta et al., 1996). Additionally, one of the Matsumoto victims that experienced prolonged seizure activity was followed up for at least 1 year and was found to have sporadic sharp wave complexes in the EEG during sleep and frequent premature ventricular contractions on Holter monitoring of the electrocardiogram (Sekijima et al., 1995). In addition to these neuropsychological changes that could be attributed to the sarin exposure alone, many of the Japanese victims suffered PTSD (Kawana et al., 2001). There have been a number of reports that have dealt specifically with neurological and psychological changes that appear to be specifically attributed to that condition. Matsuo et al. (2003) reported Tokyo subway sarin attack victims with diagnosed PTSD showed significantly greater activation of the prefrontal cortex as assessed by near-infrared spectroscopy and skin conductance response to stimuli directly related to the exposure incident than did victims without PTSD or controls. Yamasue et al. (2003) reported that victims of the sarin attack with the clinical diagnosis of PTSD showed a significant reduction in grey matter volume of the left cingulate cortex as assessed by voxel-based magnetic resonance imaging (MRI) than did victims of the attack that did not develop PTSD. A similar reduction in anterior cingulate cortex volume has been reported in combat veterans with PTSD (Woodward et al., 2006) and in individuals with PTSD of other etiologies. It has been hypothesized that the anterior cingulate cortex may become hypofunctional as a consequence of repeated glucocorticoid activation during the exaggerated fear responses of PTSD victims and that as this condition goes on the volume of this area may physically shrink (Villarreal and King, 2001; Nutt and Malizia, 2004; Shin et al., 2006). Araki et al. (2005) followed up on the previously reported P300 event-related potential deficits and PTSD. They showed PTSD victims had significantly greater reductions in P300 amplitude than did victims with no PTSD. Moreover, within the group of victims with PTSD there was a positive correlation between P300 amplitude and anterior cingulated cortex grey matter density. Given these findings, it might appear that reduced brain volume or other physical neurologic changes of some of the sarin victims might be confounded by changes in brain function that accompany severe cases of PTSD. Most of these changes in brain volume and functioning that accompany PTSD have been reported over the last 8 years and it is clear that this is still an active area of research to decipher the exact neurophysiological etiology of the changes. Romano et al. (2007) look closely at the stress component of CWA exposure and its possible health effects, to include PTSD (see Chapter 22). Finally, Yanno and Musiychuk (1997) published a short summary of 209 acute poisonings by sarin, soman, or VX in Russian nerve agent production facilities. Twenty-eight percent of the victims required hospitalization that ranged from a few to 120 days. Long-term consequences of these exposures were described as memory loss, signs of asthenia, sleep disorders, diencephalic paroxysms, vegetative changes in the cardiovascular system, and microorganic disorders of the CNS. It was noted that CNS symptoms were most prominent and persistent following soman poisoning, confirming observations made by Sidell (1974). Outside of accidental exposures to nerve agent at military facilities and the Japanese terrorist incidents, the other notable instance of exposure to high doses of nerve agent occurred during the Iran–Iraq war (1981–1987). From 1984 to 1987 there were numerous instances of Iranian troops suffering exposure to supralethal doses of tabun or sarin and surviving due to prompt medical intervention. Experiences from this war in treating nerve agent casualties were described by Dr. Syed Foroutan who published his reminiscences of nerve agent and sulfur mustard casualty care in a series of articles in the Farsi-language Kowsar Medical Journal in the late 1990s. These treatment protocols and general experiences have been summarized in an English-language review paper (Newmark, 2004). It is surprising that there has been no published follow-up medical studies
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
78
46616_C004 Final Proof page 78
6.11.2007 5:27pm Compositor Name: JGanesan
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
of any long-term effects in the many thousand of nerve agent casualties that survived, although there have been a number of studies published on long-term persistent adverse health effects of victims of sulfur mustard exposure from that conflict (Balali-Mood and Hefazi, 2006; Hashemian et al., 2006). In one of the major OP pesticide studies, Savage et al. (1988) retrospectively (approximately 9 year after the poisoning) examined 100 individuals with documented acute OP pesticide poisoning and compared them with matched-pair nonpoisoned controls. They reported no differences between the two groups in visually inspected EEGs or a number of neurological tests. There were, however, significant differences between the two groups in their performance on a number of neuropsychological tests, as well as self- and family-assessment of functioning ratings. They stated that their results showed subtle long-term neuropsychological sequel to acute OP poisoning that are difficult to detect with standard neurological exams that stress sensory and motor function. Rosenstock et al. (1991) performed a retrospective neuropsychological study of OP-poisoned agricultural workers and compared them with a matched control group. They found that when tested 2 years after exposure, poisoned workers self-reported significantly higher numbers of neuropsychological difficulties and had significantly lower test scores than controls on tests of verbal attention, visual memory, and visuomotor and motor functions, as well as tests of visuomotor sequencing and problem solving. Likewise, Steenland et al. (1994) found deficits in vibrotactile sensitivity and sustained attention among previously intoxicated subjects versus controls. These effects showed a rough dose–response relationship in that there were significant trends to worse performance on other neurobehavioral tests by those subjects who were more severely poisoned (longer hospitalization, took more days off from work). However, as with other studies, nerve conduction tests and neurological examinations were negative. There was no evidence of changes in postural sway in poisoned subjects as was reported for the sarin-exposed subjects from Tokyo indicating, perhaps, a difference between OPs and nerve agents with regard to effects on motor activity (Yokoyama et al., 1998a, 1998b). Wesseling et al. (2002) assessed long-term neurobehavioral effects of mild OP or n-methyl carbamate poisoning in banana workers. The subjects (81 exposed, 130 controls) were tested on average after 27 months exposure and assessed on measures of psychomotor and visuomotor performance and neuropsychiatric symptoms. The exposed group showed a modest yet significant decreased performance on a visuomotor (digit symbol substitution) test and an increase in neuropsychiatric symptoms. These effects were especially pronounced in the OP exposed subgroup, and those exposed individuals that reported a subsequent exposure to OPs within 90 days of testing showed even poorer performance. This same research group has followed individuals that were acutely poisoned with OPs up to 2 years after exposure (Delgado et al., 2004). Fifty-three poisoned individuals and 28 controls were given a standardized neurobehavioral test battery at the time of hospital discharge, 7 weeks later and 2 years later. The authors reported decreased visuomotor performance (digit symbol substitution) and verbal memory at the time of discharge, whereas only visuomotor performance was decreased at the 7 week test. No effects were detected at the 2 year testing point, although the exposed subjects reported significantly greater neuropsychiatric symptoms at that time. Studies in animals of long-term effects of acute, nonlethal exposures to nerve agent are numerous in the literature since 1980. Following high-dose exposure (approximately 0.6 LD50 and higher), seizures are a prominent sign of nerve agent intoxication and these prolonged seizures can produce both neural and cardiovascular lesions if not promptly treated (McDonough and Shih, 1997). Neurological, behavioral, and cardiac deficits are predictable long-term effects following exposure to such doses. Animals exposed to convulsant doses of nerve agent can develop spontaneous seizures, display hyper-reactive and aggressive behavior (rats), and display profound deficits in learning and performance of a variety of behavioral tasks. In fact, animal studies have demonstrated deficits in acquisition of several types of operant tasks (differential reinforcement of low rates, alternation), performance of serial probe recognition task, acquisition and performance of several maze tasks, and passive avoidance learning following acute intoxication with nerve
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C004 Final Proof page 79
Health Effects of Low-Level Exposure to Nerve Agents
6.11.2007 5:27pm Compositor Name: JGanesan
79
agents (McDonough, Smith and Smith, 1986; Raffaele et al., 1987; Modrow and Jaax, 1989; Castro et al., 1991; McDonough and Shih, 1997; Raveh et al., 2002, 2003). Invariably, animals displaying such behavioral changes also are shown to have brain lesions in cortical and subcortical limbic structures. Exemplifying the relationships seen between such neuropathology and deficient behavior is the demonstration of EEG and performance changes following near LD50 challenge with soman (GD) in a comprehensive paper by Phillippens et al. (1992). In this study, rats were intoxicated with an LD50 of soman and immediately treated with an antidotal combination of atropine and diazepam (described as a ‘‘low-dose combination’’). These rats had been trained to an overlearned criteria of 80% correct avoidance response (i.e., avoidance of a signaled foot shock). After a period of recovery of motor capacity, animals demonstrated impaired performance of the conditioned response for three test sessions before they approached the prechallenge performance level. Similarly, electrographic correlates of lesions and ultimately, light microscopic observation of lesions suggested the neuroanatomic basis for this deficit. By contrast, animals exposed to the same challenge dose of agent and receiving a ‘‘high-dose combination’’ of atropine and diazepam performed at or near the level of prechallenge performance and were somewhat (but not completely) protected from electrographic and neuropathologic changes. This report demonstrates a general theme found in most of these ‘‘high-dose’’ exposure studies; animals exposed to nerve agents that develop seizures that are not promptly controlled develop brain damage and consequent neurobehavioral problems, animals that do not develop seizures or those that seize and are rapidly and effectively treated with drugs that stop the seizures suffer no brain lesions, and display no long-term neurobehavioral deficits. In the case of acute ‘‘low-level’’ exposures to nerve agents, exposures that produce minimal or no acute CNS signs of intoxication, an earlier study by Burchfield et al. (1976) suggested that a ‘‘clinically sign-free’’ dose of sarin (1 mg=kg, i.m.) given repeatedly (1 time=week for 10 weeks) to nonhuman primates (three rhesus monkeys) resulted in subtle, but persistent, EEG changes (increases in the percentage of high-frequency beta activity) that were virtually identical to those already described above that are seen after an acute high-dose exposure (5 mg=kg, i.v.) that provoked seizures. Pearce et al. (1999) followed behavioral and electrographic outcomes in nine marmoset monkeys for up to 15 months following exposure to a single low dose of sarin (2.5–3 mg=kg, i.m.). Although the dose of sarin caused 36%–67% inhibition of RBC–AChE, there were no acute behavioral signs of intoxication (thus, the exposure was subtoxic), there was no significant change or decrement in performance on a series of touch-screen mediated discrimination tasks either immediately or over a 12–15 month period following the exposure. There were also no significant long-term changes in EEG patterns in this study. Although there were changes in beta-2 amplitude that approached significance (p ¼ 0.07), this was entirely due to a long-term change in the EEG of a single subject out of the nine animals that were exposed. The parameters chosen in this study were employed because they had been used to demonstrate deficits caused by cholinergic lesions or ChE inhibitors in previous studies (Roberts et al., 1992; Sohakian and Coull, 1993). More recently, van Helden et al. (2004) reported that the lowest observable adverse effect level (LOAEL) for vapor exposure to sarin to modify EEG activity in marmoset monkeys produced LOAEL values (0.2 and 0.1 mg=min=m3) for untreated and pyridostigmine pretreated monkeys, respectively, at least an order of magnitude lower than the previously established LOAEL for miosis. When evaluated 1 year after exposure, vehicle pretreated animals had significant increases in total power within each EEG band compared with their recordings a year earlier. A similar, but more attenuated effect was seen in the pyridostigmine pretreated animals. Visual examination of the EEG records at 1 year showed that both groups of sarin-exposed animals had greater number of bursts within the alpha frequency that resembled sleep spindles than did the controls. These results are different than those reported by Pearce et al. (1999) or by Burchfield et al. (1976) that reported changes in the highfrequency beta bands. Genovese and colleagues (Genovese et al., 2007a, 2007b) have reported on several studies on the potential for long-term behavioral effects of acute exposure to several nerve agents. In a study of nonhuman primates, rhesus and African green monkeys were trained to perform a serial probe
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
80
46616_C004 Final Proof page 80
6.11.2007 5:27pm Compositor Name: JGanesan
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
recognition task (a test of short-term memory similar to list learning) and then exposed to doses of approximately 0.25 LD50 of sarin. The animals were tested for up to 3 months following exposure and showed no decrements or changes in performance over that time even though there were significant reductions in blood ChE over that time. These results are similar to the reports of Lattal et al. (1971) and Pearce et al. (1999). In two other studies (Genovese et al., 2007a, 2007b), rats were trained preexposure to perform on a food-motivated variable interval 56 s (VI 56; the first lever press response after a variable interval that averages 56 s produces food reinforcement; this schedule produces steady intermediate rates of lever press responding) operant task. The rats were then exposed to varying doses of cyclosarin or VX using a whole-body inhalation exposure system and then tested repeatedly for up to 3 months on the VI 56 task. In addition, they were tested for their ability to acquire normal performance on a radial arm maze, a task that assesses spatial memory. In both studies, the highest levels of exposure produced transient mild signs of nerve agent intoxication (miosis, fasciculations, mild ataxia) and transient decreases in VI 56 performance at these high doses; doses that produced no signs were without immediate behavioral effects. Across all doses, there were no lasting effects of nerve agent exposure on VI 56 performance or on the acquisition or performance on the radial arm maze task. The authors concluded that doses of nerve agent that produce acute mild signs of intoxication can produce transient disruptions in performance on a well-learned task, but these effects quickly dissipate and there were no evident long-term effects; asymptomatic exposure produces no behavioral effects. In an extensive series of studies, Kassa and colleagues have reported changes in immune function, biochemical parameters, protein and nucleic acid metabolism, and various aspects of neurobehavioral function and learning following single or repeated exposure to sarin or soman in mice and rats. Following a single asymptomatic exposure to sarin, changes in immune function (Kassa et al., 2003, 2004a, 2004b) were seen up to one week after exposure. This group reported that a single inhalation exposure of rats to sarin produced increases in stress markers (plasma cortisol levels, liver tyrosine aminotransferase activity), decreases in DNA synthesis, increases in CNS excitability, and impairments in spatial discrimination (T-maze, Y-maze) that persisted as long as 3 months after exposure (Kassa et al., 2004c). Many of the effects were dose-dependent, animals that were exposed to the highest dose and developed moderate signs of poisoning were most affected, asymptomatic animals showed attenuated and less persistent effects, whereas animals that received repeated asymptomatic exposures showed more long-lasting effects. Many of these effects on immune function have also been reported by Henderson et al. (2001, 2002) and others in that research group (Kalra et al., 2002; Penna-Philippides et al., 2007). They have shown that F344 rats exposed either once or multiple times to asymptomatic levels of sarin vapor had decreases in immune function that typically recovered over weeks after the exposures stopped. Pretreatment of the rats with chlorisondamine attenuated the effects of sarin on immune response, implicating the autonomic nervous system in these sarin-induced changes. They also reported that there were reductions in serum adrenal corticotrophic hormone (ACTH) and corticosterone levels that were still evident after 4 weeks exposure. It is quite possible that many of the effects on the immunological system reported for sarin exposure may be due to the central nicotinic effects of ACh stimulation, since this same group has reported similar immunological function changes following chronic nicotine exposure (Langley et al., 2004; Razani-Boroujerd et al., 2004). Marrs et al. (1996) and Sidell (1996) have provided an extensive overview of human studies of nerve agent exposures conducted by the US and the UK military as well as accidental exposures that occurred at production or test facilities. Although this report does not come to any conclusions about long-term effects, there is no indication that asymptomatic exposures to nerve agents have produced long-term, adverse health effects. This is the same conclusion reached by the National Academy of Sciences, committee that reviewed the then available literature, to include the EEG studies of Burchfield et al. (1976) and Duffy et al. (1979). They stated that while there may be subtle
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C004 Final Proof page 81
6.11.2007 5:27pm Compositor Name: JGanesan
Health Effects of Low-Level Exposure to Nerve Agents
81
long-term EEG changes, the clinical significance and functional relevance of such changes had not been demonstrated (National Academy of Science, 1982).
IV. CHRONIC HEALTH EFFECTS OF REPEATED LOW-LEVEL EXPOSURE For chronic or repeated subclinical exposures to OP compounds, whether they are CW nerve agents or OP pesticides, the data in regard to long-term health effects are less consistent. As regards to the nerve agents, the report of Burchfield et al. (1976) about the effects of repeated low doses of sarin to rhesus monkeys producing a long-term increase in relative power in the EEG beta frequency bands is the most cited study in support for a long-term health effect. There are no human studies known to these authors, other than the National Academy of Science report (1982) on the volunteer program mentioned earlier, which directly address the possible adverse long-term health effects of repeated subclinical exposures to nerve agents. Workers exposed to small amounts of nerve agents that produced mild, nonthreatening medical signs of exposure, reported CNS effects such as headache, insomnia, excessive dreaming, restlessness, drowsiness, and weakness (Marrs et al., 1996). The medical officers describing these patients suggested that ‘‘mental processes used in making judgments and decisions were also affected’’ (Marrs et al., 1996). Out of 53 patients with mild exposures not requiring antidotal therapy, CNS symptoms often were fully resolved within 3 days after exposure. However, Sidell cautions that psychological symptoms are probably more common than usually recognized and may persist in more subtle forms for much longer days or weeks than physical symptoms (Sidell, 1974). Reports in the literature of animal studies show that nerve agents can be administered repeatedly with minimal overt neurobehavioral effects if care is taken in choosing the dose and the time between doses (Sterri et al., 1980, 1981). Blood and brain AChE levels can be reduced to >20% of normal with no observable signs of toxicity with appropriate dosing schedules. Animal studies performed at the USAF School of Aerospace Medicine have demonstrated a progressive and longlasting inhibition of ChE in the CNS following repeated administration of low doses of the nerve agent soman, a finding recently corroborated by Olson using the nerve agent sarin (Hartgraves and Murphy, 1992; Olson et al., 2000). There appear to be differential sensitivities among various brain regions, with frontal and pyriform cortex being most sensitive to the ChE inhibiting effects of CW nerve agents, whereas the neostriatum and the hypothalamus are relatively less sensitive. These studies and others did not demonstrate a tolerance to the CNS ChE inhibiting effects of repeated administration of low levels of CW nerve agents. Recovery from the ChE inhibition produced by chemical warfare nerve agents or other OP compounds is not a simple matter, however. The recovery of CNS ChE does not parallel the recovery of plasma ChE, with plasma ChE often recovering much more rapidly than RBC–AChE, which more closely parallels the recovery of brain AChE (McDonough et al., 1983; Russell et al., 1986) Thus, these and other tolerance studies (Clement 1989, 1991) suggest that behavior has often recovered to near baseline, while AChE is still significantly lowered. This has been noted clinically and Sidell (1992) cautions, ‘‘Analysis of blood for ChE is useful for occupational monitoring, but in an exposed patient, one treats the patient, not the ChE activity.’’ Recently, Olson et al. (2000) and Benschop et al. (1998) have provided reports of animal studies of effects of repeated low-level exposure to nerve CWA. In rats, Olson et al. determined the LOAEL and NOEL of subacute dosages of sarin, administered, i.m. They found that the dose of sarin (GB) needed to produce a low but measurable blood ChE inhibition was 0.75 mg=kg once a day for 4 days. Thus, the exposure in Olson’s study would be described as subclinical. GB was paired with a variety of other chemicals to include chlorpyrifos, DEET (N,N-diethyl-m-toluamide), carbaryl, and PB. No neurobehavioral or neuropathologic effects could be attributable to dosing with GB alone or in any combination with the other chemicals. Rats were also evaluated using a functional observational battery (FOB) and a Figure 8 Activity Monitor with no significant behavioral effects reported. Benschop et al. (1998) reported on the toxicokinetics of low-level inhalation exposure to soman in
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
82
46616_C004 Final Proof page 82
6.11.2007 5:27pm Compositor Name: JGanesan
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
atropinized guinea pigs. Animals were exposed to 200 ppb for 5 h of a toxic steroisomer of soman, which resulted in a gradual inhibition of RBC–AChE to approximately 10% of baseline. This level of exposure resulted in an insignificant reduction of AChE activity in brain and diaphragm although it was equivalent to Ct values of 0–48 mg min=m3, a dose well above one sufficient to cause an incapacitating miosis. The observed lack of inhibition of AChE in brain and diaphragm at the end of the long-term, low-level exposure was interpreted to mean that systemic intoxication is unlikely despite extensive inhibition of blood AChE. Furthermore, Benschop et al. argued that the development of persistent neuropsychological disorders under these conditions would be unlikely. The authors cautioned that studies in animals without the benefit of carboxylesterase binding sites, such as primates, would most probably reflect a different outcome. This last study points out the influence of dose rate in determining whether a given exposure would be ‘‘nonlethal,’’ ‘‘subtoxic,’’ or ‘‘subclinical,’’ a point made as long ago as 1975 by Sim. The latter wrote that a patient appearing in a clinic without measurable ChE, yet not appearing to be intoxicated, ‘‘emphasizes that the poison is cumulative and if taken into the body slowly, can be accommodated without the appearance of critical illness.’’ The most notable effect of repeated low doses of nerve agents seen in animal experiments is the development of tolerance to the disruptive effects of each acute exposure on certain behaviors (Russell et al., 1986; van Dongen and Wolthuis, 1989; Hymowitz et al., 1990; Wolthius et al., 1990; Clement, 1991). This is primarily thought to be brought on by downregulation (i.e., reduction in the number) of muscarinic receptors in the brain, which will remain lowered (maximal reduction 30%–40%) for the duration of the exposure and then recover in parallel with the erythrocyte ChE activity following the cessation of exposure (McDonough et al., 1983; Churchill et al., 1984). During the period of reduction in muscarinic receptor numbers, the animals are subsensitive to antiChEs or direct acting muscarinic agonists and suprasensitive to the effects of antimuscarinic drugs (e.g., atropine) (Modrow and McDonough, 1986). In this respect, nerve agents act much like other OP compounds and the possibility and mechanisms of tolerance development have been addressed in several studies (see the review by Russell and Overstreet [1987] for an overview of these animal studies). The question of behavioral tolerance is seen by some authors as a masked toxicity in a vulnerable organism (DeMenti, 1999) or as an adaptive response to a changed internal physiologic state (Young et al., 1999). Bignami et al. (1985) have suggested that while some of the tolerance developed to OPs may be attributable to cholinergic receptor changes, behavioral (test) variables may also play a role. These authors studied feeding and drinking responses and examined the role of practice factors in tolerance to paraoxon. Specifically, they measured the decrease in food consumption and the strength of a conditioned flavor aversion (CFA) produced by repeated doses of low levels of paraoxon. They qualified their finding of reductions in the depression of food intake or extinction of CFA by stating that treatment–behavior interactions may produce apparent attenuations of toxicity, which are often not maintained when the situation is changed, leaving open entirely the nature of the purported response. Munro et al. (1994) reviewed both animal and human studies of the nerve agents tabun, sarin, and VX and paid special attention to the phenomenon of organophosphorous induced delayed neuropathy (OPIDN). Reproductive toxicity and carcinogenicity tests were reviewed as well as in vitro studies of mutagenicity. Munro et al.’s findings can be summarized as follows: (1) for the nerve agent tabun, no evidence of subchronic toxicity was observed at any dose other than effects on ChE activity. No evidence of teratogenicity was found and tabun was a weakly active in an in vitro assay as a mutagen, (2) for nerve agent sarin, no evidence of acute or chronic toxicity was found at low intermittent exposure levels, sufficient to significantly depress AChE levels. No evidence for carcinogenicity, teratogenicity, or mutagenicity was found for sarin, but a data gap in the area of reproductive toxicity was noted, and (3) for nerve agent VX, no evidence for likely development of OPIDN was found. VX exposure sufficient to significantly depress RBC–AChE activity produced no subchronic toxicity, no evidence of carcinogenicity was found, and based on multiple studies VX was not considered a potential mutagen or a teratogen. Thus, the authors concluded that the
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C004 Final Proof page 83
Health Effects of Low-Level Exposure to Nerve Agents
6.11.2007 5:27pm Compositor Name: JGanesan
83
overriding concern with regard to exposure to tabun, sarin, or VX was their extraordinarily high acute toxicity (Munro et al., 1994). Since the original preparation of this chapter, a number of other animal studies have been published that involve repeated low level, asymptomatic, exposure to nerve agents, primarily sarin. In a series of reports, Scremin and colleagues used a standard exposure paradigm to evaluate the effects of repeated sarin exposure, chronic pyridostigmine exposure, or repeated sarin þ pyridostigmine exposure on a variety of physiological and behavioral parameters at 2, 4, and 16 weeks after the conclusion of the exposures. They gave rats regular drinking water or water adulterated with pyridostigmine (to produce ~30% reduction in RBC–AChE) and then exposed them to 0.5 3 LD50 of sarin or saline by SC injection three times a week for 3 weeks. In the first study (Scremin et al., 2003), the animals were then evaluated on various neurobehavioral tests (passive avoidance, acoustic startle response, open-field locomotion, nocioceptive threshold) at 2, 4, and 16 weeks after the cessation of exposure. The sarin exposure produced no acute observable signs of OP intoxication. At 2 weeks after exposure, acoustic startle was enhanced while locomotor activity was decreased in sarin-exposed animals; these effects were not seen in the sarin þ pyridostigmine or pyridostigmine groups. At 4 weeks after exposure, there were no differences between groups. At 16 weeks, the sarin animals had reduced habituation in the open field while there was more rapid habituation and an increase in nocioceptive threshold in the sarin þ pyridostimine group. Brain AChE was not affected by sarin exposure, although they did measure a reduction in brain muscarinic receptors at 2 weeks after exposure. In a second report (Scremin et al., 2005), regional cerebral blood flow and glucose utilization were measured. There were significant increases in regional cerebral blood flow, but not glucose utilization, in neocortex at 2 weeks after exposure for the sarin þ pyridostigmine group, with a similar pattern of change being seen in the sarin group at 4 weeks after exposure. Changes seen at 16 weeks after exposure were few and random. The authors concluded that there were no long-term changes in cerebral activity as indexed by cerebral glucose use or blood flow produced by repeated sarin exposure or any of the other treatments. Likewise, this group has recently reported (Scremin et al., 2006) that such chronic sarin and sarin þ pyridostigmine treatments produced lower heart rates and changes in heart rate power spectrum that were prominent at different times of the daily circadian cycle in freely moving rats 2 weeks posttreatment. These differences were not seen at the 4 and 16 week observation times, nor were there changes in locomotor activity at any time. In a final report (Shih et al., 2006), levels of both endogenous and synthesized choline (Ch) and ACh were determined in a variety of brain regions at the three postexposure time points. There were significant differences in endogenous levels of ACh and Ch at the 2 and 4 week time points between controls and exposed groups; there was no difference in the ability to synthesize ACh at any of the test times. There were no group differences on any of these measures at the 16 week observation time, leading the authors to conclude that there were no persistent changes in these measures of cerebral cholinergic function. A study by Atchison et al. (2004) provided information on the initial validation of a guinea pig model of low-dose exposure to the nerve agents sarin, soman, and VX. This model was then used in a number of subsequent studies that evaluated physiological, electrophysiological, biochemical, and behavioral effects of this exposure paradigm. In the Atchison et al. (2004) study, male guinea pigs were injected (sc) once a day, 5 days a week (M–F), for 2, 4, or 13 weeks with 0.2, 0.4, 0.6, and 0.8 3 acute LD50s previously established of sarin, soman, or VX. These exposure times (2, 4, and 13 weeks) were designed to cover the subacute to chronic durations of exposure as defined by Klaassen and Eaton (1991). Signs of cholinergic toxicity (for 2 h after exposure) and body weights were monitored throughout the exposure period. After the initial study, a second study was performed using asymptomatic doses (vehicle, 0.2 and 0.4 3 LD50) administered for 2 or 4 weeks according to the same protocol. In these animals, red-blood cell AChE was measured 1 h after the last injection, then 3 days later, the animals were sacrificed and diaphragm tissue was collected for measurement of AChE activity, blood was sampled for standard chemistries and hematology, and tissues (brain, heart, lung, liver, gallbladder, kidney, adrenal gland, skeletal muscle, sciatic nerve,
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
84
46616_C004 Final Proof page 84
6.11.2007 5:27pm Compositor Name: JGanesan
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
and testes) were collected for histopathology (hematoxylin and eosin stain) examination by a board certified veterinary pathologist. Doses of 0.2 or 0.4 3 LD50 of any of the three agents were tolerated with no lethality or toxic signs throughout the 13 week exposure. In contrast, 0.8 3 LD50 of the three agents were lethal to all animals exposed to this dose, and 0.6 3 LD50 of sarin was also lethal while these same dose fractions of soman or VX were survived by ~20% of the animals. In the 2 and 4 week exposure study with 0.2 and 0.4 3 LD50 of each agent, blood AChE was inhibited from 75% to 91% of control activity on the last day of exposure depending upon the agent and the dose regardless of whether the animals were exposed for 2–4 weeks. Diaphragm AChE measured 3 days after the last exposure was inhibited 18%–30% depending upon the agent, but the differences were not statistically significant compared with controls. There were no differences in body weight gains, body temperature, blood chemistries, hematology, or histopathology of any of the tissues collected between exposed guinea pigs and the controls. It should be noted that in the 4 week exposure study, animals received cumulative doses of 4 and 8 3 the acute LD50 of each of these nerve agents. The 2 week repeated exposure paradigm in guinea pigs has been used in subsequent studies of the effects of repeated nerve agent exposure on learned and unlearned behaviors, EEG activity, and brain neurochemistry. Hulet and colleagues (Hulet et al., 1993; Shih et al., 2006) used this exposure protocol with guinea pigs to determine any adverse effects of repeated doses (saline, 0.4 3 or 0.5 3 LD50) of sarin. The animals were assessed for changes in body weight, RBC–AChE levels, neurobehavioral reactions to an FOB, cortical EEG power spectrum, and intrinsic ACh neurotransmitter regulation over the 2 weeks of sarin exposure and for up to 12 days postinjection. Animals receiving the 0.5 3 LD50 showed signs of cholinergic toxicity and gained significantly less weight than the 0.4 3 LD50 or saline animals, which did not differ from each other. RBC–AChE levels had dropped to 11% and 10% of control values for the 0.4 and 0.5 3 LD50 groups, respectively, by the end of the sarin-exposure period, although the rate of AChE depression was faster in the 0.5 3 LD50 group. Both the 0.4 and 0.5 3 LD50 groups failed to display evidence of habituation to aspects of being handled over the period of exposure, unlike the controls which showed a significant decline in these scores on the FOB test. Power spectral analysis of the EEG showed that saline-injected animals tended to fall asleep after exposure and showed a progressive increase in the power of the lower (delta, theta) bandwidths. The high-dose sarin-exposed animals (0.5 3 LD50) failed to show any change in distribution in EEG power over this time while the 0.4 3 LD50 sarin animals were intermediate between the controls and the high-dose group. These changes persisted for 6 days after the exposure ended for the high-dose group. Six days after the end of the exposure, sarin-exposed animals showed a greater increase in striatal ACh output than controls, as measured by microdialysis, in response to a pharmacological challenge with atropine. The authors concluded that the results suggested subtle, but transient, effects on neurobehavioral function, EEG, and brain neurochemistry for the asymptomatic animals that received the 0.4 3 LD50 sarin, and possibly more persistent changes in the symptomatic 0.5 3 LD50 sarin group. Langston et al. (2005) trained dietary restricted guinea pigs responding for food on progressive ratio (PR) schedule. Once performance had stabilized, the animals were exposed daily (5 day=week) to 0.1, 0.2, or 0.4 3 LD50 sarin for 2 weeks and performance was measured during the 2 weeks of exposure and for 2 weeks following the exposure. The two lower doses (0.1 and 0.2 3 LD50) produced no effects on performance during or after the period of exposure. However, the 0.4 3 LD50 dose group showed decreases in body weight and concurrent decreases in response rates and break points that was due to increases in pausing following receipt of food reinforcement. These performance changes reverted to preexposure levels following termination of the exposure. There are several other reports that have demonstrated the disruptive effects of the 0.4 3 LD50 chronic sarin, soman, or VX exposure in food-restricted animals, which has also been reported by others. Sipos et al. (2001; and in Thompson et al., 2004, 2005) evaluated the effects of repeated lowdose exposure of guinea pigs to sarin, soman, or VX using this same procedure and evaluate acoustic startle response and active avoidance (two-way; air puff) performance. Chronic low-level exposure to sarin, soman, or VX enhanced acoustic startle. This enhancement started after several
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C004 Final Proof page 85
Health Effects of Low-Level Exposure to Nerve Agents
6.11.2007 5:27pm Compositor Name: JGanesan
85
days of exposure with sarin (0.4 3 LD50) and abated over the weekend when sarin was not administered; this effect on acoustic startle was more robust (occurred earlier) in animals exposed to soman or VX. Only soman produced any effect (decreased avoidance) on active avoidance performance. There are numerous studies of humans that have addressed the issue of chronic or repeated subclinical (asymptomatic) exposures to OP pesticides, but there is no consensus among the results and this has been reflected in several recent reviews (Colosio et al., 2003; Kamel and Hoppin, 2004). Korsak and Sato (1977) reported that pesticide workers with relatively high occupational levels of exposure to OP pesticides, in comparison with workers with low levels of exposure, tended to have increased EEG power within the beta frequencies, primarily in frontal areas of the brain. In addition, the high exposure level group had lower performance on a Trail Making Test and the Bender Visual Motor Gestalt test of a neuropsychological test battery. The authors suggested that these results indicated subtle frontal lobe dysfunction in the exposed subjects. Stephens et al. (1995), studied a population of 146 sheep dippers with an average of 15 years of potential exposure to several OPs (diazinon, propetamphos, chlorfenvinphos) found these individuals compared with a control group (quarry workers) has slower simple reaction time latencies, slower latencies in a symbol digit substitution test and slower correct reaction times in a syntactic reasoning test. Only the syntactic reasoning effect showed a significant dose–effect relationship when analyzed with an analysis of covariance. Tests of memory and learning showed no effect and there were no self-reported drops in intellectual performance. On the other hand, Ames et al. (1995) surveyed 45 pesticide applicators, each of whom had at least one documented episode of asymptomatic exposure. He reported no CNS or PNS effects. Rodnitsky et al. (1975) evaluated 23 workers chronically exposed to a mild degree to pesticides (farmers and commercial pesticide applicators) using a battery of neurobehavioral tests. They found no differences between the exposed versus a control group on tests of memory, signal processing, vigilance, language, and proprioceptive feedback performance even though plasma ChE levels of the exposed group were lowered below the control values. Similarly, Daniell et al. (1992) studied 49 pesticide applicators over a 7 month period of spraying. Performance of the cohort was compared with a control group of 40 subjects (slaughterhouse workers). Both groups were given a computerized neuropsychological test battery that consisted of visuomotor coordination tests, memory and cognition tests, and tests of motor coordination. The pesticide applicators were known to have generally well-controlled, low, intermittent exposure, as part of a program of occupational health training and monitoring. The authors found no evidence for clinically significant decrements in neuropsychological performance following the 7 month season of such exposure among the applicators, the main pesticide being Guthion (azinphosmethyl). Maizlish et al. (1987) examined 99 pest control workers (46 exposed workers versus a group of nonapplicators). The 46 workers applied diazinon to residential lawn properties. Both applicators and nonapplicators were monitored for the appearance of diethylthiophosphate (DETP) in their urine. Subjects were given a comprehensive neurobehavioral test battery, and had urine samples taken, before and after their 8 h work shift. The application season lasted 39 days. The following tests were included in the neurobehavioral battery: Continuous Performance test (measures attention=vigilance), Finger Tapping (motor speed), Digit Symbol Substitution (visual=motor speed), and so on. Median diazinon exposure per workday for applicators versus nonapplicators was 2.1 versus 0.03 mg, respectively. No adverse DETP-related changes were found in pre- or postshift neurobehavioral function. The authors concluded that there were no demonstrable behavioral effects of short-term, low-level diazinon exposure in a pest control program characterized by adequate personal protective equipment and direct supervision (Maizlish, 1987). More recently Bazylewicz-Walczak et al. (1999) published their study of greenhouse workers occupationally exposed to pesticides. They gave greenhouse workers and a matched control group neuropsychological tests (simple reaction time, digit symbol, digit span, Benton visual retention test, Santa Ana test, aiming test, POMS) and a subjective symptom questionnaire before and then 4 months later after the heaviest period of OP pesticide application. Overall, when compared with
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
86
46616_C004 Final Proof page 86
6.11.2007 5:27pm Compositor Name: JGanesan
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
the controls, the exposed subjects showed slower simple reaction times, lower hand movement efficiency on the aiming test, and reported a higher degree of anxiety, anger, depression, and fatigueinertia. In addition they also reported more complaints relating to absent-mindedness and neurological symptoms. There were no differences in the exposed group over the one season. There was no change or an improvement in scores on the neuropsychological tests across the season while there was an improvement in mood and general feeling scores between the pre- and the postseason tests. The authors concluded that even low, long-term OP pesticide exposure may be associated with subtle adverse behavioral effects, and that they are characterized by increased tension and anxiety states, depression, fatigue, and a slow-down of perceptual-motor functions. Since we first reviewed the above studies, several other reports have been published that further examined the relationship between low-level asymptomatic exposure to pesticides and changes in neuropsychological function. Farahat et al. (2003) evaluated neurobehavioral performance on a battery of tests given to unexposed controls and Egyptian workers that applied pesticides (OPs, carbamates, insect growth regulators, pyrethroids) to cotton crops during the height of the application season. The pesticide applicators had slightly (20%) lowered serum ChE levels compared with the controls, but these levels were still within the normal range. The exposed group showed significantly poorer performance than the controls on six of the neurobehavioral battery tests (similarities, digit symbol substitution, trailmaking parts A and B, letter cancellation, digit span, and Benton visual retention). In addition, exposed subjects reported higher instances of the neurological symptoms of dizziness and numbness and significantly higher neuroticism (nervousness, anxiety) scores than controls. Serum ChE was not significantly correlated with task performance, but duration of pesticide exposure was. The authors suggested that the deficits in a wider array of neurobehavioral tests observed in this than in other studies, coupled with the neurological signs, indicated a higher level of exposure in this study population. Roldan-Tapia et al. (2005) studied neurobehavioral performance of greenhouse workers exposed occupationally to both OPs and carbamate pesticides. Individuals with a high cumulative exposure risk (‘‘years working with pesticides’’) displayed worsened perceptive function performance, visuomotor praxis, and integrative task performance times. These findings were taken as evidence that long-term use of these pesticides has adverse effects on neurobehavioral functioning. Rothlein et al. (2006) reported that neurobehavioral performance of Hispanic farm workers with high risk for exposure to pesticides was lower than similar Hispanic immigrants in nonagricultural jobs. Within the exposed farm worker population there was a positive correlation between severity of exposure, as measured by urinary OP metabolite levels, and poorer performance on some of the neurobehavioral tests. This same group has also used a computerized test battery to examine whether adolescent farm workers exposed to pesticides are any more susceptible to these neurobehavioral effects than adults (Rohlman et al., 2006). Although there was no evidence of selective sensitivity between adolescents and adults in this study, the results showed that cumulative exposure to low levels of pesticides is associated with neurological impairment as measured by tests of selective attention, digit symbol substitution, and reaction time. In contrast, Eckerman et al. (2007) have assessed neurobehavioral function in rural adolescents involve with agriculture and urban controls. When level of pesticide exposure was factored into a multiple linear regression analysis of performance, it was found that poorer performance on finger tapping, digit span, and selective attention was associated with high levels of exposure and that this relationship was especially strong for the youngest (10–11 years) age group. In summary, the above studies show that neurobehavioral evaluation of pesticide workers reveal increased prevalence of neurologic symptoms and changes in neurobehavioral performance indicative of mild cognitive and psychomotor dysfunction. These effects appear to be more prevalent during the period of exposure, but also persist beyond the period of exposure. Total cumulative exposure seems to be a greater risk factor for poor performance than any other covariant. Deficits in visuomotor speed as indexed by the digit symbol substitution test and the trailmaking tests have been shown to be consistently effected as well as tests of selective attention and memory
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C004 Final Proof page 87
6.11.2007 5:27pm Compositor Name: JGanesan
Health Effects of Low-Level Exposure to Nerve Agents
87
(digit span). Many of these same neurobehavioral functions were also reported to be long-term effects of OP pesticide poisoning (Savage et al., 1988; Rosenstock et al., 1991; Steenland et al., 1994; Wesseling et al., 2002; Delgado et al., 2004) as well as sequel of sarin poisoning (Murata et al., 1997; Yokoyama et al., 1998a, 1998b;. Nishiwaki et al., 2001; Miyaki et al., 2005).
V. DEVELOPMENT OF IMPROVED MEDICAL COUNTERMEASURES The major medical research efforts since the 1940s focused on developing the best possible lifesaving therapeutic interventions and pretreatments for nerve agents. More recently, focus has been on prevention of long-term changes in CNS function following a moderate to severe intoxication using anticonvulsant drugs. This refocusing on the health effects of nonlethal exposures while improving protection from otherwise lethal exposures has resulted in several new approaches to improved treatment of nerve agent intoxication. A number are in full-scale development in the United States today. The major efforts are described subsequently.
A. ADVANCED ANTICONVULSANT SYSTEM In 1990, the benzodiazepine drug diazepam was introduced by the US military as an anticonvulsant to control nerve agent-induced seizures that are associated with severe intoxication. Diazepam was fielded in automatic injectors with a dose of 10 mg per injector and up to three injectors were authorized to be administered to a convulsing casualty in the field by a combat medic or corpsman. A prodrug formulation of diazepam, known as Avizafone, is used by the UK as the anticonvulsant in their nerve agent treatment kit (McDonough et al., 1999; Lallement et al., 2000; Taysse et al., 2003, 2006). Diazepam had been shown to be capable of controlling nerve agent-induced seizures and to prevent or reduce associated brain damage that resulted from prolonged seizure activity (Lipp, 1972, 1973; Martin et al., 1985; Hayward et al., 1991; Philippens et al., 1992; McDonough and Shih, 1997). Just as importantly, diazepam was already recognized as effective and approved for the acute treatment of seizures by the Food and Drug Administration (FDA). However, animal studies have shown control of nerve agent seizures by diazepam is slow when the drug is administered by the intramuscular route and full control of seizure activity may require higher doses than are currently approved (Philippens et al., 1992; Murphy et al., 1993; McDonough et al., 1999). The later the control of nerve agent seizures, the greater the probability that an individual may experience neurological damage (Lallement et al., 1994; McDonough et al., 1995). Because of these concerns there were continuing research efforts to identify a more effective anticonvulsant treatment for nerve agent-induced seizures. A number of animal studies have shown that the benzodiazepine midazolam is more rapidly acting and more potent in controlling nerve agent seizures than diazepam (Bokonjic and Rosic, 1991; Anderson et al., 1997; McDonough et al., 1999; Shih et al., 2003, 2007). This is apparently due to the greater potency and more rapid pharmacokinetics of midazolam compared with diazepam when administered via the intramuscular route (as with an autoinjector). This, in turn, equates to more rapid anticonvulsant effectiveness of midazolam (Capacio et al., 2001, 2004). In addition to these animal studies, human clinical data from a variety of investigators have shown that midazolam is highly effective in controlling generalized convulsive status epilepticus seizures that result from a variety of etiologies (Fountain and Adams, 1999; Towne and DeLorenzo, 1999; Galdames-Contreras et al., 2006; Kyrkou et al., 2006). This anticonvulsant effectiveness has been reported in both adults and children and when midazolam was given by intravenous, intramuscular, intranasal, or buccal routes of administration. It is for these reasons that midazolam has been chosen for advanced development as an anticonvulsant treatment to eventually replace diazepam. Efforts are currently under way to provide data demonstrating the effectiveness of midazolam against nerve agent-induced seizures in two animal species to satisfy the ‘‘two animal’’ rule of the FDA. Other formulation, stability, pharmacokinetic, and safety studies are also planned to support this effort.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
88
46616_C004 Final Proof page 88
6.11.2007 5:27pm Compositor Name: JGanesan
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
B. IMPROVED OXIME THERAPIES
FOR
NERVE AGENTS
Like other OP anti-ChE compounds, the nerve agents react with AChE by phosphylating the active site of the enzyme. Oximes are nucleophilic compounds that are capable of splitting off the phosphorus atom from the active site, thereby restoring enzyme activity. However, oxime treatment of a nerve agent casualty is complicated by several factors. First, the ability of a given oxime to reactivate nerve agent-inhibited enzyme is highly dependent on the specific nerve agent, owing to individual differences in the structures of the enzyme–inhibitor complex. For example, 2-PAM Cl, the only oxime approved for use in the United States, is highly effective in reactivating enzyme inhibited by the agents sarin and VX, but is substantially less effective in reactivating enzyme inhibited by the agents tabun, cyclosarin or soman. Second, the phosphylated enzyme can undergo a dealkylation reaction, termed ‘‘aging,’’ which makes the resultant enzyme–inhibitor complex totally resistant to oxime reactivation. The different agents vary considerably in their rates of aging, 1 with soman (GD) being the fastest (t =2 ¼ several min) and the others considerably slower 1 (t =2 ¼ several h). Third, oximes are quaternary drugs, do not penetrate the blood–brain barrier, and thus provide minimal reactivation of CNS-inhibited enzyme. For these reasons, no single oxime has been developed that provides equivalent therapeutic efficacy against all nerve agents (Dawson, 1994). By combining enzyme kinetics (inhibition, reactivation, aging) with OP toxicokinetics and oxime pharmacokinetics many investigators have developed dynamic in vitro models to calculate AChE activities at different scenarios. These models were validated with data from pesticidepoisoned patients and simulations were performed for intravenous and percutaneous nerve agent exposure and intramuscular oxime treatment. These dynamic models have led to the conclusion that reactivation of inhibited ‘‘non-aged’’ AChE sufficient to preserve life may be possible. Two conditions must be met: (1) the exposure to the nerve agent must not be supralethal and (2) the oxime must be administered early and in sufficient titration. Thieman et al. (2006), reported that when RBC–AChE activity is kept at 30% or restored to that level, neuromuscular transmission is maintained at near normal levels. Using these data a number of oximes have been identified as more effective than 2-PAM Cl against soman or several other OPs. In fact, an oxime is currently in advanced development in the US Department of Defense. This oxime would be the first developed in the United States in more than 30 years. This oxime development program is known as the Improved Nerve Agent Treatment System (INATS). The goal of INATS is to develop a treatment system that offers optimal protection against a broad spectrum of nerve agents. Of course, it will not eliminate the need for other protective and therapeutic systems. The new oxime candidate (MMB4) transitioned to advanced development in 2005. In 2005, initial preclinical studies were completed and cGMP manufacturing efforts continued.
C. CARBAMATE PRETREATMENT Pyridostigmine (bromide) has been employed as a pretreatment drug against possible nerve agent exposure. It has been suggested that its effectiveness is due to carbamylation of a portion of tissue AChE that protects it against irreversible inhibition by nerve agents. Spontaneous decarbamylation of pyridostigmine produces sufficient AChE to preserve life when followed by prompt atropinization. Pyridostigmine is most appropriate for anticipated exposure to nerve agents capable of rapid ‘‘aging, such as soman.’’ PB was approved in 2003 for pretreatment use by military personnel under the threat of exposure to nerve agents, specifically soman (Couzin, 2003). The use of PB is always to be accompanied by immediate treatment after OP exposure with atropine and an oxime such as pralidoxime (2-PAM), the current doctrinal treatments after exposure. PB was chosen not to cross the blood–brain barrier to avoid possible CNS impairment or incapacitation, an effect particularly undesirable in soldiers engaged in combat, at least those not being exposed to OPs. Several other anti-ChEs that do cross the blood-barrier, including physostigmine,
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C004 Final Proof page 89
Health Effects of Low-Level Exposure to Nerve Agents
6.11.2007 5:27pm Compositor Name: JGanesan
89
tacrine, and huperzine A, have been found to offer better protection than pyridostigmine, but at the cost of undesirable central effects. These carbamate anti-ChEs are discussed by Pereira et al. in Chapter 10 and by Saxena et al. in Chapter 7. Pereira et al. (Chapter 10) suggest that galantamine preferentially blocks peripheral AChE, but does bind to central AChE and this may account for part of the superiority of galantamine over other centrally acting anti-ChEs in terms of side effects. Unlike pyridostigmine, galantamine inhibits BuChE poorly, leaving intact this scavenger site for OPs in blood. In fact, galantamine is approximately 50-fold more potent as an AChE inhibitor than a BuChE inhibitor. It also interacts directly with nAChRs, potentiating their activation by subsaturating concentrations of classical agonists. Additionally, Pereira et al. suggest that galantamine is reported to have anticonvulsant and neuroprotective properties, both of which are promising in the context of OP poisoning.
D. ENZYMES
AS
SCAVENGERS
Recent research has explored approaches leading to a transient ‘‘immunity’’ or drugs that would provide protection against lethal nerve agents, yet be devoid of side effects. It has been suggested that human BuChE from plasma participates in the endogenous scavenging of naturally occurring drugs (e.g., physostigmine, cocaine), man-made therapeutics (e.g., succinylcholine). A novel approach is to use enzymes, whether wild type or altered through directed mutation, to scavenge these highly toxic nerve agents before they attack their intended targets. The accumulated work has shown that if a scavenger is present at the time of nerve agent exposure, rapid reduction of toxicant levels is observed (Lenz et al., 2001). This reduction is so rapid and profound that the need to administer a host of pharmacologically active drugs as antidotes is, in theory, eliminated. The promise afforded by the use of scavenger enzymes is so great and their applications so diverse that three different chapters in this text (see Chapters 7, 8, and 9) are devoted to their discussion.
VI. SUMMARY AND CONCLUSIONS Following the first Gulf War, reports of unexplained illness in returning US veterans, and episodes of chemical agent terrorism, a renewed interest in the health consequences of nerve agent chemical weapons took place. The US government increased its investment into studies of the health of Persian Gulf War veterans as it might have been affected by possible exposure to low levels of chemical warfare agents. It also increased its emphasis on research, both epidemiological and experimental, into the health effects of exposure to nerve chemical warfare agents, with the intent on improving medical response to chemical agents. We believe that a comprehensive assessment of the health consequences of nerve agent chemical weapons is unfolding and has already begun to improve our understanding of this problem. Finally, it has already begun to improve our ability to deal with these health consequences effectively.
REFERENCES Aas, O. 2003. Future considerations for the medical management of nerve-agent intoxication. Prehospital Disaster Med., 18:208–216. Albuquerque, E.X., Pereira, E.F., Aracava, Y., Fawcett, W.P., Oliveira, M., Randall, W.R., Hamilton, T.A., Kan, R.K., Romano, J.A. and Adler, M. 2006. Effective countermeasure against poisoning by organophosphorus insecticides and nerve agents. Proc. Natl. Acad. Sci. U.S.A., 103:13220–13225. Ames, R., Steenland, K., Jenkins, B., Chrislop, D. and Russo, J. 1995. Chronic neurologic sequelae to cholinesterase inhibition among agriculture pesticide applicators. Arch. Environ. Health, 50:440–444. Anderson, D.R., Harris, L.W., Chang, F.-C.T., Baze, W.B., Capacio, B.R., Byers, S.L. and Lennox, W.J. 1997. Antagonism of soman-induced convulsion by midazolam, diazepam and scopolamine. Drug Chem. Toxicol., 20:115–131.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
90
46616_C004 Final Proof page 90
6.11.2007 5:27pm Compositor Name: JGanesan
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Annual Report to Congress—Federally Sponsored Research on Gulf War Veterans’ Illness for 1997, Department of Veterans Affairs, URL http:==www.va.gov=resrpt=for U.S. General Accounting Office Report to Congressional Requesters, Chemical Weapons: DoD Does Not Have a Strategy to Address Low-level Exposures, GAO=NSIAD-98–228. Atchison, C.R., Sheridan, R.E., Duniho, S.M. and Shih, T.-M. 2004. Development of a guinea pig model for low-dose, long-term exposure to organophosphorus nerve agents. Toxicol. Mech. Methods, 14:183–194. Balali-Mood, M. and Hefazi, M. 2006. Comparison of early and late effects of sulfur mustard on Iranian veterans. Basic Clin. Pharmacol. Toxicol., 99:273–282. Bazylewicz-Walczak, B., Majczakowa, W. and Szymczak, M. 1999. Behavioral effects of occupational exposure to organophosphate pesticides in female greenhouse planting workers. Neurotoxicology, 20:819–826. Benschop, H.P., Trap, H., Spruit, H., van der Wiel, H., Langenberg, J.P. and DeJong, L.P.A. 1998. Low-level nose-only exposure to the nerve agent soman: atropinized guinea pigs. Toxicol. Appl. Pharmacol., 152:179–185. Bignami, G., Giardini, V. and Scorrano, M. 1985. Behaviorally augmented versus other components in organophosphate tolerance: the role of reinforcement and response factors. Fundam. Appl. Toxicol., 5:S213–S224. Bokonjic, D. and Rosic, N. 1991. Anticonvulsive and protective effects of diazepam and midazolam in rats poisoned by highly toxic organophosphorus compounds. Arh. Hig. Rada Toksikol., 42:359–365. Bowers, M.B., Goodman, E. and Sim, V.M. 1964. Some behavioral changes in man following anticholinesterase administration. J. Nerv. Ment. Dis., 138:383–389. Brown, M. and Brix, K., 1998. Review of health consequences from high-, intermediate- and low-level exposure to organophosphorus nerve agents. J. Appl. Toxicol., 18:393–408. Burchfiel, J.L., Duffy, F.H. and Sim, V.M. 1976. Persistent effects of sarin and dieldrin upon the primate electroencephalogram. Toxicol. Appl. Pharmacol., 35:365–379. Capacio, B.R., Whalley, C.E., Byers, C.E. and McDonough, J.H. 2001. Intramuscular diazepam pharmacokinetics in soman-exposed guinea pigs. J. Appl. Toxicol., 21 Suppl 1:S67–S74. Capacio, B.R., Byers, C.E., Merk, K.A., Smith, J.R. and McDonough, J.H. 2004. Pharmacokinetic studies of intramuscular midazolam in guinea pigs challenged with soman. Drug Chem. Toxicol., 27:95–110. Castro, C.A., Larsen, T., Finger, A.V., Solana, R.P. and McMaster, S.B. 1991. Behavioral efficacy of diazepam against nerve agent exposure in rhesus monkey. Pharmacol. Biochem. Behav., 41:159–164. Churchill, L., Pazdernik, T.L., Jackson, J.L., Nelson, S.R., Samson, F.E. and McDonough, J.H. 1984. Topographical distribution of decrements and recovery in muscarinic receptors from rat brains repeatedly exposed to sublethal doses of soman. J. Neurosci., 4:2069–2079. Clement, J.G. 1989. Survivors of soman poisoning: recovery of the soman LD50 to control value in the presence of extensive acetylcholinesterase inhibition. Arch. Toxicol., 63:150–154. Clement, J.G. 1991. Hypothermia: limited tolerance to repeated soman administration and cross-tolerance to oxotremorine. Pharmacol. Biochem. Behav., 39:305–312. Colosio, C., Tiramani, M. and Maroni, M. 2003. Neurobehavioral effects of pesticides: state of the art. Neurotoxicology, 24:577–591. Couzin, J. 2003. Clinical trials. New rule triggers debate over best way to test drugs. Science, 299:1651–1653. Daniell, W., Barhart, S., Demers, P., Cost, L.G., Eaton, D., Miller, M. and Rosenstock, L. 1992. Neuropsychological performance among agricultural pesticide applicators. Environ. Res., 59:217–228. Davis, D.R., Holland, P. and Reumens, M.J. 1960. The relationship between the chemical structures and neurotoxicity of alkyl organophosphorous compounds, Br. J. Pharmacol., 15:271–278. Delgado, E., McConnell, R., Miranda, J., Keifer, M., Lundberg, I., Partanen, T. and Wesseling, C. 2004. Central nervous system effects of acute organophosphate poisoning in a two-year follow-up. Scand. J. Work Environ. Health, 30:362–370. DeMenti, B. 1999. Cholinesterase literature review and comment. Pestic. People Nat., 1:59–126. Duffy, F.H., Burchfiel, J.L., Bartels, P.H., Gaon, M. and Sim, V.M. 1979. Long-term effects of an organophosphate upon the human encephalogram. Toxicol. Appl. Pharmacol., 47:161–176. Dunn, M.A. and Sidell, F.R. 1989. Progress in medical defense against nerve agents. JAMA, 262:649–652. Eckerman, D.A., Gimenes, L.S., de Souza, R.C., Galvao, P.R., Sarcinelli, P.N. and Chrisman, J.R. 2007. Age related effects of pesticide exposure on neurobehavioral performance of adolescent farm workers in Brazil. Neurotoxicol. Teratol., 29:164–175.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C004 Final Proof page 91
Health Effects of Low-Level Exposure to Nerve Agents
6.11.2007 5:27pm Compositor Name: JGanesan
91
Farahat, T.M., Abdelrasoul, G.M., Amr, M.M., Shebl, M.M., Fareahat, F.M. and Anger, W.K. 2004. Neurobehavioral effects among workers occupationally exposed to organophosphorous pesticides. Occup. Environ. Med., 60:279–286. Fountain, N.B. and Adams, R.E. 1999. Midazolam treatment of acute and refractory status epilepticus. Clin. Neuropharmacol., 22:261–267. Galdames-Contreras, D., Carrasco-Poblete, E., Aguilera-Olivares, L., Fabres-Oyarzo, L. and GaldamesPoblete, D. 2006. Intramuscular midazolam in the initial treatment of status epilepticus. Rev. Neurol., 42:332–335. Genovese, R.F., Benton, B.J., Shippee, S.J., Jakubowski, E.M. and Bonnell, J.C. 2006. Effects of low-level inhalation exposure to cyclosarin on learned behaviors in Sprague-Dawley rats. J. Toxicol. Environ. Health A., 69:2167–2180. Genovese, R.F., Benton, B.J., Lee, E.H., Shippee, S.J. and Jakubowski, E.M. 2007a. Behavioral and biochemical evaluation of sub-lethal inhalation exposure to VX in rats. Toxicology, 232:109–118. Genovese, R.F., Oubre, J.L., Jakubowski, E.M., Fleming, P.J., Saxena, A., Rockwood, G.A., Tipparaju, P. and Willmore, C.B. 2007b. Evaluation of cognitive and biochemical effects of low-level exposure to sarin in rhesus and African green monkeys. Toxicology, 231:11–20. Gray, P.J. and Dawson, R. 1987. Kinetic constants for the inhibition of eel and rabbit brain acetylcholinesterase by some organophosphates and carbamates of military significance. Toxicol. Appl. Pharmacol., 91:140–144. Grob, D. and Harvey, A.M. 1953. The effects and treatment of nerve gas poisoning. Am. J. Med., 14:52–63. Grob, D. and Harvey, A.M. 1958. Effects in man of the anticholinesterase compound sarin (isopropyl methyl phosphonofluoridate). J. Clin. Invest., 37:350–368. Grob, D., Harvey, A.M., Langworthy, O.R. and Lilenthal, J.L. 1947. The administration of di-isopropyl fluorophosphate (DFP) to man, III. Effect on the central nervous system with special reference to the electrical activity of the brain. Bull. Johns Hopkins Hosp., 81:257–266. Hartgraves, S.L. and Murphy, M.R. 1992. Behavioral effects of low-dose nerve agents. In, Chemical Warfare Agents, ed. S. Somani. New York: Academic Press, pp. 125–154. Hashemian, F., Khoshnood, K., Desai, M., Falahati, F., Kasl, S. and Southwick, S. 2006. Anxiety, depression and posttraumatic stress in Iranian survivors of chemical warfare. J. Am. Med. Assoc., 296:560–566. Hatta, K., Miura, Y., Asukai, N. and Harnabe, Y. 1996. Amnesia from sarin poisoning. Lancet, 347:1343. Hayward, I.J., Wall, H.G., Jaax, N.K., Wade, J.V., Marlow, D.D. and Nold, J.B. 1990. Decreased brain pathology in organophosphate-exposed rhesus monkeys following benzodiazepine therapy. J. Neurol. Sci., 98:99–106. Henderson, R.F., Barr, E.B., Blackwell, W.B., Clark, C.R., Conn, C.A., Kalra, R., March, T.H., Sopori, M.L., Tesfaigzi, Y., Menache, M.G., Mash, D.C., Dokladny, K., Kozak, W., Kozak, A., Wachulec, M., Rudolph, K., Kluger, M.J., Singh, S.P., Razani-Boroujerdi, S. and Langley, R.J. 2001. Response of F344 rats to inhalation of subclinical levels of sarin: exploring potential causes of Gulf War illness. Toxicol. Ind. Health, 17:294–297. Henderson, R.F., Barr, E.B., Blackwell, W.B., Clark, C.R., Conn, C.A., Kalra, R., March, T.H., Sopori, M.L., Tesfaigzi, Y., Menache, M.G. and Mash, D.C. 2002. Response of rats to low levels of sarin. Toxicol. Appl. Pharmacol., 184:67–76. Historical Survey of the Porton Down Service Volunteer Programme 1939–1989 http:==www.mod. uk=DefenceInternet=AboutDefence=WhatWeDo=HealthandSafety=PortonDownVolunteers=HistoricalSurveyOfThePortonDownServceVounteerProgramme19391989.htm Holmes, J.H. and Gaon, M.D. 1956. Observations on acute and multiple exposure to anticholinesterase agents. Trans. Am. Clin. Climatol., 68:86–100. Hulet, S.W., McDonough, J.H. and Shih, T.-M. 2002. The dose–response effects of repeated subacute sarin exposure on guinea pigs. Pharmacol. Biochem. Behav., 72:835–845. Hymowitz, N., Brezenoff, H.E., McGee, J., Campbell, K. and Kargut, V. 1985. Effects of repeated intraperitoneal injections of soman on schedule-controlled behavior in the rat. Psychopharmacology, 86:404–408. Ianno, L.V. and Musiychuk, Y.I. 1997. Acute poisoning by neuroparalytic agents and its long-term effects. Meditsina Truda Promyshelnnaia Ekologiia, 6:5–7. Inoue, N. 1995. Psychiatric symptoms following accidental exposure to sarin: a case study. Fukuokaishi Igaku Zasshi (Neurology), 86:373–377.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
92
46616_C004 Final Proof page 92
6.11.2007 5:27pm Compositor Name: JGanesan
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Kalra, R., Singh, S.P., Razani-Boroujerdi, S., Langley, R.J., Blackwell, W.B., Henderson, R.F. and Sopori, M.L. 2002. Subclinical doses of the nerve gas sarin impair T cell responses through the autonomic nervous system. Toxicol. Appl. Pharmacol., 184:82–87. Kamel, F. and Hoppin, J.A. 2004. Association of pesticide exposure with neurologic dysfunction and disease. Environ. Health Perspect., 112:950–958. Kassa, J., Krocova, Z., Sevelova, L., Sheshko, V., Kasalova, I. and Neubauerova, V. 2003. Low-level sarininduced alteration of immune system reaction in inbred BALB=c mice. Toxicology, 187:195–203. Kassa, J., Krocova, Z., Sevelova, L., Sheshko, V., Kasalova, I. and Neubauerova, V. 2004a. The influence of single or repeated low-level sarin exposure on immune functions of inbred BALB=c mice. Basic Clin. Pharmacol. Toxicol., 94:139–143. Kassa, J., Krocova, Z., Sevelova, L., Sheshko, V. and Pavlis, O. 2004b. The influence of low-level sarin inhalation exposure on the host resistance and immune reaction of inbred BALB=c mice after their infection with Francisella tularensis LVS. Cent. Eur. J. Public Health, 12 Suppl:S36–S38. Kassa, J., Krejcova, G., Skopec, F., Herink, J., Bajgar, J., Sevelova, L., Tichy, M. and Pecka, M. 2004c. The influence of sarin on various physiological functions in rats following single or repeated low-level inhalation exposure. Inhal. Toxicol., 16:517–530. Kawana, N., Ishimatsu, S. and Kanda, K. 2001. Psycho-physiological effects of the terrorist sarin attack on the Tokyo subway system. Mil. Med., 166 Suppl 12:23–26. Klaasen, C.D. and Eaton, D.L. 1991. Principles of toxicology. In, Casarett and Doull’s Toxicology: The Basic Science of Poisons (4th Edn.), eds. M. Amdur, J. Doull and C.D. Klaasen. New York: Pergamon Press, pp. 12–49. Koelle, G.B. 1963. Cholinesterases and anticholinesterase agents. Handbuch Der Experimentellen Pharmakologie XV, Berlin, Germany: Springer-Verlang. Korsak, R.J. and Sato, M.M. 1977. Effects of chronic organophosphate pesticide exposure on the central nervous system. Clin. Toxicol., 11:83–95. Kyrkou, M., Harbord, M., Kyrkou, N., Kay, D. and Coulthard, K. 2006. Community use of intranasal midazolam for managing prolonged seizures. J. Intellect. Dev. Disabil., 31:131–138. Lallement, G., Pernot-Marino, I., Baubichon, D., Burckhart, M.F., Carpentier, P. and Blanchet, G. 1994. Modulation of soman-induced neuropathology with an anticonvulsant regimen. Neuroreport, 5:2265–2268. Lallement, G., Renault, F., Baubichon, D., Peoc’h, M., Burckhart, M.F., Galonnier, M., Clarencon, D. and Jourdil, N. 2000. Compared efficacy of diazepam or avizafone to prevent soman-induced electroencephalographic disturbances and neuropathology in primates: relationship to plasmatic benzodiazepine pharmacokinetics. Arch. Toxicol., 74:480–486. Langley, R.J., Kalra, R., Mishra, N.C. and Sopori, M.L. 2004. Central but not the peripheral action of cholinergic compounds suppresses the immune system. J. Neuroimmunol., 148:140–145. Langston, J.L., Adkins, A.L., Moran, A.V., Rockwood, G.A. and Deford, M.S. 2005. Effects of sarin on the operant behavior of guinea pigs. Neurotoxicol. Teratol., 27:841–853. Lattal, K.A., Maxey, G.C. and Wilbur, E.M. 1971. Effects of a single 1=2 LD50 of GB upon delayed response and conditional avoidance tests. Aberdeen Proving Ground, MD: Edgewood Arsenal Technical Report 4489. Lenz, D.E., Broomfield, C.A., Maxwell, D.M. and Cerasoli, D.M. 2001. Nerve agent bioscavengers: protection against high- and low-dose organophosphorus exposure. In, Chemical Warfare Agents: Toxicity at Low Levels, eds. S. Somani, S. and J.A. Romano. Boca Raton, FL: CRC Press, pp. 215–243. Lekov, D., Dimitrov, V. and Mizkow, Z. 1966. Clinical observations of individuals contaminated by a pinacolic ester of methylfluorophosphine acid (soman). Voenno Meditsinsko Delo., 4:47–52. Lipp, J.A. 1972. Effects of diazepam on soman-induced seizure activity and convulsions. EEG Clin. Neurophysiol., 32:557–560. Lipp, J.A. 1973. Effect of benzodiazepine derivatives on soman-induced seizure activity and convulsions in the monkey. Arch. Int. Pharmacodyn. Ther., 202:244–251. Maizlish, N., Schenker, M., Weisskopf, C., Seiber, J. and Samuels, S. 1987. A behavioral evaluation of pest control workers with short-term, low-level exposure to the organophosphate Diazinon. Am. J. Ind. Med., 12:153–172. Marrs, T.C., Maynard, R.L. and Sidell, F.R. 1996. Organophosphorus nerve agents. In, Chemical Warfare Agents-Toxicology and Treatment. New York: Wiley and Sons, pp. 83–100. Matsuo, K., Kato, T., Taneichi, K., Matsumoto, A., Ohtani, T., Hamamoto, T., Yamasue, H., Sakano, Y., Sasaki, T., Sadamatsu, M., Iwanami, A., Asukai, N. and Kato, N. 2003. Activation of the prefrontal cortex
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C004 Final Proof page 93
Health Effects of Low-Level Exposure to Nerve Agents
6.11.2007 5:27pm Compositor Name: JGanesan
93
to trauma-related stimuli measured by near-infrared spectroscopy in posttraumatic stress disorder due to terrorism. Psychophysiolology, 40:492–500. Maxwell, D. and Doctor, B.P. 1992. Enzymes as pretreatment drugs for organophosphate toxicity. In, Chemical Warfare Agents, ed. S. Somani. New York: Academic Press, pp. 195–207. McDonough, J.H. and Shih, T.-M. 1997. Neuropharmacological mechanisms of nerve agent-induced seizure and neuropathology. Neurosci. Biobehav. Rev., 21:559–579. McDonough, J.H., Shih, T.-M., Kaminskis, S.A., Jackson, J. and Alvarez, R. 1983. Depression and recovery of rat blood and brain acetylcholinesterase activity after repeated exposure to soman. Soc. Neurosci. Abstr., 9:964. McDonough, J.H., Smith, R.F. and Smith, C.D. 1986. Behavioral correlates of soman-induced neuropathology: deficits in DRL acquisition. Neurobehav. Toxicol. Teratol., 8:179–187. McDonough, J.H., Dochterman, L.W., Smith, C.D. and Shih, T.-M. 1995. Protection against nerve agentinduced neuropathology, but not cardiac pathology, is associated with the anticonvulsant action of drug treatment. Neurotoxicology, 16:123–132. McDonough, J.H., McMonagle, J., Copeland, T., Zoeffel, D. and Shih, T.-M. 1999. Comparative evaluation of benzodiazepines for control of soman-induced seizures. Arch Toxicol., 73:473–478. Metcalf, D.R. and Holmes, J.W. 1969. EEG, psychological and neurological alterations in humans with organophosphorus exposure. Ann. N.Y. Acad. Sci., 160:357–365. Miyaki, K., Nishiwaki, Y., Maekawa, K., Ogawa, Y., Asukai, N., Yoshimura, K., Etoh, N., Matsumoto, Y., Kikuchi, Y., Kumagai, N. and Omae, K. 2005. Effects of sarin on the nervous system of subway workers seven years after the Tokyo subway sarin attack. J. Occup. Health, 47:299–304. Modrow, H.E. and McDonough, J.H. 1986. Changes in atropine dose effect curve after subacute administration. Pharmacol. Biochem. Behav., 24:845–848. Modrow, H.E. and Jaax, N.K. 1989. Effect of soman exposure on the acquisition of an operant alternation task. Pharmacol. Biochem. Behav., 32:49–53. Morris, M., Key, M.P. and Farah, V. 2007. Sarin produces delayed cardiac and central autonomic changes. Exp. Neurol., 203:110–115. Munro, N.B., Ambrose, K.R. and Watson, A.P. 1994. Toxicity of the organophosphate chemical warfare agents GA, GB and VX: implications for public protection. Environ. Health Perspect., 102:18–30. Murata, K., Araki, S., Yokoyama, K., Okumura, T., Ishimatsu, S., Takasu, N. and White, R.F. 1997. Asymptomatic sequelae to acute sarin poisoning in the central and autonomic nervous system 6 months after the Tokyo subway attack. J. Neurol., 244:601–606. Murphy, M.R., Blick, D.W., Dunn, M.A., Fanton, J.W. and Hartgraves, S.L. 1993. Diazepam as a treatment for nerve agent poisoning in primates. Aviat. Space Environ. Med., 64:110–115. Nakajima, T., Ohta, S., Morita, H., Midorikawa, Y., Mimura, S. and Yanagisawa, N. 1998. Epidemiological study of sarin poisoning in Matsumoto City, Japan. J. Epidemiol., 8:33–41. National Academy of Science, Committee on Toxicology. 1982. Possible long-term health effects of short-term exposure to chemical agents. Vol I: anticholinesterases and anticholinergics. Prepared by Panel on Anticholinesterase Chemicals, Panel on Anticholinergic Chemicals, Committee on Toxicology, National Academy of Science, National Academy Press, Washington, D.C. Nishiwaki, Y., Maekawa, K., Ogawa, Y., Asukai, N., Minami, M. and Omae, K. 2001. Effects of sarin on the nervous system in rescue team staff members and police officers 3 years after the Tokyo subway sarin attack. Environ. Health Perspect., 109:1169–1173. Nozaki, H., Aikawa, N., Fujishima, S., Suzuki, M., Shinozawa, Y., Horis, S. and Nogawa, S. 1995. A case of VX poisoning and the difference from sarin. Lancet, 346:698–699. Nutt, D.J. and Malizia, A.L. 2004. Structural and functional brain changes in posttraumatic stress disorder. J. Clin. Psychiatry, 65 Suppl 1:11–17. Olson, C.T., Blank, J.A., Kinney, P.H. and Singer, A.W. 2000. Neurologic assessment of rats following low doses of sarin, pyridostigmine, chlorpyrifos and DEET. Toxicologist, 54: 265. Pena-Philippides, J.C., Razani-Boroujerdi, S., Singh, S.P., Langley, R.J., Mishra, N.C., Henderson, R.F. and Sopori, M.L. 2007. Long- and short-term changes in the neuroimmune-endocrine parameters following inhalation exposures of F344 rats to low-dose sarin. Toxicol. Sci., Feb 14 [Epub ahead of print]. Pearce, P.C., Crofts, H.W., Maggleton, N.G., Redout, D. and Scott, E.A.M. 1999. The effects of acutely administered low-dose sarin on cognitive behavior and the electroencephalogram in the common marmoset. Psychopharmacology, 13:128–135.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
94
46616_C004 Final Proof page 94
6.11.2007 5:27pm Compositor Name: JGanesan
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Philippens, I.H.C.H.M., Melchers, B.P.C., De Groot, D.M.G. and Wolthuis, O.L. 1992. Behavioral performance, brain histology and EEG sequelae after combined atropine=diazepam treatment of somanintoxicated rats. Pharmacol. Biochem. Behav., 42: 711–719. Porton Down Technical Note 120. A ‘‘follow up’’ of volunteers to GB (Sarin). Feb 72. [R]. Porton Down Technical Note 175. A long-term ‘‘follow-up’’ of volunteers exposed to GB (Sarin). Jul 73. [R]. Porton Down Technical Note 1010. Possible long term sequelae of exposure to nerve agents: a retrospective study. Aug 89. Presidential Advisory Committee on Gulf War Veterans’ Illnesses: Final Report, Washington, D.C., U.S. Government Printing Office, December 1996. Raffaele, K., Hughey, D., Wenk, G., Olton, D., Modrow, H. and McDonough, J.H. 1987. Long-term behavioral changes in rats following organophosphate exposure. Pharmacol. Biochem. Behav., 27:407–412. Raveh, L., Weissman, B.A., Cohen, G., Alkalay, D., Rabinovitz, I., Sonego, H. and Brandeis, R. 2002. Caramiphen and scopolamine prevent soman-induced brain damage and cognitive dysfunction. Neurotoxicology, 23:7–17. Raveh, L., Brandeis, R., Gilat, E., Cohen, G., Alkalay, D., Rabinovitz, I., Sonego, H. and Weissman, B.A. 2003. Anticholinergic and antiglutamatergic agents protect against soman-induced brain damage and cognitive dysfunction. Toxicol. Sci., 75:108–116. Razani-Boroujerdi, S., Singh, S.P., Knall, C., Hahn, F.F., Pena-Philippides, J.C., Kalra, R., Langley, R.J. and Sopori, M.L. 2004. Chronic nicotine inhibits inflammation and promotes influenza infection. Cell Immunol., 230:1–9. Riddle, J.R., Brown, M., Smith, T.C., Ritchie, E., Brix, K. and Romano, J.A. 2003. Chemical warfare and the Gulf War: a review of the impact on Gulf War veterans’ health. Mil. Med., 168:606–613. Roberts, A.C., Robbins, T.W., Everitt, B.J. and Muir, J.L. 1992. A specific form of cognitive rigidity following excitotoxic lesions of the basal forebrain in marmosets. Neuroscience, 47:251–264. Rodnitsky, R.L. 1975. Occupational exposure to organophosphate pesticides: a neurobehavioral study. Arch. Environ. Health, 30:98–103. Rohlman, D.S., Lasarev, M., Anger, W.K., Scherer, J., Stupfel, J. and McCauley, L. 2006. Neurobehavioral performance of adult and adolescent agricultural workers. Neurotoxicology. 2006 Dec 1 [Epub ahead of print] PMID: 17141876. Roldan-Tapia, L., Parron, T. and Sanchez-Santed, F. 2005. Neuropsychological effects of long-term exposure to organophosphate pesticides. Neurotoxicol. Teratol., 27:259–266. Romano, J.A., Lumley, L., King, J.M. and Saviolakis, G.A. 2007. Chemical warfare, chemical terrorism, and traumatic stress responses: an assessment of psychological impact. In, Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics, eds. J.A. Romano, B.J. Lukey and H. Salem. Boca Raton, FL: CRC Press. Rosenenstock, L., Keifer, M., Daniell, W.E., McDonnell, R. and Claypoole, K. 1991. Chronic central nervous system effects of acute organophosphate pesticide intoxication. The Pesticide Health Effects Study Group. Lancet, 338:223–227. Rothlein, J., Rohlman, D., Lasarev, M., Phillips, J., Muniz, J. and McCauley, L. 2006. Organophosphate pesticide exposure and neurobehavioral performance in agricultural and non-agricultural Hispanic workers. Environ. Health Perspect., 114:691–696. Roy, D.E. 1998. Chronic effects of low-level exposure to anticholinesterases—a mechanistic review. Toxicol. Lett., 102–103:527–533. Russell, R.W. and Overstreet, D.H. 1987. Mechanisms underlying sensitivity to organophosphorus anticholinesterase compounds. Prog. Neurobiol., 28:97–129. Russell, R.W., Booth, R.A., Lauretz, S.D., Smith, C.A. and Jenden, D.J. 1986. Behavioral, neurochemical, and physiological effects of repeated exposure to subsymptomatic levels of the anticholinesterase, soman. Neurobehav. Toxicol. Teratol., 8:675–685. Savage, E.P., Keefe, T.J., Mounce, L.M., Heaton, R.K., Lewis, J.A. and Burcar, P.J. 1988. Chronic neurological sequelae of acute organophosphate pesticide poisoning. Arch. Environ. Health, 43:38–45. Scremin, O.U., Shih, T,-M., Huynh, L., Roch, M., Booth, R. and Jenden, D.J. 2003. Delayed neurologic and behavioral effects of subtoxic doses of cholinesterase inhibitors. J. Pharmacol. Exp. Ther., 304:1111–1119. Scremin, O.U., Shih, T.-M., Huynh, L., Roch, M., Sun, W., Chialvo, D.R. and Jenden, D.J. 2005. Low-dose cholinesterase inhibitors do not induce delayed effects on cerebral blood flow and metabolism. Pharmacol. Biochem. Behav., 80:529–450.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C004 Final Proof page 95
Health Effects of Low-Level Exposure to Nerve Agents
6.11.2007 5:27pm Compositor Name: JGanesan
95
Scremin, O.U., Shih, T.-M., Huynh, L., Roch, M., Sun, W., Chialvo, D.R. and Jenden, D.J. 2006. Circadian rhythms of heart rate and locomotion after treatment with low-dose acetylcholinesterase inhibitors. J. Appl. Toxicol., 26:410–418. Sekijima, Y., Morita, H., Shindo, M., Okudera, H., Shibata, T. and Yanagisawa, N. 1995a. A case of severe sarin poisoning in the sarin attack at Matsumoto—one-year follow-up on the clinical findings and laboratory data. Rinsho Shinkeijaku (Clin. Neurol.), 35:1241–1245. Shih, T-.M., Duniho, S.M. and McDonough, J.H. 2003. Control of nerve agent-induced seizures is critical for neuroprotection and survival. Toxicol. Appl. Pharmacol., 188:69–80. Shih, T.M., Rowland, T.C. and McDonough, J.H. 2007. Anticonvulsants for nerve agent-induced seizures: the influence of the therapeutic dose of atropine. J. Pharmacol. Exp. Ther., 320:154–161. Shin, L.M., Rauch, S.L., Pitman, R.K. 2006. Amygdala, medial prefrontal cortex, and hippocampal function in PTSD. Ann. N. Y. Acad. Sci., 1071:67–79. Sidell, F.R. 1974. Soman and sarin: clinical manifestations and treatment of accidental poisoning by organophosphates. Clin. Toxicol., 7:1–17. Sidell, F.R. 1992. Clinical considerations in nerve agent intoxication. In, Chemical Warfare Agents, ed. S. Somani. New York: Academic Press, pp. 155–194. Sidell, F.R. 1996. A history of human studies with nerve agents by the UK and USA. In, Chemical Warfare Agents: Toxicology and Treatment, eds. T.C. Marrs, R.L. Maynard and F.R. Sidell. Chichester, England: Wiley, pp. 115–137. Sidell, F.R. 1997. Nerve agents. In, Textbook of Military Medicine—Medical Aspects of Chemical and Biological Warfare, eds. R. Zajtchuk and R.F. Bellamy. Washington, D.C.: Office of The Surgeon General, Department of the Army, pp. 129–179. Sidell, F.R. and Hurst, C.G. 1997. Long-term health effects of mustard. In Textbook of Military Medicine— Medical Aspects of Chemical and Biological Warfare, R. Zajtchuk and R.F. Bellamy, eds. Washington, D.C.: office of The Surgeon General, Department of the Army, pp. 229–246. Sim, V.M. 1975. Anticholinesterase poisoning. In, Cholinergic Mechanisms, ed. P.G. Waser. New York: Raven Press. Sipos, M.L., Smrcka, V.L., Zinkand, S.E., Kahler, D.W., Moran, A.V. and Atchison, C.R. 2001. Effects of subacute low dose exposure to sarin and soman on the acoustic startle response in guinea pigs. Soc. Neurosci. Abstr., 27: No. 959.17. Smith, T.C., Gray, G.C., Weir, J.C., Heller, J.M. and Ryan, M.A. 2003. Gulf War veterans and Iraqi nerve agents at Khamisiyah: postwar hospitalization data revisited. Am. J. Epidemiol., 158:457–467. Smith, B., Smith, T.C., Ryan, M.A. and Gray, G. 2006. A comparison of the postwar hospitalization experience of US military personnel following service in the 1991 Gulf War, Southwest Asia after the Gulf War, and Bosnia. J. Occup. Environ. Hyg., 3:660–670. Sohakian, B.J. and Coull, T.J. 1993. Tetrahydroaminoacridine (THA) in Alzheimer’s Disease: an assessment of attentional and mnemonic function using CANTAB. Acta Neurol. Scand., 149 Suppl:29–35. Somani, S.M., Solana, R.P. and Dube, S.N. 1992. Toxicodynamics of nerve agents. In, Chemical Warfare Agents, ed. S. Somani. New York: Academic Press, Inc., pp. 67–123. Steenland, K., Jenkins, B., Ames, R.G., O’Malley, M., Chrislop, D. and Russo, J. 1994. Chronic neurological sequelae in organophosphate pesticide poisoning. Am. J. Public Health, 84:731–736. Stephens, R., Spurgeon, A., Calvert, I.A., Beach, J., Levy, L.S., Berry, H. and Harrington, J.M. 1995. Neuropsychological effects of long-term exposure to organophosphates in sheep dip. Lancet, 345:1135–1139. Sterri, S.H., Lyngaas, S. and Fonnum, F. 1980. Toxicity of soman after repetitive injection of sublethal doses in rats. Acta Pharmacol. Toxicol., 46:1–7. Taylor, P. 2001. Anticholinesterase agents. In, Goodman and Gilman’s The Pharmacological Basis of Therapeutics (10th Edn.), eds. J.G. Hardman, L.E. Limbird and A.G. Gilman. New York: McGrawHill, pp. 175–191. Taysse, L., Calvet, J.H., Buee, J., Christin, D., Delamanche, S. and Breton, P. 2003. Comparative efficacy of diazepam and avizafone against sarin-induced neuropathology and respiratory failure in guinea pigs: influence of atropine dose. Toxicology, 188:197–209. Taysse, L., Daulon, S., Delamanche, S., Bellier, B. and Breton, P. 2006. Protection against soman-induced neuropathology and respiratory failure: a comparison of the efficacy of diazepam and avizafone in guinea pig. Toxicology, 225:25–35.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
96
46616_C004 Final Proof page 96
6.11.2007 5:27pm Compositor Name: JGanesan
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Thiermann, H., Szinicz, L., Eyer, P., Felgenhauer, N., Zilker, T. and Worek, F. 2006. Lessons to be learnt from organophosphorus pesticide poisoning for the treatment of nerve agent poisoning. Toxicology, Nov 19 [Epub ahead of print]. Thomson, S.A. et al. 2004. Low Level Chemical Warfare Agent Toxicology Research Program—FY03 Report and Analysis, Report number AFRL-HE-WP-TR-2004–0011. Thomson, S.A. et al. 2005. Low Level Chemical Warfare Agent Toxicology Research Program—FY04 Report and Analysis, Report number AFRL-HE-WP-TR-2005–0054. Towne, A.R. and DeLorenzo, R.J. 1999. Use of intramuscular midazolam for status epilepticus. J. Emerg. Med., 17:323–328. van Dongen, C.J. and Wolthuis, O.L. 1989. On the development of behavioral tolerance to organophosphates, I. Behavioral and biochemical aspects. Pharmacol. Biochem. Behav., 34:473–481. van Helden, H.P., Vanwersch, R.A., Kuijpers, W.C., Trap, H.C, Philippens, I.H.C.H.M. and Benschop, H.P. 2004. Low levels of sarin affect the EEG in marmoset monkeys: a pilot study. J. Appl. Toxicol., 24:475–483. Villarreal, G. and King, C.Y. 2001. Brain imaging in posttraumatic stress disorder. Semin. Clin. Neuropsychiatry, 6:131–145. Wesseling, C., Keifer, M., Ahlbom, A., McConnell, R., Moon, J.D., Rosenstock, L. and Hogstedt, C. 2002. Long-term neurobehavioral effects of mild poisonings with organophosphate and n-methyl carbamate pesticides among banana workers. Int. J. Occup. Environ. Health, 8:27–34. Wolthuis, O.L., Philippens, I.H.C.H.M. and Vanwersch, R. 1990. On the development of behavioral tolerance to organophosphates, III: behavioral aspects. Pharmacol. Biochem. Behav., 35:561–565. Yamasue, H., Kasai, K., Iwanami, A., Ohtani, T., Yamada, H., Abe, O., Kuroki, N., Fukuda, R., Tochigi, M., Furukawa, S., Sadamatsu, M., Sasaki, T., Aoki, S., Ohtomo, K., Asukai, N. and Kato, N. 2003. Voxelbased analysis of MRI reveals anterior cingulate gray-matter volume reduction in posttraumatic stress disorder due to terrorism. Proc. Natl. Acad. Sci. U.S.A., 100:9039–9043. Yokoyama, K., Araki, S., Murata, K., Nishikitani, M., Okumura, T., Ishimatsu, S. and Takasu, N. 1998a. A preliminary study on delayed vestibulo-cerebellar effects of Tokyo subway sarin poisoning in relation to gender difference: frequency analysis of postural sway. J. Occup. Environ. Med., 40:17–21. Yokoyama, K., Araki, S., Murata, K., Nishikitani, M., Okumura, T., Ishimatsu, S. and Takasu, N. 1998b. Chronic neurobehavioral and central autonomic nervous system effects of Tokyo subway sarin poisoning. J. Physiol. (Paris), 92:317–323. Young, R.A., Opresko, D.M., Watson, A.D., Ross, R.H., King, J. and Choudhoury, H. 1999. Deriving toxicity values for organophosphate nerve agents: a position in support of procedures and rationale for deriving Oral RfDs for chemical warfare agents. Human Ecolog. Risk Asses., 5:589–634.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C005 Final Proof page 97
7.11.2007 5:20pm Compositor Name: BMani
of Nerve 5 Toxicokinetics Agents Marcel J. van der Schans, Hendrik P. Benschop, and Christopher E. Whalley CONTENTS I. Introduction ......................................................................................................................... 97 II. Nerve Agent Stereo-Isomers: Chiral Analysis.................................................................... 98 III. Experimental ....................................................................................................................... 99 IV. Intravenous Toxicokinetics of Soman, Sarin, and VX ..................................................... 101 A. Soman ........................................................................................................................ 101 B. Sarin........................................................................................................................... 104 C. VX ............................................................................................................................. 104 V. Percutaneous Toxicokinetics of VX ................................................................................. 109 VI. Elimination Pathways of Soman, Sarin, and VX ............................................................. 111 VII. Effect of Human Plasma Butyrylcholinesterase as Scavenger on the Toxicokinetics of Nerve Agents ................................................................................................................ 113 VIII. Concluding Remarks......................................................................................................... 117 References ..................................................................................................................................... 118
I. INTRODUCTION Toxicokinetic studies, together with toxicodynamic studies of nerve agents, provide a quantitative basis for the design of new strategies against intoxication with nerve agents. There is a long tradition of investigations on the toxicodynamics of nerve agents since their introduction as potential agents of chemical warfare during World War II. These studies have led to strategies in which phosphorylated cholinesterase is reactivated with oximes, often in combination with the administration of a central nervous depressant suppress convulsions and other central effects, and through administration of the muscarinic cholinergic antagonist, atropine. Toxicokinetic studies were initiated in the last two decades of the last century. The reasons for the late development were twofold. First, it was assumed that nerve agents react so quickly and are so rapidly degraded that it is impossible to measure these low levels of agent. Second, the expected levels were so low that the analytical capability was not sufficient to detect the nerve agent at relevant levels. With the advent of sophisticated sensitive analytical capabilities using capillary gas chromatography combined with sensitive detectors such as Nitrogen Phosphorus Detection (NPD), Flame Photometric Detection (FPD), and Mass Selective Detection (MSD), it is possibile to measure these extremely low levels of nerve agent. Moreover, there was reason to believe that the nerve agents might be more persistent than anticipated. Wolthuis et al.1 showed in 1981 that rats initially surviving a challenge with a supra-lethal dose of soman by immediate treatment with atropine and the oxime HI-6 became fatally reintoxicated 4–6 h later. Hence, soman appeared to be far more persistent than anticipated. The persistence is even more pronounced in the case of percutaneous VX intoxication, which is caused by a slow penetration through the skin and slow enzymatic hydrolysis. Especially in the case 97
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C005 Final Proof page 98
98
7.11.2007 5:20pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
intoxication with VX, toxicokinetic studies are of ultimate importance because the time period of the intoxication might span several hours, which means that the timing of the antidote administration has to be adapted to the toxicokinetic process. The toxicokinetics of soman and sarin has also been thoroughly described by Benschop and De Jong in the previous version of this book, Chemical Warfare Agents: Toxicity at Low Levels.2 This chapter is not meant as a duplicate of the contribution in the first edition. However, the intravenous (i.v.) toxicokinetics of soman and sarin will be presented again because they serve as a reference for the toxicokinetics of VX after i.v. administration and percutaneous application that will be presented. Additionally, the effect of human butyrylcholinesterase as scavenger on the toxicokinetics of nerve agents will be mentioned. The discussion of the toxicokinetics will be preceded by a section discussing the importance of distinguishing the stereo-isomers of nerve agents. Finally, the distribution of sarin over tissues will be discussed in the last section of this chapter as a reasoning for the elimination pathways of nerve agents. Readers who are interested in the inhalation toxicokinetics of sarin and soman are referred to Chapter 2 in the first edition of the already-mentioned Chemical Warfare Agents book in this series.
II. NERVE AGENT STEREO-ISOMERS: CHIRAL ANALYSIS Interpretation and understanding of the toxicokinetics of nerve agents would not be possible without taking into consideration that these agents consist of mixtures of stereo-isomers, which are often extremely different in their toxicokinetic and toxicodynamic properties.3 A common feature of these agents is the chirality on the phosphorous atom. (+)-Sarin, C(+)P(+)-soman, and (+)-VX consist of an equimolar mixture of P()- and P(þ)-stereo-isomers. In the case of sarin and soman, the P()stereo-isomers appeared to be far more toxic and persistent in vivo than the P(þ)-stereo-isomers. In contrast, the difference in rates of inhibition of AChE and lethality between the stereo-isomers of VX are only moderate. In addition, soman consists of four stereo-isomers denoted as C(þ)P(þ), C(þ)P (), C()P(), and C()P(þ), in which C stands for asymmetry in the pinacolyl moiety and P for asymmetry at phosphorus atom. The enantiomeric pairs [C(þ)P(þ) þ C()P()] and [C(þ)P() þ C ()P(þ)] are present in synthetic C(+)P(+)-soman in a ratio of 45:55, with equal amounts of the two enantiomers within each pair. Separation of the various stereo-isomers became feasible with optically active stationary phases in chromatography. The four isomers of soman can be separated on a ChiraSil-Val column and the isomers of sarin on a Cyclodex column, whereas the isomers of VX can be separated by HPLC using Chiracel OD-H column.4–6 With the analytical methodology available, it is possible to monitor the progress of the isolation and purification of the stereo-isomers. In the case of soman, synthetic resolution of the pinacolyl alcohol and subsequent synthesis of soman from these stereo-isomers yielded C(þ)P(+) and C()P(+)-soman.3 After incubation with a-chymotrypsin, which binds the P()-isomers of soman, the P(þ)-isomers could be isolated. Incubation with rabbit plasma hydrolyzes the C(+)P(þ)-isomers and yields therefore the C(+)P ()-isomers. Similarly, the incubation of sarin with rabbit plasma gave ()-sarin. The two stereoisomers of VX are easily obtained synthetically from optically resolved precursors.7–9 With sufficient amounts of the stereo-isomers available, it is possible to study the affinity for binding with AChE, rate of hydrolysis, and finally the lethality of the different isomers.10–13 As expected, the degree of lethality correlated with the binding constant of AChE (see Table 5.1). Apparently the P()-isomers of soman and sarin inhibit AChE with rate constants that are 3–4 orders of magnitude higher than those of the corresponding P(þ)-isomers. The determination of the binding constant of the P(þ)-isomers requests a high concentration of the inhibitor, whereas it cannot be excluded that small impurities of the P()-isomer bias the bimolecular reaction. In contrast to sarin and soman, the difference of the binding constant of the P()-isomer of VX is only two orders of magnitude higher than the P(þ)-isomers. In this case, the LD50 of both isomers could be determined, which verified that the P()-isomer is only eightfold more toxic than the P(þ)-isomer. This
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C005 Final Proof page 99
7.11.2007 5:20pm Compositor Name: BMani
99
Toxicokinetics of Nerve Agents
TABLE 5.1 Stereoselectivity in Binding to AChE and Acute Lethality of Nerve Agent Stereo-Isomers Nerve Agent C(þ)P()-Soman C()P()-Soman C(þ)P(þ)-Soman C(þ)P(þ)-Soman C(+)P(+)-Soman ()-Sarin (þ)-Sarin (+)-Sarin ()-VX (þ)-VX (+)-VX a
b c d
Rate Constant 1 (M1 min )a
LD50 Mouse (mg=kg)
2:8 108 1:8 108 <5 103 <5 103
99b 38b >5000b >2000c 156b 41c
1:4 107 <3 103 4 108 2 106
83c 12.6c 165c 20.1c
References [9] [9] [9] [9] [9] [3,10] [10] [3]d [3,11] [3,11] [3]d
Electric eel AChE (pH 7.5, 258C) for soman stereo-isomers; bovine erythrocyte AChE for sarin and VX stereo-isomers (pH 7.7, 258C). Subcutaneous administration. Intravenous administration. Estimated from an experiment with optically enriched sarin (64% enantiomeric excess).
data make clear that it is essential to distinguish the isomers of the nerve agents from each other in toxicokinetic studies, because one is mostly interested in the elimination rate of the toxic compound.
III. EXPERIMENTAL Toxicokinetic studies are only interesting if the agents can be determined at levels that are toxicologically relevant. The relevant levels should be related to the binding constant of the agent with AChE. Since nerve agents inhibit AChE with rates up to 108 M1 min1 , it can be derived that blood levels down to a few picograms per milliliter can still cause a significant inhibition over a period of hours. Only the most sophisticated gas chromatographic techniques combined with sensitive detection methods such as NPD, FPD, or MS are sensitive enough to fulfill this task. During the period of time in which the toxicokinetic studies mentioned in this chapter were performed, only the NPD detector was available.5,14 Nowadays, organophosphofluoridates are analyzed by means of mass spectrometry with chemical ionization using ammonia as a reaction gas.15,16 This ionization mode is efficient for ionization of organophosphofluoridates but also more selective than electron impact ionization since it is a softer ionization mode. As mentioned in the previous section, it is also essential that the isomers can be distinguished from each other in view of the extreme difference in toxicity of the isomers. The combination of chiral-sensitive analysis was realized by two-dimensional gas chromatography in combination with large volume sample introduction (up to 400 mL) by means of thermal desorption. This allows the detection of low concentration nerve agent, that is, in the picogram per milliliter range. The two-dimensional chromatography utilized the heart-cutting technique. The configuration comprises two GC-columns, that is, a precolumn and a second analytical chiral column, which are connected in series. The sample is introduced on the precolumn. After separation on the precolumn, a small fraction of the effluent is injected on the second analytical chiral column. The reason for utilization of twodimensional chromatography is twofold. First, the combination of two stationary phases creates
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
100
46616_C005 Final Proof page 100 7.11.2007 5:20pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
additional selectivity that is required for the detection of nerve agents at trace levels in biological samples. Second, the configuration preserves the chiral column, which has a fragile stationary phase that deteriorates by the formation of liquid phases onto the column wall and elution of interfering matrix components. With this configuration, it was possible to detect amounts of soman and sarin down to 1–5 pg when separating all isomers of sarin and soman.21–23 The separation of the VX isomers was only successful using HPLC on a Chiracel OD-H column with a mixture of n-hexane:ethanol (95:5) as a mobile phase.6,17 Detection was accomplished by electrochemical detection, which is possible by oxidation of VX at the sulfur or nitrogen atom. The mobile phase leaving the chiral column was postcolumn mixed with a 0.1 M potassium perchlorate in ethanol solution to ensure conductivity, which is necessary for electrochemical detection. The method was workable for testing optical purity of the isomers or analysis of biological samples at high concentrations of VX (>10 ng=mL). The selectivity of the separation was not sufficient for the analysis of VX at lower concentrations in biological samples. As an alternative, it appeared possible to separate the isomers of VX on the Chiracel OD-H column and fractionate the VX isomers.17 Next, the collected samples were off-line analyzed with GC-NPD. VX itself can be analyzed with GC-NPD using a rather straightforward technique.18 Due to the low volatility of VX, the sample can be concentrated in a vial with a gentle stream of nitrogen. Typically, a volume of 8 mL VX in hexane can be injected onto the column, whereas the detection limit of VX was down to 2 pg. The lowest concentration of VX isomers that could be detected using off-line separation of isomers and detection with GC-NPD was 1 ng=mL. Recently, the method was further improved using chiral LC-MS=MS. The combination of chiral LC-MS was already published by Smith,19 albeit at relatively high concentrations of VX. Recently, we analyzed the isomers of VX on an LC-MS=MS configuration using APCI conditions. It appeared possible to analyze the two stereo-isomers down to 100 pg=mL. At the time that the toxicokinetics of VX was studied, this analytical configuration was not available yet, which means that the isomers of VX were measured using the off-line LC-GC-NPD method. The sample preparation of the nerve agent samples appeared to be a critical step as well. In vivo, the stereo-isomers of soman and sarin are subject to a rapid process of elimination by binding to AChE, BuChE, or CaE and enzymatic hydrolysis. It is essential that these processes should be frozen once the biological sample has been taken for the time period that is required for the further sample preparation. It appeared that enzymatic hydrolysis can be sufficiently suppressed by immediate acidification of the sample using an acetate buffer at pH 4. A second essential step is the saturation of available binding sites such as AChE, BuChE, and CaE. The enzymes were blocked by addition of excess of another organophosphate such as neopentyl sarin. Finally, it appeared that the presence of a significant amount of fluoride ions from natural sources or from hydrolysis of the nerve agent itself results in regeneration of the organophosphofluoridate, which leads to substantially higher levels of soman or sarin in the samples.14 This complication was effectively suppressed by addition of aluminum sulfate, which binds the fluoride ions, mostly in the complex [AlF2 ]þ . Next, the stabilized mixture was extracted into ethyl acetate using a solid-phase extraction procedure with Nexus or Seppak C18 cartridges. Some experiments described in this chapter refer to the analysis of regenerated sarin from regenerable binding sites. In that case, aluminum sulfate is not added to the sample. On the contrary, the regeneration of sarin is even accelerated by the addition of a high concentration (250 mM final concentration) of fluoride ions.20 The regenerated sarin is also extracted into ethyl acetate by solidphase extraction. Next, the sample is analyzed without the use of a chiral column: regeneration with a high concentration of fluoride ions occurs with rapid racemization of the organophosphofluoridate, which means that a chiral analysis is redundant. The isolation of (+)-VX from a biological matrix is even simpler.17 The sample is first stabilized by the addition of an excess of organophosphate, for example, neopentyl sarin, made alkaline to deprotonate the nitrogen atom and extracted with a mixture of n-hexane:methanol (95:5). The extract appeared to be clean enough to be analyzed directly with GC-NPD or LC-MS=MS.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C005 Final Proof page 101 7.11.2007 5:20pm Compositor Name: BMani
101
Toxicokinetics of Nerve Agents
Additionally, preconcentration of the sample to a smaller volume was possible by evaporation of the solvent with a gentle stream of nitrogen and reconstitution of the sample in a small volume of n-hexane.
IV. INTRAVENOUS TOXICOKINETICS OF SOMAN, SARIN, AND VX A. SOMAN Initial investigations on the toxicokinetics of nerve agents were performed after i.v. administration at dosages corresponding with multiple LD50 values to obtain the toxicokinetic data at 100% bioavailability.21–24 This data can be used in the interpretation of the results from more relevant exposure routes such as the respiratory and percutaneous route. Animal species selected for the investigations were the rat, guinea pig, and marmoset, with the latter species serving as model for man. In order to be able to perform the experiments, animals were anesthetized, atropinized, and mechanically ventilated through a tracheal cannula. Blood samples were drawn from a carotid cannula. Intravenous injection was performed in the dorsal penis vein or in the vena jugularis. The LD50 values of soman are highly species dependent since the amount of CaE in blood is species dependent.25 These enzymes act as scavengers of nerve agents by irreversibly binding to the nerve agent. The enzyme is present in large amounts in blood of rats, in significantly smaller amounts in guinea pigs, and almost absent in blood of marmoset and man. Accordingly, the LD50 values decrease in the order rat > guinea pig > marmoset. Blood levels of the C(þ)P() and C()P()-isomers are shown in Figures 5.1 through 5.6. The relatively nontoxic C(+)P(þ)-isomers were eliminated from the blood stream within 5 min, which is mainly caused by the rapid enzymatic hydrolysis of C(+)P(þ)-soman. In contrast with the C(+)P (þ)-isomers, the C(+)P()-isomers can be measured for several hours. Almost all curves were best described with a three exponential curve. Areas under the curve have been calculated using the coefficients of these equations. The toxicokinetic data of the i.v. soman experiments are summarized in Table 5.2. The derivation of the time period during which acutely toxic levels of soman stereoisomers is based, somewhat arbitrarily, on a scenario of intoxication in which an animal resumes spontaneous respiration presumably due to about 5%–7% reactivation by oxime (or protection by carbamate) of completely inhibited AChE in diaphragm. Since the concentration of AChE in
Concentration C(+)P(−)-GD (ng/mL)
1000
100
10
1
0.1
0.01 0
50
100
150
200
250
300
350
400
Time (min)
FIGURE 5.1 Semi-logarithmic plot of the concentrations in blood of C(þ)P()-soman (GD) versus time after i.v. administration of 0.8 3 LD50 (66 mg=kg, µ), 3 3 LD50 (n), and 6 3 LD50 (u) of C(+)P(+)-soman to anesthetized, atropinized, and mechanically ventilated rats. (From Benschop, H.P. and De Jong, L.P.A., Neurosci. Biobehav. Rev., 15, 73, 1991. With permission.)
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
102
46616_C005 Final Proof page 102 7.11.2007 5:20pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Concentration C(−)P(−)-GD (ng/mL)
1000
100
10
1
0.1
0.01 0
50
100
150
200
250
300
350
400
450
Time (min)
FIGURE 5.2 Semi-logarithmic plot of the concentrations in blood of C()P()-soman (GD) versus time after i.v. administration of 0.8 3 LD50 (66 mg=kg, µ), 3 3 LD50 (n), and 6 3 LD50 (u) of C(+)P(+)-soman to anesthetized, atropinized, and mechanically ventilated rats. (From Benschop, H.P. and De Jong, L.P.A., Neurosci. Biobehav. Rev., 15, 73, 1991. With permission.)
diaphragm of guinea pigs is approximately 2–2.6 nM, this reactivated fraction corresponds with approximately 150–200 pM AChE. Based on a bimolecular rate constant of AChE by soman of about 108 M1 min1 , it is calculated that this reactivated fraction of AChE can be reinhibited by 150 pM (approx. 30 pg=mL) soman with a half-life of about 1 h. An order of magnitude lower concentration soman can only cause insignificant inhibition. Therefore, it is assumed that 150 pM soman represents the lowest concentration having toxicological relevance. In a more generalized way, it may be reasoned that an area under the curve of 30 pg=mL 60 ¼ 1:8 ng min mL1 in the last part of the blood level curve is needed for toxicological relevance. The period of time in between intoxication and the point on the time axis at which this area starts can be regarded as the period of time in which
Concentration C(+)P(−)-GD (ng/mL)
1000
100
10
1
0.1
0.01 0
50
100
150
200
Time (min)
FIGURE 5.3 Semi-logarithmic plot of the concentrations in blood of C(þ)P()-soman (GD) versus time after i.v. administration of 0.8 3 LD50 (22 mg=kg, µ), 3 3 LD50 (n), and 6 3 LD50 (u)of C(+)P(+)-soman to anesthetized, atropinized, and mechanically ventilated guinea pigs.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C005 Final Proof page 103 7.11.2007 5:20pm Compositor Name: BMani
103
Toxicokinetics of Nerve Agents
Concentration C(−)P(−)-GD (ng/mL)
1000
100
10
1
0.1
0.01 0
50
100
150
200
Time (min)
FIGURE 5.4 Semi-logarithmic plot of the concentrations in blood of C()P()-soman (GD) versus time after i.v. administration of 0.8 3 LD50 (22 mg=kg, µ), 2 3 LD50 (n), and 6 3 LD50 (u) of C(+)P(+)-soman to anesthetized, atropinized, and mechanically ventilated guinea pigs.
toxicologically relevant levels of soman are present. Table 5.2 shows that these time periods in rat, guinea pig, and marmoset range between 50 and 100 min after receiving a dose corresponding with 2 3 LD50. Based on the earlier-mentioned ratio of the C(þ)P() and C()P()-isomers of soman it would be expected that the AUC of the C(þ)P()-isomer is 20% higher than that of the C()P()-isomer. Instead, the AUC of C(þ)P()-isomer is often equal to or even lower than C()P()-isomer. This outcome can be explained by taking into consideration the difference in binding rate constant with CaE, which is 30-fold higher for the C(þ)P()-isomer.26,27 The relative effect of differential binding of C(þ)P()- and C()P()-soman with CaE becomes more pronounced at lower doses of soman, because the elimination route of binding to a finite amount of CaE is relatively more
Concentration C(+)P(−)-GD (ng/mL)
1000
100
10
1
0.1
0.01 0
20
40
60
80
100
120
Time (min)
FIGURE 5.5 Semi-logarithmic plot of the concentrations in blood of C(þ)P()-soman (GD) versus time after i.v. administration of 2 3 LD50 (20 mg=kg, n) and 6 3 LD50 (u) of C(+)P(+)-soman to anesthetized, atropinized, and mechanically ventilated marmosets.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
104
46616_C005 Final Proof page 104 7.11.2007 5:20pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Concentration C(−)P(−)-GD (ng/mL)
1000
100
10
1
0.1
0.01 0
20
40
60
80
100
120
Time (min)
FIGURE 5.6 Semi-logarithmic plot of the concentrations in blood of C()P()-soman (GD) versus time after i.v. administration of 2 3 LD50 (20 mg=kg, n) and 6 3 LD50 (u) of C(+)P(+)-soman to anesthetized, atropinized, and mechanically ventilated marmosets.
important at lower doses of soman. Indeed, it was observed that the differences of the AUC between the two isomers increase with decreasing dose.
B. SARIN In comparison with soman, little work has been done so far on the toxicokinetics of sarin.23,28 In order to obtain reference data for inhalational studies, the i.v. toxicokinetics of sarin was investigated at doses corresponding with 0.8 3 LD50 (19:2 mg=kg) and 2 3 LD50. Blood levels of ()-sarin are shown in Figure 5.7. The (þ)-isomer of sarin was not detectable in the blood of the guinea pigs after an i.v. bolus of a dose corresponding with 0.8 3 LD50 and 2 3 LD50. The half-life of distribution appears to be 0.15 min after a dose of 0.8 3 LD50 and 0.98 min after 2 3 LD50, whereas the terminal half-lives resulting from these doses are 58 and 389 min, respectively. The calculated AUC values are 15:3 ng min mL1 for 0.8 3 LD50 and 109 ng min mL1 for 2 3 LD50, indicating nonlinearity of the toxicokinetics with the dose, as was also observed for 0.8 3 LD50 and 2 3 LD50 of C(+)P(+)-soman (Table 5.3).28 It can be observed that ()-sarin is more persistent in guinea pigs than C(+)P()-soman at an i.v. dose corresponding with 0.8 3 LD50 and 2 3 LD50. It is remarkable that the concentrations of ()-sarin remain rather constant at a relatively low level for a long period of time. Interestingly, we hardly ever have seen the concentrations of either of the P()-isomers of soman to persist in the terminal phase. Tentative explanations for the leveling-off or increase of the ()-sarin concentration in the terminal phase of the toxicokinetics are release from rather aspecific, noncovalent binding sites, or reactivation from covalent binding sites induced by endogenous fluoride ions. The latter reaction proceeds more readily in the case of sarin than in the case of soman.
C. VX Data on toxicokinetics of (+)-VX are very scarce. However, it can be anticipated that the toxicokinetics of (+)-VX differs substantially from that of the phosphofluoridates, since: 1. (+)-VX circulates in vivo as a protonated amine (pKa ¼ 9:4).17 2. (+)-VX is hydrolyzed much more slowly than phosphonofluoridates.29,30
877
806
317
111 233 61 1 1.2 0.10 0.017 40
136 253 63 0.55 1.3 0.11 0.011 64
C() P()
Rat
95
308
68 301 41 0.9 5.0 0.19 0.032 22
C(1) P()
320
56 259 37 1.1 4.7 0.15 0.042 16
C() P()
3 LD50
6
7
37
76
0.57 0.12
0.45 0.096
81
18.6 15 5.9
C() P()
22.7 18 3.9
C(1) P()
1 LD50
126
458
45.4 339 35 2.8 3.8 0.12 0.034 20
C(1) P()
520
37.1 406 40 9.9 4.3 0.19 0.046 15
C() P()
6 LD50
104
169
15.1 318 11 1 3.8 0.19 0.033 21
C(1) P()
228
12.4 354 15 1.7 3.9 0.21 0.042 16.5
C() P()
2 LD50
Guinea Pig
6
C(1) P()
10.6
5.8
0.95 0.12
5 3.8 0.8
C() P()
0.8 LD50
74
218
16.5 285 30 1.9 3.9 0.27 0.052 13
C(1) P()
191
13.5 172 22 1.6 3.0 0.22 0.047 15
49
81
5.5 61 9.9 1.8 2.2 0.35 0.073 9.5
85
4.5 52 9.1 2.1 2.0 0.30 0.073 9.4
C() P()
2 LD50 C(1) P()
Marmoset C() P()
6 LD50
a
After administration of C(+)P(+)-soman. It is assumed that the area under the curve of 1.8 ng=mL for C(+)P()-soman is the minimum area with toxicological relevance.
Note: Toxicokinetic parameters are calculated on the basis of 55:45 ratio of the [C(þ)P() þ C()P(þ)]-stereo-isomers and the [C(þ)P(þ) þ C()P())]-stereo-isomers. The concentration of each isomer at time t (conct ) is described by: conct ¼ Aeat þ Bebt þ Cect .
Dose (mg=kg) A (ng=mL) B (ng=mL) C (ng=mL) a (min1 ) b (min1 ) c (min1 ) Terminal half-life (min) AUC (ng min mL1) Acute toxic levels until (min)a
Parameter
C(1) P()
6 LD50
TABLE 5.2 Toxicokinetic Parameters of C(1)P()- and C()P()-Soman in Anesthetized, Atropinized, and Mechanically Ventilated Rats, Guinea Pigs, and Marmosets after i.v. Administration
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C005 Final Proof page 105 7.11.2007 5:20pm Compositor Name: BMani
Toxicokinetics of Nerve Agents 105
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
106
46616_C005 Final Proof page 106 7.11.2007 5:20pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Concentration (−)-GB (ng/mL)
100
10
1
0.1
0.01 0
10
20
30
40
50
60
Time (min)
FIGURE 5.7 Semi-logarithmic plot of the concentrations in blood of ()-sarin (GB) versus time after i.v. administration of 0.8 3 LD50 (n) and 2 3 LD50 (u) of (+)-sarin to anesthetized, atropinized, and mechanically ventilated guinea pigs. (From Spruit, H.E.T., Langenberg, J.P., Trap, H.C., Van der Wiel, H.J., Helmich, R.B., Van Helden, H.P.M., and Benschop, H.P., Toxicol. Appl. Pharmacol., 169, 249, 2000. With permission.)
3. (+)-VX is probably also metabolized by other routes than hydrolysis, for example, by means of oxidation reactions at nitrogen and sulfur, and by undefined anaerobic mechanisms.31–34 4. (+)-VX reacts hardly with carboxylesterases (TNO-PML, unpublished results), which may imply that the differences in its toxicokinetics in various species, for example, rats, TABLE 5.3 Toxicokinetic Parameters of ()-Sarin and C(+)P()-Soman after i.v. Administration of 0.8 3 LD50 of (+)-Sarin and 0.8 3 LD50 of Soman to Anesthetized, Atropinized, and Mechanically Ventilated Guinea Pigs Sarin Parameter Dose (mg=kg) A (ng=mL) B (ng=mL) C (ng=mL) a (min1 ) b (min1 ) c (min1 ) Terminal half-life (min) AUC (ng min mL1 ) Acute toxic levels until (min)a
Soman
0.8 LD50
2 LD50
0.8 LD50
2 LD50
9.6 35.9 0.09
24 17.1 0.151
4.95 3.75 0.8
27.5 683 27 3.8 3.9 0.21 0.039 18 397 104
4.6 0.012 58 15.3 10
0.705 0.00178 389 109 480
0.95 0.12 5.8 11
Note: The concentration of each isomer at time t (conct ) is described by: conct ¼ Aeat þ Bebt þ Cect . a
After administration of C(+)P(+)-soman or (+)-sarin. It is assumed that the area under the curve of 1:8 ng min mL1 for C(+)P()-soman or 6:9 ng min mL1 for ()-sarin is the minimum area with toxicological relevance.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C005 Final Proof page 107 7.11.2007 5:20pm Compositor Name: BMani
107
Toxicokinetics of Nerve Agents
guinea pigs, and marmosets, are much smaller than that for phosphonofluoridates. This assumption is also supported by the rather small range of LD50 values for (+)-VX in various species when compared with, for example, soman.25,35 In order to obtain the basic data, the toxicokinetics of VX was investigated in anesthetized, atropinized, and mechanically ventilated hairless guinea pigs and marmosets after i.v. administration at doses corresponding with 1 3 LD50 (28 mg=kg) and 2 3 LD50.17 The LD50 of VX in marmosets is not known but is assumed to have the same value as that in guinea pigs because the influence of CaE on the toxicokinetics is expected to be minimal. In the case that the expected (+)-VX levels were higher than 1 ng=mL, the sample was split and one part was analyzed with the off-line chiral LC-GC-NPD method. In the case that the expected concentrations of (+)-VX were lower than 1 ng=mL, the samples were analyzed with GC-NPD, without off-line separation of the stereo-isomers. It appeared that the ratio of the enantiomers [(þ)-VX=()-VX] never exceeded the value of 1.5, indicating that the stereoselectivity in the sequestration of the VX isomers is not as pronounced as with sarin and soman. Some in vitro experiments with plasma and liver homogenates from hairless guinea pigs confirmed that the sequestration of the enantiomers is lower than that observed with the G-agents. For lack of better alternatives, we have assumed that equal amounts of (þ)-VX and ()-VX are present in all phases of our toxicokinetic experiments and calculated the toxicokinetic parameters for (+)-VX rather than for the individual isomers. The curve of the toxicokinetics of VX in hairless guinea pigs is shown in Figure 5.8. For comparison, analogues data for soman are also given in Figure 5.8. The toxicokinetic data of the VX and soman are shown in Table 5.4. The value of the AUC experiments at doses corresponding with 1 3 LD50 and 2 3 LD50 shows that the toxicokinetics is reasonably linear with the dose. Evidently, the detoxification processes in the animal are not saturated with an excess of VX. The outcome is not surprising since the binding of VX to CaE is very slow, although this route is a major elimination route for the G-agents. The AUCs of the toxicokinetic experiments are summarized in Figure 5.9. This figure shows clearly the nonlinearity of the AUC as function of the dose in the
Concentration in blood (ng/mL)
1000
100
10
1
0.1
0.01 0
100
200
300
400
500
Time (min)
FIGURE 5.8 Semi-logarithmic plot of the nerve agent concentrations in blood versus time after i.v. administration of 2 3 LD50 soman (n) and 2 3 LD50 VX (µ) to anesthetized, atropinized, and mechanically ventilated guinea pigs. VX was administered to hairless guinea pigs. (From Van der Schans, M.J., Lander, B.J., Van der Wiel, H., Langenberg, J.P., and Benschop, H.P., Toxicol. Appl. Pharmacol., 191, 48–62, 2003.)
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
108
46616_C005 Final Proof page 108 7.11.2007 5:20pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
TABLE 5.4 Toxicokinetic Parameters of VX and C(+)P()-Soman after i.v. Administration of 1 3 LD50 and 2 3 LD50 of Soman and VX to Anesthetized, Atropinized, and Mechanically Ventilated Guinea Pigs or Marmosets Parameter Dose (mg=kg) Dose (nmol=kg) A (ng=mL) B (ng=mL) C (ng=mL) a (min1 ) b (min1 ) c (min1 ) Terminal half-life (min) AUC (ng min mL1 ) AUC (nmol min mL1 ) Acute toxic levels until (min)a
HGP VX
HGP VX
Marmoset VX
GP Soman
Marmoset Soman
56 210 77 17 0.48 0.67 0.033 0.0042 165 744 2.8 1153
28 106 48 8.7 0.39 0.71 0.045 0.0071 98 318 1.2 583
28 106 14 12 1.1 0.42 0.039 0.0062 111 504 1.9 841
27.5 151 683 27 3.8 3.9 0.21 0.039 18 397 2.2 104
10 54 113 19 3.9 2.1 0.33 0.073 9.5 166 0.91 49
Note: The concentration of each isomer at time t (conct ) is described by: conct ¼ Aeat þ Bebt þ Cect . HGP ¼ hairless guinea pig, GP ¼ guinea pig. a
After administration of C(+)P(+)-soman or (+)-VX. It is assumed that the area under the curve of 1:8 ng min mL1 for C(+)P()-soman or 0:9 ng min mL1 for (+)-VX is the minimum area with toxicological relevance.
experiments with rats, guinea pigs, and marmosets. The curves with a straight line through the origin pertain to experiments with a minor influence of CaE on the toxicokinetics because of the absence of this enzyme (in case of marmosets) or a low affinity of this enzyme with the nerve agent (in case of VX).
AUC [(ng min)/mL)]
2000
1500
1000
500
0 0
50
100
150
200
250
300
Dose (µg/kg)
FIGURE 5.9 AUC as function of the dose of nerve agent after i.v. administration to anesthetized, atropinized, and mechanically ventilated animals. Soman-rat (u), soman-guinea pig (n), soman-marmoset (µ), and VX-guinea pig (.).
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C005 Final Proof page 109 7.11.2007 5:20pm Compositor Name: BMani
109
Toxicokinetics of Nerve Agents
Concentration (±)-VX (ng/mL)
100
10
1
0.1
0.01 0
100
200
300
400
500
Time (min)
FIGURE 5.10 Semi-logarithmic plot of the concentrations in blood of VX versus time after i.v. administration of 1 3 LD50 to anesthetized, atropinized, and mechanically ventilated hairless guinea pigs (µ) or marmosets (n). (From Van der Schans, M.J., Lander, B.J., Van der Wiel, H., Langenberg, J.P., and Benschop, H.P., Toxicol. Appl. Pharmacol., 191, 48, 2003. With permission.)
Figure 5.8 shows also that the elimination rates of the two types of agents differ widely. Both the terminal half-life and the period of time that toxicologically relevant concentrations are present are approximately one order of magnitude longer for VX than for soman. As shown in Figure 5.10, the toxicokinetics of VX in marmosets and guinea pigs at a dose corresponding with 1 3 LD50 in hairless guinea pigs reveals that after a short time, the blood levels in the marmoset are in between the levels found in blood of guinea pigs at dosages corresponding with 1 3 LD50 and 2 3 LD50. Correspondingly, the AUC and period of time in which toxicologically relevant concentrations of VX are present are for the marmoset in between the values of 1 3 LD50 and 2 3 LD50 for guinea pigs. Nevertheless, the data show that the difference between marmoset and guinea pig is not as large due to the lack of affinity of VX for CaE.
V. PERCUTANEOUS TOXICOKINETICS OF VX Due to the low volatility of VX, the main porte d’entrée for this agent is by penetration through the skin. The toxicokinetics of VX was investigated in hairless guinea pigs after percutaneous application of VX in 2-propanol at a dose corresponding with 1 3 LD50 (125 mg=kg).36–38 Blood samples were taken up to 7 h after the application. Unfortunately, it was not possible to take blood samples for a longer period of time for technical reasons. Therefore, the experiments pertain only to the first phase of the toxicokinetic curve, where the levels of VX just start to decrease after increasing for several hours. The concentration of VX in blood versus time after percutaneous application is shown in Figure 5.11. Evidently, a large variation is observed in the data of the levels of VX in blood. Presumably, this spread is caused by the variation in thickness and permeability of the skin in the various animals.39 The curve through the data points has been drawn by the eye. The AUC was estimated at 43 8 ng min mL1 and was calculated as the mean of the individual curves. The bioavailability can be calculated as the ratio of the AUC after percutaneous application and the extrapolated AUC that would have been derived after i.v. injection of the same dose. The bioavailability after percutaneous (p.c.) application appeared to be only 2.5%. In view of
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
110
46616_C005 Final Proof page 110 7.11.2007 5:20pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Concentration (±)-VX (pg/mL)
200
100
0 0
50
100
150
200
250
300
350
400
450
Time (min)
FIGURE 5.11 Concentration of VX in blood of anesthetized, atropinized, and artificially ventilated guinea pig after percutaneous application of VX at a dose of 125 mg=kg, corresponding with 1 3 LD50. (From Van der Schans, M.J., Lander, B.J., Van der Wiel, H., Langenberg, J.P., and Benschop, H.P., Toxicol. Appl. Pharmacol., 191, 48–62, 2003.)
the low bioavailability, it is possible that a significant part of the administered dose of VX is still present in depot in the skin. The blood levels of VX build up slowly and reach a maximum level of approximately 140 pg=mL at 6 h after the application of the toxicant. Figure 5.12 shows the degree of AChE inhibition for three individual animals, together with the corresponding individual blood levels of VX. A qualitative agreement between the two sets of data was observed since a rapid
Percentage inhibition of AChE in blood
100
1678 1375
80
1684
2387
257
249
273 213
165
34 41 45
60 53
40 40
68
105 115
85
20
68
0 0
100
200
300
400
500
Time (min)
FIGURE 5.12 Progressive inhibition of AChE of anesthetized, atropinized, and artificially ventilated hairless guinea pigs after percutaneous application of VX at a dose of 125 mg=kg, which corresponds with 1 3 LD50. Numbers at the data points correspond with the concentration (pg=mL) VX in blood in that particular sample. (From Van der Schans, M.J., Lander, B.J., Van der Wiel, H., Langenberg, J.P., and Benschop, H.P., Toxicol. Appl. Pharmacol., 191, 48–62, 2003.)
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C005 Final Proof page 111 7.11.2007 5:20pm Compositor Name: BMani
Toxicokinetics of Nerve Agents
111
decrease of AChE activity corresponds with relatively high levels of VX and a slow decrease of AChE corresponds with relatively low levels of VX. The experiment in which the most rapid decrease of AChE activity and high levels of VX were observed was not used in the construction of the toxicokinetic curve (Figure 5.11). This result was considered as an outlier. As shown in Table 5.4, the period of time that toxicological relevant levels of VX circulate after i.v. administration is 10–20 h, but this time period might be considerably longer after p.c. exposure. Moreover, these time periods are considerably longer than those observed with G-agents, that is, at most 2 h for an i.v. dose corresponding with 2 3 LD50. This difference in combination with the gradual build-up of the blood levels after p.c. exposure may cause specific problems in the diagnosis and treatment of intoxications with V-agents. These findings are in agreement with the description of the symptoms of a victim who was attacked with VX by a member of the AUM Shinrikyo sekt.40 With G-agents, the most important porte d’entrée is the respiratory route, where the symptoms occur shortly after the exposure. With p.c. exposure of liquid VX, there will be a certain lag time between exposure and symptoms, which may complicate the timely diagnosis. The traditional treatment of nerve agent intoxication with atropine and oximes might be hampered by the rapid pharmacokinetics of the oxime and slow elimination of the VX, which might still circulate at toxic relevant levels when the blood levels of the oxime have decreased to ineffective levels. In that case, oxime therapy must be continued until the VX levels drop below the toxicologically relevant level. In accordance with the latter scenario Clarkson et al.41 treated VX-intoxicated guinea pigs with repetitive oxime administration and was able to treat the animals up to challenges of 10 3 LD50. However, the animals were euthanized at 24 h after the application of the agent. Presumably, this period is too short to judge whether the treatment has been truly effective because it is possible that animals would have died after that period of time. Interestingly, the paper mentioned also a positive effect of pyridostigmine in treatment. The reports in the literature contradict each other. Gordon et al.42 reported a positive effect of pretreatment with carbamates in case of a s.c. challenge of guinea pigs with VX. However, Koplovitz et al.43 reported a negative influence of pretreatment with pyridostigmine on the efficacy of treatment with an oxime. It should be mentioned that a treatment with scavengers such as BuChE would be more effective in this respect, since these scavengers have a longer half-life time than oximes.44
VI. ELIMINATION PATHWAYS OF SOMAN, SARIN, AND VX The rapid decrease of soman levels in blood after i.v. administration or respiratory exposure is due to three processes, that is, distribution to various tissues, spontaneous or enzymatic hydrolysis, and covalent binding.45–49 It has been established that the toxic C(+)P()-isomers react rapidly with covalent binding sites. The less toxic C(+)P(þ)-isomers are hydrolyzed several orders of magnitude faster than the C(+)P()-isomers. The low toxicity of the C(+)P(þ)-isomers is primarily due to a low intrinsic reactivity toward AChE and rapid hydrolysis. The elimination of VX deviates from that of soman. As observed in the toxicokinetic studies, the elimination of VX proceeds much slower than that for the G-agents. In addition to the major detoxification route of VX, which leads to the formation of O-ethyl methylphosphonic acid, it cannot be excluded that toxic metabolites will be formed. Possible toxic metabolites are the dealkylated form of VX or desethyl-VX and the N-oxide of VX.31–34 Neither metabolite has been found in blood samples taken for toxicokinetic experiments. In vitro experiments, in which high concentrations of VX (10 mg=mL) were incubated in plasma or liver homogenate, did not yield any of these toxic metabolites either. However, desethyl-VX could be detected in reasonable amounts when plasma was derived from blood that was drawn in tubes with EDTA as anticoagulant. EDTA binds metal ions that are essential for the enzymatic hydrolysis of VX, which leads to the formation of EMPA. When that route is inhibited, the formation of desethyl-VX may increase.50 Elimination products such as hydrolyzed organophosphate or covalently bound organophosphate are the biomarkers of choice for detection of exposure, since the persistence of the intact nerve agents, although sufficiently long to interfere with therapeutic measures, is too short for this
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
112
46616_C005 Final Proof page 112 7.11.2007 5:20pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
purpose.* Incubation of inhibited CaE or BuChE with fluoride ions can regenerate the phosphyl moiety from the protein, thus creating the phosphofluoridate, which can be analyzed with gas chromatography. The method can also be used to study the distribution of the nerve agent over the tissues, provided that the nerve agent can be regenerated with fluoride ions, which is the case for sarin and VX but not for soman.y Whalley et al.51 exposed several guinea pigs to sarin through the respiratory route and by subcutaneous administration. Next, the animals were euthanized at different time points and the amount of regenerable sarin in the tissues was determined. Figure 5.13 shows the amount of sarin 10
Eye
9
Lung
8
Kidney
7
Brain Heart
rGb (ng/g)
6
Liver
5
Diaphragm
4 3 2 1 0 120
160
200 Time (min)
240
360
60 Eye Lung
50
Kidney Brain
rGb (ng/g)
40
Heart Liver
30
Diaphragm 20
10
0 120
160
200 Time (min)
240
360
FIGURE 5.13 Concentration (ng=g) of regenerated sarin (GB) in various tissues of guinea pigs after subcutaneous administration of sarin at dosages corresponding with 0.1 3 LD50 (4.2 mg=kg, left) and 0.4 3 LD50 (16.8 mg=kg, right). * For a comprehensive review of methods for diagnosis of exposure to CW-agents see Noort et al.78 Soman cannot be regenerated with fluoride ions because dealkylation of the pinacolyl group of soman once bonded to BuChE (a process known as aging) prevents the regeneration of soman.
y
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Toxicokinetics of Nerve Agents
46616_C005 Final Proof page 113 7.11.2007 5:20pm Compositor Name: BMani
113
that could be regenerated from the tissues after subcutaneous administration of doses corresponding with 0.1 3 LD50 and 0.4 3 LD50. The figures show that after subcutaneous administration of sarin corresponding with 0.1 3 LD50, the majority of sarin adducts is found in the lungs and only a small portion in the other organs. After administration of sarin at a dose corresponding with 0.4 3 LD50, the kidney appears to be also an important site for binding of sarin. The amount of regenerable sarin seems to correlate with the flow of blood through that organ. Intact sarin is supplied by the blood stream and reacts with the available binding sites. The lungs are the only organ where 100% of the cardiac output flows through, which may be an explanation for the high amount of regenerable sarin in that particular organ. The liver is an organ with an extremely high number of binding sites, but the limited blood flow through that organ causes a moderate amount of bonded sarin. Figure 5.14 shows the amount of regenerable sarin in tissues of guinea pigs after whole-body exposure to sarin at dosages corresponding with 0.1 3 LCt50 and 0.4 3 LCt50. It is obvious that the amount of regenerable sarin in the eyes is relatively high, because the uptake of sarin takes place directly from the air into the eyes. It cannot be excluded that the amount of measured sarin partly consists of intact sarin that is not necessarily regenerated from binding sites. At a higher exposure level, the amount of regenerable sarin is highest in the lungs. It is remarkable that the amounts of regenerable sarin in the lungs after whole-body exposure or subcutaneous administration at comparable dosages (0.4 3 LCt50 or 0.4 3 LD50) are roughly the same. It might be expected that the amount of bonded sarin upon whole-body exposure is higher because sarin is inhaled. However, the absorption of sarin does not occur in the lungs but proceeds most likely in the upper airways rather than in the lungs. In this way, intact sarin has to be transported by blood to the lungs, where it can react with the binding sites in that organ.
VII. EFFECT OF HUMAN PLASMA BUTYRYLCHOLINESTERASE AS SCAVENGER ON THE TOXICOKINETICS OF NERVE AGENTS In the previous section, it was discussed that binding is one of the most effective elimination routes for nerve agents. The difference in lethality of various nerve agents in rats, guinea pigs, and marmosets is a result of the presence of different amounts of CaE, which reacts as a scavenger in blood of these species. Therefore, attention has been paid to pretreatment with highly reactive scavengers, which would intercept or destroy the nerve agent before it could reach its target site, when entering the blood stream. It is anticipated that effective scavengers offer protection against both lethal and incapacitating effects of an acutely toxic dose. In addition, if a scavenger remains in circulation at an effective concentration during a relatively long period of time, the pretreatment will, a fortiori, protect against a long-term exposure to low doses of a nerve agent.52 It is further anticipated that bioscavengers do not induce adverse physiological effects, particularly when bioscavengers from human origin are applied. As early as 1957, Cohen and Warringa53 achieved some protection in rats against a lethal subcutaneous dose of diisopropyl phosphorofluoridate and sarin by pretreatment with an enzyme capable of hydrolyzing organophosphates.54 In more recent years, the feasibility of using bioscavengers that can rapidly bind nerve agents has been studied. For this purpose, monoclonal antibodies,55,56 serum AChE,57–60 and human plasma butyrylcholinesterase (HuBuChE)61–71 have been investigated. Very promising results were obtained with HuBuChE as a scavenger. The enzyme is rapidly distributed in laboratory animals, such as mice, rats, guinea pigs, and rhesus monkeys, after i.v. administration, followed by a slow elimination.61,63,69 In addition, the enzyme is sufficiently absorbed following an intramuscular (i.m.) administration to provide therapeutically significant blood levels over a time period of 10–70 h in laboratory animals, which is a prerequisite for practical
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
114
46616_C005 Final Proof page 114 7.11.2007 5:20pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 14 Eye 12
Lung Kidney
10 rGb (ng/g)
Brain Heart
8
Liver 6
Diaphragm
4 2 0 120
160
200
240
360
Time (min) 30 Eye Lung
25
Kidney Brain
rGb (ng/g)
20
Heart Liver
15
Diaphragm 10
5
0 120
160
200
240
360
Time (min)
FIGURE 5.14 Concentration (ng=g) of regenerated sarin in various tissues of guinea pigs after respiratory exposure to sarin (GB) at dosages corresponding with 0.1 3 LCt50 (0.4 mg m3 for 60 min, left) or 0.4 3 LCt50 (1.6 mg m3 for 60 min, right).
application.61,63,69 The peak level in blood after i.m. administration amounted to 50%–60% of the concentration obtained immediately after i.v. administration of the same amount of enzyme. Pretreatment with the enzyme resulted not only in an increase in survival of mice, rats, and rhesus monkeys intoxicated (i.v.) with C(+)P(+)-soman or other nerve agents, but also in a significant alleviation of postexposure incapacitation. An effective protection of guinea pigs against respiratory exposure to C(+)P(+)-soman has been reported.63 Since the efficacy of HuBuChE as a scavenger
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C005 Final Proof page 115 7.11.2007 5:20pm Compositor Name: BMani
115
Toxicokinetics of Nerve Agents
is based on the inhibitory properties of the challenging agent, it can be expected that such scavengers will be effective against nerve agents having a wide variety of chemical structures. Moreover, the stereoselectivity of HuBuChE as scavenger is in favor of the P()-isomers, which means that the toxic isomer of the nerve agents is preferentially eliminated. The ultimate goal is to use these scavengers as pretreatment to protect humans against nerve agent intoxication. Toxicokinetic studies can be an adequate tool for the quantitative description of the protective mechanism, which is needed for registration of the enzyme as pretreatment drug for application in humans. The toxicokinetics of soman in anesthetized, atropinized, and artificially ventilated naive and HuBuChE-pretreated guinea pigs was studied.72 Animals were pretreated with HuBuChE by an i.m. administration at 24 h before administration of the nerve agent. The enzyme was administered i.m., since this route is much more appropriate than i.v. administration for application of a scavenger in a realistic scenario. The ratio of the dose of HuBuChE relative to the dose of the nerve agent was chosen on the basis of results reported by Ashani et al.61 or Allon et al.63 in order to obtain sufficient protection in a similar experiment. The dose of HuBuChE was a 0.7-fold fraction of the molar dose of soman, which corresponds with 0.7 3 55=182 ¼ 211 nmol HuBuChE=kg. The levels of HuBuChE in blood at 24 after i.m. administration of HuBuChE was approximately 690 nM, which is over an order of magnitude higher than the baseline level of BuChE, which is approximately 20 nM. In order to study the effect of the scavenger we compared the toxicokinetic data of the HuBuChE-pretreated and nonpretreated animals. Figure 5.15 shows the concentration–time curves of C()P()-soman after i.v. administration of soman in naive and HuBuChE-pretreated animals. Evidently, the concentrations of C()P()-soman in HuBuChE-pretreated animals are much lower than those in naive animals. This effect of the scavenger is also clearly reflected in the values of the AUC shown in Table 5.5. The difference in AUC of the P()-isomers between naive and HuBuChE-pretreated animals is 65:9 2:9 ¼ 63 ng min mL1 , which is equal to 0:34 nmol min mL1 . The period of time that acutely toxic levels of soman exist is reduced from 40 to 1 min. After one injection of soman only the C()P()-isomer of soman could be detected in the HuBuChE-pretreated guinea pigs. The C(þ)P()-isomer had completely disappeared from the blood stream. In a qualitative sense, this result was expected in view of the higher binding constant of C(þ)P() with BuChE compared with the binding constant of the C()P()-isomer with BuChE.
Concentration C(−)P(−)-GD (ng/mL)
100
10
1
0.1
0.01 0
10
20
30
40
50
60
Time (min)
FIGURE 5.15 Mean concentration + SEM (ng=mL) of C()P()-soman (GD) in blood of individual anesthetized, atropinized, and mechanically ventilated naive (u) and HuBuChE-pretreated (200 nmol=kg, n) guinea pigs after i.v. bolus administration of a dose of C(+)P(+)-soman corresponding with 2 3 LD50 (55 mg=kg).
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
116
46616_C005 Final Proof page 116 7.11.2007 5:20pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
TABLE 5.5 Effect of Pretreatment (i.m.) with HuBuChE on the Toxicokinetic Parameters for Soman and VX in Anesthetized, Atropinized, and Artificially Ventilated Guinea Pigs after i.v. Administration Parameter Isomer Dose scavenger (nmol=kg) Dose nerve agent (mg=kg) A (ng=mL) B (ng=mL) C (ng=mL) a (min1 ) b (min1 ) c (min1 ) Terminal half-life (min) AUC (ng min=mL) Acutely toxic levels until (min)
Soman
Soman
Soman
Soman
VX
VX
C(þ)P() 0 15.1 2.05 0.658 — 0.277 0.054 — 14.7 19.6
C()P() 0 12.4 70.0 4.05 0.356 3.11 0.256 0.0445 15.5 46.3 40
C(þ)P() 200 15.1 — — — — — — — 0 —
C()P() 200 12.4 1.11 0.274 — 0.815 0.179 — 3.8 2.89 1
(+) 0 56 77 17 0.48 0.67 0.033 0.0042 165 744 1153
(+) 200 56 54.2 11.0 — 0.817 0.0257 — 26.9 494 230
Note: The concentration of each isomer at time t (conct ) is described by: conct ¼ Aeat þ Bebt þ Cect . It is assumed that the area under the curve of 1:8 ng min mL1 for C(+)P()-soman or 0:9 ng min mL1 for (+)-VX is the minimum area with toxicological relevance.
Experiments analogous to those performed with soman were also performed with VX, that is, the effect of pretreatment of HuBuChE at 0.7 3 LD50 the molar dose of VX corresponding with 2 3 LD50 of VX on the toxicokinetics of the agent was investigated. As shown in Figure 5.16, the VX levels in blood of HuBuChE-pretreated guinea pigs are somewhat lower. However, this effect seems not to be very large during the first 180 min. A more pronounced difference between the two curves in the time period beyond 200 min is observed, but the contribution of this part to the AUC of
Concentration VX (ng/ml)
100
100
10
1 10
0
5
10 Time (min)
15
20
0.1
0.01 0
100
200
300
400
500
Time (min)
FIGURE 5.16 Mean concentration + SEM (ng=mL) of (+)-VX in blood of individual anesthetized, atropinized, and mechanically ventilated naive (u) and HuBuChE-pretreated (200 nmol=kg, n) guinea pigs after i.v. bolus administration of a dose of (+)-VX corresponding with 2 3 LD50 (56 mg=kg). Inset shows the data for the first 20 min plotted on an expanded scale.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C005 Final Proof page 117 7.11.2007 5:20pm Compositor Name: BMani
117
Toxicokinetics of Nerve Agents
TABLE 5.6 AUC (nmol.min.ml1) of (+)-VX and C(+)P()-Soman in Blood of Naive or HuBuChEPretreated Anesthetized, Atropinized and Mechanically Ventilated Guinea Pigs. Guinea Pigs were i.v. Injected with VX (56 mg=kg) or C(+)P(+)-Soman (55 mg=kg) AUC of (+)-VX (nmol.min.ml1)
Time (min) 0 0–30’ 0–60’ 0–90’ 0–120’ 0–180’ 0–240’
Without HuBuChE
HuBuChE (200 nmol=kg)
Difference as Result of HuBuChE Treatment
0 1.69 2.18 2.39 2.49 2.58 2.62
0 1.11 1.51 1.69 1.78 1.84 1.85
0 0.58 0.67 0.70 0.81 0.74 0.77
AUC of C(+)P()-Soman (nmol.min.ml1)
Without HuBuChE
HuBuChE (200 nmol=kg)
Difference as Result of HuBuChE Treatment
0 0.337 0.356 0.360
0 0.014 0.015 0.015
0 0.32 0.34 0.35
the toxicokinetic curve is less than 7%. Table 5.5 shows a summary of the toxicokinetic parameters derived from the blood levels of soman and VX. The decline of the AUC for the summated stereo-isomers of VX on pretreatment with 200 nmol=kg HuBuChE was 744 494 ¼ 260 ng min mL1 , which is equal to 0:97 nmol min mL1 . By comparison, the decrease of the AUC of C(+)P()-soman in guinea pigs challenged with 55 mg=kg C(+)P(+)-soman was 0:34 nmol min mL1 . The P(þ)-isomers of soman were not detected but it cannot be excluded that these P(þ)-isomers consumed a part of the scavenger.72 Although it cannot be excluded that the P(þ)-isomers consumed a part of the scavenger, this will not suffice to explain the lesser decrease of the AUC for soman than for VX. The AUCs of the VX curves are calculated over a time span of 360 min, whereas the AUCs of the soman curves are calculated over a time span of 60 min. Table 5.6 Please provide ‘‘Table 5.6’’. Please provide ‘‘Table 5.6’’ shows the AUCs of both experiments expressed in nmol min mL1 for different time spans. The decrease of AUC as result of HuBuChE pretreatment is larger for VX than for soman. However, the relative decline of the AUC of the soman curve (97% at t ¼ 90 min) is more pronounced than that for VX (29% at t ¼ 90 min). The elimination of soman in nonpretreated animals is caused by enzymatic hydrolysis and binding to CaE, whereas the elimination of VX in such animals is driven by slow enzymatic hydrolysis and slow binding to CaE. Additional binding sites such as BuChE will be consumed rapidly. Addition of fast binding sites to soman will only increase the number of multiple fast binding sites. It is therefore explicable that the scavenger will not be consumed completely by soman, which means that the effect of the scavenger on the toxicokinetics of soman is less in this case. Table 5.5 shows clearly that the time period in which acutely toxic levels of VX circulate is reduced from 1153 to a still considerable 230 min after administration of 200 nmol=kg HuBuChE. HuBuChE acts as a stoichiometric scavenger for nerve agents, which means that the efficacy of the protection by HuBuChE depends on the balance between the amount of nerve agent and the amount of scavenger. In these experiments, the amount of HuBuChE was not sufficient to decrease the concentration of VX below the acutely toxic level within a reasonable time window.
VIII. CONCLUDING REMARKS With the analytical methodology available, it appeared possible to measure nerve agents at the toxicologically relevant level. This capability allowed to measure the toxicokinetics of nerve agents after a variety of exposure routes at several doses, and to determine the time period for which
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
118
46616_C005 Final Proof page 118 7.11.2007 5:20pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
acutely toxic levels exist. The relevance of such studies has been shown since the persistence of nerve agent in vivo is longer than that anticipated, with the percutaneous exposure to VX as being the most remarkable. It is evident that these studies can be used for the development of strategies for timely administration of antidotes in case of nerve agent intoxication. For example, the efficacy of HuBuChE as a scavenger for nerve agents was demonstrated by toxicokinetic studies. Analysis of regenerated sarin from binding sites has provided more insight into the elimination pathways of nerve agents. This is especially true for the lungs and the eyes, which appeared to contain many binding sites for nerve agents following whole-body exposure. Both organs are also the porte d’entrée for the agent, and for the eyes it cannot be excluded that the amount of measured sarin partly consists of intact sarin. Exposure studies at lower levels (occupational exposure) are near the lower limit of what can be reached with regard to toxicokinetics based on in vivo measurement of the intact nerve agent. Ultra low level exposure can only be studied after analysis of fluoride-regenerated nerve agents.73 With these studies, it is possible to quantify the link between external and internal dosages, which is highly relevant in the area of regulatory toxicology. Eventually, the toxicokinetic data, together with the distribution data, are very useful for the validation of physiologically based pharmacokinetic modeling (PBPK).74–77 These models are needed because the experiments that were discussed in this chapter can never be performed in humans, whereas extrapolation of the results obtained in these animal experiments to man is still the ultimate goal of these investigations.
REFERENCES 1. Wolthuis, O.L., Benschop, H.P., and Berends, F., Persistence of the anticholinesterase soman in rats antagonism with a non-toxic simulator of this organophosphate, Eur. J. Pharmacol., 69, 379, 1981. 2. Benschop, H.P. and De Jong, L.P.A., Toxicokinetics of nerve agents, in Chemical Warfare Agents: Toxicity at Low Levels, Somani, S.M. and Romano Jr., J.A., eds., CRC Press, Boca Raton FL, USA Chapter 2, 2001. 3. Benschop, H.P. and De Jong, L.P.A., Nerve agent stereoisomers: analysis, isolation and toxicology, Acc. Chem. Res., 21, 368, 1988. 4. Benschop, H.P., Konings, C.A.G., and De Jong, L.PA., Gas chromatographic separation and identification of the four stereoisomers of 1,2,2-trimethylpropyl methylphosphonofluoridate (soman). Stereospecificity of in vitro ‘‘detoxification’’ reactions, J. Am. Chem. Soc., 103, 4260, 1981. 5. Spruit, H.E.T., Trap, H.C., Langenberg, J.P., and Benschop, H.P., Bioanalysis of the enantiomers of (+)-sarin using automated thermal cold trap injection combined with two-dimensional gas chromatography, J. Anal. Toxicol., 25, 57–61, 2001. 6. Kientz, C.E., Langenberg, J.P., and Brinkman, U.A.Th., Microcolumn liquid chromatography with thermionic detection of the enantiomers of O-ethyl S-diisopropylaminoethylmethylphosphonothioate (VX), J. High Resolut. Chromatogr., 17, 95, 1994. 7. Mehlsen-Sorensen, A., (R)-(þ)-O-isopropyl-S-(trimethylammonioethyl) methylphosphonothioate iodide, Acta Crystallogr., Sect. B, B33, 1693, 1977. 8. Benschop, H.P., Absolute configuration of chiral organophosphorus anticholinesterases, Pestic. Biochem. Physiol., 5, 348, 1975. 9. Ordentlich, A., Barak, D., Kronman, C., Benschop, H.P., De Jong, L.PA., Ariel, N., Barak, R., Segall, Y., Velan, B., and Shafferman, A., Exploring the active center of human acetylcholinesterase with stereoisomers of an organophosphorus inhibitor with two chiral centers, Biochemistry, 38, 3055, 1999. 10. Benschop, H.P., Konings, C.A.G., Van Genderen, J., and De Jong, L.P.A., Isolation, anticholinesterase properties and acute toxicity in mice of the four stereoisomers of soman, Toxicol. Appl. Pharmacol., 90, 61, 1984. 11. Boter, H.L. and Van Dijk, C., Stereospecificity of hydrolytic enzymes on reaction with asymmetric organophosphorus compounds. The inhibition of acetylcholinesterase and butyrylcholinesterase by enantiomeric forms of sarin, Biochem. Pharmacol., 18, 2403, 1969.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Toxicokinetics of Nerve Agents
46616_C005 Final Proof page 119 7.11.2007 5:20pm Compositor Name: BMani
119
12. De Jong, L.P.A. and Benschop, H.P., Biochemical and toxicological implications of chirality in anticholinesterase organophosphates, in Stereoselectivity of Pesticides. Biological and Chemical Problems, Ariens, E.J., Van Rensen, J.J.S., and Welling, W., eds., Elsevier, Amsterdam, Chapter 4, 1988. 13. Hall, C.R., Inch, T.D., Inns, R.H., Muir, A.W., Sellers, D.J., and Smith, A.P., Differences between some biological properties of enantiomers of alkyl S-alkyl methylphosphonothioates, J. Pharm. Pharmacol., 29, 574, 1977. 14. Benschop, H.P., Bijleveld, E.C., Otto, M.F., Degenhardt, C.E.A.M., Van Helden, H.P.M., and De Jong, L.P.A., Stabilization and gas chromatographic analysis of the four stereoisomers of 1,2,2-trimethylpropyl methyl phosphonofluoridate (soman) in rat blood, Anal. Biochem., 151, 242, 1985. 15. Degenhardt, C.E.A.M., Pleijsier, K., van der Schans, M.J., Langenberg, J.P., Preston, K.E., Solano, M.I., Maggio, V.L., and Barr, J.R., Improvements of the fluoride reactivation method for the verification of nerve agent exposure, J. Anal. Toxicol., 28(5), 364–371, 2004. 16. Jakubowski, E.M., McGuire, J.M., Evans, R.A., Edwards, J.L., Hulet, S.W., Benton, B.J., Forster, J.S., Burnett, D.C., Muse, W.T., Matson, K., Crouse, C.L., Mioduszewski, R.J., and Thomson, S.A., Quantitation of fluoride ion released sarin in red blood cell samples by gas chromatography–chemical ionization mass spectrometry using isotope dilution and large-volume injection, J. Anal. Toxicol., 28(5), 357–363, 2004. 17. Van der Schans, M.J., Lander, B.J., Van der Wiel, H., Langenberg, J.P., and Benschop, H.P., Toxicokinetics of the nerve agent (+)-VX in anesthetized and atropinized hairless guinea pigs and marmosets after intravenous and percutaneous administration, Toxicol. Appl. Pharmacol., 191, 48–62, 2003. 18. Bonierbale, E., Debordes, L., and Coppet, L., Application of capillary gas chromatography to the study of the hydrolysis of the nerve agent VX in rat plasma, J. Chromatogr., 668, 255–264, 1996. 19. Smith, J.R., Analysis of the enantiomers of VX using normal-phase chiral liquid chromatography with atmospheric pressure chemical ionization–mass spectrometry, J. Anal. Toxicol., 28(5), 390–392, 2004. 20. Polhuijs, M., Langenberg, J.P., and Benschop, H.P., New method for retrospective detection of exposure to organophosphorus anticholinesterases. Application to alleged sarin victims of Japanese terrorists, Toxicol. Appl. Pharmacol., 146, 156–161, 1997. 21. Benschop, H.P. and De Jong, L.PA., Toxicokinetic investigations of C(+)P(+)-soman in the rat, guinea pig and marmoset at low doses—quantification of elimination pathways, Final Report Grant DAMD17-877015, NTIS AD-A 226 807, 1990. 22. Benschop, H.P. and De Jong, L.P.A., Toxicokinetics of the four stereoisomers of soman in the rat, guinea pig and marmoset, Final Report Grant DAMD17-85-G-5004, NTIS AD-A 199 573, 1987. 23. Benschop, H.P. and Van Heiden, H.P.M., Toxicokinetics of inhaled soman and sarin in guinea pigs, Final Report Contract DAMD17-90-Z-0034, NTIS AD-A277 585, 1993. 24. Benschop, H.P. and De Jong, L.P.A., Toxicokinetics of soman: species variation and stereospecificity in elimination pathways, Neurosci. Biobehav. Rev., 15, 73, 1991. 25. Maxwell, D.M., Brecht, K.M., and O’Neill, B.L., The effect of CaE inhibition on interspecies differences in soman toxicity, Toxicol. Lett., 39, 35, 1987. 26. De Jong, L.P.A., Physiologically based modeling of C(+)P(+)-soman toxicokinetics in guinea pig, Final Report for Cooperative Agreement DAMD17-95-2-5009, 1996. 27. De Jong, L.P.A., Determination of parameters for development of a physiologically based model for the toxicokinetics of C(+)P(+)-soman, Final Report for Cooperative Agreement DAMD17-92-V-2004, 1993. 28. Spruit, H.E.T., Langenberg, J.P., Trap, H.C., Van der Wiel, H.J., Helmich, R.B., Van Helden, H.P.M., and Benschop, H.P., Intravenous and inhalation toxicokinetics of sarin stereoisomers in atropinized guinea pigs., Toxicol. Appl. Pharmacol., 169, 249–254, 2000. 29. Wang, Q., Sun, M., Zhang, H., and Huang, C., Purification and properties of soman-hydrolyzing enzyme from human liver, J. Biochem. Mol. Toxicol., 12(4), 213–217, 1998. 30. Bajgar, J., Fusek, J., Patocka, J., and Hrdina, V., Detoxification of phosphonothioates and phosphonofluoridates in the rat, Acta Biol. Med. Ger., 37, 1261, 1978. 31. Fu, F. and Sun, M., Occurrence of (+)-VX oxidase, Chin. J. Pharmacol. Toxicol., 3, 264–270, 1990; Chem. Abstr., 112, 74346, 1989. 32. Fu, F. and Sun, M., Aerobic metabolism of (+)-VX and mixed function oxidases, Acta Pharmacol. Sin., 11, 123–126, 1990; Chem. Abstr., 112, 212942, 1990.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
120
46616_C005 Final Proof page 120 7.11.2007 5:20pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
33. Scaife, J.F. and Campbell, D.H., The destruction of O,O-diethylaminoethyl phosphorothiolate by liver microsomes, Can. J. Biochem. Physiol., 37, 297–305, 1959. 34. Wing, K.D., Glickman, A.H., and Casida, J.E., Oxidative bioactivation of S-alkyl phosphorothiolate pesticides: stereospecificity of profenofos insecticide activation, Science, 219, 63–65, 1983. 35. Maxwell, D.M., The specificity of carboxylesterase protection against the toxicity of organophosphorus compounds, Toxicol. Appl. Pharmacol., 114, 306, 1992. 36. Dalton, C.H., Hattersley, I.J., Rutter, S.J., and Chilcott, R.P., Absorption of the nerve agent VX (O-ethylS-[2-di-isopropylamino)ethyl] methyl phosphonothioate) through pig, human and guinea pig skin in vitro, Toxicol. In Vitro, 20(8), 1532–1536, 2006. 37. Chilcott, R.P., Dalton, C.H., Hill, I., Davison, C.M., Blohm, K.L., Clarkson, E.D., and Hamilton, M.G., In vivo skin absorption and distribution of the nerve agent VX (O-ethyl-S-[2-diisopropylamino)ethyl]methyl phosphonothioate) in the domestic white pig, Hum. Exp. Toxicol., 24(7), 347–352, 2005. 38. Chilcott, R.P., Dalton, C.H., Hill. I., Davison, C.M., Blohm, K.L., and Hamilton, M.G., Clinical manifestations of VX poisoning following percutaneous exposure in the domestic white pig, Hum. Exp. Toxicol., 22(5), 255, 2003. 39. Boutsiouki, P., Thompson, J.P., and Clough, G.F., Effects of local blood flow on the percutaneous absorption of the organophosphorus compound malathion: a microdialysis study in man, Arch. Toxicol., 75, 321–328, 2001. 40. Nozaki, H., Aikawa, N., Fujishima, S., Suzuki, M., Shinozawa, Y., Hori, S., and Nogawa, S., A case of VX poisoning and the difference from sarin, Lancet, 346, 698–699, 1995. 41. Clarkson, E.D., Schulz, S.M., Railer, R.F., Douglas, A., Kelleher, C.C., Logan, T.P., Shutz, M.B., and Washington, N., Cutaneous exposure to GD and VX: timing of antidotes, Proceedings TG004, Hradec Kralove, Czech Republic, 2005. 42. Gordon, J.J., Leadbeater, L., and Maidment, M.P., The protection of animals against organophosphate poisoning by pretreatment with a carbamate, Toxicol. Appl. Pharmacol., 43, 207–216, 1978. 43. Koplovitz, I., Harris, L.W., Anderson, D.R., Lennox, W.J., and Stewart, J.R., Reduction by pyridostigmine pretreatment of the efficacy of atropine and 2-PAM treatment of sarin and VX poisoning in rodents, Fundam. Appl. Toxicol., 18, 102–106, 1992. 44. Sidell, F.R. and Groff, W.A., Intramuscular and intravenous administration of small doses of 2-pyridinium aldoxime methochloride to man, J. Pharm. Sci., 60, 1224–1227, 1971. 45. Mazur, A., An enzyme in animal tissues capable of hydrolyzing the phosphorus-fluorine bond of alkyl fluorophosphates, J. Biol. Chem., 164, 271, 1946. 46. Mounter, L.A., Metabolism of organophosphorus anticholinesterase agents, in Handbuch der Experimentellen Pharmakologie. Vol. XV Cholinesterases and Anticholinesterase Agents, Koelle, G.B., ed., Springer, Berlin, Chapter 10, 1963. 47. Adie, P.A. and Tuba, J., The intracellular localization of liver and kidney sarinase, Can. J. Biochem. Biophys., 36, 21, 1958. 48. Adie, P.A., Hoskin, F.C.G., and Trick, G.S., Kinetics of the enzymatic hydrolysis of sarin, Can. J. Biochem. Biophys., 64, 80, 1958. 49. Augustinsson, K.-B. and Heimburger, G., The enzymic hydrolysis of organophosphorus compounds. 1. Occurrence of enzymes hydrolyzing tabun, Acta Chem. Scand., 8, 753, 1954. 50. Van der Schans, M.J., Langenberg, J.P., and Benschop, H.P., Toxicokinetics of O-ethyl S-(2-diisopropylaminoethyl) methylphosphonothioate [(+)-VX] in hairless guinea pigs and marmosets—identification of metabolic pathways, Final Report Contract DAMD17-97-2-7001, 2000. 51. Whalley, C.E., McGuire, J.M., Jakubowski, E.M., Miller, D.B., Mioduszewski, R.J., Thomson, S.A., Lumley, L.A., McDonough, J.H., and Shih, T.-M.A., Kinetics of inhaled and parenteral sarin (GB) following single and multiple sub-lethal exposures in the guinea pig, ECBC-TR-XXX, 2006. 52. Benschop, H.P., Trap, H.C., Spruit, W.E.T., Van der Wiel, H.J., Langenberg, J.P., and De Jong, L.P.A., Low level nose-only exposure to the nerve agent soman: toxicokinetics of soman stereoisomers and cholinesterase inhibition in atropinized guinea pigs, Toxicol. Appl. Pharmacol., 153, 179–185, 1998. 53. Cohen, J.A. and Warringa, M.G.P.J., Purification and properties of dialkylfluorophosphates. Biochim. Biophys. Acta, 26, 29–39, 1957. 54. Millard, C.B., Lockridge, O., and Broomfield, C.A., Organophosphorus acid anhydride hydrolase activity in human butyrylcholinesterase: synergy results in a somanase, Biochemistry, 37, 237–247, 1998.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Toxicokinetics of Nerve Agents
46616_C005 Final Proof page 121 7.11.2007 5:20pm Compositor Name: BMani
121
55. Lenz, D.E., Brimfield, A.A., Hunter, Jr., K.W., Benschop, H.P., De Jong, L.P.A., Van Dijk, C., and Clow, T.R., Studies using a monoclonal antibody against soman, Fundam. Appl. Toxicol., 4, S156–S164, 1984. 56. Brimfield, A.A., Hunter, Jr., K.W., Lenz, D.E., Benschop, H.P., Van Dijk, C., and De Jong, L.P.A., Structural and stereochemical specificity of mouse monoclonal antibodies to the organophosphorus cholinesterase inhibitor soman, Mol. Pharmacol., 28, 32–39, 1985. 57. Wolfe, A.D., Rush, R.S., Doctor, B.P., Koplovitz, I., and Jones, D., Acetylcholinesterase prophylaxis against organophosphate toxicity, Fundam. Appl. Toxicol., 9, 266–270, 1987. 58. Ashani, Y., Shapira, S., Levy, D., Wolfe, A.D., Doctor, B.P., and Raveh, L., Butyrylcholinesterase and acetylcholinesterase prophylaxis against soman poisoning in mice, Biochem. Pharmacol., 41, 37–41, 1991. 59. Maxwell, D.M., Castro, C.A., De La Hoz, D., Gentry, M.K., Gold, M.B., Solana, R.P., Wolfe, A.D., and Doctor, B.P., Protection of rhesus monkeys against soman and prevention of performance decrement by pretreatment with acetylcholinesterase, Toxicol. Appl. Pharmacol., 115, 44–49, 1992. 60. Wolfe, A.D., Blick, D.W., Murphy, M.R., Miller, S.A., Gentry, M.K., Hartgraves, S.L., and Doctor, B.P., Use of cholinesterase as pretreatment drugs for the protection of rhesus monkeys against soman toxicity, Toxicol. Appl. Pharmacol., 117, 189–193, 1992. 61. Ashani, Y., Grunwald, J., Raveh, L., Grauer, E., Brandeis, R., Marcus, D., Papier, Y., Kadar, T., Allon, N., Gilat, E., and Lerer, S., Cholinesterase prophylaxis against organophosphorus poisoning, Final Report Contract DAMD17-90-C-0033; AD-A277-096, 1993. 62. Raveh, L., Grauer, E., Grunwald, J., Cohen, E., and Ashani, Y., The stoichiometry of protection against soman and VX toxicity in monkeys pretreated with human butyrylcholinesterase, Toxicol. Appl. Pharmacol., 145, 43–53, 1997. 63. Allon, N., Raveh, L., Gilat, E., Cohen, E., Grunwald, J., and Ashani, Y., Prophylaxis against soman inhalation toxicity in guinea pigs by pretreatment alone with human serum butyrylcholinesterase, Toxicol. Sci., 43, 121–128, 1998. 64. Ashani, Y., Prospective of human butyrylcholinesterase as detoxifying antidote and potential regulator of controlled-release drugs, Drug Dev. Res., 50, 298–308, 2000. 65. Ashani, Y. and Pistinner, S., Estimation of the upper limit of human butyrylcholinesterase dose required for protection against organophosphates toxicity: a mathematically based toxicokinetic model, Toxicol. Sci., 77, 358–367, 2004. 66. Broomfield, C.A., Maxwell, D.M., Solana, R.P., Castro, C.A., Finger, A.V., and Lenz, D.E., Protection by butyrylcholinesterase against organophosphorus poisoning in non human primates, J. Pharmacol. Exp. Ther., 259, 633–638, 1991. 67. Doctor, B., Blick, D.W., Caranto, G., Castro, C.A., Gentry, M.K., Larrsion, R., Maxwell, D.M., Murphy, M.R., Schutz, M., Waibel, K., and Wolfe, A.D., Cholinesterase as scavengers for organophosphorus compounds: protection of primate performance against soman toxicity, Chem. Biol. Interact., 87, 285–293, 1993. 68. Maxwell, D.M., Saxena, A., Gordon, R.K., and Doctor B.P., Improvements in scavenger protection against organophosphorus agents by modification of cholinesterases, Chem. Biol. Interact., 119–120, 419–428, 1999. 69. Raveh, L., Grunwald, J., Marcus, D., Papier, Y., Cohen., E., and Ashani, Y., Human butyrylcholinesterase as a general prophylactic antidote for nerve agent toxicity, Biochem. Pharmacol., 45(12), 2465–2474, 1993. 70. Sweeney, R.E. and Maxwell, D.M., A theoretical model of the competition between hydrolase and carboxylesterase in protection against organophosphorus poisoning, Math. BioSci., 160, 175–190, 1999. 71. Sweeney, R.E. and Maxwell, D.M., A theoretical expression for the protection associated with stoichiometric and catalytic scavengers in a single compartment model of organophosphorus poisoning, Math. BioSci., 181, 133–143, 2003. 72. Van der Schans, M.J. and Langenberg, J.P., Effect of pretreatment with human butyrylcholinesterase scavengers on the toxicokinetics and binding of nerve agents in guinea pigs and marmosets, Final Report Grant DAMD17-00-2-0032, 2005. 73. Van Helden, H.P.M., Trap, H.C., Oostdijk, J.P., Kuijpers, W.C., Langenberg, J.P., and Benschop, H.P., Long-term, low-level exposure of guinea pigs and marmosets to sarin vapor in air: lowest observable effect level, Toxicol. Appl. Pharmacol., 189, 170–179, 2003.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
122
46616_C005 Final Proof page 122 7.11.2007 5:20pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
74. Langenberg, J.P., Van Dijk, C., Sweeney, R.E., Maxwell, D.M., De Jong, L.P.A., and Benschop, H.P., Development of a physiologically based model for the toxicokinetics of C(+)P(+)-soman in the atropinized guinea pig, Arch. Toxicol., 71, 320–331, 1997. 75. Ramsey, J.C. and Andersen, M.E., A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans, Toxicol. Appl. Pharmacol., 73, 159, 1984. 76. Maxwell, D.M., Vlahacos, C.P., and Lenz, D.E., A pharmacodynamic model for soman in the rat, Toxicol. Lett., 43, 175, 1988. 77. Gearhart, J.M., Jepson, G.W., Clewell, H.J., Andersen, M.E., and Conolly, R.B., Physiologically based pharmacokinetics and the pharmacodynamic model for inhibition of acetylcholinesterase by diisopropyl fluorophosphate, Toxicol. Appl. Pharmacol., 106, 295, 1990. 78. Noort, D., Benschop, H.P., and Black R.M., Biomonitoring of exposure to chemical warfare agents: a review, Toxicol. Appl. Pharmacol., 184, 116–126, 2002.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C006 Final Proof page 123 16.11.2007 12:16pm Compositor Name: VAmoudavally
of Genomic, 6 Application Proteomic, and Metabolomic Technologies to the Development of Countermeasures against Chemical Warfare Agents Jennifer W. Sekowski and James F. Dillman III CONTENTS I. Introduction ........................................................................................................................ 123 II. Genomics, Transcriptomics, and Gene Expression Profiling............................................. 125 III. Proteomics .......................................................................................................................... 126 IV. Metabolomics and Metabonomics...................................................................................... 129 V. Results ................................................................................................................................ 130 A. Microarray Analysis of Sulfur Mustard Exposure Reveals Potential Therapeutic Targets Confirmed by Protein Analysis ................................................. 130 B. Microarray Analysis of Phosgene Exposure Reveals Mechanisms of Toxicity that Correlate with Biochemical Data ..................................................... 132 C. Metabolomic Investigation of Liver and Blood Plasma Following Low-Level Exposure to VX Vapor ............................................................................ 137 VI. Conclusions ........................................................................................................................ 137 A. Biomarker Discovery.................................................................................................. 138 B. Mechanisms of Toxicity and Therapeutics................................................................. 138 C. Advanced Development of Therapeutics (FDA Approval)........................................ 139 D. Use of Animals in Research (Reduction, Refinement, and Replacement) ................ 139 VII. Summary............................................................................................................................. 139 References ..................................................................................................................................... 140
I. INTRODUCTION Since World War I, chemical warfare agents (CWAs) have been manufactured and stockpiled in numerous countries and remain a threat to both civilian and military personnel. CWAs have been used both in the context of military battle (e.g., World War I, the Iran–Iraq War) and in terrorist plots (e.g., Aum Shinrikyo attack on the Tokyo subway system) (Smart, 1997). CWAs are categorized into several classes based on chemical composition and toxicological effects. These include vesicants or blistering agents (sulfur mustard [HD], Lewisite [L]), blood agents (cyanide), choking 123
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C006 Final Proof page 124 16.11.2007 12:16pm Compositor Name: VAmoudavally
124
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
or pulmonary agents (phosgene [CG], chlorine [CL]), and nerve agents (tabun [GA], sarin [GB], soman [GD], cyclosarin [GF], VX). To protect military and civilian personnel from the threat posed by CWAs, research and development is ongoing into CWA detection methods, diagnosis of CWA exposure, treatment of CWA-exposed personnel, and decontamination of CWA-exposed personnel and equipment. Early CWA detectors were quite primitive and included primarily chemical-reactive dyes in paints. These were insensitive and therefore unreliable (Smart, 1997). Later technology used more sensitive chemical dyes in other formats such as paper tickets. Modern detectors now consist of fieldable IR spectrometers and an alarm system designed to warn of the presence of CWAs on the battlefield or in an enclosed space. Several reliable tests for the diagnosis of CWA exposure have been developed. To detect HD exposure, the level of thiodiglycol, a metabolite of HD, is quantitated in the urine using a gas chromatography=mass spectrometry (GC=MS) analytical method (Jakubowski et al., 1990; TB MED 296, 1996). Nerve agent exposure is detected in the field by the use of a fieldable Ellman assay to determine cholinesterase inhibition in the blood (Ellman et al., 1961; TB MED 296, 1996). In addition to the fieldable Ellman assay, the metabolites of GB, GD, and GF can be quantitated in urine using GC=MS analytical methods (Shih et al., 1991; TB MED 296, 1996). Cyanide levels in the blood can be detected using a fluorometer (TB MED 296, 1996). Early medical treatments for CWA exposure were primarily supportive in nature, as there was no therapeutic regimen for the first CWAs used in war (i.e., blister agents and choking agents). British anti-Lewisite was developed for Lewisite exposure. However, there is as yet no approved therapeutic treatment for cutaneous, pulmonary, or ocular HD exposure. For systemic HD exposure, granulocyte colony-stimulating factor, which is Food and Drug Administration (FDA) approved for treatment of neutropenia following chemotherapy, has been shown to be effective in the treatment of HD-induced neutropenia (Anderson et al., 2006). In the case of the nerve agents, atropine was in use as an antidote from the time nerve agents were first uncovered after World War II (Smart, 1997; Maynard, 2000). Oxime was added to the treatment regimen after the development of oxime therapy in the 1950s (Maynard, 2000). The oxime 2-PAM was available at the battalion aid station starting in the late 1960s. The United States first put an oxime in an autoinjector in 1975 with the TAB antidote (T ¼ TMB-4, A ¼ atropine, B ¼ benactyzine). The TAB antidote received an Investigational New Drug (IND) status from the FDA. Although it was deployed, it was never used. In 1979, work began to obtain approval of 2-PAM for autoinjector use; it was approved by the FDA in the early 1980s. The anticonvulsant therapeutic diazepam was fielded in 1990 to alleviate the seizures induced by nerve agent intoxication (Lipp, 1972, 1973; Departments of the Army, Navy, Air Force, and Commandant Marine Corps, 1995; Sidell, 1997; Maynard, 2000). Although these advances have served to protect personnel from the threat of CWAs, research and development are moving into new paradigms to improve on these current countermeasures. By gaining a greater understanding of the effects of CWA exposure on biological systems at the molecular and cellular levels, we can identify new therapeutic targets, develop high throughput drug screening assays, and identify biomarkers of exposure and effect for improved diagnosis, detection, and risk assessment. In addition, the detection, diagnosis, and treatment of subacute, lowlevel, and chronic exposure to CWAs are of concern to the military. Given that these are primarily asymptomatic exposures, any deleterious effects will need to be observed at the molecular and cellular levels rather than at the organism level. In the past, molecular and cellular biology techniques allowed investigators to focus on only one or a small number of genes or proteins at a time. However, large-scale genome sequencing projects, such as the Human Genome Project, have revolutionized applied biology and toxicology. Over the past decade, there has been a move away from a reductionist approach of studying one gene or protein at a time toward a more global approach of studying molecular and cellular networks and how these networks integrate information and respond to the environment (Farr and Dunn, 1999). Recent technological developments allow researchers to study the function of a single gene or
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C006 Final Proof page 125 16.11.2007 12:16pm Compositor Name: VAmoudavally
Application of Genomic, Proteomic, and Metabolomic Technologies
125
protein in the context of cellular and molecular networks, or to study the response of numerous genes, proteins, or metabolites to an environmental stimulus (e.g., CWA exposure). These new molecular techniques allow for higher throughput studies and are well suited to elucidating the mechanisms of cellular responses to toxicants (e.g., CWAs) (Steiner and Anderson, 2000). This has resulted in the development of several disciplines focused on global analysis of gene expression (genomics, transcriptomics), global analysis of protein expression, modification, and function (proteomics), and global analysis of metabolism and metabolites (metabonomics, metabolomics). Within the Army life science research community, we are following the lead of the pharmaceutical and biotechnology industries in applying these global approaches and associated technologies to the problem of CWA countermeasures. In this chapter, we provide an overview of each of these technologies and their current state of the art, and provide examples of how these approaches are being applied to the development of CWA countermeasures.
II. GENOMICS, TRANSCRIPTOMICS, AND GENE EXPRESSION PROFILING Genomics, transcriptomics, and gene expression profiling are all related to studying gene expression of hundreds to thousands of genes simultaneously from a single biological sample. The primary tool that advanced these fields is the nucleic acid microarray (oligonucleotide microarray, cDNA microarray). The development of microarrays resulted from the convergence of several disparate technologies. One was high throughput DNA sequencing, which led to the complete sequencing of the genome of a number of model organisms (e.g., human, rat, mouse, yeast). Having this information publicly available provided the material that was needed to develop techniques for assaying a large number of genes simultaneously. Advances in robotics made simultaneous, parallel assaying of numerous genes possible on a large scale. Application of integrated circuit manufacturing processes and inkjet=micropin fabrication technology to nucleic acids made microarray fabrication possible. The widespread use of confocal microscopy and associated optical systems made microarray scanners possible. From these foundations, two basic types of microarray formats have emerged. One format is the oligonucleotide-based microarray. These are primarily commercial products consisting of 20–60 base pair oligonucleotides synthesized directly onto a chip surface (e.g., silicon, glass) using one of several different processes. One widely used oligonucleotide microarray format utilizes photolithography techniques used in the manufacture of integrated circuits combined with the use of masks to synthesize oligonucleotides onto a silicon wafer (Fodor et al., 1991, 1993; Pease et al., 1994). Another format utilizes a digital light processor to synthesize oligonucleotides onto a derivatized chip surface using only light focused by rotating mirrors (Singh-Gasson et al., 1999; Nuwaysir et al., 2002). In a different approach, modified piezoelectric (inkjet) processes deposit nucleic acid directly onto a derivatized glass surface, and oligonucleotides are subsequently synthesized on the chip using phosphoramidite chemistry (Hughes et al., 2000). Other oligonucleotide platforms use micro-electric fields (Sosnowski et al., 1997), microelectrodes (Dill et al., 2004), or polymers (Ramakrishnan et al., 2002) in the manufacture or application of oligonucleotide microarrays. Oligonucleotide microarrays use a single fluorophore to label a sample (single channel fluorescence) and can provide complete or near complete genome coverage for model organisms (e.g., human, rat, mouse). Typically, the mRNA or total RNA extracted from the test tissue is amplified by means of two in vitro reactions. First, the mRNA is reverse transcribed into cDNA. Next, the resultant cDNA is in vitro transcribed into cRNA. This reaction also incorporates a label, often biotin, into the cRNA. The labeled cRNA is then hybridized to the oligonucleotides on the microarray. After several washing steps, the array is then stained. In the case where biotin was incorporated into the sample cRNA, the stain is composed of a fluorescently labeled streptavidin, which binds with high affinity to the biotin label. The fluorescent signal is detected by means of a confocal laser array scanner. The levels of fluorescence of the experimental cRNA hybridized to the oligonucleotides on one microarray are compared with those of the control cRNA hybridized
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C006 Final Proof page 126 16.11.2007 12:16pm Compositor Name: VAmoudavally
126
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
to the oligonucleotides on another microarray. This comparison determines which genes are up- or down-regulated. Control oligonucleotides within the array are used to normalize the signal between arrays. Due to the hardware infrastructure required and the costs associated with manufacture, oligonucleotide microarrays are available primarily as commercial products. The other microarray format is the cDNA microarray (Schena et al., 1995; Shalon et al., 1996). These were the first type of array, and are still primarily noncommercial products generated in a laboratory or core facility. They are composed of 200–300 base pair long cDNA clones printed onto specially treated glass microscope slides (Schena et al., 1996). The building blocks for these arrays are homemade or commercially available cDNA libraries from the organism of interest. The control sample and the experimental sample (usually cDNA) are labeled separately, each with a different fluorescent dye (e.g., Cy3 and Cy5), pooled together in equal amounts, and hybridized to the same microarray. The fluorescent signal is detected using a confocal laser scanner with dual fluorescence capability. The ratio of the two fluorescent dyes at each cDNA spot on the microarray (control sample compared with experimental sample) is used to calculate the level of expression of each gene in the study and determine which genes are up- and down-regulated. The applications for microarrays have grown since their initial introduction in the mid-1990s. One of the first uses of microarrays was to compare the gene expression profile of a healthy cell or tissue with a diseased one (DeRisi et al., 1996; Heller et al., 1997; Golub et al., 1999; Iyer et al., 1999; Alizadeh et al., 2000; Bittner et al., 2000; Perou et al., 2000). This provided a description of the genes expressed in a disease state and provided insight into the molecular pathways involved in the disease state. The field of toxicology in particular realized the potential of microarrays to aid in understanding toxicant mechanisms at the molecular level (Yang et al., 2004). From this, the field of toxicogenomics was developed. Toxicogenomics seeks to characterize the changes in gene expression between a control sample and a sample exposed to a toxicant of interest, to identify genes upand down-regulated due to the toxicant, to map regulatory pathways activated or antagonized by the toxicant, and in some cases (such as in the development of CWA medical countermeasures) to identify potential therapeutic targets in these pathways. Toxicogenomics has also been used as a tool for biomarker discovery, whereby microarrays are used to screen for alterations in gene expression that consistently correlate with a given exposure or effect. This technique provides a ‘‘net’’ with which to ‘‘catch’’ potential genes (and thus, their expressed polypeptide) to be evaluated for their utility as biomarkers. Both individual protein biomarkers (e.g., adipsin, Searfoss et al., 2003) and gene expression profiles or signatures (e.g., Thomas et al., 2001; Hamadeh et al., 2002) have been identified using microarrays. Although microarrays can provide a global view of an organism’s response to a toxicant, their primary limitation lies in the fact that they can only assess gene expression changes. Any effects due to changes in protein function or modification will not be observed using these techniques, and techniques from the field of proteomics must be used.
III. PROTEOMICS Proteomics seeks to characterize the protein complement of a cell, tissue, or organism. Unlike genomics and transcriptomics, in which the target molecules (nucleic acid) are chemically more homogeneous, proteomics techniques must deal with a set of target molecules (proteins), which are chemically more heterogeneous and exist in many diverse states. Not only can each gene have multiple splice variants, each transcribed into slightly different polypeptides, but each of those polypeptides can be modified by posttranslational processes such as phosphorylation, glycosylation, ribosylation, and myristylation (Guo et al., 2007). Given the myriad modifications and variations of proteins coded from the genome, the number of chemically distinct proteins in a cell at any given point of time for a certain genetic composition has been estimated to be in the range of 1 million (Jensen, 2004). This is much greater than the number of genes in the genome, which is currently estimated to be 20,000–25,000 genes (Stein, 2004). Given that the final functional proteins in a
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C006 Final Proof page 127 16.11.2007 12:16pm Compositor Name: VAmoudavally
Application of Genomic, Proteomic, and Metabolomic Technologies
127
system are much more complex than the basic DNA code from which they are translated, a study of the complete proteome, on the scale of what was accomplished in the Human Genome Project, is practically impossible given the current technology. With the present state of the art, the best approach for understanding the proteome is to carefully dissect it using the latest tools of proteomic investigation to identify key proteins (or protein networks) important in response to precisely defined environmental conditions, life stages, or disease processes. Regardless of whether the goal is to understand one protein among many, or to reveal an overall ‘‘profile’’ of a large set of proteins, many of the same techniques are used. Current proteomic analyses rely on four key technologies: (1) Fractionation techniques (e.g., anion-exchange chromatography, differential centrifugation) are used to separate the complex mixture of proteins into biochemically or sizedistinct fractions with fewer components. (2) Whole protein analysis methods such as liquid- and gel-based two-dimensional (2D) separation methods are useful to elucidate larger structural changes, including some posttranslational modifications (PTMs) where antibody-based detection is possible. (3) Fragmented polypeptide analysis methods, such as tryptic digestion followed by electrospray ionization (ESI) or liquid chromatography (LC)–tandem mass spectrometry (ESI-MS-MS or LC-MS-MS). These ‘‘bottom-up’’ approaches are better suited for quantitating increases or decreases in protein abundance. (4) Databases and computer algorithms that are able to predict protein identity, folding, and 3D structure. These can correlate mass spectrometry data with the latest published protein sequence databases. One of the first preparative steps in a proteomics investigation involves fractionation. This step is often necessary to obtain adequate resolution in a complex mixture of polypeptides (i.e., whole cell homogenates, cellular and subcellular fractions, protein complexes, etc.). Fractionating a protein mixture can be accomplished by size exclusion chromatography or differential centrifugation (i.e., functioning as a molecular ‘‘sieve’’ to separate proteins based on size) and other methods, such as anion-exchange chromatography or isoelectric focusing (i.e., separate proteins based on protein pH or charge). Typically, the analytical resolution of a protein mixture is much greater when fractionation is used before a two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) or a mass spectrometry-based investigation. The traditional workhorse technique of proteomics is 2D-PAGE (or 2DE) (Klose, 1975; O’Farrell, 1975; Bjellqvist, 1982). In this method, proteins in a mixture are separated first by isoelectric focusing. In this step, the proteins migrate in a liquid or gel matrix by electric current along a pH gradient (isoelectric focusing gradient) to a point where their charge is neutral. The point along the pH gradient where a protein has a neutral charge is termed the isoelectric point (pI). In the second dimension, the proteins, held at their isoelectric points, are separated by mass. The separated polypeptides are then stained (e.g., silver, Coomassie blue, Sypro Ruby) in the gel and located by their isoelectric point and mass. Identification can be made by Western blotting (in the case where an antibody is available for a protein of interest), or staining and excision (manual or robotic) followed by mass spectrometry in the case where a protein is unknown. Western blotting can be a useful method of identifying large shifts in protein abundance or shifts in isoelectric point, if antibodies that recognize the proteins of interest are available. In most cases of discovery, however, shifts in either intensity or position on the gel are detected by staining all proteins and using image analysis software to identify differences in position and abundance of spots. After the locations of these spots of interest are mapped, the spots can be excised manually or robotically for identification by mass spectrometry. Although this technique has been used for years to successfully identify proteins altered by a particular disease state, toxicant exposure, or drug or other treatment, it does have several limitations. There is a good deal of art involved, and even for the most practiced, it is extremely difficult to solve the problem of gel to gel variability. To resolve some of the uncertainty created by gel variability, multiple gels (i.e., n ¼ 5–10) can be combined (‘‘piled up’’) to create a consensus image for a given condition. Moreover, the problem of solubilizing certain proteins (i.e., highly lipophilic membrane proteins) in a buffer suitable for running through the gel can be very challenging.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C006 Final Proof page 128 16.11.2007 12:16pm Compositor Name: VAmoudavally
128
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
One last problem that is yet to be completely solved is that the dynamic range (both in pH and protein abundance) is limited. The isoelectric focusing dimension requires that a range of separation be predetermined (e.g., pH 3–10). With the most sensitive staining methods it is possible to detect as little as 1–10 ng for silver-stained proteins and 1–100 pg for radioactive-labeled proteins (Jungblut and Thiede, 1997). However, very low abundance proteins can go undetected, or are masked by higher abundance proteins. Given the limitations associated with 2D-PAGE, the field of proteomics has developed newer techniques with greater reproducibility and sensitivity. Mass spectrometry (MS) techniques have been long used as follow-on techniques after 2DPAGE separation to identify shifted or new spots discovered on the gel. However, several MS-based techniques are now being used in ways that are rapidly superseding 2D-PAGE as a means to rapidly, accurately, and reproducibly measure and identify proteins and polypeptides in mixtures. There are many other methods that can be used to separate proteins before characterization by mass spectrometry. Often in characterizing unknown proteins in a mixture, the constituent polypeptides are first enzymatically digested to yield a mixture of peptides. The peptides then are analyzed by MS either with or without some prior chromatographic or electrophoretic separation. With the aid of database search algorithms, the MS data are then evaluated to identify the proteins represented in the mixture (Abersold and Mann, 2003; Elia et al., 2005). Matrix-assisted laser desorption ionization–time of flight (MALDI–TOF) MS employs laser energy to generate peptide ions from co-crystallized mixtures of peptides and ultraviolet-absorbing organic acids. MALDI–TOF analyses yield mass measurements of peptides, which can then be searched against databases with algorithms to identify the proteins from which the peptides were derived. This technique, termed peptide mass fingerprinting, has been shown to accurately identify proteins, particularly in organisms for which completed genome sequences or extensive protein sequence databases are available (Gevaerrt and Vandekeckhove, 2000). However, this approach is very difficult in organisms for which there is little or no reliably annotated genome and protein sequence. Electrospray ionization–tandem mass spectrometry (ESI-MS-MS) has emerged as the second major MS technique for analytical proteomics (Loo et al., 1999). In ESI-MS-MS, peptides are ionized under high voltage at atmospheric pressure and then analyzed with ion trap, triplequadruple, or quadruple-TOF mass analyzers. In these analyses, the peptide ions are subjected to collision-induced dissociation, which generates fragment ions that are detected by the tandem mass analyzer. The main advantage of this approach is that is does not require crystallization in a matrix before ionization. This method is also a more ‘‘gentle’’ ionization, allowing the possibility to capture the mass of native (nondenatured) proteins. Lastly, the mass accuracy is generally +0.5% or better, allowing accurate measurement of dilute samples (Loo et al., 1999). The resulting MS-MS spectra represent the fragmentation patterns produced. The spectra provide fingerprints that define the sequence of peptide ions. Searching algorithms such as SEQUEST (http:==fields.scripps.edu=sequest), Peptident (http:==ca.expasy.org=tools), and MASCOT (http:==matrixscience.com) makes the identification of proteins possible by correlating peptide MS-MS data with predicted MS-MS data generated from protein and nucleotide sequence databases. Automated liquid chromatography–tandem mass spectrometry (LC-MS-MS) scanning acquires MS-MS spectra for hundreds to thousands of peptides in a single LC analysis. The combination of data-dependent scanning and the use of search algorithms facilitates the identification of proteins from complex peptide mixtures using LC-MS-MS data. Combining MS-MS with reverse-phase or tandem LC (e.g., ion-exchange reverse phase) makes LC-MS-MS the most powerful approach for protein identification and characterization. Moreover, fragmentation of peptides using MS-MS provides unambiguous confirmation not only of sequence but also of the location and character of posttranslational modifications, protein adducts, and sequence variants (Loo et al., 1999). The tools of proteomics allow us to gain both breadth and depth in our perspective of the complexities of the molecular response to CWA exposure. However, there is another more complex layer of responsive molecules that is beginning to open a new window into the entirety of the molecular-level impact of CWA exposure.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C006 Final Proof page 129 16.11.2007 12:16pm Compositor Name: VAmoudavally
Application of Genomic, Proteomic, and Metabolomic Technologies
129
IV. METABOLOMICS AND METABONOMICS The metabolome is defined as the entirety of the rapidly changing metabolic processes and molecules present in the body at any given point of time (Lindon et al., 2006). As such, the entirety, or profile, of these molecules is very sensitive to subtle changes in study variables. Every process in the body, from transcription, translation, protein modification, and transport to active physiological metabolism, influences the tissue-level and global metabolomic composition at any given time point. Thus, the ability to carry out meaningful measures and interpretation of the metabolome relies on both sound experimental design and sensitive measurement techniques. Sometimes referred to as ‘‘biochemical profiling,’’ metabolomics is a parallel and complementary discipline to transcriptomics and proteomics. Although transcriptomics and proteomics can generate hypotheses for both molecular mechanisms of toxicity and potential biomarkers of exposure, they are limited to identifying the presence or structure of the transcript or protein. Certainly, these end points serve their own purposes, such as defining a protein target for therapeutics or revealing a blood-based biomarker indicative of an exposure. However, they are not able to assess the overall functional significance of these changes within the widely interconnected system of biochemical processes in the body (Lindon et al., 2006). The goal of metabolomics is to fully understand the dynamic complexity and identities of the metabolites present in a given condition. Metabonomics, on the other hand, takes a global view of the data, striving to capture the overall pattern or signature of the MS or nuclear magnetic resonance (NMR) peaks (Waters et al., 2001; Holmes and Antti, 2002; Lindon et al., 2006). Metabonomics is often used when examining urine or other complex body fluids for changes in metabolic composition. In contrast, metabolomics is more often used when examining a tissue or organ, as the metabolites are somewhat less complex primary or secondary metabolic processes. Both approaches are sometimes used in the same study. The advantages of each approach create an especially valuable screening tool. Databases can be built around these data, against which metabonomic patterns can be compared, and presumptive identifications of unknown exposures can be made. If metabolomic work has been done on the key metabolic product peaks, this information can open avenues for research to reveal more complete mechanisms of toxicity and potential biochemical points for developing effective CWA countermeasures. The techniques currently used in metabolomics and metabonomics give researchers the ability to make an unbiased assessment of biochemical status at the cellular, tissue, or organism level. MS and NMR are the primary technologies of choice with which to explore the metabolome (Choi et al., 2001). Both technologies have made recent advances in sensitivity and data manipulation and storage. Mass spectrometry is the most common technique because of its high accuracy and sensitivity. When examining a typical metabolomic reservoir, such as blood plasma or urine, there is relatively little upfront sample preparation. In a complex tissue such as liver or brain, dissection, microdissection, homogenization, and differential centrifugation are often used to further define the sample. Another common sample separation method applied before MS analysis is liquid chromatography (LC) or gas chromatography (GC) (Choi et al., 2001). Both techniques partition the sample as it enters the MS instrument, increasing the temporal resolution of the data. Mass spectrometry can measure biochemical changes in the nanomolar to femtomolar range. Simple quadrapoles, triplequadrapoles, ions traps, TOF, Fourier Transform (FT), or hybrid systems have all been used. The flavor of MS chosen depends on the appropriate combination of accuracy, robustness, and sensitivity needed for the particular application (Choi et al., 2001). Regardless of type of MS, one of the main bottlenecks lies in the handling and analysis of the massive volumes of data generated. There are many ongoing efforts to develop new tools to resolve this problem. NMR, and specifically, 1H magic angle spinning NMR, has been used for years (Nicholson et al., 1999). Its main advantages lie in the fact that NMR does not require any upfront chromatographic separation, nor does it destroy the samples during analysis. It has the ability to measure
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C006 Final Proof page 130 16.11.2007 12:16pm Compositor Name: VAmoudavally
130
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
molecular compartmentalization and dynamic biochemical changes in real time. Thus, it is not surprising that its data output is more information dense than MS. Although it can be more difficult to define the individual peaks in NMR, NMR is slightly better than MS at identifying and defining very dense patterns of peaks (Nicholson et al., 1999). For these reasons, NMR is routinely used to define relative concentrations of hundreds of compounds in complex, undefined mixtures. The biochemical reactions at the tissue and organism levels induced by CWA, or any xenobiotic stimuli, are very complex and often not linear. To create biochemical order, the cell compartmentalizes these reactions. This is necessary in any living system to ensure robustness and redundancy in the network. Crude tissue homogenates created during any transcriptomic, proteomic, or metabolomic examination usually disrupts this order. Thus, it is very difficult to sort out what levels of individual biochemicals are ‘‘normal.’’ Therefore, it is much more informative and valuable to think about defining the function of key networks, rather than simply defining a list of distinct biochemicals (Glassbrook et al., 2000; Marcotte, 2001). Metabolomics is an important adjunct to the more linear way of thinking in transcriptomics and proteomics. However, to date, there is no automated way to interpret complex metabolomic data and create clear pathways (sometimes termed the ‘‘interactome’’) from metabolomic data. Manual interpretation of metabolomic data is still the norm. The automated tool is a critical development toward which many bioinformatics and ‘‘omics’’ researchers are working. One of the current goals is the development of in silico models of metabolism into which metabolomic, transcriptomic, and proteomic data can be fed (Loew and Schaff, 2001; Stefanovski et al., 2003; Borodina and Nielsen, 2005). As these types of models become increasingly sophisticated, and being able to receive input from a wider variety of platforms, these tools will become invaluable to many types of researchers. The ability to illustrate and test interactively changing pathway diagrams will help to build a more comprehensive understanding of both the molecular and biochemical pathway level effects of any xenobiotic exposure or other environmental changes. Overall, the integration of the data from all three approaches, transcriptomic, proteomic, and metabolomic, is synergistic and will continue to accelerate the development of a complete understanding of the molecular and biochemical toxicity of CWA.
V. RESULTS A. MICROARRAY ANALYSIS OF SULFUR MUSTARD EXPOSURE REVEALS POTENTIAL THERAPEUTIC TARGETS CONFIRMED BY PROTEIN ANALYSIS Wide-ranging molecular, cellular, and tissue injuries have been described in a number of organ systems after exposure to SM (Papirmeister et al., 1991). The pulmonary system in particular is severely affected by SM. The development of pulmonary injury over the first 24 h postexposure involves multifocal, petechial hemorrhages on the pleural surface of the lung; lesions of the trachea, bronchi, and larger bronchioles; a progressive depletion of the bronchiolar-associated lymphoid tissue with necrosis of the lymphoid cells; necrosis and sloughing of the tracheal and bronchial epithelia followed by the formation of fibrinous pseudomembranes within the bronchi; and pulmonary edema with occasional alveolar hemorrhage (Anderson et al., 1996). Treatment of SM-induced pulmonary injury is primarily supportive in nature, requiring medical management that creates a heavy logistical burden (Papirmeister et al., 1991). In an effort to develop effective SM therapeutics, microarray analysis of SM-exposed rat lung tissue was used to elucidate the molecular mechanism of SM toxicity and to identify potential therapeutic targets (Dillman et al., 2005). These studies monitored changes in gene expression across a significant portion of the rat genome (~16K genes) and revealed temporal and dose–response effects of SM exposure. One of the most prominent molecular effects of SM exposure is DNA damage due to cross-linking at the N-7 of guanine (Papirmeister et al., 1991). Based on microarray analysis, Dillman et al. (2005) reported that there is a p53-mediated response following SM exposure. p53 is a protein transcription factor involved in the cellular response to DNA damage (Vogelstein and Kinzler, 2004). p53 up-regulates genes involved in cell cycle regulation and DNA
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C006 Final Proof page 131 16.11.2007 12:16pm Compositor Name: VAmoudavally
131
Application of Genomic, Proteomic, and Metabolomic Technologies
repair following DNA damage. The conclusion that there is a p53 response following SM exposure was based on the observation that many of the most significantly altered genes in SM-exposed rat lung are p53-responsive genes involved in cell cycle regulation, including cyclin G (Okamoto and Beach, 1994), p21 (el-Deiry et al., 1993), mdm2 (Barak et al., 1993), and transducer of ErbB2 (Tob) (Matsuda et al., 2001) (Figure 6.1). Many other p53-responsive genes, including Eph2A (Dohn et al., 2001), IEX1 (Schafer et al., 1998), Bax (Miyashita and Reed, 1995), snk (Burns et al., 2003), ATF3 (Zhang et al., 2002), and metallothionein (Fan and Cherian, 2002) were altered following SM exposure. The significant modulation of p53-responsive genes is depicted in Figure 6.2. The modulation of p53-responsive genes observed by microarray analysis correlates with past observations and suggests that DNA damage is the most likely source of the initial injury. Interestingly, it has been
Cyclin G1 (NM_012923)
Cyclin-dependent kinase inhibitor 1A (p21) (U24174) 9.0 Signal intensity (log2)
Signal intensity (log2)
11.0
10.0
9.0
8.0
7.0
7.0 6.0 5.0 4.0 3.0
0.5 1
(a)
8.0
3
6
Time (h)
24
0.51
(b)
Similar to mdm2 gene product (loci 314856)
6
Signal intensity (log2)
9.5
8.0
7.0
6.0 0.5 1
3
6
(c)
9.0 8.5 8.0 7.5 7.0 0.5 1
24
3
6 Time (h) Cut (Drosophilia)-like 1 (AW527515)
E
9.0 Signal intensity (log2)
Signal intensity (log2)
9.5
24
(d)
Time (h) C-terminal binding protein 2 (NM_053335)
9.0
8.5
8.0
8.0
7.0 1 mg/kg SM 3 mg/kg SM 6 mg/kg SM Isopropyl alcohol Saline
6.0
5.0 0.5 1
(e)
24
Time (h)
Transducer of ErbB2, 1 (tob1) (NM_133317)
9.0 Signal intensity (log2)
3
3
6
0.5 1
24 Time (h)
(f )
3
6
24 Time (h)
FIGURE 6.1 Expression profiles of cell cycle regulatory genes modulated by SM in rat lung. A two-way plot of log2 expression level versus time for each treatment or SM dose was generated. (m) 1 mg=kg SM; (r) 3 mg=kg SM; (j) 6 mg=kg SM; (d) isopropyl alcohol; (‚) Saline. Error bars represent standard deviation. (Reprinted from Dillman, J.F., C.S. Phillips, L.M. Dorsch, M.D. Croxton, A.I. Hege, A.J. Sylvester, T.S. Moran, and A.M. Sciuto., Chem Res Toxicol, 18:28–34, 2005. With permission.)
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C006 Final Proof page 132 16.11.2007 12:16pm Compositor Name: VAmoudavally
132
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics SM p53-responsive genes up-regulated by SM DNA damage TOB1
P-Rb
p21WAF1
p53
Rb/E2F-1/DP-1
Cyclin G cutl1
S-phase initiation Up-regulated genes
mdm2 CTBP
Apoptosis
snk
Regulation of mitosis
ATF3
Transcriptional regulation
PP 2A
Cyclin D/cdk4
Eph2A IEX1/IER3 Bax
Metallothionein
Tissue injury
Down-regulated genes
FIGURE 6.2 Gene expression data from SM-exposed rat lung reveal a potential p53 response. Microarray data were used to identify a critical pathway in the molecular response to SM exposure in the lung. (Reprinted from Dillman, J.F., C.S. Phillips, L.M. Dorsch, M.D. Croxton, A.I. Hege, A.J. Sylvester, T.S. Moran, and A.M. Sciuto., Chem Res Toxicol, 18:28–34, 2005. With permission.)
shown that there is a high incidence of lung cancer in former mustard gas workers and there are p53 mutations in many of these cancers (Manning et al., 1981; Tokuoka et al., 1986; Easton et al., 1988; Nishimoto et al., 1988; Takeshima et al., 1994). Although these microarray data strongly suggest a p53 response following SM exposure in the lung, they do not directly show activation of p53 protein. A p53 response is typically characterized by increased phosphorylation of the p53 protein after a DNA-damaging event (Rosenthal et al., 1998). Thus, monitoring phosphorylation of p53 can serve as a rapid indicator of a p53 response. Phosphorylated p53 accumulates in normal human epidermal keratinocytes (NHEK) within 15–30 min after exposure to SM in a concentration-dependent manner (Figure 6.3; Minsavage and Dillman, 2007). These data suggest that exposure of human keratinocytes to SM can initiate signaling involved in directing the initial events of the p53 response. Altogether, these studies show that microarray analyses can identify mechanisms of toxicity, provide a rationale for selection of potential therapeutic targets for drug development, and identify potential biomarkers of toxicity.
B. MICROARRAY ANALYSIS OF PHOSGENE EXPOSURE REVEALS MECHANISMS OF TOXICITY THAT CORRELATE WITH BIOCHEMICAL DATA Phosgene is a toxic industrial chemical that has been used in the past as a CWA. It is a potential threat to civilian and military personnel, particularly in urban environments where industrial areas are located in close proximity to residential areas. The primary route of exposure is via inhalation, with the pulmonary system being the most prominent target of toxicity. Sciuto et al. (2005) used oligonucleotide microarrays to assay global changes in lung gene expression following phosgene inhalation in mice. Gene expression data from phosgene-exposed mouse lungs were analyzed by principal component analysis (PCA) (Figure 6.4). PCA reduces the complexity of high-dimensional data and simplifies the task of identifying patterns and sources of variability in a large data set. The samples (three biological replicates for each time point and exposure condition) are represented by
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C006 Final Proof page 133 16.11.2007 12:16pm Compositor Name: VAmoudavally
133
Application of Genomic, Proteomic, and Metabolomic Technologies
240
120
60
30
15
5
SM time (min)
None
SM concentration (µM)
12.5 25
50
100 200 IB: anti-phospho-p53 (ser 15) NHEK whole cell extract 200 IB: anti-total p53 NHEK whole cell extract
FIGURE 6.3 SM induces phosphorylation of p53. Normal human epidermal keratinocytes were exposed to 12.5, 25, 50, 100, or 200 mM SM for 5, 15, 30, 60, 120, or 240 min. Whole cell extracts were isolated, proteins fractionated by SDS–PAGE, and immunoblotted (IB) using antibodies that specifically recognize phosphorylated p53 (top panels). Total p53 was also analyzed. (Reprinted from Minsavage, G.D., Dillman III, J.F., J. Pharmacol. Exp. Ther., 321, 202, 2007. With permission.)
the points in the three-dimensional plot. The distance between any pair of points is related to the similarity between the two observations in high-dimensional space. Samples that are near each other in the plot are similar in a large number of variables (i.e., expression level of individual genes). Conversely, samples that are far apart in the plot are different in a large number of variables. In this data set one of the major sources of data variability is exposure condition (air or phosgene). There is a clear separation of the air-exposed samples as compared with the phosgene-exposed samples regardless of time (Figure 6.4). The time interval following phosgene exposure (0.5–72 h) is also a major source of data variability (Sciuto et al., 2005). This information was used to design an analysis of variance (ANOVA) using exposure, time, and sample as factors. The genes were ranked by p value based on this three-way mixed model ANOVA. Figure 6.5 reports the most significantly changed genes over time and dose. One of the most significantly altered genes is glutamate cysteine ligase (GCL) catalytic subunit, the rate-limiting enzyme in the synthesis of glutathione. The temporal profile of GCL gene expression in mice is shown in Figure 6.6. The expression level of GCL begins to significantly increase after 0.5 h and is higher than levels in the 8 h time-pointmatched air-exposed mice. From 24 to 72 h, GCL gene expression trends toward the levels observed in controls, but remains elevated. The microarray results for GCL described here were cross-validated with biochemical data from a previous study (Sciuto et al., 2003). The gene expression of GCL in phosgene-exposed lung tissue was compared with glutathione levels measured in bronchoalveolar lavage fluid (BALF) from phosgene-exposed lung tissue. The data are plotted as statistical means from both analytical
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C006 Final Proof page 134 16.11.2007 12:16pm Compositor Name: VAmoudavally
134
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Treatment
Air Naive
Phosgene
PC2
PC3 PC1 (a)
Treatment Air Naive Phosgene
PC2
PC3 PC1 (b)
FIGURE 6.4 Principal component analysis (PCA) of gene expression data from phosgene-exposed mouse lung. Gene expression values were transformed by the addition of a constant followed by the log2 and were visualized by PCA (a, b). Point color corresponds to treatment group (red, air; green, naïve; blue, phosgene). The axes correspond to principal component 1 (PC1, x-axis), PC2 (y-axis), and PC3 (z-axis). The PCA in (b) is the same as (a) and shows ellipsoids representing a space two standard deviations from the mean of the data points. (Reprinted from Sciuto, A.M., C.S. Phillips, L.D. Orzolek, A.I. Hege, T.S. Moran, and J.F. Dillman., Chem Res Toxicol, 18:1654–1660, 2005. With permission.)
methods over the course of 72 h (Figure 6.7). GCL itself was not measured in the previous biochemical studies (Sciuto et al., 2003), but because it is the rate-limiting enzyme in GSH synthesis (Tian et al., 1997), it should serve as an appropriate indicator of GSH formation. It is clear that phosgene exposure caused an increase in the expression levels of GCL that matches the increased levels determined for BALF GSH from the previous study (Sciuto et al., 2003). Taken together, these results demonstrate that gene expression data are an important component in understanding the mechanism of toxicity following a chemical exposure and can elucidate specific toxic effects of chemical exposure.
2.96
2.52
0.5 h
−1.30
−1.09
1.43
1.08
2.66
3.83
2.63
2.13
33.46
21.94
1.46
11.65
5.60
2.22
3.52
2.22
2.76
1.36
1.27
1.93
1.58
1.49
5.04
8.64
3.77
2.75
2.96
2.34
2.41
2.18
3.68
1.65
1.42
2.03
4.22
2.74
1h
2.52
−1.87
4.47
4h
2.46
8h
−1.57
7.11
2.06
35.50
31.17
2.83
14.02
9.11 3.31
14.32
19.16
15.09
3.10
3.23
12 h
2.14
−1.47
2.94
1.94
37.74
3.83
2.14
3.52
4.30
5.01
6.35
2.24
2.43
6.23
41.91
2.39
1.87 2.79
3.05
2.65
6.02
25.94
2.71
5.09
2.50
10.93
74.31
7.83
5.01 2.71
13.32
20.10
8.47
2.02
2.42
20.04
3.83
1.81
3.41
2.10
8.22
62.72
24 h
1.99
−1.44
2.42
2.17
31.58
2.17
2.08
2.66
3.30
4.63
3.99
2.14
2.83
4.96
1.55 2.40
2.70
2.28
5.49
10.88
48 h
2.69
−1.63
2.47
1.40
17.95
1.91
2.24
2.42
2.97
3.38
3.88
2.33
2.44
5.98
1.93 2.53
2.51
2.57
2.86
24.83
1.50
72 h
−1.64
1.80
1.29
11.70
1.86
1.79
2.08
3.48
1.57
2.34
2.03
2.25
2.44
1.47 1.61
2.07
2.23
3.61
8.42
1421134_at amphiregulin 1428942_at metallothionein 2 1448169_at keratin complex 1, acidic, gene 18 1421811_at thrombospondin 1 1415899_at Jun-B oncogene 1416129_at RIKEN cDNA 1300002F13 gene 1448612_at stratifin 1435989_x_at keratin complex 2, basic, gene 8 1420647_a_at keratin complex 2, basic, gene 8 1418571_at tumor necrosis factor receptor superfamily, member 12a 1418936_at v-maf musculoaponeurotic fibrosarcoma oncogene family, protein F (avian) 1449363_at activating transcription factor 3 1422557_s_at metallothionein 1 1448894_at aldo-keto reductase family 1, member B8 1424296_at glutamate cysteine ligase, catalytic subunit 1436879_x_at alpha fetoprotein 1428306_at DNA-damage-inducible transcript 4 1418572_x_at tumor necrosis factor receptor superfamily, member 12a 1451601_a_at cDNA sequence BC011467
FIGURE 6.5 Heat map revealing gene expression profiles following phosgene exposure. The expression profiles of the most significantly changed genes (20 most significantly changed genes based on Bonferroni-corrected p-value) were visualized using a heat map. The fold changes in gene expression were calculated from the antilog2 intensity data as: fold change ¼ (signal intensity after phosgene exposure)=(signal intensity after air exposure). A fold change of 20-fold was used as the maximum value in the color scale (left of map) to show greater resolution in the heat map. Genes that show a change in expression greater than 20-fold are colored in orange. The time points are indicated below the map. (Reprinted from Sciuto, A.M., C.S. Phillips, L.D. Orzolek, A.I. Hege, T.S. Moran, and J.F. Dillman., Chem Res Toxicol, 18:1654–1660, 2005. With permission.)
−2
8
20
Fold change
13.04
4.70
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C006 Final Proof page 135 16.11.2007 12:16pm Compositor Name: VAmoudavally
Application of Genomic, Proteomic, and Metabolomic Technologies 135
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C006 Final Proof page 136 16.11.2007 12:16pm Compositor Name: VAmoudavally
136
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 12.0
Glutamate cysteine ligase, catalytic subunit (BC019374)
Signal intensity (log2)
11.0
10.0
9.0
8.0
Air Phosgene None
7.0 0.5 1
4
8 12
24
48
72
Time (h)
FIGURE 6.6 Glutamate cysteine ligase (GCL) subunit gene expression in mice exposed to phosgene. The log2 signal intensity represents gene expression level. Sample sizes were three mice per time point for air or phosgene and replicate chips were probed. Data are expressed as mean + SEM. There was a significant exposure treatment by time interaction at a level of p < 2.8 3 1022 (three-way ANOVA). (Reprinted from Sciuto, A.M., C.S. Phillips, L.D. Orzolek, A.I. Hege, T.S. Moran, and J.F. Dillman., Chem Res Toxicol, 18:1654–1660, 2005. With permission.)
Gene expression (log transformed signal intensity)
Total glutathione/glutathione cysteine ligase 8 7.75 7.5 7.25 7 6.75 6.5 6.25 6 0
50
100
150
200
250
300
350
Lavage (nM)
FIGURE 6.7 Correlation between gene expression and biochemical analyses. The correlation between microarray gene expression data from phosgene-exposed mouse lung tissue in this study and biochemical data from phosgene-exposed mouse lung BALF generated in our earlier study (Sciuto et al., 2003) is shown. An average of the gene expression data (ordinate, log2 signal intensity) plotted against the average of the BALF data (abscissa) for total glutathione=glutathione cysteine ligase for air (m) and phosgene exposed (j). The smaller m and j represent the individual values from individual experiments for each gas exposure treatment. (Reprinted from Sciuto, A.M., C.S. Phillips, L.D. Orzolek, A.I. Hege, T.S. Moran, and J.F. Dillman., Chem Res Toxicol, 18:1654–1660, 2005. With permission.)
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C006 Final Proof page 137 16.11.2007 12:16pm Compositor Name: VAmoudavally
137
Application of Genomic, Proteomic, and Metabolomic Technologies
TABLE 6.1 Summary of Perturbed Components: By Dose and Tissue=Biofluid Tissue
Dose
Total
p < 0.05
p < 0.01
Plasma Plasma Liver Liver
Low High Low High
975 1034 1763 1763
64 70 71 160
12 32 13 50
C. METABOLOMIC INVESTIGATION EXPOSURE TO VX VAPOR
OF
LIVER AND BLOOD PLASMA FOLLOWING LOW-LEVEL
The metabolomic profiles of plasma and liver of 109 adult (6–8 weeks old) male Sprague-Dawley rats exposed by whole body inhalation to VX vapor were determined using liquid chromatography coupled with mass spectrometry (LC=MS). Of these animals, 39 were air exposed, 35 were exposed to 0.0007 mg=m3 VX vapor for 240 min (low dose, no significant miosis), and 40 were exposed to 0.0018 mg=m3 VX vapor for 240 min (high dose, significant miosis). Briefly, the LC=MS data were then mined for perturbed components using parametric and nonparametric statistical methods. Unsupervised analyses were also conducted using hierarchical clustering to identify groups of perturbed metabolic components in the liver and in the plasma (Table 6.1). As would be expected given a typical dose–response scenario, the livers from the higher-dosed animals exhibited greater perturbation in metabolites than the lower-dosed ones. This could be because of the greater concentration of toxicant in the liver, which can trigger involvement of more metabolic processes as the concentration increases to ameliorate the greater toxicity. The plasma was also a fruitful reservoir of potentially informative markers of exposure. The metabolites with the largest degree of change in the plasma are shown in Table 6.2. From this pilot study, work is ongoing to verify these findings by repetition in other CWA exposure studies.
VI. CONCLUSIONS Advances in science often come as a result of advances in technology, and this has been especially true in the fields of genomics, proteomics, and metabolomics. The development of microarrays, advancements in MS and NMR instrumentation, and computing power to analyze large multivariate data sets have provided scientists with unprecedented ability to measure biological response at the TABLE 6.2 Plasma Components with Largest Change in Response 5-Hydroxyxanthotoxin Poly-L-glutamate Pyridoxal Uridine L-Citrulline L-Tryptophan L-Arginine Creatine L-Serine L-Glutamine L-Methionine L-Valine
2-Naphthylamine 4-Oxoproline 5-Methyl-2-deoxyxytidine DNA Glycocholate N(pai)-Methyl-L-histidine Sulfate Uridine
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C006 Final Proof page 138 16.11.2007 12:16pm Compositor Name: VAmoudavally
138
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
FIGURE 6.8 Applications of genomic, proteomic, and metabolomic approaches to force protection against chemical warfare agents.
whole cell or whole tissue level. This has expanded the capacity for identifying genes and proteins involved in disease, pathways involved in cellular response to toxicants, and biomarkers of effect, exposure, or efficacy (Figure 6.8).
A. BIOMARKER DISCOVERY Biomarker discovery has been an accelerating field of research since the advent of genomics, proteomics, and metabolomics. Despite the seemingly recent emergence of biomarker discovery as an important component of medical research, biomarkers have been used clinically for decades. Cholinesterase activity is a prototypical biomarker used in both civilian and military settings to determine exposure to organophosphate pesticides or nerve agents. In the military, cholinesterase testing has been used routinely for force health protection by testing soldiers before deployment to an area where CWAs may be used (TB Med 590, 2001). In addition, cholinesterase testing is used for occupational screening of agent workers. Given the ease of the assays used, the specificity of cholinesterase inhibition by nerve agents, and the link between cholinesterase activity and exposure, cholinesterase has proven to be a useful biomarker of exposure to nerve agent. However, the tests lack the specificity necessary to unequivocally identify the agent responsible for cholinesterase inhibition. To identify the specific agent responsible for cholinesterase inhibition, an analytical chemistry technique is required (e.g., CG=MS). This requires additional sample, time, and expertise that may not be readily available in a battlefield scenario or terrorist attack. In addition, identifying exposure to and effects of low levels of CWA has been problematic. Genomic, proteomic, and metabolic technologies provide a new way to uncover novel biomarkers for rapid and accurate force health protection and monitoring.
B. MECHANISMS
OF
TOXICITY
AND
THERAPEUTICS
Understanding the mechanism of toxicity of a CWA is critical for the rational development of CWA therapeutics. As described, genomics, proteomics, and metabolomics approaches are an important
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C006 Final Proof page 139 16.11.2007 12:16pm Compositor Name: VAmoudavally
Application of Genomic, Proteomic, and Metabolomic Technologies
139
component for understanding mechanisms of toxicity. Identifying the key genes and proteins involved in the cellular response to a toxicant uncovers not only the mechanism of toxicity itself, but also identifies potential therapeutic targets in the pathways that are activated by the toxicant, as well as potential biomarkers of exposure. The information derived from these global approaches can also lead to the design of drug screening assays and to the identification of candidate biomarkers for development of detection strategies and diagnostics.
C. ADVANCED DEVELOPMENT
OF
THERAPEUTICS (FDA APPROVAL)
One important area where genomics, proteomics, and metabolomics can play a critical role is in the advanced development of CWA therapeutics. Since traditional clinical trials are not an option for the testing of CWA therapeutics, we must rely solely on animal data to determine efficacy. (New Drug and Biological Drug Products; Evidence Needed to Demonstrate Effectiveness of New Drugs when Human Efficacy Studies are not Ethical or feasible. 2002). The FDA has recognized this challenge and has developed the ‘‘Animal Rule’’ (www.fda.gov= CBER=rules=humeffic.htm). Under this rule, FDA can rely on animal studies to provide substantial evidence of the effectiveness of therapeutics when (1) there is a reasonably well-understood pathophysiological mechanism for the toxicity, (2) the effect is demonstrated in more than one animal species expected to react with a response predictive for humans, (3) the animal study end point is clearly related to the desired benefit in humans, and (4) the data or information on the pharmacokinetics and pharmacodynamics of the product or other relevant data or information in animals and humans are sufficiently well understood to allow selection of an effective dose in humans, and it is therefore reasonable to expect the effectiveness of the product in animals to be a reliable indicator of its effectiveness in humans (quoted from www.fda.gov=CBER=rules=humeffic. htm). Genomics and proteomics technologies and approaches can play an important role by helping understand the pathophysiological mechanism for the toxicity (see (1) above). This will also aid in understanding the molecular mechanism of efficacy of the countermeasure. Genomics and proteomics technologies may also be used to extrapolate CWA exposure data from animals to humans (Dillman and Phillips, 2005). Recently, the FDA has encouraged the submission of genomic data as part of the application for a new drug (Guidance for Industry: Pharmacogenomic Data Submissions, 2005). They have proposed broad guidelines to govern the use of this data in the regulatory process. Though this guidance is not specifically addressed to the Animal Rule, it is likely to become an important component of new drug applications that relies on the Animal Rule for approval.
D. USE OF ANIMALS
IN
RESEARCH (REDUCTION, REFINEMENT, AND REPLACEMENT)
The use of genomics and proteomics approaches allows researchers to obtain more data from a single animal experiment than was previously possible. Thousands of response variables can be measured from a single animal sample (gene expression profiles, protein expression, metabolic profile). This allows data gathering from animal experiments to be much broader in scope, more efficient, and more informative. This contributes to the goal of the ‘‘Three Rs’’ (reduction, refinement, and replacement) in animal research in the DoD.
VII. SUMMARY The application of genomics, proteomics, and metabolomics has revolutionized research in the life sciences. These approaches hold much promise to accelerate the mission of developing countermeasures against CWA, improving the development of protective material, and enhancing our capabilities for force health protection.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C006 Final Proof page 140 16.11.2007 12:16pm Compositor Name: VAmoudavally
140
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
REFERENCES Abersold R, Mann M. 2003. Mass spectrometry based proteomics. Nature 422:198–207. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu S, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM. 2000. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503–511. Anderson DR, Yourick JJ, Moeller RB, Petrali JP, Young GD, Byers SL. 1996. Pathologic changes in rat lungs following acute sulfur mustard inhalation. Inhal Toxicol 8:285–297. Anderson DR, Holmes WW, Lee RB, Dalal SJ, Hurst CG, Maliner BI, Newmark J, Smith WJ. 2006. Sulfur mustard-induced neutropenia: treatment with granulocyte colony-stimulating factor. Mil Med 171:448–453. Barak Y, Juven T, Haffner R, Oren M. 1993. mdm2 expression is induced by wild type p53 activity. EMBO J 12:461–468. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, Radmacher M, Simon R, Yakhini Z, Ben-Dor A, Sampas N, Dougherty E, Wang E, Marincola F, Gooden C, Lueders J, Glatfelter A, Pollock P, Carpten J, Gillanders E, Leja D, Dietrich K, Beaudry C, Berens M, Alberts D, Sondak V, Hayward N, Trent J. 2000. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406:536–540. Bjellqvist B, Ek K, Righetti PG, Gianazza E, Gorg A, Westermeier R, Postel W. 1982. Isoelectric focusing in immobilized pH gradients: principle, methodology and some applications. J Biochem Biophys Methods 6:317–339. Borodina I, Nielsen J. 2005. From genomes to in silico cells via metabolic networks. Curr Opin Biotechnol 16 (3):350–355. Burns TF, Fei P, Scata KA, Dicker DT, El-Deiry WS. 2003. Silencing of the novel p53 target gene Snk=Plk2 leads to mitotic catastrophe in Paclitaxel (Taxol)-exposed cells. Mol Cell Biol 23:5556–5571. Choi BK, Hercules DM, Zhang T, Gusev AI. 2001. Comparison of quadruple time of flight and Fourier Transform mass analyzers for LC-MS. LC GC 19:514–520. Departments of the Army, Navy, Air Force, and Commandant Marine Corps. 1995. Field Manual: Treatment of Chemical Agent Casualties and Conventional Military Chemical Injuries. Army FM-8-285; Navy NAVMED P-5041; Air Force AFJMAN 44–149; and Marine Corps FMFM 11-11. Washington, DC, December 1995. DeRisi J, Penland L, Brown PO, Bittner ML, Meltzer PS, Ray M, Chen Y, Su YA, Trent JM. 1996. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet 14(4):457–460. Dill K, Montgomery DD, Ghindilis AL, Schwarzkopf KR. 2004. Immunoassays and sequence-specific DNA detection on a microchip using enzyme amplified electrochemical detection. J Biochem Biophys Methods 59:181–187. Dillman JF III, Phillips CS. 2005. Whole blood gene expression profiles from model nonhuman primates and humans. Toxicol Sci 87(1):306–314. Dillman JF, Phillips CS, Dorsch LM, Croxton MD, Hege AI, Sylvester AJ, Moran TS, Sciuto AM. 2005. Genomic analysis of rodent pulmonary tissue following bis-(2-chloroethyl) sulfide exposure. Chem Res Toxicol 18:28–34. Dohn M, Jiang J, Chen X. 2001. Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis. Oncogene 20:6503–6515. Easton DF, Peto J, Doll R. 1988. Cancers of the respiratory tract in mustard gas workers. Br J Ind Med 45:652–659. el-Deiry WS, Tokino T, Velculescu VE, Leby DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817–825. Elia JS, Haas W, Faherty BK, Gygi SP. 2005. Comparative evaluation of mass spectrometry platforms used in large scale proteomics investigations. Nat Methods 2(9):667–675. Ellman GL, Courtney KD, Andres V Jr, Feather-Stone RM. 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88–95. Fan LZ, Cherian MG. 2002. Potential role of p53 on metallothionein induction in human epithelial breast cancer cells. Br J Cancer 87:1019–1026.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C006 Final Proof page 141 16.11.2007 12:16pm Compositor Name: VAmoudavally
Application of Genomic, Proteomic, and Metabolomic Technologies
141
Farr S, Dunn RT 2nd. 1999. Concise review: gene expression applied to toxicology. Toxicol Sci 50(1):1–9. Fodor SPA, Read JL, Pirrung MC, Stryer L, Lu AT, Solas D. 1991. Light-directed, spatially addressable parallel chemical synthesis. Science 251:767–773. Fodor SPA, Rava RP, Huang XC, Pease AC, Holmes CP, Adams CL. 1993. Multiplexed biochemical assays with biological chips. Nature (Lond) 364:555–556. Gevaerrt K, Vandekeckhove J. 2000. Protein identification methods in proteomics. Electrophoresis 21:1145–1154. Glassbrook N, Beecher C, Ryals J. 2000. Metabolic profiling on the right path. Nat Biotechnol 18:1142–1143. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES. 1999. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286:531–537. Guidance for Industry: Pharmacogenomic Data Submissions, March, 2005, www.fda.gov=Cber=gdlns=pharmd tasub.htm (accessed March 2007). Guo Y, Fu Z, Van Eyk JE. 2007. A proteomic primer for the clinician. Proc Am Thorac Soc 4:9–17. Hamadeh HK, Bushel PR, Jayadev S, DiSorbo O, Bennett L, Li L, Tennant R, Stoll R, Barrett JC, Paules RS, Blanchard K, Afshari CA. 2002. Prediction of compound signature using high density gene expression profiling. Toxicol Sci 67(2):232–240. Heller RA, Schena M, Chai A, Shalon D, Bedilion T, Gilmore J, Woolley DE, Davis RW. 1997. Discovery and analysis of inflammatory disease-related genes using cDNA microarrays. Proc Natl Acad Sci USA 94:2150–2155. Holmes E, Antti H. 2002. Chemometric contributions to the evolution of metabonomics: mathematical solutions to characterizing and interpreting complex biological NMR spectra. Analyst 127:1549–1557. Hughes TR, Mao M, Jones AR, Burchard J, Marton MJ, Shannon KW, Lefkowitz SM, Iyer VR, Eisen MB, Ross DT, Schuler G, Moore T, Lee JCF, Trent JM, Staudt LM, Hudson Jr. J, Boguski MS, Lashkari D, Shalon D, Botstein D, Brown PO. 1999. The transcriptional program in the response of human fibroblasts to serum. Science 283:83–87. Hughes TR, Mao M, Jones AR, Burchard J, Marton MJ, Shannon KW, Lefkowitz SM, Ziman M, Schelter JM, Meyer MR, Kobayashi S, Davis C, Dai H, He YD, Stephaniants SB, Cavet G, Walker WL, West A, Coffey E, Shoemaker DD, Stoughton R, Blanchard AP, Friend SH, Linsley PS. 2001. Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer. Nat Biotechnol 19(4):342–347. Iyer VR, Eisen MB, Ross DT, Schuler G, Moore T, Lee JC, Trent JM, Staudt LM, Hudson J Jr, Boguski MS, Lashkari D, Shalon D, Botstein D, Brown PO. 1999. The transcriptional program in the response of human fibroblasts to serum. Science 283(5398):83–87. Jakubowski EM, Woodard CL, Mershon MM, Dolzine TW. 1990. Quantification of thiodiglycol in urine by electron ionization gas chromatography–mass spectrometry. J Chromatogr 528(1):184–190. Jensen ON. 2004. Modification-specific proteomics: characterization of post-translational modifications by mass spectrometry. Curr Opin Chem Biol 8:33–41. Jungblut P, Thiede B. 1997. Protein identification from 2-DE gels by maldi mass spectrometry. Mass Spectrom Rev 16:145–162. Klose J. 1975. Protein mapping by combined isoelectric focusing and electrophoresis of mouse tissues. A novel approach to testing for induced point mutations in mammals. Humangenetik 26:231–243. Lindon JC, Holmes E, Nicholson JK. 2006. Metabonomics techniques and applications to pharmaceutical research and development. Pharm Res 23(6):1075–1088. Lipp JA. 1972. Effect of diazepam upon soman-induced seizure activity and convulsions. Electroencephalogr Clin Neurophysiol 32:557–560. Lipp JA. 1973. Effects of benzodiazepine derivatives on soman-induced seizure activity and convulsions in the monkey. Arch Int Pharmacodyn Ther 202:244–251. Loew LM, Schaff JC. 2001. The Virtual Cell: a software environment for computational cell biology. Trends Biotechnol 19(10):401–406. Loo JA, Brown J, Critchley G, Mitchell C, Andrews P, Ogorzalek-Loo R. 1999. Hugh sensitivity mass spectrometric methods for obtaining intact molecular weights from gel separated proteins. Electrophoresis 20:743–748. Manning KP, Skegg DCG, Stell PM, Doll R. 1981. Cancer of the larynx and other occupational hazards of mustard gas workers. Clin Otolaryngol 6:165–170.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C006 Final Proof page 142 16.11.2007 12:16pm Compositor Name: VAmoudavally
142
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Marcotte EM. 2001. The path not taken. Nat Biotechnol 19:626–627. Matsuda S, Rouault J, Magaud J, Berthet C. 2001. In search of a function for the TIS21=PC3=BTG1=TOB family. FEBS Lett 497:67–72. Maynard RL. 2000. Toxicology of chemical warfare agents. In Ballantyne B, Maris TC, Syvesen T (Eds.), General and Applied Toxicology, 2nd edn, Vol. 3. (pp. 2079–2110). London, Macmillan Reference Ltd. Minsavage GD, Dillman III JF. 2007. Bifunctional alkylating agent-induced p53 and nonclassical nuclear factor kappa B responses and cell death are altered by caffeic acid phenethyl ester: a potential role for antioxidant=electrophilic response-element signaling. J Pharmacol Exp Ther 321:202–212. Miyashita T, Reed JC. 1995. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293–299. New Drug and Biological Drug Products; Evidence Needed to Demonstrate Effectiveness of New Drugs When Human Efficacy Studies Are Not Ethical or Feasible. 21CFR Parts 314 and 601, Federal Register: May 31, 2002 Vol. 67, No 105, 37988–37998. Nicholson JK, Lindon JC, Holmes E. 1999. Metabonomics: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xeno biotica 29(11):1181–1189. Nishimoto Y, Yamakido M, Ishioka S, Shigenobu T, Yukutake M. 1988. Epidemiological studies of lung cancer in Japanese mustard gas workers. In Miller RW and Watanabe S (Eds.), Unusual Occurrences as Clues to Cancer Etiology (pp. 95–101). Tokyo, Japan Scientific Society Press=Taylor and Francis, Ltd. Nuwaysir EF, Huang W, Albert TJ, Singh J, Nuwaysir K, Pitas A, Richmond T, Gorski T, Berg JP, Ballin J, McCormick M, Norton J, Pollock T, Sumwalt T, Butcher L, Porter D, Molla M, Hall C, Blattner F, Sussman MR, Wallace RL, Cerrina F, Green RD. 2002. Gene expression analysis using oligonucleotide arrays produced by maskless photolithography. Genome Res 12(11):1749–1755. O’Farrell PH. 1975. High resolution two-dimensional electrophoresis of proteins. J Biol Chem 250:4007–4021. Okamoto K, Beach D. 1994. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO J 13:4816–4822. Papirmeister B, Feister AJ, Robinson SI, Ford RD. 1991. Medical Defense Against Mustard Gas: Toxic Mechanisms and Pharmacological Implications. CRC Press, Boca Raton, FL. Pease AC, Solas D, Sullivan EJ, Cronin MT, Holmes CP, Fodor SPA. 1994. Light-generated oligonucleotide arrays for rapid DNA sequence analysis. Proc Natl Acad Sci USA 91:5022–5026. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge Ø, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale A, Brown PO, Botstein D. 2000. Molecular portraits of human breast tumours. Nature (Lond) 406:747–752. Ramakrishnan R, Dorris D, Lublinsky A, Nguyen A, Domanus M, Prokhorova A, Gieser L, Touma E, Lockner R, Tata M, Zhu X, Patterson M, Shippy R, Sendera TJ, Mazumder A. 2002. An assessment of Motorola CodeLink microarray performance for gene expression profiling applications. Nucleic Acids Res 30:e30. Rosenthal DS, Simbulan-Rosenthal CM, Iyer S, Spoonde A, Smith W, Ray R, Smulson ME. 1998. Sulfur mustard induces markers of terminal differentiation and apoptosis in keratinocytes via a Ca2þ-calmodulin and caspase-dependent pathway. J Invest Dermatol 111:64–71. Schafer H, Trauzold A, Sebens T, Deppert W, Folsch UR, Schmidt WE. 1998. The proliferation-associated early response gene p22=PRG1 is a novel p53 target gene. Oncogene 16:2479–2487. Schena M, Shalon D, Davis RW, Brown PO. 1995. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270:467–470. Schena M, Shalon D, Heller R, Chai A, Brown PO, Davis RW. 1996. Parallel human genome analysis: microarray-based expression monitoring of 1000 genes. Proc Natl Acad Sci USA 93:10614–10619. Sciuto AM, Cascio MB, Moran T, Forster J. 2003. The fate of antioxidant enzymes in bronchoalveolar lavage fluid over seven days in mice with acute lung injury. Inhal Toxicol 15:675–685. Sciuto AM, Phillips CS, Orzolek LD, Hege AI, Moran TS, Dillman JF. 2005. Genomic analysis of murine pulmonary tissue following carbonyl chloride inhalation. Chem Res Toxicol 18:1654–1660. Searfoss GH, Jordan WH, Calligaro DO, Galbreath EJ, Schirtzinger LM, Berridge BR, Gao H, Higgins MA, May PC, Ryan TP. 2003. Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor. J Biol Chem 278(46):46107–46116. Shih ML, Smith JR, McMonagle JD, Dolzine TW, Gresham VC. 1991. Detection of metabolites of toxic alkylmethylphosphonates in biological samples. Biol Mass Spectrom 11:717–723.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C006 Final Proof page 143 16.11.2007 12:16pm Compositor Name: VAmoudavally
Application of Genomic, Proteomic, and Metabolomic Technologies
143
Shalon D, Smith SJ, Brown PO. 1996. A DNA microarray system for analyzing complex DNA samples using two-color fluorescent probe hybridization. Genome Res 6:639–645. Sidell FR. 1997. Nerve agents. In R. Zajtuchuk (Ed.), Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare (pp. 129–179). Washington, DC: Office of The Surgeon General. Singh-Gasson S, Green RD, Yue Y, Nelson C, Blattner F, Sussman MR, Cerrina F. 1999. Maskless fabrication of light-directed oligonucleotide microarrays using a digital micromirror array. Nat Biotechnol 17:974–978. Smart JK. 1997. History of chemical and biological warfare: an American perspective. In R. Zajtuchuk (Ed.), Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare (pp. 9–86). Washington, DC: Office of The Surgeon General. Stefanovski D, Moate PJ, Boston RC. 2003. WinSAAM: a windows-based compartmental modeling system. Metabolism 52(9):1153–1166. Stein LD. 2004. Human genome: end of the beginning. Nature 431:915–916. Steiner S, Anderson NL. 2000. Expression profiling in toxicology—potentials and limitations. Toxicol Lett 112–113(8):467–471. Sosnowski RG, Tu E, Butler WF, O’Connell JP, Heller MJ. Rapid determination of single base mismatch mutations in DNA hybrids by direct electric field control. 1997. Proc Natl Acad Sci USA 94:1119–1123. Takeshima Y, Inai K, Bennett WP, Metcalf RA, Welsh JA, Yonehara S, Hayashi Y, Fujihara M, Yamakido M, Akiyama M, et al., 1994. p53 mutations in lung cancers from Japanese mustard gas workers. Carcinogenesis 15:2075–2079. TB MED 296. 1996. Technical Bulletin Assay Techniques for Detection of Exposure to Sulfur Mustard, Cholinesterase Inhibitors, Sarin, Soman, GF, and Cyanide. Headquarters, Department of the Army, Washington, DC, 22 May 1996. TB MED 590. 2001. Technical Bulletin Occupational and Environmental Health Red Blood CellCholinesterase Testing and Quality Assurance, Headquarters, Department of the Army, Washington DC, 30 November 2001. Thomas RS, Rank DR, Penn SG, Zastrow GM, Hayes KR, Pande K, Glover E, Silander T, Craven MW, Reddy JK, Jovanovich SB, Bradfield CA. 2001. Identification of toxicologically predictive gene sets using cDNA microarrays. Mol Pharmacol 60(6):1189–1194. Tian L, Shi MM, Forman HJ. 1997. Increased transcription of the regulatory subunit of g-glutamylcysteine synthetase in rat lung epithelial L2 cells exposed to oxidative stress or glutathione depletion. Arch Biochem Biophys 342:126–133. Tokuoka S, Hayashi Y, Inai K, Egawa H, Aoki Y, Akamizu H, Eto R, Nishida T, Ohe K, Kobuke T, Nambu S, Takemoto T, Kou E, Nishina H, Fujihara M, Yonehara S, Tsuya T, Suehiro S, Horiuchi K. 1986. Early cancer and related lesions in the bronchial epithelium in former workers of mustard gas factory. Acta Pathol Jpn 36:533–542. Vogelstein B, Kinzler KW. 2004. Cancer genes and the pathways they control. Nat Med 10:789–799. Waters NJ, Holmes E, Williams A, Waterfield CJ, Farrant RD, Nicholson JK. 2001. NMR and pattern recognition studies on the time-related metabolic effects of alpha-naphthylisothiocyanate on liver, urine, plasma in the rat: an integrative metabonomics approach. Chem Res Toxicol 14:1401–1412. Yang Y, Blomme EA, Waring JF. 2004. Toxicogenomics in drug discovery: from preclinical studies to clinical trials. Chem Biol Interact 150(1):71–85. Zhang C, Gao C, Kawauchi J, Hashimoto Y, Tsuchida N, Kitajima S. 2002. Transcriptional activation of the human stress-inducible transcriptional repressor ATF3 gene promoter by p53. Biochem Biophys Res Commun 297:1302–1310.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C006 Final Proof page 144 16.11.2007 12:16pm Compositor Name: VAmoudavally
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C007 Final Proof page 145 16.11.2007 12:17pm Compositor Name: VAmoudavally
Approaches to Medical 7 Novel Protection against Chemical Warfare Nerve Agents Ashima Saxena, Chunyuan Luo, Nageswararao Chilukuri, Donald M. Maxwell, and Bhupendra P. Doctor CONTENTS I. Introduction.......................................................................................................................... 146 II. Enzyme-Based Bioscavengers ............................................................................................. 146 A. Plasma-Derived Human Butyrylcholinesterase ........................................................... 147 1. Isolation and Purification...................................................................................... 147 2. Characterization .................................................................................................... 148 3. Pharmacokinetics and Toxicity............................................................................. 148 4. Behavioral and Physiological Safety .................................................................... 149 5. In Vitro and In Vivo Stability ............................................................................... 150 6. Efficacy ................................................................................................................. 150 7. Immunoreactivity .................................................................................................. 152 B. Recombinant Human Butyrylcholinesterase ................................................................ 153 1. Sources.................................................................................................................. 153 2. Characterization .................................................................................................... 154 3. Efficacy ................................................................................................................. 154 4. Improving Efficacy by Mutagenesis..................................................................... 155 5. Gene Therapy........................................................................................................ 156 C. Catalytic Bioscavengers ............................................................................................... 156 1. Enhancing Activity of Stoichiometric Bioscavengers .......................................... 156 2. Sources of OP Hydrolases .................................................................................... 157 3. Evolving Mammalian Paraoxonases..................................................................... 158 D. Extrapolation of Animal Data to Humans ................................................................... 158 III. Oxime-Based Therapy ......................................................................................................... 159 A. In Vitro Evaluation of Oxime Reactivation................................................................. 159 B. In Vivo Evaluation of Oximes...................................................................................... 161 C. Design and Development of the Next Generation of Oximes..................................... 162 IV. Centrally Acting Pretreatment Drugs .................................................................................. 164 V. Summary .............................................................................................................................. 165 References ..................................................................................................................................... 166
The opinions or assertions contained herein are the private views of the authors and are not to be construed as reflecting the view of the Department of the Army or the Department of Defense.
145
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C007 Final Proof page 146 16.11.2007 12:17pm Compositor Name: VAmoudavally
146
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
I. INTRODUCTION Nerve agents are organophosphorus (OP) compounds that are among the most toxic substances known to mankind (Dacre, 1984). Originally, OPs were developed for use as insecticides (Ballantyne and Marrs, 1992), but their extreme toxicity toward higher vertebrates led to their adoption as weapons of warfare (Maynard and Beswick, 1992). The most likely route of exposure to these agents is through inhalation or by absorption through the skin. All OPs produce their acute toxic effects by irreversibly inhibiting acetylcholinesterase (AChE, E.C. 3.1.1.7), the enzyme that breaks down the neurotransmitter acetylcholine (ACh) (Koelle, 1963; Taylor, 1990). The accumulation of ACh in response to OP exposure causes an overstimulation of cholinergic receptors at the neuromuscular junctions (Stewart, 1959; Stewart and Anderson, 1968; Heffron and Hobbinger, 1979), which can lead to muscle weakness, increased secretions, respiratory depression, seizures, coma, and ultimately death resulting from respiratory or cardiovascular failure or convulsion consequences (de Candole, 1953). The conventional approach for the treatment of OP intoxication involves efforts to counteract the effects of AChE inhibition, which includes the administration of an anticholinergic drug such as atropine sulfate to antagonize the effects of elevated ACh levels and an oxime such as 2-PAM chloride to reactivate OP-inhibited AChE (Wilson and Ginsburg, 1955; Bajgar et al., 1971; Heath and Meredith, 1992). In addition, an anticonvulsant drug such as diazepam may also be administered to control OP-induced tremors and convulsions. In conjunction with therapy, individuals at high risk for exposure to GD are pretreated with the spontaneously reactivating AChE inhibitor pyridostigmine bromide, which temporarily protects about 30% of peripheral AChE from irreversible inhibition by OP (Gordon et al., 1978; Leadbeater et al., 1985). Although these antidotal regimens are effective in increasing survivability, they suffer from several disadvantages: (1) they do not prevent postexposure incapacitation, convulsions, performance deficits, or in the case of recurring seizures, permanent brain damage (Leadbeater et al., 1985); (2) a greater than marginal improvement of these pharmacological approaches is not possible, because stronger drugs or higher doses are likely to produce unacceptable performance decrements by themselves (Dunn and Sidell, 1989; Castro et al., 1991); (3) the efficacy of this antidotal regimen demands precise timing and sequencing of drug administration at the time of OP exposure, which is very difficult to execute on the battlefield; and (4) some nerve agents, such as GD, present an additional challenge due to the rapid dealkylation of inhibited AChE that is resistant to therapeutic reversal by oxime (Fleisher and Harris, 1965). The contents of this article describe the progress made in the last 5 years in exploring and developing nerve agent medical countermeasures that provide higher survival rates, avoid or reduce enduring adverse effects to survivors, and significantly lengthen the windows in which prophylaxes or treatments can be effectively administered. Because of the fast inactivation of AChE by OPs and the inability to distinguish between nerve agents, medical treatment must be administered within ~1 min and it must be effective for all OP nerve agents. In this regard, significant advances were made on the development of bioscavengers for human use, and the search for broad-spectrum oximes and reversible cholinesterase inhibitors was initiated.
II. ENZYME-BASED BIOSCAVENGERS A novel approach to treating OP poisoning is the use of enzymes to sequester these compounds in circulation before they reach their physiological target, the central nervous system (CNS) AChE. Ideally, the scavenger should enjoy a long residence time in circulation, should be biologically innocuous in the absence of nerve agent, and should not present an antigenic challenge to the immune system. For these reasons, a formal program to identify candidate bioscavengers was begun in 1993 and has focused on enzymes of mammalian (specifically human) origin. Candidate bioscavenger proteins, in general, function either by stoichiometrically binding and sequestering
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C007 Final Proof page 147 16.11.2007 12:17pm Compositor Name: VAmoudavally
Novel Approaches to Medical Protection against Chemical Warfare Nerve Agents
147
toxic OPs or by catalytically cleaving OPs into nontoxic products. In the former category are naturally occurring human proteins that bind or react with nerve agents, including enzymes such as cholinesterases (ChEs) and carboxylesterases (CaEs). One mole of each of these stoichiometric scavengers has the capacity to bind one mole of nerve agent. Candidate enzymes with catalytic activity against nerve agents include the human organophosphorus acid anhydride hydrolases (OPAHs) (Masson et al., 1998), such as paraoxonase (Hu PON). In general, the use of catalytic scavengers would be advantageous because small amounts of enzyme would be sufficient to detoxify large amounts of nerve agent.
A. PLASMA-DERIVED HUMAN BUTYRYLCHOLINESTERASE Because the use of ChEs as stoichiometric bioscavengers was most extensively characterized and the goal of research on scavenger molecules was to generate a means to protect humans from the toxic effects of nerve agents, efforts for the past 5 years primarily focused on plasma-derived human butyrylcholinesterase (Hu BChE, EC 3.1.1.8). Hu BChE has several advantages as an exogenously administered prophylactic for human use (Ashani, 2000). First, it reacts rapidly with all OP nerve agents including, soman (GD), sarin (GB), tabun (GA), and VX. Second, it is readily absorbed from sites of injection and remains in human circulation for long periods of time. Third, because the enzyme is from a human source, it is not expected to produce any adverse immunological responses on repeated administration into humans. Fourth, because the enzyme has no known physiological function in the body, it is unlikely to produce any physiological side effect. Because the biochemical mechanism underlying prophylaxis by exogenous Hu BChE was established and tested in several species, including nonhuman primates, this concept should enable a reliable extrapolation of results from animal experiments to human application. A dose of 200 mg of Hu BChE is envisioned as a prophylactic treatment in humans that can protect from exposure of up to 2 3 LD50 of GD. Recent efforts focused on advancing the use of Hu BChE in humans are described below. 1.
Isolation and Purification
The primary requirement to advance Hu BChE as a bioscavenger for human use was to obtain sufficient amounts of purified enzyme for conducting preclinical pharmacological studies. A procedure for the large-scale purification of Hu BChE from Cohn Fraction IV-4 paste, a by-product of human plasma generated during the production of human blood proteins, such as g-globulin, clotting factors, and others, was developed. This procedure involved resuspension of 80 kg of Cohn fraction IV-4 paste in nine volumes of cold distilled water followed by adjustment of pH of the suspension to 4.90. The suspension was clarified by centrifugation and filtration, and the pH was adjusted to 8.0. The supernatant was filtered and purified by procainamide affinity chromatography followed by anion exchange chromatography. The final product contained ~5 million units corresponding to ~8 g of Hu BChE. The enzyme was filtered through a 0.45 mm filter and stored in 25 mg batches in lyophilized form at 208C. The purity of the Hu BChE preparations was followed by specific activity, evidence of a single protein band on SDS-PAGE and HPLC. The specific activity of the purified enzyme was about 700 U=mg measured in 50 mM sodium phosphate buffer at pH 8.0 at 258C, using 1 mM butyrylthiocholine as the substrate (Grunwald et al., 1997). Active-site titration of purified enzyme with 7-(O,O-diethylphosphinyloxy)-1-methylquinolinium methyl sulfate (DEPQ) revealed that 1 mg of enzyme contains 11 nmol of active sites. Each nmol of enzyme contains 64–68 U of activity. The absorbance of a 1 mg=mL solution at 280 nm varies from 1.8 to 1.92 (Lockridge et al., 1979; Grunwald et al., 1997). The enzyme migrated as a single band on a reducing SDS-PAGE, with a subunit molecular weight of 85 kDa as shown in Figure 7.1. The size of the band was reduced to 65 kDa upon treatment with N-glycosidase F (Figure 7.1). The intact protein migrated as a single band on native polyacrylamide gel electrophoresis, which could be stained for enzyme activity.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C007 Final Proof page 148 16.11.2007 12:17pm Compositor Name: VAmoudavally
148
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 1
2
3
4
(kDa)
200 97 68 43 29
FIGURE 7.1 SDS-PAGE of Hu BChE. 5 U of purified Hu BChE native or following deglycosylation with N-glycosidase F was analyzed on a 10% SDS-polyacrylamide gel. Following electrophoresis at 100 V for 75 min, the gel was stained with Bio-Safe Coomassie. Samples are N-glycosidase F (lane 1), deglycosylated Hu BChE (lane 2), Native Hu BChE (lane 3), and molecular weight markers (lane 4).
2.
Characterization
Hu BChE is present in serum as a soluble, globular tetrameric form, consisting of four identical subunits (Lockridge et al., 1979, 1987). The tetramer has a molecular weight of 340 kDa and it migrates as a single peak on sucrose density gradients, with a sedimentation coefficient (s20,w) of 12.44 (Das and Liddell, 1970). The complete amino acid sequence of this enzyme was determined by amino acid as well as nucleotide sequencing (Lockridge et al., 1979; McTiernan et al., 1987). Glu is the residue at the amino terminus and Leu is the amino acid at the carboxyl terminus. Each subunit consists of 575 amino acids, which contain three disulfide bridges. The molecular weight of each subunit is 85 kDa, of which 65 kDa is for the protein and 20 kDa (24%–26%) for the carbohydrate (Haupt et al., 1966; Saxena et al., 1998a). N-linked carbohydrate structures are present on Asn at positions 17, 57, 106, 241, 256, 341, 455, 481, and 486 (Lockridge et al., 1987). The sitespecific carbohydrate structures for 8 of 9 N-linked glycosylation sites were determined (Garcia et al., 2004). The major structures consist of an asialylo, galactosylated bi-antennary oligosaccharide primarily without core fucosylation. Asn 481 and Asn 486 were inseparable with the cleavage strategies employed, which precluded an absolute assignment of carbohydrate structures for these sites. Although all the sites displayed some degree of microheterogeneity, some sites were more heterogeneous; for example, Asn 241 had 25% oligo-mannose structures, whereas Asn 256 and Asn 455 consisted of 11% and 12% tri-galactose, tri-antennary structures, respectively. The x-ray crystal structure of a genetically engineered low glycosylation form of monomeric Hu BChE was recently described (Nicolet et al., 2003). 3.
Pharmacokinetics and Toxicity
The bioavailability and circulatory stability of purified Hu BChE, administered by different routes of administration, was examined in mice, guinea pigs, and monkeys. Purified Hu BChE displayed high bioavailability in the circulation of mice, guinea pigs, and nonhuman primates when administered by i.v., i.m., or i.p. injections (Figure 7.2). The enzyme displayed a mean residence time (MRT) of about 48 h in mice, 109–110 h in guinea pigs, and 72–74 h in monkeys (Doctor and Saxena, 2005). This prolonged circulatory stability was previously reported in rats and mice (Raveh et al., 1989, 1993; Ashani et al., 1991), guinea pigs (Allon et al., 1998), and rhesus monkeys
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C007 Final Proof page 149 16.11.2007 12:17pm Compositor Name: VAmoudavally
149
400
400
300
300
200 100 0
(a)
BChE (U/ml)
BChE (U/ml)
Novel Approaches to Medical Protection against Chemical Warfare Nerve Agents
0
48
96
144 192 Time (h)
240
200 100 0
288
0
48
96
240
288
(b)
144 192 Time (h)
240
288
BChE (U/ml)
400 350 300 250 200 150 100 50 0
0
48
(c)
96
144 192 Time (h)
FIGURE 7.2 Time course of Hu BChE in the blood of mice (a), guinea pigs (b), and rhesus monkeys (c) following i.m. (!), i.p. (~), or i.v. (&) bolus injections. The dose of enzyme administered was 90 mg=kg for mice, 60 mg=kg for guinea pigs, and 30 mg=kg for monkeys. Data at each time point is an average of six animals for mice and guinea pigs and four for monkeys.
(Raveh et al., 1997). The route of administration affected the time at which the enzyme attained peak activity in circulation, but did not affect the MRT, and an enzyme level between 80% and 100% of peak activity was maintained for a period of ~3–10 h. Also, regardless of the route of administration, 60%–90% of administered enzyme was found in the circulation of animals. Because the animals were administered large doses of Hu BChE, which resulted in up to 300-fold increases in circulating BChE levels, it was important to demonstrate that Hu BChE was not toxic to these animals. The animals were observed for any abnormal physiological or behavioral signs for 2 weeks; they were euthanized and blood was collected for determining hematology and serum chemistry parameters. A gross necropsy was also performed and a full set of tissues, including brain, heart, lung, liver, intestine, kidney, eye, spleen, and muscle injection sites, were examined for any gross or histological changes. General observation of mice and guinea pigs with circulating levels of Hu BChE as high as 300 U=mL did not reveal any signs of clinical toxicity. Also, results of necropsy together with those from analysis of hematology and serum chemistry parameters did not show any clinical signs of pathology following administration of large doses of Hu BChE (Saxena et al., 2005). Similarly, guinea pigs administered 60 mg=kg of Hu BChE did not show any signs of toxicity as observed by histopathology or hematology or serum chemistry parameters (Sun et al., 2005). 4.
Behavioral and Physiological Safety
Since the major use of bioscavengers is prophylactic, it was essential to demonstrate that Hu BChE is devoid of undesirable effects. Thus, several studies evaluated behavioral and physiological effects of equine (Eq) BChE administered alone as well as prior to nerve agent exposure (Broomfield et al., 1991; Genovese and Doctor, 1995; Matzke et al., 1999). Administration of Eq BChE to rats (resulting in circulating BChE levels as high as ~55 U=mL) did not affect acquisition or retention of a passive avoidance task or disrupt performance of a food-maintained
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C007 Final Proof page 150 16.11.2007 12:17pm Compositor Name: VAmoudavally
150
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
operant behavior task (Genovese and Doctor, 1995). The enzyme was also shown to provide significant protection against performance degradation produced by MEPQ ( (7-methylethoxyphosphinyloxy)-1-methylquinolinium iodide), a peripherally active OP compound. Similarly, the safety and efficacy of Eq BChE was also demonstrated in rhesus monkeys using a memory-intensive serial probe recognition (SPR) task, in which subjects were required to recall a list of stimuli. Repeated administration of a commercial preparation of Eq BChE, which produced a 7- to 18-fold increase in circulating BChE level, did not systematically affect performance on the task (Matzke et al., 1999), and rhesus monkeys pretreated with 460–503 nmol of Eq BChE were protected against 2 or 3 3 LD50 of GD or GB (Broomfield et al., 1991). Similar studies were conducted to address the safety and efficacy of Hu BChE in mice (Ashani et al., 1991a), rats (Brandeis et al., 1993), guinea pigs (Allon et al., 1998), and rhesus monkeys (Raveh et al., 1997). In all cases, doses of Hu BChE sufficient to protect against OP exposure were devoid of behavioral side effects. More recently, the behavioral safety of large doses of Hu BChE alone, physostigmine alone, and Hu BChE pretreatment followed by physostigmine challenge were evaluated in mice (Clark et al., 2005). Clark et al., 2005 demonstrated that mice that were administered 2000 U of Hu BChE (30 times the dose required to protect humans from 2 3 LD50 of GD) did not show any significant alteration in acoustic startle or prepulse inhibition behavior. As expected, mice that received physostigmine (0.4 mg=kg) by s.c. injection showed significant decreases in the amplitude of acoustic startle reflex to 50 ms, 120 dB noise pulses. In addition, the time to peak startle reflex and the amount of prepulse inhibition of the acoustic startle reflex were significantly increased. This effect was partially mitigated in mice pretreated with Hu BChE. The behavioral and physiological safety of large doses of Hu BChE was also examined in rhesus monkeys using an SPR task designed to assess attention and short-term memory (Myers et al., 2003). Concurrent with the cognitive-behavioral assessment, blood was collected at critical points throughout the study and analyzed for BChE activity, production of antiBChE antibody, and gross clinical pathology. Each monkey received 150 mg (105,000 U or 32 mg=kg) of Hu BChE by i.v. injection, 60 min prior to testing on the SPR task. No cognitive-behavioral decrements of any kind were detected in SPR performance tests and no robust or consistent signs of clinical pathology were detected in any of the blood assays during the 5 week observation period. These results provide strong support for the behavioral and physiological safety of Hu BChE in mice and rhesus monkeys. 5.
In Vitro and In Vivo Stability
The thermal stability of purified Hu BChE in lyophilized (1 mg) or liquid form (10 mg=mL in 50 mM sodium phosphate, pH 8.0 þ 10% glycerol þ 1 mM EDTA) was examined by measuring enzyme activity following storage at 48C, 258C, 378C, or 458C. Lyophilized samples were resuspended in 1 mL of 50 mM sodium phosphate buffer, pH 8.0 for measuring BChE activity using the Ellman assay (Ellman et al., 1961). Hu BChE preparations were found to be stable when stored in lyophilized form at 48C, 258C, 378C, or 458C for over 2 years (Saxena et al., 2005). The enzyme was also stable when stored in liquid form at 48C and 258C for 1 year. The effect of storage in lyophilized form at 208C on in vivo circulatory stability of Hu BChE preparations was determined by measuring the pharmacokinetic profile of the enzyme following i.m. administration into Balb=c mice as described above. As shown in Table 7.1, the pharmacokinetic properties of the enzyme were not affected by storage at 208C for at least 3 years. 6.
Efficacy
Due to the limited availability of purified Hu BChE, previous studies examined the efficacy of Hu BChE against 2–3 3 LD50 of OP nerve agents (Ashani et al., 1991; Brandeis et al., 1993; Raveh et al., 1997). More recently, the efficacy of Hu BChE was evaluated in guinea pigs and cynomolgus monkeys against multiple LD50 challenges of nerve agents (Lenz et al., 2005). Guinea pigs were protected against a cumulative of 5 3 LD50 of either GD or VX and there was a decrease in molar
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C007 Final Proof page 151 16.11.2007 12:17pm Compositor Name: VAmoudavally
151
Novel Approaches to Medical Protection against Chemical Warfare Nerve Agents
TABLE 7.1 In Vivo Stability of Hu BChEa in Mice Time of Storage at 208C (Months) Parameters
5
12
19
27
37
MRT (h) Tmax (h) Cmax (U=mL) AUC
50.2 + 3.2 24 10.1 + 0.5 754 + 44
55.2 + 0.9 24 11.6 + 0.4 806 + 25
50.5 + 1.4 24 17.7 + 0.6 1,216 + 35
49.3 + 0.8 24 20.6 + 0.8 1,411 + 20
50.6 + 2.7 24 17.7 + 2.7 1,097 + 82
a
The circulatory stability of Hu BChE following storage at different time periods was evaluated in mice by measuring the pharmacokinetic parameters of 100 U of enzyme following i.m. administration.
concentration of circulating Hu BChE activity equivalent to the amount of OP administered at a given time period (Saxena et al., 2004). For example, guinea pigs administered with Hu BChE that was sufficient to provide protection against 8 3 LD50 of GD attained peak blood BChE levels of ~300 U=mL and the enzyme level was reduced to ~100 U=mL following challenge with 5.5 3 LD50 of GD. This decrease of ~200 U=mL in blood BChE level corresponds to the amount of enzyme required to neutralize ~5–5.5 3 LD50 of GD. With VX challenge, less enzyme was administered since the LD50 of VX is lower than that for GD. No signs of OP poisoning were observed in animals that received Hu BChE pretreatment and all animals survived the duration of challenge. Animals were subjected to necropsy, 7 or 14 days following nerve agent challenge and all tissues appeared normal on light microscopic examination. In nonhuman primates, cynomolgus monkeys were protected against a cumulative challenge of 5.5 3 LD50 of GD. Of the six animals challenged, one died after the final challenge dose of GD (a total dose of 5.5 3 LD50 within 4 h) and one was euthanized 48 h after the final dose of GD. The four surviving animals displayed no signs of poisoning and exhibited no signs of delayed toxicity as revealed by examinations of blood chemistry and hematology parameters for 14 months (Sun et al., 2005). Table 7.2 summarizes the results of efficacy studies with Hu BChE using i.v. or s.c. challenge of OP nerve agents.
TABLE 7.2 Protection by Hu BChE Against Nerve Agent Poisoning Test Species Mouse Mouse Rat Guinea pig Guinea pig Rhesus monkey Rhesus monkey Cynomolgus monkey a b
Nerve Agent
Protection (LD50)a
Impairment
Recovery
Reference
GD GA, GB, GD, VX GD GD VX GD VX GD
2.6 1.6–4.9 1.5 5.5 5.0 3.3 2.1 5.5
1 of 11 None None None None 4 of 8 2 of 4 1 of 5
10 of 11 Immediate Immediate Immediate Immediate 15 min to 2 h 20 min to 2 h 4 of 6b
Ashani et al., 1991 Raveh et al., 1993 Brandeis et al., 1993 Lenz et al., 2005 Lenz et al., 2005 Raveh et al., 1997 Raveh et al., 1997 Lenz et al., 2005
Values represent multiple of median lethal doses (LD50s) of nerve agent survived after Hu BChE administration. One animal died after the third dose of GD and one was impaired and euthanized 48 h later. The four surviving animals were held for long-term observations.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C007 Final Proof page 152 16.11.2007 12:17pm Compositor Name: VAmoudavally
152
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
The pharmacokinetics, onset time, and severity of toxic manifestations following exposure to OPs depend not only on the animal species but also on the route of entry of OP challenge. Because inhalation is the most likely route of exposure to OPs on the battlefield or in public places, the efficacy of Hu BChE should be evaluated against inhalation exposure to OP vapor. The first such study was described by Allon et al. (1998), who reported that exogenously administered Hu BChE was effective in protecting guinea pigs from inhalation toxicity due to nose only exposure to GD. More recently, Saxena et al. (2006) evaluated the efficacy of Hu BChE against a whole-body exposure to GB vapor. The study was conducted in Göttingen minipigs because the pig offers many similarities in anatomy and physiology to humans. The efficacy of two doses of Hu BChE (3 and 7.5 mg=kg) in protecting male Göttingen minipigs from an exposure of 4.1 mg=m3 of GB vapor for 60 min was evaluated. This dose of GB vapor was lethal to 99% of untreated exposed pigs (LCt99). Hu BChE was administered by i.m. injection, 24 h prior to whole-body exposure to GB vapor. EEG, ECG, and pupil size were monitored throughout exposure, and blood drawn from a surgically implanted jugular catheter before and during exposure was analyzed for AChE and BChE activities and the amount of GB present in plasma. A dose of 3 mg=kg of Hu BChE resulted in a peak blood BChE activity of 14.88 + 82.1 U=mL, whereas 7.5 mg=kg of Hu BChE resulted in a peak blood BChE activity of 41.28 + 80.9 U=mL. All animals exposed to GB vapor alone or pretreated with 3 mg=kg of Hu BChE died following exposure to GB vapor, whereas animals pretreated with 7.5 mg=kg of Hu BChE survived the GB exposure. The amount of GB bound in plasma of minipigs pretreated with 7.5 mg=kg of Hu BChE was 200-fold higher compared to that in plasma from pigs that did not receive Hu BChE, suggesting that Hu BChE was effective in scavenging GB in blood and in preventing it from reaching other tissues. In addition to increasing survivability, pretreatment with Hu BChE was effective in preventing acute cardiac and neurological toxicity due to exposure to GB vapor. As it is most likely that inhalation will be the human route of exposure, more efficacy studies using this route are needed before one can establish the protective dose of enzyme in man. 7.
Immunoreactivity
A critical prerequisite for any potential bioscavenger is a prolonged circulatory residence time and the absence of antienzyme antibodies following repeated administrations of enzyme. It was demonstrated that multiple injections of Eq BChE into rabbits, rats, or rhesus monkeys, resulted in a MRT spanning several days, and the induction of antienzyme antibodies (Genovese et al., 1993; Gentry et al., 1993, 1996). On the other hand, administration of purified macaque (Ma) BChE into macaques of the same species resulted in much longer MRT (225 + 19 h) compared to that reported for heterologous Hu BChE (33.7 + 2.9 h). After a smaller second injection of Ma BChE, given 4 weeks later, predicted peak plasma levels of enzyme activity were attained, although the four macaques showed wide variation in the MRT (54–357 h). No antibody response was detected in macaques following either injection of enzyme (Rosenberg et al., 2002). More recently, the consequences of repeated injections of Hu BChE and plasma-derived mouse (Mo) BChE from CD-1 mice were examined in Balb=c (Sun et al., 2003) and CD-1 (Saxena et al., 2004) mice following two i.m. injections 4 weeks apart. The fate of two heterologous (Hu BChE) and homologous (Mo BChE) injections were followed by measuring blood BChE activity and antiBChE IgG levels. In Balb=c mice, the first injection of Mo BChE cleared slowly with an MRT ¼ 91.8 h compared to an MRT ¼ 56.7 h for the heterologous Hu BChE injection. As expected, the second injection of Hu BChE cleared much faster from the circulation of mice compared to the first injection. Surprisingly, the second injection of Mo BChE also cleared faster (MRT ¼ 61.6 h) than the first injection and did not attain the predicted peak enzyme level. No circulating antiHu BChE IgG was detected following the first Hu BChE injection but, significant levels of antibodies to Hu BChE were detected 2 days following the second Hu BChE injection. Similarly, no circulating antiMo BChE IgG was detected following the first Mo BChE injection. However, antibodies to
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C007 Final Proof page 153 16.11.2007 12:17pm Compositor Name: VAmoudavally
Novel Approaches to Medical Protection against Chemical Warfare Nerve Agents
153
Mo BChE, although 100-fold less than the levels observed with Hu BChE, were detected 5 days following the second Mo BChE injection. This could be due to differences in BChEs from the two strains of mice, which was subsequently confirmed by repeating the study in CD-1 mice. In CD-1 mice, the clearance of homologous Mo BChE activity following the first injection also occurred slowly (MRT ¼ 73 h) compared to the heterologous Hu BChE injection (MRT ¼ 48 h). As expected, the second injection of Hu BChE cleared much faster from the circulation of mice compared to the first injection (MRT ¼ 26 h). The second injection of homologous Mo BChE on the other hand, attained a peak enzyme level that was similar to that observed following the first injection and displayed an MRT of 79 h. As expected, circulating antiHu BChE IgG could be detected 5 days following the first Hu BChE injection, which increased dramatically after the second injection. No significant antibody response was detected following either of the two homologous Mo BChE injections. The observation that the second injection of Mo BChE resulted in a pharmacokinetic profile that was similar to that of the first injection is in agreement with the lack of a humoral response to the injected enzyme. The observed extended stability of exogenously administered Mo BChE into mice and Ma BChE into macaques suggests that even a single injection of homologous BChE is sufficient to maintain the enzyme at a long-lasting therapeutic level. The results of both studies with two injections of BChE clearly demonstrated the utility of homologous BChE as an effective and safe scavenger, exhibiting high stability and low immunogenicity in recipient animals. With respect to the potential use of Hu BChE in humans, these results are consistent with a reported in vivo half-life of 8–11 days and the absence of untoward immunological and physiological side effects following blood transfusions and i.v. injections of partially purified Hu BChE into humans (Jenkins et al., 1967; Stovner and Stadskleiv, 1976; Cascio et al., 1988; Ostergaard et al., 1988).
B. RECOMBINANT HUMAN BUTYRYLCHOLINESTERASE 1.
Sources
Hu BChE, which is currently under advanced development, represents a first generation biological scavenger. This material is obtained from outdated human plasma (Cohn Fraction IV-4 paste) and the overall availability is related to the quantity of processed human plasma available at any given time. Sufficient amounts of Cohn Fraction IV-4 paste are generated in the United States by blood processing establishments to produce at least 100,000 doses of the product per year. Although this amount of material may be adequate for use by first responders in case of civilian exposure, deliberate or accidental or limited combat engagement, it is not sufficient to protect the entire population or even the entire military. To identify a more reliable source of Hu BChE, recent research efforts are focused on the development of recombinant Hu BChE (rHu BChE), which is compatible with humans. If successful, such efforts will allow a constant supply of material of reproducible purity and activity. There are a variety of potential sources of rHu BChE, which include transgenic plants (Mor et al., 2001), transgenic animals (Cerasoli et al., 2005a), transfected insect larva (Choudary et al., 1995), or algae (Siripornadulsil et al., 2002). In addition, rHu BChE can be expressed in mammalian cell lines. For example, Altamirano and Lockridge (1999) expressed and purified rHu BChE from Chinese Hamster Ovary (CHO) cells, which was a mixture of monomers, dimers, and tetramers. Subsequently, predominantly tetrameric rHu BChE was obtained from both CHO and human embryonic kidney epithelial (HEK 293A) cells by coexpressing it with the proline rich attachment domain of the collagen tail (Duysen et al., 2002; Chilukuri et al., 2005a). A major limitation of these cell-based expression systems is the low yield of the recombinant product which makes them impractical for producing therapeutic quantities of the bioscavenger. This problem was recently overcome with the availability of Protexiay, which is rHu BChE expressed in the milk of transgenic goats (Cerasoli et al., 2005a).
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C007 Final Proof page 154 16.11.2007 12:17pm Compositor Name: VAmoudavally
154
2.
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Characterization
The successful use of recombinant enzymes as OP bioscavengers requires that their biochemical properties be similar to those of the native enzyme, they have a long mean residence time in circulation and be devoid of behavioral side effects and immunological responses. The catalytic properties of rHu BChE expressed in CHO or HEK 293A cells were compared with those of Hu BChE. In general, rHu BChEs were shown to possess similar catalytic parameters (Km and kcat) to those for Hu BChE for substrates such as butyrylthiocholine and benzoylcholine (Duysen et al., 2002; Chilukuri et al., 2005a). Similarly, the inhibition of Protexia by OP nerve agents and carbamates was found to be comparable to that of Hu BChE (Cerasoli et al., 2005a). Although the catalytic and inhibitory properties of recombinant enzyme were similar to those of Hu BChE, a major difference was observed when it was injected into mice and rats; rHu BChE was cleared from circulation within 2 min, as compared to Hu BChE which circulated with an MRT of 46–56 h (Duysen et al., 2002; Chilukuri et al., 2005a). This difference in the pharmacokinetic parameters of recombinant and native Hu BChE appears to be due to the combined effect of the molecular weight, and charge- and size-based heterogeneity in glycans (Saxena et al., 1998a). Indeed it was shown that rHu BChE expressed in CHO cells and goat milk consists mainly of monomers and dimers (Cerasoli et al., 2005a; Garcia et al., 2005), whereas Hu BChE is predominantly tetrameric. The tetramerization of rHu BChE improved its MRT from 2 min to 16–18 h (Duysen et al., 2002; Chilukuri et al., 2005a). Glycan analysis revealed that the glycans of rChEs including rHu BChE display a remarkable heterogeneity in size and consist of hybrid and complex bi-antennary, tri-antennary, and tetra-antennary structures. On the other hand, plasma ChEs, including Hu BChE, contain mature glycans that are predominantly of the complex bi-antennary type, confirming that these structures are responsible for the extended MRTs of the enzymes (Saxena et al., 1998a; Garcia et al., 2004). In addition, Protexia has a different glycosylation pattern than that of Hu BChE and contains a carbohydrate moiety which has been demonstrated to be immunogenic in humans (Garcia et al., 2005). These problems with rHu BChE prompted investigations to reduce its immunogenicity and improve its circulatory stability through posttranslational modifications. 3.
Efficacy
The short MRT of rHu BChE in animals has precluded the testing of its protective properties against OP agents. Using tetrameric rHu BChE in mice, which has an MRT of 16 h, Duysen et al. (2002) demonstrated that it conferred 50% protection from cocaine toxicity. Because rHu BChE protects against cocaine toxicity by hydrolyzing cocaine, the improvement in its MRT from 2 min to 16 h was sufficient to protect mice. However, the circulatory stability and bioavailability of tetrameric rHu BChE were still not comparable to that for Hu BChE (Table 7.3), which
TABLE 7.3 Pharmacokinetic Parameters of Native and Recombinant Hu BChE in Mice Parameters
rHu BChE
PEG-rHu BChE
Hu BChE
MRT (h) Cmax (U=mL) AUC (U)
18.3 + 1.7 1.2 + 0.2 23.1 + 4.7
36.2 + 2.0 29.2 + 3.6 1,258 + 300
45.7 + 1.7 30.3 + 1.3 1,768 + 39
a
The circulatory stabilities of rHu BChE, PEG-rHu BChE, and Hu BChE were determined in mice by measuring the pharmacokinetic parameters of 100 U of enzyme following i.p. administration.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C007 Final Proof page 155 16.11.2007 12:17pm Compositor Name: VAmoudavally
Novel Approaches to Medical Protection against Chemical Warfare Nerve Agents
155
indicated that large quantities of stoichiometric rHu BChE would be needed to demonstrate its efficacy against OP nerve agents. To improve their biological residence time, rHu BChEs produced in goat milk and 293A cells were modified to include polyethylene glycol adducts (PEGylation). PEGylation of therapeutic proteins, namely colony stimulating factor, interleukin-2, tumor necrosis factor, and interleukin-6, was shown to alter their molecular properties and improve their stability, biological half-life, water solubility, and immunologic characteristics (Charles et al., 2000). Indeed it was shown that PEG modification of tetrameric and monomeric rHu BChE (Chilukuri et al., 2005a, 2005b) did not alter their enzymatic properties but greatly enhanced their circulatory residence time and bioavailability in animals (Table 7.3). Similarly, it was reported that PEGylated Protexia had a pharmacokinetic profile very similar to that of the Hu BChE (Cerasoli et al., 2005b), suggesting that differences in the pharmacokinetics between plasma-derived and recombinant enzymes can be addressed using in vitro posttranslational modifications. Furthermore, efficacy studies with PEGylated Protexia in guinea pigs yielded results that appear to be similar to those described previously with Hu BChE, that is, complete protection against 5.5 3 LD50 of GD or VX. These preliminary results suggest that an effective recombinant stoichiometric bioscavenger that is comparable to the native bioscavenger can be developed. 4.
Improving Efficacy by Mutagenesis
Studies have demonstrated that it is indeed possible to influence the bioscavenging performance of rHu BChE by site-directed mutagenesis. This technique was used to obtain mutant rHu BChEs which possessed an increased affinity for OPs or were more easily reactivated by oximes or possessed a reduced rate of aging. For example, a mutant rHu BChE in which Asp at position 70 located at the peripheral anionic site was mutated to Gly, demonstrated a threefold and eightfold lower rate of aging for paraoxon- and DFP-inhibited mutant BChE, respectively, compared to wild-type enzyme (Masson et al., 1997). Similarly, the mutation of Glu197 to Asp or Gln and Trp82 to Ala resulted in reductions in the rate constants for inactivation with three stereoisomers of GD (Saxena et al., 1998b). The GD-inhibited Glu197Gln and Trp82Ala rHu BChEs also had slower rates of reactivation by 2-PAM as well as lower rates of aging compared to wild-type enzyme. Further attempts were made to design mutations in rHu BChE that would impart OP-hydrolyzing activity to this enzyme. The rationale for the design of these mutations was based on the fact that OP inhibitors are in reality hemisubstrates for these enzymes. Their acylation reaction with enzyme is similar to that of normal substrates, but the subsequent reaction, equivalent to deacylation of the active-site serine, cannot be affected because the amino acid group responsible for dephosphylation is not in the appropriate position (Jarv, 1984; Millard et al., 1995). The perceived solution to this problem was to insert a second catalytic center into the active site specifically to carry out the dephosphylation step of the reaction (Millard et al., 1995). Applying this rationale, a mutant rHu BChE was created in which Gly at position 117 was mutated to His (Lockridge et al., 1997). This mutant enzyme not only hydrolyzed butyrylthiocholine, benzoylcholine, and O-nitrophenyl butyrate but also acquired the ability to hydrolyze OPs including echothiophate, paraoxon, GB, and VX. Wild-type rHu BChE was irreversibly inactivated by echothiophate and paraoxon whereas the Gly117His rHu BChE regained 100% activity within 2–3 min following reaction with these OPs. Recently, it was shown that transgenic mice expressing Gly117His rHu BChE were protected from toxicity due to echothiophate whereas wild-type mice showed severe cholinergic signs of toxicity and died following exposure to the same amount of OP (Wang, 2004). To affect the hydrolysis of rapidly aging nerve agents such as GD it was necessary to inhibit the aging reaction by replacing the carboxyl group (Glu197) adjacent to the active site Ser with an amide group (Millard et al., 1998). Unfortunately, these mutants have catalytic activities that are too slow for practical use, and thus the search for a catalytic bioscavenger continues.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C007 Final Proof page 156 16.11.2007 12:17pm Compositor Name: VAmoudavally
156
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
FIGURE 7.3 Concept of gene therapy.
5.
Gene Therapy
An alternate approach to introducing Hu BChE in circulation is via gene therapy. Gene therapy involves the introduction of genetic material such as the gene for Hu BChE into cells for therapeutic purposes. Today, the hope is that gene therapy will be the ultimate method of protein delivery in which the delivered gene enters the body’s cells and turns them into small factories to produce the therapeutic protein for prolonged periods (Figure 7.3). Technologies for gene introduction have advanced significantly over the past 30 years since the introduction of DEAE-dextran and calcium phosphate coprecipitation methods. Gene-delivery techniques can be categorized into viral and nonviral methods. Viral methods use genetically engineered retroviruses, adenoviruses, adenoassociated viruses (AAV), and other viruses that have been optimized for facilitated gene transfer procedures. Nonviral methods make use of cationic lipids, polymers, targeting proteins, as well as mechanical methods such as electroporation. Both methods have advantages and disadvantages, strengths and weaknesses, making them rapidly advancing fields of biotechnology with great promise for treating inherited and acquired diseases. So far, only viral methods to introduce genes for stoichiometric and catalytic bioscavengers have been attempted. Recombinant adenoviruses containing genes for Hu PON1 when administered into mice 4 days prior to pesticide challenge, boosted PON1 levels in blood and significantly prevented inactivation of brain AChE (Cowan et al., 2001). Recently, Li et al. (2006) showed that introduction of AAV containing Hu AChE gene into AChE knockout mice, resulted in the expression of AChE in liver, lung, and heart for several months and protected mice from DFP toxicity. The gene therapy approach was also tested using a double mutant Ala328Trp=Tyr332Ala rHu BChE with enhanced cocaine hydrolase activity for protection against cocaine toxicity in rats. Adenoviral vectors containing this mutant enzyme when administered into rats shortened the half-life of cocaine and blunted cardiovascular effects (Gao et al., 2004). These preliminary studies suggest that gene therapy can be a method of choice for introducing catalytic and stoichiometric bioscavengers in vivo. However, this method cannot be applied in its present form because of the toxicity and immunogenicity associated with it, as reported in recent clinical trials against cancer and enzyme deficiency diseases.
C. CATALYTIC BIOSCAVENGERS 1.
Enhancing Activity of Stoichiometric Bioscavengers
The stoichiometric scavengers are extremely efficient in providing protection against all OP nerve agents. However, due to their high molecular weight, relatively large amounts of enzymes are
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C007 Final Proof page 157 16.11.2007 12:17pm Compositor Name: VAmoudavally
Novel Approaches to Medical Protection against Chemical Warfare Nerve Agents
157
required to neutralize smaller amounts of nerve agents. Caranto et al. (1994) demonstrated that the catalytic activity of OP-inhibited AChE could be rapidly and continuously restored in the presence of an appropriate oxime. The improved detoxification of OP compounds by AChE in combination with an oxime was also demonstrated in vivo. For example, the therapeutic addition of HI-6 following pretreatment of mice with FBS (fetal bovine serum) AChE endowed pseudocatalytic properties to this stoichiometric scavenger, such that the ratio of GB neutralized per FBS AChE molecule increased from 1:1 to ~65:1. Unfortunately, recent studies indicate that none of the existing oximes were efficient in reactivating OP-inhibited Hu BChE (Saxena et al., 2000; Luo et al., 2004). Therefore, efforts were expanded to identify a catalytic enzyme capable of hydrolyzing OP nerve agents. The advantages of such a molecule would be twofold: (1) smaller quantities of the same high molecular weight catalytic bioscavenger would potentially produce the same or greater extent of protection and (2) because it would not be inactivated in the process of detoxifying the nerve agent, it would be available to provide protection against prolonged exposures to OPs. 2.
Sources of OP Hydrolases
Enzymes from a variety of sources were examined for their ability to degrade OPs: (1) bacterial OPAH or phosphotriesterase from Pseudomonas diminuta or Flavobacterium sp. exhibited hydrolytic activity toward various nerve agents (Dumas et al., 1990), (2) organophosphorus acid anhydrolase or OPAA from Alteromonas haloplanktis was shown to hydrolyze GD, DFP, and GF (DeFrank et al., 1993), (3) squid DFPase from Loligo vulgaris hydrolyzed DFP and other OPs (Scharff et al., 2001), and (4) PON1 from human and other mammalian plasma (Gan et al., 1991; Masson et al., 1998; Tuovinen et al., 1999; Josse et al., 1999, 2001). Some of these enzymes were also shown to function as catalytic bioscavengers in vivo. For example, recombinant OPAH from P. diminuta was shown to protect mice against behavioral side effects and lethality due to GD (Broomfield et al., 1993). Similarly, pretreatment alone with OPAH purified from Pseudomonas sp. was shown to protect mice from lethality due to paraoxon, diethylfluorophosphate, and GA (Ashani et al., 1991b; Raveh et al., 1992). Most of these enzymes possess short circulation times in vivo and they have neither the ability to hydrolyze all known toxic OPs nor the high turnover required to dispose off the OPs from blood in one circulation time. In addition, these bacterial enzymes are likely to initiate potent immune responses in humans; therefore, they are not suitable for repeated use in humans. Hu PON1, on the other hand, has the potential for providing protection without the complication of inducing an immune response. PON 1 is a member of a multienzyme family (PON1, PON2, and PON3) that possess 60%–70% DNA identity. They are calcium-dependent enzymes that hydrolyze a broad variety of esters and lactones (Billecke et al., 2000; Jakubowski, 2000; Aharoni et al., 2004). PONs are also able to hydrolyze various OPs, including several nerve agents (Davis et al., 1996), although at much lower rates. PON1 is involved in drug metabolism and is used in drug inactivation. PON1 and PON3 appear to be associated with HDL. In vitro assays show that PON1 inhibits the oxidation of lipids in low-density lipoprotein, thereby reducing the level of oxidized lipids involved in the initiation and progression of atherosclerosis (Aviram et al., 1998; Biggadike et al., 2000; Lusis, 2000; Ahmed et al., 2001). The level of PON1 in blood and its catalytic efficiency appear to have a major impact on the individual’s susceptibility to pollutants, OPs, and atherosclerosis (Lusis, 2000). However, this enzyme does not possess the desired catalytic activity at a rate that is fast enough for use as a catalytic bioscavenger. Since the agent must be cleared from the bloodstream within one circulation time (Broomfield et al., 1991), a functional catalytic scavenger must have both a lower Km and a high kcat. Therefore, Hu PON1 is currently being subjected to mutation in efforts to generate faster catalytic anti-nerve agent enzymes. Since OPs are ‘‘accidental’’ substrates for PON (Masson et al., 1998), it is likely that improvement in activity can be realized through protein engineering.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C007 Final Proof page 158 16.11.2007 12:17pm Compositor Name: VAmoudavally
158
3.
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Evolving Mammalian Paraoxonases
The two major difficulties in designing appropriate site-directed mutations in Hu PON1 were the lack of knowledge on the residues at the active site and its three-dimensional structure. Based both on site-directed mutations of amino acids believed to be at or near the active site of Hu PON1 and on limited sequence homology with squid DFPase, Josse et al. (1999, 2001) proposed that the enzyme had the shape of a sixfold beta propeller. Subsequently, Yeung et al. (2004, 2005) used this homology-built model to conduct site-directed mutagenesis studies to identify and ‘‘map’’ amino acid residues critical for binding and hydrolysis of substrate. The x-ray crystal structure of a mouse–rat–rabbit–human chimera of PON1 obtained through gene shuffling experiments and expressed in Escherichia coli (Aharoni et al., 2004) was obtained and shown to be a sixfold beta propeller (Harel et al., 2004). The successful expression of a functionally active PON1 in a bacterial expression system paved the way for designing a recombinant version of a naturally occurring mammalian enzyme that is capable of being developed as a catalytic biological scavenger to protect against nerve agent poisoning. More recently, Amitai et al. (2006) assessed the ability of various OP hydrolases obtained by directed evolution and expressed in E. coli to catalytically scavenge toxic OP nerve agents. Nine directly evolved PON1 variants were tested for detoxification of GF, GD, and other toxic OPs. GF detoxification was 10-fold faster with PON1 mutants Val346Ala and Leu69Val compared to wildtype enzyme. Val346Ala mutant also exhibited four-, seven, and ninefold faster rates of hydrolysis for DFP, cloropyrophos-oxon, and GD, respectively. This study identified three key positions in PON1 structure that affect OP hydrolysis, Leu69, Val346, and His115 and several amino acid replacements that significantly enhance the hydrolysis of toxic OPs. It also indicated that PON1 was less active toward the more toxic optical isomers of GF, GB, and O-isopropyl-O-(p-nitrophenyl) methyl phosphonate. Therefore, variants of PON1 evolved in E. coli, although much improved over the wild-type enzyme, do not possess the desired catalytic activity at a rate that is fast enough for use as nerve agent antidotes. Also, the effect of multiple catalytic activities against other substrates (e.g., lactones, fatty acids) on the health of the individual receiving this enzyme will have to be properly evaluated. In addition, the enzyme derived from E. coli will certainly produce an immune reaction in humans and will have poor retention time. Therefore, research efforts should continue toward creating such an enzyme by specific mutation of Hu PON1 and searching for other appropriate catalytic enzymes from a human source.
D. EXTRAPOLATION
OF
ANIMAL DATA
TO
HUMANS
The exogenous administration of FBS AChE (Ashani et al., 1991a; Maxwell et al., 1992), Eq BChE (Broomfield et al., 1991), and Hu BChE (Ashani et al., 1991a; Raveh et al., 1993, 1997; Saxena et al., 2006) were successfully used as a prophylactic measure in mice, rats, guinea pigs, minipigs, and nonhuman promates to protect against several OPs. The animals were pretreated with one of these enzymes delivered by either i.v. or i.m. injection and challenged with multiple doses of OPs. The animals not only survived the multiple lethal doses of OP exposure but did not show any postexposure toxicity usually observed after multiple drug treatment. The examination of enzyme activity data from these investigations demonstrated that in all cases the decrease in molar concentration of circulating enzyme was proportional to the molar concentration of the given OP challenge. This was true until most of the enzyme (>75%–90%) was inhibited by the administered OP, regardless of the routes of administration of the enzyme or OP. Thus, the protection conferred after sequential exposure to OP could be predicted in all species of animals. The efficacy of ChEs as antidote is dependent on their rate of OP detoxification and their availability in blood circulation. Protection with ChEs is therefore independent of the test species as long as sequestration takes place in circulation before the OP reaches the physiological target sites (Ashani et al., 1998). The ex vivo titration of AChE and BChE with various OPs in the fresh human and animal blood provided the amounts of these enzymes available for sequestration of OPs. In addition, Ashani and Pistinner (2004) spiked human blood with Hu BChE and titrated it with
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C007 Final Proof page 159 16.11.2007 12:17pm Compositor Name: VAmoudavally
Novel Approaches to Medical Protection against Chemical Warfare Nerve Agents
159
GB, GD, and VX to determine the in vitro mass balance of these OPs. They developed a mathematically based toxicokinetic model for the estimation of the upper limit of Hu BChE dose required for protection against OP toxicity. The model addressed the relationship between the Hu BChE dose needed to maintain 30% of residual red blood cell (RBC) AChE activity and other parameters (level and duration of OP exposure, bimolecular rate constants of inhibition of Hu AChE and Hu BChE by OPs, and time elapsed from enzyme administration). They validated the Hu BChE dose by in vitro experiments and data from published human studies (Ashani et al., 1998; Ashani and Pistinner, 2004). The proposed model suggested that the upper limit doses of 134, 115, and 249 mg=kg of Hu BChE were sufficient to protect RBC AChE above 30% following a challenge with 1 3 LD50 of VX, GD, and GB, respectively. Allon et al. (1998) observed that in guinea pigs pretreated with Hu BChE and exposed to GD vapor, only one-fourth of the enzyme was used for the sequestration of 2 3 LD50 of GD. Recently, Saxena et al. (2006) observed a similar sequestration of GB vapor in the Göttingen minipig. These results indicate that ~200 mg of Hu BChE may be sufficient to protect humans against an exposure of 2 3 LD50 or more of GD.
III. OXIME-BASED THERAPY A. IN VITRO EVALUATION
OF
OXIME REACTIVATION
As mentioned earlier, conventional oxime-based therapy for nerve agent poisoning consists of a muscarinic antagonist such as atropine, an anticonvulsant such as diazepam, and an oxime reactivator such as 2-PAM. The effectiveness of this antidotal regimen is highly dependent on the oxime, which is responsible for the reactivation of OP-inhibited AChE. The reactivation of AChE activity restores the normal function of the cholinergic system and reverses the chain reaction that follows nerve agent poisoning. The in vivo screenings of oximes are conducted in animal models and results from are extrapolated to humans. Since the in vivo efficacy of an oxime depends on its pharmacokinetic and pharmacological properties, the potency of a nerve agent in inhibiting different AChEs, and the presence of endogenous bioscavengers, the results of in vivo screening are highly dependent on the animal model used. To allow a reasonable animal to human extrapolation of experimental results, in vitro comparisons of reactivation of nerve agent inhibited animal and human AChEs by oxime are conducted. The advantages of this method are several-fold. First, kinetic measurements of oxime reactivation yield multiple parameters, such as oxime affinity and oxime reactivity, that can be used to design better oximes. Second, the interaction of an oxime with the pharmacological target (i.e., AChE) is not influenced by its pharmacokinetics and can be more precisely analyzed. Third, AChE reactivation is a more sensitive measure of oxime effectiveness than in vivo survival because the background signal (i.e., AChE activity) for reactivation is much lower than the background signal (i.e., agent LD50) for in vivo efficacy in animals. Although this simplified in vitro evaluation does not consider other factors that affect in vivo antidotal efficacy, several investigations have demonstrated that there is a reasonable correlation between in vitro and in vivo data, and the efficacy of an oxime primarily depends on its ability to reactivate nerve agent inhibited AChE (Oldiges and Schoene, 1970; Schoene and Oldiges, 1973; Schoene, 1980). If the in vitro oxime reactivation of nerve agent inhibited animal AChE is similar to that of human AChE, it is likely that the results of in vivo animal study will reliably extrapolate to humans. Due to the high degree of homology between the amino acid sequences of different AChEs and the similarity in their active sites, the enzymes generally show similarity in their interaction with substrates and inhibitors. However, the reactivation of nerve agent inhibited AChE by oxime is more sensitive to subtle changes in the conformation of the enzyme. In the early 1980s, it was shown that although the reactivation of nerve agent inhibited human erythrocyte AChE by different oximes was similar to rat and bovine AChEs, the reactivation of GD-inhibited electric eel AChE by HI-6 was markedly slower than that of Hu AChE (de Jong and Wolring, 1984). Therefore, the
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C007 Final Proof page 160 16.11.2007 12:17pm Compositor Name: VAmoudavally
160
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
TABLE 7.4 Second-Order Reactivation Rate Constants (mM1 min1) of Nerve Agent-Inhibited Human and Guinea Pig Erythrocyte AChEs by Different Oximes Hu AChE Oxime Obidoxime 2-PAM HI-6 HLo-7
Guinea Pig AChE
GB
VX
GF
GB
VX
GF
29.98 9.06 13.5 35.08
32.63 7.67 20.98 63.16
0.42 0.06 27.55 92.75
14.18 2.70 0.33 3.91
12.51 3.34 0.14 3.63
0.06 0.03 0.19 0.63
Source: Data from Worek, F. et al., Biochem. Pharmacol., 68, 2237, 2004.
authors concluded that electric eel AChE was not a suitable model for conducting in vitro oxime evaluations. However, studies using different mammalian AChEs or AChEs from various tissues of the same species have shown similar behavior in oxime reactivation of nerve agent inhibited AChE. For example, AChEs purified from human brain and muscle did not show significant differences in the reactivation of nerve agent inhibited enzyme by HI-6, obidoxime, and 2-PAM (Puu et al., 1986). Similarly, de Jong and Wolring (1985) reported that GD-inhibited AChEs from three different mouse tissues displayed very similar reactivation and aging properties. However, two recent studies revealed significant species-related differences between the reactivation of nerve agent inhibited guinea pig and Hu AChEs. Using erythrocyte ghosts, Worek et al. (2002) showed that the reactivation rates of GB-, VX-, and GF-inhibited Hu AChE were always faster than that of guinea pig AChE, and in some cases the rate constants were well over 100-fold for Hu AChE compared with those for guinea pig AChE (Table 7.4). More recently, studies with purified recombinant Hu AChE and guinea pig erythrocyte AChE demonstrated that reactivation rates of human enzyme inhibited by nerve agents containing bulky side chains such as GD, GF, and VR by HI-6 and HLo-7, were 100- to 400-fold faster than those for guinea pig enzyme. This species-related difference was significantly reduced when monopyridinium oxime 2-PAM was used as a reactivator (Table 7.5). The results of these two studies suggest that TABLE 7.5 Second-Order Reactivation Rate Constants (M1 min1) of Nerve Agent-Inhibited AChEs by Oximes AChE
Oxime
GD
GF
VR
Guinea piga
2-PAM HI-6 HLo-7 2-PAM HI-6 HLo-7 2-PAM HI-6 HLo-7
17 51 139 55 19,610 NDb 51 21,506 26,180
7 133 195 26 26,843 23,767 28 29,700 85,060
17 81 243 130 64,406 98,814 252 19,580 43,800
Rhesus monkey
Humana
Source: Data for guinea pig and human AChEs from Luo et al. (2006a). a b
kR values were determined at 258C in 50 mM sodium phosphate buffer, pH 8.0. ND Not determined
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C007 Final Proof page 161 16.11.2007 12:17pm Compositor Name: VAmoudavally
Novel Approaches to Medical Protection against Chemical Warfare Nerve Agents
161
guinea pig is not a suitable model for the in vivo evaluation of oximes. However, because the oxime-induced reactivation of nerve agent inhibited Hu AChE is faster than guinea pig AChE, if an oxime is effective in guinea pigs, it is likely to be effective in humans. Another valuable animal model that is used for evaluating nerve agent toxicity and oxime efficacy are nonhuman primates such as monkeys. However, no direct comparison was made on the oxime reactivation of nerve agent inhibited monkey and Hu AChEs. Reactivation studies using rhesus monkey erythrocyte ghost AChE showed much smaller species-related differences between the oxime reactivation of nerve agent inhibited monkey and Hu AChEs than those found between guinea pig and Hu AChEs. The second-order rate constants for the reactivation of monkey AChEs by all three oximes were within four-fold of that of Hu AChE (Table 7.5). These results suggest that monkeys are a suitable animal model for evaluating the efficacy of oximes against nerve agent poisoning.
B. IN VIVO EVALUATION
OF
OXIMES
Many of the oximes that are currently being evaluated as candidates for clinical use against nerve agents were originally identified by in vivo screening in rodents. For example, Hagedorn et al. (1978) performed in vivo screening of hundreds of oximes against nerve agents to identify compounds, such as HI-6 and HLo7, that were worthy of advanced research and development. However, in recent years in vivo screening has not identified oximes that are further improvements on these oximes (Aas, 2003). There are several issues that probably contribute to the declining effectiveness of in vivo screening as a method to identify improved oxime candidates. First, animals such as mice are rather insensitive to small improvements in oxime efficacy because they have high baseline LD50 values for nerve agents against which small increases in agent LD50 values resulting from oxime therapy are difficult to demonstrate. High LD50 values for nerve agents in mice are due to high levels of CaE in blood that produces LD50 values that are 10-fold higher than those in nonhuman primates, which do not contain this endogenous scavenger in their blood (Maxwell and Brecht, 1991). Second, the in vivo efficacy of an oxime is a result of the combined effect of itsz pharmacological effect and pharmacokinetics. An oxime that produced an improvement in pharmacological effect but had poor pharmacokinetics would probably not be identified by in vivo screening. Third, the only pharmacological effect that is evaluated by in vivo screening is an increase in survival whether it is due to increased affinity for a pharmacological target or increased reactivity with that target. As a result of these issues, the initial screening of oximes to identify improvements has been shifting to in vitro screening of the ability of oximes to reactivate nerve agent inhibited AChE (Kuca et al., 2005). Although the aforementioned problems with in vivo screening methodology have in recent years slowed the identification of new oximes with improved efficacy against nerve agents, other advances have improved the potential for licensure of improved oximes once they are identified. Since nerve agents cannot be administered to humans due to ethical prohibitions, drugs used to treat nerve agent poisoning are approved by the U.S. Food and Drug Administration (FDA) under a regulatory mechanism known as the ‘‘animal rule.’’ Two critical requirements of the FDA animal rule are the demonstration of drug efficacy in multiple animal species and the identification of the mechanism of action of the proposed drug to allow extrapolation of drug efficacy from animals to humans. A recent advance in the identification of the mechanism of action of oximes has been the demonstration of a high correlation between in vitro oxime reactivation of nerve agent inhibited AChE and in vivo efficacy (Maxwell et al., 2006). The in vivo efficacy of 2-PAM and obidoxime against several nerve agents in guinea pigs was expressed as protective ratios (i.e., agent LD50 in oxime-treated group=agent LD50 in control group). In vitro oxime reactivation of AChE inhibited by these nerve agents was expressed as reactivation rate constants. Because variation in atropine dose can have a significant effect on in vivo oxime efficacy, the dose of atropine used in these animals was
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C007 Final Proof page 162 16.11.2007 12:17pm Compositor Name: VAmoudavally
162
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Log10 (PR-1)
2
1
0 −3
−2
−1
0
Log10 (kR (Oxime))
FIGURE 7.4 Regression analysis of in vitro oxime reactivation and in vivo oxime efficacy in guinea pigs. (Data from Maxwell, D.M. et al., Arch. Toxicol., 80, 756, 2006.)
held constant but the dose of oxime was varied. The variation in the dose of oxime was normalized by using the product of the oxime reactivation rate constant (kR) and the dose of oxime administered to guinea pigs. A regression analysis of the relationship between the in vivo protective ratio (PR) of oximes at different doses and their in vitro (kR) is shown in Figure 7.4. Efficacy of oximes against VX, GB, and GF was expressed as PR-1 because a PR of 1 denotes an absence of oxime protection, and oxime reactivation was expressed as kR(Oxime). Regression analysis showed that PR-1 was proportional to (kR(Oxime))0.56 with r2 ¼ 0.91. This evaluation demonstrated that in vitro oxime reactivation explained 91% of the 23-fold variation in the in vivo efficacy of oximes against nerve agents, which provides a strong argument to regulatory agencies that the mechanism of oxime efficacy is understood well enough to satisfy the requirements of the animal rule. Another recent advance that has strengthened the ability of developers to gain approval of oximes by regulatory agencies is the development of a kinetic method to estimate in vivo efficacy of oximes, providing that the necessary in vitro oxime reactivation kinetic parameters have been determined (Worek et al., 2005). This method is able, for example, to use the kinetic parameters for in vitro oxime reactivation of Hu AChE to calculate the concentration of oxime that is necessary to produce 20% reactivation of inhibited AChE in 5 min in humans. It also allows the theoretical comparison of repetitive versus single injections of oximes to design an optimal drug regimen for nerve agent casualties. This kinetic method was validated with data from pesticide-poisoned patients and simulations were also performed for intravenous and percutaneous nerve agent exposure and intramuscular oxime treatment using published data. This method of estimating the concentration of oxime necessary to produce in vivo efficacy in humans is a significant advance over the previous method of estimating human doses of oximes from doses determined in animal experiments (Sundwall, 1961; Sidell, 1997) because the kinetic parameters for reactivation of animal and Hu AChEs have been found to differ significantly (Worek et al., 2002).
C. DESIGN AND DEVELOPMENT
OF THE
NEXT GENERATION
OF
OXIMES
Since the 1970s, the U.S. Army has fielded the monopyridinium oxime 2-PAM as an antidote for treating nerve agent poisoning. However, the efficacy of 2-PAM is very limited against poisoning by some nerve agents such as GD and GF (Boskovic et al., 1984; de Jong and Kosen, 1985; Lundy et al., 1992; Luo and Liang, 1997; Worek et al., 1998). For this reason, numerous studies in the last several decades have focused on developing improved oximes. The ideal next generation oxime should be able to effectively reactivate AChE inhibited by nerve agents of diverse structures. The
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C007 Final Proof page 163 16.11.2007 12:17pm Compositor Name: VAmoudavally
Novel Approaches to Medical Protection against Chemical Warfare Nerve Agents
163
design and development of a broad-spectrum oxime, however, requires a better understanding of the mechanism of oxime-induced reactivation of AChE. The first study with 2-PAM in the 1950s showed that the interaction of the quaternary pyridinium structure with the anionic site at the active site of AChE was responsible for its increased reactivation potency compared with hydroxylamine. More potent bis-pyridinium oximes such as TMB4 and obidoxime were studied and obidoxime was fielded by most European countries (Moore et al., 1995). Obidoxime is somewhat better than 2-PAM in treating poisoning by these nerve agents, but this 4-position oxime forms a stable phosphoryl oxime that inhibits reactivated AChE, which may limit its use in the treatment of nerve agent and OP pesticide poisoning (Luo et al., 1999; Herkenhoff et al., 2004; Kiderlen et al., 2005). In the 1970s and 1980s, new promising Hagerdorn oximes HI-6 and HLo-7 were synthesized and shown to be the most potent reactivators of GD-inhibited AChE (Hagedorn et al., 1978; de Jong et al., 1989). Despite the rapid aging (dealkylation) of GD-inhibited AChE (de Jong and Wolring, 1984; Talbot et al., 1988; Shafferman et al., 1996; Worek et al., 2004), HI-6 was very effective in protecting GD-poisoned monkeys (Lipp and Dola, 1980; Clement and Erhardt, 1994). In addition, these two oximes are potent reactivators of AChE inhibited by other nerve agents that contain bulky side chains, such as GF and VR. Other bis-pyridinium oximes including obidoxime are significantly less potent reactivators of GF- and VR-inhibited AChE (de Jong et al., 1989; Worek et al., 2002; Luo et al., 2006a). However, a significant limitation for the use these two H-series oximes on the battlefield is their poor stability in aqueous solution (Eyer et al., 1986, 1989). To overcome this problem, countries, like Canada, have fielded an auto-injector containing the powder form of HI-6 (Moore et al., 1995). Another drawback of HI-6 as a nerve agent antidote is its lack of reactivity for GA-inhibited AChE (de Jong et al., 1989). HLo-7 is superior to HI-6 in reactivating GA-inhibited AChE, but the potency is much less than that for AChE inhibited by other nerve agents such as GB, GD, GF, VX, and VR (Eyer et al., 1992; Luo et al., 2006a). Although it has been 30 years since the synthesis of the first H-series oxime HI-6, the mechanism for its potency in reactivating GD-inhibited AChE is still unknown. Also, GA-inhibited AChE is resistant to reactivation by HI-6, but can be reactivated by 4-position oximes including obidoxime, TMB4, HLo-7, and MMB4. Recent site-directed mutagenesis studies showed that the superior reactivation by bis-pyridinium oximes is due to the interaction of the second pyridinium ring with the peripheral anionic site of AChE which facilitates attack by the oxime group (Ashani et al., 1995; Luo et al., 2006a). Mutagenesis studies further indicated that the high reactivation potencies of HI-6 and HLo-7 depend not only on the 4-carboxylamide pyridinium structure, but also on the ether oxygen of the linker. To avoid problems due to the poor stability of HI-6 and HLo-7, the U.S. Army has down selected another oxime candidate, MMB4, to replace the current oxime 2-PAM in the antidotal regimen. MMB4 is a bis-pyridinium bis-oxime with the oxime group at 4-position and a single methylene group linking the two pyridinium rings. MMB4 was shown to be efficacious in protecting animals against GD poisoning (Koplovitz and Stewart, 1992). Its ability to reactivate AChE inhibited by different nerve agents including GB, GD, GF, VX, VR, and GA was demonstrated both in vitro and in vivo (Shih et al., 2004; Luo et al., 2006a). However, with the exception of guinea pig AChE, the reactivation potency of MMB4 for nerve agent inhibited animal and Hu AChEs is significantly lower than that for HI-6 and HLo-7 (Luo et al., 2006a, 2006b). Recently, scientists in the Czech Republic have been actively involved in the development of new oximes as nerve agent antidotes (Kuca et al., 2006). Their most notable effort has been the synthesis of several new oxime candidates for the reactivation of GA-inhibited AChE including K027, K048, K074, and K075. These compounds are comparable or superior to TMB4, in either reactivating GA-inhibited AChE in vitro or protecting animals from GA poisoning (Cabal et al., 2005; Kuca et al., 2005; Cali et al., 2006). They are bis-pyridinium 4-oximes, similar to TMB4, the best previously known reactivator for GA-inhibited AChE. However, these promising oximes are significantly less effective than HI-6 in reactivating AChE inhibited by other nerve agents such as
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C007 Final Proof page 164 16.11.2007 12:17pm Compositor Name: VAmoudavally
164
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
GB, GD, or GF (Kuca et al., 2004, 2006; Kuca et al., 2005). On the other hand, HI-6, as well as its analog ICD-585, failed to reactivate GA-inhibited AChE (Kuca et al., 2004; Luo et al., 2006b), demonstrating the uniqueness of AChE–GA conjugate. This was confirmed by the recent x-ray crystallographic study of GA-inhibited mouse AChE conjugate, which revealed a unique repositioning of two amino acids (Phe338 and His447) in the active center of the enzyme conjugate (Ekstrom et al., 2006a). x-Ray crystallography was also used to study the interaction of oximes with AChE. The x-ray crystal structures of Mo AChE with different oximes revealed differences in the binding of oximes both at the active and the peripheral anionic site of the enzyme, which may be responsible for the observed differences in the ability of these oximes to reactivate GA–AChE conjugates (Ekstrom et al., 2006b). Further studies on the interactions between different oximes and the amino acid residues at the active and peripheral anionic site of AChE using site-directed mutagenesis and x-ray crystallographic techniques should be continued to uncover important information on the reactivation of nerve agent inhibited AChE by oximes and aid the design and development of the next generation of oximes.
IV. CENTRALLY ACTING PRETREATMENT DRUGS Another approach used to protect against OP toxicity is to pretreat with low, nonlethal doses of reversible AChE inhibitors. These agents act by transiently binding to a fraction of AChE and protecting it from inhibition by OP nerve agents. Indeed it was shown that pretreatment with pyridostigmine, a quaternary carbamate inhibitor of both AChE and BChE in conjunction with postexposure therapy with oxime and atropine, increased survivability of guinea pigs (Leadbeater et al., 1985) as well as nonhuman primates (Dirnhuber et al., 1979) from multiple LD50s of GD. Therefore, pyridostigmine was given to many soldiers during the Persian Gulf War (Keller, 2006) and subsequently approved by the U.S. FDA for use by military personnel who are under threat of exposure to GD. However, because pydridostigmine does not cross the blood–brain barrier, it does not prevent CNS impairment. Therefore, the use of reversible inhibitors of AChE that are capable of crossing the blood–brain barrier and potentially protecting against the CNS effects of OP nerve agents were considered (Leadbeater et al., 1985). Pretreatment with the tertiary carbamate physostigmine was shown to protect mice and guinea pigs from the incapacitating effect of OP exposure (Deshpande et al., 1986; Lim et al., 1988, 1991; Anderson et al., 1991; Harris et al., 1991; Miller et al., 1993; Meshulam et al., 1995; Lallement et al., 2001a). Because physostigmine readily enters the brain, it was shown to afford protection to both peripheral and central AChEs. However, AChE inhibition in the CNS by physostigmine raised concerns of unwanted centrally mediated side effects. These side effects could be partly compensated through the combinatory use of physostigmine with trihexyphenidyl (Artane) or scopolamine, a centrally acting antimuscarinic drug, to counteract the accumulation of brain ACh due to AChE inhibition in the CNS (Lim et al., 1988; Meshulam et al., 1995; Philippens et al., 2000). Thus, pretreatment with physostigmine and scopolamine or physostigmine and trihexyphenidyl not only provided complete protection to nonhuman primates from lethality of GD, but also prevented convulsions and loss of consciousness (von Bredow et al., 1991). In addition, centrally active physostigmine was more effective than pydridostigmine in protecting from toxicity due to GD, GB, and other OP compounds (Leadbeater et al., 1985; Solana et al., 1990; Miller et al., 1993). Although physostigmine appears to be an effective pretreatment for OP nerve agent toxicity, there are several problems with its use: (1) it has a short half-life in vivo and (2) it has severe side effects, including nausea, vomiting, and diarrhea (Coehlo and Birks, 2001). Over the past decade, several reversible centrally acting AChE inhibitors including donepezil, rivastigmine, metrifonate, galanthamine, and huperzine A (HUP) were developed for the treatment of Alzheimer’s disease. These inhibitors have great potential as pretreatments and treatments to counteract the toxicity of OP nerve agents. The efficacy of various pretreatments such as
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C007 Final Proof page 165 16.11.2007 12:17pm Compositor Name: VAmoudavally
Novel Approaches to Medical Protection against Chemical Warfare Nerve Agents
165
pyridostigmine, physostigmine, physostigmine þ scopolamine, and HUP were compared against GD toxicity (Lim et al., 1998; Lallement et al., 2001b). Surprisingly, the measurement of peripheral and central ChE activities indicated that HUP but not physostigmine inhibited central AChE. These pretreatments did not increase tolerance to cumulative GD poisoning, but delayed death from 30 min to 8–24 h after the last GD injection. Subsequently, HUP was demonstrated to protect mice, monkeys (Grunwald et al., 1994), and guinea pigs (Lallement et al., 1997) against nerve agent toxicity by pretreatment of animals prior to challenge with GD. A protective ratio of 2.0 was obtained 6 h after pretreatment of monkeys with HUP, with no postchallenge supporting therapy. In guinea pigs, pretreatment with HUP was shown to prevent seizures and neuropathological damage to the hippocampus following exposure to GD. These studies highlighted the superiority of HUP as an antidote against nerve agent toxicity compared to pyridostigmine and physostigmine in as much as the duration of protection conferred following a single dose administration of the prophylactic drug. Recently, Janowsky et al. (2005) showed that pretreatment with donepezil significantly attenuated the hyperthermia, hypoactivity, and diarrhea in rats that were exposed to DFP. Similarly, Albuquerque et al., (2006) demonstrated that another centrally acting AChE reversible inhibitor, galanthamine, was far more effective than pyridostigmine when combined with atropine and less toxic than HUP when administered before or soon after acute exposure to lethal doses of GD, GB, and paraoxon. Taken together, these studies suggest that these and other CNS acting reversible AChE inhibitors can be developed as drugs for treating OP nerve agent toxicity.
V. SUMMARY Over the last 5 years, unprecedented progress was made in the development of an enzyme bioscavenger to protect against chemical warfare nerve agents. The main objective of developing an enzyme bioscavenger was to sequester the nerve agent before it reached its physiological target, the CNS AChE. This has to be accomplished within one circulation time and Hu BChE has been proven to perform this task. Hu BChE will be advanced to phase 1a clinical trials in the very near future. It is an ideal pretreatment that is: (1) safe because it is derived from a human source and (2) efficacious because its effectiveness was demonstrated in a variety of animal species against almost all OPs. Its stockpiling is not an issue because it was shown to be stable in lyophilized form for more than 3 years. Many alternate approaches were attempted to acquire sufficient quantities of the enzyme. Recombinant Hu BChE was produced in the milk of transgenic goats, plants, algae, and mammalian cell lines. Of these, material derived from transgenic goat milk, namely Protexia has advanced more rapidly. However, further studies need to be done with this material for making it safe for human use. The presence of potentially immunoreactive glycans on this molecule needs to be thoroughly addressed. Also the lower MRT of Protexia compared to Hu BChE will have to be addressed before it can be used as an efficient bioscavenger. In this regard, PEGylation of select lysines on the surface of rHu BChE appears to increase its MRT although this chemical modification may not eliminate its immunoreactivity. Another alternative is the search or development of a catalytic scavenger. Several OP hydrolases were identified that have the potential to catalytically hydrolyze OPs. Most of them are of bacterial source, and thus are not suitable for human use. Also, efforts were extended to explore the utility of Hu PON1 as a scavenger that can hydrolyze OPs at a rate that is sufficient to prevent them from reaching the CNS. With the application of gene shuffling technology, much progress was made in this regard; however, the search for the right enzyme that has a broad specificity to hydrolyze OPs in humans will have to be continued. A promising advance was made with the application of gene therapy for introducing catalytic and stoichiometric bioscavengers in vivo. It was shown that recombinant adenoviruses containing genes for Hu PON1 when administered into mice boosted PON1 levels in blood. Similarly, the
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C007 Final Proof page 166 16.11.2007 12:17pm Compositor Name: VAmoudavally
166
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
introduction of AAV containing Hu AChE gene into AChE knockout mice resulted in the expression of AChE in liver, lung, and heart for several months and protected mice from DFP toxicity. The gene therapy approach was also tested with a double mutant Ala328Trp=Tyr332Ala rHu BChE with enhanced cocaine hydrolase activity for protection against cocaine toxicity in rats. These preliminary studies suggest that viral vectors can be used for the delivery of bioscavengers in vivo. However, this method is not applicable in its present form because of the toxicity and immunogenicity associated with these vectors. In addition to investigations on bioscavengers as pretreatment drugs, efforts were also focused on developing broad-spectrum oximes for the treatment of OP nerve agent poisoning. Recent efforts at developing new and improved oximes employed in vitro evaluation more often than in vivo evaluation. Although this simplified in vitro evaluation does not consider other factors that affect in vivo antidotal efficacy, there is a reasonable correlation between in vitro and in vivo data, and the efficacy of an oxime depends primarily on its ability to reactivate nerve agent inhibited AChE. If the in vitro oxime reactivation of nerve agent inhibited animal AChE is similar to that of Hu AChE, it is likely that the results of in vivo animal study will reliably extrapolate to humans. A comparative in vitro study using guinea pig, monkey, and Hu AChEs, however, indicated that there were significant differences in the reactivation of guinea pig and Hu AChEs. These remarkable species variations were not found between monkey and Hu AChE, indicating that more reliable results on oxime efficacy will be obtained from monkeys than guinea pigs. Recent efforts in developing broad-spectrum oxime have not yet resulted in the identification of an oxime that can reactivate AChE inhibited by all nerve agents at reasonable rates. For example, several bis-pyridinium 4-oximes that were found to be highly effective for the reactivation of GA-inhibited AChE were ineffective in reactivating GD-inhibited AChE. To further our understanding on the interaction between AChE, OPs, and oximes, x-ray crystallographic and sitedirected mutagenesis studies were initiated. These studies revealed the crucial role of peripheral anionic site of AChE in interacting with the second pyridinium structure of HI-6 and HLo-7, which is responsible for the enhanced potency of these oximes. Further studies on the mechanism of oxime reactivation may pave the way for the discovery of more efficient and broad-spectrum nextgeneration oximes for the treatment of nerve agent poisoning. It was also shown that the efficacy of postexposure therapy for OP toxicity could be enhanced by pretreating with low, nonlethal doses of reversible AChE inhibitors. These agents act by transiently binding to a fraction of AChE and protecting it from inhibition by OP nerve agents. Pyridostigmine, a quaternary carbamate, was the first inhibitor approved by the USFDA for use by military personnel who are under threat of exposure to GD. However, because pydridostigmine does not cross the blood–brain barrier, it does not prevent CNS impairment. Therefore, some of the centrally acting AChE inhibitors are being tested as replacements for pyridostigmine. Prominent among the ones that were tested recently are physostigmine, galanthamine, HUP, and donepezil. Although results with galanthamine are encouraging, much more needs to be done before any of these inhibitors can be considered as effective pretreatments.
REFERENCES Aas, P. Future considerations for the medical management of nerve-agent intoxication, Prehospital Disaster Med., 18, 208, 2003. Aharoni, A. et al. Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization, Proc. Natl. Acad. Sci. U.S.A., 101, 482, 2004. Ahmed, Z. et al. Apolipoprotein A-1 promotes the formation of phosphatidylcholine core aldehydes that are hydrolyzed by paraoxonase (PON-1) during high density lipoprotein oxidation with a peroxynitrite donor, J. Biol. Chem., 276, 24473, 2001. Albuquerque, E.X. et al. Effective countermeasure against poisoning by organophosphorus insecticides and nerve agents, Proc. Natl. Acad. Sci. U.S.A., 103, 13220, 2006.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C007 Final Proof page 167 16.11.2007 12:17pm Compositor Name: VAmoudavally
Novel Approaches to Medical Protection against Chemical Warfare Nerve Agents
167
Allon, N. et al. Prophylaxis against soman inhalation toxicity in guinea pigs by pretreatment alone with human serum butyrylcholinesterase, Toxicol. Sci., 43, 121, 1998. Altamirano, C.V. and Lockridge, O. Conserved aromatic residues of the C-terminus of butyrylcholinesterase mediates the association of tetramers, Biochemistry, 38, 13414, 1999. Amitai, G. et al. Enhanced stereoselective hydrolysis of toxic organophosphates by directly evolved variants of mammalian paraoxonase. FEBS J., 273, 1906, 2006. Anderson, D.R. et al. Effects of subacute pretreatment with carbamate together with adjunct pretreatment against nerve agent exposure, Drug Chem. Toxicol., 14, 1, 1991. Ashani, Y. Prospective of human butyrylcholinesterase as a detoxifying antidote and potential regulator of controlled-release drugs, Drug Dev. Res., 50, 298, 2000. Ashani, Y. and Pistinner, S. Estimation of the upper limit of human butyrylcholinesterase dose required for protection against organophosphates toxicity: a mathematically based toxicokinetic model, Toxicol. Sci., 77, 358, 2004. Ashani, Y. et al. Prophylaxis against organophosphate poisoning by an enzyme hydrolyzing organophosphorus compounds in mice, Life Sci., 49, 367, 1991a. Ashani, Y. et al. Butyrylcholinesterase and acetylcholinesterase prophylaxis against soman poisoning in mice, Biochem. Pharmacol., 41, 37, 1991b. Ashani, Y. et al. Amino acid residues controlling reactivation of organophosphonyl conjugates of acetylcholinesterase by mono- and bisquaternary oximes, J. Biol. Chem., 270, 6370, 1995. Ashani, Y. et al. Current capabilities in extrapolating from animal to human the capacity of human butyrylcholinesterase to detoxify organophosphates, in Structure and Function of Cholinesterases and Related Proteins, Doctor, B.P., Quinn D.M., and Taylor, P., Eds., Plenum Press, New York, 255, 1998. Aviram, M. et al. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase, J. Clin. Invest., 101, 1581, 1998. Bajgar, J., Jakl, A. and Hrdina, V. Influence of trimedoxime and atropine on acetylcholinesterase activity in some parts of the brain of mice poisoned by isopropylmethyl phosphonofluoridate, Biochem. Pharmacol., 20, 3230, 1971. Ballantyne, B. and Marrs, T.C. Overview of the biological and clinical aspects of organophosphates and carbamates, in Clinical and Experimental Toxicology of Organophosphates and Carbamates, Ballantyne, B. and Marrs, T.C., Eds., Butterworth, Oxford, England, 1, 1992. Biggadike, H.G. et al. Selective plasma hydrolysis of glucocorticoid gamma-lactones and cyclic carbonates by the enzyme paraoxonase: an ideal plasma inactivation mechanism, J. Med. Chem., 43, 19, 2000. Billecke, S. et al. Human serum paraoxonase (PON 1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters, Drug Metab. Dispos., 28, 1335, 2000. Boskovic, B., Kovacevic, V. and Jovanovic, D. PAM-2 Cl, HI-6, and HGG-12 in soman and tabun poisoning, Fundam. Appl. Toxicol., 4, S106, 1984. Brandeis, R. et al. Prevention of soman-induced cognitive deficits by pretreatment with human butyrylcholinesterase in rats, Pharmacol. Biochem. Behav., 46, 889, 1993. Broomfield, C.A. A purified recombinant organophosphorus acid anhydrase protects mice against soman, Chem. Biol. Interact., 87, 279, 1993. Broomfield, C.A. et al. Protection by butyrylcholinesterase against organophosphorus poisoning in nonhuman primates, J. Pharm. Exp. Ther., 259, 633, 1991. Cabal, J. et al. A comparison of the efficacy of the reactivators of acetylcholinesterase inhibited with tabun, Ceska Slov. Farm., 54, 192, 2005. Cali, M. et al. In vitro and in vivo evaluation of pyridinium oximes: mode of interaction with acetylcholinesterase, effect on tabun- and soman-poisoned mice and their cytotoxicity, Toxicology, 219, 85, 2006. Caranto, G.R. et al. Amplification of the effectiveness of acetylcholinesterase for detoxification of organophosphorus compounds by bis-quaternary oximes, Biochem. Pharmacol., 47, 347, 1994. Cascio, C. et al. The use of serum cholinesterase in severe phosphorus poisoning. Personal experience, Minerva Anestesiol., 54, 337, 1988. Castro, C.A. et al. Behavioral efficacy of diazepam against nerve agent exposure in rhesus monkeys, Pharmacol. Biochem. Behav., 41, 159, 1991. Cerasoli, D.M. et al. In vitro and in vivo characterization of recombinant human butyrylcholinesterase (Protexia) as a potential nerve agent bioscavenger, Chem. Biol. Interact., 157–158, 363, 2005a.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C007 Final Proof page 168 16.11.2007 12:17pm Compositor Name: VAmoudavally
168
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Cerasoli, D.M. et al. Pretreatment with pegylated protexia protects against exposure to the nerve agents VX and soman, presented at Society for Neuroscience meeting, 31, 337, 2005b. Charles, S.A. et al. Improving hepatitis therapy; attaching polyethylene glycol ‘‘tail’’ to interferon for better clinical properties, Mod. Drug Discov., 5, 59, 2000. Chilukuri, N. et al. Polyethylene glycosylation prolongs the circulatory stability of recombinant human butyrylcholinesetrase, Chem. Biol. Interact., 157–158, 115, 2005a. Chilukuri, N. et al. Purification and characterization of recombinant human monomeric butyrylcholinesterase, in Joint Service Scientific Conference on Chemical and Biological Defense Research, Timonium, MD, 2005b. Choudary, P.V., Kamita, S.G. and Maeda, S. Expression of foreign genes in Bombyx mori larvae using baculovirus vectors, Methods Mol. Biol., 39, 243, 1995. Clark, M.G. et al. Effects of physostigmine and human butyrylcholinesterase on acoustic startle reflex and prepulse inhibition in C57BL=6J mice, Pharmacol. Biochem. Behav., 81, 497, 2005. Clement, J.G. and Erhardt, N. In vitro oxime-induced reactivation of various molecular forms of soman-inhibited acetylcholinesterase in striated muscle from rat, monkey and human, Arch. Toxicol., 68, 648, 1994. Coehlo, F. and Birks, J. Physostigmine for Alzheimer’s disease, Cochrane Database Syst. Rev., 2, CD001499, 2001. Cowan, J. et al. Gene therapy to prevent organophosphate intoxication, Toxicol. Appl. Pharmacol., 173, 1, 2001. Dacre, J.C. Toxicology of some anticholinesterases used as chemical warfare agents—a review, in Cholinesterases, Fundamental and Applied Aspects, Brzin, M., Barnard, E.A. and Sket, D., Eds., de Gruyter, Berlin, Germany, 415, 1984. Das, P.K. and Liddell, J. Purification and properties of human serum cholinesterase, Biochem. J., 116, 875, 1970. Davis, H.G. et al. The effect of the human serum paraoxonase polymorphism is reversed with diazooxon, soman and sarin, Nat. Genet., 14, 334, 1996. de Candole, C.A. et al. The failure of respiration in death by anticholinesterase poisoning, Br. J. Pharmacol. Chemother., 6, 466, 1953. de Jong, L.P. and Wolring, G.Z. Stereospecific reactivation by some Hagedorn-oximes of acetylcholinesterases from various species including man, inhibited by soman, Biochem. Pharmacol., 33, 1119, 1984. de Jong, L.P.A. and Kosen, S.P. Stereospecific reactivation of human brain and erythrocyte acetylcholinesterase inhibited by 1,2,2-trimethylpropyl methyl-phosphonofluoridate (soman), Biochim. Biophys. Acta, 830, 345, 1985. de Jong, L.P.A. and Wolring, G.Z. Aging and stereospecific reactivation of mouse erythrocyte and brain acetylcholinesterases inhibited by soman, Biochem. Pharmacol., 34, 142, 1985. de Jong, L.P.A. et al. The bispyridinium-di-oxime HLo-7: a potent reactivator for acetylcholinesterase inhibited by the stereoisomers of tabun and soman, Biochem. Pharmacol., 38, 633, 1989. DeFrank, J.J. et al. Screening of halophilic bacteria and Alteromonas species for organophosphorus hydrolyzing activity, Chem. Biol. Interact., 87, 141, 1993. Deshpande, S.S. et al. Effectiveness of physostigmine as a pretreatment drug for protection of rats from organophosphate poisoning, Fundam. Appl. Toxicol., 6, 566, 1986. Dirnhuber, P. et al. The protection of primates against soman poisoning by pretreatment with pydridostigmine, J. Pharm. Pharmacol., 31, 295, 1979. Doctor, B.P. and Saxena, A. Bioscavengers for the protection of humans against organophosphate toxicity, Chem. Biol. Interact., 157–158, 167, 2005. Dumas, D.P. et al. Inactivation of organophosphorus nerve agents by the phosphotriesterase from Pseudomonas diminuta, Arch. Biochem. Biophys., 277, 155, 1990. Dunn, M.A. and Sidell, F.R. Progress in medical defense against nerve agents, J. Am. Med. Assoc., 262, 649, 1989. Duysen, E.G., Bartels, C.F. and Lockridge, O. Wild-type and A328W mutant human butyrylcholinesterase tetramers expressed in Chinese hamster ovary cells have a 16-hour half-life in the circulation and protect mice from cocaine toxicity, J. Pharmacol. Exp. Ther., 302, 751, 2002. Ekstrom, F. et al. Crystal structures of acetylcholinesterase in complex with HI-6, Ortho-7 and obidoxime: structural basis for differences in the ability to reactivate tabun conjugates, Biochem. Pharmacol., 72, 597, 2006a.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C007 Final Proof page 169 16.11.2007 12:17pm Compositor Name: VAmoudavally
Novel Approaches to Medical Protection against Chemical Warfare Nerve Agents
169
Ekstrom, F. et al. Structural changes of phenyalanine 338 and histidine 447 revealed by the crystal structure of tabun-inhibited murine acetylcholinesterase, Biochemistry, 45, 74, 2006b. Ellman, G.L. et al. A new and rapid colorimetric determination of acetylcholinesterase activity, Biochem. Pharmacol., 7, 88, 1961. Eyer, P. et al. Studies on the decomposition of the oxime HI 6 in aqueous solution, Arch. Toxicol., 59, 266, 1986. Eyer, P. et al. Studies on the stability and decomposition of the Hagedorn-oxime HLo-7 in aqueous solution, Arch. Toxicol., 63, 59, 1989. Eyer, P., Hagedorn, I. and Klimmek, R. HLo-7 dimethanesulfonate, a potent bispyridinium-dioxime against anticholinesterases, Arch. Toxicol., 66, 603, 1992. Fleisher, J.H. and Harris, L.W. Dealkylation as a mechanism for aging of cholinesterase after poisoning with pinacolyl methylphosphonofluoridate, Biochem. Pharmacol., 14, 641, 1965. Gan, K.N. et al. Purification of human serum paraoxonase=arylesterase, Drug. Metab. Dispos., 19, 100, 1991. Gao, Y. et al. Gene transfer of cocaine hydrolase suppresses cardiovascular responses to cocaine in rats, Mol. Pharmacol., 67, 204, 2004. Garcia, G. et al. Human serum butyrylcholinesterase: site-specific glycan analysis, Glycomics, 2004. Cambridge, MA. Garcia, G.E. et al. Glycan structure comparison of native human plasma butyrylcholinesterase (Hu-BChE) and transgenic goat produced Hu-BChE, FASEB J., 19, A867, 2005. Genovese, R.F. and Doctor, B.P. Behavioral and pharmacological assessment of butyrylcholinesterase in rats, Pharmacol. Biochem. Behav., 51, 647, 1995. Genovese, R.F. et al. Evaluation of purified horse serum butyrylcholinesterase in rats, in Proceedings of the Medical Defense Bioscience Review, Baltimore, MD, 3, 1035, 1993. Gentry, M.K., Nuwayser, E.S. and Doctor, B.P. Effects of repeated administration of butyrylcholinresterase on antibody induction in rabbits, in Proceedings of the Medical Defense Bioscience Review, Baltimore, MD, 3, 1051, 1993. Gentry, M.K., Nuwayser, E.S. and Doctor, B.P. Immunological effect of repeated administration of cholinesterases in rabbits, in Proceedings of the Medical Defense Bioscience Review, Baltimore, MD, 1, 183, 1996. Gordon, J.J., Leadbeater, L. and Maidment, M.P. The protection of animals against organophosphorous poisoning by pretreatment with a carbamate, Toxicol. Appl. Pharmacol., 43, 207, 1978. Grunwald, J. et al. Large scale purification and long term stability of human butyrylcholinesterase: a potential bioscavenger drug, J. Biochem. Biophys. Methods, 34, 123, 1997. Grunwald, J. et al. Huperzine A as a pretreatment candidate drug against nerve agent toxicity, Life Sci., 54, 991, 1994. Hagedorn, I., Schoene, K. and Schenkel, H. Reactti-vierung phosphorylierter acetylcholinesterase: insomere bisquartare salze von pyridine-aldoxime Salts, Arzneim Forsch, 28, 2055, 1978. Harel, M. et al. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes, Nat. Struct. Mol. Biol., 11, 412, 2004. Harris, L.W. et al. Physostigmine (alone and together with adjunct) pretreatment against soman, sarin, tabun and VX intoxication, Drug Chem. Toxicol., 14, 265, 1991. Haupt, H. et al. Isolation and physico-chemical characterization of cholinesterase in human serum, Blut, 14, 65, 1966. Heath, A.J.W. and Meredith, T. Atropine in the management of anticholinesterase poisoning, in Clinical and Experimental Toxicology of Organophosphates and Carbamates, Ballantyne B. and Marrs, T.C., Eds., Butterworth, Oxford, 543, 1992. Heffron, P.F. and Hobbinger, F. Relationship between inhibition of acetylcholinesterase and response of the rat phrenic nerve-diaphragm preparation to indirect stimulation at higher frequencies, Br. J. Pharmacol., 66, 323, 1979. Herkenhoff, S. et al. Effect of organophosphorus hydrolysing enzymes on obidoxime-induced reactivation of organophosphate-inhibited human acetylcholinesterase, Arch. Toxicol., 78, 338, 2004. Jakubowski, H. Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation, J. Biol. Chem., 275, 3957, 2000. Janowsky, D.S., Davis, J.M. and Overstreet, D.H. Anticholinesterase (DFP) toxicity antagonism by chronic donepezil: a potential nerve agent treatment, Pharmacol. Biochem. Behav., 81, 917, 2005.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C007 Final Proof page 170 16.11.2007 12:17pm Compositor Name: VAmoudavally
170
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Jarv, S. Stereochemical aspects of cholinesterase catalysis, Bioorg. Chem., 12, 259, 1984. Jenkins, T., Balinsky, D. and Patient, D.W. Cholinesterase in plasma: first reported absence in the Bantu: halflife determination, Science, 156, 1748, 1967. Josse, D. et al. Identification of residues essential for human paraoxonase (PON1) arylesterase=organophosphatase activities, Biochemistry, 38, 2816, 1999. Josse, D. et al. The active site of human paraoxonase (PON1), J. Appl. Toxicol., 21, S7, 2001. Keller, K.J. Overcoming inhibitions, Proc. Natl. Acad. Sci. U.S.A., 103, 13263, 2006. Kiderlen, D., Eyer, P. and Worek, F. Formation and disposition of diethylphosphoryl-obidoxime, a potent anticholinesterase that is hydrolyzed by human paraoxonase (PON1), Biochem. Pharmacol., 69, 1853, 2005. Koelle, G.B. Cholinesterases and anticholinesterases, in Handbuch der Experimentallen Pharmakologie, Vol. XV, Ekhler, O. and Farah, A., Eds., Springer-Verlag, Berlin, Germany, 1963. Koplovitz, I. and Stewart, J.R. Efficacy of oxime plus atropine treatment against soman poisoning in the atropinesterase-free rabbit, Drug Chem. Toxicol., 15, 117, 1992. Kuca, K., Cabal, J. and Kassa, J. A comparison of the efficacy of a bispyridinium oxime–1,4-bis-(2-hydroxyiminomethylpyridinium) butane dibromide and currently used oximes to reactivate sarin, tabun or cyclosarin-inhibited acetylcholinesterase by in vitro methods, Pharmazie, 59, 795, 2004. Kuca, K. et al. Strategy for the development of new acetylcholinesterase reactivators—antidotes used for treatment of nerve agent poisonings, Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub., 149, 429, 2005. Kuca, K., Juna, D. and Musilek, K. Structural requirements of acetylcholinesterase reactivators, Mini Rev. Med. Chem., 6, 269, 2006. Lallement, G. et al. Efficacy of huperzine in preventing soman-induced seizures, neuropathological changes and lethality, Fundam. Clin. Pharmacol., 11, 387, 1997. Lallement, G. et al. Subchronic administration of various pretreatments of nerve gas poisoning II. Compared efficacy against soman toxicity, Drug Chem. Toxicol., 24, 165, 2001a. Lallement, G. et al. Subchronic administration of various pretreatments of nerve agent poisoning. I. Protection of blood and central cholinesterases, innocuousness towards blood–brain barrier permeability, Drug Chem. Toxicol., 24, 151, 2001b. Leadbeater, L., Inns, R.H. and Rylands, J.M. Treatment of soman poisoning, Toxicol. Appl. Pharmacol., 5, S225, 1985. Lenz, D.E. et al. Protection against soman poisoning by human butyrylcholinesterase in guinea pigs and cynomolgus monkeys, Chem-Biol. Interact., 157–158, 205, 2005. Li, B. et al. Protection from the toxicity of diisopropylfluorophosphate by adeno-associated virus expressing acetylcholinesterase, Toxicol. Appl. Pharmacol., 214, 152, 2006. Lim, D.K. et al. Prevention of soman toxicity after the continuous administration of physostigmine, Pharmacol. Biochem. Behav., 31, 482, 1988. Lim, D.K. et al. Trihexyphenidyl enhances physostigmine prophylaxis against poisoning in guinea pigs, Fundam. Appl. Toxicol., 16, 482, 1991. Lipp, J. and Dola, T. Comparison of the efficacy of HS-6 versus HI-6 when combined with atropine, pyridostigmine and clonazepam for soman poisoning in the monkey, Arch. Int. Pharmacodyn. Ther., 246, 138, 1980. Lockridge, O., Eckerson, H.W. and La Du, B.N. Interchain disulfide bonds and subunit organization in human serum cholinesterase, J. Biol. Chem., 254, 8324, 1979. Lockridge, O. et al. Complete amino acid sequence of human serum cholinesterase, J. Biol. Chem., 262, 549, 1987. Lockridge, O. et al. A single amino acid substitution, Gly117His, confers phosphotriesterase (organophosphorus acid anhydride hydrolase) activity on human butyrylcholinesterase, Biochemistry, 36, 786, 1997. Lundy, P.M. et al. Comparison of several oximes against poisoning by soman, tabun and GF, Toxicology, 72, 99, 1992. Luo, C. and Liang, J. Evaluation of combined toxic effects of GB=GF and efficacy of jielin injection against combined poisoning in mice, Toxicol. Lett., 92, 195, 1997. Luo, C. et al. Phosphoryl oxime inhibition of acetylcholinesterase during oxime reactivation is prevented by edrophonium, Biochemistry, 38, 9937, 1999.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C007 Final Proof page 171 16.11.2007 12:17pm Compositor Name: VAmoudavally
Novel Approaches to Medical Protection against Chemical Warfare Nerve Agents
171
Luo, C. et al. Strategy for reactivation of organophosphate-inhibited human butyrylcholinesterase, in Cholinesterases in the Second Millenium: Biomolecular and Pathological Aspects, Inestrosa, N.C. and Campos, E.O., Eds., Diseno e Impresiones J&J Ltda, Chile, 251, 2004. Luo, C. et al. Aging and oxime-induced reactivation of nerve agent-inhibited human and guinea pig acetylcholinesterases, presented at the Bioscience Review, Maryland, USA, 2006a. Luo, C. et al. Development of a broad-spectrum oxime for the treatment of nerve agent toxicity, in Proceedings of the 25th Army Science Conference, Orlando, FL, 2006b. Lusis, A.J. Artherosclerosis, Nature, 407, 233–241, 2000. Masson, P. et al. Importance of aspartate-70 in organophosphate inhibition oxime re-activation and aging of human butyrylcholinesetrase, Biochem. J., 325, 53, 1997. Masson, P. et al. Enzymes hydrolyzing organophosphates as potential catalytic scavengers against organophosphate poisoning, J. Physiol., 92, 357, 1998. Matzke, S.M. et al. Behavioral and immunological effects of exogenous butyrylcholinesterase in rhesus monkeys, Pharmacol. Biochem. Behav., 62, 523, 1999. Maxwell, D.M. and Brecht, K.M. The role of carboxylesterase in species variation of oxime protection against soman, Neurosci. Biobehav. Rev., 15, 135, 1991. Maxwell, D.M. et al. Acetycholinesterase inhibition: does it explain the toxicity of organophosphorus compounds? Arch. Toxicol., 80, 756, 2006. Maxwell, D.M. et al. Protection of rhesus monkeys against soman and prevention of performance decrement by pretreatment with acetylcholinesterase, Toxicol. Appl. Pharmacol., 115, 44, 1992. Maynard, R.L. and Beswick, F.W. Organophosphorus compounds as chemical warfare agents, in Clinical and Experimental Toxicology of Organophosphates and Carbamates, Ballantyne, B. and Marrs, T.C., Eds., Butterworth, Oxford, England, 373, 1992. McTiernan, C. et al. Brain cDNA clone for human cholinesterase, Proc. Natl. Acad. Sci U.S.A., 84, 6682, 1987. Meshulam, Y. et al. Prophylactic transdermal treatment with physostigmine and scopolamine against soman intoxication in guinea-pigs, J. Appl. Toxicol., 15, 263, 1995. Millard, C.B., Lockridge, O. and Broomfield, C.A. Design and expression of organophosphorous acid anhydride hydrolase activity in human butyrylcholinesterase activity, Biochemistry, 34, 15925, 1995. Millard, C.A., Lockridge, O. and Broomfield, C.A. Organophosphorus acid anhydride hydrolase activity in human butyrylcholinesterase: synergy results in a somanase, Biochemistry, 37, 237, 1998. Miller, S.A. et al. Efficacy of physostigmine as a pretreatment for organophosphate poisoning, Pharmacol. Biochem. Behav., 44, 343, 1993. Moore, D.H. et al. Review of nerve agent inhibitors and reactivators of acetylcholinesterase, in Enzymes of the Cholinesterase Family, Quinn, D.M. et al. Eds., Plenum Press, New York, 297, 1995. Mor, T.S. et al. Expression of recombinant human acetylcholinesterase in transgenic tomato plants, Biotechnol. Bioeng., 75, 259, 2001. Myers, T.M. et al. Safety evaluation of human serum butyrylcholinesterase in rhesus monkeys, in Proceedings of the Joint Service Scientific Conference on Chemical and Biological Defense Research, Hunt Valley, MD, 2003. Nicolet Y. et al. Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products, J. Biol. Chem., 278, 41141, 2003. Oldiges, H. and Schoene, K. Pyridinium and imidazolium salts as antidotes for soman and paraoxon poisoning in mice, Archiv fur Toxikologie, 26, 293, 1970. Ostergaard, D. et al. Half-life of plasma cholinesterase, Acta Anaesth. Scand., 32, 266, 1988. Philippens, I.H. et al. Scopolamine augments the efficacy of physostigmine against soman poisoning in guinea pigs, Pharmacol. Biochem. Behav., 65, 175, 2000. Puu, G., Artursson, E. and Bucht, G. Reactivation of nerve agent inhibited human acetylcholinesterases by HI-6 and obidoxime, Biochem. Pharmacol., 35, 1505, 1986. Raveh, L. et al. Acetylcholinesterase prophylaxis against organophosphate poisoning: quantitative correlation between protection and blood-enzyme level in mice, Biochem. Pharmacol., 38, 529, 1989. Raveh, L. et al. Protection against tabun toxicity in mice by prophylaxis with an enzyme hydrolyzing organophosphate esters, Biochem. Pharmacol., 44, 397, 1992. Raveh, L. et al. Human butyrylcholinesterase as a general prophylactic antidote for nerve agent toxicity, Biochem. Pharmacol., 45, 2465, 1993.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C007 Final Proof page 172 16.11.2007 12:17pm Compositor Name: VAmoudavally
172
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Raveh, L. et al. The stoichiometry of protection against soman and VX toxicity in monkeys pretreated with human butyrylcholinesterase, Toxicol. Appl. Pharmacol., 145, 43, 1997. Rosenberg, Y. et al. Pharmacokinetics and immunologic consequences of exposing macaques to purified homologous butyrylcholinesterase, Life Sci., 72,125, 2002. Saxena, A. et al. Role of oligosaccharides in the pharmacokinetics of tissue-derived and genetically engineered cholinesterases, Mol. Pharmacol., 53, 112, 1998a. Saxena, A. et al. The pH dependence of dealkylation in soman-inhibited cholinesterases and their mutants: further evidence for a push-pull mechanism, Biochemistry, 37, 15086, 1998b. Saxena, A. et al. Edrophonium as a reactivator of organophosphate-inhibited human butyrylcholinesterase, presented at the Second Singapore International Symposium on Protection Against Toxic (SISPAT) Substances, Singapore, 4–7 December 2000. Saxena, A. et al. Development of human serum butyrylcholinesterase as a bioscavenger for medical protection against organophosphate chemical warfare agents, in Proceedings of the 4thSingapore International Symposium on Protection Against Toxic Substances, Singapore, 2004. Saxena, A. et al. Human serum butyrylcholinesterase: in vitro and in vivo stability, pharmacokinetics, and safety in mice, Chem. Biol. Interact., 157–158, 199, 2005. Saxena, A. et al. Göttingen minipigs are protected against sarin vapor by human serum butyrylcholinesterase, in Proceedings of the 5thSingapore International Symposium on Protection Against Toxic Substances, Singapore, 2006. Scharff, E.I. et al. Crystal structure of di-isopropylfluorophosphatase from Loligo vulgaris, Structure, 9, 493, 2001. Schoene, K. Pyridinium salts as organophosphate antagonists. Monogr. Neural Sci., 7, 85, 1980. Schoene, K. and Oldiges H. Efficacy of pyridinium salts in tabun and sarin poisoning in vivo and in vitro. Arch. Int. Pharmacodyn. Ther., 204, 110–123, 1973. Shafferman, A. et al. Aging of phosphylated human acetylcholinesterase: catalytic processes mediated by aromatic and polar residues of the active centre, Biochem. J., 318, 833, 1996. Shih, T.M., Kan, R.K. and McDonough, J.H. In vivo reactivation by oximes of nerve agent-inhibited cholinesterase activity in guinea pigs, presented at the Bioscience Review, Hunt Valley, Maryland, 2004. Sidell, F.R. Nerve agents, in Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare, Zajchuk, R. and Bellamy, R.F., Eds., Walter Reed Army Medical Center, Washington, DC, USA: The Office of The Surgeon General, TTM Publications, Bordon, Institute, 129, 1997. Siripornadulsil, S. et al. Molecular mechanisms of proline-mediated tolerance to toxic heavy metals in transgenic microalgae, Plant Cell, 14, 2837, 2002. Solana, R.P. et al. Evaluation of the efficacy of two carbamates, physostigmine and pydridostigmine, when used in conjunction for protection against organophosphate exposure, Fundam. Appl. Toxicol., 15, 814, 1990. Stewart, W.C. The effects of sarin and atropine on the respiratory center and neuromuscular junctions of the rat, Can. J. Biochem. Physiol., 37, 651, 1959. Stewart, W.C. and Anderson, E.A. Effects of a cholinesterase inhibitor when injected into the medulla of the rabbit, J. Pharmacol. Exp. Ther., 162, 309, 1968. Stovner, J. and Stadskleiv, K. Suxamethonium apnea terminated with commercial serum cholinesterase, Acta Anaesth. Scand., 20, 211, 1976. Sun, W. et al. Pharmacokinetics, stability, safety and toxicity of purified human serum butyrylcholinesterase in mice. NATO TG-004 Meeting, 29 Sept-3 Oct 2003, Medicine Hat, Canada. Sun, W. et al. Long term effect of human butyrylcholinesterase pretreatment followed by acute soman challenge in cynomolgus monkeys, in Joint Service Scientific Conference on Chemical and Biological Defense Research, Timonium, MD, 2005. Sun, W. et al. Safety and pharmacokinetics of human serum butyrylcholinesterase in guinea pigs, Chem-Biol. Interact., 157–158, 428, 2005. Sundwall, A. Minimum concentrations of N-methylpyridinium-2-aldoxime methane suphonate (P2S) which reverse neuromuscular block, Biochem. Pharmacol., 8, 413, 1961. Talbot, B.G. et al. A comparison of in vivo and in vitro rates of aging of soman-inhibited erythrocyte acetylcholinesterase in different animal species, Drug Chem. Toxicol., 11, 289, 1988. Taylor, P. Anticholinesterase agents, in The Pharmacological Basis of Therapeutics, Gilman, A.G., Rall, T.W., Nies, A.S. and Taylor, P., Eds., Macmillan, New York, 131, 1990.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C007 Final Proof page 173 16.11.2007 12:17pm Compositor Name: VAmoudavally
Novel Approaches to Medical Protection against Chemical Warfare Nerve Agents
173
Tuovinen, K. et al. Success of pyridostigmine, physostigmine, eptastigmine and phosphotriesterase treatments in acute sarin intoxication, Toxicology, 134, 169, 1999. von Bredow, J. et al. Efficacy evaluation of physostigmine and anticholinergic adjuncts as a pretreatment for nerve agent intoxication, Fundam. Appl. Toxicol., 17, 782, 1991. Wang, Y. Resistance to organophosphorous agent toxicity in transgenic mice expressing G117H mutant of human butyrylcholinesetrase, Toxicol. Appl. Pharmacol., 196, 356, 2004. Wilson, I.B. and Ginsburg, S.A powerful reactivator of alkyl phosphate-inhibited acetylcholinesterase, Biochim. Biophys. Acta., 18, 168, 1955. Worek, F., Eyer, P. and Szinicz, L., Inhibition, reactivation and aging kinetics of cyclohexylmethylphosphonofluoridate-inhibited human cholinesterases, Arch. Toxicol., 72, 580, 1998. Worek, F. et al. Reactivation kinetics of acetylcholinesterase from different species inhibited by highly toxic organophosphates, Arch. Toxicol., 76, 523, 2002. Worek, F. et al. Kinetic analysis of interactions between human acetylcholinesterase, structurally different organophosphorus compounds and oximes, Biochem. Pharmacol., 68, 2237, 2004. Worek, F. et al. Evaluation of oxime efficacy in nerve agent poisoning: development of a kinetic-based dynamic model, Toxicol. Appl. Pharmacol., 209, 193, 2005. Yeung, D.T. et al. Structure=function analyses of human serum paraoxonase (HuPON1) mutants designed from a DFPase-like homology model, Biochim. Biophys. Acta, 1702, 67, 2004. Yeung, D.T., Lenz, D.E. and Cerasoli, D.M., Analysis of active-site amino-acid residues of human serum paraoxonase using competitive substrates, FEBS J., 272, 2225, 2005.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C007 Final Proof page 174 16.11.2007 12:17pm Compositor Name: VAmoudavally
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C008 Final Proof page 175 7.11.2007 6:03pm Compositor Name: JGanesan
Agent Bioscavengers: 8 Nerve Progress in Development of a New Mode of Protection against Organophosphorus Exposure David E. Lenz, Clarence A. Broomfield, David T. Yeung, Patrick Masson, Donald M. Maxwell, and Douglas M. Cerasoli CONTENTS I. Introduction ....................................................................................................................... 176 II. Current Therapy for Nerve Agent Exposure .................................................................... 177 III. Nerve Agent Bioscavengers: An Alternative to Conventional Approaches..................... 177 IV. Stoichiometric Scavengers and the Protection they Offer ................................................ 179 V. Catalytic Bioscavengers .................................................................................................... 185 VI. Behavioral Effects ............................................................................................................. 191 VII. Behavioral Effects of Scavengers Alone .......................................................................... 191 VIII. Summary ........................................................................................................................... 192 References ..................................................................................................................................... 193 Although treatment for intoxication by organophosphorus (OP) poisons exists, the treatment regimen suffers from certain deficiencies. To overcome these disadvantages, the concept of using a bioscavenger has emerged as a new approach to reduce the in vivo toxicity of chemical warfare nerve agents. Bioscavengers fall into two broad categories, stoichiometric, that is, proteins that bind and detoxify a poison in some fixed molecular ratio, and catalytic, that is, proteins that can cause the breakdown of a molecule of a poison, regenerate, and then repeat the process until all of the poison molecules have been destroyed. To be an improvement over current treatment, a biological scavenger should have minimal or no behavioral or physiological side effects, should provide protection against exposure to as much as five LD50s of one or more nerve agents, and should reduce or eliminate any behavioral or physiological side effects normally associated with the currently fielded therapy. Studies with equine or human butyrylcholinesterase or fetal bovine serum acetylcholinesterase showed that none of these scavengers elicited behavioral side effects
The opinion or assertions contained herein are the private views of the authors and are not to be constructed as reflecting the view of the Department of the Army or the Department of Defense.
175
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C008 Final Proof page 176 7.11.2007 6:03pm Compositor Name: JGanesan
176
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
when administered to rats or monkeys. These three scavenger enzymes as well as carboxylesterase were each capable of providing protection against 2–16 LD50s of GD, GB, or VX depending on the scavenger and the test species (rat, mouse, rabbit, guinea pig, or rhesus monkey). When behavioral testing was performed on animals, that is, mouse, rat, or rhesus monkey, pretreated with a bioscavenger, following administration of up to 5 LD50s of GD or VX, either no, or only very minor and transient deficits were reported. These results were in stark contrast to the prolonged, up to 14 days, behavioral incapacitation experienced by animals that were pretreated with pyridostigmine and received the same dose of nerve agent followed by the standard atropine and oxime therapy with or without diazepam. Although several challenges still remain to be met before bioscavengers could augment or replace the current therapeutic regimes for nerve agent intoxication, the results to date offer impressive evidence for the value of this approach as the next generation of pharmaceuticals to afford protection against nerve agent poisoning with a virtual absence of behavioral side effects.
I. INTRODUCTION Organophosphorus anticholinesterases (OPs) are among the most toxic substances that have been identified (Dacre, 1984). Originally, OPs were developed for use as insecticides (Ballantyne and Marrs, 1992), but their extreme toxicity toward higher vertebrates has led to their adoption as weapons of warfare (Maynard and Beswick, 1992). The OPs most commonly used as chemical weapons (referred to as nerve agents), which the U.S. military forces might expect to encounter, are tabun (GA), sarin (GB), soman (GD), cyclosarin (GF), VX, and VX-like compounds such as the Russian V-agent, VR. However, OP pesticides can also be regarded as a potential threat in a terrorist context. The molecular weights of OP nerve agents range from 140 to 267 Da, and under standard conditions they are all liquids that differ in their degrees of volatility (Somani et al., 1992). They have median lethal dose (LD50) values in mammals, including estimates for humans, in the mg=kg dose range for all routes of exposure except dermal, where LD50 doses are in the mg=kg range (Maynard and Beswick, 1992). OPs produce their acute toxic effects by irreversibly inhibiting the enzyme acetylcholinesterase (AChE, E.C. 3.1.1.7) (Koelle, 1963; Taylor, 2001b). This inhibition leads to an increase in the concentration of acetylcholine in the cholinergic synapses of both the peripheral and central nervous systems. Because numerous lines of evidence indicate that the sister enzyme butyrylcholinesterase (BuChE, E.C. 3.1.1.8) plays a functional role in the cholinergic system (Mesulam et al., 2002; Duysen et al., 2007), inhibition of BuChE could also contribute to the increase in concentration of acetylcholine in the cholinergic synapses, including those in the central nervous system. The physiological consequences of elevated acetylcholine include alterations in the function of the respiratory center (de Candole et al., 1953; Stewart, 1959; Stewart and Anderson, 1968; Brimblecombe, 1977) and overstimulation at neuromuscular junctions (Bajgar et al., 1971; Heffron and Hobbiger, 1979; Chabrier and Jacob, 1980). A sufficiently high level of acetylcholine or a sufficiently rapid increase in acetylcholine concentration precipitates a cholinergic crisis, resulting in dimming of vision, headache, shortness of breath, muscle weakness, and seizures. In the extreme, organophosphorus intoxication can be a life-threatening event, with death usually resulting from respiratory failure. This is often accompanied by secondary cardiovascular components, including hypotension, cardiac slowing, and arrhythmias (Taylor, 2001a, 2001b). The time lapse between exposure (except dermal) and significant inhibition of synaptic AChE is very short (one or two circulation times), so therapy must be administered rapidly upon exposure or immediately after onset of symptoms to be effective. This suggests that a prophylactic approach based on the reduction of the concentration of OP toxicant in the blood before it can reach its site of action (synaptic endplates) should be particularly attractive; potentially incapacitating or even fatal exposures could be mitigated to mild symptoms such as salivation or shortness of breath and lower level exposures could be rendered inconsequential.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C008 Final Proof page 177 7.11.2007 6:03pm Compositor Name: JGanesan
Nerve Agent Bioscavengers
177
II. CURRENT THERAPY FOR NERVE AGENT EXPOSURE The conventional approach adopted by the United States and its NATO allies for treatment of OP intoxication seeks to counteract the effects of AChE inhibition and to reactivate the enzyme. Cholinolytic drugs such as atropine are administered at the onset of signs of OP intoxication to antagonize the effects of the elevated acetylcholine levels that result from the inhibition of AChE (Heath and Meredith, 1992). Additionally, an oxime nucleophile is given, which reacts with the inhibited ‘‘phosphylated’ enzyme to displace the phosphyl group and restore normal activity (Heath and Meredith, 1992). In the United States, the oxime of choice for treatment of nerve agent poisoning is the chloride salt of 2-PAM, usually referred to as 2-PAM-Cl. In France, the methylsulfate salt of 2-PAM is recommended and is registered as Contrathion. In the United Kingdom, the sulfate salt of 2-PAM, usually referred to as P2S, is the oxime of choice, although bis-pyridinium oximes may be more effective depending on the particular organophosphorus agent (Bismuth et al., 1992). Anticonvulsant drugs such as diazepam are also administered to control OP-induced tremors, convulsions, and seizures. In conjunction with therapy, individuals at high risk for exposure to the nerve agent GD are pretreated with the spontaneously reactivating AChE inhibitor pyridostigmine bromide (PB), which when used at recommended dosages (which produce less than 30% inhibition of plasma AChE) temporarily masks the active site of some AChE molecules, and thus protects a fraction of the enzyme from irreversible inhibition by the OP agent (Gordon et al., 1978). These treatment regimens, with minor variations, have been the standard in the United States and in NATO countries for many years; although beneficial, they suffer from a number of disadvantages. Although current approaches can be effective in preventing lethality, they do not prevent performance deficits, behavioral incapacitation, loss of consciousness, or the potential for permanent brain damage, all of which can result from acute OP toxicity (Leadbeater et al., 1985). Furthermore, it appears that greater than marginal improvement of these pharmacological approaches will be difficult because stronger drugs or higher doses of currently fielded drugs are likely to produce unacceptable performance decrements by themselves (Dunn and Sidell, 1989; Castro et al., 1992). Several nerve agents, including cyclosarin, sarin, and in particular soman, present an additional therapeutic challenge in that after they inhibit AChE, they undergo a second reaction in which the phosphonyl group attached to the inhibited enzyme is dealkylated. This process, known as aging, results in a phosphylated AChE that is refractory to either spontaneous or oxime-mediated reactivation (Fleisher and Harris, 1965). The rate of aging depends on the chemical structure of the alkoxy chain being dealkylated; the bulkiest branched chains promote very rapid aging, for example, the halftime of aging of soman-phosphonylated human AChE is 2 min at 378C, whereas that of the sarin-phosphonylated enzyme is about 4 h (Harris et al., 1966). The ineffectiveness of therapeutically administered oxime as a treatment for exposure to some nerve agents explains the continued research efforts aimed at alternative approaches to protection (Dunn and Sidell, 1989). One approach in particular has focused on preventing the critical enzyme AChE from becoming inhibited in the first place.
III. NERVE AGENT BIOSCAVENGERS: AN ALTERNATIVE TO CONVENTIONAL APPROACHES Although successful to a degree, current treatments for acute nerve agent poisoning always result in the victim suffering a toxic insult that subsequently must be therapeutically managed. To avoid the onset of a toxic insult, recent efforts have focused on identifying proteins that can act as biological scavengers of organophosphorus compounds and can remain stable in circulation for long periods of time. The concept of using a protein that can react with a nerve agent, either on a one to one basis (stoichiometrically) or with the capability to breakdown the nerve agent (catalytically) to protect against the toxic effects of those compounds is not new. As early as 1956 it was shown that injection
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C008 Final Proof page 178 7.11.2007 6:03pm Compositor Name: JGanesan
178
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
of exogenous paraoxonase (EC. 3.1.8.1) could protect rats against several times the LD50 of paraoxon (Main, 1956). This approach avoids the side effects and the requirement for rapid administration associated with current antidotes (Erdmann et al., 1965; Wiezorek et al., 1968; Sidell and Groff, 1970; Vojvodic, 1970; Wenger, 1979; Clement, 1982; Huff, 1986; Dunn and Sidell, 1989; McDonough, 2002) by prophylactically inactivating (through sequestration or hydrolysis) anticholinesterase agents before they can react with the target AChE. The time frame for this inactivation to occur before endogenous AChE is affected is quite narrow [estimated to be approximately 2 min in humans (Talbot et al., 1988)], so for situations involving acute exposure, the scavenger function must be very rapid, irreversible, and specific. Ideally, the scavenger would enjoy a long residence time in the bloodstream, would be biologically innocuous in the absence of nerve agent, and would not present an antigenic challenge to the immune system. For these reasons, a formal program to identify candidate bioscavengers was started in 1993 by the U.S. Army Medical Research Materiel Command, and it has focused on enzymes of mammalian (particularly human) origin. Candidate bioscavenger proteins, in general, function either by stoichiometrically binding and sequestering the anticholinesterase or by catalytically cleaving the OP substrate into biologically inert products. In the former category are naturally occurring human proteins that bind or react with nerve agents, including enzymes such as cholinesterases (ChEs) and carboxylesterases (CaEs). Each of these stoichiometric scavengers has the capacity to bind one molecule of nerve agent per molecule of protein scavenger. Although this approach has been proven to be effective in laboratory animals, it has the disadvantage that the extent of protection is directly proportional to the concentration of unreacted, active scavenger in the bloodstream at the time of nerve agent exposure. Because the molecular weight of the protein scavengers listed above is in the range of 60–80,000 Da and the molecular weight of the nerve agents is about 180 Da, the concentration mass ratio of scavenger to nerve agent is ~500:1. Thus, a high concentration of scavenger protein in circulation is necessary to protect against exposure to multiples of an LD50 dose of nerve agent, although lower concentrations would be sufficient to prevent inactivation of synaptic AChE after a low-dose OP exposure. It might be possible to mitigate the need for large amounts of scavenger by also administering, either prophylactically or immediately after exposure, a currently fielded oxime. Oxime treatment might allow the continual reactivation of the bioscavenger in vivo, in effect converting the stoichiometric scavenger into a pseudocatalytic one. Candidate enzymes with bona fide catalytic activity against nerve agents include the human organophosphorus acid anhydride hydrolases (OPAHs) (Masson et al., 1998), such as paraoxonase 1 (PON1) (Yeung et al., 2004, 2005). The ability to engineer site-specific amino acid mutations into naturally occurring scavenger enzymes can allow investigators to alter the binding and catalytic activities of these enzymes. In general, the use of scavengers with catalytic activity would be advantageous because small amounts of enzyme, meaning lower concentrations in circulation, would be sufficient to detoxify large amounts of nerve agent (as in an acute exposure). By nearly all criteria, the use of biological scavengers, either stoichiometric or catalytic, as a prophylactic approach to providing protection against an exposure to a nerve agent offers numerous advantages over conventional treatments. One way to evaluate the potential benefits of a bioscavenger enzyme is to consider the extent to which its presence would reduce the concentration of an OP in vivo. Indeed, the halftime for reaction of a nerve agent with a biological scavenger in vivo can be calculated using some very conservative assumptions. Based on toxicity estimates in humans, the expected concentration of a nerve agent in the blood at an LD50 dose would be about 8 3 107 M (Lenz et al., 1997). The bimolecular rate constant for reaction of soman with AChE is ~9 3 107 M1 min1 (Hanke and Overton, 1991; Ordentlich et al., 1993). If a scavenger such as BuChE were present in blood at a concentration of 1 mg=mL (1 3 105 M), then the rate constant for reaction of scavenger with toxicant would be pseudo first order and the t1=2 for the reduction of toxicant would be ~3–7 3 104 min. Under those conditions, which assume perfect mixing and that all of the scavenger and all of the toxicant remain in the bloodstream, the concentration of toxicant would be
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C008 Final Proof page 179 7.11.2007 6:03pm Compositor Name: JGanesan
179
Nerve Agent Bioscavengers
reduced to 1=1000th of its initial concentration within 10 half-lives (2–4 3 103 min). Where actual measurements have been made of the rate of reduction of concentration of soman in animals (guinea pigs), it was found that, in the absence of an exogenous scavenger, the concentration of a 2 LD50 dose of soman in circulation was reduced by 1000-fold in about 1.5 min (Langenberg et al., 1997). These results support the contention that if a bioscavenger were present in circulation at a sufficiently high concentration at the time of exposure, the reduction in toxicant concentration to a physiologically insignificant level (with no measurable inhibition of synaptic AChE) would be very rapid, and it would certainly occur in less than one circulation time at most concentrations of OP that might be encountered in a battlefield or civilian exposure setting. The need to administer, repetitively, a host of pharmacologically active drugs with a short duration of action at a precise time following exposure is all but eliminated if a scavenger is used. The potential for military personnel to require use mission oriented protective posture (MOPP) gear is greatly reduced. Finally, with the appropriate scavengers, such an approach could afford protection against all of the current threat agents, including those that induce rapid aging of AChE and are refractory to treatment by the current atropine and oxime treatment regime.
IV. STOICHIOMETRIC SCAVENGERS AND THE PROTECTION THEY OFFER Several different enzymes that react with OPs but do not catalyze their hydrolysis have been tested over the last 15 years for their ability to provide protection against nerve agent poisoning. Wolfe et al. (1987) first reported the use of exogenously administered AChE as a bioscavenger (Table 8.1). In that study, fetal bovine serum acetylcholinesterase (FBS-AChE) was administered to mice 20 h before a multiple LD50 challenge of VX was administered. Complete protection was afforded against a 2 LD50 dose of VX (100% survival of exposed animals), whereas moderate protection (80% survival of exposed animals) was observed after a challenge of three times the LD50. No protection was observed against higher multiple LD50 challenges of VX. When animals pretreated with FBS-AChE were exposed to soman, little protection was afforded, probably due to the fact that high levels of CaE in mouse plasma raise the LD50 of soman, but not VX, much higher than it is in other mammals (see below). Because protection is calculated as a multiple of the normal LD50, the scavenger concentration used was not high enough to produce a statistically significant difference. However, FBS-AChE pretreatment in conjunction with postexposure atropine and 2-PAM treatment
TABLE 8.1 Protection from Organophosphorus Intoxication by the Bioscavenger FBS-AChE Bioscavenger
Test Species
Nerve Agent
Protection (LD50)a
Serum t1=2b
References
30–40 h 40–50 h
Maxwell et al. (1992), Wolfe et al. (1992) Wolfe et al. (1987)
~24 h
Doctor et al. (1991)
24–26 h ~24 h ~24–50 h
Ashani et al. (1991), Maxwell et al. (1991, 1993) Doctor et al. (1991), Maxwell et al. (1991) Wolfe et al. (1987), Doctor et al. (1991), Maxwell et al. (1991)
FBS-AChE FBS-AChE
Rhesus monkey Mouse
GD GD
FBS-AChE
Mouse
GD
FBS-AChE
Mouse
GD
2–5 2 (w=Atropine þ 2-PAM) 2 (after CBDP treatment) 2–8
FBS-AChE FBS-AChE
Mouse Mouse
MEPQ VX
4 2–3.6
a b
Values represent multiples of median lethal doses (LD50s) of nerve agent survived after FBS-AChE administration. Half-life of administered FBS-AChE in blood circulation.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C008 Final Proof page 180 7.11.2007 6:03pm Compositor Name: JGanesan
180
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
protected mice from exposure to 2 LD50s of soman. The authors reported that animals displayed no detectable side effects in response to administration of FBS-AChE. Maxwell et al. (1993) carried out a similar set of experiments using rhesus monkeys pretreated with the scavenger FBS-AChE. When monkeys pretreated with FBS-AChE were challenged with either 1.5 or 2.5 LD50s of soman, there was protection (Table 8.1) with no decrements in performance as compared with animals treated with FBS-AChE alone when assessed by a serial probe recognition (SPR, discussed in Section VI) task. The animals were also monitored for the generation of an antibody response against the administered FBS-AChE, but none was detected. The authors cautioned, however, that whenever a foreign protein is administered to an animal, the potential for an antibody-mediated immune response must be assessed on a case-by-case basis. Maxwell et al. (1993) also compared the relative protection against soman afforded to CaE-inhibited (CDBP treated) mice by three different treatments: pyridostigmine pretreatment with atropine therapy postexposure, postexposure oxime (HI-6), and atropine therapy, or FBS-AChE pretreatment alone. The authors concluded that the FBS-AChE pretreatment offered superior protection against both soman toxicity (survival after 8–10 LD50 doses) and behavioral incapacitation. The results of these and other studies using FBS-AChE are summarized in Table 8.1. Broomfield et al. (1991) reported that equine-BuChE (eq-BuChE) afforded complete protection against a 2 LD50 challenge dose of soman in rhesus monkeys (Table 8.2) with no supporting therapy and against 3–4 LD50 doses when atropine was administered (postexposure). Protection against a single LD50 dose of sarin was also demonstrated. There were no fatalities in any of these cases (Table 8.2). Furthermore, when animals were assessed for behavioral deficits, again using an SPR task, they all returned to baseline performance within 9 h after soman exposure (vide infra) (Castro et al., 1992). In a related study, Wolfe et al. (1992) assessed the ability of pretreatment with either FBS-AChE or eq-BuChE to protect rhesus monkeys against multiple LD50 doses of soman (Tables 8.1 and 8.2). Survival and the ability to perform the primate equilibrium platform (PEP) behavioral task were the variables assessed. The animals that received FBS-AChE as a pretreatment were protected against a cumulative exposure of 5 LD50s of soman and showed no decrement in the PEP task. Two of the four monkeys that received purified eq-BuChE did show some transient decrement in PEP task performance when the cumulative dose of soman exceeded 4 LD50s. All of the experimental animals were observed for an additional 6 weeks, and none displayed any residual or delayed performance decrements, suggesting that no residual adverse effects were present. These results were reviewed and expanded upon by Doctor et al. (1993) in studies where mice pretreated with FBS-AChE were also administered the oxime HI-6 immediately postexposure to sarin. In theory, the oxime will continuously regenerate the inhibited scavenger enzyme in vivo; this approach is predicted to increase the amount of sarin that could be scavenged by a given amount of AChE, endowing this stoichiometric scavenger with pseudocatalytic properties. The therapeutic addition of HI-6 after pretreatment with FBS-AChE was found to enhance the efficacy of the scavenger enzyme against sarin in vivo, increasing the ratio of neutralized organophosphorus compound per FBS-AChE TABLE 8.2 Protection from Organophosphorus Intoxication by the Bioscavenger eq-BuChE Bioscavenger eq-BuChE eq-BuChE eq-BuChE a b
Test Species
Nerve Agent
Protection (LD50)a
Serum t1=2b
References
Rhesus monkey Rhesus monkey Rhesus monkey
GB GD GD
1 2 (4 w=atropine) 5
620 h 620 h 30–40 h
Broomfield et al. (1991) Broomfield et al. (1991) Wolfe et al. (1992)
Values represent multiples of median lethal doses (LD50s) of nerve agent survived after eq-BuChE administration. Half-life of administered eq-BuChE in blood circulation.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C008 Final Proof page 181 7.11.2007 6:03pm Compositor Name: JGanesan
181
Nerve Agent Bioscavengers
TABLE 8.3 Protection from Organophosphorus Intoxication by Endogenous Plasma CaE Bioscavenger CaEb CaE CaE CaE CaE CaE CaE CaE a
b
Test Species
Nerve Agent
Protection (LD50)a
References
Mouse Guinea pig Rabbit Rat Rat Rat Rat Rat
GD GD GD GD GB GA VX Paraoxon
16 3.5 3 8–9 8 4–5 1 2
Maxwell et al. (1987) Maxwell et al. (1987) Maxwell et al. (1987) Maxwell et al. (1987), Ember (1991) Maxwell (1992) Maxwell (1992) Maxwell (1992) Maxwell (1992)
Values represent multiples of median lethal doses (LD50s) of nerve agent survived due to the presence of CaE. Because CaE is an endogenous plasma protein in these species, the protection it offers was measured by comparing LD50 values in untreated and CBDP-treated animals; 2 mg=kg CBDP completely abolishes endogenous plasma CaE activity (Maxwell, 1992). For each species, the activity of the host’s endogenous CaE was tested.
molecule from 1:1 (in the presence of AChE alone) to ~65:1. To date, similar in vivo studies using BuChE with oximes have not been reported, although preliminary in vitro data suggest that currently fielded oximes do not reactivate OP-inhibited BuChE rapidly enough to make this enzyme pseudocatalytic. CaE is another enzyme with the potential to be a good antiorganophosphorus scavenger molecule (results summarized in Table 8.3) (Maxwell et al., 1991). Although AChE and BuChE were found to be more efficient scavengers for soman in mice than CaE (i.e., they have higher bimolecular rate constants), the latter enzyme was capable of affording equal protection on a molar basis. CaEs (EC 3.1.1.1) catalyze the hydrolysis of a wide variety of aliphatic and aromatic esters and amides (Augustinsson, 1958; Satoh, 1987). Catalysis occurs by a two-step process in which the substrate acylates the active site serine of CaE, which subsequently deacylates by the addition of water (Aldridge and Reiner, 1972). CaE can be distinguished from AChE and BuChE by the fact that AChE and BuChE react with positively charged carboxylesters, such as acetylcholine and butyrylcholine, and are readily inhibited by carbamates, whereas CaE does not react with positively charged substrates and is inhibited by carbamates only at high concentrations (Aldridge and Reiner, 1972). These differences in substrate specificity also extend to the reaction of CaE with OP compounds. Positively charged OP compounds, such as VX, react poorly with CaE whereas neutral OP compounds, such as soman, sarin, and paraoxon, react rapidly. Dephosphylation of the active site phosphorylated serine of CaE is a very slow process compared to deacylation (Satoh and Hosokawa, 1998), and therefore CaE has usually been considered to be a stoichiometric detoxification mechanism for OP compounds. CaE is 60 kDa enzyme that is found in many mammalian tissues—lung, liver, kidney, brain, intestine, muscle, and gonads—usually as a microsomal enzyme. In some species, CaE is also found in high concentrations in plasma; plasma CaE is synthesized in the liver and secreted into the circulation via the Golgi apparatus of hepatocytes (Miller et al., 1999). Secretion of CaE appears to be controlled by the presence or absence of a retention signal at the carboxy terminal of the enzyme (Figure 8.1). CaE that is retained in the liver has a highly conserved carboxy-terminal tetrapeptide sequence (HXEL in single letter amino acid code, where X represents any amino acid), whereas the secretory form of CaE has a disrupted version of this retention signal in which the terminal leucine residue is replaced by either histidine–lysine or histidine–threonine (Miller et al., 1999). Mammalian species that have high levels of secretory CaE in their plasma require much larger doses of OP
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C008 Final Proof page 182 7.11.2007 6:03pm Compositor Name: JGanesan
182
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics Biochemical basis for CaE cellular trafficking Enzyme COOH-terminal residues Intracellular CaEs ..TEHIEL Rabbit Es-1 Rabbit Es-2 ..QKHTEL ..GKHSEL Hamster AT51p ..TEHIEL Human CaE-1 ..ERHTEL Human CaE-2 Pig CaE ..IKHAEL ..WKHVEL Rat Es-10(pI6.1) Rat Es-B ..PHHNEL ..REHVEL Mouse Es-X Mouse Es-22 ..TEHTEL Consensus ..HXEL Secreted CaEs Mouse Es-1 Rat Es-1
..TEHTEHK ..TEHTEHT
Reference Korza and Ozols, 1988 Ozols, 1989 Sone et al., 1994 Shibata et al., 1993 Schwer et al., 1997 Matsushima et al., 1991 Robbi et al., 1990 Yan et al., 1994 Ellinghaus et al., 1998 Ovnic et al., 1991a
Ovnic et al., 1991b Long et al., 1988; Robbi and Beaufay, 1992; Murakami et al., 1993
FIGURE 8.1 The carboxy-terminal amino acid residues of carboxylesterase enzymes from disparate species are aligned to show the conserved ‘‘HXEL’’ motif found among intracellular enzymes (shown in bold letters), and the disrupted versions of this retention motif found in the mouse and rat secreted carboxylesterase isoenzymes (alterations to the motif shown in italics). The capacity of the carboxy-terminal HXEL motif to act as an endoplasmic reticulum retention signal has been directly demonstrated. (From Medda and Proia, 1992.)
LD50 Soman (µg /kg)
compounds to produce toxicity than do species with low levels of plasma CaE (Maxwell et al., 1987). For example, the LD50 dose for soman in rats is 10-fold larger than the LD50 in nonhuman primates, which correlates with the differences in the plasma concentrations of CaE found in these species (Figure 8.2). Studies comparing the levels of CaE in the plasma of rats, guinea pigs, nonhuman primates, and humans as determined by the extent of binding of a radiolabelled organophosphorus compound, diisopropylfluorophosphate (DFP), clearly demonstrate the potential protective effect of this enzyme (Patel et al., 2005). Notably, human plasma has recently been shown to be devoid of CaE (Li et al., 2005; Satoh and Hosokawa, 2006). Although a human CaE gene has been cloned and expressed (Miller et al., 1999), there is no commercial source of highly purified CaE for use in in vivo testing of protective efficacy. Therefore, the primary evidence demonstrating the effectiveness of CaE as a stoichiometric scavenger against OPs, especially sarin and soman, has been by comparison of OP LD50s in animals with high endogenous plasma levels of CaE to OP
120
80
40
0
0
2 4 Plasma CaE (µM)
6
FIGURE 8.2 Effect of plasma CaE concentration on soman LD50 (administered subcutaneously) in different species. Data points (from lower left to upper right of graph) for species were monkey, rabbit, guinea pig, rat, and mouse. (Data taken from Maxwell, D.M. et al., Cholinesterases: Structure, Function, Mechanism, Genetics and Cell Biology, J. Massoulie et al., eds., American Chemical Society, Washington DC, 1991.)
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C008 Final Proof page 183 7.11.2007 6:03pm Compositor Name: JGanesan
183
Nerve Agent Bioscavengers
LD50 levels in animals of the same species whose plasma CaE has been chemically inhibited (Maxwell et al., 1987). For example, inhibition of plasma CaE prior to the LD50 determination of soman in rats reduces its LD50 by approximately eightfold (Table 8.3) strongly suggesting that circulating CaE is an effective endogenous bioscavenger against OP compounds. Recent investigations of the reactivation of OP-inhibited CaE have suggested that it may be possible to increase its potential as an OP scavenger by exploiting its turnover of OP compounds. Maxwell et al. (1994) observed that OP-inhibited CaE does not undergo the aging process that prevents oxime reactivation of OP-inhibited ChEs, whereas Jokanovic et al. (1996) found that OP-inhibited CaE from plasma underwent spontaneous reactivation with a halftime of 1–2 h. Comparisons of the amino acid sequences of CaE, AChE, and BuChE are informative with regard to the critical amino acid residues required for occurrence of aging versus spontaneous reactivation. Of the seven conserved amino acid residues that have been identified by theoretical studies and confirmed by site-directed mutagenesis to be important for aging of OP-inhibited AChE and BuChE, only two are conserved in CaE (Maxwell et al., 1998). Conversely, a highly conserved histidine found in CaE from six mammalian species and two insect species, but not in mammalian ChEs, correlates with the higher level of spontaneous reactivation of OP-inhibited CaE compared with OP-inhibited ChE (Maxwell et al., 1994). Interestingly, introduction of a histidine into BuChE at a position nearly identical to the position of the conserved histidine of CaE, that is, in the oxyanion hole, produces spontaneous reactivation of OP-inhibited BuChE (Millard et al., 1995; Lockridge et al., 1997; Millard et al., 1998). A more detailed discussion of the relative merits of FBS-AChE, eq-BuChE, and plasma CaE as scavengers, which describes the extent of protection they offer against a variety of nerve agents, both in vitro and in vivo in mice, was presented by Doctor et al. (1991). The authors note that some of the in vivo differences seen in sensitivity and protection may be due to variations in the circulatory pharmacodynamics of the different organophosphorus compounds, such that those inhibitors that distribute more slowly from circulation are more readily scavenged. This concept provided early support for the feasibility of using scavengers to protect against exposures to nerve agent. Ultimately, the goal of research on scavenger molecules is to generate a means to protect humans from the toxic effects of nerve agents. In an effort to minimize any physiological, immunological, or psychological side effects of scavenger use in humans, research efforts have focused primarily on the use of human BuChE (Hu-BuChE), with additional work on the model systems of either intracellular human CaE or FBS-AChE, which does not induce an immune response in rhesus monkeys (Maxwell et al., 1992). In a series of studies, Ashani et al. examined the scavenger properties of FBS-AChE and particularly plasma-derived Hu-BuChE in mice, rats, and rhesus monkeys with respect to several different nerve agents as well as other organophosphorus compounds (Table 8.4) (Ashani et al., 1991; Raveh et al., 1993, 1997). They found that TABLE 8.4 Protection from Organophosphorus Intoxication by Exogenous Hu-BuChE Bioscavenger Hu-BuChE Hu-BuChE Hu-BuChE Hu-BuChE Hu-BuChE Hu-BuChE Hu-BuChE Hu-BuChE a b
Test Species
Nerve Agent
Protection (LD50)a
Serum t1=2b
Rhesus monkey Rhesus monkey Rat Rat Mouse Mouse Mouse Mouse
GD VX GD VX GD GB GA VX
2 1.5 2–3 2 2.1 1.6 1.8 4.9
~30 h ~30 h 46 h 46 h 21 h 21 h 21 h 21 h
References Raveh et al. Raveh et al. Raveh et al. Raveh et al. Raveh et al. Raveh et al. Raveh et al. Raveh et al.
(1997) (1997) (1993) (1993) (1997) (1997) (1997) (1997)
Values represent multiples of median lethal doses (LD50s) of nerve agent survived after Hu-BuChE administration. Half-life of administered Hu-BuChE in blood circulation.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C008 Final Proof page 184 7.11.2007 6:03pm Compositor Name: JGanesan
184
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
TABLE 8.5 Protection by Hu-BuChE against Nerve Agent Poisoning Species Guinea pig Guinea pig Cynomolgus
Toxin
Dose (LD50)
Impairment
Recovery
GD VX GD
5.5 5.5 5.5
None None 1=5
Immediate Immediate 4=6a
Source: All data are from Lenz, D.E., et al., Chem. Biol. Interact., 157–158, 205, 2005. a
One animal died after the third dose of GD and one was impaired and later euthanized after 48 h. Remaining four animals were normal, survived and they were held for long-term observations.
following administration of exogenous ChE, there was a linear correlation between the concentration of ChE in the blood and the level of protection against organophosphorus poisoning. Furthermore, the extent of protection granted to mice was sufficient to counteract multiple LD50 doses of soman. When the protective effect of pretreatment with Hu-BuChE was compared in mice and rats, it was found that in both species the same linear correlation existed between blood concentration of Hu-BuChE and protection against soman, sarin, or VX (Table 8.5). They further noted that to be effective, a scavenger had to be present before exposure to the organophosphorus compound, because (as discussed above) the nerve agent had to be scavenged within one blood circulation time period (Raveh et al., 1993). In the final paper in this series, the authors report similar protection results against a 3.3 LD50 dose of soman or a 2.1 LD50 dose of VX in rhesus monkeys (Raveh et al., 1997). They also report considerable protection against soman-induced behavioral deficits in a spatial discrimination task. Those efforts have recently been expanded upon by Lenz et al. (2005), Saxena et al. (2005), and Doctor and Saxena (2005). Lenz et al. determined the pharmacokinetics and efficacy of Hu-BuChE in guinea pigs and cynomolgus monkeys against multiple LD50 challenges of nerve agents. The halftime for elimination of the plasma-derived Hu-BuChE was about 70–75 h for guinea pigs or cynomolgus monkeys, respectively. Guinea pigs were protected against a cumulative 5.5 LD50 of either soman or VX. At necropsy, 7 or 14 days after surviving the nerve agent challenge, all tissues appeared normal upon light microscopic examination. No signs of poisoning were observed in the experimental animals during the efficacy studies. Cynomolgus monkeys were protected against a cumulative challenge of 5.5 LD50 of soman as well. Of six animals challenged, one died after the final challenge dose of soman (total dose of 5.5 LD50s administered within 4 h) and one was euthanized 48 h after the final dose of soman. The remaining animals displayed no immediate signs of poisoning and exhibited no lasting effects of poisoning as assessed by blood chemistry examinations and long-term (>20 month) observations. The efficacy results are summarized in Table 8.5. These studies were complimented by the work of Saxena et al. (2005) who measured the in vitro stability of the plasma-derived Hu-BuChE. They found that the lyophilized form of the enzyme had a shelf life of over 24 months at 4, 25, or 378C. In addition, the material, when reconstituted, showed no alteration in its in vivo properties with respect to the pharmacokinetics in mice or rhesus monkeys. When plasma-derived Hu-BuChE was administered to mice or rhesus monkeys at a dose in 10-fold excess of that needed for protection against a 5 LD50 challenge of soman, no deficits on a variety of behavioral tasks were observed. The overall conclusion from these studies was that plasma-derived Hu-BuChE was both safe and efficacious as a biological scavenger. Based on these data, the U.S. Army transitioned the plasmaderived Hu-BuChE to advanced development in October 2004. This product was awarded Investigational New Drug (IND) status by the Food and Drug Administration (FDA) in October of 2006 and is currently being produced by Baxter Pharmaceuticals under good manufacturing practice for additional testing pursuant to a New Drug Application (NDA) submission.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C008 Final Proof page 185 7.11.2007 6:03pm Compositor Name: JGanesan
185
Nerve Agent Bioscavengers
Plasma-derived Hu-BuChE represents a first-generation biological scavenger. This material is obtained from outdated blood and so the overall availability is dependent on the quantity of outdated blood available at any given time. Because this supply is dependent on the extent of donor participation and the need for blood under other circumstances such as natural disasters or unforeseen medical emergencies, basic research efforts are being focused on the development of Hu-BuChE from a recombinant source. If successful, such efforts would allow for a constant supply of material of reproducible purity and activity without affecting the supply of whole blood, collected for other purposes. There are a variety of potential sources of human recombinant protein, to include material from transgenic plants (Mor et al., 2001; Fletcher et al., 2004), transgenic animals (Cerasoli et al., 2005a), transgenic larval sources (Welch et al., 2006), or algae capable of expressing human proteins (Siritunga and Sayre, 2003; Xiong and Sayre, 2004). Reported attempts to express functional Hu-BuChE in bacteria or yeast have failed (Masson et al., 1992; Nachon et al., 2003; Patel, personal communication). To date, recombinant Hu-BuChE (rHuBuChE) enzymes purified from transgenic plants (Mor et al., 2001; Fletcher et al., 2004) and from the milk of transgenic goats (Cerasoli et al., 2005a) have been the most extensively studied (Cerasoli et al., 2005a; Garcia et al., 2005). Studies with rHuBuChE from the milk of transgenic goats have yielded efficacy results in guinea pigs that are very similar to those described previously (vide supra) with plasma-derived material, that is, complete protection against 5.5 LD50s of GD or VX. In its native form, rHuBuChE from transgenic goat milk is primarily either a dimer or a monomer, in contrast to the plasma-derived material which is a tetramer. Additionally, the goat milk derived rHu-BuChE has a glycosylation pattern different from that of the plasma material (Garcia et al., 2005). As a result, goat milk derived rHuBuChE has a different pharmacokinetic profile, with a shorter circulatory half-life. To enhance its biological residence time, the efficacy studies described were carried out with rHuBuChE that had been modified by attachment of several molecules of polyethylene glycol (PEGylated). The PEGylated material had a pharmacokinetic profile very similar to that of plasma-derived BuChE, suggesting that any differences in pharmacokinetics of a recombinant product can be addressed through modification of the protein product (Cerasoli et al., 2005b). The rHuBuChE from goat milk did not evoke any behavioral side effects of its own in guinea pigs, and in addition to survival, animals protected were devoid of any of the typical postpoisoning side effects such as the delayed recovery of function seen when traditional therapy is used. These preliminary results suggest that some form of a recombinant stoichiometric bioscavenger can be developed, thereby providing sufficient material to protect the entire U.S. fighting force.
V. CATALYTIC BIOSCAVENGERS Although stoichiometric scavengers are able to afford good protection as long as they are present in high levels in the blood stream, they are molecules of high-molecular weight (vide supra); a comparatively large quantity is required to neutralize a small amount of nerve agent. A catalytic scavenger, even having the same high-molecular weight, could be administered in smaller quantities and could produce the same or greater degree of protection. It would also have the advantage of not being consumed in the process of detoxifying the nerve agent, so it would be available to protect against multiple exposures of either high or low dose. Some of these potential bioscavenger proteins along with parameters of their catalytic activities are summarized in Table 8.6 through Table 8.8. As discussed above, in conjunction with an oxime such as HI-6, AChEs that have not undergone aging can be continually reactivated to function pseudocatalytically, eliminating substantially more molar equivalents of organophosphorus compounds than would be predicted based on binding alone. BuChEs are reactivated by currently fielded oximes substantially more slowly, raising questions about their suitability for use in a pseudocatalytic application. Some enzymes, such as the OPAH from Pseudomonas diminuta (Serdar and Gibson, 1985), the prolidase from Alteromonas haloplanktis (Cheng et al., 1997), the DFPase from Loligo vulgaris (Hartleib and Ruterjans, 2001), or HuPON1
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C008 Final Proof page 186 7.11.2007 6:03pm Compositor Name: JGanesan
186
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
TABLE 8.6 Kinetic Properties of Naturally Occurring Catalytic Bioscavengers Bioscavenger
Source Species
Substrate Specificity
Km (mM)
Vmax (nmol min1 mg1)
Phosphotriesterase
P. diminuta
GD
36=500
15=7.3
Phosphotriesterase Phosphotriesterase Phosphotriesterase
P. diminuta P. diminuta P. diminuta
GB Paraoxon DFP
700 50 100
N.D.a 3200 64
References Broomfield (1992), Masson et al. (1998) Dumas et al. (1990) Dumas et al. (1990) Dumas et al. (1990)
Bimolecular Rate Constant (kcat=Km [M1 min1]) Q191=R191b PON1 PON1 PON1 PON1 a b
Human Human Human Human
2.8 3 106=2.1 3 106 9.1 3 105=6.8 3 104 3.7 3 104=N.D. 6.8 3 105=2.4 3 106
GD GB DFP Paraoxon
Masson et Masson et Masson et Masson et
al. (1998) al. (1998) al. (1998) al. (1998)
Not determined. Two most commonly occurring natural allelic variants of PON1 (Q191 and R191) have been identified. The activity of each form is shown.
TABLE 8.7 Kinetic Properties of Catalytic Mutated BuChE Bioscavengers
Bioscavenger Wild-type Hu-BuChE Wild-type Hu-BuChE Wild-type Hu-BuChE G117H BuChEb G117H BuChE G117H BuChE G117H E197Q BuChEc G117H E197Q BuChE G117H E197Q BuChE G117H E197Q BuChE G117H E197Q BuChE GD G117H E197Q BuChE a
b c
d
Substrate
Specificity Spontaneous Reactivation Rate Constant (3103 min1)a
GB VX GD GB VX GD GB VX GD (PSCR)d GD (PRCR)d (PSCS)d GD (PRCS)d
<0.05 <0.05 <0.05 5 7 <0.05 62 78 6 6 77 128
References Lockridge et Lockridge et Lockridge et Lockridge et Lockridge et Lockridge et Lockridge et Lockridge et Lockridge et Lockridge et Lockridge et Lockridge et
al. (1997), Millard et al. (1997), Millard et al. (1997), Millard et al. (1997), Millard et al. (1997), Millard et al. (1997), Millard et al. (1997), Millard et al. (1997), Millard et al. (1997), Millard et al. (1997), Millard et al. (1997), Millard et al. (1997), Millard et
al. (1998) al. (1998) al. (1998) al. (1998) al. (1998) al. (1998) al. (1998) al. (1998) al. (1998) al. (1998) al. (1998) al. (1998)
The rate-limiting step in the hydrolysis of organophosphate nerve agents by mutated Hu-BuChEs is the enzyme reactivation step (Lockridge et al., 1997; Millard et al., 1998). A version of BuChE in which the glycine at amino acid residue 117 has been replaced by histidine. A double mutant of BuChE containing both histidine (rather than glycine) at amino acid residue 117 and glutamine in place of glutamic acid at residue 197. The reactivity with each of the four stereoisomers of GD was determined independently.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C008 Final Proof page 187 7.11.2007 6:04pm Compositor Name: JGanesan
187
Nerve Agent Bioscavengers
TABLE 8.8 Kinetic Properties of Mouse-Derived Catalytic Antibody Bioscavengers Bioscavenger Antibody IIA12-ID10 Antibody DB-108Q Antibody DB-108P
Substrate Specificity
Km (mM)
Vmax (nmol min1 mg1)
References
GD, others? GD, others? GD, others?
330 110 100
25 16 53
Brimfield et al. (1993) Yli-Kauhaluoma et al. (1999) Yli-Kauhaluoma et al. (1999)
(Gan et al., 1991; Masson et al., 1998; Josse et al., 1999a, 1999c, 2001, 2002; Tuovinen et al., 1999; Yeung et al., 2004, 2005) have intrinsic catalytic antiorganophosphorus activity. The P. diminuta enzyme has been shown to afford protection against soman lethality in mice and to protect against behavioral side effects (Table 8.6) (Broomfield, 1992). However, because this bacterially derived enzyme has no known mammalian homologs, it will likely be a potent initiator of immune responses and is therefore unlikely to be appropriate for use as a prophylactic scavenger in humans. However, a recent study suggested that encapsulation of bacterially derived OP-hydrolyzing enzymes in liposomes may extend their stability; this approach was shown to protect rats from multiple LD50s of OP pesticides (Petrikovics et al., 2004). Bacterial enzymes conceivably could also be used for skin protection as active components of topical skin protectants (TSPs) or covalently bound to the cornified layer of epidermis (Parsa and Green, 2001). Detoxification of OPs does not need to proceed through hydrolysis; inactivation of these compounds can also be achieved through enzymatic oxidation of their alkyl chains. In particular, breakdown of VX by horseradish peroxidase (Amitai et al., 2002) or by Caldariomyces fumago chloroperoxidase (Amitai et al., 2003) could be used in polyfunctional active TSP and for skin decontamination. Additionally, the P. diminuta OPAH could be used as a one-time pretreatment either in addition to or in place of conventional therapy, because in the short-term this enzyme is highly effective against GD, GB, and VX, and alone, it induces no known behavioral effects. The human PON1 (HuPON1) enzyme has been identified as having a similar potential for affording protection (Table 8.6), but without the complication of inducing an immune response; the human immune system should recognize HuPON1 as ‘‘self’’ and thus remain quiescent. The HuPON1 enzyme belongs to a family of plasma paraoxonases consisting of PON1, PON2, and PON3 (Primo-Parmo et al., 1996; La Du et al., 1999; Draganov et al., 2000; Furlong et al., 2002; Teiber et al., 2003; Aharoni et al., 2004; Harel et al., 2004b; van Himbergen et al., 2006). The three PON genes are located adjacent to each other at bands q21–q22 on chromosome 7 (Furlong et al., 2002). Of the three PON enzymes, PON1 is the most studied and best understood (Clendenning et al., 1996; Furlong et al., 2000a, 2000b). It was initially identified by Abraham Mazur (1946) when he reported the discovery of an OP-hydrolyzing enzyme in animal tissue (van Himbergen et al., 2006). Although the enzyme was named after its capacity to hydrolyze paraoxon, it was later discovered that it actually exhibits a broad spectrum of activities (Aldridge, 1953a, 1953b). Among the arrays of possible substrates of PON1 are aryl-esters, lactones, phospholipids, and organophosphates (Li et al., 1995, 2000; Davies et al., 1996; Furlong et al., 1998, 2000a, 2000b; Josse et al., 1999a, 1999c, 2002; Billecke et al., 2000; Broomfield et al., 2000; Jakubowski et al., 2001; Rodrigo et al., 2001; Teiber et al., 2003; Lacinski et al., 2004; Yeung et al., 2004; Khersonsky and Tawfik, 2005; Gaidukov et al., 2006). The enzyme is synthesized in the liver and bound to high-density lipoprotein (HDL) and possibly phosphate binding protein (PBP) before it is secreted into circulation (Blatter et al., 1993; Sorenson et al., 1999; Harel et al., 2004b; James and Deakin, 2004; Gaidukov et al., 2006; Morales et al., 2006; Rosenblat et al., 2006). The concentration of PON1 in human plasma is ~50 mg=L, but can vary by as much as 13-fold from one individual to another (Rochu et al., 2007). Of note, the level of PON1 in the circulation of small nonprimate mammals has been inversely correlated with susceptibility to OP intoxication (Li et al., 1993; Furlong et al., 1998, 2000b; Costa et al., 1999, 2003b, 2005). More
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C008 Final Proof page 188 7.11.2007 6:04pm Compositor Name: JGanesan
188
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
importantly, the exogenous administration of purified rabbit PON1 has been shown to protect against OP toxicity in both rats and mice (Li et al., 1995), whereas PON1 knockout mice are more sensitive to OP pesticides than wild-type mice (Shih et al., 1998). Several polymorphisms of HuPON1 are known to exist, where the most prominent is the Q192R allozyme, which can have a substantial impact on PON1 activities (Furlong et al., 1998, 2000b, 2002; Billecke et al., 2000; Li et al., 2000; Costa et al., 2003a; Yeung et al., 2004; Gaidukov et al., 2006). Although the in vivo substrate of HuPON1 is presently unknown, there is substantial evidence that it may act as a lactonase in vivo (Jakubowski et al., 2001; Teiber et al., 2003; Lacinski et al., 2004; Khersonsky and Tawfik, 2005, 2006). HuPON1 also appears to have antiatherosclerotic properties, protecting low-density lipoprotein (LDL) from oxidation (Aviram et al., 1998; Shih et al., 1998; Brites et al., 2004; van Himbergen et al., 2006). The mature enzyme retains its N-terminus signal peptide and contains 354 amino acid residues. Depending on its glycosylation state, the molecular weight of HuPON1 can range from 38 to 45 kDa (Hassett et al., 1991; Clendenning et al., 1996; Furlong et al., 2000a). Although the exact structure and catalytic mechanism of the HuPON1 enzyme are unknown, results from analyses of a gene-shuffled, bacterially expressed PON1 variant suggest that HuPON1 is a sixfold beta-propeller protein and that catalysis is mediated by a unique His–His dyad (Harel et al., 2004b). It has been established that the PON1 enzyme is a serum OP hydrolase with an absolute requirement for two Ca2þ ions (Sorenson et al., 1995; Kuo and La Du, 1998). One calcium is required to maintain the overall structural integrity of the protein, while the other is essential for enzymatic activities (Sorenson et al., 1995; Kuo and La Du, 1998; Josse et al., 1999c; Jakubowski, 2000). Additionally, through chemical modification and site-directed mutagenesis studies, a number of amino acid residues have also been identified as essential for activity (Doorn et al., 1999; Josse et al., 1999a, 1999b, 1999c, 2001, 2002; Aharoni et al., 2004; Harel et al., 2004b; Yeung et al., 2004, 2005; Amitai et al., 2006; Khersonsky and Tawfik, 2006; Rosenblat et al., 2006). A preliminary study showed that in animals not pretreated with CBDP to inhibit plasma CaE (Maxwell et al., 1987) a dose of 1 mg=mouse of HuPON1 administered in the vein tail 5 min prior to subcutaneous injection of soman does not provide protection against 1 LD50 of this OP; however, a mild protective effect in terms of seizure rate and incapacitation was observed for lower doses of soman (Lallement et al., unpublished). Because the effects of plasma CaE were not reduced (Maxwell et al., 1987, 1998), these results suggest that protection against multiple LD50s of nerve agents could be achieved by using either higher doses of wild-type HuPON1 (5–10 mg=mouse) or mutants of the enzyme with enhanced catalytic activity toward OPs. In addition, the effects would be expected to be more pronounced in a species with little or no plasma CaE. Although the enzymes discussed above possess the desired catalytic activity, none of them is enzymatically fast enough for use as a nerve agent pretreatment. Because the organophosphorus anticholinesterases have been in the environment for only a little over 50 years, it is not likely that any of the enzymes identified as OPAHs have as their primary function the destruction of OPs. In fact, an OPAH from an Alteromonas species has been identified as a prolidase, a dipeptidase that cleaves the penultimate proline from the carboxyl end of a peptide (Cheng et al., 1997). Recently, it was suggested that HuPON1 is a homocysteine thiolactone hydrolase and can protect against protein N-homocysteinylation (Jakubowski, 2000; Jakubowski et al., 2001; Lacinski et al., 2004; Khersonsky and Tawfik, 2005, 2006). Because these enzymes are not likely to have evolved to efficiently hydrolyze OP compounds, it is probable that through mutagenesis, substantial improvements in their catalytic efficiencies can be obtained. To be functional, a catalytic scavenger must have an enzymatic efficiency (the ratio kcat=Km) as high as possible; none of the catalytic anti-OP enzymes identified to date have a sufficiently low KM (a measure of the strength of binding of a substrate to the enzyme) or sufficiently high kcat (turnover number) to clear OPs from the bloodstream within the 1–2 min before they can reach critical targets (Broomfield et al., 1991). Therefore, efforts to enhance the catalytic efficiency of human enzymes through introduction of specific amino acid substitutions were initiated. Obvious candidates for such attempts include members of the ChE family (including CaE) and the paraoxonases, which already possess the
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C008 Final Proof page 189 7.11.2007 6:04pm Compositor Name: JGanesan
189
Nerve Agent Bioscavengers
desired activity but at insufficient levels. The rationale for the design of mutations in the ChE family was based on the fact that for these enzymes, the organophosphorus inhibitors are in reality hemisubstrates; their initial reaction with the enzyme is similar to that of normal substrates. However, the subsequent reaction, equivalent to deacylation of the active site serine, is blocked because of the geometry of the active site. The amino acid group responsible for deacylation is not in an appropriate position to effect dephosphorylation (Jarv, 1984; Broomfield et al., 1995). The perceived solution to this problem was to insert a second catalytic center into the active site specifically to carry out the dephosphylation step of the reaction (Broomfield et al., 1995). Applying this rationale, the human wild-type BuChE has been mutated in the oxyanion hole (Figure 8.3 and Table 8.7) to express a mutant enzyme, G117H, with the ability to catalyze the hydrolysis of sarin, DFP, paraoxon, VX, and other nonaging nerve agents (Broomfield et al., 1995; Lockridge et al., 1997). Aging and reactivation are parallel first-order reactions in phosphylated enzymes. In the reactivation reaction, the phosphoryl group is removed from the active site serine residue (S198), restoring activity, whereas in the aging reaction one of the alkyl groups is removed from the phosphoryl group, rendering the group nonreactivatable. To affect the hydrolysis of rapidly aging nerve agents such as soman it is necessary to inhibit the aging reaction so that reactivation is faster. This was accomplished by replacing the carboxyl group (Glutamic acid, E197) adjacent to the active site serine with an amide (Glutamine, Figure 8.4) (Lockridge et al., 1997). Unfortunately, these mutants have catalytic activities that are too slow for practical use (Table 8.7), though they might have applications as self-reactivating stoichiometric scavengers that would be useful for protection against chronic, low-level or percutaneous exposures. As an alternative to such protein engineering, it is possible through careful design and synthesis of transition state analogs to immunize mice and 100
G117H G117H / E197Q
90 80
G117H / E197Q 0.2 0.0
60 In[(v-v)/(v-v)]
% Activity recovered
70
50 40 30
−0.2 −0.4 −0.6 −0.8 −1.0
20
−1.2
0
10
500 1000 1500 2000 2500 3000 S
0 0
2
4
6
8
10
Time after GD removal (s
12
14
80 90 100
⫻ 10−3)
FIGURE 8.3 Comparative reactivation kinetics of soman-inhibited human butyrylcholinesterase single mutant G117H (&) and double mutant G117H=E197Q (.). Note that the recovery rate of the double mutant is very fast (with reaction rates of 77,000 and 128,000=min for the PSCS and PSCR isomers of soman, respectively), whereas the single mutant does not recover measurably. The insert shows that reactivation of the double mutant with soman can be treated as a first-order reaction for at least 2.5 3 103 s. (Data are from Millard, C.B. et al., Biochemistry, 37, 237, 1998.)
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C008 Final Proof page 190 7.11.2007 6:04pm Compositor Name: JGanesan
190
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Glu 325
His
5.05 Gln 197 GD
Ser 198 His 117
FIGURE 8.4 A ball-and-stick computer model of the active site of the double mutant of butyrylcholinesterase G117H=E197Q. In addition to the His 117 and Gln 197, the active site triad amino acid residues of His 438, Ser 198, and Glu 325 are also depicted with soman at the active site. The distances between the phosphorus atom of soman and His 117 is 5.05 Å and distance between the phosphorus atom of soman and the active site His 438 is 5.94 Å. (Data are from Millard et al., 1998.)
elicit antibodies with catalytic activities against substrates. This approach has been used to create catalytic anti-soman antibodies, albeit with catalytic efficiencies too low to be useful as in vivo scavengers (Table 8.8). In addition to BuChE, AChE, human CaE, and PON1 are currently being subjected to mutation in efforts to generate additional, faster catalytic anti-nerve agent enzymes. For example, multiple mutations to the active site of an AChE enzyme were recently reported to result in an OP hydrolyase, albeit with slower activity than the G117H mutant of Hu-BuChE (Poyot et al., 2006). It is important to note that in the case of HuPON1, the desired catalytic activity is already present at low levels in the native enzyme. Because OPs are ‘‘accidental’’ substrates for PON1 [see above (Masson et al., 1998; Tuovinen et al., 1999)] it is likely that improvement in activity can be realized through protein engineering. Two of the major difficulties in designing appropriate site-directed mutations of PON1, the lack of knowledge of the residues at the active site and of the enzyme’s three-dimensional structure, were recently overcome by the work of Josse et al. (1999a, 1999b, 1999c, 2001), Aharoni et al. (2004), Harel et al. (2004a,b), and Yeung et al. (2004, 2005). Josse postulated, based on site-directed mutations of amino acids predicted to be at or near the active site of PON1 and by structural homology modeling with squid DFPase, that HuPON1 is a sixfold beta-propeller protein. Harel et al. and Aharoni et al., using a mouse–rat–rabbit–human chimeric gene obtained through gene shuffling and expressed in bacteria, confirmed the postulated structure through x-ray crystallographic studies. Yeung et al. (2004, 2005) have subsequently created sitedirected mutants of HuPON1 to identify and ‘‘map’’ amino acids critical for substrate binding and catalytic activity. Other studies have revealed a degree of stereospecificity in the hydolysis of soman by native HuPON1 (Amitai et al., 2006; Yeung et al., 2007). These findings all support the goal to design a recombinant version of PON1 with enhanced anti-OP catalytic activity. Because PON1 is a naturally occurring plasma enzyme produced in the liver, an alternative approach would be to enhance the endogenous enzyme biosynthesis by inducing increased activity of its gene promoter. Recent results on increased expression levels of PON1 by HuH7 hepatoma cells upon action of fibrates and dietary polyphenols are promising in this regard (Gouedard et al., 2003, 2004).
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C008 Final Proof page 191 7.11.2007 6:04pm Compositor Name: JGanesan
191
Nerve Agent Bioscavengers
Although most of the potential catalytic scavengers described here have not yet been tested for efficacy in animal models, they are indicative of the types of drugs that may soon be available for use in animals, including humans. Because mutations of BuChE, CaE, and PON1 involve changes of internal amino acid residues in human proteins, the expectation is that these proteins would induce minimal immunological or behavioral side effects.
VI. BEHAVIORAL EFFECTS Because overt signs, symptoms, or physiological responses may not accompany many low-level exposures to OPs, behavioral toxicological measures may be chosen to detect any toxic changes wrought by exposure. Under such conditions, it is important to ensure that biological scavengers, represented either as elevated levels of naturally occurring proteins or as mutant forms thereof, do not elicit behavioral effects of their own after administration. Unique behavioral effects might also result after pretreatment with a biological scavenger followed by exposure to a nerve agent; it is of great interest to compare the extent of behavioral side effects that ensue from pretreatment with scavenger alone or followed by nerve agent exposure versus those induced by exposure to nerve agent followed by conventional therapy. The discussion here will be limited only to the side effects, if any, resulting from administration of scavengers alone. The other topics, including the ability of scavengers to ameliorate behavioral side effects following nerve agent exposure and the advantages of scavengers versus conventional therapy are discussed in detail elsewhere (Lenz and Cerasoli, 2002).
VII. BEHAVIORAL EFFECTS OF SCAVENGERS ALONE Most studies that have examined the behavioral effects of biological scavengers have done so by comparing a behavior before scavenger administration, after scavenger administration, and then after exposure to nerve agent (see Lenz and Cerasoli, 2002). There are, however, several studies that have examined the behavioral effects of the biological scavengers themselves in the absence of ChE inhibitors. In a study by Genovese and Doctor (1995), rats were trained to perform three behavioral paradigms: a passive avoidance task, a motor activity, and a scheduled–controlled behavior (Table 8.9). The performance of animals before and after administration of purified eq-BuChE at a dose that would be expected to provide protection against an exposure of several LD50s of an OP compound was assessed. They determined the pharmacokinetic profile of eq-BuChE in rats and then examined the behavior of the animals in the passive avoidance task when the levels of administered eq-BuChE were maximal. Subsequently, the animals were tested after enzyme levels had started to diminish, to enhance the opportunity of detecting any behavioral effects. During the activity tests, individually housed animals were allowed to habituate. Enzyme was given such that maximum levels would be present in circulation about 1 h before the beginning of dark cycle. Motor activity was then monitored for 10 days. As a final test, the effects of excess enzyme were examined in rats trained to perform a variable interval 56 s (VI56 s) schedule of food reinforcement. Previously, cholinergic compounds had been shown to disrupt performance of this task. Animals were observed for 10 days to ensure that any prolonged or delayed effects would be noted. In all cases for all test paradigms, the authors report that eq-BuChE did not disrupt performance of any of the learned tasks, did not upset the circadian cycle of light=dark activity and had no effect on motor activity. They noted that these outcomes were in contrast to those observed when the standard cholinolytic, atropine, was administered. Finally, they evaluated the protective effects of the levels of enzyme given to the rats in the behavioral studies against MEPQ, a peripherally active organophosphorus compound. Although the level of protection observed was lower than the theoretical prediction, the authors suggested that the simultaneous administration of scavenger and MEPQ might have reduced the efficacy of the administered eq-BuChE. In a separate study, also using eq-BuChE, rhesus monkeys were trained to perform an SPR task (Matzke et al., 1999). Using a six-object list, the monkeys were tested for same–different
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C008 Final Proof page 192 7.11.2007 6:04pm Compositor Name: JGanesan
192
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
TABLE 8.9 Extent of Behavioral Deficits Following Bioscavenger Administration or Conventional Therapy Protection
Species
Atropine
Rat
eq-BuChE
Rat
BuChE Pyridostigmine
Rat Rhesus monkey
eq-BuChE
Rhesus monkey
eq-BuChE
Rhesus monkey
Passive avoidance, VI56 s schedule Passive avoidance, motor activity, VI56 s schedule Morris water maze Primate equilibrium platform (PEP) Serial probe recognition (SPR) Observation, SPR
eq-BuChE BuChE
Rhesus monkey Rhesus monkey
Observation, SPR Spatial discrimination
a b c
Impairmenta
Behavioral Tests
Recovery Timeb
References
Total
>1 week
None
Immediate
None Substantial
Immediate N.D.c
Brandeis et al. (1993) Blick et al. (1994)
None
Immediate
Matzke et al. (1999)
Subtle SPR defect None Minor (1=4 had errors)
~6 days
Castro et al. (1994)
Immediate 1 day
Matzke et al. (1999) Raveh et al. (1997)
Genovese and Doctor (1995) Genovese and Doctor (1995)
Behavioral impairment relative to untreated animals. Time elapsed before performance returns to pretreatment levels. Not determined.
discrimination and delayed same–different discrimination. Once the animals became proficient at the task (80% correct for three successive sessions on three consecutive days) they received eq-BuChE in a dose similar to that reported by Broomfield et al. as sufficient to afford protection against 2 or 3 LD50s of soman (vide supra) (Fidder et al., 1994). The authors reported that repeated administration of commercially prepared eq-BuChE had no effect on the behavior of the monkeys as measured by the SPR studies (Table 8.9). Given the lack of behavioral effects and the relatively long in vivo half-life of the eq-BuChE, they concluded that this biological scavenger was potentially more effective than current chemotherapeutic treatments for organophosphorus intoxication. Other studies in rodents or monkeys using human BuChE also showed virtually no behavioral effects following administration of this enzyme (Brandeis et al., 1993; Raveh et al., 1997; Matzke et al., 1999). In particular, it has recently been reported that administration of high doses (90 mg=kg, i.e., a dose 30-fold higher than that necessary for protection of 2 LD50 of soman in humans) of BuChE to mice induced no toxic behavioral effects (Saxena, 2002).
VIII. SUMMARY Organophosphorus nerve agents represent a very real threat not only to warfighters in the field but also to the public at large (Ember, 1991). Nerve agents have already been used by terrorist groups against a civilian population and, due to their low cost and relative ease of synthesis, are likely to be used again in the future (Masuda et al., 1995). In addition, many commonly used pesticides and chemical manufacturing by-products can act as anticholinesterases and may be a low-dose exposure threat to workers in a variety of professions. Also, we cannot rule out the possibility of the use of anticholinesterase pesticides against civilians in a terrorist context. Current therapeutic regimens for acute nerve agent exposure are generally effective at preventing fatalities if administered in an appropriate time frame. For acute multi-LD50 levels of exposure, pyridostigmine pretreatment
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C008 Final Proof page 193 7.11.2007 6:04pm Compositor Name: JGanesan
193
Nerve Agent Bioscavengers
coupled with postexposure administration of an oxime, atropine, and an anticonvulsant does not prevent the substantial behavioral incapacitation or, in some cases, permanent brain damage that can result from organophosphorus poisoning, although it does enhance survival. It is therefore important from both military and domestic security perspectives to develop novel defenses against nerve agents, including the use of bioscavenger molecules that avoid many of the difficulties associated with current treatments. Although the use of nerve agents on the battlefield may be somewhat predictable, their use in a terrorist situation will be, in all probability, an unanticipatable event. The ability to afford long-term protection for first-responders exposed to toxic or incapacitating concentrations of OPs is a notable potential advantage of biological scavengers. The use of bioscavengers as a defense against OP intoxication has many advantages and few apparent disadvantages. As discussed in detail above, bioscavengers can afford protection against not only mortality, but also most or all of the adverse physiological and behavioral effects of nerve agent exposure. They can be administered prophylactically, precluding the need for immediate postexposure treatment. In addition, the use of bioscavengers has several psychological benefits that are likely to result in a higher degree of user acceptability than exists for conventional therapy. No postexposure autoinjectors are necessary, and protection is afforded with little chance of short- or long-term side effects. Of particular significance is the fact that current candidate bioscavenger proteins are, for the most part, enzymes of human origin. From a scientific standpoint, these proteins are good candidates because they are less likely to be recognized by cells of the immune system and will enjoy prolonged residence times in circulation. From a user point of view, individuals are in essence being protected against nerve agents using a substance that their bodies already produce, rather than being injected with drugs and enzyme inhibitors that alone can produce potent side effects; such a distinction may enhance the comfort and compliance of end users. There are several challenges that must be met in the future before bioscavengers can augment or replace the current therapeutic regimes for nerve agent intoxication. First, scavenger proteins, either alone or in combination, with a range of specificities that encompasses all known nerve agents, must be defined. It is recognized that the immunogenicity and serum half-life of the scavengers must be determined in humans, and efforts may be required to minimize the former and maximize the latter. Finally, appropriate dosages of scavengers that will, based on animal models, protect against concentrations of nerve agents likely to be encountered under a wide range of scenarios must be determined. Although the majority of the research to date has focused on stoichiometric scavengers, the use of either naturally occurring or genetically engineered enzymes with catalytic activity holds the greatest theoretical promise for the development of a broad specificity prophylactic scavenger. Future efforts are likely to focus on generating, characterizing, and using such enzymes in rodent and nonhuman primate models.
REFERENCES Aharoni, A., Gaidukov, L., Yagur, S., Toker, L., Silman, I., and Tawfik, D.S. 2004, ‘‘Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization,’’ Proc. Natl. Acad. Sci. U.S.A., vol. 101, no. 2, pp. 482–487. Aldridge, W.N. 1953a, ‘‘Serum esterases. I. Two types of esterase (A and B) hydrolysing p-nitrophenyl acetate, propionate and butyrate, and a method for their determination,’’ Biochem. J., vol. 53, no. 1, pp. 110–117. Aldridge, W.N. 1953b, ‘‘Serum esterases. II. An enzyme hydrolysing diethyl p-nitrophenyl phosphate (E600) and its identity with the A-esterase of mammalian sera,’’ Biochem. J., vol. 53, no. 1, pp. 117–124. Aldridge, W.N. and Reiner, E. 1972, ‘‘Enzyme Inhibitors as Substrates,’’ North Holland, Amsterdam. Amitai, G., Adani, R., Rabinovitz, I., and Meshulam, H. 2002, ‘‘In vitro Skin Decontamination of VX by Enzymatic Peroxidation,’’ U.S. Army Medical Research Command, Hunt Valley, MD. Amitai, G., Adani, R., Hershkovitz, M., Bel, P., Rabinovitz, I., and Meshulam, H. 2003, ‘‘Degradation of VX and sulfur mustard by enzymatic haloperoxidation,’’ J. Appl. Toxicol., vol. 23, no. 4, pp. 225–233.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C008 Final Proof page 194 7.11.2007 6:04pm Compositor Name: JGanesan
194
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Amitai, G., Gaidukov, L., Adani, R., Yishay, S., Yacov, G., Kushnir, M., Teitlboim, S., Lindenbaum, M., Bel, P., Khersonsky, O., Tawfik, D.S., and Meshulam, H. 2006, ‘‘Enhanced stereoselective hydrolysis of toxic organophosphates by directly evolved variants of mammalian serum paraoxonase,’’ FEBS J., vol. 273, no. 9, pp. 1906–1919. Ashani, Y., Shapira, S., Levy, D., Wolfe, A.D., Doctor, B.P., and Raveh, L. 1991, ‘‘Butyrylcholinesterase and acetylcholinesterase prophylaxis against soman poisoning in mice,’’ Biochem. Pharmacol., vol. 41, no. 1, pp. 37–41. Augustinsson, K.B. 1958, ‘‘Electrophoretic separation and classification of blood esterases,’’ Nature, vol. 131, p. 1786. Aviram, M., Billecke, S., Sorenson, R., Bisgaier, C., Newton, R., Rosenblat, M., Erogul, J., Hsu, C., Dunlop, C., and La Du, B. 1998, ‘‘Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase=paraoxonase activities: selective action of human paraoxonase allozymes Q and R,’’ Arterioscler. Thromb. Vasc. Biol., vol. 18, no. 10, pp. 1617–1624. Bajgar, J., Jakl, A., and Hrdina, V. 1971, ‘‘Effect of atropine and trimedoxime on the acetylcholinesterase activity in some parts of the mouse brain,’’ Cesk. Farm., vol. 20, no. 7, pp. 257–260. Ballantyne, B. and Marrs, T.C. 1992, ‘‘Overview of the biological and clinical aspects of organophosphates and carbamates,’’ in Clinical and Experimental Toxicology of Organophosphates and Carbamates, B. Ballantyne and T.C. Marrs, eds., Butterworth, Oxford, London, p. 1. Billecke, S., Draganov, D., Counsell, R., Stetson, P., Watson, C., Hsu, C., and La Du, B.N. 2000, ‘‘Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters,’’ Drug Metab. Dispos., vol. 28, no. 11, pp. 1335–1342. Bismuth, C., Inns, R.H., and Marrs, T.C. 1992, ‘‘Efficacy, toxicity, and clinical use of oximes in anticholinesterase poisoning,’’ in Clinical and Experimental Toxicology of Organophosphorus and Carbamates, B. Ballantyne and T.C. Marrs, eds., Butterworth, Oxford, London, p. 555. Blatter, M.C., James, R.W., Messmer, S., Barja, F., and Pometta, D. 1993, ‘‘Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase,’’ Eur. J. Biochem., vol. 211, no. 3, pp. 871–879. Blick, D.W., Murphy, M.R., Brown, G.C., Yochmowitz, M.G., Fanton, J.W., and Hartgraves, S.L. 1994, ‘‘Acute behavioral toxicity of pyridostigmine or soman in primates,’’ Toxicol. Appl. Pharmacol., vol. 126, no. 2, pp. 311–318. Brandeis, R., Raveh, L., Grunwald, J., Cohen, E., and Ashani, Y. 1993, ‘‘Prevention of soman-induced cognitive deficits by pretreatment with human butyrylcholinesterase in rats,’’ Pharmacol. Biochem. Behav., vol. 46, no. 4, pp. 889–896. Brimblecombe, R.W. 1977, ‘‘Drugs acting on central cholinergic mechanisms and affecting respiration,’’ Pharmacol. Ther. [B], vol. 3, no. 1, pp. 65–74. Brimfield, A.A., Lenz, D.E., Maxwell, D.M., and Broomfield, C.A. 1993, ‘‘Catalytic antibodies hydrolysing organophosphorus esters,’’ Chem. Biol. Interact., vol. 87, no. 1–3, pp. 95–102. Brites, F.D., Verona, J., Schreier, L.E., Fruchart, J.C., Castro, G.R., and Wikinski, R.L. 2004, ‘‘Paraoxonase 1 and platelet-activating factor acetylhydrolase activities in patients with low hdl-cholesterol levels with or without primary hypertriglyceridemia,’’ Arch. Med. Res., vol. 35, no. 3, pp. 235–240. Broomfield, C.A. 1992, ‘‘A purified recombinant organophosphorus acid anhydrase protects mice against soman,’’ Pharmacol. Toxicol., vol. 70, no. 1, pp. 65–66. Broomfield, C.A., Maxwell, D.M., Solana, R.P., Castro, C.A., Finger, A.V., and Lenz, D.E. 1991, ‘‘Protection by butyrylcholinesterase against organophosphorus poisoning in nonhuman primates,’’ J. Pharmacol. Exp. Ther., vol. 259, no. 2, pp. 633–638. Broomfield, C.A., Millard, C.B., Lockridge, O., and Caviston, T.L. 1995, ‘‘Mutations of human butyrylcholinesterase glycine 117 to histidine preserves activity but confers resistance to organophosphorus inhibitors,’’ in Enzymes of the Cholinesterase Family, D.M. Quinn et al., eds., Plenum Press, New York, p. 169. Broomfield, C.A., Morris, B.C., Anderson, R., Josse, D., and Masson, P. 2000, ‘‘Kinetics of Nerve Agent Hydrolysis by a Human Plasma Enzyme,’’ U.S. Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, MD. Castro, C.A., Larsen, T., Finger, A.V., Solana, R.P., and McMaster, S.B. 1992, ‘‘Behavioral efficacy of diazepam against nerve agent exposure in rhesus monkeys,’’ Pharmacol. Biochem. Behav., vol. 41, no. 1, pp. 159–164.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C008 Final Proof page 195 7.11.2007 6:04pm Compositor Name: JGanesan
Nerve Agent Bioscavengers
195
Castro, C.A., Gresham, V.C., Finger, A.V., Maxwell, D.M., Solana, R.P., Lenz, D.E., and Broomfield, C.A. 1994, ‘‘Behavioral decrements persist in rhesus monkeys trained on a serial probe recognition task despite protection against soman lethality by butyrylcholinesterase,’’ Neurotoxicol. Teratol., vol. 16, no. 2, pp. 145–148. Cerasoli, D.M., Griffiths, E.M., Doctor, B.P., Saxena, A., Fedorko, J.M., Greig, N.H., Yu, Q.S., Huang, Y., Wilgus, H., Karatzas, C.N., Koplovitz, I., and Lenz, D.E. 2005a, ‘‘In vitro and in vivo characterization of recombinant human butyrylcholinesterase (Protexia) as a potential nerve agent bioscavenger,’’ Chem. Biol. Interact., vol. 157–158, pp. 363–365. Cerasoli, D.M., Robison, C.L., Nwaneri, I.Y., Somsamayvong, B., Karatzas, C.N., Wilgus, H., Huang, Y., McDonough, J.H., Lenz, D.E., and Lumley, L.A. 2005b, ‘‘Pretreatment with pegylated protexia protects against exposure to the nerve agents VX and soman,’’ Soc. Neurosci., 31, 337.19. Chabrier, P.E. and Jacob, J. 1980, ‘‘In vivo and in vitro inhibition of cholinesterase by methyl-1 (S methyl phosphoryl-3) imidazolium (MSPI), a model of an ‘instantly’ aged phosphorylated enzyme,’’ Arch. Toxicol., vol. 45, no. 1, pp. 15–20. Cheng, T.C., Liu, L., Wang, B., Wu, J., Frank, J.J., Anderson, D.M., Rastogi, V.K., and Hamilton, A.B. 1997, ‘‘Nucleotide sequence of a gene encoding an organophosphorus nerve agent degrading enzyme from Alteromonas haloplanktis,’’ J. Ind. Microbiol., vol. 18, p. 49. Clement, J.G. 1982, ‘‘HI-6: reactivation of central and peripheral acetylcholinesterase following inhibition by soman, sarin and tabun in vivo in the rat,’’ Biochem. Pharmacol., vol. 31, no. 7, pp. 1283–1287. Clendenning, J.B., Humbert, R., Green, E.D., Wood, C., Traver, D., and Furlong, C.E. 1996, ‘‘Structural organization of the human PON1 gene,’’ Genomics, vol. 35, no. 3, pp. 586–589. Costa, L.G., Li, W.F., Richter, R.J., Shih, D.M., Lusis, A., and Furlong, C.E. 1999, ‘‘The role of paraoxonase (PON1) in the detoxication of organophosphates and its human polymorphism,’’ Chem. Biol. Interact., vol. 119–120, pp. 429–438. Costa, L.G., Cole, T.B., Jarvik, G.P., and Furlong, C.E. 2003a, ‘‘Functional genomics of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism,’’ Annu. Rev. Med., vol. 54, pp. 371–392. Costa, L.G., Richter, R.J., Li, W.F., Cole, T., Guizzetti, M., and Furlong, C.E. 2003b, ‘‘Paraoxonase (PON 1) as a biomarker of susceptibility for organophosphate toxicity,’’ Biomarkers, vol. 8, no. 1, pp. 1–12. Costa, L.G., Cole, T.B., Vitalone, A., and Furlong, C.E. 2005, ‘‘Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity,’’ Clin. Chim. Acta, vol. 352, no. 1–2, pp. 37–47. Dacre, J.C. 1984, ‘‘Toxicology of some anticholinesterases used as a chemical warfare agents—a review,’’ in Cholinesterases, Fundamental and Applied Aspects, M. Brzin, E.A. Barnard, and D. Sket, eds., de Gruyter, Berlin, Germany, p. 415. Davies, H.G., Richter, R.J., Keifer, M., Broomfield, C.A., Sowalla, J., and Furlong, C.E. 1996, ‘‘The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin,’’ Nat. Genet., vol. 14, no. 3, pp. 334–336. de Candole, C.A., Douglas, W.W., Evans, C.L., Holmes, R., Spencer, K.E.V., Torrance, R.W., and Wilson, K.M. 1953, ‘‘The failure of respiration in death by anticholinesterase poisoning,’’ Br. J. Pharmacol. Chemother., vol. 6, p. 466. Doctor, B.P. and Saxena, A. 2005, ‘‘Bioscavengers for the protection of humans against organophosphate toxicity,’’ Chem. Biol. Interact., vol. 157–158, pp. 167–171. Doctor, B.P., Raveh, L., Wolfe, A.D., Maxwell, D.M., and Ashani, Y. 1991, ‘‘Enzymes as pretreatment drugs for organophosphate toxicity,’’ Neurosci. Biobehav. Rev., vol. 15, no. 1, pp. 123–128. Doctor, B.P., Blick, D.W., Caranto, G., Castro, C.A., Gentry, M.K., Larrison, R., Maxwell, D.M., Murphy, M.R., Schutz, M., Waibel, K., et al. 1993, ‘‘Cholinesterases as scavengers for organophosphorus compounds: protection of primate performance against soman toxicity,’’ Chem. Biol. Interact., vol. 87, no. 1–3, pp. 285–293. Doorn, J.A., Sorenson, R.C., Billecke, S.S., Hsu, C., and La Du, B.N. 1999, ‘‘Evidence that several conserved histidine residues are required for hydrolytic activity of human paraoxonase=arylesterase,’’ Chem. Biol. Interact., vol. 119–120, pp. 235–241. Draganov, D.I., Stetson, P.L., Watson, C.E., Billecke, S.S., and La Du, B.N. 2000, ‘‘Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation,’’ J. Biol. Chem., vol. 275, no. 43, pp. 33435–33442.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C008 Final Proof page 196 7.11.2007 6:04pm Compositor Name: JGanesan
196
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Dumas, D.P., Durst, H.D., Landis, W.G., Raushel, F.M., and Wild, J.R. 1990, ‘‘Inactivation of organophosphorus nerve agents by the phosphotriesterase from Pseudomonas diminuta,’’ Arch. Biochem. Biophys., vol. 277, no. 1, pp. 155–159. Dunn, M.A. and Sidell, F.R. 1989, ‘‘Progress in medical defense against nerve agents,’’ JAMA, vol. 262, no. 5, pp. 649–652. Duysen, E.G., Li, B., Darvesh, S., and Lockridge, O. 2006, ‘‘Sensitivity of butyrylcholinesterase knockout mice to (-)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer’s disease drugs and indicates butyrylcholinesterase function in neurotransmission,’’ Toxicology, vol. 233, no. 1–3, pp. 60–69. Ellinghaus, P., Seedorf, U., and Assmann, G. 1998, ‘‘Cloning and sequencing of a novel murine liver carboxylesterase cDNA,’’ Biochim. Biophys. Acta, vol. 1397, no. 2, pp. 175–179. Ember, L. 1991, ‘‘Chemical weapons: plans prepared to destroy Iraqi arms,’’ Chem. Eng. News, vol. 19, p. 6. Erdmann, W., Bosse, I., and Franke, P. 1965, ‘‘Resorption and excretion of toxogonin following intramuscular injection in man,’’ Dtsch. Med. Wochenschr., vol. 90, pp. 1436–1438. Fidder, A., Moes, G.W., Scheffer, A.G., van der Schans, G.P., Baan, R.A., de Jong, L.P., and Benschop, H.P. 1994, ‘‘Synthesis, characterization, and quantitation of the major adducts formed between sulfur mustard and DNA of calf thymus and human blood,’’ Chem. Res. Toxicol., vol. 7, no. 2, pp. 199–204. Fleisher, J.H. and Harris, L.W. 1965, ‘‘Dealkylation as a mechanism for aging of cholinesterase after poisoning with pinacolyl methylphosphonofluoridate,’’ Biochem. Pharmacol., vol. 14, no. 5, pp. 641–650. Fletcher, S.P., Geyer, B.C., Smith, A., Evron, T., Joshi, L., Soreq, H., and Mor, T.S. 2004, ‘‘Tissue distribution of cholinesterases and anticholinesterases in native and transgenic tomato plants,’’ Plant Mol. Biol., vol. 55, no. 1, pp. 33–43. Furlong, C.E., Li, W.F., Costa, L.G., Richter, R.J., Shih, D.M., and Lusis, A.J. 1998, ‘‘Genetically determined susceptibility to organophosphorus insecticides and nerve agents: developing a mouse model for the human PON1 polymorphism,’’ Neurotoxicology, vol. 19, no. 4–5, pp. 645–650. Furlong, C.E., Li, W.F., Brophy, V.H., Jarvik, G.P., Richter, R.J., Shih, D.M., Lusis, A.J., and Costa, L.G. 2000a, ‘‘The PON1 gene and detoxication,’’ Neurotoxicology, vol. 21, no. 4, pp. 581–587. Furlong, C.E., Li, W.F., Richter, R.J., Shih, D.M., Lusis, A.J., Alleva, E., and Costa, L.G. 2000b, ‘‘Genetic and temporal determinants of pesticide sensitivity: role of paraoxonase (PON1),’’ Neurotoxicology, vol. 21, no. 1–2, pp. 91–100. Furlong, C.E., Cole, T.B., Jarvik, G.P., and Costa, L.G. 2002, ‘‘Pharmacogenomic considerations of the paraoxonase polymorphisms,’’ Pharmacogenomics, vol. 3, no. 3, pp. 341–348. Gaidukov, L., Rosenblat, M., Aviram, M., and Tawfik, D.S. 2006, ‘‘The 192R=Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux,’’ J. Lipid Res., vol. 47, no. 11, pp. 2492–2502. Gan, K.N., Smolen, A., Eckerson, H.W., and La Du, B.N. 1991, ‘‘Purification of human serum paraoxonase= arylesterase. Evidence for one esterase catalyzing both activities,’’ Drug Metab. Dispos., vol. 19, no. 1, pp. 100–106. Garcia, G.E., Moorad-Doctor, D., Doctor, B.P., Saxena, A., Lockridge, O., Lenz, D.E., Cerasoli, D., and Huang, Y. 2005, ‘‘Glycan structure comparison of native human plasma butyrylcholinesterase (Hu-BChE) and transgenic goat produced Hu-BChE,’’ FASEB J., vol. 19, p. A867. Genovese, R.F. and Doctor, B.P. 1995, ‘‘Behavioral and pharmacological assessment of butyrylcholinesterase in rats,’’ Pharmacol. Biochem. Behav., vol. 51, no. 4, pp. 647–654. Gordon, J.J., Leadbeater, L., and Maidment, M.P. 1978, ‘‘The protection of animals against organophosphate poisoning by pretreatment with a carbamate,’’ Toxicol. Appl. Pharmacol., vol. 43, no. 1, pp. 207–216. Gouedard, C., Koum-Besson, N., Barouki, R., and Morel, Y. 2003, ‘‘Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins,’’ Mol. Pharmacol., vol. 63, no. 4, pp. 945–956. Gouedard, C., Barouki, R., and Morel, Y. 2004, ‘‘Dietary polyphenols increase paraoxonase 1 gene expression by an aryl hydrocarbon receptor-dependent mechanism,’’ Mol. Cell Biol., vol. 24, no. 12, pp. 5209–5222. Hanke, D.W. and Overton, M.A. 1991, ‘‘Phosphylation kinetic constants and oxime-induced reactivation in acetylcholinesterase from fetal bovine serum, bovine caudate nucleus, and electric eel,’’ J. Toxicol. Environ. Health, vol. 34, no. 1, pp. 141–156. Harel, M., Aharoni, A., Gaidukov, L., Brumshtein, B., Khersonsky, O., Meged, R., Dvir, H., Ravelli, R.B., McCarthy, A., Toker, L., Silman, I., Sussman, J.L., and Tawfik, D.S. 2004a, ‘‘Corrigendum: structure
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C008 Final Proof page 197 7.11.2007 6:04pm Compositor Name: JGanesan
Nerve Agent Bioscavengers
197
and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes,’’ Nat. Struct. Mol. Biol., vol. 11, no. 12, p. 1253. Harel, M., Aharoni, A., Gaidukov, L., Brumshtein, B., Khersonsky, O., Meged, R., Dvir, H., Ravelli, R.B., McCarthy, A., Toker, L., Silman, I., Sussman, J.L., and Tawfik, D.S. 2004b, ‘‘Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes,’’ Nat. Struct. Mol. Biol., vol. 11, no. 5, pp. 412–419. Harris, L.W., Fleisher, J.H., Clark, J., and Cliff, W.J. 1966, ‘‘Dealkylation and loss of capacity for reactivation of cholinesterase inhibited by sarin,’’ Science, vol. 154, no. 747, pp. 404–407. Hartleib, J. and Ruterjans, H. 2001, ‘‘Insights into the reaction mechanism of the diisopropyl fluorophosphatase from Loligo vulgaris by means of kinetic studies, chemical modification and site-directed mutagenesis,’’ Biochim. Biophys. Acta, vol. 1546, no. 2, pp. 312–324. Hassett, C., Richter, R.J., Humbert, R., Chapline, C., Crabb, J.W., Omiecinski, C.J., and Furlong, C.E. 1991, ‘‘Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence,’’ Biochemistry, vol. 30, no. 42, pp. 10141–10149. Heath, A.J.W. and Meredith, T. 1992, ‘‘Atropine in the management of anticholinesterase poisoning,’’ in Clinical and Experimental Toxicology of Organophosphates and Cabamates, B. Ballantyne and T.C. Marrs, eds., Butterworth, Oxford, London, p. 543. Heffron, P.F. and Hobbiger, F. 1979, ‘‘Relationship between inhibition of acetylcholinesterase and response of the rat phrenic nerve-diaphragm preparation to indirect stimulation at higher frequencies,’’ Br. J. Pharmacol., vol. 66, no. 2, pp. 323–329. Huff, B.B. 1986, ‘‘Physician’s Desk Reference,’’ Medical Economics Co. Inc., Oradell. Jakubowski, H. 2000, ‘‘Calcium-dependent human serum homocysteine thiolactone hydrolase. a protective mechanism against protein N-homocysteinylation,’’ J. Biol. Chem., vol. 275, no. 6, pp. 3957–3962. Jakubowski, H., Ambrosius, W.T., and Pratt, J.H. 2001, ‘‘Genetic determinants of homocysteine thiolactonase activity in humans: implications for atherosclerosis,’’ FEBS Lett., vol. 491, no. 1–2, pp. 35–39. James, R.W. and Deakin, S.P. 2004, ‘‘The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity,’’ Free Radic. Biol. Med., vol. 37, no. 12, pp. 1986–1994. Jarv, S. 1984, ‘‘Stereochemical aspects of cholinesterase catalysis,’’ Bioorg. Med. Chem., vol. 12, p. 259. Jokanovic, M., Kosanovic, M., and Maksimovic, M. 1996, ‘‘Interaction of organophosphorus compounds with carboxylesterases in the rat,’’ Arch. Toxicol., vol. 70, no. 7, pp. 444–450. Josse, D., Xie, W., Masson, P., and Lockridge, O. 1999a, ‘‘Human serum paraoxonase (PON1): identification of essential amino acid residues by group-selective labelling and site-directed mutagenesis,’’ Chem. Biol. Interact., vol. 119–120, pp. 71–78. Josse, D., Xie, W., Masson, P., Schopfer, L.M., and Lockridge, O. 1999b, ‘‘Tryptophan residue(s) as major components of the human serum paraoxonase active site,’’ Chem. Biol. Interact., vol. 119–120, pp. 79–84. Josse, D., Xie, W., Renault, F., Rochu, D., Schopfer, L.M., Masson, P., and Lockridge, O. 1999c, ‘‘Identification of residues essential for human paraoxonase (PON1) arylesterase=organophosphatase activities,’’ Biochemistry, vol. 38, no. 9, pp. 2816–2825. Josse, D., Lockridge, O., Xie, W., Bartels, C.F., Schopfer, L.M., and Masson, P. 2001, ‘‘The active site of human paraoxonase (PON1),’’ J. Appl. Toxicol., vol. 21 Suppl. 1, pp. 7–11. Josse, D., Broomfield, C.A., Cerasoli, D., Kirby, S., Nicholson, J., Bahnson, B., and Lenz, D.E. 2002 ‘‘Engineering of HuPON1 for a Use as a Catalytic Bioscavenger in Organophosphate Poisoning,’’ U.S. Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, MD. Khersonsky, O. and Tawfik, D.S. 2005, ‘‘Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase,’’ Biochemistry, vol. 44, no. 16, pp. 6371–6382. Khersonsky, O. and Tawfik, D.S. 2006, ‘‘The histidine 115–134 DYAD mediates the lactonase activity of mammalian serum paraoxonases,’’ J. Biol. Chem. vol. 281, no. 11, pp. 7649–7656. Koelle, G.B. 1963, ‘‘Cholinesterases and anticholinesterases,’’ in Handbuch der Experimentallen Pharmackologie, O. Ekhler and P.I. Feder, eds., Springer-Verlag, Berlin, Germany. Korza, G. and Ozols, J. 1988, ‘‘Complete covalent structure of 60-kDa esterase isolated from 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced rabbit liver microsomes,’’ J. Biol. Chem., vol. 263, no. 7, pp. 3486–3495. Kuo, C.L. and La Du, B.N. 1998, ‘‘Calcium binding by human and rabbit serum paraoxonases. Structural stability and enzymatic activity,’’ Drug Metab. Dispos., vol. 26, no. 7, pp. 653–660.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C008 Final Proof page 198 7.11.2007 6:04pm Compositor Name: JGanesan
198
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
La Du, B.N., Furlong, C.E., and Reiner, E. 1999, ‘‘Recommended nomenclature system for the paraoxonases,’’ Chem. Biol. Interact., vol. 119–120, pp. 599–601. Lacinski, M., Skorupski, W., Cieslinski, A., Sokolowska, J., Trzeciak, W.H., and Jakubowski, H. 2004, ‘‘Determinants of homocysteine-thiolactonase activity of the paraoxonase-1 (PON1) protein in humans,’’ Cell Mol. Biol. (Noisy-le-grand), vol. 50, no. 8, pp. 885–893. Langenberg, J.P., van Dijk, C., Sweeney, R.E., Maxwell, D.M., de Jong, L.P., and Benschop, H.P. 1997, ‘‘Development of a physiologically based model for the toxicokinetics of C(þ=)P(þ=)-soman in the atropinized guinea pig,’’ Arch. Toxicol., vol. 71, no. 5, pp. 320–331. Leadbeater, L., Inns, R.H., and Rylands, J.M. 1985, ‘‘Treatment of poisoning by soman,’’ Fundam. Appl. Toxicol., vol. 5, no. 6 Pt 2, pp. S225–S231. Lenz, D.E. and Cerasoli, D.M. 2002, ‘‘Nerve agent bioscavengers: protection with reduced behavioral effects,’’ Mil. Psychol., vol. 14, p. 121. Lenz, D.E., Brimfield, A.A., and Cook, A.A. 1997, ‘‘The development of immunoassays for detection of chemical warfare agents,’’ in Development and Applications of Immunoassays for Environmental Analysis, D. Aga and E.M. Thurman, eds., ACS Books, Washington DC, p. 77. Lenz, D.E., Maxwell, D.M., Koplovitz, I., Clark, C.R., Capacio, B.R., Cerasoli, D.M., Federko, J.M., Luo, C., Saxena, A., Doctor, B.P., and Olson, C. 2005, ‘‘Protection against soman or VX poisoning by human butyrylcholinesterase in guinea pigs and cynomolgus monkeys,’’ Chem. Biol. Interact., vol. 157–158, pp. 205–210. Li, B., Sedlacek, M., Manoharan, I., Boopathy, R., Duysen, E.G., Masson, P., and Lockridge, O. 2005, ‘‘Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma,’’ Biochem. Pharmacol., vol. 70, no. 11, pp. 1673–1684. Li, W.F., Costa, L.G., and Furlong, C.E. 1993, ‘‘Serum paraoxonase status: a major factor in determining resistance to organophosphates,’’ J. Toxicol. Environ. Health, vol. 40, no. 2–3, pp. 337–346. Li, W.F., Furlong, C.E., and Costa, L.G. 1995, ‘‘Paraoxonase protects against chlorpyrifos toxicity in mice,’’ Toxicol. Lett., vol. 76, no. 3, pp. 219–226. Li, W.F., Costa, L.G., Richter, R.J., Hagen, T., Shih, D.M., Tward, A., Lusis, A.J., and Furlong, C.E. 2000, ‘‘Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds,’’ Pharmacogenetics, vol. 10, no. 9, pp. 767–779. Lockridge, O., Blong, R.M., Masson, P., Froment, M.T., Millard, C.B., and Broomfield, C.A. 1997, ‘‘A single amino acid substitution, Gly117His, confers phosphotriesterase (organophosphorus acid anhydride hydrolase) activity on human butyrylcholinesterase,’’ Biochemistry, vol. 36, no. 4, pp. 786–795. Long, R.M., Satoh, H., Martin, B.M., Kimura, S., Gonzalez, F.J., and Pohl, L.R. 1988, ‘‘Rat liver carboxylesterase: cDNA cloning, sequencing, and evidence for a multigene family,’’ Biochem. Biophys. Res. Commun., vol. 156, no. 2, pp. 866–873. Main, A.R. 1956, ‘‘The role of A-esterase in the acute toxicity of paraoxon, TEPP, and parathion,’’ Can. J. Biochem. Physiol., vol. 34, no. 2, pp. 197–216. Masson, P., Adkins, S., Pham-Trong, P., and Lockridge, O. 1992, ‘‘Expression and refolding of functional human butyrylcholinesterase from E. coli,’’ in Multidisciplinary Approaches to Cholinesterase Function, A. Shafferman and B. Velan, eds., Plenum Press, NY pp. 49–52. Masson, P., Josse, D., Lockridge, O., Viguie, N., Taupin, C., and Buhler, C. 1998, ‘‘Enzymes hydrolyzing organophosphates as potential catalytic scavengers against organophosphate poisoning,’’ J. Physiol. Paris, vol. 92, no. 5–6, pp. 357–362. Masuda, N., Takatsu, M., Morinari, H., and Ozawa, T. 1995, ‘‘Sarin poisoning in Tokyo subway,’’ Lancet, vol. 345, no. 8962, p. 1446. Matsushima, M., Inoue, H., Ichinose, M., Tsukada, S., Miki, K., Kurokawa, K., Takahashi, T., and Takahashi, K. 1991, ‘‘The nucleotide and deduced amino acid sequences of porcine liver proline- beta-naphthylamidase. Evidence for the identity with carboxylesterase,’’ FEBS Lett., vol. 293, no. 1–2, pp. 37–41. Matzke, S.M., Oubre, J.L., Caranto, G.R., Gentry, M.K., and Galbicka, G. 1999, ‘‘Behavioral and immunological effects of exogenous butyrylcholinesterase in rhesus monkeys,’’ Pharmacol. Biochem. Behav., vol. 62, no. 3, pp. 523–530. Maxwell, D.M. 1992, ‘‘The specificity of carboxylesterase protection against the toxicity of organophosphorus compounds,’’ Toxicol. Appl. Pharmacol., vol. 114, pp. 306–312. Maxwell, D.M., Brecht, K.M., and O’Neill, B.L. 1987, ‘‘The effect of carboxylesterase inhibition on interspecies differences in soman toxicity,’’ Toxicol. Lett., vol. 39, no. 1, pp. 35–42.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C008 Final Proof page 199 7.11.2007 6:04pm Compositor Name: JGanesan
Nerve Agent Bioscavengers
199
Maxwell, D.M., Wolfe, A.D., Ashani, Y., and Doctor, B.P. 1991, ‘‘Cholinesterase and carboxylesterase as scavengers for organophosphorus agents,’’ in Cholinesterases: Structure, Function, Mechanism, Genetics and Cell Biology, J. Massoulie et al., eds., American Chemical Society, Washington DC, p. 206. Maxwell, D.M., Castro, C.A., De La Hoz, D.M., Gentry, M.K., Gold, M.B., Solana, R.P., Wolfe, A.D., and Doctor, B.P. 1992, ‘‘Protection of rhesus monkeys against soman and prevention of performance decrement by pretreatment with acetylcholinesterase,’’ Toxicol. Appl. Pharmacol., vol. 115, no. 1, pp. 44–49. Maxwell, D.M., Brecht, K.M., Doctor, B.P., and Wolfe, A.D. 1993, ‘‘Comparison of antidote protection against soman by pyridostigmine, HI-6 and acetylcholinesterase,’’ J. Pharmacol. Exp. Ther., vol. 264, no. 3, pp. 1085–1089. Maxwell, D.M., Lieske, C.N., and Brecht, K.M. 1994, ‘‘Oxime-induced reactivation of carboxylesterase inhibited by organophosphorus compounds,’’ Chem. Res. Toxicol., vol. 7, no. 3, pp. 428–433. Maxwell, D.M., Brecht, K.M., Saxena, A., Feaster, S.R., and Doctor, B.P. 1998, ‘‘Comparison of cholinesterases and carboxylesterases as bioscavengers for organophosphorus compounds,’’ in Structure and Function of Cholinesterases and Related Proteins, B.P. Doctor, D.M. Quinn, and P. Taylor, eds., Plenum Press, New York, p. 387. Maynard, R.L. and Beswick, F.W. 1992, ‘‘Organophosphorus compounds as chemical warfare agents,’’ in Clinical and Experimental Toxicology of Organophosphates and Carbamates, B. Ballantyne and T.C. Marrs, eds., Butterworth, Oxford, London, p. 373. Mazur, A. 1946, ‘‘An enzyme in animal tissues capable of hydrolyzing the phosphorus-fluorine bond of alkyl fluorophosphates,’’ J. Biol. Chem., vol. 164, pp. 271–289. McDonough, J.H. 2002, ‘‘Performance impacts of nerve agents and their pharmacological countermeasures,’’ Mil. Psychol., vol. 14, no. 2, pp. 93–119. Medda, S. and Proia, R.L. 1992, ‘‘The carboxylesterase family exhibits C-terminal sequence diversity reflecting the presence or absence of endoplasmic-reticulum-retention sequences,’’ Eur. J. Biochem., vol. 206, no. 3, pp. 801–806. Mesulam, M.M., Guillozet, A., Shaw, P., Levey, A., Duysen, E.G., and Lockridge, O. 2002, ‘‘Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine,’’ Neuroscience, vol. 110, no. 4, pp. 627–639. Millard, C.B., Lockridge, O., and Broomfield, C.A. 1995, ‘‘Design and expression of organophosphorus acid anhydride hydrolase activity in human butyrylcholinesterase,’’ Biochemistry, vol. 34, no. 49, pp. 15925– 15933. Millard, C.B., Lockridge, O., and Broomfield, C.A. 1998, ‘‘Organophosphorus acid anhydride hydrolase activity in human butyrylcholinesterase: synergy results in a somanase,’’ Biochemistry, vol. 37, no. 1, pp. 237–247. Miller, A.D., Scott, D.F., Chacko, T.L., Maxwell, D.M., Schlager, J.J., and Lanclos, K.D. 1999, ‘‘Expression and partial purification of a recombinant secretory form of human liver carboxylesterase,’’ Protein Expr. Purif., vol. 17, p. 16. Mor, T.S., Sternfeld, M., Soreq, H., Arntzen, C.J., and Mason, H.S. 2001, ‘‘Expression of recombinant human acetylcholinesterase in transgenic tomato plants,’’ Biotechnol. Bioeng., vol. 75, no. 3, pp. 259–266. Morales, R., Beswick, F.W., Carpentier, P., Contreras-Martel, C., Renault, F., Nicodeme, M., Chesne-Seck, M., Bernier, F., Depuy, J., Schaeffer, C., Diemer, H., Van-Dorsselaer, A., Fontecilla-Camps, J.C., Masson, P., Rochu, D., and Chabriere, E. 2006, ‘‘Serendipitous discovery and x-ray structure of a human phosphate binding apolipoprotein,’’ Structure, vol. 14, pp. 1–9. Murakami, K., Takagi, Y., Mihara, K., and Omura, T. 1993, ‘‘An isozyme of microsomal carboxyesterases, carboxyesterase Sec, is secreted from rat liver into the blood,’’ J. Biochem. (Tokyo), vol. 113, no. 1, pp. 61–66. Nachon, F., Wieseler, S., Masson, P., and Lockridge, O. 2003, ‘‘Optimization of the Expression of Human Butyrylcholinesterase,’’ Proceedings NATO TG-004 meeting Medicine Hat, Canada. Ordentlich, A., Kronman, C., Barak, D., Stein, D., Ariel, N., Marcus, D., Velan, B., and Shafferman, A. 1993, ‘‘Engineering resistance to ‘aging’ of phosphylated human acetylcholinesterase. Role of hydrogen bond network in the active center,’’ FEBS Lett., vol. 334, no. 2, pp. 215–220. Ovnic, M., Swank, R.T., Fletcher, C., Zhen, L., Novak, E.K., Baumann, H., Heintz, N., and Ganschow, R.E. 1991a, ‘‘Characterization and functional expression of a cDNA encoding egasyn (esterase-22): the endoplasmic reticulum-targeting protein of beta-glucuronidase,’’ Genomics, vol. 11, no. 4, pp. 956–967.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C008 Final Proof page 200 7.11.2007 6:04pm Compositor Name: JGanesan
200
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Ovnic, M., Tepperman, K., Medda, S., Elliott, R.W., Stephenson, D.A., Grant, S.G., and Ganschow, R.E. 1991b, ‘‘Characterization of a murine cDNA encoding a member of the carboxylesterase multigene family,’’ Genomics, vol. 9, no. 2, pp. 344–354. Ozols, J. 1989, ‘‘Isolation, properties, and the complete amino acid sequence of a second form of 60-kDa glycoprotein esterase. Orientation of the 60-kDa proteins in the microsomal membrane,’’ J. Biol. Chem., vol. 264, no. 21, pp. 12533–12545. Parsa, R. and Green, H. 2001, ‘‘Destruction of DFP by organophosphorus acid anhydrase covalently coupled to the cornified layer of human epidermis,’’ in Proceedings of the International Symposium on Applications of Enzymes in Chemical and Biological Defense, Orlando, FL. Patel, P., Clark, C.R., Brecht, K., Maxwell, D.M., Lenz, D.E., and Cerasoli, D. 2005, ‘‘Binding of organophosphorus compounds to sera from rats, guinea pigs, monkeys and humans,’’ FASEB J., vol. 19, no. 5, Abstract 527.13 edn. Petrikovics, I., Papahadjopoulos, D., Hong, K., Cheng, T.C., Baskin, S.I., Jiang, J., Jaszberenyi, J.C., Logue, B.A., Szilasi, M., McGuinn, W.D., and Way, J.L. 2004, ‘‘Comparing therapeutic and prophylactic protection against the lethal effect of paraoxon,’’ Toxicol. Sci., vol. 77, no. 2, pp. 258–262. Poyot, T., Nachon, F., Froment, M.T., Loiodice, M., Wieseler, S., Schopfer, L.M., Lockridge, O., and Masson, P. 2006, ‘‘Mutant of Bungarus fasciatus acetylcholinesterase with low affinity and low hydrolase activity toward organophosphorus esters,’’ Biochim. Biophys. Acta, vol. 1764, no. 9, pp. 1470–1478. Primo-Parmo, S.L., Sorenson, R.C., Teiber, J., and La Du, B.N. 1996, ‘‘The human serum paraoxonase=arylesterase gene (PON1) is one member of a multigene family,’’ Genomics, vol. 33, no. 3, pp. 498–507. Raveh, L., Grunwald, J., Marcus, D., Papier, Y., Cohen, E., and Ashani, Y. 1993, ‘‘Human butyrylcholinesterase as a general prophylactic antidote for nerve agent toxicity. In vitro and in vivo quantitative characterization,’’ Biochem. Pharmacol., vol. 45, no. 12, pp. 2465–2474. Raveh, L., Grauer, E., Grunwald, J., Cohen, E., and Ashani, Y. 1997, ‘‘The stoichiometry of protection against soman and VX toxicity in monkeys pretreated with human butyrylcholinesterase,’’ Toxicol. Appl. Pharmacol., vol. 145, no. 1, pp. 43–53. Robbi, M. and Beaufay, H. 1992, ‘‘Topogenesis of carboxylesterases: a rat liver isoenzyme ending in -HTEHTCOOH is a secreted protein,’’ Biochem. Biophys. Res. Commun., vol. 183, no. 2, pp. 836–841. Robbi, M., Beaufay, H., and Octave, J.N. 1990, ‘‘Nucleotide sequence of cDNA coding for rat liver pI 6.1 esterase (ES-10), a carboxylesterase located in the lumen of the endoplasmic reticulum,’’ Biochem. J., vol. 269, no. 2, pp. 451–458. Rochu, D., Chabrieres, E., and Masson, P. 2007, ‘‘Human paraoxonase: a promising approach for pre-treatment and therapy of organophosphorus poisoning,’’ Toxicology, vol. 233, no. 1–3, pp. 47–59. Rodrigo, L., Mackness, B., Durrington, P.N., Hernandez, A., and Mackness, M.I. 2001, ‘‘Hydrolysis of platelet-activating factor by human serum paraoxonase,’’ Biochem. J., vol. 354, no. Pt 1, pp. 1–7. Rosenblat, M., Gaidukov, L., Khersonsky, O., Vaya, J., Oren, R., Tawfik, D.S., and Aviram, M. 2006, ‘‘The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux,’’ J. Biol. Chem., vol. 281, pp. 7657–7665. Satoh, T. 1987, ‘‘Role of carboxylesterases in xenobiotic metabolism,’’ in Reviews in Biological Toxicology, vol. 8 E. Hodgsen, J.R. Bend, and R.M. Philpot, eds., Elsevier, New York, p. 155. Satoh, T. and Hosokawa, M. 1998, ‘‘The mammalian carboxylesterases: from molecules to functions,’’ Annu. Rev. Pharmacol. Toxicol., vol. 38, pp. 257–288. Satoh, T. and Hosokawa, M. 2006, ‘‘Structure, function and regulation of carboxylesterases,’’ Chem. Biol. Interact., vol. 162, no. 3, pp. 195–211. Saxena, A. 2002, ‘‘Human Serum Butyrylcholinesterase: A Future Generation Antidote for Organophosphate Chemical Warfare Agent Toxicity,’’ Proceedings of the Seventh International meeting on cholinesterases, Pucon, Chile. Saxena, A., Sun, W., Luo, C., and Doctor, B.P. 2005, ‘‘Human serum butyrylcholinesterase: in vitro and in vivo stability, pharmacokinetics, and safety in mice,’’ Chem. Biol. Interact., vol. 157–158, pp. 199–203. Schwer, H., Langmann, T., Daig, R., Becker, A., Aslanidis, C., and Schmitz, G. 1997, ‘‘Molecular cloning and characterization of a novel putative carboxylesterase, present in human intestine and liver,’’ Biochem. Biophys. Res. Commun., vol. 233, no. 1, pp. 117–120. Serdar, C.M. and Gibson, D.T. 1985, ‘‘Enzymatic hydrolysis of organophosphates: cloning and expression of a parathion hydrolase gene from Pseudomonas diminuta,’’ Biotechnology, vol. 3, p. 567.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C008 Final Proof page 201 7.11.2007 6:04pm Compositor Name: JGanesan
Nerve Agent Bioscavengers
201
Shibata, F., Takagi, Y., Kitajima, M., Kuroda, T., and Omura, T. 1993, ‘‘Molecular cloning and characterization of a human carboxylesterase gene,’’ Genomics, vol. 17, p. 76. Shih, D.M., Gu, L., Xia, Y.R., Navab, M., Li, W.F., Hama, S., Castellani, L.W., Furlong, C.E., Costa, L.G., Fogelman, A.M., and Lusis, A.J. 1998, ‘‘Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis,’’ Nature, vol. 394, no. 6690, pp. 284–287. Sidell, F.R. and Groff, W.A. 1970, ‘‘Toxogonin: blood levels and side effects after intramuscular administration in man,’’ J. Pharm. Sci., vol. 59, no. 6, pp. 793–797. Siritunga, D. and Sayre, R.T. 2003, ‘‘Generation of cyanogen-free transgenic cassava,’’ Planta, vol. 217, no. 3, pp. 367–373. Somani, S.M., Solana, R.P., and Dube, S.N. 1992, ‘‘Toxiodynamics of nerve agents,’’ in Chemical Warfare Agents, S.M. Somani, ed., Academic Press, San Diego, CA, p. 68. Sone, T., Isobe, M., Takabatake, E., and Wang, C.Y. 1994, ‘‘Cloning and sequence analysis of a hamster liver cDNA encoding a novel putative carboxylesterase,’’ Biochim. Biophys. Acta, vol. 1207, no. 1, pp. 138–142. Sorenson, R.C., Primo-Parmo, S.L., Kuo, C.L., Adkins, S., Lockridge, O., and La Du, B.N. 1995, ‘‘Reconsideration of the catalytic center and mechanism of mammalian paraoxonase=arylesterase,’’ Proc. Natl. Acad. Sci. U.S. A., vol. 92, no. 16, pp. 7187–7191. Sorenson, R.C., Bisgaier, C.L., Aviram, M., Hsu, C., Billecke, S., and La Du, B.N. 1999, ‘‘Human serum Paraoxonase=Arylesterase’s retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity,’’ Arterioscler. Thromb. Vasc. Biol., vol. 19, no. 9, pp. 2214–2225. Stewart, W.C. 1959, ‘‘The effects of sarin and atropine on the respiratory center and neuromuscular junctions of the rat,’’ Can. J. Biochem. Physiol., vol. 37, no. 5, pp. 651–660. Stewart, W.C. and Anderson, E.A. 1968, ‘‘Effect of a cholinesterase inhibitor when injected into the medulla of the rabbit,’’ J. Pharmacol. Exp. Ther., vol. 162, no. 2, pp. 309–318. Talbot, B.G., Anderson, D.R., Harris, L.W., Yarbrough, L.W., and Lennox, W.J. 1988, ‘‘A comparison of in vivo and in vitro rates of aging of soman-inhibited erythrocyte acetylcholinesterase in different animal species,’’ Drug Chem. Toxicol., vol. 11, no. 3, pp. 289–305. Taylor, P. 2001a, ‘‘Agents acting at the neuromuscular junction and autonomic ganglia,’’ in Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 10th edn, J.G. Hardman, L.E. Limbird, and A.G. Gilman, eds., McGraw-Hill, New York, pp. 193–214. Taylor, P. 2001b, ‘‘Anticholinesterase agents,’’ in Goodman and Gillman’s The Pharmacological Basis of Therapeutics, 10th edn, J.G. Hardman and L.E. Limbird, eds., Macmillan Publishing Company, New York, pp. 175–192. Teiber, J.F., Draganov, D.I., and La Du, B.N. 2003, ‘‘Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3,’’ Biochem. Pharmacol., vol. 66, no. 6, pp. 887–896. Tuovinen, K., Kaliste-Korhonen, E., Raushel, F.M., and Hanninen, O. 1999, ‘‘Success of pyridostigmine, physostigmine, eptastigmine and phosphotriesterase treatments in acute sarin intoxication,’’ Toxicology, vol. 134, no. 2–3, pp. 169–178. van Himbergen, T.M., van Tits, L.J., Roest, M., and Stalenhoef, A.F. 2006, ‘‘The story of PON1: how an organophosphate-hydrolysing enzyme is becoming a player in cardiovascular medicine,’’ Neth. J. Med., vol. 64, no. 2, pp. 34–38. Vojvodic, V. 1970, ‘‘Blood levels, urinary excretion and potential toxicity of N,N0 -trimethylenebis(pyridinium4-aldoxime) dichloride (TMB-4) in healthy man following intramuscular injection of oxime,’’ Eur. J. Clin. Pharmacol., vol. 2, p. 216. Welch, R.W., Campbell, J., Toledo, A., Davis, D., Latzgo, H., Haupt, G., Love, K., Sly, J.M., Cohen, G., Eisenberg, R., Whitbeck, J.C., Aldaz-Carroll, L., Lou, H., Lenz, D.E., Patel, P., and Cerasoli, D. 2006, ‘‘Rapid production of recombinant proteins utilizing the PERLXpress platform,’’ Bioprocessing J., vol. 5, no. 2, pp. 63–70. Wenger, G.R. 1979, ‘‘Effects of physostigmine, atropine and scopolamine on behavior maintained by a multiple schedule of food presentation in the mouse,’’ J. Pharmacol. Exp. Ther., vol. 209, no. 1, pp. 137–143. Wiezorek, W., Kreisel, W., Schnitzlein, W., and Matzkowski, H. 1968, ‘‘Eigenwirkungen von trimedoxin und pralidoxim am menschen,’’ Zeitschr. Militarmed., vol. 4, p. 223.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 46616_C008 Final Proof page 202 7.11.2007 6:04pm Compositor Name: JGanesan
202
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Wolfe, A.D., Rush, R.S., Doctor, B.P., Koplovitz, I., and Jones, D. 1987, ‘‘Acetylcholinesterase prophylaxis against organophosphate toxicity,’’ Fundam. Appl. Toxicol., vol. 9, no. 2, pp. 266–270. Wolfe, A.D., Blick, D.W., Murphy, M.R., Millers, S.A., Gentry, M.K., Hartgraves, S.L., and Doctor, B.P. 1992, ‘‘Use of cholinesterases as pretreatment drugs for the protection of rhesus monkeys against soman toxicity,’’ Toxicol. Appl. Pharmacol., vol. 117, no. 2, pp. 189–193. Xiong, L. and Sayre, R.T. 2004, ‘‘Engineering the chloroplast encoded proteins of chlamydomonas,’’ Photosynth. Res., vol. 80, no. 1–3, pp. 411–419. Yan, B., Yang, D., Brady, M., and Parkinson, A. 1994, ‘‘Rat kidney carboxylesterase. Cloning, sequencing, cellular localization, and relationship to rat liver hydrolase,’’ J. Biol. Chem., vol. 269, no. 47, pp. 29688– 29696. Yeung, D.T., Josse, D., Nicholson, J.D., Khanal, A., McAndrew, C.W., Bahnson, B.J., Lenz, D.E., and Cerasoli, D.M. 2004, ‘‘Structure=function analyses of human serum paraoxonase (HuPON1) mutants designed from a DFPase-like homology model,’’ Biochim. Biophys. Acta, vol. 1702, no. 1, pp. 67–77. Yeung, D.T., Lenz, D.E., and Cerasoli, D.M. 2005, ‘‘Analysis of active-site amino-acid residues of human serum paraoxonase using competitive substrates,’’ FEBS J., vol. 272, no. 9, pp. 2225–2230. Yeung, D.T., Smith, J.R., Sweeney, R.E., Lenz, D.E., and Cerasoli, D. 2006, ‘‘Direct detection of stereospecific soman (GD) hydrolysis by wild-type human serum paraoxonase (HuPON1),’’ FEBS J. Yli-Kauhaluoma, J., Humppi, T., and Yliniemela, A. 1999, ‘‘Hydrolysis of organophosphorus nerve agent soman by the monoclonal antibodies elicited against an oxyphosphorane hapten,’’ Acta Chem. Scand., vol. 53, pp. 473–479.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C009 Final Proof page 203 7.11.2007 5:46pm Compositor Name: BMani
and Its 9 Butyrylcholinesterase Synthetic C-Terminal Peptide Confer In Vitro Suppression of Amyloid Fibril Formation Erez Podoly, Sophia Diamant, Assaf Friedler, Oded Livnah, and Hermona Soreq CONTENTS I. Introduction.......................................................................................................................... 203 II. Background.......................................................................................................................... 204 A. Butyrylcholinesterase Functions as a Natural Bioscavenger....................................... 204 B. Definition of Amyloid-b Peptides ............................................................................... 205 C. Toxic Ab Protofibrils Precede Plaque Formation ....................................................... 205 III. Methodology ........................................................................................................................ 206 A. Enzymes ....................................................................................................................... 206 B. Peptides ........................................................................................................................ 206 C. Kinetics of Ab Fibril Formation Monitored by Fluorescence Measurements ............ 206 D. Circular Dichroism Measurements .............................................................................. 206 E. Peptide Modeling......................................................................................................... 207 IV. Outcome and Discussion ..................................................................................................... 207 A. Circulation Butyrylcholinesterase Levels Increase with Age...................................... 207 B. Butyrylcholinesterase Attenuates Fibril Formation in a Dose Dependent Manner..... 208 C. Butyrylcholinesterase–Ab Interactions Affect Its Catalytic Properties....................... 209 D. Synaptic Acetylcholinesterase and Butyrylcholinesterase Have High Homology but Distinct Peripheral Anionic Sites and C Termini.................................................. 210 E. Structural Modeling Implications ................................................................................ 211 F. Aromaticity Considerations ......................................................................................... 213 G. Inverse Roles for Butyrylcholinesterase and Synaptic Acetylcholinesterase in Fibril Formation....................................................................................................... 213 H. Therapeutic Considerations.......................................................................................... 213 V. Summary and Conclusions .................................................................................................. 214 Acknowledgments......................................................................................................................... 214 References ..................................................................................................................................... 215
I. INTRODUCTION The reaction of alcohols and phosphoric acid yields organophosphate (OP) molecules that prevent the breakdown of the neurotransmitter acetylcholine (ACh) through inhibition of the hydrolytic activity of acetylcholinesterase (AChE). OPs were initially aimed to fight insects, but further 203
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
204
46616_C009 Final Proof page 204 7.11.2007 5:46pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
developments turned them into chemical weapons (Gallo and Lawryk, 1991; Chambers et al., 2001). Within the central nervous system and in the neuromuscular junctions, AChE is vital for the transmission of cholinergic impulses. A closely similar enzyme, butyrylcholinesterase (BChE) is also capable of hydrolyzing ACh. It has been suggested that human BChE from plasma participates in the endogenous scavenging of naturally occurring drugs (e.g., physostigmine, cocaine), manmade therapeutics (e.g., succinylcholine), as well as anticholinesterase-based pesticides and chemical warfare agents (Raveh et al., 1993, 1997; Jbilo et al., 1994; Schwarz et al., 1995; Sun et al., 2002; Giacobini, 2004), and as such serves as an inherent protector from the short-term damages caused by neurotoxic agents (Glick et al., 2003). Consequently, BChE administration was proposed as a putative prophylactic and therapeutic treatment of OP-poisoned subjects (Doctor and Saxena, 2005). Preclinical studies in various experimental animal models (rats, mice, and monkeys) supported the notion that this treatment may be palliatively successful (Ashani et al., 1991; Doctor and Saxena, 2005). However, the dangers of OP poisoning are not limited to the immediate effects, and it remained unclear whether BChE administration per se would not entail long-term damages. This question became particularly important in view of findings that synaptic acetylcholinesterase (AChE-S) exacerbates the formation of amyloid fibrils, the primary neuropathology characteristic of Alzheimer’s disease (AD) (Inestrosa et al., 1996a, 1996b, 2005; Rees et al., 2003, 2005). AChE and BChE show considerable similarities at the genetic, structural, and enzyme kinetics levels (Chatonnet and Lockridge, 1989; Soreq and Zakut, 1993). In the human brain, BChE is found in neurons and glial cells, as well as in neuritic plaques and tangles in AD patients (Darvesh et al., 2003). Moreover, BChE activity increases in the AD brain, whereas AChE activity decreases progressively (Greig et al., 2002; Giacobini, 2003). This finding raised the question whether BChE, like AChE-S, facilitates the formation of amyloid fibrils. Here, we present findings indicating that BChE does not facilitate—rather, it may attenuate the formation of amyloid fibrils. As such, it is advantageous over AChE-S in that its use would not entail long-term damages; rather, it may possibly serve to neuroprotect treated subjects not only at the short time range, but also in a longer time frame. Thioflavin T (ThT) fluorescence measurements (Jarrett and Lansbury, 1993) enabled us to reveal that BChE is capable of attenuating the in vitro formation of amyloid fibrils from the AD beta-amyloid peptide, unlike AChE-S, which facilitates such fibril formation. The C-terminal of BChE was identified as responsible for this attenuation function, and a synthetic peptide having the C-terminal sequence of human BChE, BSP41 was found capable of performing a similarly effective attenuation of fibril formation as BChE. AChE-S, in comparison, promoted fibril formation, and its C-terminal peptide, ASP40, failed to affect this process. Structural modeling and circular dichroism (CD) analyses revealed that both ASP40 and BSP41 peptides form symmetric amphipathic helices. Site-directed mutagenesis showed that an arginine-totryptophan substitution in BSP41 is an essential, although insufficient, cause of this intriguing feature of BSP41. Thus, the imperfect amphipathicity of this helix, and the polar properties in the microenvironment of the substituted tryptophan, cooperate to attenuate fibril formation. Together, these findings present neuronal BChE as a potential inherent natural protector from the development of AD neuropathology and increase its value for future therapeutic uses, as it can delay and prevent the long-term neurotoxic consequences of exposure to poisonous warfare agents.
II. BACKGROUND A. BUTYRYLCHOLINESTERASE FUNCTIONS
AS A
NATURAL BIOSCAVENGER
BChE (EC 3.1.1.8), the primary circulating cholinesterase, is found in addition to serum, in liver, lungs, muscles, and heart. BChE presumably functions in lipoprotein metabolism, myelin maintenance, and cellular adhesion (La Du and Lockridge, 1986; Jbilo et al., 1994). In the human brain, the enzyme is found in neurons and glia and was proposed to participate in neurogenesis and neurite
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C009 Final Proof page 205 7.11.2007 5:46pm Compositor Name: BMani
Butyrylcholinesterase and Its Synthetic C-Terminal Peptide Confer
205
growth (Darvesh and Hopkins, 2003). In AD, BChE’s activity increases in the brain (Ballard et al., 2005), where it is found in senile plaques and neurofibrillary tangles (Carson et al., 1991; Guillozet et al., 1997), co-localizing with brain fibrils of amyloid-b peptides (Ab) (Wright et al., 1993). In vitro and in vivo studies demonstrate that BChE functions as a natural bioscavenger. Operating like a sponge, it may absorb and degrade OP poisons (e.g., nerve agents) before they cause neurological damage (Grunwald et al., 1997). Of the cholinesterases evaluated so far, human serum BChE (purified from plasma) provided substantial support to this neuroprotection concept in terms of preclinical development. However, human serum proteins are available in limited quantities, and their use may entail health-related dangers. A putative alternative was offered by transgenic goats, producing human BChE in their milk (Cerasoli et al., 2005). Here, we demonstrate that BChE’s protective role expands beyond OP poisoning and includes also protection against amyloid neurotoxicity, in contrast with AChE-S, which poses putative long-term risks. Our findings predict a previously nonperceived added value to the therapeutic use of human BChE protein.
B. DEFINITION OF AMYLOID-b PEPTIDES The amyloid-b peptide (Ab) has been identified as a 4 kDa hydrophobic nonglycosylated peptide consisting of 39–43 amino acid residues. It is derived by specific endoproteolytic cleavages from a 700 amino acid residue-long membrane-associated glycoprotein, named ‘‘amyloid precursor protein’’ (APP) (Citron et al., 1996; Dickson, 1997). Ab appears in bundles of amyloid fibrils surrounded by abnormal neurites, and is believed to be the major component of the vascular and plaque filaments in individuals with AD, elderly people, and trisomy 21 carriers (Down’s Syndrome) (Head and Lott, 2004). In vitro studies indicate that synthetic Ab1–42 (Ab42) can form insoluble aggregates and cause neurotoxicity after incubation for several days (Forloni et al., 1996). These Ab42 assemblies may be stained by Congo red and Thioflavin S, similar to those observed in the AD brain (Jarrett and Lansbury, 1993). Both Ab1–40 (Ab40) and Ab42 are formed intracellularly, but exert damaging effects when transported outside of cells. Ab42 is more hydrophobic and toxic than Ab40, and its fibrils clump together to form amyloid plaques (Lue et al., 1999). Although Ab42 is the abundant Ab form in neuritic plaques, Ab40 is more abundant in cerebrovascular plaques (Lue et al., 1999).
C. TOXIC Ab PROTOFIBRILS PRECEDE PLAQUE FORMATION Several studies indicate that the toxicity of Ab and other amyloidogenic proteins lies not in the insoluble fibrils that accumulate in AD plaques, but rather in the soluble oligomeric intermediates (Hardy and Selkoe, 2002). These soluble oligomers include spherical particles of 2.7–4.2 nm in diameter and curvilinear structures called ‘‘protofibrils’’ that appear to represent strings of the spherical particles (Hartley et al., 1999). Recently, it was proposed that a 56 kDa soluble Ab assembly contributes to the cognitive deficits associated with AD (Lesne et al., 2006). The soluble Ab oligomers form protein micelles because Ab is an amphipathic surface-active peptide (Cruz et al., 1997). Intriguingly, Ab oligomers formation displays critical concentration dependence, and is correlated with the appearance of a hydrophobic environment (Soreghan et al., 1994; Tjernberg et al., 1999; Levine, 2003). The content of soluble Ab in the human brain is better correlated with the severity of the disease than are plaques (Kuo et al., 1996; Lue et al., 1999; McLean et al., 1999). Thus, soluble oligomers may be more important pathologically than the fibrillar amyloid deposits (Kayed et al., 2003), and agents counteracting their toxicity are continuously sought. In vitro toxicity studies with synthetic Ab peptides have shown that Ab, in an aggregated state (fibril, protofibril, low molecular weight oligomer, or diffusible, nonfibrillar ligand), is toxic to neurons in culture (Pike et al., 1991). Ab42 oligomers that are soluble and highly neurotoxic assemble under conditions that block fibril formation (Chromy et al., 2003). These oligomers
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
206
46616_C009 Final Proof page 206 7.11.2007 5:46pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
bind to dendritic surfaces in small clusters with ligand-like specificity and are capable of destroying hippocampal neurons at nanomolar concentrations (Standridge, 2006). AD is likely triggered by these soluble, neurotoxic assemblies of Ab rather than the late stage pathology landmarks of amyloid plaques and tangles (Standridge, 2006), suggesting that both inherent and therapeutic neuroprotective agents would operate by interacting with such assemblies and by masking their neurotoxicity.
III. METHODOLOGY A. ENZYMES Purified human BChE (from human serum, ~90% pure, as demonstrated by gel electrophoresis, data not shown) and recombinant human AChE-S were from Sigma (Jerusalem, Israel). Enzymatic activity was determined by hydrolysis rates of butyryl- or acetyl-thiocholine, respectively, at 258C or 48C, as indicated. Enzyme concentrations were calculated based on the molecular weight of a protein monomer and its known amino acid composition.
B. PEPTIDES Peptides were synthesized according to the C-terminal sequences of human AChE-S and BChE (SwissProt accession nos. P06276 and P22303, respectively) using a Pioneer or a 433A peptide synthesizer (Applied Biosystems). Purification (>90%) by reverse-phase HPLC was followed by MALDI-TOF mass spectrometry.
C. KINETICS OF Ab FIBRIL FORMATION MONITORED BY FLUORESCENCE MEASUREMENTS The fluorescence excitation spectrum of the Thioflavin T (ThT, Sigma, Jerusalem, Israel) shifts from 340 to 450 nm when interacting with b-sheet amyloid structures (Levine, 1993, 1999). Fluorescence signals (excitation, 450 nm; emission, 485 nm) reflect the amount of amyloid fibrils formed. To follow the kinetics of amyloid fibril formation, a synthetic Ab40 peptide (from Biosource, Camarillo, CA, USA or Sigma, Jerusalem, Israel) was dissolved in 1.6 mM dimethylsulfoxide (DMSO), sonicated (3 3 5 sec pulses), filtered through 0.22 mm filters, and stored at 708C. Aliquotes of Ab were diluted to a final concentration of 162 mM in 20 mL phosphate-buffered saline (PBS) containing 0.02% NaN3 (fibrillation buffer) with or without cholinesterases or synthetic peptides, using white multiwell plates (96 wells, Nunc, Roskilde, Denmark). Following 20 min pre-incubation at room temperature, 80 mL of 1.25 mM ThT in 50 mM glycine-NaOH, pH 8.5, was added for 6–10 h shaking at 200 rpm, 308C. Fluorescence was measured at 10–30 min intervals. Assessment of the fibril formation process involved measuring the lag preceding the onset of fluorescence increase (the nucleation process) and the apparent maximal rate of fluorescence increase (rate of fibril formation) for 300–600 min, depending on the duration of the lag phase. Mean standard error and the kinetic parameters were calculated using Kaleidagraph Software (Reading, PA, USA).
D. CIRCULAR DICHROISM MEASUREMENTS Synthetic peptides, based on the C-terminal sequences of AChE-S and BChE, were dissolved in double distilled water (DDW) to a final concentration of 1 3 104 M. Direct CD spectra were recorded at room temperature using a CD Jasco J-810 Spectropolarimeter (Easton, MD, USA) using Hellma 100-QS; 1 mm path length quartz cuvette (Hellma GmbHandCoKg, Germany). Recordings were at 0.5 nm intervals in the spectral range 185–260 nm.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C009 Final Proof page 207 7.11.2007 5:46pm Compositor Name: BMani
Butyrylcholinesterase and Its Synthetic C-Terminal Peptide Confer
207
E. PEPTIDE MODELING Model construction of the analyzed peptides involved the Deep View spdbv 3.7 software (Glaxo Smith Kline, Bredford, UK) followed by distance geometry minimization. Figures were created using the PyMol software (DeLano Scientific LLS, San Carlos, CA, USA). Symmetric tetramers were modeled using CHI suite of macros for CNS 1.1 (Adams et al., 1995). Calculation was carried out in vacuo in initial coordinates of a canonical alpha helix (3.6 res. per turn) and initial cross angle (258).
IV. OUTCOME AND DISCUSSION A. CIRCULATION BUTYRYLCHOLINESTERASE LEVELS INCREASE
WITH
AGE
Mean activity (nmol substrate hydrolyzed / min mL)
In a U.S. cohort of 472 subjects of Caucasians and African-Americans, the serum levels of both AChE and BChE were found to increase with age by approximately 20% between 20 and 55 years of age (Figure 9.1, Sklan et al. [2004]). Substrate hydrolysis rates per mL serum were predictably 20-fold higher for BChE as compared with AChE, in spite of the slower rate of ACh hydrolysis by BChE (Schwarz et al., 1995). This emphasizes the pivotal importance of BChE for determining the cholinergic status in the human circulation. Parallel findings were obtained in an Israeli cohort (Bryk et al., 2005), suggesting accumulation of cholinesterases in the circulation of aging individuals from various ethnic origins. The possibility of causal involvement of BChE in the progression of AD has long been discussed in the literature (Ballard et al., 2005), but its possible mode of action remained obscure. Our findings demonstrate that BChE is capable of delaying and suppressing fibril formation,
AChE
450
350 R 2 = 0.73 250 8000
BChE
6500
R 2 = 0.80 5000 15–25 25–35
35–45 45–55 55–66
Age (years)
FIGURE 9.1 Progressive elevation of serum AChE and BChE activities with age. Shown are the average values for a U.S. cohort of 472 volunteers. (From Sklan, E.H., Lowenthal, A., Korner, M., Ritov, Y., Landers, D.M., Rankinen, T., Bouchard, C., Leon, A.S., Rice, T., Rao, D.C., Wilmore, J.H., Skinner, J.S. and Soreq, H., Proc. Natl. Acad. Sci. U.S.A., 101, 5512, 2004.) R2 values for the age-dependant increases in AChE and BChE activities were calculated by using the two-tailed Student’s t test.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
208
46616_C009 Final Proof page 208 7.11.2007 5:46pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
inverse to the facilitation of this process by the highly homologous AChE-S protein. Intriguingly, the core of BChE’s action on amyloid fibrils lays in its C terminus, whereas the corresponding peptide of AChE-S failed to affect this process.
B. BUTYRYLCHOLINESTERASE ATTENUATES FIBRIL FORMATION
IN A
DOSE DEPENDENT MANNER
Fibril formation from 33 mM Ab peptide was first quantified by measuring online changes in ThT fluorescence in reaction mixtures including increasing concentrations of purified human BChE, recombinant AChE-S, or both. The presence of AChE-S or BChE conferred distinct kinetics of amyloid-b sheets formation in vitro. Our preassumption was that in the immediate vicinity of nerve cells, Ab concentrations would exceed those of BChE by far. Therefore, we used 1:100 ratios of cholinesterases to Ab. Purified BChE added to Ab prolonged the lag and reduced the apparent rate of amyloid fibril formation in a dose-dependent manner. Thus, addition of 2.4 mg BChE to 14.3 mg Ab in a total volume of 100 mL prevented fibril formation for over 600 min. In contrast, addition of similar doses of AChE-S to Ab caused an inverse effect by shortening by half the lag time before fibril formation (from 240 to 150 min) and increasing the rate of fibril formation in a dosedependent manner. Compatible with the findings of others, 1:100 molar amounts of AChE-S increased the apparent maximal rate of amyloid fibril formation from 0.36 fluorescence units=h (McLean et al., 1999) for 14.3 mg Ab alone to 0.696 for Ab in the presence of 2.3 mg AChE-S, in a total volume of 100 mL (Figure 9.2). Thus, the effects of AChE and BChE on this process were inverse to each other. Next, we challenged the capacity of BChE to compete with the AChE effect. BChE doses added to a mix of 33 mM Ab in the presence of 0.4 mM AChE-S caused dosedependent interference with the fibril formation process (Diamant et al., 2006). Importantly, the rate of fibril formation in the presence of both enzymes receded to the slow rate observed for Ab
400
Lag (min)
300
200
100
Rate (Fu /min)
0
0.1
0.05
0 Aβ
Aβ + BChE Aβ + AChE-S
FIGURE 9.2 BChE prolongs the lag and reduces the rate of fibril formation. Shown are the average values for the lag period preceding fibril formation and the rate of changes in ThT fluorescence for Ab alone, BChE þ Ab, and AChE-S þ Ab.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C009 Final Proof page 209 7.11.2007 5:46pm Compositor Name: BMani
209
Butyrylcholinesterase and Its Synthetic C-Terminal Peptide Confer
alone. This demonstrated a capacity of BChE to attenuate the fibril formation-accelerating effect of AChE-S when both proteins are present at equal doses.
C. BUTYRYLCHOLINESTERASE–Ab INTERACTIONS AFFECT ITS CATALYTIC PROPERTIES The BChE effect could be relevant to each or all of the different intermediates of the Ab fibril formation process. To address this issue, we incubated 40 mM Ab40 peptide with 1:100 (0.4 mM) BChE or AChE-S and separated the soluble and insoluble fractions by centrifugation. We then assessed the presence of catalytically active cholinesterases in each of these fractions by measuring their enzymatic activities. AChE-S predictably disappeared within 2–4 days from the soluble fraction and appeared in the pellet (data not shown), supporting the notion that it facilitates fibril formation by interacting with the forming fibrils and compatible with the findings of others (Alvarez et al., 1998). In contrast, BChE was found to be present almost exclusively (>95%) in the soluble fraction of Ab over the entire time range of fibril formation (up to 7 days) (Diamant et al., 2006). A similar distribution of BChE activity was obtained when the rate of fibril formation was enhanced by shaking and followed the time scale of hours (data not shown). These findings indicate that the attenuating effect of BChE involved interaction with soluble Ab. To challenge this prediction, the enzymatic properties of the soluble BChE–Ab mixture were tested for assessing possible effects of BChE interaction with Ab on its hydrolytic capacity. BChE’s affinity to its substrate was therefore determined following 22 h preincubation in the presence or absence of Ab. To avoid dissociation of BChE–Ab complexes, the preincubation mixture was rapidly cooled to 48C. Supernatant and pellet were separated and butyrylthiocholine hydrolytic activities were determined at 48C. The substrate affinity of soluble BChE incubated without Ab was reflected by a Km of 0.7 mM. In contrast, BChE preincubated with Ab showed substrate binding with a Km value of 2.9 mM, reflecting an over 4 times lower affinity than that for the enzyme incubated alone (Figure 9.3). This decrease in substrate affinity likely reflects binding of BChE to one or several soluble intermediates of the Ab fibrillation process, present in the labile, soluble BChE–Ab complexes in dynamic equilibrium. 35
7 BChE (S) 6
30 BChE + Aβ (S)
20 15
5 1.0 4 0.5
S P
0.0
3
+Aβ +Aβ
10
2 BChE + Aβ (P)
Pelleted BChE activity (AU)
1.5 25
Affinity (1/mM)
Soluble BChE activity (AU)
BChE
1
5 0
0 0
5
10
15
20
25
30
Butyrylthiocholine (mM)
FIGURE 9.3 BChE forms soluble complexes with Ab. Substrate affinity decreases in the bound form. BChE without or with Ab was incubated for 22 h with shaking. The mixture was separated into soluble (S—left axis) and pelleted (P—right axis) fractions. The Km values were calculated using Kaleidagraph program (Synergy Software, Reading, PA). Affinity is expressed as Km1.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
210
46616_C009 Final Proof page 210 7.11.2007 5:46pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Importantly, enzyme activity in the soluble fraction represents the activity of both free and Ab-bound enzyme species, suggesting that in this fraction the measured change in the affinity of BChE to its substrate is likely an underestimation. Additionally, the small fraction of BChE (3%), which was associated with the Ab pellet (resuspended in the original volume of PBS buffer and exhibiting high binding of ThT), showed drastically different interaction with its substrate, demonstrating over 10-fold lower affinity and a Km of 8.1 mM, as compared with the soluble unbound enzyme (Figure 9.3). Parallel decreases in substrate affinity were reported for AChE present in AChE–Ab complexes of the insoluble fibrillar fraction (Alvarez et al., 1998), and were similarly interpreted to reflect interaction of the enzyme with these peptide chains. In an in vivo context, this may imply underestimation of BChE’s increases, evaluated by its activity in the AD brain (especially when present within the plaques) (Ballard et al., 2005). However, the inverse consequences of such AChE and BChE interactions attribute to them distinct effects on fibril formation.
D. SYNAPTIC ACETYLCHOLINESTERASE AND BUTYRYLCHOLINESTERASE HAVE HIGH HOMOLOGY BUT DISTINCT PERIPHERAL ANIONIC SITES AND C TERMINI Our next attempts were directed at delineating the specific domains in BChE, which attenuate the nucleation and progression of the fibril formation process. Others reported that within the AChE-S molecule, the peripheral anionic site (PAS) domain is casually involved with the enzyme’s capacity to accelerate amyloid fibril formation (Alvarez et al., 1998). Since AChE-S and BChE show high levels of homology, this raised the question of why BChE’s PAS does not exert similar effects. Superposition of the corresponding region in the two enzymes (Figure 9.4) highlights three of the four aromatic residues that exist in AChE-S’s PAS as missing in BChE’s PAS. Importantly, BChE’s PAS region displays inverse biochemical properties to that of AChE-S (namely, it presents substrate activation in BChE rather than the substrate inhibition in AChE [Glick et al., 2003]). This suggested that BChE possesses an inert PAS domain, with regards to the fibril formation process, yet raised another question, namely, which region in BChE exerts the fibrils attenuating effect. A promising region, which is distinct in the two enzymes, was their C terminus. The C-terminal domains of both AChE-S and BChE are encoded by individual exons, suggesting specific biological
Y72
Y124
W286
FIGURE 9.4 Distinct PAS domains in AChE and BChE. BChE’s PAS region includes polar residues (asparagine, glutamine, and alanine), and lacks three out of the four aromatic residues in the corresponding positions of the AChE (tyrosine72, tyrosine124, and tryptophan286).
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C009 Final Proof page 211 7.11.2007 5:46pm Compositor Name: BMani
211
Butyrylcholinesterase and Its Synthetic C-Terminal Peptide Confer
(a) H7C10988 ACHE (chr7:100, 132, 265–100, 139, 252) 3⬘
1095
170
2056
184
36
428
5⬘
H3C16615 BCHE (chr3:166, 973, 305–167, 037, 962) 3⬘
G91
79
416
167
84
1525
159 5⬘
(b) D T L D E A E R Q W K A E F H R W S S Y M gacacgctcgacgaggcggagcgccagtggaaggccgagttccaccgctggagctcctacatg G N I D E A E W E W K A G F H R W N N Y M ggaaatattgatgaagcagaatgggagtggaaagcaggattccatcgctggaacaattacatg
V H W K N Q F D H Y - S K Q D R C S D L gtgcactggaagaaccagttcgaccactac---agcaagcaggatcgctgctcagacctgtga M D W K N Q F N D Y T S K K E S C V G L atggactggaaaaatcaatttaacgattacactagcaagaaagaaagttgtgtgggtctctaa
FIGURE 9.5 Symmetric aromaticity in the C-terminal domains of AChE and BChE. (a) The chromosomal location of the ACHE and BCHE genes is shown along with the composition of exons and introns as well as the highlighted C-terminal sequences. (b) The coil and line indicate the helical and random-coil content of the C-terminal sequences. The DNA and protein sequences (lowercase and uppercase, respectively) are aligned. Protein, but not DNA, sequences show a significant similarity, which is even higher within the helical part of the sequences. Pairs of aromatic residues (framed), spaced perfectly to form amphipathicity in both sequences, are framed; the unpaired BSP W8, spaced ‘‘incorrectly’’ for amphipathicity, is framed.
functions (Figure 9.5a). Both regions (namely from the splice site between exon 4 and exon 6 in AChE-S and downstream, and the equivalent region in BChE) share 80% similarity and display abundant aromatic residues (Figure 9.5b), implicated by others in the fibril formation process (Gazit, 2002). However, certain sequence differences between the domains appeared to entail a structural context. Synthetic peptides having the C-terminal sequence of both proteins were hence prepared and examined for their effects on amyloid fibril formation. The 41 amino acid long BChE-derived peptide, BSP41, suppressed the fibril formation process in a dose-dependent manner and in similar molar ratios as those of BChE (Figure 9.6). Like BChE, BSP41 increased the lag and decreased the rate of fibril formation. In absolute quantity terms, complete attenuation of Ab fibril formation for over 200 min was achieved with 2 mg=mL BSP41 as compared with 30 mg=mL BChE. In contrast, a synthetic ASP40 peptide, derived from the corresponding domain in AChE-S, showed no capacity to activate or inhibit fibril formation (data not shown).
E. STRUCTURAL MODELING IMPLICATIONS Structural modeling revealed that both ASP40 and BSP41 peptides form symmetric amphipathic helices, compatible with findings of others (Dvir et al., 2004) and consistent with CD analyses, which showed a clear positive band at 192 nm and two negative bands at 209 and 220 nm, characteristic of a helical structures (Diamant et al., 2006). However, BSP41 displayed imperfect amphipathicity, locally disturbed by the protruding aromatic W8 residue in the polar side of this
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
212
46616_C009 Final Proof page 212 7.11.2007 5:46pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Aβ + BSP41 (µM)
Inhibition of amyloid formation (% from Aβ alone)
Lag 100
0.1 80
60 0.3 40 0.4 BSP41
0.8
20 0
100
200 Time (min)
300
400
FIGURE 9.6 BSP41 suppresses fibril formation in a dose-dependent manner. Decreasing the rate of fibril formation was found for increasing peptide concentrations. Inset: BSP41 helical peptide (shown as both cartoon and space-filling model).
Inhibition of amyloid formation (% from Aβ alone)
helix. This indicated that the aromatic W8 residue in the polar side of BSP41 could potentially be responsible for the functional difference between ASP40 and BSP41. To challenge this hypothesis we replaced W8 with arginine, by preparing a W8R mutant of BSP41, and reciprocally replaced R8 in ASP40 with tryptophan, by preparing a R8W mutant of ASP40. Intriguingly, W8R BSP41 lost its ability to attenuate fibril formation, but R8W ASP40 did not gain such activity (Figure 9.7 and data not shown). This indicated that W8 was not the only determinant of such activities and called for further search.
100
Aβ + W8R BSP41
90 80 70
Aβ + BSP41
60 50 Aβ + BChE 40 30 300
350
400
450
500
550
Time (min)
FIGURE 9.7 Site-directed mutagenesis. Fibril formation was inhibited by incubation of 1:100 molar ratios of BChE or BSP41 with Ab. The BSP41 inactive mutant W8R was ineffective. Data is presented as percentage of the basal rate obtained with Ab alone over time.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C009 Final Proof page 213 7.11.2007 5:46pm Compositor Name: BMani
Butyrylcholinesterase and Its Synthetic C-Terminal Peptide Confer
213
F. AROMATICITY CONSIDERATIONS Aromatic residues are frequent in the cross-b core of fibrils but are not necessarily required for fibril formation. Recent studies demonstrate that aromatic residues can establish a network of hydrophobic interactions, which are casually involved in the formation of the cross-b structure (Bemporad et al., 2006). The finest example comes from the Ab40 model itself, based on solidstate nuclear magnetic resonance experiments (Petkova et al., 2002). In this study, two b-strands formed by residues 12–24 and 30–40 gave rise to two parallel b-sheets in register, which interact through two phenylalanine residues that form interstrand p-stacking. Specifically, the contacts between phenylalanine residues in fibrils are thought to be important for stabilizing interactions (Alvarez et al., 1998; Gazit, 2002; Porat et al., 2003, 2004). However, the forces that maintain the aromatic residues in close contact and stabilize fibrils do not arise from specific interactions involving the p-electrons or the aromatic nature of these residues. Rather, these powers are due to their high hydrophobicity and high tendency to form b-sheets. The stabilizing effect of aromatic residues on the resulting fibrils is also compatible with their high frequency in amyloidogenic sequences (Bemporad et al., 2006). Supporting this notion, in vitro experiments have demonstrated the importance of amphipathic molecules for inhibiting the fibril formation process: Addition of an amphiphilic surfactant, n-dodecylhexaoxyethylene glycol monoether (Lomakin et al., 1996), or the amphiphilic di-C6-PC (Gazit, 2002; Wang et al., 2005) to Ab40 was shown to decrease the rate of Ab aggregation in a concentration-dependent fashion and cause a concentration-dependent reduction in the length, but not the diameter, of Ab fibrils.
G. INVERSE ROLES FOR BUTYRYLCHOLINESTERASE IN FIBRIL FORMATION
AND
SYNAPTIC ACETYLCHOLINESTERASE
In the AChE-S molecule, the hydrophobic PAS domain located close to the lip of the active site gorge would be free to form complexes with growing fibrils, thus supporting the Ab assembly process (Alvarez et al., 1998). In variance with AChE-S, BChE (and its synthetic peptide BSP41) emerges from our study as being capable of attenuating the fibril formation process through its aromatic W8 residue, positioned outward in the polar side of the BSP helix, and in a competitive manner with AChE-S. Last, but not least, one should consider the multimeric composition of the BChE and AChE-S molecules. In the majority of such molecules, the hydrophobic (mostly aromatic) part of the amphipathic helix of the C terminus is likely engaged in G4 homo-oligomers (Fernandez et al., 1996; Altamirano and Lockridge, 1999). Because of the amphipathic nature of the C-terminal helices, their hydrophobic sides would tend to turn inward, exposing the hydrophilic surface to the outside environment. In AChE-S, the hydrophilic nature of this surface would be intact, because the outward-turned arginines do not impair it. In contrast, BChE peptides would yield outwardprotruding aromatic tryptophans, enabling Ab interactions (Figure 9.8). These protruding residues can form hetero-aromatic complexes with soluble, monomeric or low oligomeric, Ab conformers. In the naturally formed tetramers, the protruding tryptophan would likely interfere with oligomerization and the side chain stabilization of the b-sheet structure and inhibit propagation of the fibril formation process to form toxic protofibrils and insoluble fibers.
H. THERAPEUTIC CONSIDERATIONS In the human brain, AChE mRNA is 20-fold more abundant than BChE mRNA (Soreq and Zakut, 1990), whereas in human blood, BChE is threefold more abundant than AChE (Schwarz et al., 1995). In the AD brain, the declining AChE (Talesa, 2001) and increasing BChE (Ballard et al., 2005) would change this ratio considerably. In blood, the physiological importance of this ratio stems from BChE’s capacity to interact with Ab in the soluble phase and due to the continuous communication between the brain and circulation (Shaked and Soreq, 2006).
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
214
46616_C009 Final Proof page 214 7.11.2007 5:46pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
ASP Putative-tetramer
BSP Putative-tetramer
FIGURE 9.8 Illustrative four helical bundles of ASP40 and BSP41. Illustrative figures of the four helical bundles of ASP40 and BSP41 (represented here as cartoon) formed by their corresponding C-terminal peptides to yield tetramers. The aromatic side is turned inward in both, resulting in a protruding residue in position 8. In the BSP tetramer, the tryptophan side chains (W8; represented here as sticks) of each helix would be turned outward, readily available for attenuating fibril formation, unlike the nonaromatic ASP’s arginine residue (R8; represented here as sticks).
Putative therapeutic uses of BChE and the relatively short BSP peptide may involve injection, similar to erythropoietin or granulocyte=macrophage colony stimulating factor (GM-CSF) (Arndt et al., 2005; Zhang et al., 2005). Transfecting bone marrow cells for autologous transplantation, with a BSP expression vector similar to the gene therapy protocols used for adenosine deaminase replacement, would be an alternative (Aiuti et al., 2003). Intranasal administration, like that of nerve growth factor (NGF) (De Rosa et al., 2005), is also plausible. In either way, the reportedly disrupted blood–brain barrier in AD (Ballabh et al., 2004) and that cholinergic imbalances induce blood–brain barrier disruption (Meshorer et al., 2005) predicts effective BSP41 penetration into the brain.
V. SUMMARY AND CONCLUSIONS BChE, in a 1:100 ratio with synthetic amyloid peptide (Ab40), delayed the formation of Ab fibrils in a dose- and time-dependent manner. Moreover, BChE competed with AChE and slowed down the AChE-S-facilitated rate of fibril formation. A synthetic peptide derived from the BChE C terminus (BSP), but not from the AChE-S C terminus (ASP), delayed the onset and decreased the rate of Ab fibril formation in vitro. The helical conformation of the tested peptides (confirmed by CD measurements and molecular modeling), which is presumably present in the native protein, is amphipathic. Nevertheless, BSP’s amphipaticity is interrupted due to an aromatic tryptophan residue in the polar side of the C terminus, whereas ASP shows symmetric amphipathicity. Supporting the notion of the importance of this structural distinction, single amino acid substitutions in that position impaired the amyloidogenic potential of the BSP peptide. Most importantly, our findings are in favor of the therapeutic use of BChE, but not AChE-S for treating OP-poisoned patients and avoiding long-term amyloidogenic damages.
ACKNOWLEDGMENTS This work was supported by the Horowitz Fund and The Hebrew University’s Eric Roland Center for Neurodegenerative Disease (to H.S.).
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C009 Final Proof page 215 7.11.2007 5:46pm Compositor Name: BMani
Butyrylcholinesterase and Its Synthetic C-Terminal Peptide Confer
215
REFERENCES Aiuti, A., Ficara, F., Cattaneo, F., Bordignon, C. and Roncarolo, M.G. (2003) Gene therapy for adenosine deaminase deficiency. Curr Opin Allergy Clin Immunol, 3, 461–6. Adams, P.D., Arkin, I.T., Engelman, D.M. and Brunger, A.T. (1995) Computational searching and mutagenesis suggest a structure for the pentameric transmembrane domain of phospholamban. Nat Struct Biol, 2, 154–62. Altamirano, C.V. and Lockridge, O. (1999) Association of tetramers of human butyrylcholinesterase is mediated by conserved aromatic residues of the carboxy terminus. Chem Biol Interact, 119–120, 53–60. Alvarez, A., Alarcon, R., Opazo, C., Campos, E.O., Mujnoz, F.J., Calderon, F.H., Dajas, F., Gentry, M.K., Doctor, B.P., De Mello, F.G. and Inestrosa, N.C. (1998) Stable complexes involving acetylcholinesterase and amyloid-beta peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer’s fibrils. J Neurosci, 18, 3213–23. Arndt, U., Kaltwasser, J.P., Gottschalk, R., Hoelzer, D. and Moller, B. (2005) Correction of iron-deficient erythropoiesis in the treatment of anemia of chronic disease with recombinant human erythropoietin. Ann Hematol, 84, 159–66. Ashani, Y., Shapira, S., Levy, D., Wolfe, A.D., Doctor, B.P. and Raveh, L. (1991) Butyrylcholinesterase and acetylcholinesterase prophylaxis against soman poisoning in mice. Biochem Pharmacol, 41, 37–41. Ballabh, P., Braun, A. and Nedergaard, M. (2004) The blood–brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis, 16, 1–13. Ballard, C.G., Greig, N.H., Guillozet-Bongaarts, A.L., Enz, A. and Darvesh, S. (2005) Cholinesterases: roles in the brain during health and disease. Curr Alzheimer Res, 2, 307–18. Bemporad, F., Taddei, N., Stefani, M. and Chiti, F. (2006) Assessing the role of aromatic residues in the amyloid aggregation of human muscle acylphosphatase. Protein Sci, 15, 862–70. Bryk, B., BenMoyal-Segal, L., Podoly, E., Livnah, O., Eisenkraft, A., Luria, S., Cohen, A., Yehezkelli, Y., Houritz, A. and Soreq, H. (2005) Inherited and acquired interactions between ACHE and PON1 polymorphisms modulate plasma acetylcholinesterase and paraoxonase activities. J Neurochem, 92, 1216–27. Carson, K.A., Geula, C. and Mesulam, M.M. (1991) Electron microscopic localization of cholinesterase activity in Alzheimer brain tissue. Brain Res, 540, 204–8. Cerasoli, D.M., Griffiths, E.M., Doctor, B.P., Saxena, A., Fedorko, J.M., Greig, N.H., Yu, Q.S., Huang, Y., Wilgus, H., Karatzas, C.N., Koplovitz, I. and Lenz, D.E. (2005) In vitro and in vivo characterization of recombinant human butyrylcholinesterase (Protexia) as a potential nerve agent bioscavenger. Chem Biol Interact, 157–158, 363–5. Chambers, H.W., Boone, J.S., Carr, R.L. and Chambers, J.E. (2001) Chemistry of Organophosphorus Insecticides, San Diego, Academic Press. Chatonnet, A. and Lockridge, O. (1989) Comparison of butyrylcholinesterase and acetylcholinesterase. Biochem J, 260, 625–34. Chromy, B.A., Nowak, R.J., Lambert, M.P., Viola, K.L., Chang, L., Velasco, P.T., Jones, B.W., Fernandez, S.J., Lacor, P.N., Horowitz, P., Finch, C.E., Krafft, G.A. and Klein, W.L. (2003) Self-assembly of Abeta(1–42) into globular neurotoxins. Biochemistry, 42, 12749–60. Citron, M., Diehl, T.S., Gordon, G., Biere, A.L., Seubert, P. and Selkoe, D.J. (1996) Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities. Proc Natl Acad Sci U S A, 93, 13170–5. Cruz, L., Urbanc, B., Buldyrev, S.V., Christie, R., Gomez-Isla, T., Havlin, S., McNamara, M., Stanley, H.E. and Hyman, B.T. (1997) Aggregation and disaggregation of senile plaques in Alzheimer disease. Proc Natl Acad Sci U S A, 94, 7612–6. Darvesh, S. and Hopkins, D.A. (2003) Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamus. J Comp Neurol, 463, 25–43. Darvesh, S., Hopkins, D.A. and Geula, C. (2003) Neurobiology of butyrylcholinesterase. Nat Rev Neurosci, 4, 131–8. De Rosa, R., Garcia, A.A., Braschi, C., Capsoni, S., Maffei, L., Berardi, N. and Cattaneo, A. (2005) Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. Proc Natl Acad Sci U S A, 102, 3811–6.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
216
46616_C009 Final Proof page 216 7.11.2007 5:46pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Diamant, S., Podoly, E., Friedler, A., Ligumsky, H., Livnah, O. and Soreq, H. (2006) Butyrylcholinesterase attenuates amyloid fibril formation in vitro. Proc Natl Acad Sci U S A, 0602922103. Dickson, D.W. (1997) The pathogenesis of senile plaques. J Neuropathol Exp Neurol, 56, 321–39. Doctor, B.P. and Saxena, A. (2005) Bioscavengers for the protection of humans against organophosphate toxicity. Chem Biol Interact, 157–158, 167–71. Dvir, H., Harel, M., Bon, S., Liu, W.Q., Vidal, M., Garbay, C., Sussman, J.L., Massoulie, J. and Silman, I. (2004) The synaptic acetylcholinesterase tetramer assembles around a polyproline II helix. Embo J, 23, 4394–405. Fernandez, H.L., Moreno, R.D. and Inestrosa, N.C. (1996) Tetrameric (G4) acetylcholinesterase: structure, localization, and physiological regulation. J Neurochem, 66, 1335–46. Forloni, G., Tagliavini, F., Bugiani, O. and Salmona, M. (1996) Amyloid in Alzheimer’s disease and prionrelated encephalopathies: studies with synthetic peptides. Prog Neurobiol, 49, 287–315. Gallo, M. and Lawryk, N. (1991) Organic Phosphorus Pesticides, San Diego, Academic Press, Inc. Gazit, E. (2002) A possible role for pi-stacking in the self-assembly of amyloid fibrils. FASEB J, 16, 77–83. Giacobini, E. (2003) Cholinergic function and Alzheimer’s disease. Int J Geriatr Psychiatry, 18, S1–5. Giacobini, E. (2004) Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharmacol Res, 50, 433–40. Glick, D., Ben Moyal, L. and Soreq, H. (2003) Genetic Variation in Butyrylcholinesterase and the Physiological Consequences for Acetylcholinesterase Function, London, Martin Dunitz. Greig, N.H., Lahiri, D.K. and Sambamurti, K. (2002) Butyrylcholinesterase: an important new target in Alzheimer’s disease therapy. Int Psychogeriatr, 14 Suppl 1, 77–91. Grunwald, J., Marcus, D., Papier, Y., Raveh, L., Pittel, Z. and Ashani, Y. (1997) Large-scale purification and long-term stability of human butyrylcholinesterase: a potential bioscavenger drug. J Biochem Biophys Methods, 34, 123–35. Guillozet, A.L., Smiley, J.F., Mash, D.C. and Mesulam, M.M. (1997) Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol, 42, 909–18. Hardy, J. and Selkoe, D.J. (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science, 297, 353–6. Hartley, D.M., Walsh, D.M., Ye, C.P., Diehl, T., Vasquez, S., Vassilev, P.M., Teplow, D.B. and Selkoe, D.J. (1999) Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci, 19, 8876–84. Head, E. and Lott, I.T. (2004) Down syndrome and beta-amyloid deposition. Curr Opin Neurol, 17, 95–100. Inestrosa, N.C., Alvarez, A. and Calderon, F. (1996a) Acetylcholinesterase is a senile plaque component that promotes assembly of amyloid beta-peptide into Alzheimer’s filaments. Mol Psychiatry, 1, 359–61. Inestrosa, N.C., Alvarez, A., Perez, C.A., Moreno, R.D., Vicente, M., Linker, C., Casanueva, O.I., Soto, C. and Garrido, J. (1996b) Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer’s fibrils: possible role of the peripheral site of the enzyme. Neuron, 16, 881–91. Inestrosa, N.C., Sagal, J.P. and Colombres, M. (2005) Acetylcholinesterase interaction with Alzheimer amyloid beta. Subcell Biochem, 38, 299–317. Jarrett, J.T. and Lansbury, P.T., Jr. (1993) Seeding ‘‘one-dimensional crystallization’’ of amyloid: a pathogenic mechanism in Alzheimer’s disease and scrapie? Cell, 73, 1055–8. Jbilo, O., Bartels, C.F., Chatonnet, A., Toutant, J.P. and Lockridge, O. (1994) Tissue distribution of human acetylcholinesterase and butyrylcholinesterase messenger RNA. Toxicon, 32, 1445–57. Kayed, R., Head, E., Thompson, J.L., McIntire, T.M., Milton, S.C., Cotman, C.W. and Glabe, C.G. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science, 300, 486–9. Kuo, Y.M., Emmerling, M.R., Vigo-Pelfrey, C., Kasunic, T.C., Kirkpatrick, J.B., Murdoch, G.H., Ball, M.J. and Roher, A.E. (1996) Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem, 271, 4077–81. La Du, B.N. and Lockridge, O. (1986) Molecular biology of human serum cholinesterase. Fed Proc, 45, 2965–9. Lesne, S., Koh, M.T., Kotilinek, L., Kayed, R., Glabe, C.G., Yang, A., Gallagher, M. and Ashe, K.H. (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature, 440, 352–7. Levine III, H. (1993) Thioflavine T interaction with synthetic Alzheimer’s disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci, 2, 404–10. Levine III, H. (1999) Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol, 309, 274–84.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C009 Final Proof page 217 7.11.2007 5:46pm Compositor Name: BMani
Butyrylcholinesterase and Its Synthetic C-Terminal Peptide Confer
217
Levine III, H. (2003) Y10W beta(1–40) fluorescence reflects epitope exposure in conformers of Alzheimer’s beta-peptide. Arch Biochem Biophys, 417, 112–22. Lomakin, A., Chung, D.S., Benedek, G.B., Kirschner, D.A. and Teplow, D.B. (1996) On the nucleation and growth of amyloid beta-protein fibrils: detection of nuclei and quantitation of rate constants. Proc Natl Acad Sci U S A, 93, 1125–9. Lue, L.F., Kuo, Y.M., Roher, A.E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J.H., Rydel, R.E. and Rogers, J. (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer’s disease. Am J Pathol, 155, 853–62. McLean, C.A., Cherny, R.A., Fraser, F.W., Fuller, S.J., Smith, M.J., Beyreuther, K., Bush, A.I. and Masters, C.L. (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease. Ann Neurol, 46, 860–6. Meshorer, E., Biton, I.E., Ben-Shaul, Y., Ben-Ari, S., Assaf, Y., Soreq, H. and Cohen, Y. (2005) Chronic cholinergic imbalances promote brain diffusion and transport abnormalities. FASEB J, 19, 910–22. Petkova, A.T., Ishii, Y., Balbach, J.J., Antzutkin, O.N., Leapman, R.D., Delaglio, F. and Tycko, R. (2002) A structural model for Alzheimer’s beta-amyloid fibrils based on experimental constraints from solid state NMR. Proc Natl Acad Sci U S A, 99, 16742–7. Pike, C.J., Walencewicz, A.J., Glabe, C.G. and Cotman, C.W. (1991) In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res, 563, 311–4. Porat, Y., Kolusheva, S., Jelinek, R. and Gazit, E. (2003) The human islet amyloid polypeptide forms transient membrane-active prefibrillar assemblies. Biochemistry, 42, 10971–7. Porat, Y., Mazor, Y., Efrat, S. and Gazit, E. (2004) Inhibition of islet amyloid polypeptide fibril formation: a potential role for heteroaromatic interactions. Biochemistry, 43, 14454–62. Raveh, L., Grunwald, J., Marcus, D., Papier, Y., Cohen, E. and Ashani, Y. (1993) Human butyrylcholinesterase as a general prophylactic antidote for nerve agent toxicity. In vitro and in vivo quantitative characterization. Biochem Pharmacol, 45, 2465–74. Raveh, L., Grauer, E., Grunwald, J., Cohen, E. and Ashani, Y. (1997) The stoichiometry of protection against soman and VX toxicity in monkeys pretreated with human butyrylcholinesterase. Toxicol Appl Pharmacol, 145, 43–53. Rees, T., Hammond, P.I., Soreq, H., Younkin, S. and Brimijoin, S. (2003) Acetylcholinesterase promotes betaamyloid plaques in cerebral cortex. Neurobiol Aging, 24, 777–87. Rees, T.M., Berson, A., Sklan, E.H., Younkin, L., Younkin, S., Brimijoin, S. and Soreq, H. (2005) Memory deficits correlating with acetylcholinesterase splice shift and amyloid burden in doubly transgenic mice. Curr Alzheimer Res, 2, 291–300. Schwarz, M., Glick, D., Loewenstein, Y. and Soreq, H. (1995) Engineering of human cholinesterases explains and predicts diverse consequences of administration of various drugs and poisons. Pharmacol Ther, 67, 283–322. Shaked, I. and Soreq, H. (2006) Studying Cholinergic Features by Transgenic Manipulations of AChE Gene Expression, London, Informa Healthcare. Sklan, E.H., Lowenthal, A., Korner, M., Ritov, Y., Landers, D.M., Rankinen, T., Bouchard, C., Leon, A.S., Rice, T., Rao, D.C., Wilmore, J.H., Skinner, J.S. and Soreq, H. (2004) Acetylcholinesterase=paraoxonase genotype and expression predict anxiety scores in Health, Risk Factors, Exercise Training, and Genetics study. Proc Natl Acad Sci U S A, 101, 5512–7. Soreghan, B., Kosmoski, J. and Glabe, C. (1994) Surfactant properties of Alzheimer’s A beta peptides and the mechanism of amyloid aggregation. J Biol Chem, 269, 28551–4. Soreq, H. and Zakut, H. (1990) Expression and in vivo amplification of the human acetylcholinesterase and butyrylcholinesterase genes. Prog Brain Res, 84, 51–61. Soreq, H. and Zakut, H. (1993) Human Cholinesterases and Anticholinesterases, San Diego, Academic Press. Standridge, J.B. (2006) Vicious cycles within the neuropathophysiologic mechanisms of Alzheimer’s disease. Curr Alzheimer Res, 3, 95–108. Sun, H., Pang, Y.P., Lockridge, O. and Brimijoin, S. (2002) Re-engineering butyrylcholinesterase as a cocaine hydrolase. Mol Pharmacol, 62, 220–4. Talesa, V.N. (2001) Acetylcholinesterase in Alzheimer’s disease. Mec Ageing Dev, 122, 1961–9. Tjernberg, L.O., Pramanik, A., Bjorling, S., Thyberg, P., Thyberg, J., Nordstedt, C., Berndt, K.D., Terenius, L. and Rigler, R. (1999) Amyloid beta-peptide polymerization studied using fluorescence correlation spectroscopy. Chem Biol, 6, 53–62.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
218
46616_C009 Final Proof page 218 7.11.2007 5:46pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Wang, S.S., Chen, Y.T. and Chou, S.W. (2005) Inhibition of amyloid fibril formation of beta-amyloid peptides via the amphiphilic surfactants. Biochim Biophys Acta, 1741, 307–13. Wright, C.I., Geula, C. and Mesulam, M.M. (1993) Neurological cholinesterases in the normal brain and in Alzheimer’s disease: relationship to plaques, tangles, and patterns of selective vulnerability. Ann Neurol, 34, 373–84. Zhang, J.G., Dan, Q., Fong, T.C., Williams, C.C., Avina, M.D., Tarbiyat-Boldaji, M., Khalaghizadeh, S., Irwin, M., Nguyen, A., Zhuang, J.L., Hoa, N., Wepsic, H.T. and Jadus, M.R. (2005) Macrophage colonystimulating factor expression in retrovirally transduced cells is dependent upon both the adherence status of the target cells and its 50 flanking untranslated region. Biochem Biophys Res Commun, 330, 1275–84.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C010 Final Proof page 219 6.11.2007 6:03pm Compositor Name: BMani
Medical 10 Novel Countermeasure for Organophosphorus Intoxication: Connection to Alzheimer’s Disease and Dementia Edna F.R. Pereira, David R. Burt, Yasco Aracava, Robert K. Kan, Tracey A. Hamilton, James A. Romano Jr., Michael Adler, and Edson X. Albuquerque CONTENTS I. Introduction.......................................................................................................................... 219 II. Galantamine ......................................................................................................................... 220 A. History.......................................................................................................................... 220 B. Use in Alzheimer’s Disease ......................................................................................... 221 C. Mechanisms of Action ................................................................................................. 222 III. Galantamine in Organophosphorus Poisoning .................................................................... 222 A. Existing Treatments ..................................................................................................... 222 B. Promise of Galantamine............................................................................................... 223 C. Pretreatment with Galantamine.................................................................................... 223 D. Posttreatment with Galantamine .................................................................................. 226 E. Protection Against Brain Damage ............................................................................... 227 IV. Conclusions.......................................................................................................................... 228 Acknowledgments......................................................................................................................... 229 References ..................................................................................................................................... 229
I. INTRODUCTION Since their development just before World War II, the organophosphorus (OP) nerve agents have been potential and actual threats to soldiers on the battlefield (Wiener and Hoffman, 2004; Geoghegan and Tong, 2006). Their more recent use in 1994–1995 terrorism incidents in Japan (Tokuda et al., 2006) has added a threat to the general civilian population as well, which was already present for farm workers or exterminators using OP insecticides (Karalliedde and Senanayake, 1989). These agents’ acute toxic effects are primarily due to irreversible inhibition of acetylcholinesterase (AChE), the enzyme that breaks down the neurotransmitter acetylcholine at the neuromuscular junction and elsewhere (Maxwell et al., 2006). Other mechanisms, particularly in the brain, have also received 219
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
220
46616_C010 Final Proof page 220 6.11.2007 6:03pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
some support (Duysen et al., 2001). Symptoms vary according to the OP and route and the extent of exposure, but usually include a nicotinic cholinergic syndrome characterized by skeletal muscle fasciculations followed by desensitizing neuromuscular blockade, and a variety of other effects resulting from overstimulation of muscarinic receptors. A more complete clinical list of symptoms includes miosis, excess sweating, headache, tightness in the chest, labored breathing, dizziness, excess salivation, muscle cramps, difficulty in walking, convulsions, diarrhea, wheezing, abdominal cramps, muscle fasciculations, unconsciousness, coma, respiratory failure, and death. As suggested by this list, death is usually due to respiratory failure, resulting from both diaphragm paralysis and failure of central respiratory drive (Rickett et al., 1986). Currently used treatments for OP poisoning are far from satisfactory. They consist of atropine to block muscarinic effects, oximes to reactivate the inhibited AChE before ‘‘aging’’ of the phosphorylated enzyme occurs, and benzodiazepines to control seizures (Marrs, 2004). More recently, the Food and Drug Administration approved the use of pyridostigmine, a reversible inhibitor of AChE and butyrylcholinesterase (BuChE), as a pretreatment for military personal under threat of exposure to nerve agents (Layish et al., 2005). The intent was to protect a portion of the AChE molecules against irreversible blockade by the nerve agent by occupying them with the reversible inhibitor. This is particularly important for exposure to soman, because the soman-inhibited AChE ages rather rapidly. Symptoms observed in people intoxicated with nerve agents and other OPs are also evident in neurological disorders in which the cholinergic system is compromised. Thus, the muscle weakness and fatigue seen in OP poisoning resemble that observed in patients with myasthenia gravis, a neuromuscular disorder characterized by varying degrees of skeletal muscle weakness in the body due to the autoimmune destruction of nicotinic receptors (nAChRs) at the neuromuscular junction (Schwendimann et al., 2005). Likewise, there are reports that people who are chronically exposed to OP insecticides show measurable deficits in cognitive functions (Kamel et al., 2003) and that an association may exist between past occupational exposure to OP pesticides and increased risk to develop neurodegenerative disorders, particularly Alzheimer’s and Parkinson’s diseases (Baldi et al., 2003). Based on evidence that impairments of brain cholinergic systems contribute to the cognitive dysfunctions in Alzheimer’s disease, reversible cholinesterase inhibitors, including galantamine, rivastigmine, and donepezil, are currently approved for treatment of the disease (Lleo et al., 2006). Some members of the same class of drugs, specifically pyridostigmine, are also used to treat patients with myasthenia gravis. The primary difference between reversible cholinesterase inhibitors used for Alzheimer’s disease and myasthenia gravis lies in their lipid solubility. While the cholinesterase inhibitors used for Alzheimer’s disease promptly cross the blood–brain barrier, those used for myasthenia gravis, pyridostigmine included, do not. This consideration suggests the possible utility of Alzheimer’s disease drugs in protecting against central as well as peripheral effects of nerve agents. One such drug, galantamine (also called galanthamine), has recently been found by our group to be a superior antidote against intoxication by soman and other nerve agents, effective when administered both before and soon after exposure (Albuquerque et al., 2006).
II. GALANTAMINE A. HISTORY Amazingly enough, the history of galantamine may reach back to Homer’s Odyssey, more than a 1000 years ago. One theory of Circe’s bewitchment of Odysseus’s men is that it involved use of jimsonweed (Datura stramonium), which contains atropine, and that Odysseus’s potion to counteract it was made from the common snowdrop (Galanthus nivalis), a source of galantamine (Plaitakis and Duvoisin, 1983). Further mention of galantamine had to wait until modern times, about 1950 in Bulgaria, when a pharmacologist may have noted people rubbing their heads with snowdrops to relieve pain (reviewed in Heinrich and Lee Teoh, 2004). This or other observations evidently led to a 1951 Russian paper describing galantamine as an AChE inhibitor (Mashkovsky and
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C010 Final Proof page 221 6.11.2007 6:03pm Compositor Name: BMani
Novel Medical Countermeasure for Organophosphorus Intoxication
221
Kruglikova-Lvova, 1951) and its isolation and structural determination the next year. Further research led to its commercialization (trade name Nivalin) in Bulgaria in 1958, and its use since then in Eastern Europe to help treat the loss of motor neurons (and acetylcholine) produced by polio, as well as to restore neuromuscular function after anesthesia involving use of neuromuscular blocking agents (Pearson, 2001). It was not until 1996 that clinical trials tested the effectiveness of galantamine (as Nivalin) in patients with Alzheimer’s disease. Its chemical synthesis was followed by its approval (as Reminyl) for treating Alzheimer’s disease in the United States in 2001. In April 2005, its manufacturer, Ortho-McNeil Neurologics, Inc., changed the trade name from Reminyl to Razadyne. Galantamine is also available as a nutritional supplement extracted from plants, now primarily species of Narcissus (daffodil) and Leucojum (snowflake).
B. USE
IN
ALZHEIMER’S DISEASE
Alzheimer’s disease is a form of senile dementia described by Alois Alzheimer more than 100 years ago (Goedert and Spillantini, 2006). It is a progressive neurodegenerative disorder characterized by an incremental decline in mental function that affects memory, thinking, language, and behavior in general. As the disease progresses, cognitive impairments become severe enough to interfere with the daily activities of patients and eventually lead to death (Chung and Cummings, 2000). Even though the causes of Alzheimer’s disease remain obscure, numerous studies have reported that incremental loss of cholinergic neurons in the brain and progressive reduction of nAChR function=expression correlate well with the severity of the symptoms (Coyle et al., 1983; Perry et al., 2000; Nordberg, 2001). In particular, loss of a7 nAChRs is pronounced in the hippocampus and not as significant in the cerebral cortex of patients with Alzheimer’s disease as revealed by binding studies that have used [125I]a-bungarotoxin to label a7-containing nAChRs in postmortem brain tissue samples from patients and age-matched control subjects (Hellstrom-Lindahl et al., 1999; Wevers et al., 1999). In patients with more advanced stages of Alzheimer’s disease, such a correlation between nAChR loss and cognitive decline does not appear to exist (Sabbagh et al., 2001). Epidemiological findings that brain region specific losses of cholinergic neurons and nAChRs correlate well with the cognitive decline in the mild-to-moderate stages of Alzheimer’s disease and the evidence that nAChR activation is neuroprotective and improves memory, both support the concept that increasing nAChR activity in the brain should slow down the progression of the disease (Maelicke and Albuquerque, 1996; Coyle and Kershaw, 2001). At the neuromuscular junction, nicotinic function is enhanced by inhibition of AChE. However, unlike muscle nAChRs, some neuronal nAChRs, particularly those bearing the a7 subunit, recognize both acetylcholine and its metabolite choline as full agonists (Pereira et al., 2002). Therefore, cholinesterase inhibition may not necessarily enhance functions mediated by these nAChRs. In fact, cholinesterase inhibitors do not affect a7 nAChR-mediated synaptic transmission evoked by lowfrequency stimulation of cholinergic fibers in chick ciliary ganglia (Zhang et al., 1996). An alternative means to increase nicotinic functions in the brain is to sensitize the nAChRs to activation by the endogenous agonists using the so-called nicotinic allosteric potentiating ligands (APLs), of which galantamine is the prototype (Maelicke and Albuquerque, 1996). As discussed below, in addition to acting as a weak inhibitor of AChE, galantamine binds to and potentiates the activation of nAChRs by classical agonists (Pereira et al., 2002). Recent studies have reported that galantamine also improves the cognitive performance of patients with autism (Nicolson et al., 2006) and, unlike other cholinesterase inhibitors, decreases the negative symptoms in patients with schizophrenia (Schubert et al., 2006). For more severe Alzheimer’s disease, memantine, an antagonist of N-methyl-D-aspartate (NMDA) receptors, has also been approved. A number of newer drugs undergoing clinical trials for Alzheimer’s disease work by a variety of other mechanisms, although a common theme appears to be neuroprotection (Robertson and Mucke, 2006).
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
222
46616_C010 Final Proof page 222 6.11.2007 6:03pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
C. MECHANISMS
OF
ACTION
As mentioned above, galantamine has two basic mechanisms of action. It reversibly inhibits cholinesterases, being approximately 50-fold more potent as an AChE inhibitor than a BuChE inhibitor. It also interacts directly with nAChRs, potentiating their activation by subsaturating concentrations of classical agonists (Pereira et al., 2002). Physostigmine was the first cholinesterase inhibitor shown to activate muscle and neuronal nAChRs by directly interacting with them (Shaw et al., 1985; Sherby et al., 1985; Okonjo et al., 1991; Pereira et al., 1993, 1994). Later on, galantamine was found to act on nAChRs similar to physostigmine. Direct activation of nAChRs by galantamine or physostigmine was shown to be very weak compared to that induced by classical agonists. More importantly, activation of nAChRs by physostigmine or galantamine was detected even when the receptors were desensitized by high agonist concentrations and was found to be insensitive to blockade by competitive nicotinic antagonists (Shaw et al., 1985; Sherby et al., 1985; Okonjo et al., 1991; Pereira et al., 1993, 1994; Schrattenholz et al., 1993). Instead, it was found to be sensitive to blockade by the monoclonal antibody FK1, which recognizes an extracellular epitope that is very well conserved on the nAChR a subunits cloned to date. Evidence has been provided that the agonistic activity of physostigmine and galantamine, initially referred to as noncompetitive agonists (Storch et al., 1995), results from their binding to a site close to, but distinct from, the acetylcholine-binding site on nAChR a subunits (Pereira et al., 1993; Schrattenholz et al., 1993). The region flanking the amino acid Lys-125 on the nAChR a subunits contains essential elements of the physostigmine site and is highly conserved across species (Pereira et al., 1993; Schrattenholz et al., 1993; Schroder et al., 1994). Even though physostigmine and galantamine induce opening of nAChR single channels, the probability of channel openings by these compounds is so low that the single-channel currents they activate do not give rise to macroscopic responses (Pereira et al., 1994; Storch et al., 1995; Schrattenholz et al., 1996). In different systems, however, these compounds potentiate the nAChR activity induced by subsaturating concentrations of classical nAChR agonists, and are, therefore, referred to as nicotinic allosteric potentiating ligands (Schrattenholz et al., 1996). The nicotinic allosteric potentiating action is not common to all cholinesterase inhibitors; for instance, donepezil and rivastigmine are devoid of this action (Samochocki et al., 2000). The allosteric potentiating action of galantamine has been suggested to contribute importantly to its effectiveness in Alzheimer’s disease (Maelicke et al., 2001). Acting primarily as a nicotinic allosteric potentiating ligand, galantamine improves synaptic transmission in different areas of the brain (Santos et al., 2002) and protects neurons from different neurodegeneration-inducing insults (Geerts, 2005).
III. GALANTAMINE IN ORGANOPHOSPHORUS POISONING A. EXISTING TREATMENTS Existing treatments for OP poisoning (Bajgar, 2004; Newmark, 2004a, 2004b, 2005; Cannard, 2006) start with pyridostigmine as prophylaxis. Pyridostigmine is most appropriate for anticipated exposure to soman and was approved in 2003 for pretreatment use by military personnel under the threat of exposure to nerve agents, specifically soman (Couzin, 2003). It had already been used by military personnel in the Gulf War (1991). Its use is always to be accompanied by immediate treatment after OP exposure with atropine and an oxime such as pralidoxime (2-PAM), the previous standard treatments after exposure. Pyridostigmine was chosen not to cross the blood–brain barrier to avoid possible central nervous system impairment or incapacitation, an effect particularly undesirable (and possibly fatal) in soldiers, at least those not being exposed to OPs. Several other anticholinesterases that do cross the blood–brain barrier, including physostigmine, tacrine, and
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C010 Final Proof page 223 6.11.2007 6:03pm Compositor Name: BMani
Novel Medical Countermeasure for Organophosphorus Intoxication
223
huperzine A, have been found to offer better protection than pyridostigmine, but at the cost of undesirable central effects (Deshpande et al., 1986; Fricke et al., 1994; Grunwald et al., 1994; Lallement et al., 2002, 2002b). None of the current treatments offer any real protection against central effects of the OPs, which can contribute to acute lethality (e.g., through respiratory depression or convulsions) and presumably also lead to the delayed neurological and cognitive deficits observed after OP exposure in both animals and humans, for example, following the Tokyo sarin subway attack in 1995 (Abou-Donia, 2003; Yanagisawa et al., 2006). These deficits are accompanied by visible structural changes. They cannot be prevented merely by controlling seizures, for example, with diazepam (Bhagat et al., 2005), although seizure control does help (Shih et al., 2003). Another problem with pyridostigmine is that it blocks BuChE as well as AChE, thus reducing OP binding to this scavenger site not associated with OP toxicity.
B. PROMISE
OF
GALANTAMINE
Galantamine, at doses used for Alzheimer’s disease, is relatively devoid of side effects (Loy and Schneider, 2006). When they do appear, they are generally gastrointestinal; the most common are nausea, vomiting, and diarrhea. These side effects might be expected to be reduced for a nonoral route of administration, such as intramuscular. Such doses clearly must be blocking a significant portion of brain AChE to provide benefit. Biochemical evidence indicates that there is actually a greater blockade of peripheral AChE (Albuquerque et al., 2006), and this may account for part of the superiority of galantamine over other centrally acting anticholinesterases in terms of side effects. Unlike pyridostigmine, galantamine inhibits BuChE poorly, leaving intact this scavenger site for OPs in blood. Additionally, galantamine has been reported to have anticonvulsant (Kilimov, 1965) and neuroprotective (Arias et al., 2004, 2005) properties, both of which are promising in the context of OP poisoning.
C. PRETREATMENT
WITH
GALANTAMINE
These and later experiments were performed in guinea pigs, the best nonprimate model of OP poisoning (Maxwell et al., 1988; Maxwell and Brecht, 1991). Mice and rats have high levels of carboxylesterases, rendering them considerably less sensitive to OPs than guinea pigs and primates and giving reduced benefit of antidotes. Pretreatment is most relevant for first responders, police and firemen reporting to a scene of chemical attack, or for military personnel anticipating such an attack. Given at 30 min before OP exposure, galantamine (5–16 mg=kg, i.m. as hydrobromide) protected completely (in terms of 24 h lethality) against 1.5 LD50s of soman (42 mg=kg, s.c.) or sarin (56 mg=kg, s.c.), when given in conjunction with atropine at 1 min postexposure (10 mg=kg, i.m.) (see Figure 10.1). With the combination of pretreatment with 8 mg=kg galantamine and posttreatment with 10 mg=kg atropine, all of the animals thus protected for 24 h after soman exposure survived with no signs of toxicity for 7 days after exposure. Galantamine (8 mg=kg, i.m.) administered at 30 min prior to exposure of the guinea pigs to 1 3 LD50 soman afforded full protection against lethality in the absence of any posttreatment. In addition to effectively preventing the toxicity and lethality of nerve agents, galantamine protected guinea pigs from lethality and toxicity of paraoxon, the active metabolite of parathion, an extremely toxic OP insecticide. Although the use of paraoxon has been recently banned in the United States, Europe, and Australia, numerous countries still use it in agriculture. It was estimated that approximately 50% of atropine-treated guinea pigs (10 mg=kg, i.m.) would die within 30–40 min after they received 1.5 mg=kg paraoxon (s.c.). Galantamine (8 mg=kg) administered at 30 min prior to the exposure of the guinea pigs to 2 mg=kg paraoxon afforded full protection against lethality and toxicity of this OP (Figure 10.2). The protection afforded by a single dose of galantamine can extend up to several hours. At times up to 3 h before OP exposure, galantamine (10 mg=kg, i.m. as hydrobromide) afforded full
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
224
46616_C010 Final Proof page 224 6.11.2007 6:03pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
30 min
Galantamine (i.m.)
1 min
Atropine (i.m.)
24 h survival
Sarin (1.5 LD50) Atropine (10 mg/kg)
Soman (1.5 LD50) Atropine (10 mg/kg)
125 % of survival
Soman or sarin (s.c.)
100 75 50 25 0 0.1
1
10
0.1
Galantamine (mg/kg)
1
10
Galantamine (mg/kg)
FIGURE 10.1 Effectiveness of galantamine=atropine as an antidote against the acute toxicity and lethality of 1.5 3 LD50 soman or sarin in guinea pigs. Note that there is no need for additional supportive therapy. (From Albuquerque, E.X. et al., Proc. Natl. Acad. Sci. USA, 103, 13220, 2006. With permission.)
protection against the lethality and toxicity of 1.5 LD50s of soman, when used in conjunction with atropine postexposure treatment (10 mg=kg, i.m.) (Figure 10.3). A slightly lower dose (8 mg=kg), half of the galantamine dose at which mild side effects began to appear, protected completely for up to 1 h (Figure 10.3). Presumably oral doses could have protected for even longer than these intramuscular doses because of slower galantamine absorption. The time to peak drug concentration after oral dosing in humans is 52 min and the plasma half-life is 5.7 h (Sramek et al., 2000). Protection by galantamine was superior to that provided by pyrodostigmine, which exhibited a peak protection (about 65% survival) at 52 mg=kg (Figure 10.4). At higher doses, there was less protection, presumably because of pyridostigmine’s removal of scavenging of OPs by BuChE. The protection by galantamine was equivalent to that afforded by huperzine A (Figure 10.4),
Saline Galantamine (8 mg/kg)
Galantamine (i.m.)
30 min Paraoxon (1–3 mg/kg, s.c.) 1 min Atropine (i.m.)
% of survival
125 100 75 50 25 0 0.5
1
2
3
4
Paraoxon (mg/kg) Atropine (10 mg/kg)
24 h survival
FIGURE 10.2 Galantamine=atropine is an effective antidote against the acute toxicity and lethality of paraoxon, the active metabolite of the OP insecticide parathion. Thus, the antidotal therapy counteracts the toxicity of OP insecticides as well as it counteracts the toxicity of nerve agents. (From Albuquerque, E.X. et al., Proc. Natl. Acad. Sci. USA, 103, 13220, 2006. With permission.)
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C010 Final Proof page 225 6.11.2007 6:03pm Compositor Name: BMani
225
Novel Medical Countermeasure for Organophosphorus Intoxication
Galantamine (i.m.)
Galantamine (8 mg/kg) Galantamine (10 mg/kg)
125 % of survival
1–5 h Soman (1.5 LD50, s.c.) 1 min Atropine (10 mg/kg, i.m.)
100 75 50 25
24 h survival
0 1 2 3 4
1 2 3 5
Time (h) before soman
FIGURE 10.3 The safety window of time for pretreatment with galantamine to prevent soman-induced lethality in guinea pigs can be up to several hours. (From Albuquerque, E.X. et al., Proc. Natl. Acad. Sci. USA, 103, 13220, 2006. With permission.)
previously tried for protection against OP exposure (reviewed in Lallement et al., 2002a). However, galantamine produced no detectable behavioral effects (Figure 10.5) whereas even the minimal doses of huperzine A needed to afford full protection against lethality of 1.5 3 LD50 soman increased locomotor activity and stereotypic behavior (Figure 10.5) as well as obvious and potentially incapacitating side effects (profuse secretions, muscle fasciculations, respiratory distress, and tremors). Furthermore, this dose of huperzine A, given only once, reduced the rate of weight gain of peripubertal guinea pigs over the subsequent 7 days, again in contrast to galantamine (and atropine). More complete results are described in Albuquerque et al. (2006).
Pyridostigmine, huperzine A, or pyridostigmine (i.m.)
30 min
Soman (1.5 LD50 1 min s.c.)
Atropine (i.m.)
24 h survival
% of survival
125 100 75 50 25 0 26 40 52 65
100 200 300 400 500
Pyridostigmine (µg/kg)
Huperzine A (µg/kg)
1
3
4
6
8
Galantamine (mg/kg)
FIGURE 10.4 Galantamine=atropine is more effective than pyridostigmine=atropine and as effective as huperzine A against the acute toxicity and lethality of soman. (From Albuquerque, E.X. et al., Proc. Natl. Acad. Sci. USA, 103, 13220, 2006. With permission.)
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
226
46616_C010 Final Proof page 226 6.11.2007 6:03pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Saline, galantamine, or huperzine A (i.m.)
150
Locomotor activity
400
Saline Galantamine (8 mg/kg) Stereotypy
Total distance (cm)
200
Stereotypy
100 50 0
300 200 100 0
0–5
5 –10
30–35
0–5
35–40
Time after injection (min)
30–35
35–40
Saline 400
Huperzine (300 µg/kg)
Huperzine (300 µg/kg)
* Stereotypy
Total distance (cm)
5 –10
Time after injection (min)
Saline 300
Saline Galantamine (8 mg/kg)
200
100
300 * 200 100 0
0 0–5
5 –10
30–35
35–40
Time after injection (min)
0–5
5 –10
30–35
35–40
Time after injection (min)
FIGURE 10.5 At doses sufficient to afford full protection of guinea pigs against the lethality and acute toxicity of 1.5 3 LD50 soman, galantamine has no significant effect on the animals’ gross behavior whereas huperzine A significantly increases locomotor activity and stereotypic behavior. (From Albuquerque, E.X. et al., Proc. Natl. Acad. Sci. USA, 103, 13220, 2006. With permission.)
D. POSTTREATMENT
WITH
GALANTAMINE
Because chemical attacks, or accidents with insecticides, usually cannot be anticipated, postexposure antidotes against OP intoxication are even more desirable than preventative pretreatments. If given sufficiently soon after OP exposure, before major symptoms appear, galantamine appears to be such an antidote. In guinea pigs, galantamine (8 or 10 mg=kg, i.m.), given in conjunction with atropine (10 mg=kg, i.m.), protects completely against soman lethality (1.5 3 LD50, s.c., measured at 24 h) at times up to 5 min after exposure (Figure 10.6), with similar protection against paraoxon (Figure 10.6) and sarin (not shown). For lower doses of OP, the time after exposure for which galantamine provides effective treatment is prolonged. Thus, for guinea pigs treated with only 1 3 LD50 of soman subcutaneously, complete survival was afforded by galantamine (8 mg=kg, i.m., þ atropine 10 mg=kg, i.m.) even at 20 min after the soman injection (Albuquerque et al., unpublished results). Treatment could presumably be delayed further still when OP exposure was by routes, for example, transdermal, giving slower OP absorption. These findings of the postexposure effectiveness of galantamine are the most exciting reported in this chapter.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C010 Final Proof page 227 6.11.2007 6:03pm Compositor Name: BMani
227
Novel Medical Countermeasure for Organophosphorus Intoxication
Soman or paraoxon (s.c.)
1 min
Atropine (i.m.)
Galantamine (i.m.)
Soman (1.5 LD50) Atropine (10 mg/kg)
Paraoxon (2 or 3 mg/kg) Atropine (10 mg/kg) 2 mg/k 3 mg/kg
1 5 5 1 5 Time (min) after soman
12 20 2 10 15 Time (min) after paraoxon
125 % of survival
x min
24 h survival
100 75 50 25 0
Galantamine:
6 mg/kg
8 mg/kg
10 mg /kg
FIGURE 10.6 Posttreatment with galantamine=atropine effectively counteracts nerve agent and insecticide toxicity in guinea pigs. Lower the level of OP exposure, longer the time within which the antidotal therapy effectively maintains 100% survival of the animals with no signs of toxicity. (From Albuquerque, E.X. et al., Proc. Natl. Acad. Sci. USA, 103, 13220, 2006. With permission.)
E. PROTECTION AGAINST BRAIN DAMAGE The above results in terms of survival are extremely promising. However, survival alone is not enough if there is brain damage that can potentially lead to delayed cognitive or neurological effects. Neurodegeneration in the pyriform cortex, the amygdala, and the hippocampus is characteristic of (nonfatal) OP exposure in animals and presumably contributes to delayed cognitive effects reported in victims of the Japanese sarin attacks and others (DiGiovanni, 1999) and certain neurological effects in animal models (Jamal, 1995, 1997). Galantamine (8 mg=kg, i.m., with atropine at 1 min after OP exposure), given 30 min before or 5 min after soman (1.5 3 LD50, s.c.), protected guinea pigs virtually completely against the extensive neurodegeneration seen at 24 h in these three areas (visualized with Fluro-Jade B) in surviving animals treated with atropine (Figure 10.7). The neuroprotection afforded by galantamine is likely to result from its direct actions in the brain, as evidenced by the findings that galantamine can prevent neurodegeneration induced by treatment with staurosporine (STS) of primary cultures of the rat hippocampus. In these experiments, primary hippocampal cultures were exposed to medium-containing vehicle, galantamine, STS, or galantamine followed by STS plus galantamine. Number of apoptotic cells visualized by terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL) in cultures treated with STS alone was compared to the number of apoptotic cells in cultures subjected to each of the other treatments. As shown in Figure 10.8, STS-induced cell death was significantly decreased by the treatment with galantamine. It has been suggested that the neuroprotective effect of galantamine is a result of activation of a number of kinases, including the extracellular signal regulated kinase, secondary to the nicotinic allosteric potentiating action of the alkaloid (Capsoni et al., 2002; Kihara et al., 2004; Arias et al., 2005). It is tempting to speculate that the neuroprotection afforded by galantamine against the OP insult would contribute to protection against delayed cognitive or neurological effects, but this remains to be established. Such findings should also be correlated with effects on gene expression (Damodaran et al., 2006). It is interesting that the chronic benefit of galantamine in terms of ameliorating
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
228
46616_C010 Final Proof page 228 6.11.2007 6:03pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics Hippocampus
Pyriform cortex
Amygdala
Saline
Galantamine (8 mg/kg)
Soman (1.5 LD50) Atropine (10 mg/kg)
Pretreatment
Posttreatment
FIGURE 10.7 Pre- or posttreatment with galantamine counteracts the neurotoxic effects of lethal doses of nerve agents. Note the relative absence of staining with Fluro-Jade B in brain regions of all animals except those exposed to soman and treated only with atropine. In the pretreatment paradigm, guinea pigs received galantamine (8 mg=kg, i.m.) at 30 min before 1.5 3 LD50 soman (s.c.). In the posttreatment paradigm, guinea pigs received galantamine (8 mg=kg, i.m.) at 5 min after soman. At 1 min after the soman challenge, all animals were treated with atropine (10 mg=kg, i.m.). (From Albuquerque, E.X. et al., Proc. Natl. Acad. Sci. USA, 103, 13220, 2006. With permission.)
cognitive effects of Alzheimer’s disease seems likely to be paralleled by an acute benefit in terms of preventing delayed cognitive effects of OP exposure, with a common primary mechanism (inhibition of AChE) but different secondary mechanisms (increasing acetylcholine at remaining synapses versus occupying the enzyme reversibly to protect it against irreversible inactivation). For treatment of both Alzheimer’s disease and OP intoxication, it seems likely that other mechanisms may contribute as well.
IV. CONCLUSIONS Galantamine, used for many years for polio and for accelerated recovery from anesthesia involving neuromuscular blockers, and more recently for Alzheimer’s disease, appears to possess a fortuitous combination of properties which render it a superior preventative and therapy for OP exposure as well. It is not yet fully apparent what all these properties may be. However, it is likely that selective block of AChE versus BuChE, ability to penetrate the blood–brain barrier, and allosteric
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C010 Final Proof page 229 6.11.2007 6:03pm Compositor Name: BMani
Novel Medical Countermeasure for Organophosphorus Intoxication
229
% of TUNEL-positive cells
100 ***
80
***
60 40 20 0 Vehicle Galantamine (1 µM) STS (0.1 µM) STS (0.1 µM) + galantamine (1 µM)
FIGURE 10.8 Staurosporine (STS)-induced apoptosis in primary hippocampal cultures is reduced by pretreatment with galantamine. Primary hippocampal cultures were treated with medium containing (1) vehicle (water, 1:10,000 and DMSO 1:10,000) for 48 h, (2) galantamine for 48 h, (3) STS for 24 h, or (4) galantamine for 24 h followed by STS plus galantamine for an additional 24 h. In each group, the number of cells counted in each of three microscopic fields in a coverslip or culture dish was taken as 100% and used to normalize the number of TUNEL-positive cells. Experiments were carried out in triplicate. *** indicates that results differ from one another with a p < 0.001 according to the ANOVA. (From Albuquerque, E.X. et al., Proc. Natl. Acad. Sci. USA, 103, 13220, 2006. With permission.)
potentiation of nAChRs all contribute to the effectiveness of galantamine as a medical countermeasure against OP poisoning. The data summarized here indicate that the introduction of galantamine into clinical practice for OP poisoning will provide a major advance.
ACKNOWLEDGMENTS We thank other researchers who have contributed to the work summarized here, including Drs. William P. Fawcett, Maristela Oliveira, William R. Randall, Tracey A. Hamilton, Robert K. Kan, James A. Romano Jr., and Michael Adler. This work was supported by U.S. Army Medical Research and Development Command Contract DAMD-17-95-C-5063, Battelle Scientific Services Contract TCN 03132, U.S. Public Health Service Grant NS25296 from the National Institutes of Health, and National Institutes of Environmental Health Sciences=National Institutes of Health Training Grant T32 ES07263 (all to E.X.A.). The use of galantamine as an antidote against organophosphorus poisoning is protected under the International Patent Application PCT=US05=33789 filed on September 23, 2005.
REFERENCES Abou-Donia, M.B., Organophosphorus ester-induced chronic neurotoxicity, Arch. Environ. Health, 58, 484, 2003. Albuquerque, E.X. et al., Effective countermeasure against poisoning by organophosphorus insecticides and nerve agents, Proc. Natl. Acad. Sci. U.S.A., 103, 13220, 2006. Arias, E. et al., Galantamine prevents apoptosis induced by beta-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors, Neuropharmacology, 46, 103, 2004.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
230
46616_C010 Final Proof page 230 6.11.2007 6:03pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Arias, E. et al., Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors, J. Pharmacol. Exp. Ther., 315, 1346, 2005. Bajgar, J., Organophosphates=nerve agent poisoning: mechanism of action, diagnosis, prophylaxis, and treatment, Adv. Clin. Chem., 38, 151, 2004. Baldi, I. et al., Neurodegenerative diseases and exposure to pesticides in the elderly, Am. J. Epidemiol., 157, 409, 2003. Bhagat, Y.A. et al., Neuroprotection from soman-induced seizures in the rodent: evaluation with diffusion- and T2-weighted magnetic resonance imaging, Neurotoxicology, 26, 1001, 2005. Cannard, K., The acute treatment of nerve agent exposure, J. Neurol. Sci., 249, 86, 2006. Capsoni, S., Giannotta, S., and Cattaneo, A., Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice, Proc. Natl. Acad. Sci. U.S.A., 99, 12432, 2002. Chung, J.A. and Cummings, J.L., Neurobehavioral and neuropsychiatric symptoms in Alzheimer’s disease: characteristics and treatment, Neurol. Clin., 18, 829, 2000. Couzin, J., Clinical trials. New rule triggers debate over best way to test drugs, Science, 299, 1651, 2003. Coyle, J. and Kershaw, P., Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer’s disease, Biol. Psychiatry, 49, 289, 2001. Coyle, J.T., Price, D.L., and DeLong M.R., Alzheimer’s disease: a disorder of cortical cholinergic innervation, Science, 219, 1184, 1983. Damodaran, T.V. et al., Gene expression profiles of the rat brain both immediately and 3 months following acute sarin exposure, Biochem. Pharmacol., 71, 497, 2006. Deshpande, S.S. et al., Effectiveness of physostigmine as a pretreatment drug for protection of rats from organophosphate poisoning, Fundam. Appl. Toxicol., 6, 566, 1986. DiGiovanni, C., Domestic terrorism with chemical or biological agents: psychiatric aspects, Am. J. Psychiatry, 156, 1500, 1999. Duysen, E.G. et al., Evidence for nonacetylcholinesterase targets of organophosphorus nerve agent: supersensitivity of acetylcholinesterase knockout mouse to VX lethality, J. Pharmacol. Exp. Ther., 299, 528, 2001. Fricke, R.F. et al., Efficacy of tacrine as a nerve agent pretreatment, Drug Chem. Toxicol., 17, 15, 1994. Geerts, H., Indicators of neuroprotection with galantamine, Brain Res. Bull., 64, 519, 2005. Geoghegan, J. and Tong, J.L., Chemical warfare agents, Contin. Educ. Anaesth. Crit. Care Pain, 6, 230, 2006. Goedert, M. and Spillantini, M.G., A century of Alzheimer’s disease, Science, 314, 777, 2006. Grunwald, J. et al., Huperzine A as a pretreatment candidate drug against nerve agent toxicity, Life Sci., 54, 991, 1994. Heinrich, M. and Lee Teoh, H., Galanthamine from snowdrop—the development of a modern drug against Alzheimer’s disease from local Caucasian knowledge, J. Ethnopharmacol., 92, 147, 2004. Hellstrom-Lindahl, E. et al., Regional distribution of nicotinic receptor subunit mRNAs in human brain: comparison between Alzheimer and normal brain, Brain Res. Mol. Brain Res., 66, 94, 1999. Jamal, G.A., Long-term neurotoxic effects of organophosphate compounds, Adverse Drug React. Toxicol. Rev., 14, 85, 1995. Jamal, G.A., Neurological syndromes of organophosphorus compounds, Adverse Drug React. Toxicol. Rev., 16, 133, 1997. Kamel, F. et al., Neurobehavioral performance and work experience in Florida farmworkers, Environ. Health Perspect., 111, 1765, 2003. Karalliedde, L. and Senanayake, N., Organophosphorus insecticide poisoning, Br. J. Anaesth., 63, 736, 1989. Kihara, T. et al., Galantamine modulates nicotinic receptor and blocks Abeta-enhanced glutamate toxicity. Biochem. Biophys. Res. Commun., 325, 976, 2004. Kilimov, N., Effect of Nivalin on audiogenic seizures in mice, Dokl. Bulg. Acad. Nauk., 18, 287, 1965. Lallement, G. et al., Review of the value of huperzine as pretreatment of organophosphate poisoning, Neurotoxicology, 23, 1, 2002a. Lallement, G. et al., Subchronic administration of pyridostigmine or huperzine to primates: compared efficacy against soman toxicity, Drug Chem. Toxicol., 25, 309, 2002b. Layish, I. et al., Pharmacologic prophylaxis against nerve agent poisoning, Isr. Med. Assoc. J., 7, 182, 2005. Lleo, A., Greenberg, S.M., and Growdon, J.H., Current pharmacotherapy for Alzheimer’s disease, Ann. Rev. Med., 57, 513, 2006.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C010 Final Proof page 231 6.11.2007 6:03pm Compositor Name: BMani
Novel Medical Countermeasure for Organophosphorus Intoxication
231
Loy, C. and Schneider, L., Galantamine for Alzheimer’s disease and mild cognitive impairment, Cochrane Database Syst. Rev., 1, CD001747, 2006. Maelicke, A. and Albuquerque, E.X., New approach to drug therapy of Alzheimer’s dementia, Drugs Disc. Today, 1, 53, 1996. Maelicke, A. et al., Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer’s disease, Biol. Psychiatry, 49, 279, 2001. Marrs, T.C., The role of diazepam in the treatment of nerve agent poisoning in a civilian population, Toxicol. Rev., 23, 145, 2004. Mashkovsky, M.D. and Kruglikova-Lvova, R.P., On the pharmacology of the new alkaloid galantamine, Farmakologia Toxicologia (Moscow), 14, 27, 1951 (in Russian). Maxwell, D.M. and Brecht, K.M., The role of carboxylesterase in species variation of oxime protection against soman, Neurosci. Biobehav. Rev., 15, 135, 1991. Maxwell, D.M. et al., Effect of carboxylesterase inhibition on carbamate protection against soman toxicity, J. Pharmacol. Exp. Ther., 246, 986, 1988. Maxwell, D.M. et al., Acetylcholinesterase inhibition: does it explain the toxicity of organophosphorus compounds? Arch. Toxicol., in press, 2006. Newmark, J., Nerve agents: pathophysiology and treatment of poisoning, Semin. Neurol., 24, 185, 2004a. Newmark, J., Therapy for nerve agent poisoning, Arch. Neurol., 61, 649, 2004b. Newmark, J., Nerve agents, Neurol. Clin., 23, 623, 2005. Nicolson, R., Craven-Thuss, B., and Smith, J., A prospective, open-label trial of galantamine in autistic disorder, J. Child. Adolesc. Psychopharmacol., 16, 621, 2006. Nordberg, A., Nicotinic receptor abnormalities of Alzheimer’s disease: therapeutic implications, Biol. Psychiatry, 49, 200, 2001. Okonjo, K.O., Kuhlmann, J., and Maelicke, A., A second pathway of activation of the Torpedo acetylcholine receptor channel, Eur. J. Biochem., 200, 671, 1991. Pearson, V.E., Galantamine: a new alzheimer drug with a past life, Ann. Pharmacother., 35, 1406, 2001. Pereira, E.F.R. et al., Identification and functional characterization of a new agonist site on nicotinic acetylcholine receptors of cultured hippocampal neurons, J. Pharmacol. Exp. Ther., 265, 1474, 1993. Pereira, E.F.R. et al., Physostigmine and galanthamine: probes for a novel binding site on the a4b2 subtype of neuronal nicotinic acetylcholine receptors stably expressed in fibroblast cells, J. Pharmacol. Exp. Ther., 270, 768, 1994. Pereira, E.F.R. et al., Unconventional ligands and modulators of nicotinic receptors, J. Neurobiol., 53, 479, 2002. Perry, E. et al., Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases, Eur. J. Pharmacol., 393, 215, 2000. Plaitakis, A. and Duvoisin, R.C., Homer’s moly identified as Galanthus nivalis L.: physiologic antidote to stramonium poisoning, Clin. Neuropharmacol., 6, 1, 1983. Rickett, D.L., Glenn, J.F., and Beers, E.T., Central respiratory effects versus neuromuscular actions of nerve agents, Neurotoxicology, 7, 225, 1986. Robertson, E.D. and Mucke, L., 100 Years and counting: prospects for defeating Alzheimer’s disease, Science, 314, 781, 2006. Sabbagh, M.N. et al., Correlation of nicotinic receptor binding with clinical and neuropathological changes in Alzheimer’s disease and dementia with Lewy bodies, J. Neural Transm., 108, 1149, 2001. Samochocki, M. et al., Galantamine is an allosterically potentiating ligand of the human a4b2 nAChR, Acta Neurol. Scand. Suppl., 176, 68, 2000. Santos, M.D. et al., The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system, Mol. Pharmacol., 61, 1222, 2002. Schrattenholz, A. et al., Photoaffinity labeling of Torpedo acetylcholine receptor by physostigmine, Eur. J. Biochem., 216, 671, 1993. Schrattenholz, A. et al., Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands, Mol. Pharmacol., 49, 1, 1996. Schroder, B. et al., Monoclonal antibodies FK1 and WF6 define two neighboring ligand binding sites on Torpedo acetylcholine receptor alpha-polypeptide, J. Biol. Chem., 269, 10407, 1994. Schubert, M.H., Young, K.A., and Hicks, P.B., Galantamine improves cognition in schizophrenic patients stabilized on risperidone, Biol. Psychiatry, 50, 521, 2006.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
232
46616_C010 Final Proof page 232 6.11.2007 6:03pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Schwendimann, R.N., Burton, E., and Minagar, A., Management of myasthenia gravis, Am. J. Ther., 12, 262, 2005. Shaw, K.P. et al., The reversible cholinesterase inhibitor physostigmine has channel-blocking and agonist effects on the acetylcholine receptor-ion channel complex, Mol. Pharmacol., 28, 527, 1985. Sherby, S.M. et al., Comparison of the actions of carbamate anticholinesterases on the nicotinic acetylcholine receptor, Mol. Pharmacol., 27, 343, 1985. Shih, T.M., Duniho, S.M., and McDonough, J.H., Control of nerve agent-induced seizures is critical for neuroprotection and survival, Toxicol. Appl. Pharmacol., 188, 69, 2003. Sramek, J.J., Frackiewicz, E.J., and Cutler, N.R., Review of the acetylcholinesterase inhibitor galanthamine, Expert Opin. Investig. Drugs, 9, 2393, 2000. Storch, A. et al., Physostigmine, galanthamine and codeine act as ‘noncompetitive nicotinic receptor agonists’ on clonal rat pheochromocytoma cells, Eur. J. Pharmacol., 290, 207, 1995. Tokuda, Y. et al., Prehospital management of sarin nerve gas terrorism in urban settings: 10 years of progress after the Tokyo subway sarin attack, Resuscitation, 68, 193, 2006. Wevers, A. et al., Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer’s disease: histotopographical correlation with amyloid plaques and hyperphosphorylated-tau protein, Eur. J. Neurosci., 11, 2551, 1999. Wiener, S.W. and Hoffman, R.S., Nerve agents: a comprehensive review, J. Int. Care Med., 19, 22, 2004. Yanagisawa, N., Morita, H., and Nakajima, T., Sarin experiences in Japan: acute toxicity and long-term effects, J. Neurol. Sci., 249, 76, 2006. Zhang, Z.W., Coggan, J.S., and Berg, D.K., Synaptic currents generated by neuronal acetylcholine receptors sensitive to a-bungarotoxin, Neuron, 17, 1231, 1996.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C011 Final Proof page 233 6.11.2007 6:06pm Compositor Name: BMani
Toxicology 11 Inhalation of Nerve Agents Paul A. Dabisch, Stanley W. Hulet, Robert Kristovich, and Robert J. Mioduszewski CONTENTS I. II.
Introduction ....................................................................................................................... 233 Exposure to Nerve Agent in the Atmosphere: The Impact of Physical Properties .......... 234 A. Laboratory Scale Generation of Nerve Agent Atmospheres .................................... 235 III. Ocular Effects of Nerve Agent Vapor=Aerosol Exposure ................................................ 236 IV. Respiratory Effects of Nerve Agent Vapor=Aerosol Exposure ........................................ 238 V. Gastrointestinal Effects of Nerve Agent Aerosol Exposure ............................................. 239 VI. Other Effects following Distribution throughout the Body .............................................. 240 VII. Modeling Chemical Nerve Agent Dosage ........................................................................ 240 A. Haber’s Rule versus Toxic Load............................................................................... 240 B. Use of Animal Model Toxicity Data to Estimate Risks of Human Exposure to Nerve Agent Atmospheres .................................................................................... 242 VIII. Summary ........................................................................................................................... 243 References ..................................................................................................................................... 244
I. INTRODUCTION The chemical warfare nerve agents are a class of extremely toxic chemicals developed during the period surrounding World War II. The nerve agents are cholinesterase (ChE)-inhibiting organophosphorus compounds that are related through structure and mechanism of action to pesticides, but are much more potent. Five of the most common nerve agents are tabun, sarin, soman, cyclosarin, and VX. Exposure to nerve agent vapor or aerosol can result in a variety of toxicological effects. As with other chemical compounds, the severity of these effects depends on the concentration of the agent and the duration of the exposure. The initial signs and symptoms of nerve agent vapor involving whole-body or head-only exposure include miosis, rhinorrhea, and tightness in the chest. These responses are generally attributed to direct, local effects of nerve agent in ocular and respiratory tissue (Grob, 1956). In contrast, exposures to nerve agents resulting from routes other than inhalation (e.g., intramuscular, intravenous, intraperitoneal, or subcutaneous injection; percutaneous absorption) typically do not produce these local effects on the ocular and respiratory systems as their first noticeable effects (Frederiksson et al., 1960). Instead, local effects, such as muscle fasciculation, may be seen at the site of application or injection. Regardless of the route of exposure, systemic toxic signs will begin to appear as the agent absorbs into the systemic circulation and is distributed throughout the body. This chapter presents an overview of the toxic effects associated with inhalation of a nerve agent vapor or aerosol. Many of the studies cited were conducted at the U.S. Army Chemical Biological Center from the 1950s up to the present day. One of the objectives of these studies was to 233
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
234
46616_C011 Final Proof page 234 6.11.2007 6:06pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
characterize the health hazards of chemical nerve agent atmospheric exposure with regard to their potential impact on the performance of military operations. The results of such studies enhance human risk assessment modeling tools, support the operational risk management decision process, and help define nerve agent detection thresholds which are physiologically relevant.
II. EXPOSURE TO NERVE AGENT IN THE ATMOSPHERE: THE IMPACT OF PHYSICAL PROPERTIES The potential for exposure to nerve agents in a real-world situation is likely to occur as a result of military operations, a terrorist incident, or accidental exposure, including demilitarization of weaponized material. In these cases, the exposure would be limited to two likely routes: percutaneous and inhalation. Percutaneous exposure is possible through contact with contaminated surfaces. Inhalation of nerve agent would be a major route of exposure in unprotected individuals following explosive dissemination of nerve agent material. In this case, an aerosol cloud containing respirable particles, typically less than 10 mm in diameter, would be generated (Witschi and Last, 2001). It is also possible that explosive dissemination could produce toxicity through the percutaneous route due to settling of aerosol particles onto the skin. However, if a more volatile agent such as sarin was used, the percutaneous component of the exposure would be minimal. This is because sarin has a vapor pressure of 2.9 mmHg at 258C and would likely evaporate before having a chance to be absorbed through the skin. Indeed it has been demonstrated in open-air testing that sarin has minimal effectiveness in humans via the percutaneous route of exposure (Marzulli and Williams, 1953). Therefore, the primary hazard of sarin is through the inhalation route. For a less volatile agent such as VX, with a vapor pressure 3000 times less than that of sarin (Table 11.1), very little evaporation of material deposited onto the skin would occur. Any aerosol that did deposit onto the skin would remain until it is either removed or absorbed, and the chances of a percutaneous component to the toxic response are increased (Bramwell et al., 1963). Therefore, exposure to aerosolized VX poses potentially both an inhalation and a percutaneous exposure hazard. In addition to aerosols, nerve agent vapor also poses an inhalation hazard. Overall, greater the vapor pressure of a nerve agent, greater the inhalation hazard it poses. Relatively recent examples of real-world nerve agent vapor exposure incidents include two attacks reported in Japan. In 1994, sarin was disseminated in a residential neighborhood of Matsumoto, Japan by the group Aum Shinrikyo using a heater and an automobile fan to vaporize the agent and disperse it (Yanagisawa et al., 2006). The attack left seven people dead and over 600 casualties. In 1995 in Tokyo, the same group disseminated liquid sarin from plastic bags by poking holes in the bags. The agent leaked out from the bags and evaporated, resulting in the exposure of thousands of subway commuters to sarin vapor. This attack left 12 people dead and resulted in over 600 casualties being treated in the immediate aftermath. In both cases, inhalation of sarin vapor was the primary route of exposure.
TABLE 11.1 Physical Properties of the Nerve Agents Relevant to Vapor Generation
Vapor pressure Vapor density (relative to air) Volatility at 258C
Tabun
Sarin
Soman
VX
0.037 mmHg at 208C 5.6
2.1 mmHg at 208C 4.86
0.40 mmHg at 258C 6.3
0.0007 mmHg at 208C 9.2
610 mg=m3
22000 mg=m3
3900 mg=m3
10.5 mg=m3
Note: The ‘‘G’’ agents, namely sarin, soman, and tabun, are all relatively volatile compounds when compared with VX, making them better candidates for vapor generation (Sidell, 1997).
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C011 Final Proof page 235 6.11.2007 6:06pm Compositor Name: BMani
235
Inhalation Toxicology of Nerve Agents
A. LABORATORY SCALE GENERATION
OF
NERVE AGENT ATMOSPHERES
In the laboratory, several methods have been employed to produce nerve agent vapors and aerosols. These methods are able to generate stable vapor or aerosol atmospheres, and the exposure durations can be easily controlled, lasting from a few minutes to several hours. Although these methods attempt to reproduce a real-world exposure, it is important to realize that significant differences exist between the two exposure scenarios. Unlike many atmospheres generated in a laboratory, a realworld exposure atmosphere is likely to be much more dynamic and can have unpredictable and wide variations in the nerve agent concentration over time due to variations in wind speed, temperature, humidity, degree of ventilation, presence of objects that could alter airflow, as well as many other factors. This variation in concentration can complicate the extrapolation of toxicological data collected in a laboratory setting to a field setting. Several methods will be briefly described in this chapter; however, more complete descriptions of the methods for the generation and analysis of nerve agent atmospheres exist (Carpin et al., 2003; Anthony et al., 2004; Allon et al., 2005; Benton et al., 2006; Muse et al., 2006). Several commonly used systems are (1) the spray atomizer generation system, (2) the dual-needle air-blast generation system, and (3) the saturator-cell generation system. A spray-atomization generation system employs a syringe drive to supply a constant amount of agent to a spray atomizer (Muse et al., 2006). As liquid nerve agent enters the atomizer, compressed air is used to atomize the liquid nerve agent into a fine aerosol. With more volatile agents, such as sarin, these droplets quickly evaporate, and the resulting vapor is drawn into an inhalation chamber. This method is useful for generating vapors of relatively volatile agents, such as the ‘‘G’’ series nerve agents. Additionally, this methodology could also be used to produce aerosols of less volatile agents. A similar method has been used previously to generate nerve agent aerosols (Carpin et al., 2003). VX aerosol has been generated using a syringe drive to pump liquid nerve agent into a dual-needle air-blast generator. In the dual-needle design, liquid agent is fed down a tube, which is sheathed by a larger needle. Compressed air is delivered through the larger needle and as the liquid agent exits the smaller needle, it is blasted into a fine aerosol. A saturator-cell generation system can be used to generate a nerve agent vapor. The saturator cell generates agent vapor by passing nitrogen through a multiple-pass glass vessel containing a porous ceramic cylinder saturated with liquid nerve agent. As the nitrogen carrier gas flows over the liquid agent, nerve agent vapor is carried from the glass saturator cell to the inhalation chamber. The flow of nitrogen through the saturator cell can be manipulated to generate various concentrations of nerve agent vapor. Additionally, the concentration of nerve agent vapor can be manipulated by changing the temperature of the saturator cell, thereby changing the rate of evaporation of the nerve agent (Muse et al., 2006). Due to the ability to manipulate the temperature of the saturator cell, this system can be used to generate vapors of either the volatile ‘‘G’’ series nerve agents or less volatile agents such as VX (Benton et al., 2005, 2006). For systems that generate nerve agent vapor, the stability of the generated atmosphere can be continuously monitored by using Hydrogen Flame Emission Detection, a selective monitor for phosphorus containing species. Additionally, a quantitative measurement of the agent concentration in the chamber can be determined using solid phase sorbent tubes. Small samples of the nerve agent vapor containing environment are pulled through glass tubes containing a sorbent material, such as TENAX TA. Once the sample is collected, the amount of agent is quantified using gas chromatography. By knowing the amount of air drawn through the sorbent tube, the concentration of nerve agent (mg=m3) can be calculated (Muse et al., 2006). For systems that generate a nerve agent aerosol, there are several ways to characterize the chamber atmosphere. Real-time optical aerosol monitors can be used to monitor the concentration and stability of the chamber atmosphere. Alternatively, glass fiber filters can be used to collect aerosol from the chamber. However, this method only provides information about the average concentration of the chamber atmosphere during the period when the sample was collected and does
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
236
46616_C011 Final Proof page 236 6.11.2007 6:06pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
not provide information about the stability of the chamber atmosphere. Particle size distribution can be monitored in real time using aerodynamic particle sizer spectrometers connected to the chamber. Alternatively, particle size can be assessed using multistage impactors. As with the glass fiber filters, multistage impactors only provide an average particle size of the chamber aerosol during the period when the sample was collected and do not provide real-time information about changes in particle size. Aerosol chamber concentrations are usually expressed in mg=m3, although other units are acceptable. Particle size is usually expressed as the mass median aerodynamic diameter (MMAD), a calculation of particle size based on the weight of the collected sample and normalized to particle density. By weight, 50% of the particles will be larger than the MMAD and 50% of the particles will be smaller than the MMAD.
III. OCULAR EFFECTS OF NERVE AGENT VAPOR=AEROSOL EXPOSURE One of the first noticeable effects of a whole-body exposure to nerve agent vapor or aerosol is constriction of the pupils, or miosis (Figure 11.1). In the Tokyo and Matsumoto terrorist incidents, miosis with subsequent dim vision and narrowing of the visual field was one of the most common signs seen in exposed victims (Ohbu et al., 1997; Okudera, 2002; Yanagisawa, 2006). Additionally, a report of accidental exposures to sarin at Rocky Mountain Arsenal occurring in 1953 and 1954 found that miosis was the most common clinical effect of exposure seen (Gaon and Werne, 1955). A study conducted by the Chemical Defence Establishment at Porton Down, UK found miosis to be the only consistent sign of exposure in volunteers exposed to a low level of sarin vapor for 30 min (Baker and Sedgwick, 1996). Because it is a common finding in exposed individuals, and because it can occur at concentrations much lower than those necessary to cause other signs of toxicity, miosis is often used as a marker of exposure to sarin or cyclosarin vapor or aerosol.
(a)
(b)
(c)
(d)
FIGURE 11.1 Representative infrared images showing the progression of miosis in the Gottingen minipig during exposure to sarin vapor. Gottingen minipigs exposed to a lethal concentration of sarin vapor (LCt99, or 4.0 mg=m3) develop miosis rapidly. Once the pupil begins constricting, the progression from normal pupil size (image A) to a miotic pupil (images B through D) takes less than 3 min. Infrared images were acquired as described previously. (Hulet S.W. et al., Inhal Toxicol, 18, 143, 2006a.)
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Inhalation Toxicology of Nerve Agents
46616_C011 Final Proof page 237 6.11.2007 6:06pm Compositor Name: BMani
237
The ocular effects of nerve agents are readily explainable given the physiology of the eye. Normally, both the sympathetic and parasympathetic branches of the autonomic nervous system play a role in the control pupillary size. In both humans and rats, stimulation of the sympathetic branch releases norepinephrine onto a-adrenergic receptors located on the radial muscles of the iris, resulting in dilation of the pupil (Moroi and Lichter, 1996; Yu and Koss, 2002, 2003). Muscarinic acetylcholine receptors are present on the pupillary sphincter, and administration of muscarinic antagonists results in pupillary dilation, demonstrating the role for muscarinic receptors and the parasympathetic nervous system in the control of pupil diameter (Moroi and Lichter, 1996; Smith et al., 1996; Sokolski and Demet, 1996; Furuta et al., 1998). Nerve agent induced miosis is due to inhibition of ocular acetylcholinesterase, which results in excessive stimulation of muscarinic acetylcholine receptors and contraction of the pupillary sphincter. In guinea pigs, it has been shown that nerve agent induced contraction of the pupillary sphincter muscle is proportional to the degree of inhibition of acetylcholinesterase in the iris (Soli et al., 1980). As predicted from the physiology, administration of the muscarinic receptor antagonist atropine prior to nerve agent vapor exposure is able to prevent the miotic response (Dabisch et al., 2005a). The miotic effect of nerve agent vapors and aerosols, unlike other effects of exposure to nerve agent vapor or aerosol, is mainly due to direct contact of nerve agent vapor with the eye and not inhalation and subsequent distribution of the agent to the eye. This direct effect of nerve agents on the eye has been demonstrated previously in several studies. In the 1950s, Sim (1956) demonstrated that covering soldiers’ eyes with a bandage decreases the magnitude of the miotic response to sarin vapor exposure, suggesting that penetration of the vapor through the surface of the eye plays an important role in the development of miosis. Additionally, direct application of soman drops to the eye produced miosis in guinea pigs, again suggesting that miosis can result from agent penetration through the ocular surface (Soli et al., 1980). Different nerve agents have different miotic potencies. Several studies performed in rats have demonstrated that VX is approximately an order of magnitude more potent than sarin and cyclosarin (Mioduszewski et al., 2002a; Whalley et al., 2004; Benton et al., 2005). VX exposure data from humans (Bramwell et al., 1963) is in agreement with the animal potency data, and human estimates reflect this (Reutter et al., 2003). In addition to overall potency differences between agents, gender differences in the miotic potency of nerve agent have also been reported. Female rats appear to be more sensitive to the miotic effects of sarin, cyclosarin, and VX than male rats (Mioduszewski et al., 2002a; Whalley et al., 2004; Benton et al., 2005). Additionally, Hulet et al. (2006a) reported that in the Gottingen minipig, females were more sensitive to sarin for longer duration exposures. However, the same study reported that males were more sensitive to cyclosarin-induced miosis. In mice, males are consistently more sensitive to the effects of sarin vapor than are female mice (Long et al., 1951; McPhail, 1953). Thus, gender differences in miotic sensitivity appear to depend on both the agent being studied and the species being used to study it. The reason for the differing sensitivities between males and females remains unclear. However, several studies have reported gender differences in ocular physiology. In the rat, levels of several drug-metabolizing ocular enzymes were found to be significantly higher in females than in males (Nakamura et al., 2005). Additionally, gender differences in activities of other enzymes, including sorbitol dehydrogenase and glucose-6-phosphate dehydrogenase (Bours et al., 1988), and the structure of the tear-producing lacrimal gland (Sullivan et al., 1990) have been identified in the rat eye. In humans, lacrimal fluid peroxidase activity was found to be different between males and females (Marcozzi et al., 2003). Gender-related differences in humans have also been identified in lacrimal gland structure (Ueno et al., 1996), intraocular pressure (Qureshi, 1997), and Goblet-cell density (Connor et al., 1999). Thus, although the exact reason is unknown, it is plausible that gender differences in the sensitivity to the miotic effect of nerve agent vapor exist. However, data to date suggest that gender differences are not constant across species and type of nerve agent vapor. This makes accounting for gender in human estimates problematic. Several studies have described the effects of repeated exposure to nerve agents on the eye (Soli et al., 1980; Dabisch et al., 2005a, 2005b). These studies reported that following multiple exposures
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
238
46616_C011 Final Proof page 238 6.11.2007 6:06pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
to nerve agent, the miotic response to the nerve agent is reduced for several days. The mechanism of this response likely involves desensitization of the pupillary muscarinic receptors, resulting in a loss of parasympathetic function in the eye, and, subsequently, the response to the nerve agent. Although repeated exposures to a nerve agent are unlikely in a real-world scenario, the threshold dose for the toxicological response seen in the eye following such an exposure sequence has not been determined. Thus, it is unknown whether a single exposure in which a sufficient dose of nerve agent is received could result in decreased parasympathetic function and a diminished pupillary light reflex.
IV. RESPIRATORY EFFECTS OF NERVE AGENT VAPOR=AEROSOL EXPOSURE In addition to the ocular effects of a whole-body nerve agent exposure, respiratory effects due to direct contact of nerve agent with the upper airways are also among the first noticeable signs of exposure. These respiratory effects include tightness in the chest, salivation, and rhinorrhea. A report of accidental exposures to sarin at Rocky Mountain Arsenal occurring in 1953 and 1954 found tightness in the chest present in more than half of the exposed personnel (Gaon and Werne, 1955). Similarly, Baker and Sedgwick (1996) reported dyspnea in sarin exposures that also produced 40%–50% inhibition of red cell acetylcholinesterase. In the Matsumoto and Tokyo terrorist incidents, salivation, rhinorrhea, and dyspnea were commonly reported among exposed individuals (Yanagisawa et al., 2006). As in the eye, the toxicological effects of inhalation of nerve agent vapor into the respiratory tract can be explained by examining the physiology of the respiratory system. The airways are surrounded by smooth muscle, with the muscular thickness decreasing from the bronchioles to the alveoli (Levitzky, 1999). As in the eye, innervation by the autonomic nervous system plays a major role in controlling the tone of this smooth muscle. Beta-adrenergic receptors present in the large airways and bronchioles mediate the bronchodilator response to beta agonists (Barnes 2004; Proskocil and Fryer, 2005). Additionally, stimulation of beta receptors results in an increase in mucus clearance (Proskocil and Fryer, 2005). Muscarinic receptors located on airway smooth muscle mediate the bronchoconstriction induced by cholinergic agonists by several mechanisms. Stimulation of muscarinic receptors produces a direct increase in airway tone through a phospholipase C mediated mechanism. Additionally, stimulation of muscarinic receptors on airway smooth muscle results in inhibition of beta-receptor mediated relaxation of airway smooth muscle (Fryer and Jacoby, 1998). Normally, acetylcholine released from parasympathetic neurons terminating near these receptors is responsible for the control of airway tone. Stimulation of muscarinic receptors also increases mucus secretion from nasal and submucosal glands (Proskocil and Fryer, 2005). The initial effects of a nerve agent vapor or aerosol in the respiratory system are due to direct action of the agent on the airways as it is inhaled. Inhibition of acetylcholinesterase associated with parasympathetic neurons results in the buildup of acetylcholine, producing bronchoconstriction and increased secretions from cholinergic glands. This results in the tightness in the chest, salivation, and rhinorrhea that are commonly noted following exposure to nerve agent vapor (Gaon and Werne, 1954; Baker and Sedgwick, 1996; Yanagisawa et al., 2006). In severely poisoned individuals, airway obstruction due to increased secretions and bronchoconstriction can be life threatening (Grob, 1956). The degree to which the toxic effects of inhalation of a nerve agent vapor or aerosol are manifested depends on the amount of nerve agent that is deposited in the airways or absorbed systemically. Nerve agents can be inhaled as a vapor, an aerosol, or a combination of both. The distribution of nerve agent vapor in the respiratory tract will follow normal respiratory gas flow patterns (Urbanetti, 1997). The inspiration of nerve agent contaminated air leads to the distribution of the agent vapor over the nasal and oral cavities, the pharynx, and the trachea, through the primary, secondary, and tertiary bronchi, into the bronchioles and eventually the alveoli (Figure 11.2). Nerve agent vapor deposition in the upper airways of the respiratory tract is responsible for the early respiratory signs of nerve agent vapor exposure. Nerve agent penetration to the distal
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C011 Final Proof page 239 6.11.2007 6:06pm Compositor Name: BMani
239
Inhalation Toxicology of Nerve Agents
Nasal / oral cavity Pharynx Trachea Primary bronchi
Lung Secondary / tertiary bronchi
Alveoli
FIGURE 11.2 Anatomy of the human respiratory tract. Deposition of nerve agent vapor or aerosols in the different regions of the lung can lead to different symptomology. Upper airway deposition can lead to immediate respiratory distress. Alveolar deposition leads to systemic distribution of the nerve agent.
regions of the respiratory system increases at higher flow rates, such as during exercise (Ainsworth and Sheppard, 1961). In the alveoli, the inhaled nerve agent vapor is absorbed through the alveolar epithelium into the systemic circulation, resulting in distribution throughout the body. The deposition of aerosols in the lung is more complicated than the distribution of nerve agent vapor. The geometry of the respiratory tract and the diameter of the inhaled liquid aerosol determine the deposition of the inhaled material. The geometry of the respiratory tract varies from species to species. However, it is consistent within a species. Therefore, within a given species, the deposition of aerosols is primarily dependent on the aerodynamic size of the inhaled aerosol droplet. Classically, aerosols are classified into four groups with each having significantly different deposition behavior (Anderson et al., 1988; Casillas et al., 1999). In humans, aerosols greater than 10 mm in diameter are classified as nonrespirable because they do not penetrate the respiratory tract deeper than the larynx due to impaction. Very small particles, with aerodynamic diameters less than 0.01 mm, are also trapped in the upper airways and are considered nonrespirable (Witschi and Last, 2001). The largest respirable aerosols in humans have an aerodynamic diameter between 2.5 and 10 mm. Aerosols in this size range deposit in the nose, mouth, and airways greater than 2 mm in diameter. As the aerodynamic size of the aerosols becomes less than 2.5 mm, deposition begins to occur in more distal region of the respiratory tract, mainly in airways less than 2 mm in diameter. Aerosols with very small diameters (<0.1 mm, but >0.01 mm) tend to deposit primarily in the alveoli.
V. GASTROINTESTINAL EFFECTS OF NERVE AGENT AEROSOL EXPOSURE For aerosol delivery systems used for drugs such as albuterol, a high percentage of the inhaled aerosol is swallowed (Serafin, 1996). Thus, it is possible that an individual exposed to a nerve agent aerosol may swallow a significant amount of nerve agent. As with the other systems discussed, the gastrointestinal system has a significant degree of cholinergic innervation. Thus, a nerve agent would be expected to produce local signs of cholinergic overstimulation in the gastrointestinal tract. Indeed, oral administration of sarin by humans resulted in abdominal cramps and loose stool in some exposed individuals (Grob and Harvey, 1958). Additionally, it is possible that absorption through the gastrointestinal tract may represent an additional route of absorption for an aerosol exposure. Data from several studies support this. It has been shown previously that ingestion of VX-contaminated drinking water can result in a decrease in red blood cell cholinesterase activity
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
240
46616_C011 Final Proof page 240 6.11.2007 6:06pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
(Sim et al., 1964), suggesting that VX is absorbed through the human gastrointestinal tract into the systemic circulation. Similarly, orally administered sarin produced significant systemic signs of intoxication in exposed individuals (Grob and Harvey, 1958).
VI. OTHER EFFECTS FOLLOWING DISTRIBUTION THROUGHOUT THE BODY Irrespective of the exposure route, once the nerve agent enters the systemic circulation it will be distributed throughout the tissues of the body, possibly resulting in a cascade of additional toxic signs (Frederiksson et al., 1960). These effects are discussed in detail in other chapters of this volume.
VII. MODELING CHEMICAL NERVE AGENT DOSAGE A. HABER’S RULE VERSUS TOXIC LOAD It is widely known that the toxicity caused by inhalation of vapor of a harmful agent is dependent on dosage which, in turn, is a function of both the concentration of the substance in the air (C) and the duration of the exposure (T). As early as 1924, Haber developed a formula for assessing the toxic affects of harmful vapors. Haber’s rule is described by the equation CT ¼k where k is a constant for some biological effect or response (Derelanko, 2002). Toxicologists use the term LCt50 to describe the product of the atmospheric concentration of a vapor and the duration of exposure that results in lethality to 50% of the exposed population. Similarly, other endpoints are defined using the term ECT50, or an effective concentration 3 time that results in a designated biological endpoint. Effective concentrations as a result of inhalation of nerve agent vapors have been described for miosis (Mioduszewski et al., 2002a; Whalley et al., 2004; Benton et al., 2005; Hulet et al., 2006a), incapacitation (Cresthull et al., 1957; Oberst and Woodson, 1957), and cholinesterase depression (Marzulli and Callahan, 1954). However, the most common effects investigated are miosis and lethality. Miosis is often referred to as the ‘‘first noticeable effect’’ of a G-agent vapor exposure. As discussed previously, the pupil constriction is generally attributed to a local inhibition of cholinesterase in the eye rather than a systemic effect (Grob, 1956). In contrast, after intravenous, subcutaneous, or percutaneous exposures miosis occurs after other signs of toxicity or is an irregular finding (Frederiksson et al., 1960). Pupil constriction is often used as a biological endpoint for investigating G-agent vapor exposures because it occurs at concentrations much lower than those necessary to produce severe or lethal signs of toxicity; for V-agent vapor, this issue is still under study. Previously, military and other organizations dealing with inhalation toxicology have accepted the principle of dosage (concentration 3 time) as constant over time (Haber’s rule) when assessing the impact of exposures to nerve agent vapor. Vapor studies conducted during the 1950s and 1960s on experimental animals and human volunteers used durations of exposures ranging from several seconds to several minutes. Haber’s rule was then used to extrapolate dose–response data based upon relatively short exposure times to predict response probabilities involving longer exposure times. It was assumed that a calculated LCt50 was valid regardless of the duration of exposure. However, this concept has been found to be inadequate for assessing biological effects resulting from exposure to many acutely toxic gases and aerosols (ten Berge et al., 1986; Sommerville et al., 2006). ten Berge varied both exposure concentration and duration of exposure to several toxic vapors and determined that the concentration and the exposure duration were not equally important in determining the toxic effect. ten Berge modeled the relationship between the concentration, exposure duration, and resulting biological effect using a toxic load model. The toxic load model can be described using the following equation: Cn T ¼ k
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C011 Final Proof page 241 6.11.2007 6:06pm Compositor Name: BMani
241
Inhalation Toxicology of Nerve Agents
where C is the concentration T is exposure duration k is a constant for some biological effect or response n is the toxic load exponent, which is unique to a particular vapor and exposure scenario In the toxic load model, dosage is not constant over time. Rather, the effective dosage increases with exposure time in a nonlinear relationship. If the toxic load exponent is 1, then CT ¼ k and the data are best modeled with Haber’s rule. If the toxic load exponent is greater than 1, then the concentration of the agent plays a larger role in determining the biological response than time. If the toxic load exponent is less than 1, then the time of exposure plays a greater role in determining the biological response than concentration. Sommerville et al. (2006) discuss the mathematics of the toxic load model in detail. A comparison between the toxic load model and Haber’s rule is shown in Figure 11.3. ten Berge’s findings suggesting that the toxicity of gases was not constant over time necessitated the reexamination of nerve agent toxicity estimates. Subsequently a focused research effort by investigators (Mioduszewski et al., 2002a, 2002b; Anthony et al., 2003; Whalley et al., 2004; Benton et al., 2005, 2006: Hulet et al., 2006a, 2006b, 2006c) at the Edgewood Chemical Biological Center was undertaken to assess the effects of exposure to low concentrations of nerve agent vapors for extended exposure durations. These reports address the vapor toxicity of the nerve agents sarin, cyclosarin, and VX in rats and swine with separate endpoints for miosis and lethality. The conclusion of all the reports is that toxicity caused by exposure to nerve agent vapors is not constant over time as would be predicted by Haber’s rule. Rather the data were best modeled with toxic load equations. Table 11.2 gives the toxic load exponents for vapor exposures to sarin, cyclosarin, and VX in rats and swine. Subsequently, even for a clear toxicological endpoint such as lethality, historical assumptions previously used to extend the prediction of exposures out in time have been shown to be overly conservative for sarin, the best-studied agent. As stated previously, higher the toxic load exponent, greater the influence that the vapor concentration has on toxicity. The only instance in which the toxic load exponent was not greater
Dose (concentration⫻ time)
100 Haber’s rule (n = 1) Toxic load model (n > 1)
10
1 1
10
100
Exposure time
FIGURE 11.3 Comparison of Haber’s rule and toxic load model. If Haber’s rule applies (n ¼ 1), then the dose required to produce a given response is constant relative to exposure time. However, for a toxic load model with an n > 1, the dose required to produce a given response increases as the exposure time increases. For a toxic load model with an n < 1 (not shown), the dose required to produce a given response decreases as the exposure time increases.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
242
46616_C011 Final Proof page 242 6.11.2007 6:06pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
TABLE 11.2 Experimentally Determined Toxic Load Exponents for Nerve Agent Vapor in Rat and Swine Endpoint Miosis
Species Rat
Swine Lethality
Rat
Swine
Agent
Toxic Load Exponent
References
sarin cyclosarin VX sarin cyclosarin sarin cyclosarin VX sarin cyclosarin
1.96 1.98 1.65 1.32 1.60 1.66 1.27 0.92 1.38 1.28
Mioduszewski et al. (2002a) Whalley et al. (2004) Benton et al. (2005) Hulet et al. (2006a) Hulet et al. (2006a) Mioduszewski et al. (2002b) Anthony et al. (2003) Benton et al. (2006) Hulet et al. (2006b) Hulet et al. (2006c)
than 1 was in the study of Benton (2006) investigating lethality of vapor VX in the rat where a toxic load exponent of 0.92 was calculated. A toxic load exponent less than 1 suggests that the duration of the exposure has more influence on the toxicity than does the concentration. This finding is most likely due to the physical properties of VX. As seen in Table 11.1, VX is several orders of magnitude less volatile than any of the G agents making evaporation of VX deposited on the rats’ fur less likely. Thus, for longer exposure durations it is possible that there was sufficient time for VX to enter the systemic circulation by percutaneous absorption and oral ingestion (due to grooming habits of rodents). This absorption of VX would be in addition to the vapor inhalation component. Because of their relatively higher volatilities, G-agent vapor exposures are not associated with significant additional body burden from percutaneous (Marzulli and Williams, 1953) and oral routes. Therefore, the primary hazard of sarin vapor is inhalation whereas VX may have both inhaled and percutaneous components when generated as a vapor. However, because of the extremely low vapor pressure of VX it requires temperatures in excess of 408C to generate significant amounts of VX vapor (Benton et al., 2005, 2006). Although this requirement makes generation of VX vapor less likely, it is still reasonable to assume VX vapor could be present given the right environmental conditions.
B. USE OF ANIMAL MODEL TOXICITY DATA TO NERVE AGENT ATMOSPHERES
TO
ESTIMATE RISKS OF HUMAN EXPOSURE
In the approximately 70 years since the discovery of the toxic G agents and 50 years since the subsequent development of the V agents, humans have only occassionally served as test subjects in laboratory studies designed to determine threshold toxic effects associated with low-level (nonlethal) sarin and VX vapor exposures (2–10 min) (Johns, 1952; Sim, 1956; Bramwell et al., 1963). In addition, although the toxic effects of accidental exposures and nonexperimental exposures from terrorist or military attacks are documented, critical information related to the exposure conditions can only be estimated at best. Thus, estimates of human dose–responses to nerve agent vapor exposures from such sources are often associated with significant uncertainty and are of limited utility in predicting health hazard risks. The current human estimates for nerve agent vapor and aerosol toxicity are based upon data from animal models. Rodents are popular animal models in that they are readily available, cheap, and convenient to handle. Additionally, there is a great amount of background data on rodents available in the literature for comparison to many biological endpoints. However, nonrodent models are preferred for studies of prophylactic and therapeutic efficacy associated with nerve agent exposure due to the protective buffering impact of relatively high blood carboxylesterase levels in
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C011 Final Proof page 243 6.11.2007 6:06pm Compositor Name: BMani
243
Inhalation Toxicology of Nerve Agents
TABLE 11.3 LCt50 Values for 10 min Exposures to Sarin Vapor Species Mouse Rats Rabbits Cats Monkeys Swine Gottingen Yorkshire Human (estimate)
LCt50 (mg min=m3)
References
380 231 115 79 74
McGrath and Fuhr (1948) Mioduszewski et al. (2002b) McGrath and Fuhr (1948) McGrath and Oberst (1952) Cresthull et al. (1957)
73 34 60
Hulet et al. (2006b) Crook et al. (1952) Reutter et al. (2003)
rodents (Maxwell et al., 1987). Nevertheless, rodents are routinely used as an initial component in a multispecies database for extrapolation to human estimates. An example of the variation in species sensitivity to the lethal effects of sarin vapor is listed in Table 11.3 where experimentally obtained LCt50 values for 10 min sarin vapor exposures are compared in several species. Table 11.3 also includes current human lethal estimates for comparison. In general, it is obvious that the larger animals (pigs, dogs, cats, and monkeys) have lower threshold values than do smaller animals (mice, rats, and rabbits). The differences are most likely due to the variations in body mass, respiratory parameters, and the presence of relatively high carboxylesterase levels in rodents. Reutter et al. (2003) estimated the human LCt50 for a 10 min sarin vapor exposure to be 60 mg min=m3. The estimates from this report were incorporated into U.S. Army Field Manual 3–11.9 (2005). This estimate was extrapolated based on data taken from studies involving eight species (mice, rat, guinea pig, rabbit, cat, dog, swine, and monkey). The estimate took into account the nonanesthetized minute volume (MV) to body weight (BW) ratio for most of the species (Bide et al., 2000). The small rodents (guinea pigs, rats, and mice) all had MV=BW ratios above 0.594. The MV=BW ratio in dogs was 0.328. The MV=BW ratio in monkeys was 0.384. The MV=BW ratio of pigs was 0.225 (Denac et al., 1977). The calculated MV=BW ratio for humans was 0.223. These findings highlight the importance of the choice of animal model and exposure route in investigating nerve agent toxicity and the difficulties associated with extrapolating data obtained from one species and exposure route to data obtained by another species and exposure route.
VIII. SUMMARY Exposure to chemical nerve agent atmospheres leads to a myriad of toxic signs that are primarily mediated though acetylcholinesterase inhibition at target tissues. The initial signs of chemical nerve agent vapor and aerosol exposure are attributed to direct effects on target tissues which are most accessible to vapor=aerosols including the eyes and respiratory tract. Thus, some of the first noticeable effects of nerve agent vapor or aerosol inhalation exposure are miosis, rhinorrhea, and tightness in the chest. Because it is a common finding in exposed individuals, and because it can occur at concentrations much lower than those necessary to cause other signs of toxicity, miosis is often used as a marker of exposure to a nerve agent vapor or aerosol. In a real-world situation, the most common scenarios of exposure would involve the percutaneous or inhalation routes. In the Inhalation Toxicology Laboratory at the U.S. Army Edgewood Chemical Biological Center, several methods have been employed to produce nerve agent vapors and aerosols that act via these routes and, in that regard, mimic likely exposure scenarios. The challenge for laboratory studies is to safely generate stable vapor or aerosol atmospheres and verify their chamber atmospheric concentration, chemical characterization, and stability throughout the exposure period. The combination of these
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
244
46616_C011 Final Proof page 244 6.11.2007 6:06pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
methods with toxicity studies in multiple animal models has resulted in significantly improved confidence intervals on estimates of human exposure risks to nerve agent atmospheres. This in turn, provides the basis for defendable criteria for chemical nerve agent detection, protection, decontamination, and countermeasure technologies.
REFERENCES Ainsworth M and Sheppard RJ. ‘‘The intrabronchial distribution of soluble vapours at selected rates of gas flow’’ In: Inhaled Particles and Vapours: Proceedings of an International Symposium organized by the British Occupational Hygiene Society, 29 March–1 April 1960 (Davies CN, Ed.), pp. 233–247, Pergamon Press, 1961. Allon N, Rabinovitz I, Manistersky E, Weissman BA, Grauer E. Acute and long-lasting cardiac changes following a single whole-body exposure to sarin vapor in rats. Toxicol Sci 87(2):385–390, 2005. Anderson M, Svartengren M, Philipson K, Camner P. Regional human lung deposition studied by repeated investigations. J Aerosol Sci 19(77):1121–1124, 1988. Anthony JS, Haley MV, Manthei JH, Way RA, Burnett DC, Gaviola BP, Sommerville DR, Crosier RB, Crouse CL, Matson KL, Mioduszewski RJ, Thomson SA. Inhalation toxicity of GF vapor in rats as a function of exposure concentration and duration and its potency comparison to GB. US Government Technical Report ECBC-TR-335, August 2003. Anthony JS, Haley M, Manthei J, Way R, Burnett D, Gaviola B, Sommerville D, Crosier R, Mioduszewski R, Thomson S, Crouse C, Matson K. Inhalation toxicity of cyclosarin (GF) vapor in rats as a function of exposure concentration and duration: potency comparison to sarin (GB). Inhal Toxicol 16(2):103–111, 2004. Barnes PJ. Distribution of receptor targets in the lung. Proc Am Thorac Soc 1:345–351, 2004. Baker DJ and Sedgwick EM. Single fibre electromyographic changes in man after organophosphate exposure. Human Exp Toxicol 15:369–375, 1996. Benton BJ, Sommerville DR, Scotto J, Burnett DC, Gaviola BI, Crosier RB, Jakubowski EM, Whalley CE, Anthony JS, Hulet SW, Dabisch PA, Reutter SA, Forster JS, Mioduszewski RJ, Thomson SA. Low level effects of VX vapor exposure on pupil size and cholinesterase levels in rats. US Government Technical Report ECBC-TR-428, 2005. Benton BJ, Sommerville DR, Scotto J, Burnett DC, Gaviola BI, Crosier RB, Jakubowski EM, Whalley CE, Anthony JS, Hulet SW, Dabisch PA, Reutter SA, Forster JS, Mioduszewski RJ, Thomson SA. Effects of whole-body VX vapor exposure on lethality in rats. Inhal Toxicol 18:1091–1099, 2006. Bide RW, Armour SJ, Yee E. Allometric respiration=body mass data for animals to be used for estimates of inhalation toxicity to young adult humans. J Appl Toxicol 20:273–290, 2000. Bours J, Fink H, Hockwin O. The quantification of eight enzymes from the ageing rat lens with respect to sex differences and special reference to aldolase. Curr Eye Res 7(5):449–55, 1988. Bramwell ECB, Ladell WSS, Shepard RJ. Human exposure to VX vapour. Porton Technical Paper 830, January 1963. Carpin JC, McCaskey D, Cameron K. The Inhalation Toxicity of VX Aerosols Assessed in the McNamara Glove Box Facility. Proceedings of the 2003 Joint Conference on Chemical and Biological Defense Research, Nov 2003. Casillas AM, Hiura T, Li N, Nel AE. Enhancement of allergic inflammation by diesel exhaust particles: permissive role of reactive oxygen species. Ann Asthma Allergy Immunol 83(6):624–629, 1999. Connor CG, Flockencier LL, Hall CW. The influence of gender on the ocular surface. J Am Optom Assoc 70 (3):182–186, 1999. Cresthull P, Koon WS, McGrath FP, Oberst FW. Inhalation effects (incapacitation and mortality) for monkeys exposed to GA, GB, and GF vapors. CWLR #2179, 1957. Crook JW, Koon WS, McGrath FP, Oberst FW. Acute inhalation toxicity of GB vapors to pigs exposed for 10-minutes. Medical Laboratories Research Report No. 150, 1952. Denac M, Sporri H, Beglinger R. The Gottinger minipig as a laboratory animal. Resp Exp Med 170:283–288, 1977. Dabisch PA, Miller DB, Reutter SA, Mioduszewski RJ, Thomson SA. Miotic tolerance to sarin vapor exposure: role of the sympathetic and parasympathetic nervous systems. Toxicol Sci 85(2):1041–1047, 2005a.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Inhalation Toxicology of Nerve Agents
46616_C011 Final Proof page 245 6.11.2007 6:06pm Compositor Name: BMani
245
Dabisch PA, Miller DB, Burnett DC, Jakubowski EM, Muse WT, Forster JS, Davis EA, Jarvis JR, Scotto JA, Hulet SW, Reutter SA, Mioduszewski RJ, Thomson SA. Tolerance to the miotic effect of sarin vapor following multiple low-level exposures. J Ocular Pharmacol Ther 21(3):182–195, 2005b. Derelanko MJ. Risk assessment. In: Handbook of Toxicology (Derelanko MJ and Hollinger MA Eds.), 2nd Ed, pp. 999–1096, CRC Press, Boca Raton, FL, USA, 2002. Frederiksson T, Hansson CH, Holmstedt B. Effects of sarin in the anesthetized and unanesthetized dog following inhalation, percutaneous absorption, and intravenous infusion. Arch Int Pharmacodyn 3–4:288–302, 1960. Fryer AD and Jacoby DB. Muscarinic receptors and control of airway smooth muscle. Am J Respir Crit Care Med 158:154–160, 1998. Furuta M, Ohya S, Imaizumi Y, Watanabe M. Molecular cloning of m3 muscarinic acetylcholine receptor in rat iris. J Smooth Muscle Res 34(3):111–122, 1998. Gaon MD and Werne J. Report of a study of mild exposures to GB at Rocky Mountain Arsenal. Rocky Mountain Arsenal Technical Report AD-130 96, 1955. Grob D. Manifestations and treatment of nerve gas poisoning in man. US Armed Forces Med J 7(6):781–789, 1956. Grob D and Harvey JC. Effects in man of the acetylcholinesterase compound sarin (isopropyl methyl phosphonofluoridate). J Clin Invest 37(3):350–368, 1958. Hulet SW, Sommerville DR, Crosier RB, Dabisch PA, Miller DB, Benton BJ, Forster JS, Scotto JA, Jarvis JR, Krauthauser C, Muse WT, Reutter SA, Mioduszewski RJ, Thomson SA. Comparison of low-level sarin and cyclosarin vapor exposure on pupil size of the Gottingen minipig: effects of exposure concentration and duration. Inhal Toxicol 18(2):143–153, 2006a. Hulet SW, Sommerville DR, Benton BJ, Forster JS, Manthei JH, Scotto JA, Way RA, Muse WT, Crosier RB, Reutter SA, Miller DB, Jarvis JR, Mioduszewski RJ, Thomson SA. Estimating lethal and severe toxic effects in minipigs following 10, 60 and 180-minutes of whole-body GB vapor exposure. US Government Technical Report ECBC-TR-451, 2006b. Hulet SW, Sommerville DR, Benton BJ, Forster JS, Manthei JH, Scotto JA, Way RA, Muse WT, Crosier RB, Reutter SA, Miller DB, Jarvis JR, Mioduszewski RJ, Thomson SA. Estimating lethal and severe toxic effects in minipigs following 10, 60 and 180-minutes of whole-body GF vapor exposure. US Government Technical Report AFRL-HE-WP-TR-06–0073 Low Level Report FY05, 2006c. Johns RJ. The effects of low concentrations of GB on the human eye. Medical Laboratories Research Report No. 100, Feb 1952. Levitzky MG. Pulmonary Physiology. New York: McGraw Hill, 1999. Long EK, Thompson OA, Woolsey RD. Dispersion of GB from miniature bombs in an explosion chamber. US Army Chemical Center Technical Report AD-E471 391, April 1951. Marcozzi G, Liberati V, Madia F, Centofanti M, de Feo G. Age- and gender-related differences in human lacrimal fluid peroxidase activity. Ophthalmologica 217(4):294–297, 2003. Marzulli FN and Callahan JC. Some studies on the relation between LD50 and Che50 in nerve gas poisoning. Medical Laboratories Research Report No. 249, March 1954. Marzulli FN and Williams MR. Studies on the evaporation, retention and penetration of GB applied to intact human and intact and abraded rabbit skin. Medical Laboratories Research Report No. 199, Jul 1953. Maxwell DM, Brecht KM, O’Neill BL. The effect of carboxylesterase inhibition on interspecies differences in soman toxicity. Toxicol Lett 39(1):35–42, 1987. McGrath FP and Fuhr I. LC50 of GB to pigeons, rabbits, rats and mice. MDR #140, May 1948. McGrath FP and Oberst FW. Acute inhalation toxicity of GA and of GB vapors to cats exposed for ten minutes. Medical Laboratories Research Report No. 136, 1952. McPhail MK. Sex and the response to G agents. Suffield Technical Report No. 38. Suffield Experimental Station, Ralston Alberta, 1953. Mioduszewski RJ, Manthei JH, Way RA, Burnett DC, Gaviola BP, Muse WT, Thomson SA, Sommerville DR, Crosier RB, Scotto JA, McCaskey DA, Crouse CL, Matson KL. Low-level sarin vapor exposure in rats: effect of exposure concentration and duration on pupil size. US Government Technical Report ECBCTR-235, 2002a. Mioduszewski RJ, Manthei JH, Way RA, Burnett DC, Gaviola BP, Muse WT, Thomson SA, Sommerville DR, Crosier RB. Interaction of exposure concentration and duration in determining acute toxic effects of sarin vapor in rats. Toxicol Sci 66:176–184, 2002b.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
246
46616_C011 Final Proof page 246 6.11.2007 6:06pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Moroi SE and Lichter PR. ‘‘Ocular Pharmacology’’ In: The Pharmacological Basis of Therapeutics (Limbird LE and Hardman JG, Eds.), 9th Ed., pp. 1619–1645. McGraw-Hill Medical Publishing Division, New York, NY, 1996. Muse WT, Crouse C, Matson K, Thomson S. Generation, sampling, and analysis for low-level GB (Sarin) and GF (Cyclosarin) vapor for inhalation toxicology studies. Inhal Toxicol 18(14):1101–1108, 2006. Nakamura K, Fujiki T, Tamura HO. Age, gender, and region-specific differences in drug metabolizing enzymes in rat ocular tissues. Exp Eye Res 81(6):710–715, 2005. Oberst FW and Woodson GS. Incapacitation resulting from nerve gas poisoning. CWL Technical Memorandum 24–2, 1957. Ohbu S, Yamashina A, Takasu N, Yamaguchi T, Murai T, Nakano K, Mikami R, Sakurai K, Hinohara S. Sarin poisoning on Tokyo subway. South Med J 90:587–593, 1997. Okudera H. Clinical features of nerve gas terrorism in Matsumoto. J Clin Neurosci 9:17–21, 2002. Proskocil BJ and Freyer AD. b2-Agonist and anticholinergic drugs in the treatment of lung disease. Proc Am Thorac Soc 2:305–310, 2005. Qureshi IA. Intraocular pressure: a comparative analysis in two sexes. Clin Physiol 17(3):247–255, 1997. Reutter SA, Sommerville DR, Miller LL. Review and recommendations for human toxicity estimates for FM 3–11.9. US Government Technical Report ECBC-TR-349, 2003. Serafin WE. ‘‘Drugs used in the treatment of asthma’’ In: The Pharmacological Basis of Therapeutics (Limbird LE and Hardman JG, Eds.), 9th Ed., pp. 659–682. McGraw-Hill Medical Publishing Division, New York, NY, 1996. Sidell FR. ‘‘Nerve agents’’ In: Textbook of Military Medicine (Zajtchuk R and Bellamy RF, Eds.), pp. 129–173, Office of the Surgeon General, 1997. Sim VM. Effect on pupil size of exposure to sarin vapour. Porton Technical Paper 531, 1956. Sim VM, McClure C, Vocci FJ, Feinsilver L, Groff WA. Tolerance of Man to VX-Contaminated Water. US Army Edgewood Arsenal, Chemical Research and Development Laboratories, CRDLR 3231, October 1964. Smith RD, Grzelak ME, Belanger B, Morgan CA. The effects of tropicamide on mydriasis in young rats exhibiting a natural deficit in passive-avoidance responding. Life Sci 59(9):753–60, 1996. Sokolski KN and Demet EM. Increased pupillary sensitivity to pilocarpine in depression. Prog Neuropsychopharmacol Biol Psychiatr 20(2):253–262, 1996. Soli NE, Karlsen RL, Opsahl M, Fonnum F. Correlations between acetylcholinesterase activity in the guineapig iris and pupillary function: a biochemical and pupillographic study. J Neurochem 35(3):723–728, 1980. Sommerville DR, Park KH, Kierzewski MO, Dunkel MD, Hutton MI, Pinto NA. ‘‘Toxic load modeling, Chapter 8’’ In: Inhalation Toxicology (Katz SA and Salem H, Eds.), 2nd Ed., Boca Raton, FL: CRC Press, 2006. Sullivan DA, Hann LE, Yee L, Allansmith MR. Age- and gender-related influence on the lacrimal gland and tears. Acta Opthalmol (Copenh) 68(2):188–194, 1990. ten Berge WF, Zwart A, Appelman LM. Concentration-time-mortality response relationship of irritant and systemically acting vapours and gases. J Hazard Mater 13:301–309, 1986. Ueno H, Ariji E, Izumi M, Uetani M, Hayashi K, Nakamura T. MR imaging of the lacrimal gland. Age-related and gender-dependent changes in size and structure. Acta Radiol 37(5):714–719, 1996. Urbanetti JS. ‘‘Toxic inhalational injury’’ In: Textbook of Military Medicine (Zajtchuk R and Bellamy RF, Eds.), pp. 247–270, Washington, DC: Office of the Surgeon General, Walter Reed Army Medical Center 1997. Whalley CE, Benton BJ, Manthei JH, Way RA, Jakubowski EM, Burnett DC, Gaviola BI, Crosier RB, Sommerville DR, Muse WT, Forster JS, Mioduszewski RJ, Thomson SA, Scotto JA, Miller DB, Crouse CL, Matson KL, Edwards JL. Low-level cyclosarin (GF) vapor exposure in rats: effect of exposure concentration and duration on pupil size. US Government Technical Report ECBC-TR-407, 2004. Witschi HR and Last JA. ‘‘Toxic responses of the respiratory system’’ In: Toxicology: The basic science of poisons (Klaassen CD, Ed.), pp. 515–534, McGraw-Hill Publishing, New York, NY, 2001. Yanagisawa N, Morita H, Nakajima T. Sarin experiences in Japan: acute toxicity and long term effects. J Neurol Sci 249:76–85, 2006. Yu Y and Koss MC. a1A-adrenoceptors mediate sympathetically evoked pupillary dilation in rats. J Pharmacol Exp Ther 300:521–525, 2002. Yu Y and Koss MC. Functional characterization of alpha-adrenoceptors mediating pupillary dilation in rats. Eur J Pharmacol 471:135–140, 2003.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C012 Final Proof page 247 6.11.2007 6:07pm Compositor Name: BMani
and Oxidative 12 Vesicants Stress Milton G. Smith, William Stone, Ren-Feng Guo, Peter A. Ward, Zacharias Suntres, Shyamali Mukherjee, and Salil K. Das CONTENTS I. Background ....................................................................................................................... 248 II. Introduction ....................................................................................................................... 249 III. Mustard.............................................................................................................................. 249 A. Poly ADP-Ribose Polymerase .................................................................................. 250 B. Metabolites of Sulfur Mustard .................................................................................. 251 C. Signaling ................................................................................................................... 251 D. Tumor Necrosis Factor-Alpha Increases with CEES Exposure ............................... 252 E. Activation of Sphingomyelinase Activities after CEES Exposure........................... 253 F. Accumulation of Ceramide in Lungs after CEES Exposure .................................... 253 G. Activation of Nuclear Factor Kappa in Lungs after CEES Exposure...................... 254 H. Activation of Caspases after CEES Exposure .......................................................... 254 I. Effects of Ceramide Treatment on Lung Microsomal CPT Activity ....................... 258 J. CEES Induces Oxidative Stress................................................................................ 260 IV. Chlorine ............................................................................................................................. 261 V. Phosgene............................................................................................................................ 261 VI. Lewisite ............................................................................................................................. 262 VII. Antidotes or Ameliorative Agents..................................................................................... 262 A. Lewisite ..................................................................................................................... 262 B. Mustard...................................................................................................................... 263 1. Effect of NAC on Signal Transduction ............................................................. 265 C. Antioxidant Liposomes ............................................................................................. 267 D. Chlorine..................................................................................................................... 269 E. Phosgene ................................................................................................................... 269 VIII. Oxidative Stress in Different Organ Systems ................................................................... 271 A. Lung .......................................................................................................................... 271 1. Monitoring Oxidative Stress in Live Cells ........................................................ 273 2. Hydrogen Peroxide and Superoxide Radical Generation in Bronchoalveolar Fluids.................................................................................. 273 3. Antioxidant Status in Lung................................................................................ 273 4. Hydroxydeoxyguanosine, an Indicator of DNA Damage ................................. 273 5. Direct Measurements of Oxygen Free Radicals ................................................ 273 6. Exhaled Breath Condensate ............................................................................... 274 7. Analysis of Expired Air for Oxidation Products ............................................... 274
247
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
248
46616_C012 Final Proof page 248 6.11.2007 6:07pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
B.
Skin .............................................................................................................................. 274 1. Role of Skin Mast Cells in Vesicant Toxicity...................................................... 274 C. Eyes .............................................................................................................................. 275 1. Vesicant-Induced Ocular Injury and Oxidative Stress ......................................... 276 2. Redox Proteomics ................................................................................................. 277 IX. Oxidative Stress: the Concept and the Effect on Gene Expression .................................... 277 A. Definition of Oxidative Stress ..................................................................................... 277 B. Molecules that Influence the Redox Potential ............................................................. 278 1. Nicotinamide Adenosine Dinucleotide Phosphate ............................................... 278 2. Thioredoxin........................................................................................................... 279 C. Apoptosis...................................................................................................................... 279 D. Gene Expression Controlled by Redox-State Transcription Factors........................... 279 1. NF-kB ................................................................................................................... 280 2. Ref-1 ..................................................................................................................... 280 3. Activator Protein-1................................................................................................ 280 4. Heat Shock Transcription Factor .......................................................................... 280 X. Summary .............................................................................................................................. 280 A. Antidotes ...................................................................................................................... 281 References ..................................................................................................................................... 281
I. BACKGROUND The primary treatment of vesicant exposure is decontamination and supportive therapies; there is only one vesicant that has an antidote. The paucity of the treatment options continues to confer their tactical advantage. The development of an ameliorative or antidote would accomplish, at a minimum, two goals: (1) effective treatment, if needed, and (2) decreased tactical advantage. Vesicants are considered to be of low technology and are relatively simple to manufacture. Barrier protection gear, otherwise known as Mission Oriented Protective Posture (MOPP), provides significant protection if donned before exposure. During battlefield conditions, errors would be expected in the use of the MOPP gear because of stressful situations, tears in the suit, false positive or negative alarms, etc. Vesicants share some common properties that are noteworthy in attempts to achieve a better understanding of their pathogenesis. One characteristic is that they all induce an acute inflammatory reaction (Sidell et al., 1997; Sciuto, 1998; Ricketts et al., 2000; Naghii, 2002; Segal and Lang, 2005), of which a subcomponent is oxidative stress (OS) (Bartsch and Nair, 2006). A consequence of OS is the oxidation of thiol groups, which is seen in all of the vesicant exposures (Vissers and Winterbourn, 1995; Pant et al., 2000; Carr et al., 2001). The oxidation of thiol groups disrupts redox balance (defined later in this chapter), which can set into motion a cascade of events, such as apoptosis, oxidant production, and increased activity of redox-regulated transcription factors (e.g., nuclear factor kappa beta [NF-kB]). The occurrence of OS is not isolated to the vesicant class of weapons of mass destruction (WMD). Radiation (Kang et al., 2006), bacterial infections (e.g., anthrax) (Hanna et al., 1994; Kuhn et al., 2006), viral infections (e.g., influenza) (Ghezzi and Ungheri, 2004), and ricin (Kumar et al., 2003; Suntres et al., 2005) exposures also induce OS as part of the host pathogen response, which is acute inflammation. Sublethal OS induces varying degrees of damage in cellular organelles. Lethal OS occurs when antioxidant defenses completely fail, resulting in necrosis (Virag, 2005) or apoptosis (Haddad, 2004). In this chapter, OS will be discussed as a concept, along with its occurrence in the organ systems that are most notably affected by the vesicants. Antioxidant defenses that are critical to the maintenance of redox balance are also discussed. Achieving a deeper understanding of OS is important for the elucidation of all acute inflammatory disorders. The OS component of vesicant exposure has not been a focal point of research, by
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C012 Final Proof page 249 6.11.2007 6:07pm Compositor Name: BMani
249
Vesicants and Oxidative Stress Mustard gas (sulfur mustard) CH2 CH2 Cl
Nitrogen mustard CH2 CH2 Cl N
S CH2 CH2 Cl
CH2 CH2 Cl
FIGURE 12.1 Chemical structure of sulfur and nitrogen mustards.
and large for vesicants or other WMD. It is hoped that this chapter will help to spur future research in the area.
II. INTRODUCTION There are four primary vesicating agents–mustard, phosgene, chlorine, and Lewisite. Strategically, they are poor weapons because they are subject to being redirected by the wind. Sulfur mustards (SM) are considered to be one of the vesicants that cause the most concern. There are two types of mustards, sulfur- and nitrogen-based compounds (see Figure 12.1). The nitrogen mustards have been found to be unsuitable for warfare; therefore, there will be no further mention of them. Any further references to mustards will be to SM. Strategically, Lewisite is the least important since there is a proven antidote. British anti-Lewisite, the antidote for Lewisite, has been known for decades (Goldman and Dacre, 1989). A significant component of acute inflammation is OS (Nonas et al., 2006). One aspect of OS is the production of oxidants and proinflammatory cytokines. It is defined as an imbalance of antioxidant=oxidant ratio, which has a consequent effect on gene expression. The maintenance of the antioxidant=oxidant ratio in the nonstressed cell would be termed redox homeostasis. Thiol groups that are part of intracellular proteins and glutathione (GSH) are critical for the maintenance of redox homeostasis. The vesicants as a class are either oxidants themselves, or they indirectly produce oxidants. Oxidants can be water soluble and fat soluble; therefore, they can arise in any compartment of the cell. They are able to attack any cellular structure, rendering them partially or completely dysfunctional. The chemical WMD classified as vesicants cause blistering of the skin, which is why they are referred to as blistering agents. They incapacitate more so than kill the exposed person because burns occur on any tissue that it contacts. They all have prolonged systemic effects. The reader is referred to the individual sections of this book and other excellent reviews on the agents for a more detailed classic description of their effects, usage, and history (Goldman and Dacre, 1989; Naghii, 2002; Sciuto and Hurt, 2004; Segal and Lang, 2005). The agents themselves will be reviewed with the features of OS highlighted where information was available.
III. MUSTARD Vesicants were first deployed against troops during World War I (WWI). They were used as recently as 1988 by Saddam Hussein against the Kurds in Halabja. SM (2-bis-chloroethyl ethyl chloride) is a straw-colored liquid that disseminates with a garlic-like odor on evaporation (DukeElder and MacFaul, 1972; Dahl et al., 1985). SM is composed of small, oily droplets with volatility significantly higher in warmer climates (e.g., the Middle East). At a temperature of 388C, it can be present in the environment for 7 h, whereas at 108C, it persists for 100 h. The density of mustards is 5.4-fold greater than air and tends to be found 6–12 inches above the ground. This ground-hugging characteristic causes it to sink into trenches and gullies. In WWI, soldiers frequently removed their masks in the morning, assuming that the mustard threat had subsided, and were unaware that the
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
250
46616_C012 Final Proof page 250 6.11.2007 6:07pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
mustard persisted in the environment. As the ambient temperature increased at sunrise, there was an increase in evaporation of the mustard at the ground-level atmosphere, and the soldiers would unknowingly inhale the newly evaporated gas. Mustard has a high freezing temperature (578F). This freezing temperature can be reduced by mixing it with other agents, such as chlorobenzene or carbon tetrachloride (Borak and Sidell, 1992; Sidell et al., 1997). Similar reductions in freezing point can be accomplished by mixing it with Lewisite. SM is commonly referred to as an alkylating agent, but recent evidence has shown it to be a potent inducer of oxidants (Levitt et al., 2003; McClintock et al., 2006). Mustard gas has a strong, irritating effect on living tissue and induces long-lasting, toxic effects (Safarinejad et al., 2001). Additionally, its destructive effects are not localized to the site of application; remote cells and tissues are also affected. SM damages DNA mainly by alkylating and cross-linking the purine bases (Fox and Scott, 1980). Cysteine groups in proteins make them sensitive to SM, resulting in covalently cross-linked dimers on exposure (Byrne et al., 1996). This cross-linking causes conformational change or dysfunction of enzymes. The potent alkylating activity of SM is due to the formation of highly electrophilic ethylene episulphonium derivative (Lundlum et al., 1984; Papirmeister et al., 1991). A portion of the inhalation pathogenesis of SM is due its cholinergic properties (mediating the action of acetylcholine) that stimulates both muscarinic and nicotinic receptors (Anslow, 1946). On contact with human skin, 80% of the liquid evaporates and 20% penetrates (half remains on the skin and the other half is absorbed systemically). Systemic absorption results in partitioning to organs, such as the spleen, liver, and bone marrow (Langenberg et al., 1998). It is mutagenic and carcinogenic (Papirmeister et al., 1985; Somani and Babu, 1989; Wormser, 1991; Langenberg et al., 1998). The lethal dose for humans is 200 mg if ingested and 3 g with cutaneous exposure (Javadi et al., 2005). A property that has received little attention, but should be kept in mind, is that SM is also a radiomimetic, a property that is shared with other radiation-emitting agents. Additional properties that both radiation and mustards share are the inducement of apoptosis, burns, and OS.
A. POLY ADP-RIBOSE POLYMERASE Alkylation of DNA by SM leads to the activation of poly ADP-ribose polymerase (PARP), which reduces the availability of oxidized nicotinamide adenine dinucleotide (NADþ) and ATP in the cell (Fox and Scott, 1980). The consequent change in cellular bioenergetics leads to the inhibition of glycolysis, activation of hexosemonophosphate shunt, induction of plasminogen activator, and ultimately, production of skin lesions (Mol et al., 1989). Other alterations in cellular metabolism due to the loss of NADþ are microfilament architecture and function in keratinocytes (Papirmeister et al., 1985). PARP uses NADþ for a two-electron donor in an oxidation step to catalyze the polymerization of ADP-ribose units on target proteins to attach PARP. PARP has a multiplicity of functions, such as DNA damage sensor and repair chromatin modification, transcription, cell death pathways, insulator function, and mitotic apparatus function. These processes are important to several physiological and pathophysiological processes that involve genome maintenance, carcinogenesis, aging, inflammation, and neuronal function. Poly ADP-ribose polymerase-1 (PARP-1) is the most abundantly expressed member of the family of PARP proteins; it binds to DNA structures that have single and double strand breaks, crossovers, cruciforms, and supercoils (Kim et al., 2005). During normal cellular metabolism, the level of PARP-1 is very low. The enzymatic activity is greatly increased, as much as 500-fold, with allosteric activators, such as damaged and undamaged DNA occurrence (D’Amours et al., 1998, 1999; Kun and Bauer, 2001; Oei and Shi, 2001). The attachment of PARP or PARrylation, in response to oxidation, alkylation, or ionizing radiation, is dramatic and immediate. At minimal levels of DNA damage, PARP-1 acts as a survival factor involved in DNA damage detections and repair. At high levels of DNA damage, PARP-1 promotes cell death (Burkle, 2001). Elevated levels of PARP in response to DNA damage canpromote necrosis secondary to exhaustion of cellular NADþ and ATP (cellular energy failure) (Decker and Muller, 2002; Bouchard et al., 2003). PARP-1 even facilitates apoptosis by a caspase-independent
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Vesicants and Oxidative Stress
46616_C012 Final Proof page 251 6.11.2007 6:07pm Compositor Name: BMani
251
apoptotic cell death via apoptosis inducing factor (AIF). AIF, a potent trigger of apoptosis, is a flavoprotein, which resides in the mitochondrial intermembrane (similar to cytochrome c). However, it is unclear what the exact trigger of AIF release is, but it could be the result of the depletion of NADþ due to excessive PARP synthesis and activity. PARP preferentially depletes cytosolic NADþ (Zong et al., 2004), which would be expected to affect the overall cellular bioenergetics.
B. METABOLITES
OF
SULFUR MUSTARD
The metabolites of SM are noteworthy because of their utilization of thiol compounds. These metabolites, in addition to OS, diminish the thiol cellular pool. Some metabolites occur by direct hydrolysis, but the majority are conjugates of GSH (Black et al., 1992; Black and Read, 1995); other metabolites are N-acetyl-L-cysteine (NAC) conjugates or methylthio=methylsulfhinyl derivatives. Enzymatic conjugation of alkylating agents utilizing GSH can occur through glutathione-S-transferase (GST); but alkylating agents can also combine directly with thiols (Moore and Ray 1983; Colvin et al., 1993). Spontaneous or enzymatic conjugation of alkylating agents occurs through an aziridium intermediate (Colvin et al., 1993).
C. SIGNALING There are a multitude of activators of NF-kB, such as viral infections, bacterial infections, radiation, interleukin (IL)-1, and tumor necrosis factor (TNF). Most of the activators of NF-kB can be blocked with the use of antioxidants (Schulze et al., 1997). Other transcription factors, such as AP-1 (Xanthoudakis et al., 1994), MAF, and NRL (Kerppola and Curran, 1994), and NF-IL6 (Hsu et al., 1994) are regulated by oxygen-dependent mechanisms that cause redox cycling of cysteinyl residues. NF-kB regulates many genes involved in inflammation, such as inducible nitric oxide synthase (iNOS), proinflammatory cytokines, IL-1, tumor necrosis factor-alpha (TNF-a), IL-6, chemokine, IL-8, E-selectin, vascular cell adhesion molecule 1 (ICAM-1), and granulocyte-macrophage colony stimulating factor (GM-CSF) (Brennan et al., 1995; Akira and Kishimoto, 1997; Barnes and Adcock, 1998; Rahman and MacNee, 1998; McClintock et al., 2002). Arroyo et al. (2000) found a dose-dependent increase in TNF-a, IL-6, and interleukin-1-beta (IL-1-beta) in SM-treated human keratinocyte cells. Although inflammatory cytokine profiles differ depending on the skin models used (Ricketts et al., 2000; Sabourin et al., 2002), they were shown to be elevated in response to SM. In contrast, in guinea pig lungs exposed to 2-chloroethyl ethyl sulfide (CEES) (a mustards analog), the inflammatory cytokine TNF-a was found to be markedly elevated (Das et al., 2003). The inflammatory cytokines exacerbate the effects of CEES (Stone et al., 2003), which would imply that there is an amplification of the initial injury by the mustards. Lipopolysaccharide (LPS), a ubiquitous entity in our environment, also upwardly modulates the damage that CEES inherently causes to cells (Stone et al., 2003). SM activates phospholipase A2 and liberates arachidonic acid by acting on linolenic acid found in cellular membranes. Activated neutrophils show an amplification of their respiratory burst in the presence of arachidonic acid (Bostan et al., 2003). Metabolites of arachidonic acid produce oxidants, which would be additional contributors to OS. Arachidonic acid itself and several of its metabolites, such as 12 HETE and 15 HETE, induce FOS and JUN expression (Haliday et al., 1991; Sellmayer et al., 1991; Rao et al., 1996). One class of signaling pathways that has received considerable attention involves the action of cytokine-stimulated sphingomyelinase (SHM-ase) (Hannun and Obeid, 1997). Ceramide generated from SHM-ase activation plays a critical role in cytokine-mediated apoptosis, cellular differentiation, and senescence, each of which may be important in the inflammatory response. Ceramide can be generated through several different pathways, such as synthesis within the cell, hydrolysis of SHM by SHM-ase, and breakdown of glycosphingolipids. The degradation of ceramide by acid ceramidase liberates sphingosine, a free fatty acid in the lysosomal compartment
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
252
46616_C012 Final Proof page 252 6.11.2007 6:07pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
(Alphonse et al., 2002). Ceramide can also be increased by the inhibition of ceramide breakdown by ceramidase and the inhibition of sphingomyelin synthase. SHM-ase has been proposed as a key enzyme involved in stress-induced ceramide formation (Hannun and Obeid, 1997). Multiple pathways may be regulated, which in turn ultimately determine the levels of ceramide.
D. TUMOR NECROSIS FACTOR-ALPHA INCREASES
WITH
CEES EXPOSURE
A single, intratracheal injection (0.5 mg=kg body weight) of CEES in guinea pigs was done at different time points. The guinea pigs were dissected and the lung was removed after perfusion. The lung was lavaged and TNF-a concentrations were measured in lung lavage fluid, lung lavage macrophages, and in lung tissue. The level of TNF-a in lavage fluid was very low, whereas high levels accumulated in lung as well as in lung macrophages within 1 h of CEES exposure. The level of TNF-a decreased rapidly after 1 h and returned to normal levels within 24 h of CEES exposure (Figure 12.2a). Further studies revealed that the induction of TNF-a by CEES is dose dependent, and optimal TNF-a accumulation was observed at 2 mg=kg dose of CEES exposure (Figure 12.2b).
TNF-α (pg/mg protein)
1200
900
600
300
0
1
2
3
4
6
1
Hours (a)
7
14
Days Exposure time
TNF-α (pg/mg or protein)
1200
900 Macrophage
600
300
0 (b)
Lung
0
0.25 0.5 1 2 4 Dose (mg/kg body weight)
6
FIGURE 12.2 Accumulation of TNF-a in guinea pig lung and macrophages after exposure to CEES. (a) Timedependent induction of TNF-a after intratracheal injection of CEES (0.5 mg=kg body weight). (b) Accumulation of TNF-a 1 h after exposure to CEES at different doses (ranging from 0.5 to 6.0 mg=kg body weight).
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C012 Final Proof page 253 6.11.2007 6:07pm Compositor Name: BMani
253
Vesicants and Oxidative Stress
E. ACTIVATION
OF
SPHINGOMYELINASE ACTIVITIES
AFTER
CEES EXPOSURE
Both the neutral and acid SHM-ase activities showed fourfold to fivefold increases after CEES treatment. The basal level of acidic SHM-ase activity (Figure 12.3b and d) was much higher than the basal level of neutral SHM-ase (Figure 12.3a and c). Both neutral and acid SHM-ase activities started to increase, along with the increase of TNF-a; these activities reached a maximum peak between 4 and 6 h in the lung and between 3 and 4 h in macrophages. It is not known at this time whether this difference between lung and macrophages is functionally significant or not. The SHM-ase activities (both neutral and acidic) were found to be higher in lavage macrophages than those in the lung tissue. It is possible that macrophages are more sensitive to CEES than other cell types in the lung. The level of SHM-ase decreased rapidly and returned to near normal level within 24 h. It was also found that a 2 mg=kg dose of CEES is sufficient to reach the maximum level of both neutral and acid SHM-ase activity (Figure 12.3c and d).
F. ACCUMULATION
OF
CERAMIDE
IN
LUNGS
AFTER
CEES EXPOSURE
The ceramide accumulation after CEES exposure demonstrated a biphasic pattern. Within 1 h of CEES exposure, ceramide levels became very high and reached a peak accumulation within 2 h (Figure 12.4a). After 2 h, there was some decrease in the ceramide level, but then the level increased very high and remained almost to a steady state, even up to 14 days later (Figure 12.4a). CEESinduced ceramide accumulation was found to be saturated at 4 mg=kg dose of CEES. At 2 mg=kg dose of CEES, about 90% induction of ceramide was achieved (Figure 12.4b).
Activity (nmol/h/mg protein)
6 4 2 0 0
Activity (nmol/h/mg protein)
(a)
(c)
1
2 3 4 5 1 7 14 Hours Days Exposure time
50 40 Macrophage 30
Lung
20 10 0
(b)
0 1 2 3 4 5 1 7 14 Days Hours Exposure time
5 4 3 2 1 0
0 0.5 1.0 2.0 4.0 6.0 Dose (mg/kg body weight)
Activity (nmol/h/mg protein)
Activity (nmol/h/mg protein)
8
(d)
30 24 18 12 6 0
0 0.5 1.0 2.0 4.0 6.0 Dose (mg/kg body weight)
FIGURE 12.3 Activation of acid and neutral sphingomyelinase in guinea pig lung and macrophages following CEES exposure. Time course of induction of neutral (a) and acid (b) sphingomyelinase after intratracheal injection of CEES (0.5 mg=kg body weight). Accumulation of neutral (c) and acid (d) sphingomyelinase at 4 h after exposure to CEES at different doses (ranging from 0.5 to 6.0 mg=kg body weight).
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Amounts (g/mg protein)
254
46616_C012 Final Proof page 254 6.11.2007 6:07pm Compositor Name: BMani
Ceramide a
0 1 2 3 4 6 Hours
100 75 50 25 0
1 7 14 std. Days
0
Amounts (g/mg of protein)
Exposure time
Ceramide
b
Std. 0
.25
.5 1 2 4 6
1
2 3 4 6 1 7 14 Days Hours Exposure time
150 120 90 60 30 0 0.0 0.250.50 1.0 2.0 4.0 6.0 Dose (mg/kg)
FIGURE 12.4 Accumulation of ceramide in guinea pig lung after CEES exposure. (a) Time course of induction of ceramide after intratracheal injection of CEES (0.5 mg=kg body weight). (b) Accumulation of ceramide at 1 h after exposure to CEES at different doses (ranging from 0.5 to 6.0 mg=kg body weight). In both cases (a and b), the left panel is the autoradiograph showing the accumulated ceramides, and the right panel represents the quantitative analysis of accumulated ceramide as determined by 32P incorporation.
G. ACTIVATION
OF
NUCLEAR FACTOR KAPPA
IN
LUNGS
AFTER
CEES EXPOSURE
The activation of NF-kB was measured in the nuclear extracts of lungs after exposure to CEES. NF-kB, which is well known to inhibit TNF-a-mediated apoptosis, showed activation only up to 1–2 h after CEES exposure (Figure 12.5a). This may explain the biphasic effect of CEES on the lung. After initial lung damage by TNF-a, within 2 h there was some recovery due to activation of NF-kB. After 2 h, the NF-kB level went down, ceramide level increased, and secondary lung damages were observed. Dose-dependent studies revealed that 4 mg=kg CEES was needed for the optimum activation of NF-kB (Figure 12.5b). Super shift assay using specific antibodies to p50 and p65 revealed that both the p50 and p65 subunits were activated in lung because of CEES exposure (Figure 12.5c).
H. ACTIVATION
OF
CASPASES AFTER CEES EXPOSURE
Activation of different caspases in guinea pig lung after the CEES exposure is shown in Figure 12.6. Within 1 h of exposure, some activation was observed for all four caspases, but the activity came back to the basal level within 2 h of exposure. The activity of caspase 2, caspase 3, caspase 8, as well as caspase 9 increased significantly between 4 and 6 h of exposure and then declined again. No activity for any of the caspases was observed at 24 h and thereafter. Here also, the activation of caspases was found to be optimum at 2 mg=kg body weight of CEES. Our study clearly demonstrated the involvement of an SHM-ase=ceramide signal transduction pathway in the mustard gas-mediated lung injury. After intratracheal injection of CEES to guinea pigs, the TNF-a level increased sharply within 1 h of exposure. The TNF-a level started, declined after 1 h, and returned to basal level within 24 h.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C012 Final Proof page 255 6.11.2007 6:08pm Compositor Name: BMani
255
Vesicants and Oxidative Stress
(a)
0 .25 .5 1 2 4 6 Mut (b) Dose (mg/kg body weight)
0 1 2 3 4 6 1 7 14 Mut Exposure time
p65 p50 NF-κB
C = Control 1 = −Antibody 2 = +Anti p50 3 = +Anti p65
(c)
C 1
2
3
FIGURE 12.5 Activation of NF-kB in guinea pig lung following CEES exposure. (a) Time-dependent activation of NF-kB after intratracheal injection of CEES (0.5 mg=kg body weight), as observed by mobility shift assay. (b) Mobility shift assay showing the accumulation of NF-kB after 1 h of CEES exposure at different doses (ranging from 0.5 to 6.0 mg=kg body weight). (c) Supershift assay, using subunit specific antibodies, to identify the subunits (p50 and p65) of NF-kB activated due to CEES exposure in guinea pig lung.
Followed by the accumulation of TNF-a, both the acid and neutral SHM-ase activities were stimulated, peaking within 4–6 h after CEES exposure. Though both the acid and neutral SHM-ase activities were stimulated, the level of acid SHM-ase was found to be much higher after CEES exposure. The higher levels of TNF-a, as well as both the acid and neutral SHM-ase activities in lung macrophages compared with those in lung tissue were expected because lung tissue consists of several types of cells, all of which were not responsive to CEES. We observed a biphasic effect of CEES on lung. After initial damage by TNF-a, there was some recovery due to activation of NF-kB within 2 h. This biphasic pattern was also observed in caspases activation. Significant but small activation of caspase 2, caspase 3, caspase 8, and caspase 9 was observed within 1 h of CEES exposure. This activation of caspases declined thereafter and reappeared within 4–6 h, initiating the cell apoptosis in lung as observed by light as well as electron microscopy (unpublished observation). One explanation for this biphasic action of mustard gas is that NF-kB is activated by TNF-a through a phosphatidylcholine-specific phospholipase C=diacylglycerol (DAG)=protein kinase C (PKC) or phosphatidylcholine-specific phospholipase C=DAG=acid SHM-ase=ceramide model (Chatterjee et al., 2004). These studies indicate that CEES exposure causes accumulation of TNF-a-activated SHM-ases, resulting in the production of ceramides and simultaneous activation of caspases and finally apoptosis. Ceramides are known to cause apoptosis via the activation of caspases (Alphonse et al., 2002; Hearps et al., 2002; Hetz et al., 2002).
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
256
46616_C012 Final Proof page 256 6.11.2007 6:08pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Activity (O.D./mg protein)
1.00 Caspase 2 Caspase 3 0.50
Caspase 8 Caspase 9
0.00
0 1 2 3 4 6 1 7 14 Hours Days
Activity (O.D./mg protein)
(a)
Exposure time 2.50
0.5 mg/kg
2.00
1.0 mg/kg
1.50
2.0 mg/kg
1.00
4.0 mg/kg
0.50
6.0 mg/kg
0.00 C2
(b)
C3 C8 Caspases
C9
FIGURE 12.6 Activation of different caspases in guinea pig lung after CEES exposure. (a) Time course of activation of different caspases after intratracheal injection of CEES (0.5 mg=kg body weight). (b) Accumulation of different caspases at 4 h after exposure to CEES at different doses (ranging from 0.5 to 6.0 mg=kg body weight).
Our study also revealed that there was some initial damage of the lung tissue when exposed to CEES, but self-defense mechanisms of the lung played a significant role in the recovery from the damage and the prevention of any further damage. Furthermore, the present investigation enhances our understanding of mustard gas-mediated proapoptotic signaling pathways and characterizes the events of mustard gas-induced lung dysfunction. Mustard gas exposure also causes inflammatory lung diseases, including acute respiratory distress syndrome (ARDS) (Calvet et al., 1994; Sohrabpour, 1984). A defective secretion of surfactant by alveolar type II cells has been implicated as one of the causative factors for the development of ARDS (Ansceschi, 1989). A major component of lung surfactant is DPPC (Stith and Das, 1982). The precursor of DPPC is normally 1-palmitoyl-2-oleolyl PC. DPPC is produced by deacylation and subsequent reacylation with palmitic acid at 2-position of glycerol moiety of the unsaturated phospholipid. The CDP-choline pathway is the major pathway for the synthesis of PC in the lung, and cholinephosphotransferase (CPT) is a terminal enzyme in this pathway. Regulation of PC metabolism is one of the vital aspects of the cell cycle with implications in the control of cell proliferation as well as in apoptosis (Cui et al., 1996; Baburina and Jackowski, 1998). PC is the most abundant phospholipid in mammalian cells, and it is synthesized via the CDPcholine pathway (Kent, 1995). CPT is the terminal enzyme of this pathway and plays a direct role in the final production of PC in the lung. This pathway is important for both cell proliferation and cell death (Ghosh et al., 2002; Ryan et al., 2003), and selective inhibition of this pathway has been shown to induce cellular apoptosis (Miquel et al., 1998). Any modulation in the expression and activity of this enzyme is expected to result in abnormal functioning of the cells.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C012 Final Proof page 257 6.11.2007 6:08pm Compositor Name: BMani
257
Vesicants and Oxidative Stress
Activity (nmol/ min/ mg protein)
5.00
Microsomes Mitochondria
2.50
0.00
0
1 h 2 h 4 h 6 h 1 d 7 d 14 d 21 d Exposure time
FIGURE 12.7 Time-dependent effects of 0.5 mg=kg body weight. CEES treatment on the mitochondrial and microsomal CPT activity. N ¼ 3.
The time-dependent effects of CEES treatment showed a biphasic effect on CPT activity in both mitochondria and microsomes. The time-dependent studies indicated that a single infusion of CEES (0.5 mg=kg body weight) caused an increase in the activity for a short time after CEES exposure (up to 4 h), followed by a decrease (6 h onward) (Figure 12.7). The dose-dependent studies indicated that CEES treatment caused an initial increase in the CPT activity at low doses (0–2 mg=kg body weight), followed by a decrease at higher doses (4 and 6 mg=kg body weight) at incubation times of 1 and 4 h. This decrease was more acute in microsomes than in the mitochondria (Figure 12.8). We have previously demonstrated that in addition to its predominant localization in the microsomes, CPT also exists in the mitochondria (Stith and Das, 1982; Sikpi and Das, 1987). Thus, it is possible that during the early stage of lung injury as observed in this study, cells try to repair the membrane damage by stimulating PC synthesis. Therefore, with increased CPT activity
6
2
Microsomes
Mitochondria
3
0 (a)
Activity (nmol/min/mg protein)
Activity (nmol/min/mg protein)
Microsomes
0
0.5
1.0
2.0
Dose (mg/kg)
4.0
Mitochondria
1
0
6.0 (b)
0
0.5
1.0
2.0
4.0
6.0
Dose (mg/kg)
FIGURE 12.8 Dose-dependent effects of CEES on cholinephosphotransferase activity in mitochondria and microsomes. (a) After 1 h CEES treatment. (b) After 4 h CEES treatment. N ¼ 3.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
258
46616_C012 Final Proof page 258 6.11.2007 6:08pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
over time, lung cells lose their ability to repair membrane damage, as evident from decreased CPT activity in both mitochondria and microsomes isolated from lungs of CEES-treated animals (Figures 12.7 and 12.8). Hence, CEES has both short-term (stimulation) and long-term (inhibition) effects on lung CPT activity. Since CPT activity is crucial to the synthesis of surfactant, these effects may cause ARDS with long-term CEES exposure because of lack of surfactant synthesis.
I. EFFECTS
OF
CERAMIDE TREATMENT
ON
LUNG MICROSOMAL CPT ACTIVITY
Ceramides are intracellular signaling molecules implicated in the induction of cellular apoptosis (Kolesnick and Krönke, 1998; Hannun and Luberto, 2000), and are known to induce several protein kinases and phosphatases (Mathias et al., 1991; Dobrowsky et al., 1993; Vietor et al., 1993). Ceramide analogs have been shown to inhibit PC synthesis (Bladergroen et al., 1999; Allan, 2000; Ramos et al., 2000; Vivekananda et al., 2001). Ceramides may directly affect the biosynthesis of PC and phosphatidylethanolamine (PE) by inhibiting the enzymes of the CDP-choline and CDPethanolamine pathways (Bladergroen et al., 1999; Awasthi et al., 2001; Ramos et al., 2002). It has been reported that cells treated with ceramides may undergo programmed cell death, become growth arrested, or in rare cases, become stimulated to proliferate. The diversity of biological responses of cells to ceramides reflects the complexity of the role of these sphingolipids as second signal molecules (van Blitterswijk et al., 2003). Furthermore, ceramide treatment of lung cancerderived A-549 cells promotes apoptosis in a caspase-dependent process (Kurinna et al., 2004). Other laboratories have also shown that enzymes of the CDP-choline pathway for the production of PC in the cells, including CPT, show reduced activity when cells are incubated with cellpermeable C2=C6 ceramides (Bladergroen et al., 1999; Ramos et al., 2002), and it has been predicted that this inhibition may be due to the competitive inhibition by ceramides owing to the similarity in the structure to one of the substrates for CPT, DAG. The downstream signal transduction events in lung following CEES exposure involve the induction of TNF-a, which in turn activates both acid and neutral SHM-ases, resulting in the subsequent accumulation of ceramides in the lung (Chatterjee et al., 2003, 2004). The level of ceramide was found to be ~60 mg=mg protein after 7 days (with 0.5 mg=kg body weight of CEES) and ~130 mg=mg protein for 2 mg=kg body weight of CEES (after 1 h; Figure 12.4). When the lung microsomal fraction from control animals was incubated with C2 ceramide at different concentrations (50, 100, and 200 mM) and time periods (0, 0.5, 1, and 6 h) before the assay for CPT activity, CPT activity decreased significantly in a time- and dose-dependent manner (Figure 12.9).
% Inhibition of CPT activity
60
5 1
40
2
20
0
0
0.5 1 Time (h)
6
FIGURE 12.9 Effect of C2 ceramide treatment on lung microsomal CPT activity. N ¼ 3.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C012 Final Proof page 259 6.11.2007 6:08pm Compositor Name: BMani
259
Vesicants and Oxidative Stress
However, the effect was more pronounced when the microsomal fraction was preincubated with the ceramide before assay of the CPT activity. The degree of inhibition was increased with the increase in incubation time (0.5, 1, and 6 h). The highest inhibition (50%) was achieved after 6 h of incubation. However, only 20% inhibition was observed when ceramide was directly added into the assay mixture. It has been shown that a 30% inhibition could be obtained in CPT activity when ceramides were directly added to the assay mixture at 50 mM concentrations (Bladergroen et al., 1999). Since this inhibition of 30% was less than the 64% obtained when cells were incubated directly, it would indicate competitive inhibition was not the only mechanism. In the present work, we found similar results with lung microsomal fraction, that is, with an increase in the incubation time with ceramides, the inhibition of the enzyme activity increases. Therefore, we support the observations by Bladergroen et al. (1999) that ceramide inhibition of CPT activity may be only partially through direct competitive inhibition with DAG; ceramide may act through interaction with other CPT enzyme inhibitors present in the microsomal fraction. It is known that the short-chain ceramides often do not mimic the endogenous long-chain ceramides produced as a result of SHM-ase activity. However, the lipophilic nature of the both short- and long-chained ceramides makes these molecules likely candidates for altering biological processes as components of the lipid bilayer (Gidwani et al., 2003). We can therefore predict that ceramides accumulated in the lung because of exposure of CEES can alter the activity of the membrane-bound enzymes like CPT and can also act as a membrane perturbant. This ceramide-induced membrane perturbation can result in mitochondrial release of cytochrome c and subsequent release of different caspases (Figure 12.6) (Gidwani et al., 2003; Chatterjee et al., 2004) as a part of the apoptotic pathway. Furthermore, CEES exposure (2.0 mg=kg body weight for 7 days) caused a significant decrease of both CPT activity (~1.5-fold; Figure 12.10) and gene expression (~1.7-fold; Figure 12.11) in the lung (Gidwani et al., 2003; Sinha Roy et al., 2005). This decrease in CPT activity was not associated with any mutation of the CPT gene. Thus, the inhibition of CPT activity as a chronic effect of CEES exposure may be directly responsible for the
3
Activity (nmol/mg protein/min)
Control CEES
2
1
0 Treatment
FIGURE 12.10 CPT enzyme activity in the lung microsomal fraction of 2 mg=kg body weight CEES (for 7 days) treated lung as compared with the control (only vehicle) showing significant decrease in activity. p 0.05, N ¼ 3.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
260
46616_C012 Final Proof page 260 6.11.2007 6:08pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics 3
Control
CEES CPT
Normalized CPT expression
Control CEES 2
1
GAPDH 0 (a)
(b)
Treatment
FIGURE 12.11 Northern blot analysis for the expression of the CPT gene. (a) One representative blot for CPT mRNA from control and CEES-treated guinea pig lung and same blot reprobed for GAPDH expression. (b) Graph showing downregulation of CPT expression as the result of mustards gas treatment normalized with GAPDH. N ¼ 3.
reduction in the lung surfactant production, resulting in subsequent development of ARDS and pulmonary fibrosis, and is probably mediated by accumulation of ceramides.
J. CEES INDUCES OXIDATIVE STRESS Stone et al. (2003) have found that OS and inflammatory agents play a key role in the toxicity of CEES. Both HD and CEES are known to provoke acute inflammatory responses in the skin (Blaha et al., 2000a, 2000b; Sabourin et al., 2002). It is interesting that RAW 264.7 macrophages stimulated with LPS or inflammatory cytokines are more susceptible to the cytotoxic effect of CEES than unstimulated macrophages. LPS (bacterial endotoxin) is a well-characterized inflammatory factor found in the cell wall of Gram-negative bacteria and is a ubiquitous natural agent found in the environment. LPS is present in serum, tap water, and dust. Military and civilian personnel would always have some degree of exposure to environmental LPS. Very low levels of LPS (20 ng=mL) were found to dramatically enhance the toxicity of CEES at concentrations greater than 400 mM (Stone et al., 2003). CEES alone is not toxic to RAW 264.7 macrophages at levels lower than about 500 mM (Stone et al., 2003). LPS is known to trigger a variety of inflammatory reactions in macrophages and other cells having CD14 receptors (Wright et al., 1990; Downey and Han, 1998). In particular, LPS is known to stimulate the macrophage secretion of inflammatory cytokines such as TNF-a and IL-1-beta (Shapira et al., 1994). It is interesting, therefore, that both TNF-a and IL-1-beta were also found to enhance the cytotoxic effects of CEES but to a lesser extent than LPS (Stone et al., 2003). LPS stimulation of macrophages is known to involve the activation of protein phosphorylation by kinases as well as the activation of nuclear transcription factors such as NF-kB (Fujihara et al., 1994; Shapira et al., 1994, 1997; Chen et al., 1998). The activation of PKC by DAG is also a key event in LPS macrophage activation (Downey and Han, 1998). In vitro experiments have shown that the secretion of TNF-a and IL-1-beta by LPS-stimulated monocytes is dependent on PKC activation (Shapira et al., 1997; Coffey et al., 2000). Stone et al. (2003) also determined that phorbol myristate acetate (PMA) activation of PKC also enhanced CEES toxicity. These data suggest that the activation of PKC may play a key role in the molecular mechanism whereby LPS and inflammatory cytokines enhance the cytotoxicity of CEES (and potentially other vesicant weapons
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C012 Final Proof page 261 6.11.2007 6:08pm Compositor Name: BMani
261
Vesicants and Oxidative Stress
as well). Evidence suggests that LPS (deRojas et al., 1995; Fu et al., 2001) as well as TNF-a (Ye et al., 1999) also stimulate the production of free radicals by macrophages. Collectively, this information supports the view that inflammatory factors and OS are key factors in understanding vesicant toxicity, and are important factors in designing effective countermeasures (Veness-Meehan et al., 1991; Yourick et al., 1991; Elsayed et al., 1992; Pant et al., 2000; Schlager and Hart, 2000; Kadar et al., 2001; Naghii, 2002; Levitt et al., 2003).
IV. CHLORINE Chlorine is a pulmonary irritant that affects both the upper and the lower respiratory tracts. It is similar to SM in that its density is greater than that of air. Therefore, it characteristically hugs the ground, as does SM when deployed. It is only slightly water soluble; on contact with water or moisture, it forms hypochlorous acid (HClO) and hydrochloric acid (HCl). HClO is unstable and readily decomposes to oxygen-centered radicals. In animal models, 2000 ppm exposure will induce respiratory arrest. Subacute exposures of 9 ppm and acute exposures of 50 ppm can cause chemical pneumonitis (an inflammatory process) and bronchiolitis olbiterans (Segal and Lang, 2005). The LD50 is in the range of 800–1000 ppm. HOCl, whether exogenously obtained from Cl2 gas, or from an oxidative burst from neutrophils, the product reacts with a number of functional thiol groups present in enzymes (Winterbourn, 1985; Pullar et al., 2002). HOCl reactivity with thiol groups could inactivate such enzymes as GSH peroxidase and catalase (Aruoma and Halliwell, 1987). Inactivation of enzymes involved in antioxidant defense system renders the cell vulnerable to OS (a disruption of redox homeostasis). Glutamylcysteine synthetase, cysteine, or methionine was 100 times more reactive to hypochlorous acid in comparison with amino acids that did not contain thiol groups (Folkes et al., 1995). Sublethal exposures to HOCl decreased GSH levels in several cell types (Vissers and Winterbourn, 1995; Pullar et al., 1999). In a study by Pullar et al. (1999) using human umbilical vein endothelial cells, doses of 25 nmol of HOCl and less were sublethal; when the exposure was done over 10 min, there was a concentration-dependent loss of intracellular GSH. Tissue exposure to HOCl resulted in a reduction of GSH. The metabolite of the HOCl interaction with GSH was an unexpected cyclic sulfonamide that was exported from the cell. The expected metabolites of glutathione disulfide (GSSH) and GSH sulfonic acid were actually minimal (Pullar et al., 2001). Inactivation of acetylcholinesterase by HOCl could be a contributory cause of airway hyperreactivity (den Hartog et al., 2002).
V. PHOSGENE Phosgene (COCl2), also referred to as carbonic dichloride, is extensively used as an industrial chemical. The gas dissolves slowly in water and is hydrolyzed to CO2 and HCl. It produces little damage to the upper airway, although the lower airways sustain the bulk of the necrosis and inflammation. There is typically a delayed onset of symptoms in the pulmonary system occurring 1–24 h after the initial exposure. The respiratory symptoms of hypoxia (shortness of breath), and in extreme cases, respiratory arrest (discontinuation of spontaneous breathing), are apparently due to leaky alveolar capillaries and the resulting pulmonary edema (Noltkamper and Burgher, 2004); also contributory to the clinical symptoms are arachidonic acid mediators and lipid peroxides (Sciuto and Hurt, 2004). In rodent models, phosgene elicits decreases in total GSH in lung tissue 48% within 45–60 min after exposure (Sciuto, 1998). Jaskot et al. (1991) confirmed similar results 2 years after the Sciuto publication. The concentration of phosgene exposure inversely affected the GSH levels (Jaskot et al., 1991). In gene expression studies in the inhalation mouse model, GSH regulation and redox regulation, in particular, were affected (Sciuto et al., 2005). A gene expression response can be seen as early as 30 min, wherein glutamate cysteine ligase increases and continues to increase at 8 h. Glutamate cysteine ligase continued to be elevated, approaching control levels in the 24–72 h time period. There was an upregulation of GST a-2, GSH peroxidase-2, glutamate, and g-glutamyl
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
262
46616_C012 Final Proof page 262 6.11.2007 6:08pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
cysteine synthetase. At 4–12 h, GSH peroxidase-2, GSH reductase was elevated. GSH synthetase increased in the 4–24 h time frame. Further evidence of the crippling of the antioxidant defense system was the decreased SOD3 gene expression and enzyme activity. Similar results were found in independent experiments by Qin et al. (2004), as were reported by Sciuto in his examination of the antioxidant enzyme defense system. In the exposed rats, the antioxidant defense enzymes GST, superoxide dismutase (SOD), catalase, GSH peroxidase, and nitric oxide synthase in serum, blood, or liver were all increased. In contrast, the nitric oxide content was decreased. Similar changes in enzymes were also noted for other gaseous toxins, such as O3 and NO2 (Jaskot et al., 1991).
VI. LEWISITE The Germans developed several arsenical-based warfare chemical agents circa 1917 (Goldman and Dacre, 1989). The allies, on the other hand, developed Lewisite (2-chlorovinydichloroarsine), adamsite (diphenylaminechloroarsine), methyldichloroarsine, and arsine. Lewisite is soluble in organic solvents; it is readily absorbed by rubber, paint, varnish, and porous materials. There are labile chlorine atoms, trivalent arsenic, carbons, and multiple bonds that make it quite reactive. Some of its reactions are due to nucleophilic substitution by water, hydrogen sulfide, thiols, and acid salts. The reactions with thiol groups (e.g., those that are found in proteins) form an alkylarsine sulfide. Mustard gas, at the same LCt50, induces vesication, whereas Lewisite does not. Apparently, Lewisite is more irritating initially to the pulmonary systems than mustard. The hydrolysis products are more persistent in soil in comparison with mustard. In ambient air, Lewisite is about 10 times more volatile than mustard. The clinical sequelae after Lewisite absorption referred to as ‘‘Lewisite Shock’’ (L shock) are similar to that of severe burns. In dog models at high dosages, exposure resulted in retching, vomiting, extreme salivation, labored breathing, inflammation of the entire respiratory system, and pulmonary edema; respiratory distress was also common, and 80% died. Inhalation of 0.05 mg=L for 15 min results in intoxication and incapacitation for several weeks, whereas 0.5 mg=L for 5 min is lethal. The exact pathophysiology of the pulmonary symptoms seen is unknown, but is likely due to the dilatation of the capillaries. Apparently, the innate immune system is also compromised because of the occurrence of bronchopneumonia. In L shock, a hemolytic anemia can occur; however, it is unclear if this is due to an autoimmune reaction or OS (McMillan et al., 2004; Sato et al., 2006). Other complications of exposure are edema and bleeding that occur in the liver and kidneys (Wardell, 1941). It is the arsenic in Lewisite that reacts with thiol groups to form alkylarsine sulfides, which is the basic reaction with thiol groups in tissues (Goldman and Dacre, 1989). The degree of enzyme dysfunction is dependent on the affinity of the enzyme to arsine. For example, it binds to the alpha and gamma thiol groups of lipoic acid, a component of pyruvate oxidase, which forms a stable six-membered ring (Stocken, 1949; Johnstone, 1963). Several other known enzymes are also inhibited–alcohol dehydrogenase, succinic oxidase, hexokinase, and succinate dehydrogenase (van Heyningen, 1941; Barron, 1947; Peters, 1946). Lewisite contact with skin results in the immediate elicitation of pain, in contrast to mustard, which would take 4–5 h (Wardell, 1941); it penetrates skin more rapidly than does mustard.
VII. ANTIDOTES OR AMELIORATIVE AGENTS A. LEWISITE Partial protection was afforded by monothiols, such as cysteine or GSH, when tested against pyruvate oxidase (Goldman and Dacre, 1989), which was thought to be one of the prime targets of Lewisite. British anti-lewisite or 2,3-dimercaptopropanol preferentially binds with arsenicals over the thiol rings in proteins to form a nontoxic five-membered stable ring, which reverses the lesion induced by
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Vesicants and Oxidative Stress
46616_C012 Final Proof page 263 6.11.2007 6:08pm Compositor Name: BMani
263
Lewisite. British anti-lewisite is also effective against other heavy metals, such as gold, excessive copper deposition seen in Wilson’s disease (El-Youssef, 2003), and mercury (Goldman and Dacre, 1989). Newer analogs of BAL have been synthesized to improve efficacy, such as DMSA, 2,3-dimercapto-1-propane sulfonic acid, and N-(2,3 dimercaptopropyl-phthalamidic acid) (DMPA).
B. MUSTARD Elsayed et al. (1992) performed subcutaneous injections of CEES that resulted in increased GST activity, increased lipid peroxides, and depleted, reduced GSH in lung tissue (Elsayed et al., 1992). Similar findings occurred in the in vitro mouse model, a neuroblastoma–rat glioma hybrid cell line, in that there was a reduction in GSH as a function of time after exposure (Moore and Ray, 1983). Within the last 5 years, there has been a greater emphasis on the inhalation effects of SM. Peter Ward and his group developed a rat instillation CEES model (McClintock et al., 2002). Leakage of radiolabeled albumin ([125I] BSA) was used as a measure of lung damage, and the rats were sacrificed after 4 h after the installation of CEES into the rat lung with CEES. Neutrophil and complement depletion was found to significantly reduce the injury. Both enzymatic and nonenzymatic protocols were used to examine their ameliorative effect on the model. Dimethyl sulfoxide (DMSO) and dimethyl thiourea (DMTU) resulted in a 51% and 35% reduction in injury, respectively. The enzymatic antioxidants catalase and SOD exhibited 47% and 23% protection, respectively. In contrast, the antioxidant found in red wine, resveratrol (a phytoalexin), showed protection at 61%. Interestingly, the iron chelators 2,3-dihydroxybenzoic acid (DHBA) and deferoxamine mesylate (desferal) did not have any protective effect. NAC was administered 10 min before instillation of CEES. A dose–response curve was generated for 5, 10, 20, 30, and 40 mg=kg1 body weight. All of the dosages of NAC were found to be protective. The dosage of NAC at 20 mg=kg1 conferred the best protection out of all antioxidants at 70% protection. In vitro, the lethal effects of SM on L-cells were reduced by thiol reagents, namely, dithiothreitol and NAC (Walker, 1967; Walker and Smith, 1969). Several observations support the concept of a pathogenic role for toxic oxygen species in CEES-induced acute lung injury. Other groups investigated the beneficial effects of agents that scavenge free radicals and other oxidant species (Wormser et al., 2000). They monitored the beneficial effects of those agents mainly by showing the recovery from damaged skin or by showing inhibition of the induction of proteolytic enzymes (Cowan et al., 1992; Cowan and Broomfield, 1993). Systemic and topical steroids administered revealed ameliorative properties in the rabbit SM skin model (Vogt et al., 1984). The Das Group investigated the effects of orally administered antioxidants on signal transduction in the guinea pig model. A single dose of NAC could not block the CEES-induced lung injury at all. On the other hand, about 76% of lung injury could be blocked by long-term pretreatment (30 days) with NAC. No significant protection of lung injury was observed by pretreatment with either Ondrox (an over-the-counter antioxidant supplement as single-dose or 3 days pretreatment) or GSH (single; Table 12.1). Similarly, a single-dose treatment of NAC just before CEES exposure was found to be ineffective, whereas 76% of lung injury could be blocked by long-term pretreatment (30 days) with NAC. There was no significant protection of lung injury by pretreatment with either Ondrox (single-dose or 3 days pretreatment) or GSH (single dose). A single-dose treatment of NAC just before CEES exposure was found to be ineffective, whereas 62% of TNF-a induction was inhibited by 3 days pretreatment with NAC. Long-term treatment with NAC gave more protection (inhibition of 73% of TNF-a induction). There was no protection for TNF-a accumulation by single dose of either Ondrox or GSH. Three days pretreatment with Ondrox and DMT could only block 13% and 8% of the TNF-a induction (Table 12.2). Additional support for an involvement of oxidants in the pathogenesis of CEES-induced acute lung injury was provided by the protective effects seen after treatment of CEES-exposed rat with NAC (McClintock et al., 2002). The protective effect of NAC was confirmed in the guinea pig lung model, as well as by others (Wormser et al., 1997).
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
264
46616_C012 Final Proof page 264 6.11.2007 6:08pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
TABLE 12.1 Effects of N-acetyl-L-Cysteine Pretreatment on CEES-Induced Lung Injury in Guinea Pigs Treatment Control Control þ NAC (3 days) CEES CEES þ NAC (single dose) CEES þ NAC (3 days) CEES þ NAC (30 days CEES þ Ondrox (single dose) CEES þ Ondrox (30 days) CEES þ GSH (single dose)
Permeability Index 0.20 0.04 0.08 0.01 2.01 0.16 2.07 0.11 0.62 0.09a 0.48 0.06a 2.04 0.03 2.00 0.08 1.98 0.10
Note: CEES was infused (6 mg=kg body weight) intratracheally into guinea pigs with or without pretreatment with NAC. NAC was given either in single dose (5 mg) by gavage directly into stomach 10 min before infusion of CEES or with drinking water (0.5 g=day=animal, for either 3 days or 30 days before CEES infusion). Information on treatment with ondrox and GSH is given in text. The lung injury was measured after 1 h of CEES exposure and expressed by permeability index, which is a measure of 125I-BSA leakage from damaged blood vessels into lung tissue. Each group had six animals. Values are mean SE (n ¼ 6). a
NAC supplementation in drinking water blocked the CEES-induced lung injury significantly ( p < 0.05).
TABLE 12.2 Inhibition of CEES-Induced TNF-a Accumulation in Guinea Pig Lung by NAC Treatment Treatment Control CEES CEES þ NAC (single dose) CEES þ NAC (3 days) CEES þ NAC (30 days) CEES þ Ondrox (single dose) CEES þ Ondrox (3 days) CEES þ DMT (3 days) CEES þ GSH (single dose)
Level of TNF-a (pg=mg Protein) 20 7 708 38 705 24 270 40a 190 64a 716 22 610 54 648 62 720 41
Note: CEES was injected (4 mg=kg body weight) intratracheally into guinea pigs with or without pretreatment with NAC. NAC was given either in single dose (5 mg) by gavage directly into stomach 10 min before injection of CEES or with drinking water (0.5 g=day=animal, for either 3 days or 30 days before CEES injection). Information on treatment with ondrox, DMT and GSH is given in the text. TNF-a was measured after 1 h exposure of CEES. Values are mean TNF-a SE (n ¼ 6). a
NAC supplementation in drinking water blocked the CEES-induced accumulation significantly ( p of TNF-a < 0.05).
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C012 Final Proof page 265 6.11.2007 6:08pm Compositor Name: BMani
265
Vesicants and Oxidative Stress
1.
Effect of NAC on Signal Transduction
Short-term (3 days) and long-term (30 days) pretreatment with NAC blocked significantly the activation of acid (4% and 49%, respectively, Figure 12.12) and neutral (46% and 61%, respectively, Figure 12.12) SHM-ases and decreased the levels of ceramide by 71% and 77% (Table 12.3). However, pretreatment with a single dose of NAC did not inhibit the activity of either neutral or acid SHM-ase and accumulation of ceramide. Exposure to CEES significantly inhibited (p < 0.05) the activity of SOD (31%), GSH peroxidase (67%), and catalase (25%) (Figure 12.13). Pretreatment of guinea pigs for 3 days with NAC before CEES infusion significantly (p < 0.05) decreased CEES-induced inhibition of SOD (from
Activity (nmol / h/ mg protein)
7.00
−42%
∗
3.50
−49%
∗
0.00 Vehicle
CEES
(a)
CEES + NAC CEES + NAC CEES + NAC Single dose 3 days 30 days
Activity (nmol /h/mg protein)
36
27 −46%
∗
18
−61%
∗
9
0 (b)
Vehicle
CEES
CEES + NAC CEES + NAC CEES + NAC Single dose 3 days 30 days
FIGURE 12.12 Inhibition of CEES-induced activation of neutral and acid sphingomyelinases in guinea pig lung by NAC treatment: Accumulation of neutral (a) and acid (b) sphingomyelinases at 4 h after exposure to CEES (4 mg=kg body weight) and their inhibition by 3 and 30 days pretreatment with NAC. Values are mean SE (n ¼ 6). Pretreatment with single dose of NAC did not inhibit the activity of either neutral or acid sphingomyelinase. *Pretreatment with NAC for 3 and 30 days before CEES exposure caused a significant inhibition of both neutral and acid sphingomyelinases (p < 0.05%).
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
266
46616_C012 Final Proof page 266 6.11.2007 6:08pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
TABLE 12.3 Inhibition of CEES-Induced Ceramide Accumulation in Guinea Pig Lung after NAC Treatment Levels of Ceramide (mg=mg Protein)
Treatment
92 148 14 146 10 39 8a 28 12a
Control CEES CEES þ NAC (single dose) CEES þ NAC (3 days CEES þ NAC (30 days) Note:
1.20
NAC supplementation in drinking water blocked the CEES-induced accumulation of ceramide significantly (p < 0.05).
+29.1%
SOD
µmol of NADPH reduced/min/mg protein
a
CEES was infused (4 mg=kg body weight) intratracheally into guinea pigs with or without pretreatment with NAC. NAC was given either in single dose (5 mg) by gavage directly into stomach 10 min before infusion of CEES or with drinking water (0.5 g=day=animal, for either 3 days or 30 days before CEES infusion. Ceramide accumulations were assayed after 1 h of infusion of CEES. Values are mean SE (n ¼ 6).
∗
+4.1%
∗
unit/mg protein
0.90
− 31% ∗
0.60
0.30
0.00 CEES
150
GSH-Px
−30% ∗ 0.25
−67% ∗
0.00
− 50% ∗
CEES CEES + NAC CEES + NAC 3 days 30 days
Vehicle
CEES + NAC CEES + NAC 3 days 30 days
µmol of H2O2 decomposed/min/mg protein
Vehicle
0.50
Catalase
120
−25% ∗
90
−9% ∗
+0.2%
∗
60
30
0 Vehicle
CEES
CEES + NAC CEES + NAC 3 days 30 days
FIGURE 12.13 Effects of NAC pretreatment on the CEES-induced alterations in the free radical-metabolizing enzymes: Guinea pigs were infused with CEES (4 mg=kg body weight) intratracheally and the free radicalmetabolizing enzymes (SOD, GSH pretreatment, catalase) were assayed in perfused lung after 4 h of CEES exposure. The samples were taken from guinea pigs with or without pretreatment with NAC for 3 days. *CEES exposure caused a significant decrease in the activity of SOD, GSH pretreatment, and catalase (p < 0.05). NAC treatment blocked the CEES-induced changes significantly (p < 0.05) for all enzymes.
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Vesicants and Oxidative Stress
46616_C012 Final Proof page 267 6.11.2007 6:08pm Compositor Name: BMani
267
31% decrease to 4.1% increase), GSH pretreatment (from 67% decrease to 50% decrease), and catalase (from 25% decrease to 9% decrease). Pretreatment of guinea pigs for 30 days with NAC provided additional resistance. For example, the activity of SOD was increased by 29% over the basal value, the activity of GSH pretreatment was decreased by only 30%, and the activity of catalase was brought back to the basal level. Both short-term (3 days) and long-term (30 days) treatments significantly (p < 0.05) blocked the CEES-induced activation of NF-kB that was observed 1 h after CEES infusion (Figure 12.14a). Furthermore, pretreatment with NAC for 3 days also blocked the activation of caspase 2, caspase 3, caspase 8, and caspase 9 by 41%, 44%, 55%, and 51% (Figure 12.14b). Protection by NAC from half-mustard, gas-induced, acute lung injury has also been demonstrated recently in rats by McClintock et al. (2006). However, in these studies, NAC was administered by liposome encapsulation directly into the lung as a method of treatment for acute exposure to mustard gas. The co-instillation with CEES of liposomes containing the pegylated (PEG)-catalase, PEG-superoxide, NAC, GSH, resvertrol, or combination greatly attenuated development of rat lung injury (McClintock et al., 2006). Thus, we suggest the following model for the action of NAC on CEES-induced guinea pig lung injury (Figure 12.15). Morphological analysis indicates that animals exposed to CEES showed symptoms of a chemical burn within 1 h; however, the severity of damage progressively increased with time. At 21 days postexposure, severe bronchial constriction with occasional apoptotic nucleus and accumulation of viscid secretion of mucins were observed in CEES-treated animals. Furthermore, both polymorphonucleus (PMNs) and eosinophilic leukocytes migration were observed in both alveoli and bronchi. However, pretreatment with NAC protected the lung from all these changes remarkably, except mucin secretion (Figure 12.16). How CEES functions as a powerful oxidant and what lung cells are targets of CEES is unclear.
C. ANTIOXIDANT LIPOSOMES Another method of increasing antioxidant tissue levels is facilitated by using liposomes. Liposomal drug delivery is advantageous to using the oral route in that there is a multiplicity of possible administration routes. They can be used topically, orally (using the gastrointestinal tract), or delivered by aerosol to the lung. Intact skin allows the passage of small lipophilic substances, but in most cases, efficiently retards the diffusion of water-soluble molecules. Lipid-insoluble drugs generally penetrate the skin slowly in comparison with their rates of absorption through other body membranes. Absorption of drugs through the skin may be enhanced by iontophoresis if the compound is ionized. Certain solvents (e.g., DMSO) may facilitate the penetration of drugs through the skin, but their use for therapeutic applications is controversial. In the formulation of topical dosage forms, attempts are being made to utilize drug carriers to ensure adequate localization or penetration of the drug within or through the skin in order to enhance the local and minimize the systemic effect. For dermatopharmacotherapy, there is a need for a drug delivery system that enhances the penetration of the active ingredient into the skin, localizes the drug at the site of action, and reduces percutaneous absorption. Antioxidant liposomes may prove very useful in this regard. Liposomes are phospholipid vesicles composed of lipid bilayers enclosing an aqueous compartment. Hydrophilic molecules can be encapsulated in the aqueous spaces, and lipophilic molecules can be incorporated into the lipid bilayers. Liposomes, in addition to their use as artificial membrane systems, are used for the selective delivery of antioxidants and other therapeutic drugs to different tissues in sufficient concentrations to be effective in ameliorating tissue injuries (Stone et al., 2002). Antioxidant liposomes containing combinations of water- and lipid-soluble antioxidants may provide a unique therapeutic strategy for mustard gas exposure because (1) the antioxidants are nontoxic and could, therefore, be used at the earliest stages of exposure; (2) the liposomes themselves are composed of nontoxic, biodegradable, and reusable phospholipids;
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
268
46616_C012 Final Proof page 268 6.11.2007 6:08pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics −42% ∗
−58% ∗ NF-κB
1
2
3
4
(a)
2.00
Caspase 2 Caspase 3
1.00
−44% −55% −51%
1.50 −41%
Activity (O.D./mg of protein)
2.50
Caspase 8
Caspase 9 0.50
0.00 Vehicle (b)
CEES
CEES + NAC 3 days
FIGURE 12.14 Inhibition of the activation of NF-kB (a) and different caspases (b) in guinea pig lung after CEES exposure by pretreatment with NAC. (a) Activation of NF-kB after 1 h of intratracheal infusion of CEES (4 mg=kg body weight) was monitored by mobility shift assay. The guinea pigs were treated with NAC either for 3 or for 30 days before CEES exposure. Panels 1, 2, 3, and 4 represent vehicle, CEES, CEES þ NAC (3 days), and CEES þ NAC (30 days), respectively. *NAC treatment caused a significant inhibition (46% and 58% for 3 and 30 days, respectively, p < 0.05) in the accumulation of NF-kB. (b) Accumulation of caspases 2, 3, 8, and 9 at 4 h after exposure to CEES (4 mg=kg body weight) and the prevention of these caspases activation by short-term pretreatment (3 days) with NAC. Values are mean SE (n ¼ 6). *NAC treatment inhibited the activation of all caspases significantly (p < 0.05).
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C012 Final Proof page 269 6.11.2007 6:08pm Compositor Name: BMani
269
Vesicants and Oxidative Stress SM
NAC Sphase
NAC
Neutrophil IκB NFκB
Caspase 8
Mitochondria
lκB
NF-κB Ceramide
ROS TNF-α
Cytochrome C
NAC CPT
Pro-caspase 9 Caspase 3
DAG
DPPC
Caspase 9 Apoptosis
Lung damage, ARDS or PF
FIGURE 12.15 Proposed mechanism of action of NAC on CEES-induced lung injury.
(3) liposomes are preferentially taken up by the reticuloendothelial system which is an early target of mustards gas toxicity; (4) chemical antioxidants are relatively inexpensive and a wide range of commercial antioxidants are available; and (5) liposomes have low immunogenicity. Furthermore, results from several studies have clearly indicated that the liposomal antioxidant formulations exert a far superior protective effect compared with that of the free (unencapsulated) antioxidants, against OS-induced tissue injuries (Fan et al., 2000). As shown in Figure 12.17, our preliminary data show that liposomes encapsulated with 5 mM GSH, a major intracellular chemical antioxidant, is effective at preventing CEES cytotoxicity to LPS-stimulated macrophages. We have also found that liposomes encapsulated with either 1 mM NAC (water-soluble antioxidant) or with 13.5 mM a-tocopherol are also effective in preventing CEES toxicity to stimulated macrophages (data not shown). Preliminary results from our ongoing collaborative research efforts have demonstrated that delivery of antioxidants as liposomal formulations were effective in protecting against CEES-induced cellular injury in an animal model.
D. CHLORINE Similar to phosgene, chlorine causes a delayed pulmonary edema. There is no specific antidote for chlorine gas inhalational exposure. Treatment for skin or eye contact is irrigation of the site. Inhalation of the gas can be treated supportively by the use of nebulized sodium bicarbonate and bronchodilators (Aslan et al., 2006). Modest improvement in animal models was obtained with the inhalation therapy using corticosteroids (Gunnarsson et al., 2000). Thiol-containing compounds are able to scavenge HOCl, which is suspected to be a significant metabolite of chlorine gas exposure (McKenzie et al., 1999). Enhancement of systemic levels of thiols by the use of orally administered NAC may be a consideration in life-threatening exposures to chlorine gas.
E. PHOSGENE In experiments using agents as a prophylaxis, there is promise. Rats were exposed to phosgene in a whole-body chamber after 23 days of supplementation of vitamin E (a-tocopherol) or N-propyl gallate (nPG) (Sciuto and Moran, 2001). The vitamin E-fed rats did not show any survival
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
270
46616_C012 Final Proof page 270 6.11.2007 6:08pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Vehicle
CEES
CEES + NAC
(a)
(b)
FIGURE 12.16 Histological analysis showing recovery from CEES-induced lung damage by pretreatment of NAC. Guinea pig lungs were examined under light microscope after 1 h (a) and after 21 days (b) of exposure to CEES (0.5 mg=kg body weight). Upper panel represents morphology of bronchi and lower panel represents morphology of the alveoli. Magnifications: 4003.
enhancement. The nPG-fed rats fed the lower doses of nPG (0.75%) showed the greatest increase in survival, and the higher dose of nPG (1.5%) was ineffective. In the lower dose of nPG, there was an obvious decrease in lipid peroxidation and increased lung tissue-reduced GSH. Gamma-tocopherol, in comparison with a-tocopherol, is a more potent anti-inflammatory agent and may have produced a much different result under the same experimental conditions that Sciuto and Moran (2001) performed (Jiang and Ames, 2003).
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C012 Final Proof page 271 6.11.2007 6:08pm Compositor Name: BMani
271
Vesicants and Oxidative Stress
Cell viability (O.D. at 575 nm)
3 Without GSH 1 mM GSH 5 mM GSH
2
1
0 CELL
LPS
CEES
LPS + CEES
Groups
FIGURE 12.17 GSH-liposomes (5 mM) protect simulated macrophages from CEES toxicity.
Postexposure drugs used as a countermeasure to phosgene are more reflective of a clinical application or military theater exposures. The arachidonic acid analog 5-, 8-, 11-, and 14-eicosatetraynoic acid (ETYA) inhibits the release of arachidonic acid metabolites, which produce both leukotrienes and prostaglandins (Farrukh et al., 1988). ETYA used as a postexposure treatment in an in situ lung model resulted in less lung edema, as well as increased gluathione levels and lower lipid peroxidation levels. It is questionable as to whether ETYA possesses any antioxidant properties (Sciuto, 2000).
VIII. OXIDATIVE STRESS IN DIFFERENT ORGAN SYSTEMS A. LUNG SM inhalation can produce hoarseness, laryngitis, acute airway obstruction, bronchopneumonia, pulmonary edema, and hemorrhage (Calvet et al., 1994). Bronchiolitis and dyspnea are common clinical findings. Examination of the pulmonary tree reveals a mild fibrosis in the parenchyma. Exaggerated fibroblast proliferation and increased collagen synthesis represent two critical events in the pathogenesis of this type of pulmonary fibrosis. The main initial changes are extreme hyperemia, exudation of inflammatory cells, cellular infiltration of the submucosa and detachment, necrosis, and cellular death of the respiratory epithelial lining (Chevillard et al., 1992). Acute, heavy exposure to SM causes loss of the columnar cells of the upper respiratory tract, peribronchial edema, hyperemia of the blood vessels, cellular infiltrations in the submucosa, and intense vacuolization and disorganization of the cytoplasmic and nuclear structures (Emad and Rezaian, 1997, 1999). Pulmonary hemorrhage, pulmonary edema, and respiratory failure similar to ARDS may also occur. These cytotoxic effects are associated with acute thermal injury sustained by the airway mucosa and lead to scarring and development of stenosis of the tracheobronchial tree as was observed in 9.64% of the SM-exposed patients. Cross-sectional study on the late pulmonary sequelae of SM-exposed veterans showed airway narrowing or stricture, asthma (10.65%), chronic bronchitis (58.88%), bronchiectasis (8.62%), and pulmonary fibrosis (PF; 12.18%) after 10 years. Crystal et al. (1984) recommended that SM be added to the various causes of interstitial lung diseases and PF (Crystal et al., 1984; DePaso and Winterbauer, 1991; Emad and Rezaian, 1997). The cellular constituents of bronchoalveolar (BAL)
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
272
46616_C012 Final Proof page 272 6.11.2007 6:08pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
fluid in patients with SM-induced PF are very similar to the cellular constituents seen in patients with idiopathic PF, and this finding indicates the presence of an ongoing active alveolitis in PF (Emad and Rezaian, 1997). Under normal physiological conditions, airway lining fluids and extracellular spaces are maintained in a highly reduced state. Typically, the levels of antioxidants and oxidants in lung are balanced in favor of a reducing state (redox homeostasis). Decreases in antioxidants or increases in oxidants can disrupt this equilibrium and can cause OS. An imbalance in oxidant–antioxidant system has been recognized as one of the first changes that ultimately lead to inflammatory reactions (Crapo, 2003a). An increased oxidizing environment can facilitate antigen-presenting cell (APC) maturation and T-cell activation, leading to the activation of the adaptive immune responses and, potentially, a hyperresponsive innate immune system. Thus, OS appears to play an important role in the pathogenesis of the asthmatic reaction. It is not surprising that OS occurs in many forms of lung disorders, such as pneumonia, adult respiratory distress syndrome, idiopathic pulmonary fibrosis, lung transplantation, chronic obstructive pulmonary disease, cystic fibrosis, bronchiectasis ischemia-reperfusion, and lung cancer (Bowler and Crapo, 2002; Crapo, 2003b; Rahman and Kelly, 2003; Rahman et al., 2004). An oxidizing state in cells can initiate intracellular signaling cascades that lead to the production of inflammatory mediators. Stress kinases (JNK, ERK, p38) and transcription factors, such as NF-kB and AP-1, are known to be redox sensitive. On their activation, these signaling pathways lead to production of TNF-a, IL-1-beta, IL-6, IL-8, IL-12, adhesion molecules (VCAM-1, ICAM-1), and GM-CSF (Mastruzzo et al., 2002). In addition to protein expression, OS favors uncoiling of DNA, thereby increasing accessibility to transcription factor binding (Rahman et al., 2004). The presence of OS can also damage alveolar epithelial cells by the induction of apoptosis. The angiotensin-converting enzyme system is also known to be redox sensitive. OS facilitates the conversion of angiotensinogen into angiotensin II, which is a bioactive peptide with a broad range of activities, including the induction of apoptosis in epithelial cells and the activation of fibroblasts. Angiotensin II can also increase the lung levels of transforming growth factor (TGF)-a, which is a crucial factor in the development of fibrosis (Mastruzzo et al., 2002). The maintenance of a reducing environment in lung is considered to be crucial in the lung function. A balance between intracellular and extracellular oxidants and antioxidants is a prerequisite for normal lung homeostasis. The lung has highly specialized and compartmentalized antioxidant defenses to protect against reactive oxygen species (ROS) and RNS. These include the following: (1) small molecular weight antioxidants (e.g., GSH, vitamins, uric acid); (2) mucins; (3) metal-binding proteins (transferrin, lactoferrin, metallothionein, etc.); (4) SODs (e.g., mitochondrial manganese SOD [MnSOD], intracellular copper zinc SOD [CuZnSOD], and extracellular SOD [ECSOD]); (5) a group of enzymes that decomposes hydrogen peroxide (H2O2) (numerous GSHassociated enzymes and catalase); (6) detoxification enzyme systems (e.g., GST); and (7) other redox-regulatory thiol proteins (e.g., thioredoxin–peroxiredoxin system and glutaredoxins) (Powis et al., 2000; Fattman et al., 2003; Kinnula and Crapo, 2003). Reduced GSH appears to be one of the most important antioxidant defense systems. In the extravascular lung fluid that coats the alveolar epithelial surfaces, GSH is present in millimolar quantities. A decrease in the ratio between GSH and oxidized glutathione (GSSG) occurring during OS leads to the activation of a variety of cellular redox-sensitive signaling pathways. Antioxidant enzymes such as SOD and catalase also play an important role in the clearance of oxidative radicals in the lung. The primary oxidant-generating enzyme is nicotinamide adenosine dinucleotide phosphate (NADPH) oxidase in phagocytes such as alveolar macrophages and neutrophils. On activation, phagocytes generate superoxide anions, which lead to the production of H2O2 for host defense. It is clear that a better understanding of the oxidative state in the lung is important for the diagnosis and treatment of lung diseases. There are many methods developed for the detection of free radicals from oxygen, ROS, and their by-products to assess the presence of OS. The techniques
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
46616_C012 Final Proof page 273 6.11.2007 6:08pm Compositor Name: BMani
Vesicants and Oxidative Stress
273
include established standard protocols and advanced methodologies using HPLC, mass spectrometry, and electron paramagnetic resonance (EPR). The following sections describe the most frequently used methods to measure lung oxidative status. 1.
Monitoring Oxidative Stress in Live Cells
ROS in live cells can be detected by using fluorogenic marker for ROS and observed under fluorescence microscopy. One of the frequently used markers is carboxy-H2DCFDA, a permeable fluorogenic marker, which is oxidized during OS in live cells and emits bright green fluorescence (Wan et al., 2005). 2.
Hydrogen Peroxide and Superoxide Radical Generation in Bronchoalveolar Fluids
H2O2 fluids in BAL can be measured by the simple assay for the detection of the presence of peroxides in both aqueous and lipid environments. The basis of these assays is the complexing of ferrous ion (Feþ2) by H2O2 in the presence of xylenol orange. Peroxides oxidize Feþ2 to Feþ3, and Feþ3 forms a colored complex with xylenol orange that can be read at 560 nm (Jones et al., 1995). Superoxide radical generation can be estimated by nitroblue-tetrazolium reduction assay (Libon et al., 1993). 3.
Antioxidant Status in Lung
The antioxidant status in the lungs can be evaluated by lung levels of SOD and catalase and their activities. SOD activity can be assessed by the OxyScan SOD-525 assay, which measures the activity of all forms of SOD. The method is based on the SOD-mediated increase in the rate of autoxidation of 5,6,6a,11b-tetrahydro-3,9,10-trihydroxybenzo[c]fluorene in aqueous alkaline solution to yield a chromophore with maximum absorbance at 525 nm. Catalase activity can be determined by a two-step reaction scheme (Catalase-520 assay). First, catalase reacts with a known quantity of H2O2 to generate H2O and O2. In the presence of horseradish peroxidase (HRP), the remaining H2O2 reacts with 3,5-dichloro-2-hydroxybenzenesulfonic acid and 4-aminophenazone to form a chromophore with a color intensity. Lipid peroxidation levels in the lung can be measured by thiobarbutiric acid reactive substances assay (Erdincler et al., 1997). The GSH=GSSG ratio, a useful measure of OS, can also be determined by a colorimetric method by using Bioxytech GSH=GSSG-412. 4.
Hydroxydeoxyguanosine, an Indicator of DNA Damage
The most common type of damage caused by ROS in the body is oxidative damage to DNA. Hydroxydeoxyguanosine (8-OHdG), a product of this type of DNA damage, is used as a biomarker for OS. It can be measured by the immunohistochemical procedure and a high-performance liquid chromatography system equipped with an electrochemical detector (HPLC-ECD) (Mei et al., 2003). More recently, it has been reported that capillary electrophoresis-mass spectrometry (CE=MS) can also be used for the analysis of 8-OHdG to study OS (Weiss and Lunte, 2000). 5.
Direct Measurements of Oxygen Free Radicals
It is very difficult to directly measure oxygen-free radicals (OFRs) due to their short half-lives. To study these OFRs, radical spin-trapping agents have to be employed to facilitate the formation of stable radical adducts with the OFRs, for detection by EPR spectroscopy. Trapping agents are generally nitrone or nitroso-containing molecules, such as 5,5-dimethyl-1-pyrroline-n-oxide (DMPO), which react with OFRs to form stable nitroxide free radicals. These radical adducts can be analyzed by using EPR (Olea-Azar et al., 2003).
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
274
6.
46616_C012 Final Proof page 274 6.11.2007 6:08pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Exhaled Breath Condensate
Exhaled breath condensate collected by cooling or freezing the exhaled air is a totally noninvasive procedure. H2O2, leukotrienes, isoprostanes, and 3-nitrotyrosine are good candidates for OS assessments (Paredi et al., 2002). These products have been shown to elevate lung inflammation. 7.
Analysis of Expired Air for Oxidation Products
Studies have shown that expired NO and CO can serve as biomarkers for OS, and ethane can serve as a marker of lipid peroxidation (Paredi et al., 2002). CO can be detected electrochemically, and it can also be measured by laser spectrophotometer and near-infrared CO analyzers. The levels of exhaled NO can be assessed by chemiluminescence. Ethane content can be detected using gas chromatography.
B. SKIN Skin is one of the major sites of damage after exposure to vesicant chemical weapons. In the case of SM, there is a latent period after exposure, followed by an erythematous rash within 4–8 h, and then blistering some 2–18 h later. Elsayed et al. (1992) found that a nonlethal, s.c. dose of the mustard analog chloroethyl 4-chlorobutyl sulfide (CECBS) in mice caused damage to distal tissues, such as the lung, that was consistent with free radical, mediated OS. These authors suggest that ‘‘antioxidants could potentially modulate the response and reduce the damage’’ (Elsayed et al., 1992). Although useful, animal models do not exactly mimic the development of SM injury to human skin. Nevertheless, the mouse ear model, the rabbit, the hairless guinea pig, the nude mouse, and the weanling swine have all been useful for studying the (1) pathophysiology; (2) molecular mechanism of action; and (3) efficacy of countermeasures for SM injury. Similarly, in vitro models have major limitations but have the advantage of being cost-effective and potentially very reproducible. A synthetic human skin model, EpiDerm, showed considerable promise as an in vitro model. EpiDerm possessed all the main characteristic features of the native skin tissue, including the cuboidal appearance of the basal cell layer, the presence of the stratum spinosum and stratum granulosum with typical stellate-shaped keratohyalin granules, and the presence of numerous lamellar bodies that are extruded at the stratum granulosum–stratum corneum interface. The EpiDerm system has the potential for identifying and developing SM therapeutic agents but does have its limitations as well. In vivo, skin damage can be accompanied by the rapid leakage of serum and leukocyte infiltration but this cannot occur in the in vitro skin models. The U.S. Army Research Institute of Environmental Medicine has used the EpiDerm model to study CEES-induced skin toxicity (Blaha et al., 2000a, 2000b, 2001). Blaha et al. (2000a), for example, studied the potential role of inflammatory cytokines on CEES-induced toxicity. Since CEES or SM is known to provoke an acute inflammatory response in skin, it is reasonable to assume that inflammatory cytokines are involved in this process and that EpiDerm would mimic the in vivo responses. Blaha et al. (2000a) found, however, that CEES depressed the levels of IL-1a and related cytokines. These authors concluded that the inflammatory responses seen in vivo are promoted by factors from sources other than keratinocytes (Blaha et al., 2000a). Stone et al. (2003, 2004) found that inflammatory cytokines dramatically enhance the toxicity of CEES in a macrophage model. It would be important, therefore, to determine if inflammatory cytokines increase CEES toxicity in the EpiDerm model. EpiDerm tissues in the presence of inflammatory cytokines may prove to be an excellent model to test the efficacy of countermeasures. Blaha et al. (2001) also demonstrated that CEES induces apoptosis in the EpiDerm model. This is a valuable observation since potential countermeasures could easily be tested for their antiapoptotic effects in this model. 1.
Role of Skin Mast Cells in Vesicant Toxicity
Rikimaru et al. (1991) have used full-thickness human skin explants to study inflammatory mediators in response to topically applied SM. These investigators found that culture fluids from
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
Vesicants and Oxidative Stress
46616_C012 Final Proof page 275 6.11.2007 6:08pm Compositor Name: BMani
275
the SM-treated skin contained increased levels of histamine, plasminogen-activating activity, and prostaglandin E2 compared with control explants. It was concluded that both mast cells and epidermal cells were apparently involved in early mediation of the inflammatory response to SM (Rikimaru et al., 1991). In contrast, Inoue et al. (1997) found that the inflammatory response of the mouse ear to SM did not differ in mast cell-deficient mice compared with normal mice. At present, there is no obvious explanation for the differences observed between the work of Rikimaru et al. (1991) and that of Inoue et al. (1997). It may well be that the mouse ear is not an optimal model for human skin. It is, however, critically important to determine if SM, or other toxic vesicants, degranulate mast cells, since this process could be a major source of inflammatory mediators.
C. EYES The eye is a complex sensory organ, which receives visual information from the environment. It encodes optical information into complex electrical signals, which are transmitted to the cortex for visual imagery through the optical nerve. The visual efficiency primarily depends on the optical clarity of the eye (e.g., cornea, crystalline lens, and intraocular media) and the neural integrity of the visual pathway (e.g., retina, optic nerve, and visual cortex). The pathogenesis of most age-related eye disorders remain poorly understood. Significant evidence points to oxidative damage as a major factor in the initiation and progression of numerous age-related diseases (Kowluru and Kennedy, 2001; Algvere and Seregard, 2002; Hogg and Chakravarthy, 2004; Shichi, 2004; Ohia et al., 2005; Truscott, 2005). Generally, OS occurs when the level of ROS exceeds the ability of the cell to respond through antioxidant defenses leading to the modification and degradation of carbohydrates, membrane lipids, proteins, and nucleic acids (Gamaley and Klyubin, 1999; Kimura et al., 2005). H2O2, a relatively stable oxidant, is present at low concentrations in the normal eye and is found at elevated concentrations in some patients with maturity-onset cataract (Beatty et al., 2001; Ohia et al., 2005; Truscott, 2005). Oxidative damage has also been hypothesized to play a role in the pathogenesis of glaucoma, as the trabecular meshwork is exposed to high levels of OS arising from aerobic metabolism, high aqueous concentrations of H2O2, and photochemical reactions in the anterior segment (Shichi, 2004; Ohia et al., 2005). The retina is particularly susceptible to OS because of its high consumption of oxygen, its high proportion of polyunsaturated fatty acids (PUFAs), its abundance of photosensitizers and its exposure to visible light (Sickel, 1972; Beatty et al., 2001). In general, it is well known that the greater the oxygen content of tissues, the more susceptible they are to oxidative and photooxidative damage. The retina is supplied with oxygen by the blood with generally high oxygen content in different portions of the retinal tissues. The lipids present in the membranes of rods contain a high percentage of PUFAs, particularly docosahexanoic acid (DHA) (22:6v-3), known to be the most highly PUFA in nature, making the retina inherently susceptible to lipid peroxidation (Sickel, 1972; Bazan, 1989; Beatty et al., 2001). Although the eye is continuously exposed to OS, cells have numerous protective mechanisms to reduce the incidence of severe oxidative damage. Damage to the eye by increases in ROS is typically avoided because of a very efficient antioxidant system. It is further protected by pigments such as the kynurenines and melanin (Roberts, 2001). The major water-soluble antioxidants are GSH and ascorbic acid (Reddy and Giblin, 1984; Reddy, 1990; Delamere, 1996; Rose et al., 1998; Lou, 2003; Rahman and Kelly, 2003). Ascorbic acid, the most effective aqueous-phase antioxidant in human blood, is present in high concentrations in the lens, cornea, retinal pigment epithelium, and aqueous humor of humans (Delamere, 1996; Rose et al., 1998). GSH is a naturally occurring tripeptide and is found mostly concentrated in the lens epithelium; its concentration in the lens is as high as that seen in the liver. GSH acts as a reductant of peroxides either by a nonenzymatic reaction or by a reaction catalyzed by GSH peroxidase. GSH may be especially important in protecting the thiol groups of crystallins, preventing them from aggregating to form opaque clusters. Aging lenses or lenses under OS show an extensively diminished size of GSH pool, with some protein thiols
Romano/Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
276
46616_C012 Final Proof page 276 6.11.2007 6:08pm Compositor Name: BMani
Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics
being S-thiolated by oxidized nonprotein thiols to form protein thiol-mixed disulfides, as proteinS-S-glutathione (PSSG), protein-S-S-cysteine (PSSC), or protein-S-S-gamma-glutamylcysteine (Megaw, 1984; Reddy and Giblin, 1984; Reddy, 1990; Rose et al., 1998; Beatty et al., 2000; Ganea and Harding, 2006). The principal lipid-soluble antioxidants are vitamin E and the carotenoids (Hunt et al., 1984; Snodderly, 1995; Khachik et al., 1997; Beatty et al., 2001). Vitamin E is the major chain-breaking, lipid-soluble antioxidant in membranes, and is thus expected to play the most important role in minimizing effects of oxidation of PUFAs. Both vitamin E and the carotenoids scavenge free radicals, particularly hydroxyl radical and singlet oxygen. Vitamin E is recycled by redox coupling with vitamin C. The retina contains high quantities of a-tocopherol (outer segments of rod) and rod and retinal pigmented epithelium (RPE), and the concentrations within these tissues are very sensitive to dietary intake of the vitamin E (Hunt et al., 1984; Beatty et al., 2001). Vitamin E deficiency has been shown to result in retinal degeneration, excessive RPE lipofuscin levels, and a decrease in the PUFA content of rod outer segments and the RPE, suggesting that vitamin E protects against retinal oxidative damage (Hayes, 1974; Beatty et al., 2001). The antioxidant properties of the carotenoids are now well established, and they possess the ability to quench singlet oxygen and triplet sensitizers, interact with free radicals, and prevent lipid peroxidation. Of the many carotenoids circulating in human sera, only lutein and zeaxanthin are accumulated throughout the tissues of the eye, where they reach their highest concentration in the